

# **SCHEDULE 1**

SCHEDULE 1

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**STATEMENT OF THE FACTS  
WHICH ARE ADMITTED AND REQUIRE NO PROOF**

SCHEDULE 1

**TABLE OF CONTENTS**

I.	THE PARTIES.....	1
II.	PATENT CLAIMS ASSERTED BY BOSTON SCIENTIFIC .....	2

SCHEDULE 1

**I. THE PARTIES**

1. Plaintiff Boston Scientific Corporation (“BSC”) is a corporation organized and existing under the laws of the State of Delaware with its principal place of business in Marlborough, Massachusetts. BSC is a developer, manufacturer, and marketer of medical devices, including endoscopic devices used in the gastrointestinal tract.

2. Plaintiff Boston Scientific SciMed, Inc. (“BSSI”) is a subsidiary of BSC that is organized and existing under the laws of the State of Minnesota with its principal place of business in Maple Grove, Minnesota. BSSI is the owner by assignment of the ’725, ’245, and ’371 Patents.

3. Plaintiffs BSC and BSSI are referred to collectively herein as “Plaintiffs” or “Boston Scientific.”

4. Defendant Micro-Tech Endoscopy USA Inc. (“Micro-Tech USA”) is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business in Ann Arbor, Michigan. Micro-Tech USA is in the business of, among other things, distributing medical instruments and devices, including endoscopic devices used in the gastrointestinal tract.

5. Defendant Micro-Tech (Nanjing) Co., Ltd. (“Micro-Tech Nanjing”) is a corporation organized and existing under the laws of China, with its principal place of business in Nanjing, China. Micro-Tech Nanjing is in the business of,

## SCHEDULE 1

among other things, manufacturing and distributing medical devices, including endoscopic devices used in the gastrointestinal tract.

6. Defendants Micro-Tech USA and Micro-Tech Nanjing are referred to collectively herein as “Micro-Tech.”

7. Defendant Henry Schein is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business located in Melville, New York. Henry Schein is in the business of, among other things, distributing medical devices.

8. Defendants Micro-Tech USA, Micro-Tech Nanjing, and Henry Schein are referred to collectively herein as “Defendants.”

## **II. PATENT CLAIMS ASSERTED BY BOSTON SCIENTIFIC**

9. On August 22, 2006, the USPTO issued U.S. Patent No. 7,094,245 (“the ’245 patent”), which lists on its face Mark L. Adams, Russell F. Durgin, Vincent Turturro, Justin Grant, Norman May, and Roy H. Sullivan, III as inventors.

10. The application that resulted in the ’245 patent was filed on October 5, 2001, as U.S. Application No. 09/971,488 (the “’488 Application”).

11. On March 10, 2015, the UPSTO issued U.S. Patent No. 8,974,371 (“the ’371 patent”), which lists on its face Russell F. Durgin, William C. Mers Kelly, Lance Alan Wolf, Brian Keith Wells, Vasiliy P. Abramov, and Gregory R. Furnish as inventors.

SCHEDULE 1

12. The application that led to the '371 patent was filed on December 16, 2011, as U.S. Application No. 13/328,171 (the "'171 Application").

13. On May 29, 2018, the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,980,725 ("the '725 patent"), which lists on its face Russell F. Durgin, William C. Mers Kelly, Lance Alan Wolf, Brian Keith Wells, Vasiliy P. Abramov, and Gregory R. Furnish as inventors.

14. The application that resulted in the '725 patent was filed on May 19, 2016, as U.S. Application No. 15/159,512 (the "'512 Application").

15. The Asserted Claims of the '245 patent are Claims 1, 3, 7, 13, and 15.

16. The Asserted Claims of the '371 patent are Claims 8 and 9.

17. The Asserted Claims of the '725 patent are Claims 1, 2, 3, 6, and 8-12.

## **SCHEDULE 2**

SCHEDULE 2

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**PLAINTIFFS' STATEMENT OF CONTESTED ISSUES OF FACT**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	TECHNOLOGY BACKGROUND .....	2
III.	PERSON OF ORDINARY SKILL IN THE ART.....	2
IV.	THE ACCUSED DEVICES.....	2
	A.    SureClip Hook and Buckle Devices and ConMed DuraClip Devices..	2
	B.    LOCKADO Devices .....	4
V.	THE ASSERTED PATENTS.....	4
VI.	INFRINGEMENT .....	6
	A.    The '245 Patent .....	7
	B.    The '371 Patent .....	9
	C.    The '725 Patent .....	11
VII.	WILLFUL INFRINGEMENT .....	16
VIII.	RELIEF.....	16
IX.	VALIDITY.....	17
X.	ENFORCEABILITY.....	18
XI.	NO PATENT MISUSE.....	19

SCHEDULE 2

**I. INTRODUCTION**

Boston Scientific presents the following statement of contested issues of fact that remain to be litigated. This statement is based on the current status of the case and the Court's rulings to date. Boston Scientific reserves the right to modify or supplement this statement in response to subsequent Court rulings and/or Defendants' attempts to introduce different or additional facts. The following statement of issues of fact is not exhaustive, and Boston Scientific reserves the right to prove any matters identified in the pleadings, interrogatory responses, and/or expert reports. Boston Scientific intends to offer evidence as to the issues of fact and issues of law identified in this Joint [Proposed] Pretrial Order. Boston Scientific further intends to offer evidence to rebut evidence offered by Defendants. Should the Court determine that any issue identified here is more appropriately considered an issue of law, Boston Scientific incorporates such issues by reference into its Statement of Issues of Law That Remain to Be Litigated. To the extent that Boston Scientific's Statement of Issues of Law That Remain to Be Litigated contains issues that the Court deems to be issues of fact, those issues are incorporated herein by reference. Boston Scientific reserves its right to revise this statement.

SCHEDULE 2

**II. TECHNOLOGY BACKGROUND**

1. Hemostatic clips are used to stop internal bleeding by clamping together the edges of a wound. They are often delivered by an endoscopist through an endoscope to the location of the bleeding. These clips can be used for various indications, including ulcers, Mallory-Weiss tears (tears in the membrane where the esophagus meets the stomach), diverticular bleeding (when pouches (diverticula) have developed in the colon that bleed), and bleeding polypectomy sites (bleeding caused by removal of colorectal polyps) in both the United States and internationally.

**III. PERSON OF ORDINARY SKILL IN THE ART**

2. A person of ordinary skill in the art (“POSA”) as of the priority date of the ’245, ’371 and ’725 patents would be a person with a bachelor’s degree in mechanical engineering or equivalent and at least three years of experience designing medical devices.

**IV. THE ACCUSED DEVICES**

**A. SureClip Hook and Buckle Devices and ConMed DuraClip Devices**

3. Micro-Tech Nanjing manufactures devices under the SureClip name, including at least the SureClip™, SureClip™ MINI, SureClip™ PLUS, and SureClip™ MAX Hemostasis Clips (the “SureClip” devices). Micro-Tech USA and Henry Schein use, sell, offer for sale, and/or import into the United States for

SCHEDULE 2

subsequent sale or use, the SureClip devices. The SureClip devices have competed and are presently competing with products marketed by Boston Scientific.

4. The SureClip devices have been sold with two different “attachment configurations”: the “hook” attachment configuration as originally sold in the United States (“Accused Original Devices,” alternatively referred to as “Accused Original (Micro-Tech) Devices”) and a later version referred to as the “Buckle” configuration (the “Accused Buckle Devices”).

5. Aside from the difference in attachment configuration, there are no differences between the Accused Original Devices and Accused Buckle Devices.

6. Micro-Tech Nanjing manufactures and imports the DuraClip™ Hemostasis Clip line of products, which is sold by a third party, ConMed. The DuraClip™ Hemostasis Clip line of products are included in the definition of “Accused Original Devices,” and are alternatively referred to as the “Accused Original (ConMed) Devices.” The Accused Original (ConMed) Devices have competed and are presently competing with products marketed by Boston Scientific.

7. There are no meaningful differences between the Accused Original Devices and the Accused Original (ConMed) Devices.

SCHE DULE 2

**B. LOCKADO Devices**

8. Micro-Tech Nanjing manufactures devices under the Lockado name.

Micro-Tech USA and Henry Schein use, sell, offer for sale, and/or import into the United States for subsequent sale or use, the Lockado devices. The Lockado Clips have competed and are presently competing with products marketed by Boston Scientific.

**V. THE ASSERTED PATENTS**

9. The '245 patent was filed on October 5, 2001, as U.S. Application No. 09/971,488 (the "'488 Application"), and does not claim priority to any earlier-filed application.

10. On March 10, 2015, the USPTO issued U.S. Patent No. 8,974,371 ("the '371 patent") and the face of the '371 patent lists Russell F. Durgin, William C. Mers Kelly, Lance Alan Wolf, Brian Keith Wells, Vasiliy P. Abramov, and Gregory R. Furnish as inventors.

11. The '371 patent was filed on December 16, 2011, as U.S. Application No. 13/328,171 (the "'171 Application"). The '171 Application is a continuation of U.S. Application No. 12/252,630 (the "'630 Application"), filed on October 16, 2008. The '630 Application is a division of U.S. Application No. 10/955,624 (the "'624 Application"), filed on September 30, 2004. The '624 Application is a

SCHEDULE 2

continuation-in-part of U.S. Application No. 10/674,512 (the “‘512 Application”), filed on September 30, 2003.

12. On May 29, 2018, the USPTO issued U.S. Patent No. 9,980,725 (“the ‘725 patent”) and the face of the ’725 patent lists Russell F. Durgin, William C. Mers Kelly, Lance Alan Wolf, Brian Keith Wells, Vasiliy P. Abramov, and Gregory R. Furnish as inventors.

13. The ’725 patent was filed on May 19, 2016, as U.S. Application No. 15/159,512 (the “‘512 Application”). The ’512 Application is a continuation of the U.S. Application No. 14/642,159 (the “‘159 Application”), which is a continuation of the ’171 Application.

14. BSSI is the assignee and owner of the ’245, ’371, and ’725 patents (collectively, “the Asserted Patents”).

15. Boston Scientific is the exclusive licensee of the Asserted Patents.

16. At the time of the launch of the Resolution™ Clips in 2004, Boston Scientific made the decision that BSC would be the exclusive/sole distributor of its hemostatic clips in the U.S.

17. That decision came along with the corporate intent and agreement that:

- a. No other Boston Scientific affiliate would have the right to sell hemostatic clips to unaffiliated third-parties in the U.S.;

SCHEDULE 2

- b. BSC would have the right to exclude any unaffiliated third-parties from practicing the patents in the U.S.;
- c. BSC would have the right to control enforcement of the patents against any infringer in the U.S.; and
- d. SciMed would not extend any license under the patents without BSC's consent.

This is how Boston Scientific and its affiliates have, in fact, operated at all times.

18. BSC has, in fact, been the only seller in the U.S. of Resolution™ Clips. BSC sought regulatory clearance to sell the clips in the US and at all times has been the only entity with 510(k) clearance to market the Resolution™ Clips in the United States. BSC has, in fact, made the decisions to enforce the patents-in-suit against Defendants and Cook. BSC controls all decisions as to who within Boston Scientific can and will perform manufacturing and distribution of the clips. BSC controls decisions regarding licensing of relevant IP to third parties.

**VI. INFRINGEMENT**

19. Whether the Accused Devices infringe the '245, '371, and '725 patents.

20. Whether Defendants have induced infringement of the '245, '371, and '725 patents.

SCHEDULE 2

21. Whether Defendants have willfully infringed the '245, '371, and '725 patents.

**A. The '245 Patent**

22. Whether the Accused Devices infringe Claims 1, 3, 7, 13, and 15 of the '245 patent.

**i. Claim 1**

23. Whether the Accused Devices include a “clip” under the Court’s construction—i.e., a “multi-legged grasping device.”

24. Whether the Accused Devices include a “control wire reversibly operable both to open the at least two clip legs and to close the at least two clip legs when the control wire is coupled to the clip” under the Court’s construction—i.e., that “when the control wire is coupled to the clip, the control wire can be both pushed and pulled to open and close the clip legs.”

25. Whether the Accused Devices include an axially rigid sheath enclosing the control wire, the sheath able to communicate a first force opposing a second force of the control wire.

26. Whether the Accused Devices include a handle coupled to the axially rigid sheath.

27. Whether the Accused Devices include an actuator coupled to the control wire, the control wire engageable by the actuator to open the at least two

SCHEDULE 2

clip legs, to close the at least two clip legs, and to uncouple the control wire from the clip.

28. Whether the Accused Devices include a “a breakable link adapted to couple a control wire to the clip and adapted to be broken by a first predetermined tensile force applied by the control wire” under the Court’s construction—i.e., “a component of the device designed to mechanically fail by fracturing at a predetermined tensile load.”

29. Whether, in the Accused Devices, when the breakable link is broken, the control wire uncouples from the clip.

**ii. Claim 3**

30. Whether the control wire in the Accused Devices is coupled to the clip by a j-hook or the equivalent of a j-hook.

31. Whether, in the Accused Devices, the j-hook or its equivalent is able to be straightened by the first predetermined tensile force.

32. Whether, in the Accused Devices, when the j-hook or its equivalent is straightened, the control wire uncouples from the clip.

**iii. Claim 7**

33. Whether the Accused Devices include a lock arrangement for locking the at least two clip legs in a closed position.

SCHEDULE 2

**iv. Claim 15**

34. In addition to the questions of identified above with respect to claim 1, whether Defendants induce infringement of the asserted method of treatment of Claim 15 of the '245 patent.

**B. The '371 Patent**

35. Whether the Accused Devices infringe Claims 8 and 9 of the '371 patent.

**i. Claim 1<sup>1</sup>**

36. Whether the Accused Devices include a flexible sheath extending from a proximal end which, in an operative configuration, extends into a living body to a target portion of tissue to be clipped, where "sheath," under the Court's construction, means "one or more components of the delivery device that enclose the control wire."

37. Whether the Accused Devices include a capsule extending from a proximal to a distal end and having an opening formed in a proximal end thereof.

38. Whether the Accused Devices include a clip assembly provided in the capsule and configured to be operably movable between a closed configuration in which first and second arms of the clip assembly are drawn toward one another and

---

<sup>1</sup> Boston Scientific does not independently assert Claim 1, but includes it here as Claims 8 and 9 depend from Claim 1.

SCHEDULE 2

an expanded configuration in which the first and second arms are separated from one another to receive target tissue therebetween, where, under the Court's construction, a "clip assembly provided in the capsule" means, "an assembly having a clip, i.e., a multi-legged grasping device, provided in the capsule," and "closed configuration" means "the configuration of the clip assembly when its clip arms are closed."

39. Whether the Accused Devices include a bushing extending between a proximal end coupled to the sheath and a distal end releasably coupled to the capsule via a tab on the distal end of the bushing engaging the opening of the capsule, where "coupled to the sheath" means, under the Court's construction, "linked together, connected, or joined, but not slid able within the sheath."

40. Whether the Accused Devices include a control member a distal end of which is releasably coupled to the clip assembly to transmit to the clip assembly forces applied thereto to move the clip assembly between the insertion and expanded configurations, where "control member" means, under the Court's construction, a "wire or other force transmission member."

**ii. Claim 8**

41. Whether the proximal end of the capsule of each of the Accused Devices includes a keyed portion that aligns the capsule in a desired rotational orientation with respect to the bushing.

SCHEDULE 2

**iii. Claim 9**

42. Whether the distal end of the bushing in each of the Accused Devices comprises a feature configured to mate with the keyed portion of the capsule.

**C. The '725 Patent**

43. Whether the Accused Devices infringe Claims 1-3, 6, and 8-12 of the '725 patent.

**i. Claim 1**

44. Whether the Accused Devices include a flexible sheath extending from a proximal end which, in an operative configuration, extends into a living body to a target portion of tissue to be clipped, where “sheath,” under the Court’s construction, means “one or more components of the delivery device that enclose the control wire.”

45. Whether the Accused Devices each include a capsule comprising a proximal end and a distal end.

46. Whether the Accused Devices include a clip assembly provided in the capsule and configured to be operably movable between a closed configuration in which first and second arms of the clip assembly are drawn toward one another and an expanded configuration in which the first and second arms are separated from one another to receive target tissue therebetween, where, under the Court’s construction, a “clip assembly provided in the capsule” means, “an assembly

SCHEDULE 2

having a clip, i.e., a multi-legged grasping device, provided in the capsule,” and “closed configuration” means “the configuration of the clip assembly when its clip arms are closed.”

47. Whether the Accused Devices include a control member a distal end of which is releasably coupled to the clip assembly via a separable yoke to transmit to the clip assembly forces applied thereto to move the clip assembly between the closed and expanded configurations, where, under the Court’s construction, “control member” means “wire or other force transmission member” and “separable yoke” means “a separable component that holds two parts in position.”

48. Whether, in the Accused Devices, the separable yoke includes first and second yoke arms extending distally from the control member on opposite sides of the clip assembly and the clip assembly includes a connecting member or its equivalent extending between the first and second yoke arms coupling the yoke to the clip assembly, the first and second yoke arms being configured to be separated from the connecting member when subjected to a predetermined force by the control member to uncouple the control member from the clip assembly, where the “connecting member” means, under the Court’s construction, a “tension member that connects the clip arms to the yoke and biases the clip arms to an open configuration.”

SCHEDEULE 2

**ii. Claim 2**

49. Whether the Accused Devices include a bushing coupled between the flexible sheath and the capsule that is releasably coupled to the proximal end of the capsule and fixed to the distal end of the sheath.

**iii. Claim 3**

50. Whether the Accused Original/Buckle Devices include a flexible sheath that is formed as a wire coil as well as a bushing that is a substantially cylindrical member extending distally therefrom with a distal portion of the bushing being received within the capsule.

**iv. Claim 6**

51. Whether, in the Accused Devices, the first and second yoke arms extend distally past proximal ends of the clip arms while the control member is coupled to the clip assembly.

**v. Claim 8**

52. Whether, in the Accused Devices, a proximal end of the first arm of the clip assembly includes a projection positioned to mechanically lock with a locking feature of the capsule when the clip assembly is deployed to lock the clip assembly in the closed configuration.

SCHEDULE 2

**vi. Claim 9**

53. Whether, in the Accused Devices, the projection at the proximal end of the first arm of the clip assembly is formed as a hook that mechanically interacts with the locking feature of the capsule to prevent the clip assembly from moving distally relative to the capsule.

**vii. Claim 10**

54. Whether, in the Accused Devices, a proximal end of the second arm of the clip assembly includes a projection positioned to mechanically lock with a locking feature of the capsule when the clip assembly is deployed to lock the first and second arms of the clip assembly in the closed configuration.

**viii. Claim 11**

55. Whether, in the Accused Devices, the clip assembly is configured so that, as the clip assembly is moved distally relative to the capsule, the first and second arms of the clip assembly are moved to the expanded configuration as the first and second arms of the clip assembly project further distally from the capsule and the first and second arms of the clip assembly are drawn into the closed configuration as the clip assembly is withdrawn proximally into the capsule.

**ix. Claim 12**

56. Whether the Accused Devices include a capsule defining a lumen therein and including openings in proximal and distal ends thereof.

SCHEDULE 2

57. Whether the Accused Devices include a clip assembly received within the lumen of the capsule for movement between a closed configuration in which first and second arms of the clip assembly are drawn toward one another and an expanded configuration in which the first and second arms are separated from one another to receive target tissue therebetween.

58. Whether the Accused Devices include a control member a distal end of which is releasably coupled to the clip assembly to transmit to the clip assembly forces applied to a proximal end of the control member to move the clip assembly between the closed and expanded configurations by moving the first and second arms of the clip assembly distally out of and proximally into the capsule.

59. Whether the Accused Devices include a separable yoke or its equivalent connecting the control member to the clip assembly, the yoke including first and second yoke arms extending distally from the control member within the capsule on opposite sides of the clip assembly, the clip assembly including a connecting member or its equivalent extending between the first and second yoke arms coupling the yoke to the clip assembly, the first and second yoke arms being configured to be separated from the connecting member when subjected to a predetermined force by the control member to uncouple the control member from the clip assembly.

SCHEDULE 2

**VII. WILLFUL INFRINGEMENT**

60. Whether Defendants have continued to infringe the Asserted Patents with knowledge of the Patents and knowledge that their conduct would infringe the Patents.

61. Whether Defendants' infringement of the Asserted Patents has been willful.

**VIII. RELIEF**

62. Whether Boston Scientific is entitled to past damages in the form of lost profits due to lost sales relating to Defendants' infringement of the Asserted Patents.

63. The amount of damages to which Boston Scientific is entitled to compensate it for Defendants' infringement of the Asserted Patents.

64. The amount of pre- and post-judgment interest to which Boston Scientific is entitled to receive on the damages it is awarded.

65. The amount of costs and attorneys' fees which Boston Scientific is entitled to receive.

66. Whether this is an exceptional case entitling Boston Scientific to recover enhanced damages.

67. The amount of enhanced damages Boston Scientific is entitled to recover.

SCHEDULE 2

68. Whether Boston Scientific is entitled to permanent injunctive relief barring Defendants from making, selling, offering to sell, and/or importing Accused Devices into the United States.

**IX. VALIDITY**

69. Whether the '371 Patent is entitled to a priority date of September 30, 2003.

70. Whether the '725 Patent is entitled to a priority date of September 30, 2003.

71. Whether any prior art reference asserted by Defendants anticipates any asserted claim of the '245 Patent.

72. Whether any prior art reference asserted by Defendants anticipates any asserted claim of the '371 Patent.

73. Whether any prior art reference asserted by Defendants anticipates any asserted claim of the '725 Patent.

74. Whether any prior art reference or combination of references asserted by Defendants renders obvious any asserted claim of the '245 Patent.

75. Whether any prior art reference or combination of references asserted by Defendants renders obvious any asserted claim of the '371 Patent.

76. Whether any prior art reference or combination of references asserted by Defendants renders obvious any asserted claim of the '725 Patent.

SCHEDEULE 2

77. Whether Defendants can demonstrate that claim 3 of the '245 Patent is invalid as indefinite.

78. Whether Defendants can demonstrate that any asserted claim of the '371 Patent is invalid as indefinite.

79. Whether Defendants can demonstrate that any asserted claim of the '725 Patent is invalid as indefinite.

80. Whether Defendants can demonstrate that any asserted claim of the '371 Patent is invalid as lacking written description.

81. Whether Defendants can demonstrate that any asserted claim of the '725 Patent is invalid as lacking written description.

82. Whether Defendants can demonstrate that any asserted claim of the '371 Patent is invalid as not enabled.

83. Whether Defendants can demonstrate that any asserted claim of the '725 Patent is invalid as not enabled.

**X. ENFORCEABILITY**

84. Whether Defendants can demonstrate that any individual with a duty of candor to the USPTO made any affirmative misrepresentation of but-for material fact, failed to disclose but-for material information, or submitted false material information with the specific intent to deceive the USPTO in connection with the prosecution of the '245 Patent.

SCHEDULE 2

85. Whether Defendants can demonstrate that any individual with a duty of candor to the USPTO made any affirmative misrepresentation of but-for material fact, failed to disclose but-for material information, or submitted false material information with the specific intent to deceive the USPTO in connection with the prosecution of the '371 Patent.

86. Whether Defendants can demonstrate that any individual with a duty of candor to the USPTO made any affirmative misrepresentation of but-for material fact, failed to disclose but-for material information, or submitted false material information with the specific intent to deceive the USPTO in connection with the prosecution of the '725 Patent.

**XI. NO PATENT MISUSE**

87. Whether Defendants can demonstrate that Boston Scientific has pursued this litigation in the interest of impermissibly restraining trade or by pursuing infringement for patent claims that it knows or reasonably should know are not infringed and/or are invalid or unenforceable, or by seeking damages or other relief beyond what is supported by law. Defendants cannot so demonstrate, particularly in light of Boston Scientific's victories against Micro-Tech in numerous European venues including Germany and the European Patent Office, demonstrating the validity of similar patents in those venues, and demonstrating Micro-Tech's infringement of similar patents in those venues.

## **SCHEDULE 3**

SCHEDULE 3

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**DEFENDANTS' STATEMENT OF CONTESTED ISSUES OF FACT**

## TABLE OF CONTENTS

CONTESTED ISSUES OF FACT .....	1
A.    Level of Ordinary Skill .....	1
B.    Alleged Infringement .....	2
C.    Invalidity .....	4
D.    Unenforceability .....	6
E.    Patent Misuse .....	7
F.    Alleged Damages / Relief / Willful Infringement.....	8

Defendants identify the following issues of fact to be litigated. If the Court concludes that any issue of law listed in Schedule 5 should be considered an issue of fact, then Defendants incorporate such issues in this Schedule. If the Court concludes that any issue identified in this Schedule should be considered an issue of law, then Defendants incorporate such issues into Schedule 5. The facts that remain to be litigated, as listed below, are subject to and modified by the admitted facts set forth in the parties' Statement of Admitted Facts in Schedule 1.

Defendants further reserve the right to supplement or amend this Statement, including in response to Court rulings on pending motions and Plaintiffs' further pretrial disclosures, and to offer additional proof in response to evidence or argument presented at trial. Nothing in this statement is intended to admit or suggest the existence of any genuine issue of material fact that might preclude summary judgment or any other ruling by the Court as a matter of law. Defendants further address herein certain issues reserved for resolution by the Court, if necessary, in post-trial proceedings, including issues under 35 U.S.C. § 285 and relating to injunctive relief.

## **CONTESTED ISSUES OF FACT**

### **A. Level of Ordinary Skill**

1. Whether the level of ordinary skill in the field, at the relevant time (circa 2001-2003, the years in which the earliest patent application to which the

Asserted Patents claim priority was filed) would be the knowledge and skill known by an engineer or similar professional with at least a bachelor's degree in engineering, or a physician having experience with designing medical devices, and would also include an understanding of engineering or medical device design principles.

**B. Alleged Infringement**

2. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1, 3, 7, and 13 of the '245 Patent by Defendants making, using, offering for sale, selling, or importing Original Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

3. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1, 3, 7, and 13 of the '245 Patent by Defendants making, using, offering for sale, selling, or importing Buckle Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

4. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1, 3, 7, and 13 of the '245 Patent by Defendants making, using, offering for sale, selling, or importing Lockado Devices

either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

5. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 8 or 9 of the '371 Patent by Defendants making, using, offering for sale, selling, or importing Original Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

6. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 8 or 9 of the '371 Patent by Defendants making, using, offering for sale, selling, or importing Buckle Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

7. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 8 or 9 of the '371 Patent by Defendants making, using, offering for sale, selling, or importing Lockado Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

8. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1-3, 6, and 8-12 of the '725 Patent by Defendants by making, using, offering for sale, selling, or importing Original

Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

9. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1-3, 6, and 8-12 of the '725 Patent by Defendants by making, using, offering for sale, selling, or importing Buckle Devices either literally or under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

10. Whether Plaintiffs can prove by a preponderance of the evidence any acts of direct infringement of any of claims 1-2, 6, and 8-12 of the '725 Patent by Defendants by making, using, offering for sale, selling, or importing Lockado Devices under the doctrine of equivalents (where asserted and not precluded by the Court) under 35 U.S.C. § 271(a).

11. Whether Plaintiffs can prove by a preponderance of the evidence that Defendants knowingly and intentionally induced acts of direct infringement by others of claim 15 of the '245 Patent, with knowledge that such acts constituted direct infringement, under 35 U.S.C. § 271(b).

### C. Invalidity

12. Whether Plaintiffs can prove that the asserted claims of the '371 Patent are entitled to a priority date earlier than December 16, 2011.

13. Whether Plaintiffs can prove that the asserted claims of the '725 Patent are entitled to a priority date earlier than May 19, 2016.

14. Whether each asserted claim of the '245 Patent is invalid as anticipated.

15. Whether each asserted claim of the '371 Patent is invalid as anticipated.

16. Whether each asserted claim of the '725 Patent is invalid as anticipated.

17. Whether each asserted claim of the '245 Patent is invalid as obvious, including any contested issues of fact regarding the scope and content of the prior art, the level of ordinary skill in the art, the differences between the claimed inventions and the prior art, and secondary considerations of obviousness or nonobviousness (to the extent Plaintiffs produce any evidence of secondary considerations of nonobviousness).

18. Whether each asserted claim of the '371 Patent is invalid as obvious, including any contested issues of fact regarding the scope and content of the prior art, the level of ordinary skill in the art, the differences between the claimed inventions and the prior art, and secondary considerations of obviousness or nonobviousness (to the extent Plaintiffs produce any evidence of secondary considerations of nonobviousness).

19. Whether each asserted claim of the '725 Patent is invalid as obvious, including any contested issues of fact regarding the scope and content of the prior art, the level of ordinary skill in the art, the differences between the claimed

SCHEDULE 3

inventions and the prior art, and secondary considerations of obviousness or nonobviousness (to the extent Plaintiffs produce any evidence of secondary considerations of nonobviousness).

20. Whether claim 3 of the '245 patent is invalid as indefinite.

21. Whether the asserted claims of the '371 patent are invalid as indefinite.

22. Whether the asserted claims of the '725 patent are invalid as indefinite.

23. Whether the asserted claims of the '371 patent are invalid as lacking written description.

24. Whether the asserted claims of the '725 patent are invalid as lacking written description.

25. Whether the asserted claims of the '371 patent are invalid as not enabled.

26. Whether the asserted claims of the '725 patent are invalid as not enabled.

**D. Unenforceability**

27. Whether individuals subject to the duty to disclose in connection with the prosecution of the '245 patent made an affirmative misrepresentation of material fact, failed to disclose material information, or submitted false material information to the U.S. Patent Office.

28. Whether individuals subject to the duty to disclose in connection with the prosecution of the '245 patent intended to deceive the U.S. Patent Office.

29. Whether individuals subject to the duty to disclose in connection with the prosecution of the '371 patent made an affirmative misrepresentation of material fact, failed to disclose material information, or submitted false material information to the U.S. Patent Office.

30. Whether individuals subject to the duty to disclose in connection with the prosecution of the '371 patent intended to deceive the U.S. Patent Office.

31. Whether individuals subject to the duty to disclose in connection with the prosecution of the '725 patent made an affirmative misrepresentation of material fact, failed to disclose material information, or submitted false material information to the U.S. Patent Office.

32. Whether individuals subject to the duty to disclose in connection with the prosecution of the '725 patent intended to deceive the U.S. Patent Office.

#### **E. Patent Misuse**

Whether Plaintiffs have sought to exclude Defendants from the U.S. hemoclip market as a means of impermissibly restraining trade by asserting against Defendants and other competitors patent claims that Plaintiffs know or reasonably should know are not infringed and/or are invalid or enforceable and by seeking damages and other relief beyond what is supported by law.

**F. Alleged Damages / Relief / Willful Infringement**

33. Whether Plaintiffs can prove that Plaintiff Boston Scientific Corporation is an exclusive licensee.

34. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can prove that Plaintiff Boston Scientific Scimed Inc. can seek damages in the form of lost profits.

35. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can prove by a preponderance of the evidence that they are entitled to lost profits damages under 35 U.S.C. § 284 for some or all of the period of time after the date Plaintiffs filed this action (November 26, 2018), and if so, the appropriate amount of damages.

36. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can prove by a preponderance of the evidence that they are entitled reasonable royalty damages under 35 U.S.C. § 284 for some or all of the period of time after the date Plaintiffs filed this action (November 26, 2018), and if so, the appropriate amount of damages and the appropriate form of damages.

37. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can prove that any

of Defendants' infringement has been willful after the date Plaintiffs filed this action (November 26, 2018).

38. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether the circumstances can justify increasing the amount of damages found or assessed.

39. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can meet all the requirements for the Court to grant an injunction, and if so, whether the Court should grant an injunction and the terms of the injunction.

40. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, whether Plaintiffs can prove that they are entitled to pre- or post-judgment interest and, if so, the amount of interest.

41. Whether this case is an exceptional case for which the Court may award Plaintiffs attorneys' fees, and if so, the amount of attorneys' fees and other relief that should be awarded to Plaintiffs.

42. Whether this case is an exceptional case for which the Court may award Defendants attorneys' fees, and if so, the amount of attorneys' fees and other relief that should be awarded to Defendants.

43. The amount of costs due to either Plaintiffs or Defendants.

## **SCHEDULE 4**

SCHEDULE 4

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**PLAINTIFFS' STATEMENT OF CONTESTED ISSUES OF LAW**

## TABLE OF CONTENTS

<b>I.</b>	<b>INFRINGEMENT.....</b>	<b>1</b>
A.	Literal Infringement .....	2
B.	Doctrine of Equivalents .....	3
C.	Ensnarement .....	4
D.	Prosecution History Estoppel.....	5
E.	Indirect Infringement.....	6
<b>II.</b>	<b>WILLFULNESS .....</b>	<b>7</b>
<b>III.</b>	<b>COSTS/EXCEPTIONAL CASE .....</b>	<b>8</b>
<b>IV.</b>	<b>VALIDITY.....</b>	<b>9</b>
A.	Prior Art.....	9
B.	Priority.....	11
C.	Anticipation .....	12
D.	Obviousness.....	14
E.	Collateral Estoppel.....	19
F.	Indefiniteness.....	20
G.	Enablement.....	21
H.	Written Description.....	22
<b>V.</b>	<b>ENFORCEABILITY.....</b>	<b>24</b>
<b>VI.</b>	<b>PATENT MISUSE .....</b>	<b>27</b>
<b>VII.</b>	<b>STANDING/OWNERSHIP .....</b>	<b>27</b>
A.	Assignee.....	27
B.	Exclusive Licensee .....	28

<b>VIII.</b>	<b>DAMAGES.....</b>	<b>30</b>
A.	Lost Profits .....	31
B.	Reasonable Royalty.....	36
<b>IX.</b>	<b>INJUNCTION.....</b>	<b>38</b>

Plaintiffs identify the following issues of law that remain to be litigated and the authorities that Plaintiffs rely on.<sup>1</sup>

Plaintiffs base this statement on the arguments that Plaintiffs expect to present and their understanding of the arguments Defendants are likely to present, based on the status of the case and the Court's rulings to date. If Defendants seek to introduce different legal arguments, Plaintiffs reserve the right to supplement this statement.

Plaintiffs reserve the right to modify or supplement this statement in response to subsequent Court rulings and/or Defendants' attempts to introduce different or additional legal arguments.

## I. INFRINGEMENT

1. Under 35 U.S.C. § 271(a), an accused infringer is liable for direct infringement if, without authorization from the patentee, the accused infringer “makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent therefor.” 35 U.S.C. § 271(a).

2. Analyzing infringement involves two steps. *Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 976 (Fed. Cir. 1995) (en banc), aff'd, 517 U.S. 370

---

<sup>1</sup> These authorities are not exhaustive; Plaintiffs may rely on authority not cited in this statement.

(1996). The first step is to construe the disputed terms of the patent consistently with how those terms would be understood by a person of ordinary skill in the art. *Id.*; *Phillips v. AWH Corp.*, 415 F.3d 1303, 1313 (Fed. Cir. 2005) (en banc). This Court construed the disputed terms in an Order dated July 1, 2020. D.I. 140. The second step is to determine whether the accused product infringes the patent, which is done by comparing the accused product to the properly construed claims. *Markman*, 52 F.3d at 976.

**A. Literal Infringement**

3. Direct infringement is a strict-liability offense. *Commil USA, LLC v. Cisco Sys., Inc.*, 135 S. Ct. 1920, 1926 (2015). “[I]ntent is not an element of direct infringement.” *Hilton Davis Chem. Co. v. Warner-Jenkinson Co.*, 62 F.3d 1512, 1527 (Fed. Cir. 1995) (en banc), *rev’d on other grounds*, 520 U.S. 17 (1997).

4. Literal infringement of a claim occurs when every limitation recited in the claim appears in the accused device. *Amgen Inc. v. F. Hoffman-La Roche Ltd.*, 580 F.3d 1340, 1374 (Fed. Cir. 2009).

5. For method claims, direct infringement occurs when “all steps of a claimed method are performed by or attributable to a single entity.” *Akamai Techs., Inc. v. Limelight Networks, Inc.*, 797 F.3d 1020, 1022 (Fed. Cir. 2015) (en banc).

**B. Doctrine of Equivalents**

6. An accused device infringes under the doctrine of equivalents when it contains an “insubstantial” change from the claimed invention. *Graver Tank & Mfg. Co. v. Linde Air Prods. Co.*, 339 U.S. 605, 610 (1950). Whether equivalency exists may be determined based on either the “insubstantial differences” test or on the “function-way-result” test (i.e., whether the element of the accused device “performs substantially the same function in substantially the same way to obtain the same result”). *Id.* at 607-08.

7. A patentee asserting the doctrine of equivalents is not limited to equivalents disclosed in the patent itself. *Warner Jenkinson, Co., Inc. v. Hilton Davis Chem. Co.*, 520 U.S. 17, 37 (1997).

8. The Federal Circuit has “never held that a patent must spell out a claim element’s function, way, and result in order for the doctrine of equivalents to apply as to that element.” *Intendis GMBH v. Glenmark Pharm, Inc., USA*, 822 F.3d 1355, 1362 (Fed. Cir. 2016). Rather, by way of example, “[w]hen the claims and specification of a patent are silent as to the result of a claim limitation . . . [the court] should turn to the ordinary skilled artisan.” *Id.*

**C. Ensnarement**

9. “[E]nsnarement is a question of law for the court, not the jury, to decide.” *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 567 F.3d 1314, 1324 (Fed. Cir. 2009).

10. “[I]n the ensnarement context, a district court may hear expert testimony and consider other extrinsic evidence regarding: (1) the scope and content of the prior art; (2) the differences between the prior art and the claimed invention; (3) the level of ordinary skill in the art; and (4) any relevant secondary considerations.” *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 567 F.3d 1314, 1324 (Fed. Cir. 2009).

11. “The hypothetical claim analysis is not the only method in which a district court can assess whether a doctrine of equivalents theory ensnares the prior art.” *Jang v. Boston Sci. Corp.*, 872 F.3d 1275, 1285 & n.4 (Fed. Cir. 2017). Indeed, “[h]ypothetical claim analysis is an optional way of evaluating whether prior art limits the application of the doctrine of equivalents.” *Int'l Visual Corp. v. Crown Metal Mfg. Co.*, 991 F.2d 768, 772 (Fed. Cir. 1993).

12. In the absence of a hypothetical claim, courts evaluate the parties’ expert testimony to determine whether the asserted range of equivalents would ensnare the prior art. See *Agrofresh Inc. v. Essentiv LLC*, No. 16-662-MN, 2020 WL 7024867, at \*14-15 (D. Del. Nov. 30, 2020).

**D. Prosecution History Estoppel**

13. Defendants may argue that certain of Plaintiffs' expert opinions are barred by prosecution history estoppel. Even if prosecution history estoppel presumptively applies, it can be rebutted in the three ways that follow. The patentee can show that “[1] [t]he equivalent may have been unforeseeable at the time of the application; [(2)] the rationale underlying the amendment may bear no more than a tangential relation to the equivalent in question; or [(3 ) there may be some other reason suggesting that the patentee could not reasonably be expected to have described the insubstantial substitute in question.” *Conoco, Inc. v. Energy & Env't Int'l, L.C.*, 460 F.3d 1349, 1364 (Fed. Cir. 2006).

14. Argument-based prosecution history estoppel only applies “by surrendering claim scope through argument to the patent examiner.” *Conoco, Inc. v. Energy & Env't Int'l, L.C.*, 460 F.3d 1349, 1363 (Fed. Cir. 2006). Moreover, “the prosecution history must evince a clear and unmistakable surrender of subject matter.” *Id.* at 1364. In contrast to amendment-based estoppel, the Federal Circuit “do[es] not presume a patentee’s arguments to surrender an entire field of equivalents through simple arguments and explanations to the patent examiner. Though arguments to the examiner may have the same effect, they do not always evidence the same clear disavowal of scope that a formal amendment to the claim

would have.” *Conoco, Inc. v. Energy & Env’t Int’l, L.C.*, 460 F.3d 1349, 1364 (Fed. Cir. 2006).

15. “The relevant inquiry is whether a competitor would reasonably believe that the applicant had surrendered the relevant subject matter.” *Conoco, Inc. v. Energy & Env’t Int’l, L.C.*, 460 F.3d 1349, 1364 (Fed. Cir. 2006).

#### **E. Indirect Infringement**

16. “Whoever actively induces infringement of a patent shall be liable as an infringer.” 35 U.S.C. § 271(b). “To establish liability under section 271(b), a patent holder must prove that once the defendants knew of the patent, they actively and knowingly aid[ed] and abett[ed] another’s direct infringement.” *DSU Med. Corp. v. JMS Co., Ltd.*, 471 F.3d 1293, 1305 (Fed. Cir. 2006) (internal quotation marks omitted).

17. Proof of intent can consist of evidence of active steps taken to encourage direct infringement such as advertising an infringing use or instructing how to engage in an infringing use. *See Vanda Pharms. Inc. v. West-Ward-Pharms. Int’l Ltd.*, 887 F.3d 1117, 1129 (Fed. Cir. 2018); *Takeda Pharms. U.S.A. Inc. v. West-Ward Pharm. Corp.*, 785 F.3d 625, 631 (Fed. Cir. 2015).

18. “Willful blindness can satisfy the knowledge requirement for active inducement.” *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, 824 F.3d 1344, 1347 (Fed.

Cir. 2016). Deliberate indifference can also satisfy the knowledge requirement. *SEB S.A. v. Montgomery Ward & Co., Inc.*, 594 F.3d 1350, 1376-78 (Fed. Cir. 2010).

19. While proof of intent is necessary, direct evidence is not required; rather, circumstantial evidence may suffice.” *DSU Med. Corp. v. JMS Co., Ltd.*, 471 F.3d 1293, 1306 (Fed. Cir. 2006); *see also Sanofi v. Watson Labs. Inc.*, 875 F.3d 636, 645 (Fed. Cir. 2017). Indeed, the “requisite intent to induce infringement may be inferred from all of the circumstances.” *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, 824 F.3d 1344, 1347 (Fed. Cir. 2016).

## II. WILLFULNESS

20. Conduct that is “willful, wanton, malicious, bad faith, deliberate, consciously wrongful, or flagrant” may justify the award of enhanced patent damages, in accordance with 35 U.S.C. § 284, of up to three times what the jury awards. *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 136 S. Ct. 1923, 1932 (2016). “The subjective willfulness of a patent infringer, intentional or knowing, may warrant enhanced damages, without regard to whether his infringement was objectively reckless.” *Id.* at 1933. An example of subjective willfulness is a defendant who acted despite a risk of infringement that was “either known or so obvious that it should have been known to the accused infringer.” *Id.* at 1930 (citation omitted).

21. “[T]he district court no longer determines as a threshold matter whether the accused infringer’s defenses are objectively reasonable. Rather, the

entire willfulness determination is to be decided by the jury.” *Exmark Mfg. Co. Inc. v. Briggs & Stratton Power Prods. Grp., LLC*, 879 F.3d 1332, 1353 (Fed. Cir. 2018).

### **III. COSTS/EXCEPTIONAL CASE**

22. Section 285 of the Patent Act authorizes a district court to award “reasonable attorney fees to the prevailing party” if a case is found to be “exceptional.” 35 U.S.C. § 285. The Supreme Court has held that “an ‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party’s litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated.” *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 134 S. Ct. 1749, 1756 (2014).

23. “District courts may determine whether a case is ‘exceptional’ in the case-by-case exercise of their discretion, considering the totality of the circumstances.” *Id.* The grant of fees does not require the Court to find “litigation-related misconduct of an independently sanctionable magnitude.” *Id.* “A case presenting either subjective bad faith or exceptionally meritless claims may sufficiently set itself apart from mine-run cases to warrant a fee award.” *Id.* at 1757.

24. A movant need only establish their right to fees by a preponderance of the evidence. *Id.* at 1758. The court may award interest on the attorneys’ fees. *See*

*Advanced Magnetic Closures, Inc. v. Rome Fastener Corp.*, 607 F.3d 817, 833 (Fed. Cir. 2010).

#### **IV. VALIDITY**

25. Issued patent claims are presumed by statute to be valid. 35 U.S.C. § 282.

26. The presumption that an issued patent claim is valid can be overturned only with clear and convincing evidence of invalidity. *Microsoft Corp. v. i4i Ltd. P'ship*, 131 S.Ct. 2238, 2240-41 (2011).

##### **A. Prior Art**

27. “Whether a reference is prior art is a question of law based on underlying factual questions.” *ATEN Int'l Co., Ltd. v. Uniclass Tech. Co., Ltd.*, 932 F.3d 1364, 1367 (Fed. Cir. 2019).

28. To demonstrate that an asserted reference is prior art to the asserted patent, the patent challenger “must prove, by clear and convincing evidence, that it predates the critical date.” *ATEN Int'l Co., Ltd. v. Uniclass Tech. Co., Ltd.*, 932 F.3d 1364, 1368 (Fed. Cir. 2019).

29. A patent claim is invalid as anticipated under Section 102(a) if “the invention was known or used by others in this country, or patented or described in a

printed publication in this or a foreign country, before the invention thereof by the applicant for patent.” 35 U.S.C. § 102(a) (pre-AIA).<sup>2</sup>

30. A patent claim is invalid as anticipated under Section 102(b) if “the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.” 35 U.S.C. § 102(b).

31. A patent claim is invalid as anticipated under Section 102(e) if the invention was described in “an application for patent . . . by another filed in the United States before the invention by the applicant for patent” or “a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent.” 35 U.S.C. § 102(e) (pre-AIA).

32. A patent claim is invalid as anticipated under Section 102(g)(2) if “before such person’s invention thereof, the invention was not made in this country by another inventor who had not abandoned, suppressed, or concealed it.” 35 U.S.C. § 102(g)(2) (pre-AIA).

---

<sup>2</sup> The America Invents Act (“AIA”), Pub. L. No. 112–29, became effective as of March 16, 2013. *Duncan Parking Techs., Inc. v. IPS Grp., Inc.*, 914 F.3d 1347, 1357 n.3 (Fed. Cir. 2019). The pre-AIA version of 35 U.S.C. § 102 applies to patent applications that were filed before that effective date, and to patents that claim priority to any such application. *Id.*

33. “[S]ection 102(g) does not address the role of patents and patents applications as prior art: That task is assigned to section 102(e).” *See Sonos, Inc. v. D&M Holdings Inc.*, No. 14-1330-WCB, 2017 WL 4969330, \*6 (D. Del. Nov. 11, 2017)

**B. Priority**

34. “Priority and its constituent issues of conception and reduction to practice are questions of law predicated on subsidiary factual findings.” *Eaton v. Evans*, 204 F.3d 1094, 1097 (Fed. Cir. 2000).

35. A patent can claim the benefit of the filing date of an earlier-filed patent application if, among other things, “it contains or is amended to contain a specific reference to the earlier filed application.” 35 U.S.C. § 120. A patent applicant can satisfy this requirement by including the priority claim in an application data sheet filed with the application. See 37 CFR § 1.76(b)(5); *see also* Manual of Patent Examining Procedure (“MPEP”) § 211.02 (9th ed., rev. Jan. 2018).

36. The Federal Circuit has rejected the idea that “the patentee has the burden of persuasion to prove it was entitled to the earlier filing date.” *Technology Licensing Corp. v. Videotek, Inc.*, 545 F.3d 1316, 1328-29 (Fed. Cir. 2008). Rather, “it is a long-standing rule of patent law that, because an issued patent is by statute presumed valid, a challenger has the burden of persuasion to show by clear and

convincing evidence that the contrary is true. That ultimate burden never shifts[.]”

*Id.*

37. Patentees bear the burden only of producing evidence to rebut a challenger’s *prima facie* invalidity case. *Id.*; *see also PowerOasis, Inc. v. T-Mobile USA, Inc.*, 522 F.3d 1299, 1305 (Fed. Cir. 2008).

38. The Federal Circuit has rejected the theory that the priority date determination requires “review[ing] the new disclosure added to the continuation-in-part application and determin[ing] whether that content corresponds to the particular claim limitations in dispute.” *Nintendo of Am. Inc. v. iLife Techs., Inc.*, 717 F. App’x 996, 1001 (Fed. Cir. 2017).

### C. Anticipation

39. “In order to anticipate the claimed invention, a prior art reference must ‘disclose all elements of the claim within the four corners of the document,’ and it must ‘disclose those elements ‘arranged as in the claim.’” *Microsoft Corp. v. Biscotti, Inc.*, 878 F.3d 1052, 1063 (quoting *Net MoneyIN, Inc. v. VeriSign, Inc.*, 545 F.3d 1359, 1369 (Fed. Cir. 2008)); 35 U.S.C. § 102.

40. There “must be no difference between the claimed invention and the reference disclosure, as viewed by a person of ordinary skill in the field of the invention.” *Scripps Clinic & Res. Found. v. Genentech, Inc.*, 927 F.2d 1565, 1576

(Fed. Cir. 1991), clarified on denial of reconsideration by 1991 WL 523489 (Fed. Cir. Apr. 30, 1991).

41. To prove anticipation by a prior art product, “the party with the burden of proof must show that ‘the subject of the barring activity met each of the limitations of the claim, and thus was an embodiment of the claimed invention.’” *See Juicy Whip, Inc. v. Orange Bang, Inc.*, 292 F.3d 728, 737 (Fed. Cir. 2002) (quoting *Scaltech Inc. v. Retec/Tetra, LLC*, 178 F.3d 1378, 1383 (Fed. Cir. 1999)) (reversing a jury verdict of anticipation by a prior art device because the record lacked evidence “regarding at least one limitation of each asserted claim”).

42. In order to prove inherent anticipation, the patent challenger must prove by clear and convincing evidence that the missing element or elements are necessarily present in the allegedly anticipating disclosure. *See Continental Can Co. USA, Inc. v. Monsanto Co.*, 948 F.2d 1264, 1268 (Fed. Cir. 1991); *see also Transclean Corp. v. Bridgewood Servs., Inc.*, 290 F.3d 1364, 1373 (Fed. Cir. 2002). Inherency “may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient.” *In re Robertson*, 169 F.3d 743, 745 (Fed. Cir. 1999) (quoting *Continental Can*, 948 F.2d at 1269).

43. “In order to anticipate a claimed invention, a prior art reference must enable one of ordinary skill in the art to make the invention without undue experimentation.” *Impax Labs., Inc. v. Aventis Pharms., Inc.*, 545 F.3d 1312, 1314 (Fed. Cir. 2008) (citing *Finisar Corp. v. DirecTV Grp., Inc.*, 523 F.3d 1323, 1336 (Fed. Cir. 2008)).

#### **D. Obviousness**

44. The ultimate determination of obviousness is a question of law based on underlying factual findings, including: (1) the scope and content of the prior art; (2) the level of ordinary skill in the pertinent art; (3) the differences between the claimed invention and the prior art; and (4) such secondary considerations as commercial success, long felt but unsolved needs, failure of others, etc. See *KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398, 406 (2007); *Graham v. John Deere Co.*, 383 U.S. 1, 17-18 (1966).

45. Obviousness is determined from the perspective of the POSA at the time of the invention. 35 U.S.C. § 103(a).

46. A patent claim is obvious if “the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art in the art to which said subject matter pertains.” 35

U.S.C. § 103(a); *see also In re Hedges*, 783 F.2d 1038, 1041 (Fed. Cir. 1986) (to determine obviousness, prior art must be considered as a whole).

47. “Generally, a party seeking to invalidate a patent as obvious must demonstrate by clear and convincing evidence that a skilled artisan would have had reason to combine the teaching of the prior art references to achieve the claimed invention, and that the skilled artisan would have had a reasonable expectation of success from doing so.” *In re Cyclobenzaprine*, 676 F.3d 1063, 1068-69 (Fed. Cir. 2012) (internal quotations and citations omitted).

48. The party challenging the patent bears the burden of persuasion with respect to the issue of obviousness and must present evidence sufficient to establish a rational reason to select and combine teachings of the prior art to produce the claimed invention with a reasonable expectation of success. *Procter & Gamble Co. v. Teva Pharms. USA, Inc.*, 566 F.3d 989, 994 (Fed. Cir. 2009).

49. A finding of obviousness cannot be based upon hindsight selection of elements of the claimed invention from among the disclosures of the prior art. *Otsuka Pharm. Co. v. Sandoz, Inc.*, 678 F.3d 1280, 1296 (Fed. Cir. 2012) (“The inventor’s own path itself never leads to a conclusion of obviousness; that is hindsight.”); *Innogenetics, N.V. v. Abbott Labs.*, 512 F.3d 1363, 1374 n.3 (Fed. Cir. 2008) (It is impermissible to use “hindsight reconstruction of references to reach the claimed invention without any explanation as to how or why the references

would be combined to produce the claimed invention.”); *In re Hedges*, 783 F.2d at 1041 (“It is impermissible within the framework of section 103 to pick and choose from any one reference only so much of it as will support a given position, to the exclusion of other parts necessary to the full appreciation of what such reference fairly suggests to one of ordinary skill in the art.” (internal citations omitted)).

50. Reasoning that simply retraces the path of the inventor with hindsight, and discounts the number and complexity of available alternatives, is always inappropriate. See *Ortho-McNeil Pharm. Inc. v. Mylan Labs., Inc.*, 520 F.3d 1358, 1364 (Fed. Cir. 2008); *In re Wesslau*, 353 F.2d 238, 241 (C.C.P.A. 1965); *Grain Processing Corp. v. Am. Maize-Prod. Co.*, 840 F.2d 902, 907 (Fed. Cir. 1988) (“Care must be taken to avoid hindsight reconstruction by using the patent in suit as a guide through the maze of prior art references, combining the right references in the right way so as to achieve the result of the claims in suit.” (internal citations omitted)).

51. “[A] patent composed of several elements is not proved obvious merely by demonstrating that each of its elements was, independently, known in the prior art.” *KSR*, 550 U.S. at 401; see also *Unigene Labs., Inc. v. Apotex Inc.*, 655 F.3d 1352, 1360 (Fed. Cir. 2011) (“Obviousness requires more than a mere showing that the prior art includes separate references covering each separate limitation in a claim under examination.”).

52. It is important that the record supply a reason, available within the knowledge of a POSA, to take particular steps or make particular modifications to achieve the claimed invention. *See KSR*, 550 U.S. at 418 (“it can be important to identify a reason that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does”); *Eli Lilly & Co. v. Teva Pharms. USA, Inc.*, 619 F.3d 1329, 1336-37 (Fed. Cir. 2010) (methods of using compound known to have low bioavailability were not obvious where there was “no evidence from before the time of the invention that would teach, suggest, or motivate or supply any common sense reason for a person of ordinary skill in the art to reject the bioavailability concerns and routinely, simply, or easily arrive at the inventive result”).

53. Merely stating that there is a “general motivation” to develop an invention is insufficient proof of a motivation to combine particular references. *See Innogenetics*, 512 F.3d at 1373 (“[K]nowledge of a problem and motivation to solve it are entirely different from motivation to combine particular references to reach the particular claimed [invention].”); *Abbott Labs. v. Sandoz, Inc.*, 544 F.3d 1341, 1352 (Fed. Cir. 2008); *Corning Inc. v. SRU Biosystems*, 400 F. Supp. 2d 653, 670-71 (D. Del. 2005) (criticizing expert’s analysis where expert relied only on references selected by counsel, used the claims of the patent-in-suit to select and focus on particular disclosures of those references, and referred only to “general

motivations” to combine references); *Personal Web Techs. LLC v. Apple Inc.*, 848 F.3d 987, 993-94 (Fed. Cir. 2017) (“not enough” to simply “say . . . that a skilled artisan, once presented with the two references, would have understood that they **could be** combined. . . . [I]t does not imply a motivation to pick out those two references and combine them to arrive at the claimed invention”) (emphasis original).

54. Consideration of whether the prior art contains a teaching, suggestion, or motivation to make the claimed invention can guard against hindsight analysis. See *Ortho-McNeil*, 520 F.3d at 1364-65 (explaining that KSR approved the “teaching, suggestion, or motivation” test for guarding against hindsight).

55. The Court must look to the hypothetical POSA to determine whether such a person would have had a reasonable expectation of success in achieving the claimed invention. See *Eli Lilly*, 619 F.3d at 1340; *Amgen Inc. v. F. Hoffmann-La Roche Ltd.*, 580 F.3d 1340, 1363 (Fed. Cir. 2009).

56. An invention claimed in a patent is not obvious unless a person of ordinary skill in the art could reasonably have predicted that the invention would succeed in solving the problem. *In re Cyclobenzaprine*, 676 F.3d at 1070-73; *Abbott Labs.*, 544 F.3d at 1351-52.

57. Objective indicia, such as long felt-but unmet need, failure of others, and licensing of the patents can serve as probative evidence of nonobviousness.

*Graham v. John Deere Co.*, 383 U.S. 1, 17-18 (1966); *see, e.g., Impax Labs., Inc. v. Lannett Holdings Inc.*, 893 F.3d 1372, 1377 (Fed. Cir. 2018).

58. Objective indicia evidence is not meant to shift the burden of persuasion from the party challenging the patent to the patentee, but rather it gives the patentee an opportunity to produce additional evidence that can be used in the Court’s analysis on the issue of obviousness. *See In re Cyclobenzaprine*, 676 F.3d at 1075-76.

#### **E. Collateral Estoppel**

59. Collateral estoppel applies when “(1) the identical issue was previously adjudicated; (2) the issue was actually litigated; (3) the previous determination was necessary to the decision; and (4) the party being precluded from relitigating the issue was fully represented in the prior action.” *Jean Alexander Cosmetics, Inc. v. L’Oreal USA, Inc.*, 458 F.3d 244, 249 (3d. Cir. 2006).

60. The first requirement is satisfied when “the issues in the case are indeed identical.” *B&B Hardware, Inc. v. Hargis Indus., Inc.*, 575 U.S. 138, 153 (2015). Further, “[i]ssues are not identical if the second action involves application of a different legal standard, even though the factual setting of both suits may be the same.” *Id.* at 154.

61. Collateral estoppel does not apply when “the adversary has a significantly heavier burden than he had in the first action.” Restatement (Second) of Judgments §28(4) (1982).

62. A prior decision invalidating patent claims does not collaterally estop a party from asserting claims that are different in a “patentably significant” way. *Amax, Inc. v. ACCO Brands Corp.*, 268 F. Supp. 3d 301, 305 (D. Mass. 2017).

#### F. Indefiniteness

63. Indefiniteness is a question of law. *Amgen Inc. v. F. Hoffman-La Roche Ltd.*, 580 F.3d 1340, 1371 (Fed. Cir. 2009). “Indefiniteness must be proven by clear and convincing evidence.” *Sonix Tech. Co., Ltd v. Publ'ns Int'l, Ltd.*, 844 F.3d 1370, 1377 (Fed. Cir. 2017).

64. “Whether a claim is invalid for indefiniteness requires a determination whether those skilled in the art would understand what is claimed when the claim is read in light of the specification.” *Takeda Pharm. Co. Ltd. v. Zydus Pharm. USA, Inc.*, 743 F.3d 1359, 1366 (Fed. Cir. 2014).

65. Claim terms that have “sufficiently objective meaning in the art” are not indefinite. *DDR Holdings, LLC v. Hotels.com, L.P.*, 773 F.3d 1245, 1260 (Fed. Cir. 2014).

66. Claims are not indefinite when the intrinsic evidence provides “a general guideline and examples sufficient to enable a person of ordinary skill in the

art to determine” the scope of the claim. *Amgen Inc. v. F. Hoffman-La Roche Ltd.*, 580 F.3d 1340, 1371 (Fed. Cir. 2009).

67. “A patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention.” *Nautilus, Inc. v. Biosig Instruments, Inc.*, 572 U.S. 898, 901 (2014).

68. “A patentee need not define his invention with mathematical precision in order to comply with the definiteness requirement.” *Sonix Tech. Co., Ltd v. Publ'ns Int'l, Ltd.*, 844 F.3d 1370, 1377 (Fed. Cir. 2017).

#### **G. Enablement**

69. A patent may be enabling even though it does not expressly state some information if a person of ordinary skill in the field could make and use the invention without having to perform undue experimentation. 35 U.S.C. § 112 ¶ 1; *Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1384 (Fed. Cir. 1986).

70. Factors considered in determining whether experimentation is undue or excessive include: (1) the scope of the claimed invention; (2) the amount of guidance presented in the patent; (3) the amount of experimentation necessary; (4) the time and cost of any necessary experimentation; (5) how routine any necessary experimentation is in the applicable field; (6) whether the patent discloses specific

working examples of the claimed invention; (7) the nature and predictability of the field; and (8) the level of ordinary skill in the field. *In re Wands*, 858 F.2d 731, 737 (Fed. Cir. 1988).

71. Even a considerable amount of routine experimentation required to practice a claimed invention does not violate the enablement requirement.

*Cephalon, Inc. v. Watson Pharms., Inc.*, 707 F.3d 1330, 1336 (Fed. Cir. 2013);

*PPG Indus. v. Guardian Indus. Corp.*, 75 F.3d 1558, 1565 (Fed. Cir. 1996).

72. The specification preferably omits information that would already be known to a POSA. *Streck v. Res. & Diagnostic Sys., Inc.*, 665 F.3d 1269, 1288 (Fed. Cir. 2012).

73. It is irrelevant whether the specification contains data proving that embodiments within the scope of the claims are operable, and the burden is on the party alleging invalidity to prove a significant number of inoperable embodiments.

*Alcon Res. Ltd. v. Barr Labs., Inc.*, 745 F.3d 1180, 1188-90 (Fed. Cir. 2014); *Atlas*

*Powder Co. v. E.I. du Pont De Nemours & Co.*, 750 F.2d 1569, 1576-77 (Fed. Cir.

1984). There is no lack of enablement where a POSA would recognize

compositions that must be excluded from the inoperative embodiment inquiry.

*Senju Pharm. Co. v. Apotex Inc.*, 717 F. Supp. 2d 404, 428-29 (D. Del. 2010).

## H. Written Description

74. The written description requirement is met if the specification and the existing knowledge in the art reasonably convey “to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” *Ariad Pharm., Inc. v. Eli Lilly & Co.*, 598 F.3d 1336, 1355 (Fed. Cir. 2010). The test for reasonably conveying possession of an invention is a flexible one, “requir[ing] an objective inquiry into the four corners of the specification from the perspective of a [POSA].” *Id.*

75. A failure to “specifically mention a limitation that later appears in the claims is not a fatal one when one skilled in the art would recognize upon reading the specification that the new language reflects what the specification shows has been invented.” *All Dental Prodx, LLC v. Advantage Dentals Prods, Inc.*, 309 F.3d 774, 779 (Fed. Cir. 2002).

76. A specification implicitly satisfies the written description requirement if a POSA would find it “reasonably clear what the invention is and that the patent specification conveys that meaning.” *All Dental Prodx.*, 309 F.3d at 779. That is, the “reasonably conveys” standard does not require the disclosure and claims to match exactly. *Ariad Pharm.*, 598 F.3d at 1352 (“the [written] description requirement does not demand any particular form of disclosure or that the specification recite the claimed invention *in haec verba*”).

77. Nor will a claim be invalidated simply because the embodiments of the specification do not contain examples explicitly covering the full scope of the claim language. *See Ralston Purina Co. v. Far-Mar-Co., Inc.*, 772 F.2d 1570, 1575-76 (Fed. Cir. 1985).

## V. ENFORCEABILITY

78. Inequitable conduct is an equitable defense to patent infringement that, if proven, may preclude enforcement of a patent. *Therasense, Inc. v. Becton, Dickinson and Co.*, 649 F.3d 1276, 1287-90 (Fed. Cir. 2011).

79. To prove inequitable conduct, a challenger must demonstrate both that a person having a duty of candor and good faith to the PTO withheld or misrepresented information, or submitted false information, that was material to the examination of the patent application, and that this individual or individuals acted with the specific intent to deceive or mislead the PTO. *Id.*; *see also Outside the Box Innovations, LLC v. Travel Caddy, Inc.*, 695 F.3d 1285, 1290 (Fed. Cir. 2012).

80. Materiality and intent to deceive are separate requirements that must each be proven by clear and convincing evidence. *Therasense*, 649 F.3d at 1287. If the accused infringer meets this burden, the district court must weigh

the equities to determine whether the applicant’s conduct before the PTO warrants rendering the entire patent unenforceable. *Id.*

81. In its seminal *en banc* *Therasense* decision, the Federal Circuit noted that the doctrine originated from a line of Supreme Court cases, each dealing with “particularly egregious misconduct, including perjury, the manufacture of false evidence, and the suppression of evidence.” *Id.* Subsequent lower court cases broadening the doctrine had “numerous unforeseen and unintended consequences,” including, “[m]ost prominently,” that the defense “has become a significant litigation strategy.” *Id.* at 1288. The Court decried the fact that litigants have flooded the courts with inequitable conduct allegations “routinely brought on ‘the slenderest grounds,’” finding that this “has plagued not only the courts but also the entire patent system.” *Id.* at 1289 (citation omitted).

82. In an effort to stem that tide, the *en banc* Court “now tightens the standards for finding both intent and materiality in order to redirect a doctrine that has been overused to the detriment of the public.” *Id.* at 1290.

83. “[T]he specific intent to deceive must be the single most reasonable inference able to be drawn from the evidence. . . . [W]hen there are multiple reasonable inferences that may be drawn, intent to deceive cannot be found.” *Id.* at 1290-91 (internal citation omitted).

84. There can be no inference of intent to deceive based solely on materiality. There must be a deliberate and conscious decision to withhold or misrepresent the information. *See id.* at 1290 (“A district court should not use a ‘sliding scale,’ where a weak showing of intent may be found sufficient based on a strong showing of materiality, and vice versa.”).

85. Moreover, “[a] finding that the misrepresentation or omission amounts to gross negligence or negligence under a ‘should have known’ standard does not satisfy this intent requirement.” *Id.* at 1290.

86. “[T]he materiality required to establish inequitable conduct is but-for materiality. When an applicant fails to disclose prior art to the PTO, that prior art is but-for material if the PTO would not have allowed a claim had it been aware of the undisclosed prior art.” *Id.* at 1291. “But-for” materiality requires “proof that the patentee withheld or misrepresented information that, in the absence of the withholding or misrepresentation, would have prevented a patent claim from issuing.” *Ohio Willow Wood Co. v. Alps South, LLC*, 735 F.3d 1333, 1345 (Fed. Cir. 2013) (citing *Therasense*, 649 F.3d at 1291). This is a reflection of “basic fairness”—a patent should only be rendered unenforceable “in instances where the patentee’s misconduct resulted in the unfair benefit of receiving an unwarranted claim.” *Therasense*, 649 F.3d at 1292.

87. “In a case involving nondisclosure of information, clear and convincing evidence must show that the applicant made a deliberate decision to withhold a known material reference.” *Therasense*, 649 F.3d at 1292 (citing *Molins PLC v. Textron, Inc.*, 48 F.3d 1172, 1181 (Fed. Cir. 1995)).

## VI. PATENT MISUSE

88. The doctrine of patent misuse has a “narrow scope.” *Princo Corp. v. Int'l Trade Comm'n*, 616 F.3d 1318, 1329 (Fed. Cir. 2010).

89. To establish patent misuse, the accused infringer must show that the patentee has committed wrongful conduct “in one of the specific ways that have been held to be outside the otherwise broad scope of the patent grant.” *Princo Corp. v. Int'l Trade Comm'n*, 616 F.3d 1318, 1329 (Fed. Cir. 2010); *see also Virginia Panel Corp. v. MAC Panel Co.*, 133 F.3d 860, 868 (Fed. Cir. 1997) (“[I]n application, the doctrine [of patent misuse] has largely been confined to a handful of specific practices by which the patentee seemed to be trying to ‘extend’ his patent grant beyond its statutory limits.”).

## VII. STANDING/OWNERSHIP

90. “[W]hether a party has standing to sue in federal court is a question of federal law.” *Paradise Creations, Inc. v. UV Sales, Inc.*, 315 F.3d 1304, 1308 (Fed. Cir. 2003).

### A. Assignee

91. “An assignee may bring an action to redress any violations of the exclusive rights conferred by the patent.” *Minco, Inc. v. Combustion Eng’g, Inc.*, 95 F.3d 1109, 1117 (Fed. Cir. 1996). “A grant of all substantial rights in a patent amounts to an assignment—that is, a transfer of title in the patent—which confers constitutional standing on the assignee to sue another for patent infringement in its own name.” *Intellectual Prop. Dev., Inc. v. TCI Cablevision of Cal., Inc.*, 248 F.3d 1333, 1345 (Fed. Cir. 2001).

**B. Exclusive Licensee**

92. “Because the legally protected interests in a patent are the exclusionary rights created by the Patent Act, a party holding one or more of those exclusionary rights—such as an exclusive licensee—suffers a legally cognizable injury when an unauthorized party encroaches upon those rights and therefore has standing to sue.” *WiAV Sols. v. Motorola, Inc.*, 631 F.3d 1257, 1264-65 (Fed. Cir 2010).

93. “[A]n exclusive licensee does not lack constitutional standing to assert its rights under the licensed patent merely because its license is subject not only to rights in existence at the time of the license but also to future licenses that may be granted only to parties other than the accused.” *WiAV Sols. v. Motorola, Inc.*, 631 F.3d 1257, 1267 (Fed. Cir 2010).

94. “To be an exclusive licensee for standing purposes, a party must have received, not only the right to practice the invention within a given territory, but also the patentee’s express or implied promise that others shall be excluded from practicing the invention within that territory as well.” *Rite-Hite Corp. v. Kelley Co.*, 56 F.3d 1538, 1552 (Fed. Cir. 1995) (en banc).

95. “Whether a party possesses all substantial rights in a patent does not implicate standing or subject-matter jurisdiction.” *Lone Star Silicon Innovations LLC v. Nanya Tech. Corp.*, 925 F.3d 1225, 1235-36 (Fed. Cir. 2019)

96. “[I]n determining patent and license rights in complex transfers, the standard is whether the evidence as a whole convinces the trier of fact of mutual intent to transfer and vest exclusive rights.” *Sanofi-Aventis Deutschland GmbH v. Glenmark Pharms. Inc.*, 748 F.3d 1354, 1364 (Fed. Cir. 2014).

97. Exclusive distributors have standing to collect lost profits as a co-plaintiff with patentee if evidence shows that “an oral contract existed between [patentee] and [distributor], under which [distributor] had an exclusive right to sell as sole distributor in the United States.” *Weinar v. Rollform*, 744 F.2d 797 (Fed. Cir. 1984).

98. A multinational company’s decision and agreement that one corporate affiliate will exclusively hold FDA authorization to sell products covered by another affiliate’s patents, for example through ownership of a New Drug

Application, supports a finding that the one affiliate is an exclusive licensee of the relevant patents. *Sanofi-Aventis Deutschland GmbH v. Glenmark Pharms. Inc.*, 748 F.3d 1354, 1363–65 (Fed. Cir. 2014).

99. Parent corporations have an implied exclusive license to their subsidiary's patent when (1) the “decision to bring [a] lawsuit [is] made within [the parent]”; (2) the parent “sets the licensing policy for [the subsidiary’s] intellectual property,” including the patent in suit; and (3) witnesses testify in support of the exclusive license. *Cognex Corp. v. Microscan Sys., Inc.*, No. 13-cv-2027, 2014 WL 2989975, at \*5-6 (S.D.N.Y. June 30, 2014).

100. Parent corporations have an exclusive license to their subsidiary's patent when the patent owner is the wholly-owned subsidiary of the parent, and the parent “always ha[s] the implicit right to make, use and sell the patented invention and to control enforcement of the patent rights.” *Atmel Corp. v. Authentec, Inc.*, 490 F. Supp. 2d 1052, 1055 (N.D. Cal. 2007)

## VIII. DAMAGES

101. When determining damages, the factfinder must ask “how much had the Patent Holder and Licensee suffered by the infringement”—in other words, “had the Infringer not infringed, what would the Patentee Holder–Licensee have made?” *Aro Mfg. Co. v. Convertible Top Replacement Co.*, 377 U.S. 476, 653 (1964).

102. When damages “cannot be ascertained with precision, any doubts regarding the amount must be resolved against the infringer.” *Lam, Inc. v. Johns-Mansville Corp.*, 718 F.2d 1056, 1065 (Fed. Cir. 1983).

103. The calculation of damages is fact and case specific, involving “mixed considerations of logic, common sense, justice, policy and precedent.” *Rite-Hite Corp. v. Kelley Co., Inc.*, 56 F.3d 1538, 1545 (Fed. Cir. 1995).

104. The Federal Circuit has expressed skepticism about using transfer pricing in a damages analysis. *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, 778 F.3d 1365, 1377 (Fed. Cir. 2015).

105. Damages are computed before taxes. *Hanover Shoe, Inc. v. United Shoe Mach. Corp.*, 392 U.S. 481, 503 (1968); *Kalman v. Berwyn Corp.*, 914 F.3d 1473, 1483 (Fed. Cir. 1990).

#### A. Lost Profits

106. To recover lost profits, “the patentee must show a reasonable probability that, ‘but for’ the infringement, it would have made the sales that were made by the infringer.” *Rite-Hite Corp. v. Kelley Co., Inc.*, 56 F.3d 1538, 1545 (Fed. Cir. 1995).

107. The patentee “need not negate every possibility that the purchaser might not have purchased a product other than its own,” but rather “need only show that there was a reasonable probability that the sales would have been made

‘but for’ the infringement.” *Rite-Hite Corp. v. Kelley Co., Inc.*, 56 F.3d 1538, 1545 (Fed. Cir. 1995).

108. A patentee proves entitlement to lost profits damages by establishing the four *Panduit* factors: “(1) demand for the patented product; (2) absence of acceptable non-infringing substitutes; (3) manufacturing and marketing capability to exploit the demand; and (4) the amount of the profit it would have made.” *Rite-Hite Corp. v. Kelley Co., Inc.*, 56 F.3d 1538, 1545 (Fed. Cir. 1995).

109. The first factor—“demand for the patented product”—“simply asks whether demand existed for the ‘patented product,’ i.e., a product that is covered by the patent in suit or that directly competes with the infringing device.” *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 567 F.3d 1314, 1331 (Fed. Cir. 2009). Further, “the focus on particular features corresponding to individual claim limitations is unnecessary when considering whether demand exists for a patented product.” *Id.* And “the *Panduit* factors place no qualitative requirement on the level of demand necessary to show lost profits.” *Versata Software, Inc. v. SAP Am., Inc.*, 717 F.3d 1255, 1265 (Fed. Cir. 2013).

110. “The substantial number of sales by [the accused infringer] of infringing products containing the patented features itself is compelling evidence of the demand for the product.” *Gyromat Corp. v. Champion Spark Plug Co.*, 735 F.2d 549, 552 (Fed. Cir. 1984).

111. To prove the second factor—“absence of acceptable non-infringing substitutes”—“the patent owner must show either that: 1) the purchasers in the marketplace generally were willing to buy the patented product for its advantages; or 2) the specific purchasers of the infringing product purchased on that basis.”

*Standard Havens Prods., Inc. v. Gencor Indus., Inc.*, 953 F.2d 1360, 1373 (Fed. Cir. 1991).

112. “[T]o be an acceptable non-infringing substitute, the product or process must have been available *or* on the market at the time of infringement.” *Grain Processing Corp. v. Am. Maize-Products Co.*, 185 F.3d 1341, 1353 (Fed. Cir. 1999).

113. “When an alleged alternative is not on the market during the accounting period, a trial court may reasonably infer that it was not available as a noninfringing substitute at that time . . . [a]cceptable substitutes that the infringer proves were available during the accounting period can preclude or limit lost profits; substitutes only theoretically possible will not.” *Grain Processing Corp. v. Am. Maize-Products Co.*, 185 F.3d 1341, 1353 (Fed. Cir. 1999).

114. For this factor, “[t]he critical time period for determining availability of an alternative is the period of infringement for which the patent owner claims damages, i.e., the ‘accounting period.’” *Grain Processing Corp. v. Am. Maize-Products Co.*, 185 F.3d 1341, 1353 (Fed. Cir. 1999).

115. “Evidence that a patented device filled a long-felt need of its users and enjoyed commercial success indicates a lack of an acceptable noninfringing substitute.” *Micro Motion, Inc. v. Exac Corp.*, 761 F. Supp. 1420, 1424 (N.D. Cal. 1991) (citing *Panduit Corp. v. Stahlin Bros. Fibre Works, Inc.*, 575 F.2d 1152, 1162 (6th Cir.1978)).

116. Further, “the mere existence of a competing device does not necessarily make that device an acceptable substitute.” *Standard Havens Prods., Inc. v. Gencor Indus., Inc.*, 953 F.2d 1360, 1373 (Fed. Cir. 1991).

117. Willful infringement can undermine an accused infringer’s identification of acceptable non-infringing substitutes. *See Stryker Corp. v. Intermedics Orthopedics, Inc.*, 96 F.3d 1409, 1418 n.3 (Fed. Cir. 1996)

118. To prove the absence of acceptable non-infringing substitutes, the law requires exclusion not only of proven infringers, but also of “likely infringers.” *State Indus., Inc. v. Mor-Flo Indus., Inc.*, 883 F.2d 1573, 1578 (Fed. Cir. 1989).

119. The third factor—capacity—can be met by showing that the patent owner “had the capacity to manufacture and sell” enough of the product to meet the added demand. *See Fonar Corp. v. Gen. Elec. Co.*, 107 F.3d 1543, 1553 (Fed. Cir. 1997).

120. A patentee’s ability to sell its market share of an accused infringer’s infringing sales can be inferred from a finding that the patentee “had sufficient

marketing and manufacturing capabilities to meet its market share of the demand.”

*State Indus., Inc. v. Mor-Flo Indus., Inc.*, 883 F.2d 1573, 1578 (Fed. Cir. 1989).

121. “[P]ast business practices and relationships are probative of the ability to meet demand.” *TEK Global, S.R.L. v. Sealant Sys. Int'l, Inc.*, 920 F.3d 777, 790 (Fed. Cir. 2019).

122. For establishing the fourth factor—amount of profit—a “well established and appropriate” approach is to award the patentee its “incremental profit” that “reflect[s] the percentage of sales revenue [patentee] lost because of [defendant's] infringement that would have been its profit.” *State Indus., Inc. v. Mor-Flo Indus., Inc.*, 883 F.2d 1573, 1579-80 (Fed. Cir. 1989). Thus, a court acts “well within its discretion when it award[s] damages for [the defendant's] infringement based on [patentee's] share of the market.” *Id.* at 1580. However, “choosing between reasonable alternative accounting methods for determining profit margin” is a discretionary decision for the Court and is reviewed under the abuse of discretion standard. *Minnesota Mining & Mfg. Co. v. Johnson and Johnson Orthopaedics, Inc.*, 976 F.3d 1559, 1577 (Fed. Cir. 1992).

123. The proper approach to allocating costs is to use cost-accounting principles, which provide for the deduction of variable costs associated with a sale. See *Paper Converting Mach. Co. v. Magna-Graphics Corp.*, 745 F.2d 11, 22 (Fed. Cir. 1984).

**B. Reasonable Royalty**

124. “Upon finding for the claimant the court shall award the claimant damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer, together with interest and costs as fixed by the court.” 35 U.S.C. § 284.

125. In determining a reasonable royalty, factfinders consider the following factors: “(1) The royalties received by the patentee for the licensing of the patent in suit, proving or tending to prove an established royalty; (2) The rates paid by the licensee for the use of other patents comparable to the patent in suit; (3) The nature and scope of the license, as exclusive or non-exclusive; or as restricted or non-restricted in terms of territory or with respect to whom the manufactured product may be sold; (4) The licensor’s established policy and marketing program to maintain his patent monopoly by not licensing others to use the invention or by granting licenses under special conditions designed to preserve that monopoly; (5) The commercial relationship between the licensor and licensee, such as, whether they are competitors in the same territory in the same line of business; or whether they are inventor and promoter; (6) The effect of selling the patented specialty in promoting sales of other products of the licensee; that existing value of the invention to the licensor as a generator of sales of his non-patented items; and the extent of such derivative or convoyed sales; (7) The duration of the patent and the

term of the license; (8) The established profitability of the product made under the patent; its commercial success; and its current popularity; (9) The utility and advantages of the patent property over the old modes or devices, if any, that had been used for working out similar results; (10) The nature of the patented invention; the character of the commercial embodiment of it as owned and produced by the licensor; and the benefits to those who have used the invention; (11) The extent to which the infringer has made use of the invention; and any evidence probative of the value of that use; (12) The portion of the profit or of the selling price that may be customary in the particular business or in comparable businesses to allow for the use of the invention or analogous inventions; (13) The portion of the realizable profit that should be credited to the invention as distinguished from non-patented elements, the manufacturing process, business risks, or significant features or improvements added by the infringer; (14) The opinion testimony of qualified experts; (15) The amount that a licensor (such as the patentee) and a licensee (such as the infringer) would have agreed upon (at the time the infringement began) if both had been reasonably and voluntarily trying to reach an agreement; that is, the amount which a prudent licensee—who desired, as a business proposition, to obtain a license to manufacture and sell a particular article embodying the patented invention—would have been willing to pay as a royalty and yet be able to make a reasonable profit and which amount would have

been acceptable by a prudent patentee who was willing to grant a license.”

*Georgia-Pacific Corp. v. U.S. Plywood Corp.*, 318 F. Supp. 1116, 1120-21 (S.D.N.Y. 1970).

## IX. INJUNCTION

126. A plaintiff seeking a permanent injunction must demonstrate “(1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391 (2006).

127. Money damages cannot compensate for “lost market share, lost business opportunities, and price erosion.” *Robert Bosch LLC v. Pylon Mfg. Corp.*, 659 F.3d 1142, 1155 (Fed. Cir. 2011). Therefore, “[i]rreparable injury encompasses different types of losses that are often difficult to quantify, including lost sales and erosion in reputation and brand distinction.” *Douglas Dynamics, LLC v. Buyers Prods. Co.*, 717 F.3d 1336, 1344 (Fed. Cir. 2013).

128. A patentee suffers irreparable harm when it is “forced to compete against products that incorporate and infringe its own patented inventions.”

*Douglas Dynamics, LLC v. Buyers Prods. Co.*, 717 F.3d 1336, 1345 (Fed. Cir. 2013).

129. The balance of the hardships favors a patentee when “requiring [patentee] to compete against its own patented invention . . . places a substantial hardship on [patentee].” *Robert Bosch LLC v. Pylon Mfg. Corp.*, 659 F.3d 1142, 1156 (Fed. Cir. 2011).

130. In considering the public interest, the Federal Circuit has “long acknowledged the importance of the patent system in encouraging innovation,” and that “encouragement of investment-based risk is the fundamental purpose of the patent grant, and is based directly on the right to exclude.” *Sanofi-Synthelabo v. Apotex, Inc.*, 470 F.3d 1368, 1383 (Fed. Cir. 2006).

131. The “detrimental effect” of inhibiting innovation, “coupled with the public’s general interest in the judicial protection of property rights in inventive technology, outweighs any interest the public has in purchasing cheaper infringing products.” *Douglas Dynamics, LLC v. Buyers Prods. Co.*, 717 F.3d 1336, 1345 (Fed. Cir. 2013).

# **SCHEDULE 5**

SCHEDULE 5

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC	)	
CORPORATION	)	
and BOSTON SCIENTIFIC SCIMED,	)	
INC.,	)	
	) C.A. No. 18-1869-SB/CJB	
Plaintiffs,	)	
	)	
v.	)	
	)	
MICRO-TECH ENDOSCOPY USA	)	
INC.,	)	
MICRO-TECH (NANJING) CO.,	)	
LTD., and	)	
HENRY SCHEIN INC.,	)	
	)	
Defendants.	)	

**DEFENDANTS' STATEMENT OF CONTESTED ISSUES OF LAW**

## **INTRODUCTION**

Defendants identify the following issues of law to be litigated. This statement is based on the parties' pleadings, documentary and testimony evidence, and Defendants' current understanding of Plaintiffs' claims. As the parties are still finalizing and exchanging the evidence each intends to present at trial, Defendants reserve the rights to supplement this statement to rebut or otherwise address the issues of law raised or otherwise identified by Plaintiffs. Defendants further reserve the right to supplement this statement to incorporate legal issues raised by Plaintiffs' proposed jury instructions.

If the Court concludes that any issues of fact listed in Schedule 3 of the Joint Pretrial Order should be considered as issues of law, then Defendants incorporate those issues in this Schedule. If the Court concludes that any issues identified in this Schedule should be considered as issues of fact, then Defendants incorporate those issues into Schedule 3 of the Joint Pretrial Order. Defendants' issues of law to be litigated may also change based on the Court's rulings on pending motions and other pretrial rulings. Defendants reserve the right to present issues of law set forth in the pending motions, if they have not been resolved by the Court before trial. Defendants further reserve their rights to appeal any issues, whether legal holdings or factual findings. The authorities cited herein are not exhaustive; Defendants may rely upon authorities not cited in this statement.

## I. INFRINGEMENT

Defendants incorporate by reference their pending motions for summary judgment of non-infringement. (D.I. 246, 248, 251, 252, 254, and 255).

### A. Infringement Generally

1. Plaintiffs bear the burden of proving by a preponderance of evidence whether Defendants infringed. *Advanced Cardiovascular Sys., Inc. v. Scimed Life Sys., Inc.*, 261 F.3d 1329, 1336 (Fed. Cir. 2001).

2. A party infringes a patent when it, without authority, “makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent.” 35 U.S.C. § 271(a).

3. Determining infringement of a patent claim requires two steps: first, interpreting the language of the claim to determine its meaning and scope, and second, comparing the construed claim to the accused device to determine whether all of the claim elements or their equivalents are present. See *Moore U.S.A., Inc. v. Standard Register Co.*, 229 F.3d 1091, 1105 (Fed. Cir. 2000); *Rexnord Corp. v. Laitram Corp.*, 274 F.3d 1336, 1341 (Fed. Cir. 2001). Claim construction is a matter of law to be decided by the Court. *Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 979-81 (Fed. Cir. 1995) (en banc), *aff'd*, 517 U.S. 370 (1996). Whether claims, as construed by the Court, are infringed is a question of fact to be

SCHEDULE 5

determined by the jury. *Ferguson Beauregard/Logic Controls, Div. of Dover Res., Inc. v. Mega Sys., LLC*, 350 F.3d 1327, 1338 (Fed. Cir. 2003).

4. “Once a district court has construed the relevant claim terms, and unless altered by the district court, then that legal determination governs for purposes of trial. No party may contradict the court's construction to a jury.” *Exergen Corp. v. Wal-Mart Stores, Inc.*, 575 F.3d 1312, 1321 (Fed. Cir. 2009); see also *EMC Corp. v. Pure Storage Inc.*, 154 F. Supp. 3d 81, 108-10 (D. Del. 2016); accord, e.g., *Integra Lifesciences Corp. v. HyperBranch Med. Tech., Inc.*, No. 15-819-LPS-CJB, 2018 WL 1785033, at \*4-5 (D. Del. Apr. 4, 2018); *Kraft Foods Grp. Brands LLC v. TC Heartland, LLC*, 232 F. Supp. 3d 632, 635 (D. Del. 2017).

5. “To prove [patent] infringement, the patentee must show that the accused device meets each claim limitation, either literally or under the doctrine of equivalents.” *PSC Comput. Prods., Inc. v. Foxconn Int'l, Inc.*, 355 F.3d 1353, 1357 (Fed. Cir. 2004).

**B. Literal Infringement**

6. “To establish literal infringement, every limitation set forth in a claim must be found in an accused product, exactly.” *Southwall Techs., Inc. v. Cardinal IG Co.*, 54 F.3d 1570, 1575 (Fed. Cir. 1995). For method claims, direct infringement occurs only when an accused method or product performs all of the steps of the claimed process. See *Joy Techs., Inc. v. Flakt, Inc.*, 6 F.3d 770, 773

SCHEDULE 5

(Fed. Cir. 1993) (“[A] method or process claim is directly infringed only when the process is performed.”); *Canton Bio-Med., Inc. v. Integrated Liner Techs., Inc.*, 216 F.3d 1367, 1370 (Fed. Cir. 2000) (“Infringement of process inventions is subject to the ‘all-elements rule’ whereby each of the claimed steps of a patented process must be performed in an infringing process....”). If an accused infringer does not infringe an independent claim, then the claims that depend on it are also not infringed as a matter of law. *Monsanto Co. v. Syngenta Seeds, Inc.*, 503 F.3d 1352, 1359 (Fed. Cir. 2007) (en banc).

7. In the situation where a party does not perform or use each and every step or element of the patent claim, to prove direct infringement the patentee must allege a joint infringer theory in which “the acts of one are attributable to the other such that a single entity is responsible for the infringement.” *Akamai Techs., Inc. v. Limelight Networks, Inc.*, 797 F.3d 1020, 1022 (Fed. Cir. 2015) (en banc) (per curiam). To show that the performance of method steps is attributable to a single entity, the patentee must prove that a party (1) directed or controlled a third party to carry out or use certain steps or elements of the patented method or product, or (2) the party and the third party constitute “a joint enterprise.” See, e.g., *Akamai Techs.*, 797 F.3d at 1022-23. “Direction or control” arises when the third party performs the steps of the patented process or uses the elements of the patented product by virtue of a contractual obligation or other relationship that gives rise to

SCHEDULE 5

vicarious liability. *See id.* Liability “can also be found when an alleged infringer conditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance.” *Id.* at 1023. “Whether a single actor directed or controlled the acts of one or more third parties is a question of fact....” *Id.*

**C. Doctrine of Equivalents**

8. The doctrine of equivalents is not “simply the second prong of every infringement charge, regularly available to extend protection beyond the scope of the claims.” *Amgen Inc. v. Sandoz Inc.*, 923 F.3d 1023, 1029 (Fed. Cir. 2019). As discussed below, a plaintiff must plead and support a claim of infringement under the doctrine of equivalence by affirmatively showing, *inter alia*, that its claim does not attempt to recapture subject matter surrendered during prosecution by a narrowing amendment or “ensnare” the prior art.

9. If sufficiently alleged and supported (which Plaintiffs’ DOE claims are not), infringement under the doctrine of equivalents is generally a question of fact. *Stryker Corp. v. Davol Inc.*, 234 F.3d 1252, 1258 (Fed. Cir. 2000). The jury must determine whether the differences between the accused products and the claim elements are insubstantial. *Warner-Jenkinson Co. v. Hilton-Davis Chem. Co.*, 520 U.S. 17, 38-39 (1997).

SCHEDULE 5

10. Infringement under the doctrine of equivalents requires that equivalency be proven by particularized testimony and linking argument as to the insubstantiality of the differences between the claimed invention and the accused device. *Tex. Instruments Inc. v. Cypress Semiconductor Corp.*, 90 F.3d 1558, 1567 (Fed. Cir. 1996).

11. “Generalized testimony as to the overall similarity between the claims and the accused infringer’s product or process will not suffice.” *Gemalto S.A. v. HTC Corp.*, 754 F.3d 1364, 1373-74, 111 U.S.P.Q.2d (Fed. Cir. 2014); see also *Miken Composites, L.L.C. v. Wilson Sporting Goods Co.*, 515 F.3d 1331, 1340–41, 85 USPQ2d 1865, 1872 (Fed. Cir. 2008); *Tex. Instruments Inc. v. Cypress Semiconductor Corp.*, 90 F.3d 1558, 1567 (Fed. Cir. 1996).

12. Evidence of infringement under the doctrine of equivalents must be presented on a limitation-by-limitation basis, and not based on the invention as a whole. *Motionless Keyboard Co. v. Microsoft Corp.*, 486 F.3d 1376, 1383 (Fed. Cir. 2007); *Freedom Seating Co. v. Am. Seating Co.*, 420 F.3d 1350, 1358 (Fed. Cir. 2005) (citing *Warner-Jenkinson*, 520 U.S. at 29). Thus, infringement under the doctrine of equivalents requires the patentee to show that for every element of the claim that is not literally present in the accused method or product, the accused method or product contains a substitute element that is only an

SCHEDULE 5

insubstantial difference from the claimed element. *See AquaTex Indus., Inc. v. Techniche Sols.*, 479 F.3d 1320, 1326 (Fed. Cir. 2007).

13. One test often applied by courts to evaluate whether a difference is insubstantial is whether the element in the accused product performs the substantially same function in substantially the same way with substantially the same result as the corresponding claim limitation. *Id.*

14. However, the patentee may not use the doctrine of equivalents to vitiate a claim limitation entirely. *See Warner-Jenkinson*, 520 U.S. at 39 n.8; *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 567 F.3d 1314, 1323 (Fed. Cir. 2009). Whether a theory of equivalence would vitiate a claim limitation entirely is a legal question for the Court to decide. *Id.*

**D. Prosecution History Estoppel**

15. The doctrine of prosecution history estoppel prevents a patentee from using the doctrine of equivalents to recapture subject matter that was relinquished during prosecution of the patent. *Id.* Although the defense of prosecution history estoppel involves underlying factual issues that may be submitted to the jury, it is ultimately a legal question for the Court to decide. *DePuy Spine*, 567 F.3d at 1323-24.

16. When “the patentee originally claimed the subject matter alleged to infringe but then narrowed the claim in response to a rejection, he may not argue

that the surrendered territory comprised unforeseen subject matter that should be deemed equivalent to the literal claims of the issued patent.” *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 535 U.S. 722, 733-34 (2002). A narrowing amendment that adds an additional claim limitation to a patent claim creates a presumptive surrender of equivalents. *Honeywell Int'l Inc. v. Hamilton Sundstrand Corp.*, 370 F.3d 1131, 1141 (Fed. Cir. 2004) (en banc). The burden is on the patentee to establish that the reason for the amendment was not related to patentability. *Festo*, 535 U.S. at 739-40 (citing *Warner-Jenkinson*, 520 U.S. at 33).

17. Once the presumption of estoppel applies, the presumption of surrender may be rebutted only if the patentee can demonstrate that: (1) the alleged equivalent would have been unforeseeable at the time the narrowing amendment was made; (2) the rationale underlying the narrowing amendment bore no more than a tangential relation to the equivalent at issue; or (3) there was some other reason suggesting that the patentee could not reasonably have been expected to have described the alleged equivalent. *Honeywell*, 370 F.3d at 1140, 1144.

18. In addition to narrowing amendments, a clear and unmistakable surrender of claim territory in argument to the examiner of record can also estop the patentee from arguing for a broader claim scope in litigation. *Deering Precision Instruments, L.L.C. v. Vector Distribution Sys., Inc.*, 347 F.3d 1314, 1326 (Fed. Cir. 2003). Thus, “[c]lear assertions made during prosecution in

support of patentability, whether or not actually required to secure allowance of the claim, may also create an estoppel.” *Southwall Techs., Inc. v. Cardinal IG Co.*, 54 F.3d 1570, 1583 (Fed. Cir. 1995). Any argument-based estoppel affecting a limitation in one claim extends to all claims in which that limitation appears. *Id.* at 1584 (“Once an argument is made regarding a claim term so as to create an estoppel, the estoppel will apply to that term in other claims.”).

#### **E. Ensnarement**

19. Ensnarement is another “limitation on the reach of the doctrine” of equivalents, which specifies that a doctrine-of-equivalents infringement theory cannot “ensnare” the prior art. *Jang v. Bos. Sci. Corp.*, 872 F.3d 1275, 1284-85, 1287-88 (Fed. Cir. 2017); *DePuy Spine*, 567 F.3d at 1322-23; *Wilson Sporting Goods Co. v. David Geoffrey & Assocs.*, 904 F.2d 677, 683 (Fed. Cir. 1990), *overruled in part on other grounds by Cardinal Chem. Co. v. Morton Int'l, Inc.*, 508 U.S. 83 (1993). It is rooted in the well-established principle that a “patentee should not be able to obtain, under the doctrine of equivalents, coverage which he could not lawfully have obtained from the PTO by literal claims.” *We Care, Inc. v. Ultra-Mark Int'l Corp.*, 930 F.2d 1567, 1570 (Fed. Cir. 1991) (citation omitted). Thus, “even if a jury has found equivalence as to each claim element,” ensnarement “limits the scope of equivalency that a patentee is allowed to assert.” *DePuy Spine*, 567 F.3d at 1323; *see also Jang*, 872 F.3d at 1286. Although the

SCHEDULE 5

defense of ensnarement involves underlying factual issues that may be submitted to the jury, it is ultimately a legal question for the Court to decide. *Id.* at 1323-24.

20. To determine whether an asserted equivalence is permissible a patentee first “construct[s] a hypothetical claim that literally covers the accused device” and then the Court can “determine whether the patentee has carried its burden of persuading the court that the hypothetical claim is patentable over the prior art.” *Jang*, 872 F.3d at 1285 (quoting *Intendis GmbH v. Glenmark Pharm. Inc.*, USA, 822 F.3d 1355, 1363-64 (Fed. Cir. 2016)). This hypothetical claim “may not add any narrowing limitations.” *Jang*, 872 F.3d at 1286. If the patentee “fail[s] to submit a proper hypothetical claim for consideration,” the patentee has not met “his burden of proving that his doctrine of equivalents theory did not ensnare the prior art.” *Id.* at 1287. And if the patentee cannot prove that his claim would not ensnare the prior art, “then it would be improper to permit the patentee to obtain that coverage in an infringement suit under the doctrine of equivalents.” *Wilson Sporting Goods*, 904 F.2d at 684; *Jang*, 872 F.3d at 1285.

**F. Indirect Infringement—Active Inducement**

21. Plaintiffs bear the burden to prove indirect infringement by establishing whether Defendants induced infringement. *See Dynacore Holdings Corp. v. U.S. Philips Corp.*, 363 F.3d 1263, 1272 (Fed. Cir. 2004).

22. Inducement is a specific-intent tort. *DSU Med. Corp. v. JMS Co.*, 471 F.3d 1293, 1305 (Fed. Cir. 2006). To establish liability for inducement under 35 U.S.C. § 271(b), a patentee must prove by a preponderance of the evidence that “once the defendants knew of the patent, they actively and knowingly aided and abetted another’s direct infringement.” *Id.* (citation and internal quotations omitted); *see also Global-Tech Appliances, Inc. v. SEB S.A.*, 563 U.S. 754, 764-66 (2011); *ACCO Brands, Inc. v. ABA Locks Mfrs. Co.*, 501 F.3d 1307, 1312 (Fed. Cir. 2007).

23. Knowledge of the existence of the patent that is alleged to be infringed and knowledge that the induced acts constitute patent infringement are required to prove inducement. *Global-Tech Appliances, Inc.*, 563 U.S at 765-66. However, mere “knowledge of the acts alleged to constitute infringement” or of the possibility of infringement is insufficient. *DSU Med. Corp.*, 471 F.3d at 1305; *Warner-Lambert Co. v. Apotex Corp.*, 316 F.3d 1348, 1363-64 (Fed. Cir. 2003). Rather, “proof of actual intent to cause the” infringing acts “is a necessary prerequisite to finding active inducement.” *Warner-Lambert Co.*, 316 F.3d at 1363 (citations and internal quotations omitted).

24. The patent holder must also prove that direct infringement by a third party has occurred in order to establish a claim for indirect infringement. *See Epcon Gas Sys., Inc. v. Bauer Compressors, Inc.* 279 F.3d 1022, 1033 (Fed. Cir.

2002); *see also Dynacore*, 363 F.3d at 1272 (“Indirect infringement, whether inducement to infringe or contributory infringement, can only arise in the presence of direct infringement, though the direct infringer is typically someone other than the defendant accused of indirect infringement.”); *Joy Techs.*, 6 F.3d at 774 (“Liability for either active inducement of infringement or for contributory infringement is dependent upon the existence of direct infringement.”).

## II. WILLFUL INFRINGEMENT

25. Plaintiffs bear the burden to prove by a preponderance of the evidence that Defendants willfully infringed the asserted patents. *Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 136 S. Ct. 1923, 1934 (2016); *Bayer Healthcare LLC v. Baxalta Inc.*, 989 F.3d 964, 987 (Fed. Cir. 2021).

26. To establish willful infringement, the patentee must show that the alleged infringer’s conduct was subjectively willful. *See Halo*, 136 S. Ct. at 1933. A finding of subjective willfulness requires the patentee to “show the accused infringer had a specific intent to infringe at the time of the challenged conduct.” *Bayer*, 989 F.3d at 987; *see also Halo*, 136 S. Ct. at 1933 (“[C]ulpability is generally measured against the knowledge of the actor at the time of the challenged conduct.”). “Knowledge of the asserted patent and evidence of infringement is necessary, but not sufficient, for a finding of willfulness.” *Bayer*, 989 F.3d at 988.

27. The type of behavior typifying subjective willfulness is “willful, wanton, malicious, bad-faith, deliberate, consciously wrongful, flagrant, or—indeed—characteristic of a pirate.” *Halo*, 136 S. Ct. at 1932. As such, a finding of willful infringement is reserved for only the most egregious behavior. *Id.*

28. Even a finding of this sort of egregious infringing behavior does not mandate enhanced damages. *See id.* at 1933. Instead, in assessing whether the conduct warrants enhanced damages, a court should “take into account the particular circumstances of each case.” *Id.*

29. “The failure of an infringer to obtain the advice of counsel with respect to any allegedly infringed patent, or the failure of the infringer to present such advice to the court or jury, may not be used to prove that the accused infringer willfully infringed the patent or that the infringer intended to induce infringement of the patent.” 35 U.S.C. § 298.

### **III. COSTS AND FEES**

#### **A. Costs**

30. Federal Rule of Civil Procedure 54 states “[u]nless a federal statute, these rules, or a court order provides otherwise, costs—other than attorney’s fees—should be allowed to the prevailing party.” Fed. R. Civ. P. 54(d)(1). Section 1920 of Title 28 of the United States Code includes the following costs: (1) fees of the clerk and marshal; (2) fees for printed or electronically recorded transcripts necessarily obtained for use in this case; (3) fees and disbursements for printing

SCHEDULE 5

and witnesses; (4) fees for exemplification and the costs of making copies of any materials where the copies are necessarily obtained for use in the case; (5) docket fees under 28 U.S.C. § 1923; and (6) compensation of court appointed experts, compensation of interpreters, and salaries, fees, expenses, and costs of special interpretation serves under 28 U.S.C. § 1828. 28 U.S.C. § 1923; *see also* D. Del. L.R. 54.1.

31. “Whenever a claim of a patent is invalid, an action may be maintained for the infringement of a claim of the patent which may be valid. The patentee shall recover no costs unless a disclaimer of the invalid claim has been entered at the Patent and Trademark Office before the commencement of the suit.” 35 U.S.C. § 288.

**B. Exceptional Case**

32. Section 285 of Title 35 of the United States Code state that “[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party.” 35 U.S.C. § 285.

33. The party seeking attorneys’ fees has the burden of proving entitlement to fees under § 285 by a preponderance of evidence. *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, 134 S. Ct. 1749, 1758 (2014).

34. An exception case is “one that stands out from others with respect to the substantive strength of a party’s litigating position (considering both the

governing law and the facts of the case) or the unreasonable manner in which the case was litigated” and “[d]istrict courts may determine whether a case is ‘exceptional’ in the case-by-case exercise of their discretion, considering the totality of the circumstances.” *Id.* at 1756. Relevant considerations in assessing whether a case is exceptional including “frivolousness, motivation, objective unreasonableness (both in the factual and legal components of the case) and the need in particular circumstances to advance considerations of compensation and deterrence. *Id.* at 1756 n.6.

35. A patentee’s conduct may be objectively unreasonable, and thus support a finding of an exceptional case, when it presses claims of infringement that were based on claim construction positions rejected by the Court as being contrary to the specification and statements made by the patentee outside of litigation. *MarcTec, LLC v. Johnson & Johnson*, 664 F.3d 907, 916-18 (Fed. Cir. 2012)

36. A patentee’s conduct may be objectively unreasonable when its continuation of the litigation after proffering a weak claim construction position is “nothing more than an effort to keep a legitimate competitor out of the market on flimsy-to-nonexistent grounds.” *Astrazeneca AB v. Dr. Reddy's Laboratories, Ltd.*, 2010 WL 1375176, \*9 (S.D. N.Y. 2010).

#### **IV. VALIDITY**

SCHEDULE 5

**A. Prior Art**

37. A patent claim is invalid under 35 U.S.C. § 102(a)<sup>1</sup> if the invention defined by the claim was known or used by others in the United States or was patented or described in a printed publication. 35 U.S.C. § 102(a). A U.S. patent constitutes prior art to a claimed invention under 35 U.S.C. § 102(a) if the date of issuance of the patent is before the date of invention. 35 U.S.C. § 102(a).

38. A patent claim is invalid under 35 U.S.C. § 102(b) if the invention defined by the claim was patented or described in a printed publication anywhere in the world or was in public use or on sale in the United States more than one year before the effective filing date of the patent in the United States. 35 U.S.C. § 102(b). In other words, a U.S. or foreign patent constitutes prior art to a claimed invention under 35 U.S.C. § 102(b) if the date of issuance of the patent is more than one year before the effective filing date of a patent application claiming the invention. A printed publication constitutes prior art to a claimed invention under 35 U.S.C. § 102(b) if the publication takes place more than one year before the filing date of a patent application claiming the invention. *Id.*

39. A patent claim is invalid under 35 U.S.C. § 102(e) if the invention defined by the claim was described in a patent by another inventor that was filed in

---

<sup>1</sup> Citations to 35 U.S.C. § 102 are to the pre-America Invents Act (2011) version of the statute.

SCHEDULE 5

the United States before the applicants' invention date. 35 U.S.C. § 102(e). A U.S. patent constitutes prior art to a claimed invention under 35 U.S.C. § 102(e) if the patent issues from an application that was filed before the invention by the applicants. *Id.*

40. A patent claim is invalid under 35 U.S.C. § 102(g) if the invention defined by the claim was made in this country by another inventor who had not abandoned, suppressed, or concealed it before the applicants' invention date. 35 U.S.C. § 102(g). A device constitutes prior art under 35 U.S.C. § 102(g)(2) if it was conceived and reduced to practice in the United States before the filing date of the patent. 35 U.S.C. § 102(g)(2) ("before such person's invention thereof, the invention was made in this country by another inventor who had not abandoned, suppressed, or concealed it").

**B. Priority of Invention**

41. Plaintiffs bear the burden of proving that it is entitled to a priority date that predates the patent's filing date. *Tech. Licensing Corp. v. Videotek, Inc.*, 545 F.3d 1316, 1327-29 (Fed. Cir. 2008).

42. "Priority of invention and its constituent issues of conception and reduction to practice are questions of law predicated on subsidiary factual findings." *REG Synthetic Fuels, LLC v. Neste Oil Oyj*, 841 F.3d 954, 958 (Fed. Cir. 2016) (citation omitted).

43. An application may receive the benefit of the filing date of an earlier application only “if it contains or is amended to contain a specific reference to the earlier filed application.” 35 U.S.C. § 120 (pre-AIA). “No application shall be entitled to the benefit of an earlier filed application under this section unless an amendment containing the specific reference to the earlier filed application is submitted at such time during the pendency of the application...” *Id.*

44. “[W]hen a dispute arises concerning whether a CIP [continuation-in-part] patent is entitled to priority to the date of the original application ... the burden of proof ordinarily should rest with the party claiming priority to the date of the original application.” *PowerOasis, Inc. v. T-Mobile USA, Inc.*, 522 F.3d 1299, 1303 (Fed. Cir. 2008)

45. Prior inventorship under 35 U.S.C. § 102(g)(2) can be proven in two ways: “(1) [the prior inventor] reduced its invention first ..., or (2) it was the first party to conceive of the invention and then exercised reasonable diligence in reducing that invention to practice.” *Mycogen Plant Sci. v. Monsanto Co.*, 243 F.3d 1316, 1332 (Fed. Cir. 2001).

46. “To have conceived of an invention, an inventor must have formed in his or her mind a definite and permanent idea of the complete and operative invention.” *Mahurkar v. C.R. Bard, Inc.*, 79 F.3d 1572, 1577 (Fed. Cir. 1996) (internal quotations and citations omitted).

47. “Because it is a mental act, courts require corroborating evidence of a contemporaneous disclosure that would enable one skilled in the art to make the invention.” *Burroughs Wellcome Co. v. Barr Labs., Inc.*, 40 F.3d 1223, 1228 (Fed. Cir. 1994). Conception “must be proven by evidence showing what the inventor has disclosed to others and what that disclosure means to one of ordinary skill in the art.” *Cordance Corp. v. Amazon.com, Inc.*, 658 F.3d 1330, 1334 (Fed. Cir. 2001) (citation omitted).

48. “Reduction to practice follows conception.” *Muhurkar*, 79 F.3d at 1578. In order to establish an actual reduction to practice, the inventor must prove: “(1) construct[ion of] an embodiment or perform[ance] of a process that met all the limitations of the interference count; … (2) … determine[ation] that the invention would work for its intended purpose, and (3) the existence of sufficient evidence to corroborate inventor testimony regarding these events.” *Medichem, S.A. v. Rolabo, S.L.*, 437 F.3d 1157, 1169 (Fed. Cir. 2006) (citations omitted). Proof of actual reduction to practice requires “more than theoretical capability; it requires showing that the apparatus of the count actually existed and worked for its intended purpose.” *Newkirk v. Lulejian*, 825 F.2d 1581, 1583 (Fed. Cir. 1987). “[C]onstructive reduction to practice occurs when a patent application on the claimed invention is filed.” *Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1376 (Fed. Cir. 1986).

49. Where a party is first to conceive but second to reduce to practice, that party must demonstrate reasonable diligence toward reduction to practice from a date just prior to the other party's conception to its reduction to practice. *Mycogen Plant Sci.*, 261 F.3d at 1363-64.

### C. Anticipation

50. "Anticipation is a question of fact." *IPXL Holding, LLC v. Amazon.com, Inc.*, 430 F.3d 1377, 1380 (Fed. Cir. 2005).

51. "A reference is anticipatory under § 102(b) when it satisfies particular requirements. First, the reference must disclose each and every element of the claimed invention, whether it does so explicitly or inherently. While those elements must be 'arranged or combined in the same way as in the claim,' the reference need not satisfy an *ipsissimis verbis* test. Second, the reference must 'enable one or ordinary skill in the art to make the invention without undue experimentation.' As long as the reference discloses all of the claim limitations and enables the 'subject matter that falls within the scope of the claims at issue; the reference anticipates – no 'actual creation or reduction to practice' is required. This is so despite the fact that the description provided in the anticipating reference might not otherwise entitle its author to a patent." *In re Gleave*, 560 F.3d 1331, 1334 (Fed. Cir. 2009) (internal citations omitted).

52. Even if a prior art reference was considered by the Patent Office, anticipation arguments can be raised before the district court. *IPXL Holdings*, 430 F.3d at 1381. Further, “reliance on extrinsic evidence is proper” in demonstrating “what is ‘necessarily present’ in a prior art’s teaching.” *Monsanto Tech. LLC v. E.I. DuPont de Nemours & Co.*, 878 F.3d 1336, 1345 (Fed. Cir. 2018).

#### D. Obviousness

53. 35 U.S.C. § 103 provides that a patent claim is obvious “if the differences between subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.” 35 U.S.C. § 103(a). Obviousness is a question of law that relies on factual determinations. *KSR Int'l Co. v. Teleflex Inc.*, 550 U.S. 398, 427 (2007). The trier of fact must consider: (1) the scope and content of the prior art; (2) the differences between the prior art and the claims at issue; (3) the level of ordinary skill in the art; and (4) evidence of relevant secondary considerations. *Western Union Co. v. MoneyGram Payment Sys. Inc.*, 626 F.3d 1361, 1369 (Fed. Cir. 2010) (*citing Graham v. John Deere Co. of Kansas City*, 38 U.S. 1, 17 (1966)). The showing requires “some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.” *KSR*, 550 U.S. at 415-418.

54. Exemplary rationales that may support a conclusion of obviousness include:

- (i) combining prior art elements according to known methods to yield predictable results;
- (ii) simple substitution of one known element for another to obtain predictable results;
- (iii) use of known technique to improve similar devices (methods, or products) in the same way;
- (iv) applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;
- (v) choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success (“obvious to try”);
- (vi) known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;
- (vii) some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention.

*See generally KSR, 550 U.S. at 415-419.*

55. Where “there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense … the fact that a combination was obvious to try might show that it was obvious under § 103.” *KSR*, 550 U.S. at 421.

#### **E. Secondary Considerations**

56. Once a prima facie case of obviousness has been established, the patentee has the burden of coming forward with rebuttal evidence regarding secondary considerations of non-obviousness. *Prometheus Labs., Inc. v. Roxane Labs., Inc.*, 805 F.3d 1092, 1101 (Fed. Cir. 2015) (quotation omitted). Secondary considerations must be taken into account, but “do not necessarily control the obviousness conclusion.” *Pfizer*, 480 F.3d at 1372. Some of the factors to be considered as secondary considerations are: (i) copying; (ii) long felt but unresolved need; (iii) failure of others to develop the invention; (iv) licenses showing industry respect for the invention; (v) commercial success; (vi) unexpected results created by the claimed invention; (vii) whether the claimed invention was praised by others in the field; and (vii) skepticism of skilled artisans before the invention. *Cheese Sys. Inc.*, 725 F.3d at 1352-53.

57. For secondary considerations such as commercial success, long felt but unresolved need, and industry praise, “evidence of commercial success, or other secondary considerations, is only significant if there is a nexus between the claimed invention and the commercial success … Thus, if the commercial success is due to an unclaimed feature of the device, the commercial success is irrelevant. So too if the feature that creates the commercial success was known in the prior art, the success is not pertinent.” *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311-12 (Fed. Cir. 2006).

58. Additionally, for copying, “[n]ot every competing product that arguably falls within the scope of a patent is evidence of copying … [r]ather, copying requires the replication of a specific product. This may be demonstrated either through internal documents, direct evidence such as disassembling a patented prototype, photographing its features, and using the photograph as a blueprint to build a virtually identical replica.” *Iron Grip Barbell Co., Inc. v. USA Sports, Inc.*, 392 F.3d 1317, 1325 (Fed. Cir. 2004).

#### **F. Invalidity Based On Collateral Estoppel**

59. Collateral estoppel prevents a party from relitigating an issue when “(1) the issue sought to be precluded is the same as that involved in the prior action; (2) that issue was actually litigated; (3) it was determined by a final and valid judgment; and (4) the determination was essential to the prior judgment.”

*Peloro v. United States*, 488 F.3d 163, 175 (3d Cir. 2007). Whether collateral estoppel applies is a question of law. *Soverain Software LLC v. Victoria's Secret Direct Brand Mgt., LLC*, 778 F.3d 1311, 1314 (Fed. Cir. 2015).

60. Collateral estoppel “appl[ies] in a court case even though the first ‘action’ was before an administrative agency if the agency proceeding meets certain standards.” *Papst Licensing GMBH & Co. v. Samsung Elecs. Am.*, 924 F.3d 1243, 1250-51 (Fed. Cir. 2019) (citing *B&B Hardware, Inc. v. Hargis Indus., Inc.*, 135 S. Ct. 1293, 1303 (2015)). Proceedings before the PTAB meet the standards for collateral estoppel to apply in district court cases. *E.g.*, *id.*

61. “[C]ollateral estoppel is not limited ‘to patent claims that are identical. Rather it is the identity of the *issues* that were litigated that determines whether collateral estoppel should apply.’” *Ohio Willow Wood Co. v. Alps S. LLC*, 735 F.3d 1333, 1342 (Fed. Cir. 2013). A difference in claim scope does not preclude the application of collateral estoppel “[i]f the differences between the unadjudicated patent claims and adjudicated patents claims do not materially alter the question of invalidity.” *Soverain Software*, 778 F.3d at 1319. District courts thus have applied collateral estoppel when “the routine incorporation of known technology into a dependent claim does not change the analysis.” *Kimberly-Clark Worldwide Inc. v. First Quality Baby Prods. LLC*, 135 F. Supp. 3d 850, 856-57 (E.D. Wis. 2015).

## G. Indefiniteness

62. Whether a claim satisfies the definiteness requirement of 35 U.S.C. § 112 is a question of law. *In re Packard*, 751 F.3d 1307, 1311 (Fed. Cir. 2014).

63. “[A] patent is invalid for indefiniteness if its claims, read in light of the specification delineating the patent, and the prosecution history, fail to inform, with reasonable certainty, those skilled in the art about the scope of the invention.” *Nautilus, Inc. v. Biosig Instruments, Inc.*, 572 U.S. 898, 901 (2014). “[A] patent must be precise enough to afford clear notice of what is claimed, thereby ‘appris[ing] the public of what is still open to them.’ Otherwise there would be ‘[a] zone of uncertainty which enterprise and experimentation may enter only at the risk of infringement claims.’” *Id.* “The definiteness requirement … mandates clarity, while recognizing that absolute precision is unattainable.” *Id.* “Notably, a claim is indefinite if its language ‘might mean several different things and no informed and confident choice is available among the contending definitions.’” *Media Rights Techs., Inc. v. Capital One Financial Corp.*, 800 F.3d 1366, 1371 (Fed. Cir. 2015).

## H. Enablement

64. Enablement is a question of law based on underlying facts. *Wyeth and Cordis Corp. v. Abbott Labs.*, 720 F.3d 1380, 1384 (Fed. Cir. 2013).

65. “To be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without

undue experimentation.” *Trs. of Boston Univ. v. Everlight Elecs. Co.*, 896 F.3d 1357, 1362 (Fed. Cir. 2018) (quotation omitted). Courts apply the *Wands* factors to determine whether “undue experimentation” would be necessary, namely “(1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.”

*In re Wands*, 858 F.2d 731, 737 (Fed. Cir. 1988).

## **I. Written Description**

66. The written description requirement is a question of fact. *Ariad Pharms., Inc. v. Eli Lilly & Co.*, 598 F.3d 1336, 1351 (Fed. Cir. 2010). The written description inquiry “requires an objective inquiry into the four corners of the specification from the perspective of a person of ordinary skill in the art” and a patent claim is invalid for lack of written description if it does not “reasonably convey[] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” *Id.*

## **V. ENFORCEABILITY**

67. “Inequitable conduct is an equitable defense to patent infringement that, if proved, bars enforcement of a patent.” *Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1285 (Fed. Cir. 2011). “Unlike validity defenses,

which are claim specific, inequitable conduct regarding a single claim renders the entire patent unenforceable.” *Renegeron Pharms., Inc. v. Merus N.V.*, 864 F.3d 1343, 1350 (Fed. Cir. 2017).

68. “To prevail on a claim of inequitable conduct in a patent case, the accused infringer must prove by clear and convincing evidence that the patentee: (1) ‘knew of the reference’ or prior commercial sale; (2) ‘knew that it was material’; and (3) ‘made a deliberate decision to withhold it.’” *GS Cleantech Corp. v. Adkins Energy LLC*, 951 F.3d 1310, 1324 (Fed. Cir. 2020) (*citing Therasense*, 649 F.3d at 1290).

## **VI. STANDING/OWNERSHIP**

69. “Standing to sue is a threshold requirement in every federal action.” *Sicom Sys., Ltd. v. Agilent Techs., Inc.*, 427 F.3d 971, 975 (Fed. Cir. 2005). “The party bringing the action bears the burden of establishing that it has standing.” *Id.* at 976.

70. “There are three general categories of plaintiffs encountered when analyzing the constitutional standing issue in patent infringement suits: those that can sue in their own name alone; those that can sue as long as the patent owner is joined in the suit; and those that cannot even participate as a party to an infringement suit.” *Morrow v. Microsoft Corp.*, 499 F.3d 1332, 1339 (Fed. Cir. 2007).

**A. Patentees and Assignees**

71. “[P]laintiffs that hold all legal rights to [a] patent as the patentee or assignee of all patent rights” are “entitled to sue for infringement in [their] own name[s].” *Id.* at 1339-40. “Additionally, if a patentee transfers all substantial rights to the patent, this amounts to an assignment or a transfer of title, which confers constitutional standing on the assignee to sue for infringement in its own name alone.” *Id.* at 1340 (citation and internal quotations omitted).

**B. Exclusive Licensees**

72. Plaintiffs that do not have all substantial rights to a patent but have exclusionary rights in the patent are exclusive licensees. *Id.* “To be an exclusive licensee for standing purposes, a party must have received, not only the right to practice the invention within a given territory, but also the patentee’s express or implied promise that others shall be excluded from practicing the invention within that territory as well.” *Rite-Hite Corp. v. Kelley Co., Inc.*, 56 F.3d 1538, 1552 (Fed. Cir. 1995) (en banc). Exclusive licensees have constitutional standing to sue but must join the patentee or assignee when commencing a patent infringement suit. *Morrow*, 499 F.3d at 1340.

73. “[A]n exclusive licensee lacks standing to sue a party who has the ability to obtain [a license under a patent] from another party with the right to grant it.” *WiAV Sols. LLC v. Motorola, Inc.*, 631 F.3d 1257, 1266 (Fed. Cir. 2010).

While an exclusive license need not be in writing for the exclusive licensee to have standing to sue as a co-plaintiff, “courts will not imply an exclusive license when there is no indication that the licensor granted its licensee any of the exclusionary rights in a patent.” *Id.*

74. Where there is no evidence of a patentee subsidiary’s express or implied promise to exclude other entities from practicing a patent, an “understanding,” based on how two related corporate entities are organized and operate, that the subsidiary is the patentee while the corporate parent is the only entity practicing the patent is insufficient evidence that the parent corporation is an implied exclusive licensee. *See Spine Sols., Inc. v. Medtronic Sofamor Danek USA, Inc.*, 620 F.3d 1305, 1317-18 (Fed. Cir. 2010), abrogated on other grounds by *Halo Elecs., Inc. v. Pulse Elecs.*, 136 S. Ct. 1923 (2016) (finding that, where “there [wa]s no agreement, either oral or written, between [patent owner] and [its sister corporation] with respect to the...patent,” but rather “an ‘understanding’ ... within the [corporate family] that [the sister corporation] has the exclusive right to practice the...patent,” the sister corporation, did not have exclusive licensee standing).

75. “Whether express or implied, a license is a contract governed by ordinary principles of state contract law.” *McCoy v. Mitsuboshi Cutlery, Inc.*, 67 F.3d 917, 920 (Fed. Cir. 1995) (internal citation and quotation omitted). Thus,

while federal patent law may permit an oral license, aspects of state contract law, such as the statute of frauds, may not. *See, e.g., Quiedan Co. v. Cent. Valley Builders Supply Co.*, at \*1 (N.D. Cal. Oct. 28, 1993), *aff'd* 31 F.3d 1178 (Fed. Cir. 1994) (ruling that plaintiff lacked standing to sue as an exclusive licensee where an alleged oral agreement granting plaintiff an exclusive license to the patent failed to meet the requirements of the California Statute of Frauds).

76. “[A] parent corporation does not have de facto standing to assert claims for monetary relief for infringement of a wholly-owned subsidiary’s patent.” *Alarm.com, Inc. v. SecureNet Techs. LLC*, 345 F. Supp. 3d 544, 550-51 (D. Del. 2018). The parent must still prove “that it has an exclusive license in the asserted patents” for standing. *Id.* at 551; *see also Spine Sols., Inc. v. Medtronic Sofamor Danek USA, Inc.*, 620 F.3d 1305, 1317-18 (Fed. Cir. 2010), *abrogated on other grounds by Halo Elecs., Inc. v. Pulse Elecs.*, 136 S. Ct. 1923 (2016).

### C. Non-Exclusive Licensees

77. “If [a] party has not received an express or implied promise of exclusivity under [a] patent, *i.e.*, the right to exclude others from making, using, or selling the patented invention,” the party is a non-exclusive licensee. *Rite-Hite*, 56 F.3d at 1552. Non-exclusive licensees have no constitutional standing “to bring suit or even to join a suit with the patentee.” *Sicom*, 427 F.3d at 976; *see also Morrow*, 499 F.3d at 1340-41.

78. A “[non-exclusive] license to sell an invention in a specified territory, even if it is the only license granted by the patentee, does not provide standing without the grant of a right to exclude others.” *Rite-Hite*, 56 F.3d at 1553.

79. A patent holder may not claim its non-exclusive licensee’s lost profits for the licensee’s sales of products practicing the invention of the asserted patent. *See Poly-Am., L.P. v. GSE Lining Tech., Inc.*, 383 F.3d 1303, 1310-12 (Fed. Cir. 2004).

## VII. DAMAGES

80. Upon a finding of infringement, “the court shall award the claimant damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer, together with interest and costs as fixed by the court.” 35 U.S.C. § 284.

81. Plaintiffs must prove the amount of damages by a preponderance of the evidence. *SmithKline Diagnostics, Inc. v. Helena Labs. Corp.*, 926 F.2d 1161, 1164 (Fed. Cir. 1991). “When a patentee seeks lost profits as the measure of damages, the patent holder bears the burden of proving the amount of the award.” *Promega Corp. v. Life Techs. Corp.*, 875 F.3d 651, 660 (Fed. Cir. 2017) (internal citation and quotation omitted).

82. To properly carry their burden of proving the amount of damages, Plaintiffs must persuade the Court using “reliable” and “legally sufficient evidence

SCHEDULE 5

regarding an appropriate reasonable royalty.” *ResQNet.com, Inc. v. Lansa, Inc.*, 594 F.3d 860, 872 (Fed. Cir. 2010). The claim for damages cannot be speculative—there must be a reasonable certainty as to the amount of damages being claimed. *Lucent Techs., Inc. v. Gateway, Inc.*, 580 F.3d 1301, 1335, 1340 (Fed. Cir. 2009) (vacating and remanding jury award as excessive); *Oiness v. Walgreen Co.*, 88 F.3d 1025, 1029-30 (Fed. Cir. 1996). Plaintiffs “must show [their] damages by evidence.” *Promega Corp.*, 875 F.3d at 660. “Damages ‘must not be left to conjecture by the jury. They must be proved, and not guessed at.’” *Id.* (citation omitted).

83. A damages theory must be based on “sound economic and factual predicates.” *Riles v. Shell Expl. & Prod. Co.*, 298 F.3d 1302, 1311 (Fed. Cir. 2002). “Any evidence unrelated to the claimed invention does not support compensation for infringement but punishes beyond the state of the statute.” *ResQNet*, 594 F.3d at 869. If the patentee fails to tie the theory to the facts of the case, the testimony must be excluded. *Uniloc USA, Inc. v. Microsoft Corp.*, 632 F.3d 1292, 1315 (Fed. Cir. 2011).

**A. Reasonable Royalty**

84. “A reasonable royalty is the predominant measure of damages in patent infringement cases.” *Uniloc.*, 632 F.3d at 1312.

85. “The methodology of assessing and computing damages under 35 U.S.C. § 284 is within the sound of the district court.” *Nickson Indus., Inc. v. Roll Mfg. Co.*, 847 F.2d 795, 798 (Fed. Cir. 1988). Deciding the amount of the reasonable royalty is a question of fact. *See Unisplay, S.A. v. Am. Elec. Sign Co.*, 69 F.3d 512, 517 (Fed. Cir. 1995).

86. One approach for calculating a reasonable royalty is through a hypothetical negotiation analysis. *See Mahurkar v. C.R. Bard, Inc.*, 79 F.3d 1572, 1579 (Fed. Cir. 1996) (“Lacking evidence of royalties in the marketplace, this court accepts evidence about hypothetical results of hypothetical negotiations between the patentee and infringer (both hypothetically willing) at the time infringement began.”). The aim of the hypothetical negotiation approach is to capture what the infringer, acting as a prudent licensee, would have been willing to pay as a royalty and yet be able to make a reasonable profit, and what amount would have been acceptable to the patent holder, acting as a prudent patentee who was willing to grant a license. *Georgia-Pacific Corp. v. U.S. Plywood Corp.*, 318 F. Supp. 1116, 1121-22 (S.D.N.Y. 1970). Thus, to determine a reasonable royalty under this approach, a jury must find the royalty that would have been agreed to in a hypothetical negotiation between a willing licensee and willing licensor. *Lucent*, 580 F.3d at 1324-25.

SCHEDULE 5

87. A determination of the reasonable royalty under the hypothetical negotiation approach is usually made by assessing factors such as those set forth in *Georgia-Pacific*. *Rite-Hite*, 56 F.3d at 1554-55. These factors include:

- i) The royalties received by the patentee for the licensing of the patent in suit, proving or tending to prove an established royalty.
- ii) The rates paid by the licensee for the use of other patents comparable to the patent in suit.
- iii) The nature and scope of the license, as exclusive or non-exclusive; or as restricted or non-restricted in terms of territory or with respect to whom the manufactured product may be sold.
- iv) The licensor's established policy and marketing program to maintain his patent monopoly by not licensing others to use the invention or by granting licenses under special conditions designed to preserve that monopoly.
- v) The commercial relationship between the licensor and licensee, such as, whether they are competitors in the same territory in the same line of business; or whether they are inventor and promoter.
- vi) The effect of selling the patented specialty in promoting sales of other products of the licensee; that existing value of the invention to the licensor as a generator of sales of his non-patented items; and the extent of such derivative or convoyed sales.
- vii) The duration of the patent and the term of the license.
- viii) The established profitability of the product made under the patent; its commercial success; and its current popularity.
- ix) The utility and advantages of the patent property over the old modes or devices, if any, that had been used for working out similar results.
- x) The nature of the patented invention; the character of the commercial embodiment of it as owned and produced by the licensor; and the benefits to those who have used the invention.
- xi) The extent to which the infringer has made use of the invention; and any evidence probative of the value of that use.
- xii) The portion of the profit or of the selling price that may be customary in the particular business or in comparable businesses to allow for the use of the invention or analogous inventions.
- xiii) The portion of the realizable profit that should be credited to the invention as distinguished from non-patented elements, the

- manufacturing process, business risks, or significant features or improvements added by the infringer.
- xiv) The opinion testimony of qualified experts.
  - xv) The amount that a licensor (such as the patentee) and a licensee (such as the infringer) would have agreed upon (at the time the infringement began) if both had been reasonably and voluntarily trying to reach an agreement; that is, the amount which a prudent licensee—who desired, as a business proposition, to obtain a license to manufacture and sell a particular article embodying the patented invention—would have been willing to pay as a royalty and yet be able to make a reasonable profit and which amount would have been acceptable by a prudent patentee who was willing to grant a license.

*Georgia-Pacific*, 318 F. Supp. at 1120.

88. The Federal Circuit has explained that “[t]he correct determination of [the hypothetical negotiation date] is essential for properly assessing damages.” *Integra Lifesciences I, Ltd. v. Merck KGaA*, 331 F.3d 860, 870 (Fed. Cir. 2003), *vacated and remanded on other grounds*, 545 U.S. 193 (2005). Generally, “the date of the hypothetical negotiation is the date that the infringement began.” *LaserDynamics, Inc. v. Quanta Comput., Inc.*, 694 F.3d 51, 75 (Fed. Cir. 2012).

89. “[T]he patent holder should only be compensated for the approximate incremental benefit derived from his invention.” *Ericsson, Inc. v. D-Link Sys., Inc.*, 773 F.3d 1201, 1233 (Fed. Cir. 2014). The patent holder must accordingly “give evidence tending to separate or apportion the defendant’s profits and the patentee’s damages between the patented feature and the unpatented features....” *VirnetX, Inc. v. Cisco Sys., Inc.*, 767 F.3d 1308, 1326 (Fed. Cir. 2014) (quoting *Garretson v. Clark*, 111 U.S. 120, 121 (1884)). The Federal Circuit has held that

“a reasonable royalty analysis requires a court to hypothesize, not to speculate.... [T]he trial court must carefully tie proof of damages to the claimed invention’s footprint in the market place.” *ResQNet*, 594 F.3d at 869; *see also Exmark Mfg. Co. v. Briggs & Stratton Power Prods. Grp., LLC*, 879 F.3d 1332, 1350-51 (Fed. Cir. 2018).

#### **B. Lost Profits**

90. Plaintiffs have the “burden to prove lost profits by a preponderance of evidence.” *Oiness*, 88 F.3d at 1031. Plaintiffs cannot “meet [their] burden of proof with mere speculation and guess work.” *Id.*; *see also BIC Leisure Prods., Inc. v. Windsurfing Int’l, Inc.*, 1 F.3d 1214, 1218 (Fed. Cir. 1993) (“An award of lost profits may not be speculative.”).

91. “To recover lost profits as actual damages, a patent holder must demonstrate that there was a reasonable probability that, but for the infringement, it would have made the infringer’s sales.” *Id.* at 1029. “The ‘but for’ inquiry therefore requires a reconstruction of the market, as it would have developed absent the infringing product....” *Grain Processing Corp. v. Am. Maize-Prods. Co.*, 185 F.3d 1341, 1350 (Fed. Cir. 1999). In reconstructing the market, Plaintiffs must provide “sound economic proof of the nature of the market and likely outcomes with infringement factored out of the economic picture.” *Id.* “Thus, an accurate reconstruction of the hypothetical ‘but for’ market takes into account any

alternatives available to the infringer.” *Id.* at 1351. “Market sales of an acceptable noninfringing substitute often suffice alone to defeat a case for lost profits.” *Id.* at 1352.

92. The “but for” inquiry, and thus lost profits, “can be proven using the test given in *Panduit Corp. v. Stahlin Bros. Fibre Works, Inc.*, 575 F.2d 1152 (6th Cir. 1978).” *Presidio Components, Inc. v. Am. Tech. Ceramics Corp.*, 875 F.3d 1369, 1380 (Fed. Cir. 2017). “The four-factor Panduit test requires the patentee to show: (1) demand for the patented product; (2) an absence of acceptable, noninfringing substitutes; (3) manufacturing and marketing capability to exploit the demand; and (4) the amount of profit that would have been made.” *Id.* (citing *Panduit*, 575 F.2d at 1156). “[A] patentee is not entitled to lost profits if the patentee fails to establish any of the above requirements.” *SmithKline*, 926 F.2d at 1165. Thus, courts have denied lost profits where a patentee failed to provide evidence to establish the absence of acceptable, noninfringing substitutes in the *Panduit* inquiry. See *Presidio*, 875 F.3d at 1380-81; *Slimfold Mfg. Co. v. Kinkead Indus.*, 932 F.2d 1453, 1458 (Fed. Cir. 1991); *SmithKline*, 926 F.2d at 1165-66.

93. Consideration of non-infringing alternative products must account for both acceptable non-infringing alternative products available in the marketplace, as well as alternative designs available to the infringer which could have been

implemented to provide an acceptable alternative to customers. *Grain Processing*, 185 F.3d 1341.

94. “[I]f the customer would have bought the infringing product without the patented feature or with a different, non-infringing alternative to the patented feature, then the patentee cannot establish entitlement to lost profits for that particular sale.” *Mentor Graphics Corp. v. EVE-USA, Inc.*, 851 F.3d 1275, 1285 (Fed. Cir. 2017).

95. “[A] patent owner may satisfy the second *Panduit* element by substituting proof of its market share for proof of the absence of acceptable substitutes.” *BIC Leisure*, 1 F.3d at 1219. However, “similarity of [the patent owner’s, infringer’s, and other manufacturers’] products is necessary in order for market share proof to show correctly satisfaction of *Panduit*’s second factor.” *Id.*

96. A patent holder may not claim its non-exclusive licensee’s lost profits for the licensee’s sales of products practicing the invention of the asserted patent. See *Poly-Am., L.P. v. GSE Lining Tech., Inc.*, 383 F.3d 1303, 1310-12 (Fed. Cir. 2004).

### VIII. INJUNCTION

97. Plaintiffs have the burden to prove it is entitled to a permanent injunction. *eBay Inc. v. MercExchange, L.L.C.*, 547 U.S. 388, 391 (2006). “[I]njunctions ‘may’ issue ‘in accordance with the principles of equity.’” *Id.* at

SCHEDULE 5

392 (citation omitted). “An injunction is a drastic and extraordinary remedy, which should not be granted as a matter of course.” *Monsanto Co. v. Geerston Seed Farms*, 561 U.S. 139, 165 (2010). Rather, “if the plaintiff’s injury can be adequately redressed with a less severe remedy, ‘recourse to the additional and extraordinary relief of an injunction’ is not warranted.” *Riverbed Tech., Inc. v. Silver Peak Sys., Inc.*, No. CV 110-484-RGA, 2014 WL 4695765, at \*3 (D. Del. Sep. 12, 2014) (citation omitted).

98. To obtain a permanent injunction, a plaintiff must demonstrate all of the following: “(1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” *eBay*, 547 U.S. at 391. “[E]very injunctive case must be considered according to its unique facts.” *ActiveVideo Networks, Inc. v. Verizon Communs., Inc.*, 694 F.3d 1312, 1338 n.6 (Fed. Cir. 2012). Plaintiff must meet all four elements of the eBay test. Failure to meet any of those factors means that the court may not grant an injunction. *Nichia Corp. v. Everlight Americas, Inc.*, 855 F.3d 1328, 1341-44 (Fed. Cir. 2017); *Amgen Inc. v. Sanofi*, 872 F.3d 1367, 1380-81 (Fed. Cir. 2017).

99. To satisfy the first *eBay* factor, “the patentee must show that it is irreparably harmed by the infringement. This requires proof that a ‘causal nexus relates the alleged harm to the alleged infringement.’” *Apple Inc. v. Samsung Elecs. Co.*, 809 F.3d 633, 639 (Fed. Cir. 2015) (*citing Apple Inc. v. Samsung Elecs. Co.*, 695 F.3d 1370, 1374 (Fed. Cir. 2012)). The causal nexus requirement “ensures that an injunction is only entered against a defendant on account of a harm resulting from the defendant’s wrongful conduct, not some other reason. For example, it ensures that an injunction is not entered on account of ‘irreparable harm caused by otherwise lawful competition.’” *Apple*, 809 F.3d at 641.

100. The absence of “meaningful competition” weighs against a finding of irreparable harm. *Nichia Corp.*, 855 F.3d at 1341. Even when two parties compete in the same market, there may be no meaningful competition when “two companies generally sell to different parties.” *Id.* at 1341.

101. The patentee’s delay in bringing suit and failure to seek a preliminary injunction may be considered in assessing a lack of irreparable injury. *Genband US LLC v. Metaswitch Networks Corp.*, 861 F.3d 1378, 1385 (Fed. Cir. 2017).

102. The “balance of hardship” factor “accesses the relative effect of granting or denying an injunction on the parties, the district court properly considered several factors in its analysis. These factors included the parties’ sizes, products, and revenue sources.” *i4i Ltd. v. Microsoft Corp.*, 598 F.3d 831, 862

SCHEDULE 5

(Fed. Cir. 2010); *see also Bio-Rad Labs, Inc. v. 10X Genomics, Inc.*, 967 F.3d 1353, 1378-80 (Fed. Cir. 2020) (holding that the balance of hardship factor weighs against a permanent injunction when the accused infringer was “a much smaller company”).

103. As to the “public interest” factor, “it was in the public interest to allow competition in the medical device arena.” *Bard Peripheral Vascular, Inc. v. W.L. Gore & Assocs., Inc.*, 670 F.3d 1171, 1192 (Fed. Cir. 2012), *vacated on other grounds*, 476 Fed. Appx. 747 (Fed. Cir. 2012) (affirming the district court’s award of ongoing royalty instead of injunction).

# **SCHEDULE 6**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-SB-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**JOINT TRIAL EXHIBIT LIST (SCHEDULE 6)**

Schedule 6 - Joint Trial Exhibit List

JTX#	PTX #	DTX#	Date	Bates Begin	Bates End	Description	Depo. Exh No.
JTX-0001	PTX-0001		8/22/2006	BSC-MT-119301	BSC-MT-119342	Certified copy of U.S. Patent 7,094,245	
JTX-0002	PTX-0002		3/10/2015	BSC-MT-119343	BSC-MT-119384	Certified copy of U.S. Patent 8,974,371	
JTX-0003	PTX-0003		5/29/2018	BSC-MT-119385	BSC-MT-119427	Certified copy of U.S. Patent 9,980,725	
JTX-0004	PTX-0004	DTX-0139	10/5/2001	BSC-MT-000119	BSC-MT-000556	Certified copy of the file history for U.S. Patent 7,094,245	
JTX-0005	PTX-0005	DTX-0140	12/16/2011	BSC-MT-000739	BSC-MT-001283	Certified copy of the file history for U.S. Patent 8,974,371	
JTX-0006	PTX-0006	DTX-0141	5/19/2016	BSC-MT-001591	BSC-MT-001788	Certified copy of the file history for U.S. Patent 9,980,725	

## **SCHEDULE 7**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-SB-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**PLAINTIFFS' TRIAL EXHIBIT LIST (SCHEDULE 7)**

## **Defendants' Statement**

Pursuant to Rule 26(a)(3)(B) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d), Defendants Micro-Tech Endoscopy USA, Inc., Micro-Tech (Nanjing) Co. Ltd., and Henry Schein, Inc. (collectively, "Defendants") hereby object to the Exhibit List provided by Plaintiffs. Defendants reserve the right to supplement, revise, correct, clarify, withdraw, or otherwise amend these objections based on new information, new positions taken by the parties, future rulings of the Court, including, but not limited to, rulings on the parties' pending motions for summary judgment, Daubert motions, motions *in limine*, and/or evidentiary objections raised by the parties prior to trial. Defendants make these objections without waiver of, and without prejudice to, any motions, arguments, or evidentiary objections Defendants have presented or may present separately to the Court. Defendants reserve the right to object to documents Plaintiffs may offer in connection with any proposed witness, whether presented live or by deposition. Defendants also incorporate herein their Objections to Plaintiffs' Deposition Designations and Objections to Plaintiffs' Witness List.

The absence of an objection to a particular document is not an admission or concession by Defendants that the document is admissible in the context and/or for the purpose for which Plaintiffs may attempt to offer it. Furthermore, for documents listed in duplicate on the list (e.g., where a document is listed as a deposition exhibit and separately, or where multiple copies of the same document have been listed with different production numbers, or where a document is listed as both a complete copy and excerpts thereof), any objections listed for one version of the document apply equally to all versions of the document. Additionally, unless expressly agreed by Defendants, Defendants object to any document being offered into evidence without a competent sponsoring witness. Unless expressly agreed by Defendants, Defendants also reserve the right to challenge or otherwise question the authenticity of any document or the accuracy of any

translation of a foreign-language document. Defendants further object to documents listed on Plaintiffs' exhibit list that are not in fact admissible documentary or physical evidence. Defendants also reserve the right to object to any physical or demonstrative exhibits in accordance with the parties' proposed pretrial order. Defendants specifically reserve the right to seek to admit into evidence documents that Defendants object to being offered into evidence by Plaintiffs.

**DEFENDANTS' OBJECTION KEY FOR  
OBJECTIONS TO PLAINTIFFS' EXHIBIT LIST**

CODE	OBJECTION
106	Incomplete. Fed. R. Evid. 106
402	Not relevant. Fed. R. Evid. 401, 402
403	Unduly prejudicial, confusing, wasteful, or cumulative. FRE 403
701	Improper lay opinion. Fed. R. Evid. 701
702	Improper expert testimony. Fed. R. Evid. 702
802	Hearsay if offered for the truth of the matter asserted. FRE 802
901	Requires authenticity or identification. Fed. R. Evid. 901
1002	Violates best evidence rule. Fed. R. Evid. 1002
1005	Not a qualifying public record. Fed. R. Evid. 1005
1006	Improper summary. Fed. R. Evid. 1006
F	Lacks foundation or violates Fed. R. Evid. 104, 602, 1003, 1005
CP	Composite; not a single document
ILL	Illegible
UT	Untimely disclosed/not produced in discovery
SJ	Subject to exclusion pending Motion for Summary Judgment
Daub	Subject to exclusion pending Daubert Motion
MIL	Subject to exclusion pending Motion <i>in Limine</i>
D	Duplicate
DESC	Inadequate, misleading, or improper description

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0001	8/22/2006	BSC-MT-119301	BSC-MT-119342	Moved to Joint Exhibit List at JTX-0001		
PTX-0002	3/10/2015	BSC-MT-119343	BSC-MT-119384	Moved to Joint Exhibit List at JTX-0002		
PTX-0003	5/29/2018	BSC-MT-119385	BSC-MT-119427	Moved to Joint Exhibit List at JTX-0003		
PTX-0004	10/5/2001	BSC-MT-000119	BSC-MT-000556	Moved to Joint Exhibit List at JTX-0004		
PTX-0005	10/16/2008	BSC-MT-000557	BSC-MT-000758	Certified copy of the file history for U.S. Patent 8,083,668	403	
PTX-0006	12/16/2011	BSC-MT-000759	BSC-MT-001283	Moved to Joint Exhibit List at JTX-0005		
PTX-0007	3/9/2015	BSC-MT-001284	BSC-MT-001590	Certified copy of the file history for U.S. Patent 9,370,371	403	
PTX-0008	5/19/2016	BSC-MT-001591	BSC-MT-001788	Moved to Joint Exhibit List at JTX-0006		
PTX-0009	11/6/2006	BSC-MT-001789	BSC-MT-001844	Assignment of patent applications and patents from Scimed Life Systems, Inc. to Boston Scientific Scimed, Inc: Reel 018505_Frame 0868	403, 1005	
PTX-0010		BSC-MT-001845	BSC-MT-001845	Assignment Abstract of Title for Application 09971488 / U.S. Patent 7,094,245	403, 1005	
PTX-0011		BSC-MT-001846	BSC-MT-001846	Assignment Abstract of Title for Application 13328171 / U.S. Patent 8,974,371	403, 1005	
PTX-0012	10/5/2001	BSC-MT-001847	BSC-MT-001855	USPTO Assignment Reel 012242_Frame 0759 Patent Application 09/971,488	403, 1005	
PTX-0013	12/16/2011	BSC-MT-001856	BSC-MT-001860	Assignment Reel_Frame 027512-0901	403, 1005	
PTX-0014	12/16/2011	BSC-MT-001861	BSC-MT-001870	Assignment Reel_Frame 027532-0727	403, 1005	
PTX-0015	8/22/2006	BSC-MT-000001	BSC-MT-000039	U.S. Patent No. 7,094,245 (Adams)	D, 1005	
PTX-0016	3/10/2015	BSC-MT-000040	BSC-MT-000078	U.S. Patent No. 8,974,371 (Durgin)	D, 1005	
PTX-0017	5/29/2018	BSC-MT-000079	BSC-MT-000118	U.S. Patent No. 9,980,725 (Durgin)	D, 1005	
PTX-0018	1/1/2015	BSC-MT-003307	BSC-MT-003312	Boston Scientific Resolution Clip Brochure	403, 901, 802, F	
PTX-0019	4/29/2014	BSC-MT-014783	BSC-MT-015021	Certified copy of file history U.S. Patent No. 8,709,027	403, 402	
PTX-0020	3/1/2016	BSC-MT-015865	BSC-MT-016223	Certified copy of file history U.S. Patent No. 9,271,731	403, 402	
PTX-0021	9/18/2012	BSC-MT-016301	BSC-MT-016712	File history U.S. Patent 7,094,245	D, 1005	
PTX-0022	2/1/2011	BSC-MT-016750	BSC-MT-017098	File history U.S. Patent 7,879,052	D, 1005	
PTX-0023	7/31/2014	BSC-MT-017136	BSC-MT-017272	File history U.S. Patent 8,444,660	D, 1005	
PTX-0024	1/26/2001	BSC-MT-022409	BSC-MT-022448	Boston Scientific Idea Disclosure, Through the Scope Endoscopic Hemostatic Clipping Device, signed by innovators Mark Adams and Russell Durgin	403, 802, 901, F, CP	
PTX-0025	7/3/2003	BSC-MT-022451	BSC-MT-022494	BSC Invention Disclosure	403, 802, 901, F, CP	
PTX-0026	4/20/2004	BSC-MT-022497	BSC-MT-022517	BSC Invention Disclosure - Update to Through the Scope Tension Member Release Clip Disclosure	403, 802, 901, F, CP	
PTX-0027	7/31/2014	BSC-MT-025132	BSC-MT-025268	Letter from USPTO Notice of Withdrawal from Issue, U.S. Patent No. 8,444,660	106, 402, 403, CP, DESC, F, 901	

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0028	7/22/1996	BSC-MT-034073	BSC-MT-034096	Laboratory Notebook N0119		403, 802, 901, 1002, F, ILL
PTX-0029	6/1/1998	BSC-MT-034813	BSC-MT-034832	Laboratory Notebook N0261		106, 403, 802, 901, 1002, F
PTX-0030	4/3/2015	BSC-MT-088634	BSC-MT-088634	Spreadsheet, R&D Financial Template		402, 403, 802, 901, F
PTX-0031		BSC-MT-091962	BSC-MT-091962	Spreadsheet, Project View		402, 403, 702, 802, 901, 1006, F, Daub
PTX-0032		BSC-MT-116680	BSC-MT-116680	Spreadsheet, Global Endoscopy Profit and Loss 2011-2017		402, 403, 802, 901, 1006, F, Daub
PTX-0033		BSC-MT-116681	BSC-MT-116681	Spreadsheet, Sales and Costs 2004-2016		402, 403, 802, 901, 1006, F, Daub
PTX-0034		BSC-MT-117941	BSC-MT-117941	Spreadsheet, 2016 Endoscopy Market Model European Roll-Up		402, 403, 802, 901, 1006, F, Daub
PTX-0035		BSC-MT-117942	BSC-MT-117942	Spreadsheet, European Market Model Rollup; Competitors - Unit Volume by Company		402, 403, 802, 901, 1006, F, Daub
PTX-0036		BSC-MT-117943	BSC-MT-117943	Spreadsheet, European Market Model Rollup; Competitors - Unit Volume by Company		402, 403, 802, 901, 1006, D, F, Daub
PTX-0037		BSC-MT-117944	BSC-MT-117944	Spreadsheet, 2015 Endoscopy Market Model European Roll-Up; Competitors - Unit Volume by Company		402, 403, 802, 901, 1006, F, Daub
PTX-0038		BSC-MT-117945	BSC-MT-117945	Spreadsheet, Market Model 2013 - Country Totals		402, 403, 802, 901, 1006, F, Daub
PTX-0039		BSC-MT-117946	BSC-MT-117946	Spreadsheet, Material (UPN) 2012-2017		402, 403, 802, 901, F, Daub
PTX-0040	4/11/2017	BSC-MT-127303	BSC-MT-127415	Transcript from the deposition of Vincent Turturro, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB (D.Del.)		403, 701, 802
PTX-0041		BSC-MT-131425	BSC-MT-131443	Presentation, Resolution Clip Marketing Plan		402, 403, 802, 901 1006, F
PTX-0042		BSC-MT-131455	BSC-MT-131480	Presentation, Welcome to the Resolution Clip Device Training		402, 403, 802, 901, F
PTX-0043		HS00000046	HS00000046	Micro-Tech Endoscopy Product Catalog		106, 403
PTX-0044		HS00000377	HS00000377	Spreadsheet, Purchase Order Data		403
PTX-0045		HS00000378	HS00000378	Spreadsheet, Purchase Order Data		403
PTX-0046		HS00000379	HS00000379	Spreadsheet, Records Retention data by department		403
PTX-0047		HS00000391	HS00000391	Spreadsheet, ConMed Sales 2018 and 2019		403
PTX-0048		HS00000394	HS00000394	Spreadsheet, 2016-2020 Net Sales by item		403
PTX-0049		HS00000395	HS00000395	Spreadsheet, Purchase Order Data		403

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0050		MT00005723	MT00005723	Spreadsheet, Purchase Summary 2016-2019		403
PTX-0051		MT00005724	MT00005724	Spreadsheet, 2016-2019 Revenue and COGS		403
PTX-0052		MT00005901	MT00005911	SureClip Repositionable Hemostasis Clip Value Analysis Presentation		403
PTX-0053		MT00005927	MT00005927	Brochure, Micro-Tech Endoscopy Introduces the SURE CLIP		403
PTX-0054	11/xx/2016	MT00011879	MT00012458	US Market Report Suite for Gastrointestinal Devices by iData Research		402, 403
PTX-0055		MT00012498	MT00012498	Spreadsheet, SureClip Purchase Summary and Detail		403
PTX-0056	1/1/2005	BSC-MT-116614	BSC-MT-116626	Distributorship Agreement between Boston Scientific Scimed, Inc. and Boston Scientific Corporation, effective January 1, 2005		402, 403, 802, 901, 1002, F, Daubert
PTX-0057	1/1/1998	BSC-MT-116639	BSC-MT-116649	Agreement for Sharing Research and Development Costs, between Scimed Life Systems, Inc. and Boston Scientific Limited, effective January 1, 1998		402, 403, 802, 901, 1002, F, Daub
PTX-0058	1/1/1998	BSC-MT-116650	BSC-MT-116662	Amended and Restated Agreement for Sharing Research and Development Costs between Scimed Life Systems, Inc., and Boston Scientific Limited, effective January 1, 1998		402, 403, 802, 901, 1002, F, Daub
PTX-0059	1/5/2009	BSC-MT-116663	BSC-MT-116679	Second Amended and Restated Agreement for Sharing Intangible Development Costs between Boston Scientific Scimed, Inc., and Boston Scientific Limited, amended and restated effective January 5,		402, 403, 802, 901, 1002, F, Daub
PTX-0060	12/31/2013	BSC-MT-140092	BSC-MT-140110	Third Amended and Restated Agreement for Sharing Intangible Development Costs between Boston Scientific Scimed, Inc., and Boston Scientific Limited, amended and restated effective December		402, 403, 802, 901, 1002, F, Daub
PTX-0061	12/31/2019	BSC-MT-140116	BSC-MT-140123	Intellectual Property Transfer Agreement between Boston Scientific Limited and Boston Scientific Medical Device Limited, effective December 31, 2019		402, 403, 802, 901, 1002, F, Daub
PTX-0062	1/1/2005	BSC-MT-140065	BSC-MT-140073	International Distributorship Agreement between Boston Scientific Limited and Boston Scientific Corporation, effective as of January 1, 2005		402, 403, 802, 901, 1002, F, Daub
PTX-0063	10/23/2020			Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725		402, 403, 702, 802, Daub, SJ,
PTX-0064				Opening Expert Report of Karl R. Leinsing Exhibit A - Curriculum Vitae		402, 403, 702, 802, Daub, SJ,
PTX-0065				Opening Expert Report of Karl R. Leinsing Exhibit B - Materials Considered		402, 403, 702, 802, Daub, SJ,
PTX-0066				Opening Expert Report of Karl R. Leinsing Exhibit C - Pictures of BSC Resolution Clips		402, 403, 702, 802 901, 1002, F, CP

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0067				Opening Expert Report of Karl R. Leinsing Exhibit D - Pictures of BSC Resolution 360 Clips		402, 403, 702, 802, 901, 1002, F, CP
PTX-0068				Opening Expert Report of Karl R. Leinsing Exhibit E - Pictures of Accused Original (Micro-Tech) Devices		402, 403, 702, 802, 901, 1002, F, CP
PTX-0069				Opening Expert Report of Karl R. Leinsing Exhibit F - Pictures of Accused Original (ConMed) Devices		402, 403, 702, 802, 901, 1002, F, CP
PTX-0070				Opening Expert Report of Karl R. Leinsing Exhibit G - Pictures of Accused Buckle Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0071				Opening Expert Report of Karl R. Leinsing Exhibit H - Pictures of Accused Lockado Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0072				Opening Expert Report of Karl R. Leinsing Exhibit I - Videos of firing Accused Original (Micro-Tech) Devices		402, 403, 702, 802, 901, 1002, F, CP, ILL
PTX-0073				Opening Expert Report of Karl R. Leinsing Exhibit J - Videos of firing Accused Original (ConMed) Devices		402, 403, 702, 802, 901, 1002, F, CP
PTX-0074				Opening Expert Report of Karl R. Leinsing Exhibit K - Hemoclip Device Inventory		402, 403, 702, 802, 901, F,
PTX-0075				Opening Expert Report of Karl R. Leinsing Exhibit L - SEM Pictures of Accused Original (Micro-Tech) Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0076				Opening Expert Report of Karl R. Leinsing Exhibit M - SEM Pictures of Accused Original (ConMed) Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0077				Opening Expert Report of Karl R. Leinsing Exhibit N - SEM Pictures of Accused Buckle Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0078				Opening Expert Report of Karl R. Leinsing Exhibit O - SEM Pictures of Accused Lockado Devices		402, 403, 702, 802, 901, 1002, Daub, SJ, F, CP
PTX-0079				Opening Expert Report of Karl R. Leinsing Exhibit P - SEM Picture of Sample 1 of Original, Buckle, Lockado		402, 403, 702, 802, 901, 1002, F
PTX-0080	1/1/2005			Fracture Mechanics, by T.L. Anderson, 3rd Edition, CRC Press 2005 by Taylor & Francis Group, LLC, ISBN: 13: 978-1-4200-5821-5		402, 403, 702, 802, 901, F, Daub, SJ

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0081	12/1/2002			"Stress-Strain Curve for 17-7 PH, a Precipitation-hardening stainless steel, including information regarding Deformation, Tensile, High temperature, Chemical composition," from Atlas of Stress-Strain Curves, Second Edition (ASM International), available at <a href="https://www.asminternational.org/web/hts/search-/journal_content/56/10192/SSTR244/PUBLICATION;jsessionid=18093BBCB7B87FD755194E53E26BE4A8?p_p_id=webcontentresults_WAR_webcontentsearchoportlet_INSTANCE_2UAoyxtTX6d6&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mod=e=view&amp;p_p_col_id=column-2&amp;p_p_col_count=1">https://www.asminternational.org/web/hts/search-/journal_content/56/10192/SSTR244/PUBLICATION;jsessionid=18093BBCB7B87FD755194E53E26BE4A8?p_p_id=webcontentresults_WAR_webcontentsearchoportlet_INSTANCE_2UAoyxtTX6d6&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mod=e=view&amp;p_p_col_id=column-2&amp;p_p_col_count=1</a>		106, 402, 403, 702, 802, 901, F, Daub, SJ
PTX-0082	1/22/2004	BSC-MT-110175	BSC-MT-110293	Resolution Hemostasis Clipping Device Traditional 510(k): K040148		106, 403, 802, 901
PTX-0083	6/30/2015	BSC-MT-111487	BSC-MT-111725	Resolution 360 Clip Traditional 510(k): K151802		403, 802, 901
PTX-0084	2/12/2020	BSC-MT-139793	BSC-MT-139848	Boston Scientific - Fracture Analysis of Deployed SureClip Hemostasis Clips		402, 403, 701, 802, 901, F
PTX-0085	11/27/2019	BSC-MT-139849	BSC-MT-139856	Boston Scientific - Micro-Tech Clip Deployment Analysis - Collin Murray Affidavit		402, 403, 701, 802, 901, F, ILL
PTX-0086	4/9/2019	BSC-MT-139857	BSC-MT-139873	Micro-Tech Test Report		403, 901, ILL
PTX-0087		CMD 0527	CMD 0534	DuraClip Repositionable Hemostasis Clip Instructions for Use		403, 901
PTX-0088				"Fracture", Definition of Fracture by Merriam-Webster		402, 403, 901, F
PTX-0089				Fracture Mechanics, by E.E. Gdoutos, Published by Springer 2005, ISBN 1-4020-3153-X (e-book).		402, 403, 802, 901, F, Daub, SJ
PTX-0090	2/15/2008			Hanson, M., "On Adhesion and Galling in Metal Forming," Acta Universitatis Upsaliensis, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology (2008) 388, ISBN 978-91-554-7072-2		402, 403, 702, 802, 901, F, Daub, SJ
PTX-0091				Metals Handbook, ASM International Handbook 1987, Vol. 12, ISBN 0-87170-007-7 (Vol. 1).		402, 403, 702, 802, 901, F, Daub, SJ

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0092	8/27/2020			Micro-Tech Endoscopy Products webpage, Hemostasis clips, available at <a href="http://Micro-Techmedical.com/products/sup_11.html">http://Micro-Techmedical.com/products/sup_11.html</a> .		403, 901, F
PTX-0093	4/30/2020			MT First Supplemental Responses to First Set of Common Interrogatories		403
PTX-0094		MT00000020	MT00000020	Video, Animation of clip		403
PTX-0095		MT00000021	MT00000021	Video, Animation of clip		403
PTX-0096	5/12/2015	MT00000035	MT00000046	Product Performance Specification for Sterile Repositionable Hemostasis Clipping Device		403
PTX-0097		MT00000093	MT00000104	SureClip Repositionable Hemostasis Clip Instructions for use		403
PTX-0098		MT00000149	MT00000149	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0099		MT00000154	MT00000154	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0100	5/12/2013	MT00000157	MT00000157	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0101	5/12/2013	MT00000166	MT00000166	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0102	9/14/2015	MT00000169	MT00000169	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0103		MT00000246	MT00000264	S10(K) Micro-Tech Submission - Device Description		106, 403, 402, MIL
PTX-0104	7/20/2015	MT00000693	MT00000693	S10(K) Micro-Tech Submission Cover Letter		106, 403, 402, MIL
PTX-0105		MT00000819	MT00000823	S10(K) Micro-Tech Submission - Substantially Equivalent Discussions		106, 403, 402, MIL
PTX-0106		MT00005879	MT00005880	Micro-Tech USA SureClip Hemostasis Clip Data Sheet		403
PTX-0107	4/24/2019	MT00011117	MT00011131	SureClip Repositionable Hemostasis Clip Instructions for Use		403
PTX-0108	4/12/2019	MT00011132	MT00011132	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0109	4/12/2019	MT00011133	MT00011133	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0110	5/14/2019	MT00011134	MT00011134	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0111	6/12/2019	MT00011253	MT00011253	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0112	3/4/2019	MT00011450	MT00011450	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0113	7/12/2019	MT00011451	MT00011451	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0114	10/10/2017	MT00011803	MT00011810	Series of Micro-Tech diagrams in Japanese		403, DESC, CP
PTX-0115	12/23/2019	MT00012532	MT00012532	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0116	12/23/2019	MT00012534	MT00012534	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0117	12/23/2019	MT00012536	MT00012536	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0118	12/23/2019	MT00012537	MT00012537	Micro-Tech Diagram in Japanese,		403, DESC
PTX-0119	9/24/2019			New Technique to Improve Ductility of Ceramics Material for Missiles and Engines.pdf, By Purdue University, 2019		402, 403, 802, 901, Daub, SJ, F
PTX-0120	7/31/2020			Plaintiffs Final Infringement Contentions with exhibits.		403, 701, 802, 901, F, SJ

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0121				Shigley, Joseph Edward, and Larry D Mitchell. "2-9 Normal Stresses in Bending." Mechanical Engineering Design, Fourth ed., McGraw-Hill Book Company, 1983.		106, 402, 403, 802, 901, F, Daub, SJ
PTX-0122				SureClip Lockado Repositionable Hemostasis Clip Instructions for Use, available at <a href="https://www.mtendoscopy.com/wp-content/uploads/2020/09/D000008502-%EF%BC%8881-0010546%EF%BC%8CREV-5-%EF%BC%89-IFUlockado-added.pdf">https://www.mtendoscopy.com/wp-content/uploads/2020/09/D000008502-%EF%BC%8881-0010546%EF%BC%8CREV-5-%EF%BC%89-IFUlockado-added.pdf</a>		403, 802, 901, 1002, F
PTX-0123	10/22/2019			Team Bone webpage, Excellence in Bone Research, available at <a href="https://teambone.com/education-basic/shear-resistance-priority-hypothesis/">https://teambone.com/education-basic/shear-resistance-priority-hypothesis/</a>		402, 403, 702, 802, 901, Daub, SJ, UT, F
PTX-0124	8/22/2006			United States Patent 7094245 (Certified copy)		403, D
PTX-0125	3/10/2015			United States Patent 8974371 (Certified copy)		403, D
PTX-0126	5/29/2018			United States Patent 9980725 (Certified copy)		403, D
PTX-0127	12/28/2020			Micro-Tech webpage, Hemostasis, micro-tech-medical.com_products_productClass14		403, 802, 901, F
PTX-0128	12/16/2020			Reply Expert Report of Karl R. Leinsing, MSME, PE Regarding Infringement of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725		402, 403, 702, 802, Daub, SJ,
PTX-0129				Reply Expert Report of Karl R. Leinsing - Exhibit A - SEM Sample Packaging		402, 403, 702, 802, 901, 1002, CP, F, DESC
PTX-0130				Reply Expert Report of Karl R. Leinsing - Exhibit B - Handle Coupled to Sheath		402, 403, 702, 802, 901, 1002, CP, F, DESC
PTX-0131				Reply Expert Report of Karl R. Leinsing - Exhibit C - Actuator Coupled to Control Wire		402, 403, 702, 802, 901, 1002, CP, F, DESC
PTX-0132	12/28/2020			Analytical Lab Boston - How to Package Samples, available at <a href="https://analyticalanswersinc.com/contact-us/how-to-package-samples/">https://analyticalanswersinc.com/contact-us/how-to-package-samples/</a>		402, 403, 802, 901, F, UT
PTX-0133	1/1/2010			ASM Handbook Volume 22B Glossary of Terms (2010)		106, 402, 403, 802, 901, F, UT
PTX-0134	12/14/2020			Compression Testing of Homogeneous Materials and Composites, ASTM Special Technical Publication, Richard Chait and Ralph Papirno, Editors		402, 403, 802, 901, F, UT

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0135	2/1/1997			Size Effect in Compression Fracture: Splitting Crack Band Propagation by Zdenek P. Bazant and Yuyin Xiang ( Journal of Engineering Mechanics Vol. 123, No. 2, Feb. 1997)		402, 403, 802, 901, UT
PTX-0136		BSC-MT-004751	BSC-MT-004751	Video, Operation of Micro-Tech v. Resolution 360		402, 403, 701, 802, 901, 1002, F
PTX-0137	7/11/2021	BSC-MT-006228	BSC-MT-006238	Competitive Analysis of Diversatek RePlay Hemostasis Clip		106, 402, 403, 701, 802, 901, 1002, F,
PTX-0138	xx/xx/2016	BSC-MT-006712	BSC-MT-006728	Report, Evaluation of Tissue Manipulation with Resolution 360 Clips in Ex Vivo Porcine Model		106, 402, 403, 701, 802, 901, 1006, F
PTX-0139	6/25/2014	BSC-MT-011021	BSC-MT-011043	Presentation, Boston Scientific Rotatable Resolution Clip Technical Review		402, 403, 701, 802, 901, 1006, F
PTX-0140	4/1/2015	BSC-MT-118046	BSC-MT-118095	Boston Scientific Resolution Clip Competitive Handling Tool		402, 403, 802, 901, 1006, F
PTX-0141	8/11/2017	BSC-MT-126649	BSC-MT-127160	Rebuttal Expert Report of Karl R. Leinsing, served in Boston Scientific v. Cook, Civil Action No. 15-980		402, 403, 702, 802, Daub
PTX-0142				Failure Analysis of Engineering Materials - Glossary		106, 402, 403, 802, 901, F, DESC, UT
PTX-0143				Fracture, Definition of Fracture by Merriam-Webster		402, 403, 802, 901, F, D, UT
PTX-0144	7/27/2020			Deposition of Christopher Li		403
PTX-0145	6/24/2020			Markman hearing transcript		403
PTX-0146	4/30/2020			MT First Supplemental Responses to First Set of Common Interrogatories		403, D
PTX-0147		MT00000770	MT00000786	510(K) Micro-Tech Submission - Micro-Tech Device Description		106, 402, 403, MIL
PTX-0148	12/11/2005			Herwig Peterlik, et al., From brittle to ductile fracture of bone, Nature Materials Vol. 5 (January 2006)		402, 403, 802, 901, UT
PTX-0149	1/1/1999			Glossary of Terms, ASM Materials Engineering Dictionary		106, 402, 403, 802, 901, DESC, F, UT
PTX-0150				SureClip Lockado Clip Instructions for Use_IFU-lockado-added		403, 802, 901, 1002, F, D, UT
PTX-0151				SureClip Micro-Tech YouTube Video link		402, 403, 901, UT, F
PTX-0152	6/9/2016			US Patent Pub 2016_0161382		402, 403, UT, F, 901, 1005
PTX-0153	2/19/2019			Huajun Wang, Three-Point Bending Fracture Properties of Multilayer Metal Hot Forging Die Specimen, IOP Conference Series: Materials Science and Engineering 472 (2019)		402, 403, 802, UT, F, 901

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0154	2/23/2020			Hui Wang, A mechanistic cutting force model based on ductile and brittle fracture material removal modes for edge surface grinding of CFRP composites using rotary ultrasonic machining, International Journal of Mechanical Sciences 176 (2020)		402, 403, 802, UT, F, 901
PTX-0155	2/1/2020			Peter Ziopoulos, et al., Ageing bone fractures: the case of a ductile to brittle transition that shifts with age, Bone Volume 131 (February 2020)		402, 403, 802, UT, F, 901
PTX-0156	12/4/2020			Rebuttal Expert Report of Karl R. Leinsing, MSME, PE Regarding Validity of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725		402, 403, 702, 802, DAUB
PTX-0157				Exhibit A to Leinsing Rebuttal Expert Report - Curriculum Vitae		402, 403, 702, 802, DAUB
PTX-0158				Exhibit B to Leinsing Rebuttal Expert Report - Materials Considered		402, 403, 702, 802, DAUB
PTX-0159				Exhibit C to Leinsing Rebuttal Expert Report - Chart Mapping Resolution Clips to the Asserted Claims		402, 403, 702, 802, DAUB
PTX-0160	12/xx/2006	BSC-MT-022347	BSC-MT-022352	Jensen, D. et al., Randomized Controlled Study of 3 different types of hemoclips for hemostasis of bleeding canine acute gastric ulcers, GASTROINTESTINAL ENDOSCOPY, Vol. 64, No. 5 (Dec. 2006).		402, 403, 802, F, 901
PTX-0161	10/xx/2010	BSC-MT-044914	BSC-MT-044918	Swellengrebel, H., et al., Evaluating long-term attachment of two different endoclips in the human gastrointestinal tract, WORLD J. GASTROINTEST. ENDOSC. 2010 October 16: 2(10): 344-48.		402, 403, 802, F, 901
PTX-0162	10/23/2020			Expert Report of John R. Bone, CPA, CFF		402, 403, 702, 802, DAUB
PTX-0163				Expert Report of John R. Bone - Tab 1 Curriculum Vitae		402, 403, 702, 802, DAUB
PTX-0164				Expert Report of John R. Bone - Tab 2 Documents Reviewed		402, 403, 702, 802, DAUB
PTX-0165				Expert Report of John R. Bone - Exhibits 1 to 26.1		402, 403, 702, 802, DAUB, CP
PTX-0166		BSC-MT-003066	BSC-MT-003111	Presentation slides, Protecting Your Business	Moscato 50	402, 403, 802, 901
PTX-0167		BSC-MT-003380	BSC-MT-003388	Product Brochure, Resolution 360 Clip		402, 403, 901
PTX-0168	3/xx/2016	BSC-MT-003721	BSC-MT-003728	Presentation, Micro-Tech Clip battling	Moscato 46	402, 403, 802
PTX-0169		BSC-MT-003745	BSC-MT-003751	Presentation, Operation Steel Curtain 2019 US Micro-Tech Competitive Response Plan		402, 403, 802, 901
PTX-0170	4/23/2019	BSC-MT-003752	BSC-MT-003764	Presentation, Project Freight Train: Kickoff Meeting	Moscato 52	402, 403, 802, 901
PTX-0171		BSC-MT-003799	BSC-MT-003845	Presentation, Resolution 360 MAX Clip - Market Overview		402, 403, 802, 901
PTX-0172		BSC-MT-017284	BSC-MT-017449	Presentation, Hemostasis Update AGW 2013		402, 403, 802, 901

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0173	10/24/2008	BSC-MT-023246	BSC-MT-023260	Presentation, Resolution Clip Global Forecast		402, 403, 802, 901
PTX-0174		BSC-MT-024723	BSC-MT-024742	Presentation, Resolution Clip Marketing Plan		402, 403, 802, 901, D
PTX-0175		BSC-MT-024754	BSC-MT-024775	Presentation, Resolution Clip Marketing Plan		402, 403, 802, 901, D
PTX-0176		BSC-MT-038006	BSC-MT-038007	Product Brochure, TriClip Endoscopic Clipping Device		402, 403, 802, 901, F
PTX-0177	11/xx/2002	BSC-MT-041095	BSC-MT-041114	Presentation, Olympus Optical Co., Ltd. Competitive Profile		402, 403, 802, 901, F
PTX-0178		BSC-MT-045865	BSC-MT-045872	Gastrointestinal Endoscopy, Volume 75, No. 1: 2012, "Prospective, randomized comparison of 3 different hemoclips for the treatment of acute upper GI hemorrhage in an established experimental setting," Masayuki Kato, MD, PhD, et al		402, 403, 802, 901, F
PTX-0179		BSC-MT-079941	BSC-MT-079962	Presentation - Hemostasis Resolution Clip and Core Hemo Market Trends and Revenue Summary		402, 403, 802, 901
PTX-0180		BSC-MT-082417	BSC-MT-082417	Chart, 2013 Resolution Demand/Capacity (per forecast dated 5/3/13)		402, 403, 802, 901
PTX-0181	12/6/2013	BSC-MT-082784	BSC-MT-082784	Email from C. Davis to C. Lafferty and others re: US Clip Market Share Analysis - Cook Impact		402, 403, 802, 901, F
PTX-0182		BSC-MT-112651	BSC-MT-112704	Presentation, Resolution 360 Clip Commercialization Plan		402, 403, 802, 901
PTX-0183	1/1/2005	BSC-MT-116599	BSC-MT-116604	Contract Manufacturing Agreement, effective January 1, 2005, between Boston Scientific Scimed, Inc., and Boston Scientific		402, 403, 901, F, D
PTX-0184		BSC-MT-116682	BSC-MT-116693	Graphs, 1Q 2011 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0185		BSC-MT-116702	BSC-MT-116713	Graphs, 4Q 2010 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0186		BSC-MT-116714	BSC-MT-116725	Graphs, 2Q 2010 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0187		BSC-MT-116726	BSC-MT-116737	Graphs, 2Q 2011 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0188		BSC-MT-116738	BSC-MT-116749	Graphs, 4Q 2007 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0189		BSC-MT-116750	BSC-MT-116761	Graphs, 3Q 2010 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0190		BSC-MT-116762	BSC-MT-116773	Graphs, 3Q 2011 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0191		BSC-MT-116774	BSC-MT-116785	Graphs, 1Q 2012 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0192		BSC-MT-116786	BSC-MT-116797	Graphs, 4Q 2011 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0193		BSC-MT-116798	BSC-MT-116809	Graphs, 3Q 2012 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0194		BSC-MT-116810	BSC-MT-116821	Graphs, 2Q 2012 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0195		BSC-MT-116822	BSC-MT-116833	Graphs, 3Q 2013 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0196		BSC-MT-116834	BSC-MT-116845	Graphs, 4Q 2012 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0197		BSC-MT-116846	BSC-MT-116857	Graphs, 4Q 2013 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0198		BSC-MT-116858	BSC-MT-116869	Graphs, 1Q 2013 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0199		BSC-MT-116870	BSC-MT-116881	Graphs, 1Q 2014 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0200		BSC-MT-116882	BSC-MT-116893	Graphs, 4Q 2014 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0201		BSC-MT-116894	BSC-MT-116905	Graphs, 2Q 2014 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0202		BSC-MT-116906	BSC-MT-116917	Graphs, 1Q 2015 Hemo Clip Percent Market Share		402, 403, 802, 901, F

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0203		BSC-MT-116918	BSC-MT-116929	Graphs, 1Q 2008 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0204		BSC-MT-116930	BSC-MT-116941	Graphs, 2Q 2015 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0205		BSC-MT-116942	BSC-MT-116953	Graphs, 4Q 2015 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0206		BSC-MT-116954	BSC-MT-116965	Graphs, 2Q 2008 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0207		BSC-MT-116966	BSC-MT-116977	Graphs, 2Q 2016 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0208		BSC-MT-116978	BSC-MT-116989	Graphs, 1Q 2009 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0209		BSC-MT-116990	BSC-MT-117001	Graphs, 3Q 2009 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0210		BSC-MT-117002	BSC-MT-117013	Graphs, 2Q 2009 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0211		BSC-MT-117014	BSC-MT-117025	Graphs, 4Q 2009 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0212		BSC-MT-117026	BSC-MT-117037	Graphs, Hemo Clip Percent Market Share 2005-2007		402, 403, 802, 901, F
PTX-0213		BSC-MT-117038	BSC-MT-117049	Graphs, 4Q 2009 Hemo Clip Percent Market Share		402, 403, 802, 901, F
PTX-0214	4/6/2012	BSC-MT-118154	BSC-MT-118194	Presentation, Clipping VOC Quantitative Findings		402, 403, 802, 901, F, D
PTX-0215		BSC-MT-118547	BSC-MT-118591	Presentation, Resolution 360 Clip Commercialization Plan		402, 403, 802, 901, F
PTX-0216	5/18/2012	BSC-MT-118592	BSC-MT-118611	Presentation, Endoscopic Hemoclip Update - DDW 2012 A/P Council Meeting		403, 802, 901, F
PTX-0217	5/9/2017	BSC-MT-122195	BSC-MT-122293	Transcript from the deposition of Matthew Sprague, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB (D.Del.)		403, 701, 802, F
PTX-0218	6/13/2017	BSC-MT-122354	BSC-MT-122415	Transcript from the deposition of Michael Lynn, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0219	4/18/2017	BSC-MT-122433	BSC-MT-122522	Transcript from the deposition of Kevin Wilcox, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0220	4/25/2017	BSC-MT-123034	BSC-MT-123162	Transcript from the deposition of Christopher Davis, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0221	4/19/2017	BSC-MT-123300	BSC-MT-123418	Transcript from the deposition of Demetrios Petrou, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0222	4/26/2017	BSC-MT-123651	BSC-MT-123735	Transcript from the deposition of Marcia Nardone, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0223	3/21/2017	BSC-MT-124111	BSC-MT-124324	Transcript from the deposition of Mark Adams, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB (D.Del.)		402, 403, 701, 802, F
PTX-0224	6/23/2017	BSC-MT-127267	BSC-MT-127302	Redacted Expert Report of Dr. Oleh Haluszka, served in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB (D.Del.)		106, 402, 403, 702, 802
PTX-0225	1/xx/2020	BSC-MT-129478	BSC-MT-129520	Presentation, Clips Market Research		402, 403, 802, 901, F,
PTX-0226	1/xx/2020	BSC-MT-129559	BSC-MT-129601	Presentation, Clips Market Research		402, 403, 802, 901, F
PTX-0227	1/xx/2018	BSC-MT-129640	BSC-MT-129675	Presentation, ESC Hemoclip Brand Perception Study		403, 802, 901, F,
PTX-0228	6/23/2016	BSC-MT-129682	BSC-MT-129739	Presentation, Final Report: Micro-Tech Competitive Analysis		402, 403, 802, 901, F
PTX-0229		BSC-MT-132913	BSC-MT-132956	Presentation, Clipping VOC Quantitative Findings		402, 403, 802, 901, F

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0230		BSC-MT-140058	BSC-MT-140058	Spreadsheet, BSC Sales & Margin		402, 403, 802, 901, F, 1006, Daub
PTX-0231		BSC-MT-140059	BSC-MT-140059	Spreadsheet, Restructuring and OCOGS		402, 403, 901, F, 1006, Daub
PTX-0232		BSC-MT-140062	BSC-MT-140062	Spreadsheet, Resolution Clip Revenue		402, 403, 901, F, 1006, Daub
PTX-0233		BSC-MT-140063	BSC-MT-140063	Spreadsheet, HQ Endoscopy P&L 2011-2018		402, 403, 901, F, 1006, Daub
PTX-0234		BSC-MT-140064	BSC-MT-140064	Spreadsheet, Legacy and Res 360 Sales 2013-2020 (Jan-June)		402, 403, 901, F, 1006, Daub
PTX-0235	8/17/2015	CMD 0614	CMD 0619	Micro-Tech Hemoclip Meeting Minutes		402, 403, 802, 901
PTX-0236	3/9/2017	CMD 2254	CMD 2258	OEM Product Release Checklist, 16mm Repositional Hemostasis Clip	Duraclip	402, 403, 802, 901
PTX-0237		CMD 2639	CMD 2653	Value Analysis Presentation 11mm & 16mm DuraClip Repositionable Hemostasis Clip		402, 403, 802, 901
PTX-0238		CMD 2823		Spreadsheet, DuraClip Revenue summary and projections 2017-2021		402, 403, 802, 901
PTX-0239	6/3/2019	CMD 4004	CMD 4012	Email from A. Carmichael re ConMed 16mm clip		402, 403, 802, 901
PTX-0240		CMD 4017	CMD 4021	Presentation, Hemostatic Clips for GI Overview and Clinical Use		402, 403, 802, 901
PTX-0241	2/xx/2016	CMD 4233	CMD 4266	Presentation, ConMed Global Sales Meeting		402, 403, 802, 901
PTX-0242		CMD 5094	CMD 5111	Redacted Presentation, Global Endoscopic Market		106, 402 403, 802, 901
PTX-0243	6/23/2017	COOK3P_BSCvMT-DE000303	COOK3P_BSCvMT-DE000573	Redacted Expert Report of John R. Bone, CPA, served in Boston Scientific Corporation and Boston Scientific SciMed, Inc. v. Cook Group Incorporated and Cook Medical LLC, Civil Action No. 15-980-LPS-CJB		106, 402, 403, 702, 802, F, CP, Daub
PTX-0244		HS00000002	HS00000003	Henry Schein GI Brochure		403
PTX-0245	5/18/2016	HS00000008	HS00000011	Question/Answers, Micro-Tech Launch May 18, 2016 - Dallas TX	HS-2	402, 403
PTX-0246		HS00000046	HS00000069	Micro-Tech Endoscopy Product Catalog	HS-5	403
PTX-0247	12/2/2015	HS00000276	HS00000302	Presentation, MT Expanding the Scope of Endoscopy Partnership		403
PTX-0248		HS00000392	HS00000392	Presentation, SureClip Sales Detail		403
PTX-0249		MT00000246	MT00000264	510(K) Micro-Tech Submission - Device Description	MT-38	106, 402, 403, MIL, D
PTX-0250	7/10/2015	MT00000693	MT00000693	510(K) Micro-Tech Submission Cover Letter	MT-32	106, 402, 403, MIL, D
PTX-0251		MT00000819	MT00000823	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	MT-34	106, 402, 403, MIL, D
PTX-0252		MT00012499	MT00012499	Spreadsheet, COGS Details through 2019		403
PTX-0253		MT00004210	MT00004212	Joseph Romagnuolo, Endoscopic clips: Past, present and future Can J. Gastroenterol Vol. 23 No. 3 March 2009		403

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0254		MT00005927	MT00005927	Brochure, Micro-Tech Endoscopy Introduces the SURE CLIP	MT-6	403
PTX-0255	10/31/2015	MT00005936	MT00005938	SureClip by Micro-Tech - Excellent Performance, winning oversea users "heart"		402, 403
PTX-0256		MT00005939	MT00005948	Micro-Tech Product Brief - Hemostasis Clip		402, 403
PTX-0257		MT00011649	MT00011649	Spreadsheet, Sales Data Micro-Tech SureClips		403
PTX-0258		MT00012459	MT00012459	Spreadsheet, Quarterly Profit and Loss Statement 2016 to 2019		403
PTX-0259		MT00012460	MT00012460	Spreadsheet, SureClip Revenue and COGS Summary		403
PTX-0260	5/14/2017	MT00012474	MT00012497	Distribution and Supply Agreement, effective May 14, 2017 between Micro-Tech Endoscopy USA and Henry Schein, Inc.		402, 403
PTX-0261	12/21/2015	MT00012502	MT00012506	Regulatory Agreement, effective December 21, 2015 between Commed Corporation and Micro-Tech (Nanjing) Co. Ltd.		402, 403
PTX-0262	9/23/2016	MT00012513	MT00012528	Supply Agreement between ConMed Corporation and Micro-Tech Endoscopy USA, Inc., effective September 23, 2016		402, 403
PTX-0263	7/10/2020			Plaintiffs Amended Complaint		
PTX-0264				S&P Capital IQ Boston Scientific SciMed, Inc. Private Company Profile		402, 403, 802, 901, F, UT
PTX-0265				Micro Tech webpage, About Us ( <a href="http://www.micro-tech.com.cn/en/web/about/about_us_1.html">http://www.micro-tech.com.cn/en/web/about/about_us_1.html</a> )		402, 403
PTX-0266				Micro Tech webpage, About Us - Milestones ( <a href="http://www.micro-tech.com.cn/en/web/about/about_us_3.html">http://www.micro-tech.com.cn/en/web/about/about_us_3.html</a> )		402, 403
PTX-0267				Micro Tech webpage, Product Center - Gastrointestinal ( <a href="http://www.micro-tech.com.cn/en/web/product/product-center_107.html">http://www.micro-tech.com.cn/en/web/product/product-center_107.html</a> )		402, 403
PTX-0268				Micro Tech webpage, Product Center - Biliary ( <a href="http://www.micro-tech.com.cn/en/web/product/product-center_106.html">http://www.micro-tech.com.cn/en/web/product/product-center_106.html</a> )		402, 403
PTX-0269				Micro Tech webpage, Product Center - Pulmonary ( <a href="http://www.micro-tech.com.cn/en/web/product/product-center_105.html">http://www.micro-tech.com.cn/en/web/product/product-center_105.html</a> )		402, 403
PTX-0270				Micro Tech webpage, Product Center - Accessories ( <a href="http://www.micro-tech.com.cn/en/web/product/product-center_104.html">http://www.micro-tech.com.cn/en/web/product/product-center_104.html</a> )		402, 403
PTX-0271				Micro Tech Endoscopy webpage, Products ( <a href="https://www.mtendoscopy.com/products/">https://www.mtendoscopy.com/products/</a> )		402, 403
PTX-0272				Henry Schein webpage, About Henry Schein ( <a href="http://investor.henryschein.com/aboutus?hsid_domain=www.henryschein.com&amp;hsid_locale=us-en">http://investor.henryschein.com/aboutus?hsid_domain=www.henryschein.com&amp;hsid_locale=us-en</a> )		402, 403
PTX-0273				Complaint filed in Boston Scientific Corporation and Boston Scientific SciMed, Inc. v. Cook Group Incorporated and Cook Medical LLC, Civil Action No. 15-980-LPS-CJB		402, 403, F

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0274				Defendant Micro-Tech Endoscopy USA Inc.'s Second Supplemental Responses to Plaintiffs' First Set of Common Interrogatories, July 21, 2020		403
PTX-0275	11/26/2018			Complaint for patent infringement		D
PTX-0276				"Endoscopy," UK National Health Service, ( <a href="http://www.nhs.uk/conditions/Endoscopy/Pages/Introduction.aspx">http://www.nhs.uk/conditions/Endoscopy/Pages/Introduction.aspx</a> )		403, 802, F
PTX-0277				Boston Scientific Hemostasis Solutions Overview, ( <a href="https://www.bostonscientific.com/content/dam/bostonscientific/end/o/portfolio/group/Gold%20Probe/hemostasis_solutions_overview.pdf">https://www.bostonscientific.com/content/dam/bostonscientific/end/o/portfolio/group/Gold%20Probe/hemostasis_solutions_overview.pdf</a> )		402, 403, 802
PTX-0278				Endoscopic Closure Devices, ( <a href="https://www.asge.org/docs/default-source/education/Technology_Reviews/doc71b1f624-8039-486a-8fae-3886b9745e15.pdf?sfvrsn=6">https://www.asge.org/docs/default-source/education/Technology_Reviews/doc71b1f624-8039-486a-8fae-3886b9745e15.pdf?sfvrsn=6</a> )		402, 403, F
PTX-0279				The History of Clips in Endoscopy, Cook Medical, <a href="https://www.cookmedical.com/endoscopy/the-history-of-clips-in-endoscopy/">https://www.cookmedical.com/endoscopy/the-history-of-clips-in-endoscopy/</a>		402, 403, F
PTX-0280				Boston Scientific webpage, Resolution 360 Clip, ( <a href="http://www.bostonscientific.com/en-US/products/clips/Resolution-360-Clip.html">http://www.bostonscientific.com/en-US/products/clips/Resolution-360-Clip.html</a> )		402, 403, 802
PTX-0281				Role of Clips in Therapeutic Endoscopy: A Review, Journal of Gastroenterology and Hepatology Research, ( <a href="http://www.ghrnet.org/index.php/joghr/article/view/605/651">http://www.ghrnet.org/index.php/joghr/article/view/605/651</a> )		402, 403, 802, F
PTX-0282				Olympus Launches New Reloadable Hemostasis Clip for GI Endoscopy, ( <a href="https://www.prnewswire.com/news-releases/olympus-launches-new-reloadable-hemostasis-clip-for-gi-endoscopy-301098925.html">https://www.prnewswire.com/news-releases/olympus-launches-new-reloadable-hemostasis-clip-for-gi-endoscopy-301098925.html</a> )		402, 403, F
PTX-0283				Quick Clip Brochure, ( <a href="http://www.olympusamerica.com/presspass/press_pass_cut/documents/QuickClip2%20Long%20brochure.pdf">http://www.olympusamerica.com/presspass/press_pass_cut/documents/QuickClip2%20Long%20brochure.pdf</a> )		402, 403, F
PTX-0284	10/25/2013			510(k) Summary K132809		402, 403
PTX-0285	9/8/2014			Olympus Launches New Hemostasis Clip with Advanced Control for GI Endoscopy, ( <a href="https://medical.olympusamerica.com/articles/olympus-launches-new-hemostasis-clip-advanced-control-gi-endoscopy">https://medical.olympusamerica.com/articles/olympus-launches-new-hemostasis-clip-advanced-control-gi-endoscopy</a> )		402, 403, F
PTX-0286				RePlay hemoclip Brochure, Diversatek Healthcare, ( <a href="https://www.diversatekhealthcare.com/replay-hemostasis-clip">https://www.diversatekhealthcare.com/replay-hemostasis-clip</a> )		403, F
PTX-0287				Boston Scientific 10-K, 2014		402, 403, 802, F
PTX-0288				Boston Scientific 10-K, 2016		402, 403, 802, F

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0289				Boston Scientific 10-K, 2018		402, 403, 802, F
PTX-0290				Boston Scientific 10-K, 2019		402, 403, 802, F
PTX-0291	5/11/2017	BSC-MT-123529	BSC-MT-123568	Transcript from the deposition of Peter Gafner, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0292	4/21/2017	BSC-MT-123419	BSC-MT-123473	Transcript from the deposition of Javier Jimenez, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0293	4/27/2017	BSC-MT-123783	BSC-MT-123884	Transcript from the deposition of William Lafferty, taken in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB		402, 403, 701, 802, F
PTX-0294	12/16/2020			Reply Expert Report of John R. Bone, CPA, CFF		402, 403, 702, 802, DAUB
PTX-0295	12/16/2020			Reply Expert Report of John R. Bone - Tab 1 Curriculum Vitae		402, 403, 702, 802, DAUB
PTX-0296	12/16/2020			Reply Expert Report of John R. Bone - Tab 2 Documents Reviewed		402, 403, 702, 802, DAUB
PTX-0297	12/16/2020			Reply Expert Report of John R. Bone - Reply Exhibits 1 to 5		402, 403, 702, 802, 1006, DAUB, CP
PTX-0298	12/16/2020			Reply Expert Report of John R. Bone - Amended Exhibit 8		402, 403, 702, 802, 1006, DAUB
PTX-0299	12/16/2020			Reply Expert Report of John R. Bone - Amended Exhibit 8.3		402, 403, 702, 802, 1006, DAUB
PTX-0300	12/16/2020			Reply Expert Report of John R. Bone - Amended Exhibit 10		402, 403, 702, 802, 1006, DAUB
PTX-0301	12/16/2020			Reply Expert Report of John R. Bone - Amended Exhibit 22		402, 403, 702, 802, 1006, DAUB
PTX-0302	12/16/2020			Reply Expert Report of John R. Bone - Amended Exhibit 22.1		402, 403, 702, 802, 1006, Daub
PTX-0303				Webpage, <a href="https://www.bostonscientific.com/en-US/products/clips/resolution-clip.html">https://www.bostonscientific.com/en-US/products/clips/resolution-clip.html</a>		402, 403, 802
PTX-0304	5/31/2016	BSC-MT-118488	BSC-MT-118515	Presentation, Resolution 360 WIDE		402, 403, 802
PTX-0305		BSC-MT-004637	BSC-MT-004657	Presentation, Micro-Tech Hemoclips Competitive Overview		402, 403, 802, 1006, F
PTX-0306		HS00000393	HS00000393	Spreadsheet, SureClip Sales detail		403
PTX-0307		HS00000396	HS00000396	Spreadsheet, Micro-Tech Endoscopy USA P&L		403
PTX-0308	9/11/2000	BSC-MT-043935	BSC-MT-043978	Hemostasis Clipping Device Integrated Business Plan, Development Phase Review		402, 403, 802, 901, F
PTX-0309	10/23/2020			Expert Report of Dr. Oleh Haluszka, M.D.		402, 403, 702, 802
PTX-0310	10/23/2020			Exhibit A to the Expert Report of Dr. Oleh Haluszka - Curriculum Vitae		402, 403, 702, 901, F
PTX-0311	10/23/2020			Exhibit B to the Expert Report of Dr. Oleh Haluszka - Materials Considered		402, 403, 702

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0312	6/23/2017	BSC-MT-127267	BSC-MT-127302	Redacted Expert Report of Dr. Oleh Haluszka, served in Boston Scientific v. Cook Group, Civil Action No. 15-980-LPS-CJB (D.Del.)		106, 402, 403, 702, 802, F
PTX-0313				SureClip Marketing Brochure, available at <a href="https://www.mtendoscopy.com/wpcontent/uploads/2019/10/SureClip_MPW3000R_Rev5.pdf">https://www.mtendoscopy.com/wpcontent/uploads/2019/10/SureClip_MPW3000R_Rev5.pdf</a>		403, 901
PTX-0314				Lockado Marketing Brochure, available at <a href="https://www.mtendoscopy.com/wpcontent/uploads/2020/08/Lockado_MPW30800A-Rev-2-FNL.pdf">https://www.mtendoscopy.com/wpcontent/uploads/2020/08/Lockado_MPW30800A-Rev-2-FNL.pdf</a>		403, 901
PTX-0315				SureClip Instructions for Use, available at <a href="https://www.mtendoscopy.com/wp-content/uploads/2020/09/D000008502-%EF%BC%881-0010546%EF%BC%8CREV-5-%EF%BC%89-IFUlockado-added.pdf">https://www.mtendoscopy.com/wp-content/uploads/2020/09/D000008502-%EF%BC%881-0010546%EF%BC%8CREV-5-%EF%BC%89-IFUlockado-added.pdf</a>		403, 901
PTX-0316				MAUDE - Manufacturer and User Facility Device Experience, FDA, available at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/results.cfm?start_search=1&amp;searchyear=&amp;productcode=PKL&amp;productproblem=1261&amp;device name=&amp;knumber=k&amp;pmanumber=p&amp;manufacturer=&amp;brandname=&amp;eventtype=&amp;reportdatefrom=01/1/2014&amp;reportdateto=&amp;pagenum=10">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/results.cfm?start_search=1&amp;searchyear=&amp;productcode=PKL&amp;productproblem=1261&amp;device name=&amp;knumber=k&amp;pmanumber=p&amp;manufacturer=&amp;brandname=&amp;eventtype=&amp;reportdatefrom=01/1/2014&amp;reportdateto=&amp;pagenum=10</a>		106, 402, 403, 901, F
PTX-0317	12/16/2020			Reply Expert Report of Dr. Oleh Haluszka, M.D.		402, 403, 702, 802
PTX-0318				Thomas J. Wang, "Choosing the right through-the-scope clip: a rigorous comparison of rotatability, whip, open/close precision, and closure strength," Gastrointestinal Endoscopy Volume 89, No. 1 (2019) 77-86		402, 403, 802, 901, F
PTX-0319				Micro-Tech USA SureClip Hemostasis Clip Data Sheet		402, 403, 901, F
PTX-0320	5/12/2015	MT00000035	MT00000046	Product Performance Specification for Sterile Repositionable Hemostasis Clipping Device		403
PTX-0321		MT00000093	MT00000104	SureClip Repositionable Hemostasis Clip Instructions for use		403, F
PTX-0322		MT00000020	MT00000020	Video, Animation of clip		403, D
PTX-0323				SureClip Repositionable Hemostasis Clip Instructions for Use		403, 901, F, D
PTX-0324				Claim Construction Order, DI 140		
PTX-0325		BSC-MT-018337	BSC-MT-018338	Instinct Endoscopic Hemoclip brochure, Cook Medical		402, 403, 802, 901, F

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0326	10/23/2020			Excerpts, Expert Report of John R. Bone, CPA, CFF, dated October 23, 2020		106, 402, 403, 702, 802, Daub
PTX-0327	10/22/2020			Excerpts, Expert Report of Dr. Oleh Haluszka, M.D., dated October 22, 2020		106, 402, 403, 702, 802
PTX-0328	12/16/2020			Excerpts, Reply Expert Report of Dr. Oleh Haluszka, M.D., dated December 16, 2020		106, 402, 403, 702, 802
PTX-0329	12/16/2020			Excerpts, Reply Expert Report of John R. Bone, CPA, CFF, dated December 16, 2020.		106, 402, 403, 702, 802, Daub
PTX-0330	12/16/2020			Excerpts, Reply Expert Report Of Karl R. Leinsing, MSME, PE, Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, And 9,980,725, Boston Sci.		106, 402, 403, 702, 802, Daub
PTX-0331	1/6/2021			Excerpts, Deposition of Michael Plishka, January 6, 2021, In The Matter Of Boston Scientific Corp. v. Micro Tech Endoscopy, dated January 6, 2021		106, 402, 403, DESC
PTX-0332				Glossary of Metallurgical and Metalworking Terms, Metals Handbook Desk Edition, Second Ed., 1998	Plishka 27	106, 402, 403, 802, 901, F, UT
PTX-0333	12/29/2020			Excerpts, Deposition of Karl Leinsing, December 29, 2020, In The Matter Of Boston Scientific Corp. v. Micro Tech Endoscopy, dated December 29, 2020		106, 402, 403, 702, 802, Daub, D, DESC
PTX-0334	10/23/2020			Excerpts, Opening Expert Report Of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, And 9,980,725, Boston Sci. Corp. v. Micro-Tech Endoscopy et al., dated October 23, 2020.		106, 402, 403, 702, 802, D, Daub
PTX-0335		BSC-MT-000001	BSC-MT-000039	U.S. Patent 7,094,245		403, 1005, D
PTX-0336		BSC-MT-000040	BSC-MT-000078	U.S. Patent 8,974,371		403, 1005, D
PTX-0337		BSC-MT-000079	BSC-MT-000118	U.S. Patent 9,980,725		403, 1005, D
PTX-0338		MT00011117	MT00011131	SureClip Repositionable Hemostasis Clip Instructions for Use		403, F, D
PTX-0339	12/4/2020			Excerpts of the Rebuttal Expert Report of Karl R. Leinsing, MSME, PE Regarding Validity of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated December 4, 2020		106, 402, 403, 702, 802, Daub
PTX-0340	10/23/2020			Excerpts from Opening Expert Report Of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, And 9,980,725, Boston Sci. Corp. v. Micro-Tech Endoscopy et al., dated October 23, 2020		106, 402, 403, 702, 802, Daub

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0341	12/16/2020			Excerpts from Reply Expert Report Of Karl R. Leinsing, MSME, PE, Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, And 9,980,725, Boston Sci. Corp. v. Micro-Tech Endoscopy et al., dated December 16, 2020		106, 402, 403, 702, 802, 901, F, Daub
PTX-0342				Certified copy of U.S. Patent No. 8,974,371		403, D
PTX-0343				Excerpts of the Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated October 23, 2020		106, 402, 403, 702, 802, Daub, DESC
PTX-0344				Excerpts of the Reply Expert Report of Karl R. Leinsing, MSME, PE Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated December 16, 2020		106, 402, 403, 702, 802, Daub, DESC
PTX-0345				Excerpts of the Rebuttal Expert Report of Karl R. Leinsing, MSME, PE Regarding Validity of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated December 4, 2020		106, 402, 403, 702, 802, Daub
PTX-0346				Excerpts from the Day 1 transcript of the deposition of Karl R. Leinsing, dated December 29, 2020		106, 402, 403, 702, 802, Daub,
PTX-0347				Excerpt from the New Oxford American Dictionary, 2001 ed., for the word "tab."		402, 403, 802, 901, F, DESC
PTX-0348				Excerpts of Plaintiffs Boston Scientific Corporation and Boston Scientific Scimed, Inc.'s Third Supplemental Responses and Objections to Defendants' Third Set of Interrogatories (Nos. 11, 13)		106, 402, 403, 802
PTX-0349				Excerpts of the deposition transcript of Michael Plishka, dated January 6, 2021		106, 402, 403
PTX-0350				Excerpts of the Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated October 23, 2020.		106, 402, 403, 702, 802, Daub
PTX-0351				Excerpts of the Reply Expert Report of Karl R. Leinsing, MSME, PE Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 dated December 16, 2020.		106, 402, 403, 702, 802, Daub
PTX-0352				Exhibit 138 to the deposition of Karl R. Leinsing.		D, 403, 901, F, 702
PTX-0353				Excerpts of the deposition transcript of Michael Plishka, dated January 6, 2021		106, 402, 403
PTX-0354				Glossary of Metallurgical and Metalworking Terms, Metals Handbook Desk Edition, Second Ed., 1998	Plishka 27	106, 402, 403, 802, 901, F, UT, D

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0355				Excerpts from the Day 1 transcript of the deposition of Karl R. Leinsing, dated December 29, 2020.		106, 402, 403, 702, 802, Daub, D, DESC
PTX-0356				Certified copy of U.S. Patent No. 7,094,245.		403, D
PTX-0357				S10(K) Micro-Tech Submission - Substantially Equivalent Discussions	Plishka 11	106, 402, 403, MIL,
PTX-0358		MT00011461	MT00011481	Excerpts of "Sterile Repositionable Hemostasis Clipping Device"		106, 402, 403, 802
PTX-0359				Excerpts of the Rebuttal Expert Report of Michael Plishka Regarding Noninfringement		106, 403, D
PTX-0360				Excerpt of Deposition Transcript of Karl Leinsing dated December 29, 2020		106, 402, 403, 702, 802, Daub
PTX-0361				Excerpts of the Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725 dated October 23, 2020		106, 402, 403, 702, 802, Daub
PTX-0362				Excerpts of the Reply Expert Report of Karl R. Leinsing, MSME, PE Regarding Infringement of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725 dated December 16, 2020		106, 402, 403, 702, 802, Daub
PTX-0363		BSC-MT-001591	BSC-MT-001788	Certified copy of File History for U.S. Patent No. 9,980,725		403, D
PTX-0364				Excerpt of Markman Hearing Transcript dated June 24, 2020		106
PTX-0365		BSC-MT-000040	BSC-MT-000078	United States Patent No. 8,974,371 ("371 patent")		403, 1005, D
PTX-0366		BSC-MT-000079	BSC-MT-000118	United States Patent No. 9,980,725 ("725 patent")		403, 1005, D
PTX-0367				Excerpts of Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725 ("Leinsing Opening Infringement Report")		106, 402, 403, 702, 802, Daub
PTX-0368				Excerpts of Rebuttal Expert Report of Karl R. Leinsing, MSME, PE Regarding Validity of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725.		106, 402, 403, 702, 802, Daub
PTX-0369	12/2/2015	HS00000276	HS00000302	Micro-Tech Partnership Presentation, Expanding the Scope of Endoscopy	HS-1	402, 403
PTX-0370	5/18/2016	HS00000008	HS00000011	Micro-Tech Launch Product Category Overview Questions and Answers	HS-2	402, 403
PTX-0371		HS00000004	HS00000007	Henry Schein Medical Brochure, One Source Henry Schein Medical has teamed up with Micro-Tech Endoscopy to deliver your GI Endoscopy needs from one source.	HS-4	403
PTX-0372		HS00000046	HS00000069	Micro-Tech Endoscopy Product Catalog	HS-5	403
PTX-0373	9/1/2019	HS00000154	HS00000257	Henry Schein Medical Featured Product Guide July-September 2019	HS-6	403
PTX-0374		HS00000264	HS00000264	GI Course & Model Summary ASC Focus FSC Curriculum, Course #2	HS-7	402, 403

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0375		HS000000271	HS000000275	ASC Curriculum Script Module 5 Script	HS-8	402, 403
PTX-0376		HS000000039	HS000000039	Micro-tech Sales Success Stories	HS-9	403
PTX-0377	7/15/2020	HS000000393	HS000000393	Spreadsheet, List of Customer Information	HS-10	403
PTX-0378	7/15/2020	HS000000394	HS000000394	Spreadsheet, 2016-2020 Net Sales by Item	HS-11	403
PTX-0379	7/15/2020	HS000000395	HS000000395	Spreadsheet, Purchase Order Data	HS-12	403
PTX-0380	7/15/2020	HS000000396	HS000000396	Spreadsheet, 2016-1Q2020, Profit and Loss Statement	HS-13	403
PTX-0381	11/20/2016	MT00011879	MT00012458	US Market Report Suite for Gastrointestinal Devices by iData Research	MT-4	402, 403
PTX-0382		MT00005901	MT00005911	SureClip Repositional Hemostasis Clip, Value Analysis Presentation	MT-5	403
PTX-0383		MT00005927	MT00005927	Brochure, Micro-Tech Endoscopy Introduces the SURE CLIP	MT-6	403
PTX-0384		MT00005939	MT00005948	Micro-Tech Endoscopy Product Brief: Hemostasis Clip	MT-7	402, 403
PTX-0385				SureClip Brochure, Clip With Confidence	MT-8	402, 403, 901
PTX-0386		MT00012460	MT00012460	Spreadsheet, SureClip Revenue and COGS 2016-2019	MT-9	403
PTX-0387				Webpage, Product Cross Reference Tool, Product Code ConMed: DCO165; Comparable Micro-Tech Product: RC30445	MT-10	402, 403
PTX-0388				Webpage, Product Cross Reference Tool, Product Code ConMed DCO235, Comparable Micro-Tech Product: RC30445	MT-11	402, 403
PTX-0389	7/22/2020	MT00012499	MT00012499	Spreadsheet, 2016-2019 Revenue and COGS	MT-12	403
PTX-0390	7/22/2020	MT00000084	MT00000084	Spreadsheet, SureClip Revenue and COGS Summary 2016-2019	MT-13	403
PTX-0391	7/22/2020	MT00012498	MT00012498	Spreadsheet, Purchase Summary 2016-2019	MT-14	403
PTX-0392	7/22/2020	MT00012459	MT00012459	Spreadsheet, Profit and Loss Statement 2016-2019	MT-15	403
PTX-0393				Image, J-Hook configuration	MT-22	402, 403, DESC, F, 901
PTX-0394				Image, Components of buckle configuration	MT-23	402, 403, DESC, F, 901
PTX-0395				Image, Components of buckle configuration	MT-24	402, 403, DESC, F, 901
PTX-0396				Image, Components of buckle configuration	MT-25	402, 403, DESC, F, 901
PTX-0397				Image, Components of the Lockado design	MT-26	402, 403, DESC, F, 901
PTX-0398				Image, Components of the Lockado design	MT-27	402, 403, DESC, F, 901
PTX-0399				Image, Components of the Lockado design	MT-28	402, 403, DESC, F, 901
PTX-0400				Image, Components of the Lockado design	MT-29	402, 403, DESC, F, 901
PTX-0401				Image, Components of the Lockado design	MT-30	402, 403, DESC, F, 901
PTX-0402	7/27/2020	MT00011649	MT00011649	Spreadsheet, Sales Data Micro-Tech SureClips	MT-31	402, 403, DESC
PTX-0403	7/10/2015	MT00000693	MT00000693	510(K) Micro-Tech Submission Cover Letter	MT-32	106, 402, 403, MIL, D
PTX-0404		MT00000770	MT00000786	510(K) Micro-Tech Submission - Micro-Tech Device Description	MT-33	106, 402, 403, DESC, D, MIL
PTX-0405		MT00000819	MT00000823	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	MT-34	106, 402, 403, DESC, MIL, D

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0406	1/4/2017	MT00001185	MT00001209	510(K) Submission - Device Descriptions Updated	MT-35	106, 402, 403, DESC, D, MIL
PTX-0407	5/23/2016	MT00001159	MT00001159	510(K) Submission Cover Letter dated 5/23/2016	MT-36	106, 402, 403, MIL
PTX-0408		MT00001276	MT00001280	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	MT-37	106, 402, 403, DESC, MIL
PTX-0409		MT00000246	MT00000264	510(K) Micro-Tech Submission - Device Description	MT-38	106, 402, 403, DESC, D, MIL
PTX-0410	9/3/2018	MT00001944	MT00001944	510(K) Micro-Tech Submission - Cover Letter	MT-39	106, 402, 403, MIL
PTX-0411	11/15/2018	MT00000446	MT00000451	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	MT-40	106, 402, 403, DESC, D, MIL
PTX-0412	1/4/2017	MT00000923	MT00000925	510(K) Micro-Tech Submission - Response to K161463/S001 Deficiencies	MT-41	106, 402, 403, DESC, D, MIL
PTX-0413		BSC-MT-110282	BSC-MT-110287	Quick Clip (Excerpted from BSCs 510K)	J 0006	106
PTX-0414		MT00018424	MT00018424	Video of Olympus Quick Clip	J 0007	403
PTX-0415				MT00018424 Screenshots, Video of Olympus Quick Clip	J 0008	403
PTX-0416				MT00018424 Screenshots2, Video of Olympus Quick Clip	J 0009	403
PTX-0417				MT00018424 Screenshots3, Video of Olympus Quick Clip	J 0010	403
PTX-0418				MT00018424 Screenshots4, Video of Olympus Quick Clip	J 0011	403
PTX-0419		MT00014279	MT00014279	Video	J 0019	
PTX-0420		MT00000770	MT00000786	510(K) Micro-Tech Submission - Micro-Tech Device Description	Plishka 8 MT-33	106, 402, 403, D, MIL
PTX-0421		MT00000819	MT00000823	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	Plishka 9 MT-34	106, 402, 403, D, MIL
PTX-0422	1/4/2017	MT00001185	MT00001209	510(K) Submission - Device Descriptions Updated	Plishka 10 MT-35	106, 402, 403, D, MIL
PTX-0423	11/15/2018	MT00000446	MT00000451	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	Plishka 11 MT-40	106, 402, 403, D, MIL
PTX-0424	1/4/2017	MT00000923	MT00000925	510(K) Micro-Tech Submission - Response to K161463/S001 Deficiencies	Plishka 12 MT-41	106, 402, 403, D, MIL
PTX-0425		MT00000246	MT00000264	510(K) Micro-Tech Submission - Device Description	Plishka 13 MT-38	106, 402, 403, D, MIL
PTX-0426				Video, Clip Animation	Plishka 14	901
PTX-0427	11/16/2020			Video, Impact of Distal Pin	Plishka 15	901
PTX-0428				Test Video	Plishka 16	403, 901
PTX-0429				Test Video	Plishka 17	403, 901
PTX-0430	11/11/2020			Buckle Test Report	Plishka 18	403, 901
PTX-0431	11/11/2020			J-Hook Test Report	Plishka 19	403, 901

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0432	11/11/2020			Lockado Test Report	Plishka 20	403, 901
PTX-0433	1/21/2020			Declaration of Michael Plishka, Becton Exhibit 2002, Baxter International v. Becton Dickson IPR2020-00024 (U.S. Patent No. 8,740,864)	Plishka 21	402, 403
PTX-0434	11/1/2017			Declaration of Michael Plishka, Nevro Corp. Ex. 1003, Nevro Corp. v. Boston Scientific Neuromodulation Corp, IPR2018-00143 (U.S. Patent No. 7,891,085)	Plishka 22	402, 403
PTX-0435	10/28/2004			US Patent Application Publication US 2004/0215300 A1, Nevro Corp Ex. 1007, Nevro Corp. v. Boston Scientific Neuromodulation Corp., IPR2018-00143 (U.S. Patent No. 7,891,085)	Plishka 23	402, 403
PTX-0436	4/1/2008			World Intellectual Property WO 03/022337	Plishka 24	402, 403, F, CP, DESC, 901, 1005
PTX-0437				Figure 3 and Figure 4	Plishka 25	106, 402, 403, 802, 901, F, DESC
PTX-0438	1/1/2010			Glossary of Terms, ASM Handbook, Volume 22B, Metals Process Simulation (2010)	Plishka 26	106, 402, 403, 802, 901, F, UT, D
PTX-0439	xx/xx/1998			Glossary of Metallurgical and Metalworking Terms, Metals Handbook Desk Edition, Second Ed., 1998	Plishka 27	106, 402, 403, 802, 901, F, UT, D
PTX-0440				Fracture Mechanics, by E.E. Gdoutos, Published by Springer 2005, ISBN 1-4020-3153-X (e-book).	Plishka 28	106, 402, 403, 802, 901, F, Daub, SJ, DESC
PTX-0441	11/15/2018	MT00000446	MT00000451	510(K) Micro-Tech Submission - Substantially Equivalent Discussions	Plishka 29 MT-40	106, 402, 403, D, MIL
PTX-0442	11/1/1997			ASM Handbook Volume 19, Fatigue and Fracture	Plishka 30	402, 403, 901
PTX-0443		MT00001503	MT00001510	Instructions for Use of Sterile of Repositionable Hemostasis Clipping Device	Plishka 31	402, 403
PTX-0444	1/1/2018	BSC-MT-129640	BSC-MT-129675	Presentation ESC Hemoclip Brand Perception Study January 2018	Milani 3	402, 403, 802, 901, F
PTX-0445	12/4/2020			Expert Report of Gary Reiss, MD	Reiss 1	
PTX-0446	11/26/2018			Complaint for Patent Infringement		D
PTX-0447	2/19/2020			Answer and Affirmative Defenses to Plaintiffs' Complaint for Patent Infringement		
PTX-0448	3/9/2020			First Amended Answer and Affirmative Defenses to Plaintiffs' Complaint for Patent Infringement		
PTX-0449	4/14/2020			Second Amended Answer and Affirmative Defenses to Plaintiffs' Complaint for Patent Infringement		
PTX-0450	7/10/2020			Plaintiffs' Amended Complaint		

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0451	7/24/2020			Answer and Affirmative Defenses to Plaintiffs' Amended Complaint for Patent Infringement		
PTX-0452	10/9/2019			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery		402, 403, 802
PTX-0453	9/27/2019			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed Inc.'s Initial Disclosures Pursuant to Federal Civil Procedure 26(a)(1)		402, 403, 802
PTX-0454	8/31/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed Inc.'s Supplemental Initial Disclosures Pursuant to Federal Civil Procedure 26(a)(1)		402, 403, 802
PTX-0455	10/2/2019			Plaintiffs' Disclosures of Accused Products, Damages Model, Infringed Patents and File Histories		402, 403, 802
PTX-0456	9/27/2019			Initial Disclosures of Defendants Micro-Tech Endoscopy USA Inc. and Henry Schein Inc.		
PTX-0457	2/14/2020			Initial Disclosures of Defendant Micro-Tech (Nanjing) Co., Ltd.		
PTX-0458	7/1/2020			Claim Construction Order, D.I. 140		
PTX-0459	8/27/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, Micro-Tech (Nanjing) Co., Ltd., and Henry Schein Inc.'s First Set of Requests for Admission (Nos. 1-5)		402, 403, 802
PTX-0460	9/11/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, Micro-Tech (Nanjing) Co., Ltd., and Henry Schein Inc.'s Second Set of Requests for Admission (Nos. 6-20)		402, 403, 802
PTX-0461	10/16/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, Micro-Tech (Nanjing) Co., Ltd., and Henry Schein Inc.'s Second Set of Requests for Admission (Nos. 9, 12, 14, 16, 17)		402, 403, 802
PTX-0462	9/27/2019			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s First Set of Interrogatories (Nos. 1-8)		402, 403, 802

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0463	12/26/2019			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s Second Set of Interrogatories (No. 9)		402, 403, 802
PTX-0464	2/3/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s First Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s First Set of Interrogatories (No. 3)		402, 403, 802
PTX-0465	3/24/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s First Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s First Set of Interrogatories (Nos. 2 and 5)		402, 403, 802
PTX-0466	4/9/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, Micro-Tech (Nanjing) Co., Ltd., and Henry Schein Inc.'s Third Set of Interrogatories (Nos. 10-13)		402, 403, 802
PTX-0467	8/3/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Third Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s Interrogatories (Nos. 2, 4, 7, and 9)		402, 403, 802
PTX-0468	8/3/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s First Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, Micro-Tech (Nanjing) Co., Ltd., and Henry Schein Inc.'s Third Set of Interrogatories (No. 12)		402, 403, 802
PTX-0469	8/28/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Supplemental Responses and Objections to Defendants' Third Set of Interrogatories (No. 11)		402, 403, 802
PTX-0470	9/8/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Fourth Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s Interrogatories (No. 5)		402, 403, 802
PTX-0471	9/11/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Fifth Supplemental Responses and Objections to Defendants Micro-Tech Endoscopy USA Inc.'s, and Henry Schein Inc.'s Interrogatories (No. 4)		402, 403, 802

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PTX-0472	9/11/2020			Plaintiffs Boston Scientific Corporation's and Boston Scientific Scimed, Inc.'s Third Supplemental Responses and Objections to Defendants' Third Set of Interrogatories (No. 11, 13)		402, 403, 802
PTX-0473		BSC-MT-137075	BSC-MT-137075	Research and Development Financial Model, Rotatable Clip		402, 403, 901, 1006, F
PTX-0474		BSC-MT-137078	BSC-MT-137078	Research and Development Financial Model, Rotatable Clip		402, 403, 901, 1006, F
PTX-0475		BSC-MT-137092	BSC-MT-137092	Research and Development Financial Model, Rotatable Clip August 15 PIB		402, 403, 901, 1006, F
PTX-0476		BSC-MT-137096	BSC-MT-137096	Research and Development Financial Model, Rotatable Clip Feb 16 Update		402, 403, 901, 1006, F
PTX-0477		BSC-MT-137677	BSC-MT-137677	Research and Development Financial Model, Rotatable Clip		402, 403, 901, 1006, F
PTX-0478		BSC-MT-140061	BSC-MT-140061	Research and Development Financial Model, New assumptions only		402, 403, 901, 1006, F
PTX-0479		BSC-MT-003056	BSC-MT-003065	Presentation, Mastering the Competition		402, 403, 901, F
PTX-0480	5/28/2019	BSC-MT-132385	BSC-MT-132397	Presentation, Target Margins - Hemo Draft		402, 403, 901, F
PTX-0481		BSC-MT-140705	BSC-MT-140705	Spreadsheet, SCRAPS Financials Update 2012-2020		402, 403, 901, F, 1006
PTX-0482		BSC-MT-140706	BSC-MT-140706	Spreadsheet, Market Share Data Update 2012-2019		402, 403, 901, F, 1006
PTX-0483		BSC-MT-140707	BSC-MT-140707	Spreadsheet, 2004-2021 Sales Update		402, 403, 901, F, 1006
PTX-0484		BSC-MT-140708	BSC-MT-140708	Spreadsheet, US Global Profit and Loss, 2011-2020		402, 403, 901, F, 1006
PTX-0485		BSC-MT-140709	BSC-MT-140709	Spreadsheet, OPEX Detail with SG&A Expenses, 2011-2020		402, 403, 901, F, 1006
PTX-0486		MT00005912	MT00005912	Sureclip Poster, Procedural Steps for Hemostatic Clip		402, 403
PTX-0487		MT00018425	MT00018425	Spreadsheet, Product Purchase Summary and Details 2020		402, 403
PTX-0488		MT00018426	MT00018426	Spreadsheet, COGS Details from 2015-2020		402, 403
PTX-0489		MT00018427	MT00018427	Spreadsheet, COGS Summary from 2015-2020		402, 403
PTX-0490		MT00018428	MT00018428	Spreadsheet, Quarterly Profit and Loss Statement 2019 to 2020		402, 403
PTX-0491		MT00018429	MT00018429	Spreadsheet, Quarterly Profit and Loss Statement 2019 to 2020 Expanded version		402, 403
PTX-0492	4/29/2021	BSC-MT-140710	BSC-MT-140757	English translation of Micro-Tech Europe GmbH v. Boston Scientific Limited, Decision of Düsseldorf Higher Regional Court		402, 403, 901, F, MIL, UT
PTX-0493	4/29/2021	BSC-MT-140758	BSC-MT-140805	Micro-Tech Europe GmbH v. Boston Scientific Limited, Decision of Düsseldorf Higher Regional Court		402, 403, 901, 1005, F, MIL, UT
PTX-0494		BSC-MT-140806	BSC-MT-140806	Spreadsheet, Clips Market Share Q1 2021		402, 403, 901, 1006, F, UT
PTX-0495	4/27/2021	BSC-MT-140807	BSC-MT-140815	Transcript, Minutes of the public hearing of the Court in Boston Scientific Limited v. Micro-Tech GmbH		402, 403, 901, 802, 1005, F, MIL, UT
PTX-0496		BSC-MT-140816	BSC-MT-140816	Video, Animation of Resolution 360 Clip		402, 403, 901, F, UT
PTX-0497		BSC-MT-140817	BSC-MT-140817	Video, Resolution 360 Clip		402, 403, 901, F, UT
PTX-0498	5/4/2020			Micro-Tech Nanjing et al. v. Boston Scientific Scimed IPR2020-00185 Paper No. 11 Decision Denying Institution of Inter Partes Review"		402, 403, MIL, Late

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PPX-001				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-002				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-003				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-004				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-005				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-006				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-007				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order

Schedule 7 - Plaintiffs' Trial Exhibit List

PTX No.	Date	Bates Begin	Bates End	Description	Depo Ex. #	Defendants' Objections
PPX-008				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-009				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order
PPX-010				Placeholders for Plaintiffs' Physical Exhibits		Defendants reserve the right to object to each of Plaintiffs' Physical Exhibits in accordance with the Pretrial Order

## **SCHEDULE 8**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-SB-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**DEFENDANTS' TRIAL EXHIBIT LIST (SCHEDULE 8)**

**SCHEDULE 8****Boston Scientific's Statement**

Pursuant to Rule 26(a)(3)(B) of the Federal Rules of Civil Procedure and D. Del. L.R. 16.3(d), Boston Scientific hereby objects to Defendants' Exhibit List and provides its objections. Boston Scientific objects to the unreasonable volume of trial exhibits as creating an unduly and unnecessary burden to specifically object to each of Defendants' exhibits and Boston Scientific reserves its right to provide further specific objections when Defendants have fairly narrowed their exhibits to a reasonable number for a one-week jury trial.

<b>Objection Key</b>	
Code	Objection
106	partial document/lacks context (FRE 106)
401/402	lacks relevance (FRE 401/402)
403	unduly prejudicial/confusing/waste of time (FRE 403)
501/502	Privilege/Work Product (FRE 501/502)
602/LOF	lacks foundation/speculative (FRE 602)
701/702	improper opinion (FRE 701/702)
801-802	hearsay (FRE 802)
901/902	lacks authenticity (FRE 901/902)
1002	original document required (FRE 1002)
1003	incomplete/illegible (FRE 1003)
1006	improper summary (FRE 1006)
ID	insufficient/incorrect description
L	late/not produced
AA	attorney argument improperly offered as evidence; contains counsel colloquy or objections
C	compound
Legal	calls for a legal conclusion
Leading	leading question of a non-hostile witness
MC	Mischaracterizes/misstates witness's testimony
NR	nonresponsive
PMIL	Subject of pending motion in limine
P	privilege
OS	beyond the scope
V	Vague and/or ambiguous

Schedule 8 - Defendants' Trial Exhibit List

DTX No.	Bates Begin	Bates End	Description	Deposition Exhibit No.	Plaintiffs' Objections
DTX-0001	BSC-MT-000001	BSC-MT-000039	U.S. Patent No. 7,094,245 by Adams et al.	Murray Deposition Ex. 4	
DTX-0002	BSC-MT-000040	BSC-MT-000078	U.S. Patent No. 8,974,371 by Durgin et al.	Murray Deposition Ex. 5	
DTX-0003	BSC-MT-000079	BSC-MT-000118	U.S. Patent No. 9,980,725 by Durgin et al.	Murray Deposition Ex. 6	
DTX-0004			Rebuttal Expert Report of Michael Plishka Regarding Noninfringement	Plishka Deposition Ex. 1	701/702, 801/802, 901/902, PMIL
DTX-0005			Curriculum Vitae for M. Plishka	Plishka Deposition Ex. 2	
DTX-0006			Exhibit 2 to Plishka Report – Materials Considered List	Plishka Deposition Ex. 3	401/402, 403, 801/802
DTX-0007			Certified Copy of U.S. Patent No. 7,094,245 by Adams et al.	Plishka Deposition Ex. 4	
DTX-0008			Certified Copy of U.S. Patent No. 8,974,371 by Durgin et al.	Plishka Deposition Ex. 5	
DTX-0009			Certified Copy of U.S. Patent No. 9,980,725 by Durgin et al.	Plishka Deposition Ex. 6	
DTX-0010			Claim Construction Order	Plishka Deposition Ex. 7	Legal
DTX-0011	MT00000770	MT00000786	Micro-Tech Device Description	Plishka Deposition Ex. 8	401/402, 403, 801/802, 901/902
DTX-0012	MT00000819	MT00000823	Micro-Tech Substantially Equivalent Discussion	Plishka Deposition Ex. 9	401/402, 403, 801/802, 901/902
DTX-0013	MT00001185	MT00001209	Micro-Tech Device Description	Plishka Deposition Ex. 10	401/402, 403, 801/802, 901/902
DTX-0014	MT00000446	MT00000451	Micro-Tech Substantially Equivalent Discussion	Plishka Deposition Ex. 11	401/402, 403, 801/802, 901/902
DTX-0015	MT00000923	MT00000925	Micro-Tech Response to K161463/S001 Deficiencies	Plishka Deposition Ex. 12	401/402, 403, 801/802, 901/902
DTX-0016	MT00000246	MT00000264	Micro-Tech Device Description	Plishka Deposition Ex. 13	401/402, 403, 801/802, 901/902
DTX-0017			Video	Plishka Deposition Ex. 14	401/402, 403, 801/802, 901/902
DTX-0018			Video	Plishka Deposition Ex. 15	401/402, 403, 801/802, 901/902
DTX-0019			Video	Plishka Deposition Ex. 16	401/402, 403, 801/802, 901/902
DTX-0020			Video	Plishka Deposition Ex. 17	401/402, 403, 801/802, 901/902
DTX-0021			Micro-Tech Testing Report	Plishka Deposition Ex. 18	401/402, 403, 701/702, 801/802, 901/902
DTX-0022			Micro-Tech Testing Report	Plishka Deposition Ex. 19	401/402, 403, 701/702, 801/802, 901/902
DTX-0023			Micro-Tech Testing Report	Plishka Deposition Ex. 20	401/402, 403, 701/702, 801/802, 901/902
DTX-0024			Declaration of M. Plishka for IPR 2020-0024	Plishka Deposition Ex. 21	401/402, 403, 701/702, 801/802, 901/902
DTX-0025			Declaration of M. Plishka for IPR 2018-00143	Plishka Deposition Ex. 22	401/402, 403, 701/702, 801/802, 901/902
DTX-0026			U.S. Patent App. Publication 2004/0215300 by Verness	Plishka Deposition Ex. 23	401/402, 403, 801/802
DTX-0027			Canadian Patent No. 2,429,357	Plishka Deposition Ex. 24	401/402, 403, 801/802
DTX-0028			Figures 3 and 4	Plishka Deposition Ex. 25	401/402, 403, 801/802
DTX-0029			ASM Handbook – Glossary of Terms	Plishka Deposition Ex. 26	401/402, 403, 701/702, 801/802
DTX-0030			Metals Handbook Desk Edition – Glossary of Terms and Engineering Data	Plishka Deposition Ex. 27	401/402, 403, 701/702, 801/802
DTX-0031			Fracture Mechanics – An Introduction (Second Edition)	Plishka Deposition Ex. 28	401/402, 403, 701/702, 801/802
DTX-0032	MT00000446	MT00000451	Micro-Tech Substantially Equivalent Discussion	Plishka Deposition Ex. 29	401/402, 403, 701/702, 801/802
DTX-0033			ASM Handbook – Fatigue and Fracture (Vol. 19), Todd Gross, "Micromechanisms of Monotonic and Cyclic Crack Growth"	Plishka Deposition Ex. 30	401/402, 403, 701/702, 801/802
DTX-0034	MT00001503	MT00001510	Micro-tech Instructions for Use of Sterile Repositionable Hemostasis Clipping Device	Plishka Deposition Ex. 31	401/402, 403, 801/802
DTX-0035			Curriculum Vitae of Michael Plishka		
DTX-0036			List of Materials Considered for Plishka Rebuttal Report		401/402, 403, 801/802
DTX-0037	MT00014378	MT00015185	Atlas of Stress-Strain Curves, Second Edition (ASM International) (2002)		401/402, 403, 801/802
DTX-0038	MT00017856	MT00017867	Merriam Webster Online Dictionary Definition of Fracture		401/402, 403, 801/802
DTX-0039	MT00018403	MT00018423	Elements of Metallurgy and Engineering Alloys, ASM International, Chapter 13 Fracture (2008)		401/402, 403, 801/802
DTX-0040	MT00018382	MT00018402	Excerpt from ASM Handbook, Volume 19 Fatigue and Fracture, ASM International, 1996		401/402, 403, 801/802
DTX-0041	MT00017827	MT00017845	U.S. Naval Academy, EN380 Naval Materials Science and Engineering Course Notes, Chapter 11		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0042	MT00014361	MT00014375	Excerpt from Fracture Mechanics, by T.L. Anderson, 3rd Edition (2005)		401/402, 403, 801/802
DTX-0043	MT00017868	MT00018258	Fracture Mechanics, by E.E. Gdoutos, 2nd Edition (2005)		401/402, 403, 801/802
DTX-0044	MT00018316	MT00018345	On the Mechanistic Origins of Toughness in Bone, M.E. Launey, et al. (2010)		401/402, 403, 801/802
DTX-0045	MT00018259	MT00018312	M. Hanson, On Adhesion and Galling in Metal Forming (2008)		401/402, 403, 801/802
DTX-0046			New Technique to Improve Ductility of Ceramics Materials for Missiles and Engines, ScienceDaily		401/402, 403, 801/802
DTX-0047	MT00017846	MT00017855	Li, et al, Nanoscale stacking fault-assisted room temperature plasticity in flash-sintered TiO2		401/402, 403, 801/802
DTX-0048			Boston Scientific Resolution Clip Device Video		401/402, 403, 801/802
DTX-0049	MT00017825	MT00017825	bandicam 2020-11-12 23-45-32-723		401/402, 403, 701/702, 801/802
DTX-0050	MT00018313	MT00018313	Impact of Distal Pin		401/402, 403, 701/702, 801/802
DTX-0051	MT00017826	MT00017826	BUCKLE-Test report_HIGHLY CONFIDENTIAL – ATTORNEYS EYES ONLY		401/402, 403, 701/702, 801/802
DTX-0052	MT00018314	MT00018314	JHOOK-Test report_HIGHLY CONFIDENTIAL – ATTORNEYS EYES ONLY		401/402, 403, 701/702, 801/802
DTX-0053	MT00018315	MT00018315	LOCKADO-Test report_HIGHLY CONFIDENTIAL – ATTORNEYS EYES ONLY		401/402, 403, 701/702, 801/802
DTX-0054	MT00018346	MT00018346	Test Video-1 HIGHLY CONFIDENTIAL – ATTORNEYS EYES ONLY		401/402, 403, 701/702, 801/802
DTX-0055	MT00018347	MT00018347	Test video-2 HIGHLY CONFIDENTIAL – ATTORNEYS EYES ONLY		401/402, 403, 701/702, 801/802
DTX-0056	MT00018349	MT00018349	Buckle-1-300		401/402, 403, 701/702, 801/802
DTX-0057	MT00018350	MT00018350	Buckle-1-500		401/402, 403, 701/702, 801/802
DTX-0058	MT00018348	MT00018348	Buckle-1-1000		401/402, 403, 701/702, 801/802
DTX-0059	MT00018352	MT00018352	Buckle-2-300		401/402, 403, 701/702, 801/802
DTX-0060	MT00018353	MT00018353	Buckle-2-500		401/402, 403, 701/702, 801/802
DTX-0061	MT00018351	MT00018351	Buckle-2-1000		401/402, 403, 701/702, 801/802
DTX-0062	MT00018355	MT00018355	Buckle-3-300		401/402, 403, 701/702, 801/802
DTX-0063	MT00018356	MT00018356	Buckle-3-500		401/402, 403, 701/702, 801/802
DTX-0064	MT00018354	MT00018354	Buckle-3-1000		401/402, 403, 701/702, 801/802
DTX-0065	MT00018358	MT00018358	Buckle-4-300		401/402, 403, 701/702, 801/802
DTX-0066	MT00018359	MT00018359	Buckle-4-500		401/402, 403, 701/702, 801/802
DTX-0067	MT00018357	MT00018357	Buckle-4-1000		401/402, 403, 701/702, 801/802
DTX-0068	MT00018361	MT00018361	Buckle-5-300		401/402, 403, 701/702, 801/802
DTX-0069	MT00018362	MT00018362	Buckle-5-500		401/402, 403, 701/702, 801/802
DTX-0070	MT00018360	MT00018360	Buckle-5-1000		401/402, 403, 701/702, 801/802
DTX-0071	MT00015197	MT00015197	S01-BUCKLE-X250		401/402, 403, 701/702, 801/802
DTX-0072	MT00015199	MT00015199	S01-BUCKLE-X300		401/402, 403, 701/702, 801/802
DTX-0073	MT00015200	MT00015200	S01-BUCKLE-X500		401/402, 403, 701/702, 801/802
DTX-0074	MT00015195	MT00015195	S01-BUCKLE-X1000		401/402, 403, 701/702, 801/802
DTX-0075	MT00015196	MT00015196	S01-BUCKLE-X2000		401/402, 403, 701/702, 801/802
DTX-0076	MT00015198	MT00015198	S01-BUCKLE-X2500		401/402, 403, 701/702, 801/802
DTX-0077	MT00015216	MT00015216	S02-BUCKLE-X250		401/402, 403, 701/702, 801/802
DTX-0078	MT00015218	MT00015218	S02-BUCKLE-X300		401/402, 403, 701/702, 801/802
DTX-0079	MT00015219	MT00015219	S02-BUCKLE-X500		401/402, 403, 701/702, 801/802
DTX-0080	MT00015214	MT00015214	S02-BUCKLE-X1000		401/402, 403, 701/702, 801/802
DTX-0081	MT00015215	MT00015215	S02-BUCKLE-X2000		401/402, 403, 701/702, 801/802
DTX-0082	MT00015217	MT00015217	S02-BUCKLE-X2500		401/402, 403, 701/702, 801/802
DTX-0083	MT00018364	MT00018364	J-hook-1-300		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0084	MT00018365	MT00018365	J-hook-1-500		401/402, 403, 701/702, 801/802
DTX-0085	MT00018363	MT00018363	J-hook-1-1000		401/402, 403, 701/702, 801/802
DTX-0086	MT00018367	MT00018367	J-hook-2-300		401/402, 403, 701/702, 801/802
DTX-0087	MT00018368	MT00018368	J-hook-2-500		401/402, 403, 701/702, 801/802
DTX-0088	MT00018366	MT00018366	J-hook-2-1000		401/402, 403, 701/702, 801/802
DTX-0089	MT00018370	MT00018370	J-hook-3-300		401/402, 403, 701/702, 801/802
DTX-0090	MT00018371	MT00018371	J-hook-3-500		401/402, 403, 701/702, 801/802
DTX-0091	MT00018369	MT00018369	J-hook-3-1000		401/402, 403, 701/702, 801/802
DTX-0092	MT00018373	MT00018373	J-hook-4-300		401/402, 403, 701/702, 801/802
DTX-0093	MT00018374	MT00018374	J-hook-4-500		401/402, 403, 701/702, 801/802
DTX-0094	MT00018372	MT00018372	J-hook-4-1000		401/402, 403, 701/702, 801/802
DTX-0095	MT00018376	MT00018376	J-hook-5-300		401/402, 403, 701/702, 801/802
DTX-0096	MT00018377	MT00018377	J-hook-5-500		401/402, 403, 701/702, 801/802
DTX-0097	MT00018375	MT00018375	J-hook-5-1000		401/402, 403, 701/702, 801/802
DTX-0098	MT00015203	MT00015203	S01-J-HOOK-X250		401/402, 403, 701/702, 801/802
DTX-0099	MT00015205	MT00015205	S01-J-HOOK-X300		401/402, 403, 701/702, 801/802
DTX-0100	MT00015206	MT00015206	S01-J-HOOK-X500		401/402, 403, 701/702, 801/802
DTX-0101	MT00015201	MT00015201	S01-J-HOOK-X1000		401/402, 403, 701/702, 801/802
DTX-0102	MT00015202	MT00015202	S01-J-HOOK-X2000		401/402, 403, 701/702, 801/802
DTX-0103	MT00015204	MT00015204	S01-J-HOOK-X2500		401/402, 403, 701/702, 801/802
DTX-0104	MT00015221	MT00015221	S02-J-HOOK-X250		401/402, 403, 701/702, 801/802
DTX-0105	MT00015223	MT00015223	S02-J-HOOK-X300		401/402, 403, 701/702, 801/802
DTX-0106	MT00015224	MT00015224	S02-J-HOOK-X500		401/402, 403, 701/702, 801/802
DTX-0107	MT00015220	MT00015220	S02-J-HOOK-X1000		401/402, 403, 701/702, 801/802
DTX-0108	MT00015225	MT00015225	S02-JHOOK-X2000		401/402, 403, 701/702, 801/802
DTX-0109	MT00015222	MT00015222	S02-J-HOOK-X2500		401/402, 403, 701/702, 801/802
DTX-0110	MT00018379	MT00018379	Lockado-1-300		401/402, 403, 701/702, 801/802
DTX-0111	MT00018380	MT00018380	Lockado-1-500		401/402, 403, 701/702, 801/802
DTX-0112	MT00018378	MT00018378	Lockado-1-1000		401/402, 403, 701/702, 801/802
DTX-0113	MT00014376	MT00014376	Lockado-2-300		401/402, 403, 701/702, 801/802
DTX-0114	MT00014377	MT00014377	Lockado-2-500		401/402, 403, 701/702, 801/802
DTX-0115	MT00018381	MT00018381	Lockado-2-1000		401/402, 403, 701/702, 801/802
DTX-0116	MT00015187	MT00015187	Lockado-3-300		401/402, 403, 701/702, 801/802
DTX-0117	MT00015188	MT00015188	Lockado-3-500		401/402, 403, 701/702, 801/802
DTX-0118	MT00015186	MT00015186	Lockado-3-1000		401/402, 403, 701/702, 801/802
DTX-0119	MT00015190	MT00015190	Lockado-4-300		401/402, 403, 701/702, 801/802
DTX-0120	MT00015191	MT00015191	Lockado-4-500		401/402, 403, 701/702, 801/802
DTX-0121	MT00015189	MT00015189	Lockado-4-1000		401/402, 403, 701/702, 801/802
DTX-0122	MT00015193	MT00015193	Lockado-5-300		401/402, 403, 701/702, 801/802
DTX-0123	MT00015194	MT00015194	Lockado-5-500		401/402, 403, 701/702, 801/802
DTX-0124	MT00015192	MT00015192	Lockado-5-1000		401/402, 403, 701/702, 801/802
DTX-0125	MT00015210	MT00015210	S01-LOCKADO-X250		401/402, 403, 701/702, 801/802
DTX-0126	MT00015212	MT00015212	S01-LOCKADO-X300		401/402, 403, 701/702, 801/802
DTX-0127	MT00015213	MT00015213	S01-LOCKADO-X500		401/402, 403, 701/702, 801/802
DTX-0128	MT00015207	MT00015207	S01-LOCKADO-X1000		401/402, 403, 701/702, 801/802
DTX-0129	MT00015208	MT00015208	S01-LOCKADO-X1500		401/402, 403, 701/702, 801/802
DTX-0130	MT00015209	MT00015209	S01-LOCKADO-X2000		401/402, 403, 701/702, 801/802
DTX-0131	MT00015211	MT00015211	S01-LOCKADO-X2500		401/402, 403, 701/702, 801/802
DTX-0132	MT00015229	MT00015229	S02-LOCKADO-X250		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0133	MT00015231	MT00015231	S02-LOCKADO-X300		401/402, 403, 701/702, 801/802
DTX-0134	MT00015232	MT00015232	S02-LOCKADO-X500		401/402, 403, 701/702, 801/802
DTX-0135	MT00015226	MT00015226	S02-LOCKADO-X1000		401/402, 403, 701/702, 801/802
DTX-0136	MT00015227	MT00015227	S02-LOCKADO-X1500		401/402, 403, 701/702, 801/802
DTX-0137	MT00015228	MT00015228	S02-LOCKADO-X2000		401/402, 403, 701/702, 801/802
DTX-0138	MT00015230	MT00015230	S02-LOCKADO-X2500		401/402, 403, 701/702, 801/802
DTX-0139	BSC-MT-000119	BSC-MT-000556	Moved to Joint Exhibit List at JTX-0004		401/402, 403
DTX-0140	BSC-MT-000759	BSC-MT-001283	Moved to Joint Exhibit List at JTX-0005		401/402, 403
DTX-0141	BSC-MT-001591	BSC-MT-001788	Moved to Joint Exhibit List at JTX-0006		401/402, 403
DTX-0142	BSC-MT-003846	BSC-MT-003861	Rotatable Resolution Clip Product Specification - Resolution 360™ Clip		401/402, 403, 701/702
DTX-0143	BSC-MT-004731	BSC-MT-004731	Video		401/402, 403, 701/702, 801/802
DTX-0144	BSC-MT-004751	BSC-MT-004751	Video		401/402, 403, 701/702, 801/802
DTX-0145	BSC-MT-006163	BSC-MT-006178	Tab Beding Test with Welded Capsule Report		401/402, 403, 701/702, 801/802
DTX-0146	BSC-MT-006351	BSC-MT-006395	Presentation: Boston Scientific - NG 360 Clip TDP - Q1 2019 TDP Update		401/402, 403, 701/702, 801/802
DTX-0147	BSC-MT-006712	BSC-MT-006728	DDW & UEGW 2016 Res 360 Report: Evaluation of Tissue Manipulation with Resolution 360 Clips in Ex vivo Porcine Model		401/402, 403, 701/702, 801/802
DTX-0148	BSC-MT-007794	BSC-MT-007805	Resolution Clip Exploratory Cycle Test Work Instructions		401/402, 403, 701/702, 801/802
DTX-0149	BSC-MT-008310	BSC-MT-008312	Manual Termination Design Freeze Test Flow Diagrams		401/402, 403, 701/702, 801/802
DTX-0150	BSC-MT-011662	BSC-MT-011662	Excel Spreadsheet, Res_360_Deployment Testing - ALT 11 3 15 (KJW)		401/402, 403, 701/702, 801/802
DTX-0151	BSC-MT-012485	BSC-MT-012511	Device Dimension and Deployment Forces Test		401/402, 403, 701/702, 801/802
DTX-0152	BSC-MT-020287	BSC-MT-020294	HCD Clip Deployment and Clamping Force Test		401/402, 403, 701/702, 801/802
DTX-0153	BSC-MT-031779	BSC-MT-031789	Boston Scientific Memorandum Re Olympus Clip Deployment Testing		401/402, 403, 701/702, 801/802
DTX-0154	BSC-MT-115971	BSC-MT-115991	Nova Light Systems Hemodip - Competitive Testing		401/402, 403, 701/702, 801/802
DTX-0155	BSC-MT-126649	BSC-MT-127160	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Rebuttal Expert Report of Karl R. Leinsing		401/402, 403
DTX-0156	BSC-MT-137027	BSC-MT-137027	Excel Spreadsheet, Fishbone for Open Close MASTER 16NOV		401/402, 403, 701/702, 801/802
DTX-0157	BSC-MT-139857	BSC-MT-139873	Micro-Tech Test Report		401/402, 403, 701/702, 801/802
DTX-0158	MT00008284	MT00008636	File History for U.S. Patent No. 9,445,821		401/402, 403
DTX-0159	MT00008970	MT00011116	File History for EP 02775909		401/402, 403
DTX-0160	MT00014022	MT00014041	Presentation: Micro-Tech - Hemostasis Clips		401/402, 403, 701/702, 801/802
DTX-0161	MT00005805	MT00005832	Micro-Tech Product Catalog		401/402, 403, 801/802
DTX-0162			Plaintiff's Objections and Responses to First Set of Interrogatories Nos. 1-8		401/402, 403, 801/802, AA, Legal
DTX-0163			Plaintiff's Objections and Responses to Second Set of Interrogatories No. 9		401/402, 403, 801/802, AA, Legal
DTX-0164			Plaintiff's First Supplemental Responses and Objections to First Set of Interrogatories No. 3		401/402, 403, 801/802, AA, Legal
DTX-0165			Plaintiff's First Supplemental Responses and Objections to First Set of Interrogatories Nos. 2 and 5		401/402, 403, 801/802, AA, Legal
DTX-0166			Plaintiff's Objections and Responses to Third Set of Interrogatories Nos. 10-13		401/402, 403, 801/802, AA, Legal
DTX-0167			Plaintiff's First Supplemental Responses and Objections to Third Set of Interrogatories No. 12		401/402, 403, 801/802, AA, Legal
DTX-0168			Plaintiff's Third Supplemental Responses and Objections to Interrogatories Nos. 2, 4, 7 and 9		401/402, 403, 801/802, AA, Legal

Schedule 8 - Defendants' Trial Exhibit List

DTX-0169			Plaintiff's Responses and Objections to First Set of Requests for Admission Nos. 1-5		401/402, 403, 801/802, AA, Legal
DTX-0170			Plaintiff's Supplemental Responses and Objections to Third Set of Interrogatories No. 11		401/402, 403, 801/802, AA, Legal
DTX-0171			Plaintiff's Fourth Supplemental Responses and Objections to Interrogatories No. 5		401/402, 403, 801/802, AA, Legal
DTX-0172			Plaintiff's Fifth Supplemental Responses and Objections to Interrogatories No. 4		401/402, 403, 801/802, AA, Legal
DTX-0173			Plaintiff's Responses and Objections to Second Set of Requests for Admission Nos. 6-20		401/402, 403, 801/802, AA, Legal
DTX-0174			Plaintiff's Third Supplemental Responses and Objections to Third Set of Interrogatories No. 11 and 13		401/402, 403, 801/802, AA, Legal
DTX-0175			Plaintiff's Supplemental Responses and Objections to Second Set of Requests for Admission Nos. 9, 12, 14, 16 and 17		401/402, 403, 801/802, AA, Legal
DTX-0176			Initial Expert Report of Morten O. Jensen Regarding Invalidity of United States Patents Nos. 7,094,245; 8,974,371; and 9,980,725	Jensen Deposition Ex. 1	701/702, 801/802, 901/902, 1006, PMIL
DTX-0177			Reply Expert Report of Morten O. Jensen Regarding Invalidity of United States Patents Nos. 7,094,245; 8,974,371; and 9,980,725	Jensen Deposition Ex. 2	701/702, 801/802, 901/902, 1006
DTX-0178			Curriculum Vitae of Morten O. Jensen	Jensen Deposition Ex. 3	
DTX-0179	BSC-MT-024914	BSC-MT-024952	U.S. Patent 7,094,245 by Adams et al.	Jensen Deposition Ex. 4	
DTX-0180	BSC-MT-000079	BSC-MT-000118	U.S. Patent 9,980,725 by Durgin et al.	Jensen Deposition Ex. 5	
DTX-0181	BSC-MT-110282	BSC-MT-110287	Quick Clip – Olympus – Disposable Clip Fixing Device	Jensen Deposition Ex. 6	401/402, 403, 701/702, 801/802
DTX-0182			Video File	Jensen Deposition Ex. 7	401/402, 403, 701/702, 801/802, ID
DTX-0183			Printout of Video	Jensen Deposition Ex. 8	
DTX-0184			Printout of Video at 4 Seconds	Jensen Deposition Ex. 9	
DTX-0185			Printout of Video at 6 Seconds	Jensen Deposition Ex. 10	
DTX-0186			Printout of Video at 12 Seconds	Jensen Deposition Ex. 11	
DTX-0187	MT00004213	MT00004221	Article: Seitz et al., "The Use of Endoscopic Clips in Nonvariceal Gastrointestinal Bleeding"	Jensen Deposition Ex. 12	401/402, 403, 801/802
DTX-0188	MT00002420	MT00002424	Article: Cioppolletta et al., "Endoclips versus heater probe in preventing early recurrent bleeding from peptic ulcer – a prospective and randomized trial"	Jensen Deposition Ex. 13	401/402, 403, 801/802
DTX-0189	MT00005265	MT00005280	U.S. Patent No. 6,808,491 by Kortenbach et al.	Jensen Deposition Ex. 14	401/402, 403, 801/802
DTX-0190	MT00005205	MT00005215	U.S. Patent No. 6,569,085 by Kortenbach et al.	Jensen Deposition Ex. 15	401/402, 403, 801/802
DTX-0191	MT00004440	MT00004464	U.S. Patent No. 5,755,184 by Matsuno et al.	Jensen Deposition Ex. 16	401/402, 403, 801/802
DTX-0192	MT00004477	MT00004488	U.S. Patent No. 5,766,189 by Matsuno et al.	Jensen Deposition Ex. 17	401/402, 403, 801/802
DTX-0193	MT00004539	MT00004584	U.S. Patent App. Publication 2002/0045909 by Kimura et al.	Jensen Deposition Ex. 18	401/402, 403, 801/802
DTX-0194			Video File	Jensen Deposition Ex. 19	401/402, 403, 801/802, ID
DTX-0195	MT00013661	MT00013666	Japanese Patent Publication No. S60-103946	Jensen Deposition Ex. 20	401/402, 403, 801/802
DTX-0196	BSC-MT-000040	BSC-MT-000078	U.S. Patent No. 8,974,371 by Durgin et al.	Jensen Deposition Ex. 21	
DTX-0197			Curriculum vitae for M. Jensen		
DTX-0198			List of Material Considered		
DTX-0199	BSC-MT-034833	BSC-MT-034854	Laboratory Notebook No. N0358 for Vince Turturro		401/402, 403, 801/802
DTX-0200	BSC-MT-037058	BSC-MT-037066	Boston Scientific - Hemo Clip Device Market Specification		401/402, 403, 801/802
DTX-0201	BSC-MT-037129	BSC-MT-037135	Boston Scientific - Product Specifications for the HCD TTS Clip		401/402, 403, 801/802
DTX-0202	BSC-MT-037507	BSC-MT-037521	Market Requirement Document - HCD Project		401/402, 403, 801/802
DTX-0203	BSC-MT-037561	BSC-MT-037562	Olympus Product Information- QuickClip™		401/402, 403, 801/802
DTX-0204	BSC-MT-054391	BSC-MT-054602	Laboratory Notebook		401/402, 403, 701/702, 801/802, ID
DTX-0205	BSC-MT-075636	BSC-MT-075636	Excel Spreadsheet, Olympus Clip Analysis 8-26-02		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0206	BSC-MT-075637	BSC-MT-075637	Email Re Olympus Hemo Clip IMS Q2 02		401/402, 403, 801/802
DTX-0207	BSC-MT-076055	BSC-MT-076074	Presentation - Boston Scientific - Resolution™ Clip Marketing Plan		401/402, 403, 801/802
DTX-0208	BSC-MT-120227	BSC-MT-120235	U.S. Patent No. 3,958,576 by Komiya		401/402, 403, 801/802
DTX-0209	BSC-MT-120236	BSC-MT-120282	U.S. Patent No. 5,626,607 by Malecki et al.		401/402, 403, 801/802
DTX-0210	BSC-MT-120817	BSC-MT-120824	U.S. Patent No. 5,275,615 by Rose		401/402, 403, 801/802
DTX-0211	BSC-MT-120850	BSC-MT-120860	U.S. Patent No. 5,373,854 by Kolozsi		401/402, 403, 801/802
DTX-0212	BSC-MT-120861	BSC-MT-120876	U.S. Patent No. 5,423,857 by Rosenman et al.		401/402, 403, 801/802
DTX-0213	BSC-MT-123783	BSC-MT-123884	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of William Lafferty		401/402, 403, 801/802, AA, Legal, MC
DTX-0214	BSC-MT-124111	BSC-MT-124324	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Mark Adams		401/402, 403, 801/802, AA, Legal, MC
DTX-0215	BSC-MT-125731	BSC-MT-126364	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Corrected Opening Expert Report of Mark Nicosia		401/402, 403, 801/802, AA, Legal, MC
DTX-0216	BSC-MT-127303	BSC-MT-127415	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript for Vincent Turturro		401/402, 403, 801/802, AA, Legal, MC
DTX-0217	MT00002284	MT00002287	Article: Binmoeller et al., "Endoscopic Hemoclip Treatment for Gastrointestinal Bleeding"		401/402, 403, 801/802
DTX-0218	MT00002396	MT00002413	German Register No. 29505619		401/402, 403, 801/802, 901/902
DTX-0219	MT00002414	MT00002416	Article: Devereaux et al., "Endoclip - Closing the Surgical Gap"		401/402, 403, 801/802
DTX-0220	MT00002425	MT00002428	Olympus Product Information		401/402, 403, 801/802
DTX-0221	MT00002485	MT00002488	Olympus Endoscopic Mucosal Resection Devices		401/402, 403, 801/802
DTX-0222	MT00002489	MT00002496	Article: Goelder et al., "Endoscopic Hemostasis State of the Art - Nonvariceal Bleeding"		401/402, 403, 801/802
DTX-0223	MT00002506	MT00002511	Article: Hachisu et al., "Endoscopic Clip-Marking of Lesions Using the Newly Developed HX-3L Clip"		401/402, 403, 801/802
DTX-0224	MT00002569	MT00002579	Article: Wang et al., "Choosing the Right Through-the Scope Clip - A Rigorous Comparison of Rotability, Whip, Open/Close Precision, and Closure Strength"		401/402, 403, 801/802
DTX-0225	MT00002764	MT00002770	Article: Gastroenterological Endoscopy Vol. 17(1), pp. 92-101 (Feb. 1975)		401/402, 403, 801/802
DTX-0226	MT00002784	MT00002793	U.S. Patent No. 4,733,664 by Kirsch et al.		401/402, 403, 801/802
DTX-0227	MT00003220	MT00003223	Japanese Patent No. 60-103946		401/402, 403, 801/802, 901/902
DTX-0228	MT00003288	MT00003291	Japanese Patent No. 63-267345		401/402, 403, 801/802, 901/902
DTX-0229	MT00003399	MT00003422	U.S. Patent No. 5,304,183 by Gourlay et al.		401/402, 403, 801/802
DTX-0230	MT00004037	MT00004053	U.S. Patent No. 5,542,432 by Slater et al.		401/402, 403, 801/802
DTX-0231	MT00004054	MT00004075	U.S. Patent No. 5,569,274 by Rapacki et al.		401/402, 403, 801/802
DTX-0232	MT00004134	MT00004157	U.S. Patent No. 5,645,075 by Palmer et al.		401/402, 403, 801/802
DTX-0233	MT00004186	MT00004188	Article: Gottumukkala, "Hemoclips - Clips to Clasp the Bleeder"		401/402, 403, 801/802
DTX-0234	MT00004210	MT00004212	Article: Romagnuolo, "Endoscopic Clips - Past, Present and Future"		401/402, 403, 801/802
DTX-0235	MT00004222	MT00004240	U.S. Patent No. 5,749,881 by Sackler et al.		401/402, 403, 801/802
DTX-0236	MT00004501	MT00004519	U.S. Patent No. 5,776,075 by Palmer		401/402, 403, 801/802
DTX-0237	MT00004751	MT00004781	U.S. Patent Application Publication 2002/0151916 by Muramatsu et al.		401/402, 403, 801/802
DTX-0238	MT00004782	MT00004795	U.S. Patent No. 5,843,000 by Nishioka et al.		401/402, 403, 801/802
DTX-0239	MT00004821	MT00004905	U.S. Patent Application Publication 2002/0177861 by Sugiyama et al.		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0240	MT00004968	MT00005006	U.S. Patent Application Publication 2003/0069592		401/402, 403, 801/802
DTX-0241	MT00005007	MT00005020	U.S. Patent No. 5,967,997 by Turturro et al.		401/402, 403, 801/802
DTX-0242	MT00005090	MT00005109	U.S. Patent Application Publication 2004/0176784 by Okada		401/402, 403, 801/802
DTX-0243	MT00005447	MT00005530	U.S. Patent No. 6,991,634 by Sugiyama et al.		401/402, 403, 801/802
DTX-0244	MT00005698	MT00005699	Article: Goldstein et al., "Curved Biopsy Forceps"		401/402, 403, 801/802
DTX-0245	MT00005700	MT00005705	U.S. Patent No. 5,133,727 by Bales et al.		401/402, 403, 801/802
DTX-0246	MT00005706	MT00005713	U.S. Patent No. 5,507,296 by Bales et al.		401/402, 403, 801/802
DTX-0247	MT00005714	MT00005722	U.S. Patent No. 5,636,639 by Turturro et al.		401/402, 403, 801/802
DTX-0248	MT00006368	MT00006374	Complaint File Summary		401/402, 403, 801/802, ID
DTX-0249	MT00012733	MT00012733	Video		401/402, 403, 801/802, ID
DTX-0250	MT00012734	MT00012734	Video		401/402, 403, 801/802, ID
DTX-0251	MT00013121	MT00013655	510(k) Summary for the Olympus HX-5/6-1 Endoscopic Clipping Device, K963160		401/402, 403, 801/802
DTX-0252	MT00013667	MT00013672	Japanese Patent Publication No. S63-267345 (English Translation)		401/402, 403, 801/802
DTX-0253	MT00013687	MT00013687	Photo of QuickClip Device		401/402, 403, 701/702, 801/802
DTX-0254	MT00013688	MT00013688	Photo of QuickClip Packaging Information		401/402, 403, 701/702, 801/802
DTX-0255	MT00013689	MT00013689	Photo of QuickClip Packaging Information		401/402, 403, 701/702, 801/802
DTX-0256	MT00013695	MT00013714	German Register No. 29505619 (English Translation)		401/402, 403, 801/802
DTX-0257	MT00013715	MT00013715	Photo of Quickclip Product Insert Information		401/402, 403, 701/702, 801/802
DTX-0258	MT00013716	MT00013716	Photo of QuickClip Packaging with Bubble Wrap		401/402, 403, 701/702, 801/802
DTX-0259	MT00013717	MT00013843	510(k) Summary – K013066		401/402, 403, 801/802
DTX-0260	MT00013844	MT00013993	510(k) Summary - K990687		401/402, 403, 801/802
DTX-0261	MT00013994	MT00013994	Endocorp USA Packaging Invoice		401/402, 403, 801/802
DTX-0262	MT00014259	MT00014263	Article: Fantin et al., "Diagnostic Quality of Biopsy Specimens - Comparison between a Conventional Biopsy Forceps and Mult bite Forceps"		401/402, 403, 801/802
DTX-0263	MT00014264	MT00014264	Quick Clip Image		401/402, 403, 801/802, ID
DTX-0264	MT00014265	MT00014265	Quick Clip Image		401/402, 403, 801/802, ID
DTX-0265	MT00014266	MT00014267	Article: Altorjay, "Value of Endoscopic Marking of the Z-Line for Detecting Short Esophagus Before Repeat Surgery for Recurrent Paraesophageal Hernias"		401/402, 403, 801/802
DTX-0266	MT00014268	MT00014278	U.S. Patent No. 5,222,973 by Sharpe et al.		401/402, 403, 801/802
DTX-0267	MT00014279	MT00014279	Video		401/402, 403, 801/802, ID
DTX-0268	MT00014280	MT00014311	U.S. Patent No. 6,299,630 by Yamamoto		401/402, 403, 801/802
DTX-0269	MT00014312	MT00014346	U.S. Patent No. 6,139,508 by Simpson et al.		401/402, 403, 801/802
DTX-0270	MT00014347	MT00014355	Article: Kirkup, "The History and Evolution of Surgical Instruments"		401/402, 403, 801/802
DTX-0271	MT00014356	MT00014356	J-Hook Image		401/402, 403, 801/802, ID
DTX-0272	MT00014357	MT00014357	Photo of Clipping Device		401/402, 403, 801/802, ID
DTX-0273	MT00014358	MT00014358	Video		401/402, 403, 801/802, ID
DTX-0274	MT00014359	MT00014359	Quick Clip Handle Image		401/402, 403, 801/802
DTX-0275	MT00014360	MT00014360	Quick Clip Handle Image		401/402, 403, 801/802
DTX-0276	OAI000001	OAI000096	Olympus Endoscopy - Instructions - Rotatable Clip Fixing Devices		401/402, 403, 801/802
DTX-0277	OAI000097	OAI000104	Olympus - Rotatable Clip Fixing Device Product Information		401/402, 403, 801/802
DTX-0278	OAI000105	OAI000289	510(k) Summary – K013066		401/402, 403, 801/802, PMIL
DTX-0279			IPR 2017-00135: Final Written Decision		401/402, 403, 801/802, AA, Legal, PMIL
DTX-0280			Plaintiff's Initial Infringement Contentions		401/402, 403, 801/802, AA, Legal
DTX-0281			Defendant's Final Invalidity Contentions		401/402, 403, 801/802, AA, Legal
DTX-0282			Notice of Deposition of C. Li.	Li Deposition Ex. 20	401/402, 403, 801/802, AA, Legal

Schedule 8 - Defendants' Trial Exhibit List

DTX-0283			Defendants First Suppl. Responses to Plaintiffs' First Set of Common Interrogatories No. 1-10	Li Deposition Ex. 21	401/402, 403, 801/802, AA, Legal
DTX-0284			Photograph of Physical Exhibit	Li Deposition Ex. 22	ID
DTX-0285			Photograph of Physical Exhibit	Li Deposition Ex. 23	ID
DTX-0286			Photograph of Physical Exhibit	Li Deposition Ex. 24	ID
DTX-0287			Photograph of Physical Exhibit	Li Deposition Ex. 25	ID
DTX-0288			Photograph of Physical Exhibit	Li Deposition Ex. 26	ID
DTX-0289			Photograph of Physical Exhibit	Li Deposition Ex. 27	ID
DTX-0290			Photograph of Physical Exhibit	Li Deposition Ex. 28	ID
DTX-0291			Photograph of Physical Exhibit	Li Deposition Ex. 29	ID
DTX-0292			Photograph of Physical Exhibit	Li Deposition Ex. 30	ID
DTX-0293	MT00011649	MT00011649	Excel Spreadsheet, 2015â€”2019â€”æ—å·ç»%â½å·å·ç»å·é@æ®æ@20200304	Li Deposition Ex. 31	401/402, 403, 801/802
DTX-0294	MT00000693	MT00000693	510K Submission Cover Letter	Li Deposition Ex. 32	401/402, 403, 801/802
DTX-0295	MT00000770	MT00000786	Micro-Tech Device Description	Li Deposition Ex. 33	401/402, 403, 801/802, 901/902
DTX-0296	MT00000819	MT00000823	Micro-Tech Substantially Equivalent Discussions	Li Deposition Ex. 34	401/402, 403, 801/802, 901/902
DTX-0297	MT00001185	MT00001209	Micro-Tech Device Description (Updated 2017-01-04)	Li Deposition Ex. 35	401/402, 403, 801/802, 901/902
DTX-0298	MT00001159	MT00001159	Micro-Tech 510K Submission Cover Letter	Li Deposition Ex. 36	401/402, 403, 801/802, 901/902
DTX-0299	MT00001276	MT00001280	Micro-Tech: Substantially Equivalent Discussions	Li Deposition Ex. 37	401/402, 403, 801/802, 901/902
DTX-0300	MT00000246	MT00000264	Micro-Tech Device Description	Li Deposition Ex. 38	401/402, 403, 801/802, 901/902
DTX-0301	MT00001944	MT00001944	Micro-Tech 510K Submission Cover Letter	Li Deposition Ex. 39	401/402, 403, 801/802, 901/902
DTX-0302	MT00000446	MT00000451	Micro-Tech Substantially Equivalent Discussions (Updated 2018-11-15)	Li Deposition Ex. 40	401/402, 403, 801/802, 901/902
DTX-0303	MT00000923	MT00000925	Micro-Tech Response to K161463/S001 Deficiencies	Li Deposition Ex. 41	401/402, 403, 801/802, 901/902
DTX-0304	CMD 0082	CMD 0083	Email Re IP Insurance	Li Deposition Ex. 42	
DTX-0305			Plaintiffs Notice of Deposition of R. Perry	Perry Deposition Ex. 1	401/402, 403, 801/802, AA, Legal
DTX-0306			Plaintiffs Notice of 30(B)(6) Deposition of Defendants	Perry Deposition Ex. 2	401/402, 403, 801/802, AA, Legal
DTX-0307			Plaintiffs Second Notice of 30(B)(6) Deposition of Defendants	Perry Deposition Ex. 3	401/402, 403, 801/802, AA, Legal
DTX-0308	MT00011879	MT00012458	U.S. Market Report Suite for Gastrointestinal Devices	Perry Deposition Ex. 4	
DTX-0309	MT00005902	MT00005911	Micro-Tech – Presentation – SureClip Repositionable Hemostasis Clip	Perry Deposition Ex. 5	401/402, 403, 701/702, 801/802
DTX-0310	MT00005927	MT00005927	SureClip Advertisement/Product Info	Perry Deposition Ex. 6	401/402, 403, 801/802
DTX-0311	MT00005939	MT00005948	Micro-Tech – Product Brief – Hemostasis Clip	Perry Deposition Ex. 7	401/402, 403, 801/802
DTX-0312			SureClip Product Information	Perry Deposition Ex. 8	401/402, 403, 801/802
DTX-0313	MT00012460	MT00012460	Excel Spreadsheet, Rev & COGS Summary through 2019 year end	Perry Deposition Ex. 9	401/402, 403, 801/802
DTX-0314			SureClip Product Info/Order Form	Perry Deposition Ex. 10	401/402, 403, 801/802
DTX-0315			SureClip Product Info/Order Form	Perry Deposition Ex. 11	401/402, 403, 801/802
DTX-0316	MT00012499	MT00012499	Excel Spreadsheet, Rev COGS Details through 2019 year end	Perry Deposition Ex. 12	401/402, 403, 801/802
DTX-0317	MT00000084	MT00000084	Excel Spreadsheet, Rev & COGS Summary from 2015 - 2019 Sep	Perry Deposition Ex. 13	401/402, 403, 801/802
DTX-0318	MT00012498	MT00012498	Excel Spreadsheet, Product Purchase Summary and Details through 2019 year end	Perry Deposition Ex. 14	401/402, 403, 801/802
DTX-0319	MT00012459	MT00012459	Excel Spreadsheet, Quarterly Profit and Loss Stmt 2016 to 2019	Perry Deposition Ex. 15	401/402, 403, 801/802
DTX-0320	MT00000001	MT00000001	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0321	MT00000002	MT00000002	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0322	MT00000003	MT00000003	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0323	MT00000004	MT00000004	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0324	MT00000005	MT00000005	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0325	MT00000006	MT00000006	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0326	MT00000007	MT00000007	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0327	MT00000008	MT00000008	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID

Schedule 8 - Defendants' Trial Exhibit List

DTX-0328	MT00000009	MT00000009	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0329	MT00000010	MT00000010	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0330	MT00000011	MT00000011	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0331	MT00000012	MT00000012	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0332	MT00000013	MT00000013	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0333	MT00000014	MT00000014	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0334	MT00000015	MT00000015	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0335	MT00000016	MT00000016	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0336	MT00000017	MT00000017	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0337	MT00000018	MT00000018	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0338	MT00000019	MT00000019	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0339	MT00000020	MT00000020	Micro-Tech Video		401/402, 403, 801/802, 901/902, ID
DTX-0340	MT00000021	MT00000021	Micro-Tech Video		401/402, 403, 801/802, 901/902, ID
DTX-0341	MT00000022	MT00000022	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0342	MT00000023	MT00000023	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0343	MT00000024	MT00000024	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0344	MT00000025	MT00000025	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0345	MT00000026	MT00000026	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0346	MT00000027	MT00000027	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0347	MT00000028	MT00000028	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0348	MT00000029	MT00000029	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0349	MT00000030	MT00000030	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0350	MT00000031	MT00000031	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0351	MT00000032	MT00000032	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0352	MT00000033	MT00000033	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0353	MT00000034	MT00000034	Micro-Tech Drawings		401/402, 403, 801/802, 901/902, ID
DTX-0354	MT00000035	MT00000046	Product Performance Specification for Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802, 901/902
DTX-0355	MT00000047	MT00000058			401/402, 403, 801/802, 901/902, ID
DTX-0356	MT00000059	MT00000066			401/402, 403, 801/802, 901/902, ID
DTX-0357	MT00000067	MT00000071			401/402, 403, 801/802, 901/902, ID
DTX-0358	MT00000072	MT00000083			401/402, 403, 801/802, 901/902, ID
DTX-0359	MT00000084	MT00000084	Excel Spreadsheet, Rev & COGS Summary from 2015 - 2019 Sep		401/402, 403, 801/802, 901/902
DTX-0360	MT00000085	MT00000085	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0361	MT00000086	MT00000086	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0362	MT00000087	MT00000087	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0363	MT00000088	MT00000088	Device Master Record - SureClip - Max Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0364	MT00000089	MT00000089	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0365	MT00000090	MT00000090	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0366	MT00000091	MT00000091	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0367	MT00000092	MT00000092	Device Master Record - SureClip - Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0368	MT00000093	MT00000104	Micro-Tech - SureClip - Instructions for Use		401/402, 403, 801/802, 901/902
DTX-0369	MT00000105	MT00000108	Micro-Tech - Test Report		401/402, 403, 701/702, 801/802, 901/902
DTX-0370	MT00000109	MT00000123	Micro-Tech - Test Report		401/402, 403, 701/702, 801/802, 901/902
DTX-0371	MT00000124	MT00000130	Micro-Tech - Test Report		401/402, 403, 701/702, 801/802, 901/902
DTX-0372	MT00000131	MT00000131	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0373	MT00000132	MT00000132	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0374	MT00000133	MT00000133	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0375	MT00000134	MT00000134	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID

Schedule 8 - Defendants' Trial Exhibit List

DTX-0376	MT00000135	MT00000135	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0377	MT00000136	MT00000136	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0378	MT00000137	MT00000137	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0379	MT00000138	MT00000138	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0380	MT00000139	MT00000139	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0381	MT00000140	MT00000146	Micro-Tech Schematics		401/402, 403, 801/802, 901/902, ID
DTX-0382	MT00000147	MT00000147	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0383	MT00000148	MT00000148	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0384	MT00000149	MT00000149	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0385	MT00000150	MT00000150	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0386	MT00000151	MT00000151	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0387	MT00000152	MT00000152	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0388	MT00000153	MT00000153	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0389	MT00000154	MT00000154	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0390	MT00000155	MT00000155	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0391	MT00000156	MT00000156	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0392	MT00000157	MT00000157	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0393	MT00000158	MT00000158	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0394	MT00000159	MT00000159	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0395	MT00000160	MT00000160	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0396	MT00000161	MT00000161	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0397	MT00000162	MT00000162	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0398	MT00000163	MT00000163	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0399	MT00000164	MT00000164	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0400	MT00000165	MT00000165	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0401	MT00000166	MT00000166	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0402	MT00000167	MT00000167	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0403	MT00000168	MT00000168	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0404	MT00000169	MT00000169	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0405	MT00000170	MT00000170	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0406	MT00000171	MT00000171	Device Master Record HemoClip 165cm		401/402, 403, 801/802, 901/902
DTX-0407	MT00000172	MT00000172	Device Master Record HemoClip 235cm		401/402, 403, 801/802, 901/902
DTX-0408	MT00000173	MT00000173	Device Master Record HemoClip 165cm		401/402, 403, 801/802, 901/902
DTX-0409	MT00000174	MT00000174	Device Master Record HemoClip 165cm		401/402, 403, 801/802, 901/902
DTX-0410	MT00000175	MT00000175	Device Master Record HemoClip 165cm		401/402, 403, 801/802, 901/902
DTX-0411	MT00000176	MT00000177	Device Master Record HemoClip 165cm		401/402, 403, 801/802, 901/902
DTX-0412	MT00000178	MT00000178	Device Master Record HemoClip 235cm		401/402, 403, 801/802, 901/902
DTX-0413	MT00000179	MT00000179	Device Master Record HemoClip 235cm		401/402, 403, 801/802, 901/902
DTX-0414	MT00000180	MT00000181	Device Master Record HemoClip 235cm		401/402, 403, 801/802, 901/902
DTX-0415	MT00000182	MT00000182	Device Master Record SureClip Maxi Repositionable 235cm		401/402, 403, 801/802, 901/902
DTX-0416	MT00000221	MT00000225	Micro-Tech 510(k) Summary		401/402, 403, 801/802
DTX-0417	MT00000418	MT00000429	CDRH Premarket Review Submission		401/402, 403, 801/802
DTX-0418	MT00000735	MT00000740	Micro-Tech Performance Testing		401/402, 403, 701/702, 801/802
DTX-0419	MT00000831	MT00000838	Micro-Tech Biocompatibility Evaluation Report		401/402, 403, 701/702, 801/802
DTX-0420	MT00000948	MT00000961	CDRH Premarket Review Submission		401/402, 403, 801/802
DTX-0421	MT00001951	MT00001955	Micro-Tech Clip Open and Close Force Test Report of Predicate Device		401/402, 403, 701/702, 801/802
DTX-0422	MT00005723	MT00005723	Excel Spreadsheet, Product Purchase Summary and Details		401/402, 403, 801/802
DTX-0423	MT00005724	MT00005724	Excel Spreadsheet, Rev & COGS Details from 2015 - 2019 Sep		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0424	MT00005733	MT00005752	Micro-Tech Endoscopy Product Catalog		401/402, 403, 801/802
DTX-0425	MT00005753	MT00005780	Micro-Tech Endoscopy Product Catalog		401/402, 403, 801/802
DTX-0426	MT00005781	MT00005804	Micro-Tech Endoscopy Product Catalog		401/402, 403, 801/802
DTX-0427	MT00005866	MT00005866	Micro-Tech SureClip C-N Evaluation Form		401/402, 403, 801/802
DTX-0428	MT00005881	MT00005884	Micro-Tech SureClip Product Information		401/402, 403, 801/802
DTX-0429	MT00005929	MT00005929	Micro-Tech SureClip C-N Evaluation Form		401/402, 403, 801/802
DTX-0430	MT00005930	MT00005930	Micro-Tech SureClip Max Evaluation Form		401/402, 403, 801/802
DTX-0431	MT00005931	MT00005931	Micro-Tech SureClip Max Evaluation Form		401/402, 403, 801/802
DTX-0432	MT00005932	MT00005932	Micro-Tech SureClip C-N Evaluation Form		401/402, 403, 801/802
DTX-0433	MT00005933	MT00005934	Micro-Tech Multiple Product Evaluation Form		401/402, 403, 801/802
DTX-0434	MT00005936	MT00005938	"SureClip by Micro-Tech - Excellent Performance, Winning Oversea Useres Heart"		401/402, 403, 801/802
DTX-0435	MT00006636	MT00006645			401/402, 403, 801/802, ID
DTX-0436	MT00006646	MT00006651			401/402, 403, 801/802, ID
DTX-0437	MT00006652	MT00006659	Micro-Tech Product Performance Monitoring Plan for SureClip Repositionable Hemostasis Clip		401/402, 403, 801/802
DTX-0438	MT00006660	MT00006665	Micro-Tech Product Performance Monitoring Plan for Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0439	MT00006666	MT00006681			401/402, 403, 801/802, ID
DTX-0440	MT00006682	MT00006692			401/402, 403, 801/802, ID
DTX-0441	MT00006693	MT00006712			401/402, 403, 801/802, ID
DTX-0442	MT00006713	MT00006726			401/402, 403, 801/802, ID
DTX-0443	MT00006727	MT00006739			401/402, 403, 801/802, ID
DTX-0444	MT00006740	MT00006764			401/402, 403, 801/802, ID
DTX-0445	MT00006765	MT00006775			401/402, 403, 801/802, ID
DTX-0446	MT00006776	MT00006790			401/402, 403, 801/802, ID
DTX-0447	MT00006791	MT00006791	Micro-Tech Nanjing		401/402, 403, 801/802, ID
DTX-0448	MT00006792	MT00006793	Micro-Tech Nanjing		401/402, 403, 801/802, ID
DTX-0449	MT00006794	MT00006801	Micro-Tech Application of Usability Engineering for Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0450	MT00006802	MT00006817			401/402, 403, 801/802, ID
DTX-0451	MT00006818	MT00006833	Micro-Tech DV Protocol of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0452	MT00006834	MT00006849	Micro-Tech DV Protocol of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0453	MT00006850	MT00006862			401/402, 403, 801/802, ID
DTX-0454	MT00006863	MT00006887	Micro-Tech DV Protocol of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0455	MT00006888	MT00006895			401/402, 403, 801/802, ID
DTX-0456	MT00006896	MT00006931	Micro-Tech Risk Management Report for Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0457	MT00006932	MT00006932	C PCT/CN2014/081316		401/402, 403, 801/802
DTX-0458	MT00006933	MT00006942	Chinese Patent 103989500		401/402, 403, 801/802
DTX-0459	MT00006943	MT00006953	Japanese Patent 62-08894		401/402, 403, 801/802
DTX-0460	MT00006954	MT00006966	EP 3081174 B1		401/402, 403, 801/802
DTX-0461	MT00006967	MT00006985	Specification for AU Appl. No. 2014394922		401/402, 403, 801/802
DTX-0462	MT00006986	MT00006995	U.S. Patent No. 9,795,390 by Jin et al.		401/402, 403, 801/802
DTX-0463	MT00011271	MT00011285	Micro-Tech DV Protocol of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0464	MT00011308	MT00011332	Micro-Tech DV Protocol of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 801/802
DTX-0465	MT00011450	MT00011450	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0466	MT00011451	MT00011451	Micro-Tech Schematic		401/402, 403, 801/802, 901/902, ID
DTX-0467	MT00011452	MT00011460	Micro-Tech Test Report		401/402, 403, 701/702, 801/802
DTX-0468	MT00011461	MT00011481	Micro-Tech Sterile Repositionable Hemostasis Clipping Device DV Protocol		401/402, 403, 801/802
DTX-0469	MT00011482	MT00011517	Micro-Tech Sterile Repositionable Hemostasis Clipping Device DV Report		401/402, 403, 801/802
DTX-0470	MT00011518	MT00011540	Micro-Tech Sterile Repositionable Hemostasis Clipping Device DV Protocol		401/402, 403, 801/802
DTX-0471	MT00011541	MT00011581	Micro-Tech Sterile Repositionable Hemostasis Clipping Device DV Report		401/402, 403, 801/802
DTX-0472	MT00011582	MT00011600	Micro-Tech Safety Effectiveness Evaluation Report of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 701/702, 801/802
DTX-0473	MT00011601	MT00011625	Micro-Tech Safety Effectiveness Evaluation Report of Sterile Repositionable Hemostasis Clipping Device		401/402, 403, 701/702, 801/802
DTX-0474	MT00011649	MT00011649	Excel Spreadsheet, Sales Statistics & Cost Details 2015 to 2019		401/402, 403, 801/802
DTX-0475	MT00012459	MT00012459	Excel Spreadsheet, Quarterly Profit and Loss Stmt 2016 to 2019		401/402, 403, 801/802
DTX-0476	MT00012460	MT00012460	Excel Spreadsheet, Rev & COGS Summary through 2019 year end		401/402, 403, 801/802
DTX-0477	MT00012461	MT00012464	Second Amendment to Distribution and Supply Agreement between Henry Schein and Micro-Tech		401/402, 403, 801/802
DTX-0478	MT00012465	MT00012466	Draft First Amendment to Distribution and Supply Agreement between Henry Schein and Micro-Tech		401/402, 403, 801/802
DTX-0479	MT00012467	MT00012473	Quality Agreement between Micro-Tech and Henry Schein		401/402, 403, 801/802
DTX-0480	MT00012474	MT00012474-1249	Distribution and Supply Agreement between Henry Schein and Micro-Tech		401/402, 403, 801/802
DTX-0481	MT00012498	MT00012498	Excel Spreadsheet, Product Purchase Summary and Details through 2019 year end		401/402, 403, 801/802
DTX-0482	MT00012499	MT00012499	Excel Spreadsheet, Rev COGS Details through 2019 year end		401/402, 403, 801/802
DTX-0483	MT00012502	MT00012506	Regulatory Agreement between ConMed and Micro-Tech		401/402, 403, 801/802
DTX-0484	MT00012513	MT00012528	Supply Agreement between ConMed and Micro-Tech		401/402, 403, 801/802
DTX-0485	MT00013995	MT00013995	Product Purchase Summary & Details		401/402, 403, 801/802
DTX-0486	MT00013996	MT00013996	Quarterly P&L Statement Expanded		401/402, 403, 801/802
DTX-0487	MT00013997	MT00013997	Quarterly P&L Condensed		401/402, 403, 801/802
DTX-0488	MT00013998	MT00013998	Rev & COGS Summary		401/402, 403, 801/802
DTX-0489	MT00013999	MT00013999	Rev & COGS Detail		401/402, 403, 801/802
DTX-0490	MT00014000	MT00014000	Excel Spreadsheet, Sales Statistics & Cost Details 2015 to July 2020		401/402, 403, 801/802
DTX-0491	MT00014001	MT00014002	Micro-Tech Lockado Production Information		401/402, 403, 801/802
DTX-0492	MT00014013	MT00014014	Micro-Tech Lockado Brochure		401/402, 403, 801/802
DTX-0493	MT00014015	MT00014016	Micro-Tech Lockado Marketing Material		401/402, 403, 801/802
DTX-0494	MT00014022	MT00014041	Micro-Tech Lockado Training Slides		401/402, 403, 801/802
DTX-0495	MT00014047	MT00014058	Micro-Tech Lockado IFU		401/402, 403, 801/802
DTX-0496	MT00014059	MT00014133	Certificate of Accuracy and Translation for MT00014000		401/402, 403, 801/802
DTX-0497	MT00014134	MT00014258	Certificate of Accuracy and Translation for MT00011649		401/402, 403, 801/802
DTX-0498	MT00018424	MT00018424	Video		401/402, 403, 801/802, ID
DTX-0499	MT00018425	MT00018425	Product Purchase and Summary Details 2020		401/402, 403, 801/802
DTX-0500	MT00018426	MT00018426	Rev & COGS Details 2015-2020		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0501	MT00018427	MT00018427	Rev & COGS Summary 2015-2020		401/402, 403, 801/802
DTX-0502	MT00018428	MT00018428	Quarterly P&L Condensed		401/402, 403, 801/802
DTX-0503	MT00018429	MT00018429	Quarterly P&L Detailed		401/402, 403, 801/802
DTX-0504	HS000000276	HS000000302	Micro-Tech – Presentation – Expanding the Scope of Endoscopy	Jackson Deposition Ex. 1	401/402, 403, 801/802
DTX-0505	HS000000008	HS00000011	Henry Schein – Micro-Tech Launch – May 18, 2016	Jackson Deposition Ex. 2	401/402, 403, 801/802
DTX-0506			Plaintiffs Notice of 30(B)(6) Deposition of Henry Schein	Jackson Deposition Ex. 3	401/402, 403, 801/802
DTX-0507	HS000000004	HS000000007	Henry Schein Company and Product Information	Jackson Deposition Ex. 4	401/402, 403, 801/802
DTX-0508	HS000000046	HS00000069	Micro-Tech Endoscopy – Product Catalog	Jackson Deposition Ex. 5	401/402, 403, 801/802
DTX-0509	HS00000154	HS00000257	Henry Schein – Featured Product Guide (July-Sept. 2019)	Jackson Deposition Ex. 6	401/402, 403, 801/802
DTX-0510	HS00000264	HS00000264	GI Course & Module Summaries – ASC Focus FSC Curriculum	Jackson Deposition Ex. 7	401/402, 403, 801/802
DTX-0511	HSC00000271	HSC00000275	Micro-Tech Endoscopy – ASC Curriculum Script – Module 5	Jackson Deposition Ex. 8	401/402, 403, 801/802
DTX-0512	HS000000039	HS000000039	Micro-Tech Sales Success Stories	Jackson Deposition Ex. 9	401/402, 403, 801/802
DTX-0513	HS00000393	HS00000393	Excel Spreadsheet, Customer & GP info 2016-YTD2020 REV	Jackson Deposition Ex. 10	401/402, 403, 801/802
DTX-0514	HS00000394	HS00000394	Excel Spreadsheet, Micro Tech By Items	Jackson Deposition Ex. 11	401/402, 403, 801/802
DTX-0515	HS00000395	HS00000395	Excel Spreadsheet, Purchases	Jackson Deposition Ex. 12	401/402, 403, 801/802
DTX-0516	HS00000396	HS00000396	Excel Spreadsheet, P&L Statement	Jackson Deposition Ex. 13	401/402, 403, 801/802
DTX-0517	HS000000001	HS000000001	Excel Spreadsheet, Sales Division Summary		401/402, 403, 801/802
DTX-0518	HS000000002	HS000000003	GI Brochure		401/402, 403, 801/802
DTX-0519	HS000000004	HS000000004	Micro-Tech Brochure		401/402, 403, 801/802
DTX-0520	HS000000040	HS00000045	GI Brochure		401/402, 403, 801/802
DTX-0521	HS00000098	HS00000153	ASC Spotlight		401/402, 403, 801/802
DTX-0522	HS00000377	HS00000377	Excel Spreadsheet, Micro-Tech Sure Clip - Item List (007)		401/402, 403, 801/802
DTX-0523	HS00000378	HS00000378	Excel Spreadsheet, Micro-Tech Sure Clip - Item List		401/402, 403, 801/802
DTX-0524	HS00000379	HS00000379	Henry Schein - Records Retention Schedule		401/402, 403, 801/802
DTX-0525	HS00000391	HS00000391	Excel Spreadsheet, ConMed Sales		401/402, 403, 801/802
DTX-0526	HS00000392	HS00000392	Excel Spreadsheet, SureClip Sales Detail		401/402, 403, 801/802
DTX-0527	HS00000397	HS00000397	Henry Schein Press Release		401/402, 403, 801/802
DTX-0528	HS00000398	HS00000398	Henry Schein Press Release		401/402, 403, 801/802
DTX-0529	HS00000399	HS00000400	Henry Schein Press Release		401/402, 403, 801/802
DTX-0530	HS00000401	HS00000402	Henry Schein Press Release		401/402, 403, 801/802
DTX-0531	HS00000403	HS00000404	Henry Schein Press Release		401/402, 403, 801/802
DTX-0532	HS00000405	HS00000406	Henry Schein Press Release		401/402, 403, 801/802
DTX-0533	HS00000407	HS00000408	Henry Schein Press Release		401/402, 403, 801/802
DTX-0534			Defendants Notice of 30(B)(6) Deposition to Boston Scientific Scimed	Murray Deposition Ex. 1	401/402, 403, 801/802, AA, Legal
DTX-0535			Defendants Notice of 30(B)(6) Deposition to Boston Scientific Corp.	Murray Deposition Ex. 2	401/402, 403, 801/802, AA, Legal
DTX-0536			Notice of Deposition of C. Murray	Murray Deposition Ex. 3	401/402, 403, 801/802, AA, Legal
DTX-0537	BSC-MT-011645	BSC-MT-011654	MedVenture: Resolution 360 – Product Performance Qualification Protocol	Murray Deposition Ex. 7	401/402, 403, 801/802
DTX-0538			FDA: Class 2 Device Recall – Boston Scientific Clipping Device – Resolution Clip	Murray Deposition Ex. 8	401/402, 403, 801/802
DTX-0539	BSC-MT-0067211	BSC-MT-0067242	Presentation: FDA & Boston Scientific Endoscopy & Urology Meeting	Murray Deposition Ex. 9	401/402, 403, 801/802
DTX-0540	BSC-MT-110175	BSC-MT-110292	Boston Scientific - ResolutionTM Hemostasis Clipping Device - Traditional 510(k): K040148	Murray Deposition Ex. 10	401/402, 403, 801/802, PMIL
DTX-0541	BSC-MT-004624	BSC-MT-004624	Video Clip	Murray Deposition Ex. 11	401/402, 403, 801/802, ID
DTX-0542	BSC-MT-139849	BSC-MT-139856	Boston Scientific: Micro-Tech Clip Deployment Analysis - Murray Affidavit	Murray Deposition Ex. 12	401/402, 403, 801/802
DTX-0543			Elements of Metallurgy and Engineering Alloys, Chapter 13: Fracture (2008)	Murray Deposition Ex. 13	401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0544			ASM Handbook – Fatigue and Fracture, "Micromechanisms of Monotonic and Cyclic Crack Growth"	Murray Deposition Ex. 14	401/402, 403, 801/802
DTX-0545	BSC-MT-139793	BSC-MT-139848	Exponent: Boston Scientific – Fracture Analysis of Deployed SureClip Hemostasis Clip	Murray Deposition Ex. 15	401/402, 403, 801/802
DTX-0546	BSC-MT-006106	BSC-MT-006106	Boston Scientific: E0630 – Clip end Effectors TDP	Murray Deposition Ex. 16	401/402, 403, 801/802
DTX-0547	BSC-MT-006228	BSC-MT-006238	Resolution 360 Clip – Competitive Analysis of Diversatek RePlay Hemostasis Clip	Murray Deposition Ex. 17	401/402, 403, 801/802
DTX-0548	BSC-MT-118046	BSC-MT-118095	Boston Scientific: Resolution Clip – Competitive Handling Tool	Murray Deposition Ex. 18	401/402, 403, 801/802
DTX-0549	BSC-MT-011021	BSC-MT-011043	Presentation: Rotatable Resolution Clip Technical Review	Murray Deposition Ex. 19	401/402, 403, 801/802
DTX-0550	BSC-MT-029392	BSC-MT-029401	Boston Scientific – Microvasive - Memo Re Hemoclip Prototype Testing	Murray Deposition Ex. 20	401/402, 403, 801/802
DTX-0551			Plaintiffs' Objections and Responses to Defendants Third Set of Interrogatories Nos. 10-13	Murray Deposition Ex. 21	401/402, 403, 801/802
DTX-0552	BSC-MT-054392	BSC-MT-054602	Lab Notebook No. N0261 for M. Adams	Murray Deposition Ex. 22	401/402, 403, 701/702, 801/802
DTX-0553	BSC-MT-022451	BSC-MT-022494	BSC Invention Disclosure: 03-D0683	Murray Deposition Ex. 23	401/402, 403, 801/802
DTX-0554	BSC-MT-022497	BSC-MT-022517	BSC Invention Disclosure: 04-D0297	Murray Deposition Ex. 24	401/402, 403, 801/802
DTX-0555	BSC-MT-034073	BSC-MT-034096	Lab Notebook No. N0119 for Russ Durgin	Murray Deposition Ex. 25	401/402, 403, 701/702, 801/802
DTX-0556			Plaintiffs' Objections and Responses to Defendants First Set of Interrogatories Nos. 1-8	Murray Deposition Ex. 26	401/402, 403, 801/802
DTX-0557	BSC-MT-109272	BSC-MT-109292	Boston Scientific: Advancing Science for Life – Micro-Tech HemoClips – Competitive Overview	Murray Deposition Ex. 27	401/402, 403, 801/802
DTX-0558	BSC-MT-003786	BSC-MT-003788	Res 360 Key Account Research Interviews – April-May 2019	Murray Deposition Ex. 28	401/402, 403, 801/802
DTX-0559	BSC-MT-075619	BSC-MT-075619	Answers for Hemo Clip Forecasting	Murray Deposition Ex. 29	401/402, 403, 801/802
DTX-0560	BSC-MT-037251	BSC-MT-037251	Excel Spreadsheet, Clinical requirement & positioning	Murray Deposition Ex. 30	401/402, 403, 801/802
DTX-0561	BSC-MT-075981	BSC-MT-075981	Excel Spreadsheet, Hemo Clip Feedback US Customers	Murray Deposition Ex. 31	401/402, 403, 801/802
DTX-0562	BSC-MT-037129		Boston Scientific – MicroVasive – Product Specifications for the HCD TTS Clip	Murray Deposition Ex. 32	401/402, 403, 801/802
DTX-0563	BSC-MT-020296	BSC-MT-020353	Boston Scientific – Preclinical Study Report – Resolution II	Murray Deposition Ex. 33	401/402, 403, 801/802
DTX-0564	BSC-MT-108862	BSC-MT-108902	Boston Scientific – Preclinical Protocol – A Non-GLP Chronic Study to Access Retention of Resolution Clips in Canine	Murray Deposition Ex. 34	401/402, 403, 801/802
DTX-0565	BSC-MT-003799	BSC-MT-003845	Boston Scientific: Resolution 360 – NPCE #1 – July 2019	Moscato Deposition Ex. 34	401/402, 403, 801/802
DTX-0566	BSC-MT-003146	BSC-MT-003156	Article: Wang et al., "Choosing the right through the scope clip: a rigorous comparison of rotatability, whip, open/close precision and closure strength"	Moscato Deposition Ex. 35	401/402, 403, 801/802
DTX-0567	BSC-MT-093269	BSC-MT-093323	Boston Scientific – Presentation – Resolution 360 Clip – Commercialization Plan	Moscato Deposition Ex. 36	401/402, 403, 801/802
DTX-0568	BSC-MT-129640	BSC-MT-129675	Presentation: ESC Hemoclip Brand Perception Study – January 2018	Moscato Deposition Ex. 37	401/402, 403, 801/802
DTX-0569	BSC-MT-129478	BSC-MT-129520	Presentation: Clips Market Research – January 2020	Moscato Deposition Ex. 38	401/402, 403, 801/802
DTX-0570	BSC-MT-139987	BSC-MT-140054	Purchasing Agreement between HealthTrust and Boston Scientific Corp.	Moscato Deposition Ex. 39	401/402, 403, 801/802
DTX-0571	BSC-MT-116614	BSC-MT-116626	Distribution Agreement between BSSI and BSC	Moscato Deposition Ex. 40	401/402, 403, 801/802
DTX-0572	BSC-MT-129682	BSC-MT-129739	IPSOS Business Consulting – Final Report – Micro-Tech Competitive Analysis	Moscato Deposition Ex. 41	401/402, 403, 801/802
DTX-0573	BSC-MT-003789	BSC-MT-003789	Boston Scientific – Res 360 Customer research	Moscato Deposition Ex. 42	401/402, 403, 801/802
DTX-0574	BSC-MT-003720	BSC-MT-003720	Document re: Pricing/Sales Program	Moscato Deposition Ex. 43	401/402, 403, 801/802
DTX-0575	BSC-MT-003743	BSC-MT-003744	Document re Lower Costs/Pricing Programs	Moscato Deposition Ex. 44	401/402, 403, 801/802
DTX-0576	BSC-MT-132385	BSC-MT-132397	Boston Scientific – Presentation – Target Margins Hemo Draft	Moscato Deposition Ex. 45	401/402, 403, 801/802
DTX-0577	BSC-MT-003721	BSC-MT-003728	Boston Scientific – Micro-Tech Clip Battling	Moscato Deposition Ex. 46	401/402, 403, 801/802
DTX-0578	BSC-MT-101455	BSC-MT-101456	Email Re Clip Pricing Strategy	Moscato Deposition Ex. 47	401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0579	BSC-MT-003021	BSC-MT-003038	Boston Scientific – Presentation- Competitive Comparison	Moscato Deposition Ex. 48	401/402, 403, 801/802
DTX-0580	BSC-MT-004690	BSC-MT-004706	Boston Scientific – Going on the Offensive 3.2 – Micro-Tech Update and Strategy	Moscato Deposition Ex. 49	401/402, 403, 801/802
DTX-0581	BSC-MT-003066	BSC-MT-003111	Boston Scientific – Presentation – Protecting Your Business	Moscato Deposition Ex. 50	401/402, 403, 801/802
DTX-0582	BSC-MT-003782	BSC-MT-003783	Project Freight Train – Kick Off – Meeting Minutes	Moscato Deposition Ex. 51	401/402, 403, 801/802
DTX-0583	BSC-MT-003752	BSC-MT-003764	Boston Scientific – Presentation – Project Freight Train – Kick Off	Moscato Deposition Ex. 52	401/402, 403, 801/802
DTX-0584	BSC-MT-003784	BSC-MT-003785	Document re Project Freight Train	Moscato Deposition Ex. 53	401/402, 403, 801/802
DTX-0585	BSC-MT-003766	BSC-MT-003780	Boston Scientific – Presentation – Project Freight Train	Moscato Deposition Ex. 54	401/402, 403, 801/802
DTX-0586	BSC-MT-003745	BSC-MT-003751	Boston Scientific – Presentation – Operation Steel Curtain	Moscato Deposition Ex. 55	401/402, 403, 801/802
DTX-0587	BSC-MT-117026	BSC-MT-117037	Hemo Clip Percent Market Share	Moscato Deposition Ex. 56	401/402, 403, 801/802
DTX-0588	BSC-MT-116918	BSC-MT-116929	1Q 2008 Hemo Clip Percent Market Share	Moscato Deposition Ex. 57	401/402, 403, 801/802
DTX-0589	BSC-MT-117014	BSC-MT-117025	4Q 2008 Hemo Clip Percent Market Share	Moscato Deposition Ex. 58	401/402, 403, 801/802
DTX-0590	BSC-MT-117002	BSC-MT-117013	2Q 2008 Hemo Clip Percent Market Share	Moscato Deposition Ex. 59	401/402, 403, 801/802
DTX-0591	BSC-MT-117038	BSC-MT-117049	4Q 2008 Hemo Clip Percent Market Share	Moscato Deposition Ex. 60	401/402, 403, 801/802
DTX-0592	BSC-MT-116822	BSC-MT-116833	3Q 2013 Hemo Clip Percent Market Share	Moscato Deposition Ex. 61	401/402, 403, 801/802
DTX-0593	BSC-MT-00116894	BSC-MT-00116905	2Q 2014 Hemo Clip Percent Market Share	Moscato Deposition Ex. 62	401/402, 403, 801/802
DTX-0594	BSC-MT-116882	BSC-MT-116893	4Q 2014 Hemo Clip Percent Market Share	Moscato Deposition Ex. 63	401/402, 403, 801/802
DTX-0595	BSC-MT-116906	BSC-MT-116917	1Q 2015 Hemo Clip Percent Market Share	Moscato Deposition Ex. 64	401/402, 403, 801/802
DTX-0596	BSC-MT-116930	BSC-MT-116941	2Q 2015 Hemo Clip Percent Market Share	Moscato Deposition Ex. 65	401/402, 403, 801/802
DTX-0597	BSC-MT-132652	BSC-MT-132704	Boston Scientific – Clipping VOC - Quantitative Findings	Moscato Deposition Ex. 66	401/402, 403, 801/802
DTX-0598	BSC-MT-002930	BSC-MT-002939	Boston Scientific – Presentation - Cook Instinct – Clip Competitive Response Plan – April 2012	Moscato Deposition Ex. 67	401/402, 403, 801/802
DTX-0599	BSC-MT-002834	BSC-MT-002868	Resolution Clip Competitive Response	Moscato Deposition Ex. 68	401/402, 403, 801/802
DTX-0600	BSC-MT-117983	BSC-MT-118045	Presentation - Resolution II Clip – Next Generation Mechanical Clip Device – Global Commercialization Plan	Moscato Deposition Ex. 69	401/402, 403, 801/802
DTX-0601	BSC-MT-111909	BSC-MT-111937	Boston Scientific – Presentation – E0455 – Rotatable Res Clip Plan Phase Exit	Moscato Deposition Ex. 70	401/402, 403, 801/802
DTX-0602	BSC-MT-092350	BSC-MT-92368	Boston Scientific – Presentation - Hemostasis	Moscato Deposition Ex. 71	401/402, 403, 801/802
DTX-0603	BSC-MT-092708	BSC-MT-092744	Boston Scientific – Presentation - Hemostasis	Moscato Deposition Ex. 72	401/402, 403, 801/802
DTX-0604	BSC-MT-140059	BSC-MT-140059	Excel Spreadsheet, Clips Insource Project Cost	Schulz Deposition Ex. 73	401/402, 403, 801/802
DTX-0605	BSC-MT-140062	BSC-MT-140062	Excel Spreadsheet, Sales Data for 2004 to 2020	Schulz Deposition Ex. 74	401/402, 403, 801/802
DTX-0606	BSC-MT-140063	BSC-MT-140063	Excel Spreadsheet, US Global PL 2011 to 2020 (8.11.2020)	Schulz Deposition Ex. 75	401/402, 403, 801/802
DTX-0607	BSC-MT-006045	BSC-MT-006045	Excel Spreadsheet, US Global PL 2011 to 2018 (9.25.2019)	Schulz Deposition Ex. 76	401/402, 403, 801/802
DTX-0608	BSC-MT-140064	BSC-MT-140064	Excel Spreadsheet, Scrap Res Clips 2012-2020Vf	Schulz Deposition Ex. 77	401/402, 403, 801/802
DTX-0609	BSC-MT-140060	BSC-MT-140060	Excel Spreadsheet, R&D Costs	Schulz Deposition Ex. 78	401/402, 403, 801/802
DTX-0610	BSC-MT-140058	BSC-MT-140058	Excel Spreadsheet, BSC Sales in Margin, Market Share	Schulz Deposition Ex. 79	401/402, 403, 801/802
DTX-0611	BSC-MT-091976	BSC-MT-091976	Excel Spreadsheet, Endoscopy Master Price List 2016 10-16	Schulz Deposition Ex. 80	401/402, 403, 801/802
DTX-0612	BSC-MT-006045	BSC-MT-006045	Excel Spreadsheet, US Global PL 2011 to 2018 (9.25.2019)	Schulz Deposition Ex. 81	401/402, 403, 801/802
DTX-0613	BSC-MT-069558	BSC-MT-069561	510(k) Summary – K040148	Hennessey Deposition Ex. 83	401/402, 403, 801/802
DTX-0614	BSC-MT-110175	BSC-MT-110293	Boston Scientific Corp. Submission to FDA: Resolution II Hemostasis Clipping Device	Hennessey Deposition Ex. 84	401/402, 403, 801/802
DTX-0615	BSC-MT-026996	BSC-MT-027007	Hazard Analysis – Resolution I Hemostatic Clipping Device	Hennessey Deposition Ex. 85	401/402, 403, 801/802
DTX-0616			FDA: Class 2 Device Recall Boston Scientific Clipping Device, Resolution Clip	Hennessey Deposition Ex. 86	401/402, 403, 801/802
DTX-0617			Section 6 – 510(k) Summary – K102764	Hennessey Deposition Ex. 87	401/402, 403, 801/802
DTX-0618	BSC-MT-131280	BSC-MT-131340	Resolution II Clip Clinical Risk/Benefit Analysis	Hennessey Deposition Ex. 88	401/402, 403, 801/802
DTX-0619	BSC-MT-055106	BSC-MT-055201	Resolution II Clip Device – Clinical Experience Summary	Hennessey Deposition Ex. 89	401/402, 403, 801/802
DTX-0620			FDA: Class 2 Device Recall Resolution II Clip	Hennessey Deposition Ex. 90	401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0621			Federal Institute for Drugs and Medical Devices – Recall for the Resolution II Clip, Boston Scientific	Hennessey Deposition Ex. 91	401/402, 403, 801/802
DTX-0622			Defective Devices, Destroyed Lives	Hennessey Deposition Ex. 92	401/402, 403, 801/802
DTX-0623	BSC-MT-006636	BSC-MT-006711	Boston Scientific – Presentation - Rotatable Res Clip Project E0455	Hennessey Deposition Ex. 93	401/402, 403, 801/802
DTX-0624	BSC-MT-032812	BSC-MT-032817	Letter from FDA	Hennessey Deposition Ex. 94	401/402, 403, 801/802
DTX-0625	BSC-MT-064003	BSC-MT-064067	Boston Scientific – Resolution Clip Commercial Strategy	Hennessey Deposition Ex. 95	401/402, 403, 801/802
DTX-0626	BSC-MT-136831	BSC-MT-136912	Boston Scientific – Presentation – Resolution 360 Clip – Human Use – Commercial Release Design Review	Hennessey Deposition Ex. 96	401/402, 403, 801/802
DTX-0627	BSC-MT-109454	BSC-MT-109498	Boston Scientific – Presentation – Resolution 360 Commercialization Review	Hennessey Deposition Ex. 97	401/402, 403, 801/802
DTX-0628	BSC-MT-138945	BSC-MT-139792	Appendix A. Acceptance Checklist for Traditional 510(k)s	Hennessey Deposition Ex. 98	401/402, 403, 801/802
DTX-0629	BSC-MT-138894	BSC-MT-138901	Email Re K193424	Hennessey Deposition Ex. 99	401/402, 403, 801/802
DTX-0630	BSC-MT-	BSC-MT-138943	Response to K193242 10 Day Hold Letter Call – Resolution 360 Ultra Clip	Hennessey Deposition Ex. 100	401/402, 403, 801/802, ID
DTX-0631			Notice of Deposition of D. Bogartz	Bogartz Deposition Ex. 111	401/402, 403, 801/802
DTX-0632	BSC-MT-140183	BSC-MT-140195	Elevate Program Agreement – January 2020	Bogartz Deposition Ex. 112	401/402, 403, 801/802
DTX-0633	BSC-MT-140204	BSC-MT-140208	Sample Flex Program Agreement	Bogartz Deposition Ex. 113	401/402, 403, 801/802
DTX-0634	BSC-MT-140196	BSC-MT-140203	Sample ASCentials Program Participation Agreement – 2015 Pricing	Bogartz Deposition Ex. 114	401/402, 403, 801/802
DTX-0635	BSC-MT-140209	BSC-MT-140212	Sample ASC Sole Flex Program Agreement	Bogartz Deposition Ex. 115	401/402, 403, 801/802
DTX-0636	BSC-MT-140143	BSC-MT-140144	Boston Scientific – Discount Pricing Agreement	Bogartz Deposition Ex. 116	401/402, 403, 801/802
DTX-0637	BSC-MT-140145	BSC-MT-140150	Boston Scientific - Sample Confidential Letter Agreement Re Earned Pricing Program	Bogartz Deposition Ex. 117	401/402, 403, 801/802
DTX-0638	BSC-MT-140151	BSC-MT-140155	Sample Inventory Solutions Program Agreement	Bogartz Deposition Ex. 118	401/402, 403, 801/802
DTX-0639	BSC-MT-140156	BSC-MT-140157	Boston Scientific – Presentation – Demo and Sample Program	Bogartz Deposition Ex. 119	401/402, 403, 801/802
DTX-0640	BSC-MT-140158	BSC-MT-140163	Sample Account Volume Discount/Rebate Growth Program	Bogartz Deposition Ex. 120	401/402, 403, 801/802
DTX-0641	BSC-MT-140164	BSC-MT-140169	Sample Account Volume Discount/Rebate Growth Program	Bogartz Deposition Ex. 121	401/402, 403, 801/802
DTX-0642	BSC-MT-080159	BSC-MT-80161	Instinct Conference Call Re Cook Clip	Bogartz Deposition Ex. 122	401/402, 403, 801/802
DTX-0643	BSC-MT-078253	BSC-MT-78255	Email re Olympic Task Force Update	Bogartz Deposition Ex. 123	401/402, 403, 801/802
DTX-0644	BSC-MT-043935	BSC-MT-043978	Hemostasis Clipping Device – Integrated Business Plan – Development Phase Review	Bogartz Deposition Ex. 124	401/402, 403, 801/802
DTX-0645	BSC-MT-064003	BSC-MT-064067	Boston Scientific – Presentation - Resolution Clip Commercial Strategy – September 23, 2015	Bogartz Deposition Ex. 125	401/402, 403, 801/802
DTX-0646	BSC-MT-101455	BSC-MT-101456	Email re Clip Pricing Strategy	Bogartz Deposition Ex. 126	401/402, 403, 801/802
DTX-0647			Plaintiff BSC and BSSI Supplemental Initial Disclosures	Andersson Deposition Ex. 127	401/402, 403, 801/802
DTX-0648	BSC-MT-078796	BSC-MT-078797	Email Re Product Name for Next Generation Rotatable Resolution Clip	Andersson Deposition Ex. 128	401/402, 403, 801/802
DTX-0649	BSC-MT-101994	BSC-MT-102050	Presentation: Boston Scientific – Financial Model Overview	Andersson Deposition Ex. 129	401/402, 403, 801/802
DTX-0650	BSC-MT-088302	BSC-MT-088303	Email Re Mucin Labs Follow-Up	Andersson Deposition Ex. 130	401/402, 403, 801/802
DTX-0651			Defendants Notice of Deposition for S. Radestorf	Radestorf Deposition Ex. 1	401/402, 403, 801/802
DTX-0652	BSC-MT-003720	BSC-MT-003720	Document re Pricing/Sales	Radestorf Deposition Ex. 2	401/402, 403, 801/802
DTX-0653	BSC-MT-003743	BSC-MT-003744	Document re Lower Costs/Pricing Program	Radestorf Deposition Ex. 3	401/402, 403, 801/802
DTX-0654	BSC-MT-003729	BSC-MT-003739	Presentation: Boston Scientific - Micro-Tech Clip Battling	Radestorf Deposition Ex. 4	401/402, 403, 801/802
DTX-0655	BSC-MT-003066	BSC-MT-003111	Boston Scientific – Presentation – Protecting Your Business	Radestorf Deposition Ex. 5	401/402, 403, 801/802
DTX-0656	BSC-MT-003766	BSC-MT-003780	Boston Scientific – Presentation – Project Freight Train	Radestorf Deposition Ex. 6	401/402, 403, 801/802
DTX-0657	BSC-MT-003786-3788	BSC-MT-003788	Res 360 Key Account Research Interviews – April-May 2019	Radestorf Deposition Ex. 7	401/402, 403, 801/802
DTX-0658	BSC-MT-018811	BSC-MT-018811	Excel Spreadsheet, Cook Clip At Risk Accounts - March 2012	Radestorf Deposition Ex. 8	401/402, 403, 801/802
DTX-0659	BSC-MT-118273	BSC-MT-118311	Boston Scientific – Presentation - Hemostasis	Radestorf Deposition Ex. 9	401/402, 403, 801/802
DTX-0660			Expert Report of Michael K. Milani dated December 4, 2020	Milani Deposition Ex. 1	701/702, 801/802, 901/902

Schedule 8 - Defendants' Trial Exhibit List

DTX-0661			Errata to Expert Report of Michael K. Milani dated December 4, 2020	Milani Deposition Ex. 2	401/402, 403, 701/702, 801/802, 901/902
DTX-0662	BSC-MT-129640	BSC-MT-129675	Presentation: ESC Hemoclip – Brand Perception Study – January 2018	Milani Deposition Ex. 3	401/402, 403, 801/802
DTX-0663			Expert Report of Michael K. Milani dated December 4, 2020		701/702, 801/802, 901/902
DTX-0664			Curriculum Vitae for M. Milani		
DTX-0665			List of Materials Considered for Milani Expert Report		
DTX-0666			COMPARISON OF COMPETITOR PRICING - 2016-2019 ASP PRICING MATRIX		401/402, 403, 701/702, 801/802
DTX-0667			COMPETITOR PRICING ANALYSIS - 2016-2019 COMPARISON OF ASP		401/402, 403, 701/702, 801/802
DTX-0668			APPORTIONMENT METRICS APPLIED TO DEFENDANTS' WEIGHTED AVERAGE INCREMENTAL PROFIT		401/402, 403, 701/702, 801/802
DTX-0669			APPORTIONMENT METRICS BASED ON HCD BUSINESS PLAN		401/402, 403, 701/702, 801/802
DTX-0670			SUMMARY OF J-HOOK & BUCKLE ACCUSED UNITS DURING LICENSE PERIOD - NOVEMBER 26, 2018 - DECEMBER 31, 2019		401/402, 403, 701/702, 801/802
DTX-0671			SUMMARY OF BUCKLE ACCUSED UNITS AND ROYALTY CALCULATION DURING LICENSE PERIOD - NOVEMBER 26, 2018 - DECEMBER 31, 2019 [1]		401/402, 403, 701/702, 801/802
DTX-0672			SUMMARY OF J-HOOK ACCUSED UNITS AND ROYALTY CALCULATION DURING LICENSE PERIOD - NOVEMBER 26, 2018 - DECEMBER 31, 2019 [1]		401/402, 403, 701/702, 801/802
DTX-0673			PERCENTAGE OF ACCUSED WIDE-JAW UNITS DURING LICENSE PERIOD - NOVEMBER 26, 2018 - DECEMBER 31, 2019 [1] [2]		401/402, 403, 701/702, 801/802
DTX-0674			SUMMARY OF ACCUSED PRODUCT UNITS DURING LICENSE PERIOD - NOVEMBER 26, 2018 - DECEMBER 31, 2019 [1]		401/402, 403, 701/702, 801/802
DTX-0675			SUMMARY OF INCREMENTAL PROFITABILITY BY DISTRIBUTION CHANNEL		401/402, 403, 701/702, 801/802
DTX-0676			SUMMARY OF INCREMENTAL PROFITABILITY BY SALES ENTITY 2016-2019		401/402, 403, 701/702, 801/802
DTX-0677			CALCULATION OF HENRY SCHEIN'S INCREMENTAL PROFIT: PER UNIT		401/402, 403, 701/702, 801/802
DTX-0678			CALCULATION OF HENRY SCHEIN'S INCREMENTAL PROFIT [1]		401/402, 403, 701/702, 801/802
DTX-0679			CALCULATION OF HENRY SCHEIN'S INCREMENTAL PROFIT: SUMMARY OF UNITS SOLD BY HENRY SCHEIN [1]		401/402, 403, 701/702, 801/802
DTX-0680			CALCULATION OF HENRY SCHEIN'S INCREMENTAL PROFIT: ADJUSTMENT OF UNITS SOLD BY HENRY SCHEIN [1]		401/402, 403, 701/702, 801/802
DTX-0681			CALCULATION OF HENRY SCHEIN'S INCREMENTAL PROFIT: INCREMENTAL EXPENSE AS A PERCENTAGE OF REVENUE [1]		401/402, 403, 701/702, 801/802
DTX-0682			CALCULATION OF MT USA INCREMENTAL PROFIT (ALL ACCUSED CLIP SALES): PER UNIT		401/402, 403, 701/702, 801/802
DTX-0683			CALCULATION OF MT USA INCREMENTAL PROFIT (ALL ACCUSED CLIP SALES)		401/402, 403, 701/702, 801/802
DTX-0684			MT USA CLIP SALES & AVERAGE SELLING PRICES [1]		401/402, 403, 701/702, 801/802
DTX-0685			ALL MT USA ACCUSED PRODUCT SALES BY DISTRIBUTION CHANNEL [1]		401/402, 403, 701/702, 801/802
DTX-0686			ALL MICRO-TECH USA ACCUSED PRODUCT SALES BY JAW SIZE CATEGORY [1]		401/402, 403, 701/702, 801/802
DTX-0687			ACCUSED AND PRACTICING PRODUCT UNIT SUMMARY		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0688		CALCULATION OF MT USA DURA_CLIP INCREMENTAL PROFIT (SALES TO CONMED) PER UNIT		401/402, 403, 701/702, 801/802
DTX-0689		CALCULATION OF MT USA DURA_CLIP INCREMENTAL PROFIT (SALES TO CONMED)		401/402, 403, 701/702, 801/802
DTX-0690		CALCULATION OF MT USA DURA_CLIP INCREMENTAL PROFIT (SALES TO CONMED) NET REVENUE		401/402, 403, 701/702, 801/802
DTX-0691		MT USA DURA_CLIP SALES BY JAW SIZE CATEGORY - SALES TO CONMED [1] [2]		401/402, 403, 701/702, 801/802
DTX-0692		MT USA DURA_CLIP SALES BY UPN - SALES TO CONMED [1]		401/402, 403, 701/702, 801/802
DTX-0693		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (SALES TO HENRY SCHEIN) PER UNIT		401/402, 403, 701/702, 801/802
DTX-0694		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (SALES TO HENRY SCHEIN)		401/402, 403, 701/702, 801/802
DTX-0695		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (SALES TO HENRY SCHEIN) NET REVENUE		401/402, 403, 701/702, 801/802
DTX-0696		MT USA SURE_CLIP SALES BY JAW SIZE CATEGORY - SALES TO HENRY SCHEIN [1] [2]		401/402, 403, 701/702, 801/802
DTX-0697		MT USA SURE_CLIP SALES BY UPN - SALES TO HENRY SCHEIN [1]		401/402, 403, 701/702, 801/802
DTX-0698		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (DIRECT SALES) PER UNIT		401/402, 403, 701/702, 801/802
DTX-0699		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (DIRECT SALES)		401/402, 403, 701/702, 801/802
DTX-0700		CALCULATION OF MT USA SURE_CLIP INCREMENTAL PROFIT (DIRECT SALES) NET REVENUE		401/402, 403, 701/702, 801/802
DTX-0701		MT USA SURE_CLIP SALES BY JAW SIZE CATEGORY - DIRECT SALES [1] [2]		401/402, 403, 701/702, 801/802
DTX-0702		MT USA SURE_CLIP SALES BY UPN - DIRECT SALES [1]		401/402, 403, 701/702, 801/802
DTX-0703		CALCULATION OF MT USA INCREMENTAL COST: ADDITIONAL COST OF GOODS SOLD [1]		401/402, 403, 701/702, 801/802
DTX-0704		CALCULATION OF MT USA INCREMENTAL COST: DISCOUNT PERCENTAGE [1]		401/402, 403, 701/702, 801/802
DTX-0705		CALCULATION OF MT USA INCREMENTAL OPERATING EXPENSES [1]		401/402, 403, 701/702, 801/802
DTX-0706		CALCULATION OF MT USA INCREMENTAL COST: OPERATING EXPENSES PRIOR TO INCREMENTAL ADJUSTMENT [1]		401/402, 403, 701/702, 801/802
DTX-0707		ANALYSIS SUPPORTING MT USA INCREMENTAL COST CALCULATION - SUMMARY [1]		401/402, 403, 701/702, 801/802
DTX-0708		ANALYSIS SUPPORTING MT USA INCREMENTAL COST CALCULATION - DETAILED [1]		401/402, 403, 701/702, 801/802
DTX-0709		MICRO-TECH USA COMPANYWIDE INCOME STATEMENT [1]		401/402, 403, 701/702, 801/802
DTX-0710		ACCUSED PRODUCT JAW SIZES		401/402, 403, 701/702, 801/802
DTX-0711		SUMMARY OF MICRO-TECH SALES BY CUSTOMER IN IDENTIFICATION OF MARKET SEGMENT[1]		401/402, 403, 701/702, 801/802
DTX-0712		MT NANJING CALCULATION OF GROSS PROFIT FROM MT ACCUSED PRODUCTS [1]		401/402, 403, 701/702, 801/802
DTX-0713		MT NANJING CONVERSION OF COST OF GOODS SOLD FROM RMB TO USD		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0714		MT NANJING CALCULATION OF YEARLY AVERAGE RMB TO USD CONVERSION RATE		401/402, 403, 701/702, 801/802
DTX-0715		BOSTON SCIENTIFIC PRACTICING PRODUCT SALES JANUARY 1, 2004 - AUGUST 31, 2020 [1]		401/402, 403, 701/702, 801/802
DTX-0716		BOSTON SCIENTIFIC ENDOSCOPY DIVISION OPERATING PROFIT - U.S. [1]		401/402, 403, 701/702, 801/802
DTX-0717		BOSTON SCIENTIFIC ENDOSCOPY DIVISION OPERATING PROFIT - WORLDWIDE [1]		401/402, 403, 701/702, 801/802
DTX-0718		BOSTON SCIENTIFIC COMPANY-WIDE INCOME STATEMENT		401/402, 403, 701/702, 801/802
DTX-0719		2018 U.S. MARKET REVENUE FOR HEMOSTASIS DEVICES [1]		401/402, 403, 701/702, 801/802
DTX-0720		BSC EXPECTED MARKET SHARE (NO LAUNCH OF RESOLUTION 360) [1]		401/402, 403, 701/702, 801/802
DTX-0721		THIRD PARTY MARKET SHARE DATA - QUARTERLY AS PRESENTED [1]		401/402, 403, 701/702, 801/802
DTX-0722		THIRD PARTY MARKET SHARE DATA - YEARLY AS PRESENTED [1]		401/402, 403, 701/702, 801/802
DTX-0723		SUMMARY OF THE PATENTS ASSERTED AGAINST MICRO-TECH ("PATENTS-IN-SUIT")		401/402, 403, 701/702, 801/802
DTX-0724		SUMMARY OF THE PATENTS ASSERTED AGAINST MICRO-TECH ("PATENTS-IN-SUIT")		401/402, 403, 701/702, 801/802
DTX-0725		REBUTTAL TO BONE: MT USA DIRECT INCREMENTAL PROFIT ATTRIBUTABLE TO CLAIMED FEATURES		401/402, 403, 701/702, 801/802
DTX-0726		REBUTTAL TO BONE: CORRECTED PROFIT ATTRIBUTABLE TO OPEN/CLOSE		401/402, 403, 701/702, 801/802
DTX-0727		REBUTTAL TO BONE: CORRECTED OPEN/CLOSE TO WIDE-JAW RATIOS		401/402, 403, 701/702, 801/802
DTX-0728		NON-INFRINGEMENT ALTERNATIVE HEMOCCLIPS APPROVED FOR SALE IN THE U.S.		401/402, 403, 701/702, 801/802
DTX-0729	BSC-MT-000557	BSC-MT-000758 File History for U.S. Patent No. 8,803,668		401/402, 403
DTX-0730	BSC-MT-001284	BSC-MT-001590 File History for U.S. Patent No. 9,370,371		401/402, 403
DTX-0731	BSC-MT-002832	BSC-MT-002833 Email Re Resolution Clips Exceeds 1 Million Units Sold in 2013		401/402, 403, 801/802
DTX-0732	BSC-MT-002869	BSC-MT-002898 Presentation: Boston Scientific - Winning Together - European Sales Meeting		401/402, 403, 801/802
DTX-0733	BSC-MT-002899	BSC-MT-002926 Presentation: Boston-Scientific - Growing Your Resolution™ Clip Business		401/402, 403, 801/802
DTX-0734	BSC-MT-002927	BSC-MT-002929 Magnetic Resonance (MR) Conventional FAQs for Resolution™ Clip		401/402, 403, 801/802
DTX-0735	BSC-MT-002940	BSC-MT-002942 Magnetic Resonance (MR) Conventional FAQs for ResolutionTM Clip		401/402, 403, 801/802
DTX-0736	BSC-MT-002943	BSC-MT-002957 Presentation: Boston Scientific - Resolution™ Clip Risk Share Program		401/402, 403, 801/802
DTX-0737	BSC-MT-002958	BSC-MT-002974 Presentation - Boston Scientific - Competitive Comparison		401/402, 403, 801/802
DTX-0738	BSC-MT-002975	BSC-MT-003020 Presentation: Boston Scientific - Protecting Your Business		401/402, 403, 801/802
DTX-0739	BSC-MT-003039	BSC-MT-003055 Presentation - Boston Scientific - Competitive Comparison		401/402, 403, 801/802
DTX-0740	BSC-MT-003056	BSC-MT-003065 Presentation - Boston Scientific- Next Level		401/402, 403, 801/802
DTX-0741	BSC-MT-003112	BSC-MT-003132 Boston Scientific - Product Information Page		401/402, 403, 801/802
DTX-0742	BSC-MT-003133	BSC-MT-003133 Boston Scientific Web Page		401/402, 403, 801/802
DTX-0743	BSC-MT-003134	BSC-MT-003138 Boston Scientific- Product Information Page		401/402, 403, 801/802
DTX-0744	BSC-MT-003139	BSC-MT-003142 DDW 2019 Social Media Posts		401/402, 403, 801/802
DTX-0745	BSC-MT-003143	BSC-MT-003143 Boston Scientific Web Page		401/402, 403, 801/802
DTX-0746	BSC-MT-003144	BSC-MT-003144 Video		401/402, 403, 801/802, ID

Schedule 8 - Defendants' Trial Exhibit List

DTX-0747	BSC-MT-003145	BSC-MT-003145	Video		401/402, 403, 801/802, ID
DTX-0748	BSC-MT-003157	BSC-MT-003157	Video		401/402, 403, 801/802, ID
DTX-0749	BSC-MT-003158	BSC-MT-003159	GI March 2019 Social Posts @bsc endoscopy		401/402, 403, 801/802
DTX-0750	BSC-MT-003160	BSC-MT-003164	GI June 2019 Twitter Posts @bsc endoscopy		401/402, 403, 801/802
DTX-0751	BSC-MT-003165	BSC-MT-003167	Article: Kamboj et al., "Diagnosing Cholangiocarcinoma Using Cholangioscopy and Treating Duodenal Ulcer with Physician Controlled Clip Rotation"		401/402, 403, 801/802
DTX-0752	BSC-MT-003168	BSC-MT-003168	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-0753	BSC-MT-003169	BSC-MT-003170	Resolution™ Clip Risk Share Program Essentials		401/402, 403, 801/802
DTX-0754	BSC-MT-003171	BSC-MT-003175	Harper Design Studio Presentation for Boston Scientific Project SGG2019		401/402, 403, 801/802
DTX-0755	BSC-MT-003176	BSC-MT-003179	Social Posts August @bsc endoscopy Twitter Feed		401/402, 403, 801/802
DTX-0756	BSC-MT-003180	BSC-MT-003184	Display: Geo-Fencing - Hyperlocal ACG		401/402, 403, 801/802
DTX-0757	BSC-MT-003185	BSC-MT-003230	Presentation: Boston Scientific- Protecting Your Business		401/402, 403, 801/802
DTX-0758	BSC-MT-003231	BSC-MT-003244	Boston Scientific Web Page		401/402, 403, 801/802
DTX-0759	BSC-MT-003245	BSC-MT-003251	Boston Scientific Web Page - Surgical Endoscopy		401/402, 403, 801/802
DTX-0760	BSC-MT-003252	BSC-MT-003253	Resolution™ Clip Device Product Information		401/402, 403, 801/802
DTX-0761	BSC-MT-003254	BSC-MT-003257	Article: Sachdev, "Endoscopic Mucosal Resection for Large Polyp Removal"		401/402, 403, 801/802
DTX-0762	BSC-MT-003258	BSC-MT-003258	Resolution™ Clip Advertisement		401/402, 403, 801/802
DTX-0763	BSC-MT-003259	BSC-MT-003260	Resolution™ Clip Advertisement		401/402, 403, 801/802
DTX-0764	BSC-MT-003261	BSC-MT-003262	Boston Scientific Web Page - Resolution™ Clip		401/402, 403, 801/802
DTX-0765	BSC-MT-003263	BSC-MT-003263	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-0766	BSC-MT-003264	BSC-MT-003275	Resolution™ Clip Instructions for Use		401/402, 403, 801/802
DTX-0767	BSC-MT-003276	BSC-MT-003280	Resolution™ Clip Banner Advertisements		401/402, 403, 801/802
DTX-0768	BSC-MT-003281	BSC-MT-003282	Resolution™ Clip Evaluation Form		401/402, 403, 801/802
DTX-0769	BSC-MT-003283	BSC-MT-003292	Resolution™ Clip Instructions for Use		401/402, 403, 801/802
DTX-0770	BSC-MT-003293	BSC-MT-003296	Resolution™ Clip Advertisement		401/402, 403, 801/802
DTX-0771	BSC-MT-003297	BSC-MT-003298	Article: "Resolution Clip - Playing an Important Role in the Practice of Hemostasis"		401/402, 403, 801/802
DTX-0772	BSC-MT-003299	BSC-MT-003300	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0773	BSC-MT-003301	BSC-MT-003306	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0774	BSC-MT-003307	BSC-MT-003312	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0775	BSC-MT-003313	BSC-MT-003313	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0776	BSC-MT-003315	BSC-MT-003317	Boston Scientific Product Information		401/402, 403, 801/802, ID
DTX-0777	BSC-MT-003318	BSC-MT-003354	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0778	BSC-MT-003355	BSC-MT-003358	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0779	BSC-MT-003359	BSC-MT-003359	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0780	BSC-MT-003360	BSC-MT-003360	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0781	BSC-MT-003361	BSC-MT-003361	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0782	BSC-MT-003362	BSC-MT-003362	Article: "Resolution Clip is First Hemostasis Clip to Receive Clearance for Prophylactic Clipping"		401/402, 403, 801/802
DTX-0783	BSC-MT-003363	BSC-MT-003367	Boston Scientific Product Information		401/402, 403, 801/802
DTX-0784	BSC-MT-003368	BSC-MT-003368	Boston Scientific Letter Re Resolution™ Clip		401/402, 403, 801/802
DTX-0785	BSC-MT-003369	BSC-MT-003369	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-0786	BSC-MT-003370	BSC-MT-003370	Boston Scientific Web Page - Expanded Indication: Prophylactic Clipping		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0787	BSC-MT-003371	BSC-MT-003372	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-0788	BSC-MT-003373	BSC-MT-003374	Boston Scientific Web Page - Expanded Indication: Prophylactic Clipping		401/402, 403, 801/802
DTX-0789	BSC-MT-003375	BSC-MT-003375	Video		401/402, 403, 801/802, ID
DTX-0790	BSC-MT-003376	BSC-MT-003376	Resolution™ Clip Advertisement		401/402, 403, 801/802, ID
DTX-0791	BSC-MT-003377	BSC-MT-003379	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0792	BSC-MT-003380	BSC-MT-003388	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0793	BSC-MT-003389	BSC-MT-003390	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0794	BSC-MT-003391	BSC-MT-003392	Resolution™ Clip Evaluation Form		401/402, 403, 801/802, ID
DTX-0795	BSC-MT-003393	BSC-MT-003400	Resolution™ Clip Technique Spotlights		401/402, 403, 801/802, ID
DTX-0796	BSC-MT-003401	BSC-MT-003402	Resolution™ Clip Use During Medical Case		401/402, 403, 801/802, ID
DTX-0797	BSC-MT-003403	BSC-MT-003404	Resolution™ Clip Clinical Summary		401/402, 403, 801/802, ID
DTX-0798	BSC-MT-003405	BSC-MT-003405	Produced in Native Format		401/402, 403, 801/802, ID
DTX-0799	BSC-MT-003406	BSC-MT-003407	Resolution™ Clip Clinical Summary		401/402, 403, 801/802, ID
DTX-0800	BSC-MT-003408	BSC-MT-003408	Resolution™ Clip Device Set-Up		401/402, 403, 801/802, ID
DTX-0801	BSC-MT-003409	BSC-MT-003411	Resolution™ Clip Use During Medical Case		401/402, 403, 801/802, ID
DTX-0802	BSC-MT-003412	BSC-MT-003415	Resolution™ Clip Product Information		401/402, 403, 801/802, ID
DTX-0803	BSC-MT-003416	BSC-MT-003416	Resolution™ Clip Procedural Steps		401/402, 403, 801/802, ID
DTX-0804	BSC-MT-003417	BSC-MT-003461	Resolution™ Clip Clinical Performance		401/402, 403, 801/802, ID
DTX-0805	BSC-MT-003462	BSC-MT-003462	Video		401/402, 403, 801/802, ID
DTX-0806	BSC-MT-003463	BSC-MT-003463	MRI Conditional Hospital Letter		401/402, 403, 801/802
DTX-0807	BSC-MT-003465	BSC-MT-003472	Boston Scientific - Competitive Hemostasis Clip Analysis		401/402, 403, 801/802
DTX-0808	BSC-MT-003542	BSC-MT-003597	Boston Scientific - Resolution 360™ Clip Directions For Use		401/402, 403, 801/802
DTX-0809	BSC-MT-003598	BSC-MT-003653	Boston Scientific - Resolution 360™ Clip Directions For Use		401/402, 403, 801/802
DTX-0810	BSC-MT-003654	BSC-MT-003664	Boston Scientific - Resolution 360™ Clip Directions For Use		401/402, 403, 801/802
DTX-0811	BSC-MT-003665	BSC-MT-003679	Boston Scientific - Resolution Clip Market Specification		401/402, 403, 801/802
DTX-0812	BSC-MT-003707	BSC-MT-003707	Hook Photo		401/402, 403, 801/802
DTX-0813	BSC-MT-003729	BSC-MT-003739	Presentation: Boston Scientific - Micro-Tech Clip Battling		401/402, 403, 801/802
DTX-0814	BSC-MT-003740	BSC-MT-003740	Excel Spreadsheet, Microsoft_Excel_Worksheet		401/402, 403, 801/802
DTX-0815	BSC-MT-003741	BSC-MT-003741	Excel Spreadsheet, Copy of Competitive Key Technology Hit List - 2019 Blended Version #2		401/402, 403, 801/802
DTX-0816	BSC-MT-003742	BSC-MT-003742	Excel Spreadsheet, Copy of Divisional Hit List - Updated 03.12.19		401/402, 403, 801/802
DTX-0817	BSC-MT-003765	BSC-MT-003765	Excel Spreadsheet, Microsoft_Excel_Worksheet		401/402, 403, 801/802
DTX-0818	BSC-MT-003781	BSC-MT-003781	Video		401/402, 403, 801/802
DTX-0819	BSC-MT-003790	BSC-MT-003790	Article: "Lower Paper Costs are not always what's best for your specialty or your lab"		401/402, 403, 801/802
DTX-0820	BSC-MT-003791	BSC-MT-003791	Article: "Lower Paper Costs are not always what's best for your specialty or your lab"		401/402, 403, 801/802
DTX-0821	BSC-MT-003798	BSC-MT-003798	Micro-Tech SureClip.tif		401/402, 403, 801/802
DTX-0822	BSC-MT-004550	BSC-MT-004571	Boston Scientific - Resolution Clip Market Specification		401/402, 403, 801/802
DTX-0823	BSC-MT-004574	BSC-MT-004601	Presentation - Boston Scientific - Clip Images		401/402, 403, 801/802
DTX-0824	BSC-MT-004602	BSC-MT-004623	Boston Scientific - Competitive Analysis of Micro-Tech Clip		401/402, 403, 701/702, 801/802
DTX-0825	BSC-MT-004625	BSC-MT-004625	Photo of Device		401/402, 403, 801/802, ID
DTX-0826	BSC-MT-004626	BSC-MT-004626	Photo of Device		401/402, 403, 801/802, ID
DTX-0827	BSC-MT-004627	BSC-MT-004627	Photo of Device		401/402, 403, 801/802, ID
DTX-0828	BSC-MT-004628	BSC-MT-004628	Photo of Device		401/402, 403, 801/802, ID
DTX-0829	BSC-MT-004629	BSC-MT-004629	Photo of Device		401/402, 403, 801/802, ID

Schedule 8 - Defendants' Trial Exhibit List

DTX-0830	BSC-MT-004630	BSC-MT-004630	Photo of Device		401/402, 403, 801/802, ID
DTX-0831	BSC-MT-004631	BSC-MT-004631	Photo of Device		401/402, 403, 801/802, ID
DTX-0832	BSC-MT-004632	BSC-MT-004632	Photo of Device		401/402, 403, 801/802, ID
DTX-0833	BSC-MT-004633	BSC-MT-004633	Photo of Device		401/402, 403, 801/802, ID
DTX-0834	BSC-MT-004634	BSC-MT-004634	Photo of Device		401/402, 403, 801/802, ID
DTX-0835	BSC-MT-004635	BSC-MT-004635	Photo of Device		401/402, 403, 801/802, ID
DTX-0836	BSC-MT-004636	BSC-MT-004636	Photo of Device		401/402, 403, 801/802, ID
DTX-0837	BSC-MT-004637	BSC-MT-004657	Presentation: Boston Scientific - Micro-Tech Hemoclips		401/402, 403, 701/702, 801/802
DTX-0838	BSC-MT-004658	BSC-MT-004658	Video		401/402, 403, 801/802, ID
DTX-0839	BSC-MT-004662	BSC-MT-004662	Excel Spreadsheet, Microsoft Excel Worksheet3		401/402, 403, 801/802, ID
DTX-0840	BSC-MT-004663	BSC-MT-004663	Excel Spreadsheet, Microsoft Excel Worksheet4		401/402, 403, 801/802, ID
DTX-0841	BSC-MT-004664	BSC-MT-004664	Excel Spreadsheet, Microsoft Excel Worksheet1		401/402, 403, 801/802, ID
DTX-0842	BSC-MT-004665	BSC-MT-004665	Excel Spreadsheet, Microsoft Excel Worksheet2		401/402, 403, 801/802, ID
DTX-0843	BSC-MT-004666	BSC-MT-004670	Boston Scientific - Cross Section and Optical for Micro-Tech Clip		401/402, 403, 701/702, 801/802
DTX-0844	BSC-MT-004671	BSC-MT-004676	Boston Scientific - X-Ray Micro-TechClip		401/402, 403, 801/802
DTX-0845	BSC-MT-004688	BSC-MT-004689	Boston Scientific - Clip Deployment Testing on Silicone		401/402, 403, 701/702, 801/802
DTX-0846	BSC-MT-004708	BSC-MT-004708	Excel Spreadsheet, Microsoft Excel Worksheet1		401/402, 403, 801/802
DTX-0847	BSC-MT-004709	BSC-MT-004729	Presentation: Boston Scientific - Micro-Tech Hemoclips		401/402, 403, 701/702, 801/802
DTX-0848	BSC-MT-004732	BSC-MT-004732	Video		401/402, 403, 801/802, ID
DTX-0849	BSC-MT-004733	BSC-MT-004733	Video		401/402, 403, 801/802, ID
DTX-0850	BSC-MT-004734	BSC-MT-004734	Excel Spreadsheet, Microsoft Excel Worksheet3		401/402, 403, 801/802, ID
DTX-0851	BSC-MT-004735	BSC-MT-004735	Excel Spreadsheet, Microsoft Excel Worksheet4		401/402, 403, 801/802, ID
DTX-0852	BSC-MT-004737	BSC-MT-004737	Excel Spreadsheet, Microsoft Excel Worksheet2		401/402, 403, 801/802, ID
DTX-0853	BSC-MT-004741	BSC-MT-004744	Presentation: Boston Scientific - Micro-Tech Capsule Bushing Attachment		401/402, 403, 701/702, 801/802
DTX-0854	BSC-MT-004745	BSC-MT-004750	Presentation: Boston Scientific - Micro-Tech Clip Internal Design		401/402, 403, 701/702, 801/802
DTX-0855	BSC-MT-004751	BSC-MT-004751	Video		401/402, 403, 801/802, ID
DTX-0856	BSC-MT-004752	BSC-MT-004752	Video		401/402, 403, 801/802, ID
DTX-0857	BSC-MT-004753	BSC-MT-004764	Presentation: Boston Scientific - Micro-Tech Clip Update		401/402, 403, 801/802, ID
DTX-0858	BSC-MT-004765	BSC-MT-004768	Article: Gwynne, "Photo Analysis of Micro-Tech Bare Coil Clip"		401/402, 403, 801/802, ID
DTX-0859	BSC-MT-004769	BSC-MT-004769	Photo of Device		401/402, 403, 801/802, ID
DTX-0860	BSC-MT-004770	BSC-MT-004770	Photo of Device		401/402, 403, 801/802, ID
DTX-0861	BSC-MT-004771	BSC-MT-004771	Photo of Device		401/402, 403, 801/802, ID
DTX-0862	BSC-MT-004772	BSC-MT-004772	Photo of Device		401/402, 403, 801/802, ID
DTX-0863	BSC-MT-004773	BSC-MT-004773	Photo of Device		401/402, 403, 801/802, ID
DTX-0864	BSC-MT-004774	BSC-MT-004774	Photo of Device		401/402, 403, 801/802, ID
DTX-0865	BSC-MT-004775	BSC-MT-004775	Photo of Device		401/402, 403, 801/802, ID
DTX-0866	BSC-MT-004776	BSC-MT-004776	Photo of Device		401/402, 403, 801/802, ID
DTX-0867	BSC-MT-004777	BSC-MT-004777	Photo of Device		401/402, 403, 801/802, ID
DTX-0868	BSC-MT-004778	BSC-MT-004778	Photo of Device		401/402, 403, 801/802, ID
DTX-0869	BSC-MT-004779	BSC-MT-004779	Photo of Device		401/402, 403, 801/802, ID
DTX-0870	BSC-MT-004780	BSC-MT-004780	Photo of Device		401/402, 403, 801/802, ID
DTX-0871	BSC-MT-004781	BSC-MT-004781	Photo of Device		401/402, 403, 801/802, ID
DTX-0872	BSC-MT-004903	BSC-MT-004903	Photo of Device		401/402, 403, 801/802, ID
DTX-0873	BSC-MT-004941	BSC-MT-004941	Photo of Device		401/402, 403, 801/802, ID
DTX-0874	BSC-MT-004942	BSC-MT-004942	Photo of Device		401/402, 403, 801/802, ID
DTX-0875	BSC-MT-004943	BSC-MT-004943	Photo of Device		401/402, 403, 801/802, ID
DTX-0876	BSC-MT-004963	BSC-MT-004963	Photo of Device		401/402, 403, 801/802, ID
DTX-0877	BSC-MT-004964	BSC-MT-004964	Photo of Device		401/402, 403, 801/802, ID

Schedule 8 - Defendants' Trial Exhibit List

DTX-0878	BSC-MT-004965	BSC-MT-004965	Photo of Device		401/402, 403, 801/802, ID
DTX-0879	BSC-MT-004989	BSC-MT-005664	iData Research - U.S. Market Report Suite for Gastrointestinal Endoscopic Devices		401/402, 403, 801/802
DTX-0880	BSC-MT-005665	BSC-MT-005666	Boston Scientific - Value Analysis Brief - Resolution™ Clip and Resolution 360™ Clip		401/402, 403, 801/802
DTX-0881	BSC-MT-005684	BSC-MT-005691	Boston Scientific - Resolution™ 360 Clip - Clip Competitive Analysis		401/402, 403, 801/802
DTX-0882	BSC-MT-005694	BSC-MT-005718	Presentation: Boston Scientific - Clip Images		401/402, 403, 801/802
DTX-0883	BSC-MT-005719	BSC-MT-005720	Boston Scientific Memorandum Re Terminology for Competitive Clip Comparisons		401/402, 403, 801/802
DTX-0884	BSC-MT-006017	BSC-MT-006032	Resolution 360™ Clip - Innovation in Design and Manufacturing		401/402, 403, 801/802
DTX-0885	BSC-MT-006033	BSC-MT-006043	Article: Wang et al., "Choosing the right through the scope clip: a rigorous comparison of rotatability, whip, open/close precision and closure strength"		401/402, 403, 801/802
DTX-0886	BSC-MT-006044	BSC-MT-006044	Excel Spreadsheet, Scrap Res Clips 2012-2017		401/402, 403, 801/802
DTX-0887	BSC-MT-006107	BSC-MT-006107	Boston Scientific - E0630 Clip End Effectors TDP		401/402, 403, 801/802
DTX-0888	BSC-MT-006108	BSC-MT-006108	Boston Scientific - E0630 Clip End Effectors TDP		401/402, 403, 801/802
DTX-0889	BSC-MT-006109	BSC-MT-006109	Boston Scientific - E0630 NG 360 Clip TDP		401/402, 403, 801/802
DTX-0890	BSC-MT-006110	BSC-MT-006110	Boston Scientific - E0630 NG 360 Clip TDP		401/402, 403, 801/802
DTX-0891	BSC-MT-006111	BSC-MT-006111	Boston Scientific - E0630 NG 360 Clip TDP		401/402, 403, 801/802
DTX-0892	BSC-MT-006112	BSC-MT-006112	Boston Scientific - E0630 NG 360 Clip TDP		401/402, 403, 801/802
DTX-0893	BSC-MT-006113	BSC-MT-006113	Boston Scientific - E0630 NG 360 Clip TDP		401/402, 403, 801/802
DTX-0894	BSC-MT-006194	BSC-MT-006203	Boston Scientific - Competitive Analysis of Diversatek RePlay Hemostasis Clip		401/402, 403, 801/802
DTX-0895	BSC-MT-006204	BSC-MT-006204	Excel Spreadsheet, Actuals 2019 Clips Std cost 2019-05-30		401/402, 403, 801/802
DTX-0896	BSC-MT-006239	BSC-MT-006260	Boston Scientific - Competitive Analysis of Micro-Tech Clip		401/402, 403, 701/702, 801/802
DTX-0897	BSC-MT-006261	BSC-MT-006261	Excel Spreadsheet, Copy of Sim-Use Comparison 10.30.2017		401/402, 403, 801/802
DTX-0898	BSC-MT-006262	BSC-MT-006274	European Patent Specification EP 3081174 B1		401/402, 403, 801/802
DTX-0899	BSC-MT-006275	BSC-MT-006278	Micro-Tech Capsule Bushing Attachment		401/402, 403, 801/802
DTX-0900	BSC-MT-006294	BSC-MT-006294	Passability Test Plan Report		401/402, 403, 801/802
DTX-0901	BSC-MT-006302	BSC-MT-006302	Excel Spreadsheet, Clip Lengths Chart		401/402, 403, 801/802
DTX-0902	BSC-MT-006303	BSC-MT-006303	Excel Spreadsheet, Microtech Clip Dimensions		401/402, 403, 801/802
DTX-0903	BSC-MT-006304	BSC-MT-006304	Excel Spreadsheet, Microtech Clips		401/402, 403, 801/802
DTX-0904	BSC-MT-006337	BSC-MT-006342	NG Res 360 Ex-Vivo		401/402, 403, 801/802
DTX-0905	BSC-MT-006343	BSC-MT-006343	Ex-Vivo Requirements		401/402, 403, 801/802
DTX-0906	BSC-MT-006344	BSC-MT-006345	Clip Placement/Model Prep; Lab Flow/Goals		401/402, 403, 801/802
DTX-0907	BSC-MT-006348	BSC-MT-006350	Boston Scientific - Clip Size Matrix		401/402, 403, 801/802
DTX-0908	BSC-MT-006442	BSC-MT-006489	Boston Scientific - Clip End Effectors (Formerly NG Clip) Q3 2019 TDP Update		401/402, 403, 801/802
DTX-0909	BSC-MT-006490	BSC-MT-006490	Excel Spreadsheet, Microsoft Excel Worksheet1		401/402, 403, 801/802
DTX-0910	BSC-MT-006491	BSC-MT-006491	Excel Spreadsheet, Microsoft Excel Worksheet		401/402, 403, 801/802
DTX-0911	BSC-MT-006492	BSC-MT-006492	Excel Spreadsheet, Microsoft Excel Worksheet2		401/402, 403, 801/802
DTX-0912	BSC-MT-006493	BSC-MT-006493	Excel Spreadsheet, Microsoft Excel Worksheet7		401/402, 403, 801/802
DTX-0913	BSC-MT-006494	BSC-MT-006494	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-0914	BSC-MT-006495	BSC-MT-006495	Excel Spreadsheet, Microsoft Excel Worksheet4		401/402, 403, 801/802
DTX-0915	BSC-MT-006496	BSC-MT-006496	Excel Spreadsheet, Microsoft Excel Worksheet3		401/402, 403, 801/802
DTX-0916	BSC-MT-006497	BSC-MT-006497	Excel Spreadsheet, Microsoft Excel Worksheet6		401/402, 403, 801/802
DTX-0917	BSC-MT-006498	BSC-MT-006543	Boston Scientific - Clip End Effectors (Formerly NG Clip) Q3 2019 TDP Update		401/402, 403, 801/802
DTX-0918	BSC-MT-006544	BSC-MT-006544	Excel Spreadsheet, Microsoft Excel Worksheet1		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0919	BSC-MT-006545	BSC-MT-006545	Excel Spreadsheet, Microsoft Excel Worksheet		401/402, 403, 801/802
DTX-0920	BSC-MT-006546	BSC-MT-006546	Excel Spreadsheet, Microsoft Excel Worksheet6		401/402, 403, 801/802
DTX-0921	BSC-MT-006547	BSC-MT-006547	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-0922	BSC-MT-006548	BSC-MT-006548	Excel Spreadsheet, Microsoft Excel Worksheet4		401/402, 403, 801/802
DTX-0923	BSC-MT-006549	BSC-MT-006549	Excel Spreadsheet, Microsoft Excel Worksheet2		401/402, 403, 801/802
DTX-0924	BSC-MT-006550	BSC-MT-006550	Excel Spreadsheet, Microsoft Excel Worksheet3		401/402, 403, 801/802
DTX-0925	BSC-MT-006615	BSC-MT-006618	Project: Clip End Effectors E0630		401/402, 403, 801/802
DTX-0926	BSC-MT-006619	BSC-MT-006622	Project: Clip End Effectors E0630		401/402, 403, 801/802
DTX-0927	BSC-MT-006623	BSC-MT-006626	Project: Clip End Effectors E0630		401/402, 403, 801/802
DTX-0928	BSC-MT-006627	BSC-MT-006629	Project: NG 360 Clip E0630		401/402, 403, 801/802
DTX-0929	BSC-MT-006630	BSC-MT-006632	Project: Short Stem Clip E0630		401/402, 403, 801/802
DTX-0930	BSC-MT-006633	BSC-MT-006635	Project: Short Stem Clip E0630		401/402, 403, 801/802
DTX-0931	BSC-MT-006730	BSC-MT-006730	Excel Spreadsheet, NYSGE Dr Aihara Data		401/402, 403, 801/802
DTX-0932	BSC-MT-006731	BSC-MT-006731	Data Sheet for Pre Clinical Study		401/402, 403, 801/802
DTX-0933	BSC-MT-006732	BSC-MT-006732	Data Sheet for Pre Clinical Study		401/402, 403, 801/802
DTX-0934	BSC-MT-006733	BSC-MT-006733	Data Sheet for Pre Clinical Study		401/402, 403, 801/802
DTX-0935	BSC-MT-007473	BSC-MT-007486	Boston Scientific - Rotatable Resolution/Resolution 360™ Clip D&D Plan		401/402, 403, 801/802
DTX-0936	BSC-MT-007501	BSC-MT-007504	Boston Scientific Endoscopy Memorandum Re May 3rd Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0937	BSC-MT-007509	BSC-MT-007512	Boston Scientific Endoscopy Memorandum Re September 13th Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0938	BSC-MT-007513	BSC-MT-007515	Boston Scientific Endoscopy Memorandum Re August 18th Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0939	BSC-MT-007523	BSC-MT-007525	Boston Scientific Endoscopy Memorandum Re September 20th Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0940	BSC-MT-007526	BSC-MT-007528	Boston Scientific Endoscopy Memorandum Re August 23rd Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0941	BSC-MT-007532	BSC-MT-007535	Boston Scientific Endoscopy Memorandum Re August 31st Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0942	BSC-MT-007536	BSC-MT-007539	Boston Scientific Endoscopy Memorandum Re August 31st Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0943	BSC-MT-007540	BSC-MT-007542	Boston Scientific Endoscopy Memorandum Re September 30th Resolution 360 Clip Team Update and Action Items		401/402, 403, 801/802
DTX-0944	BSC-MT-007543	BSC-MT-007546	Boston Scientific Endoscopy Memorandum Re August 23rd Resolution 360 Clip Team Meeting Minutes and Action Items		401/402, 403, 801/802
DTX-0945	BSC-MT-007840	BSC-MT-007843	Boston Scientific Memorandum Re Preclinical Tag-On Opportunity Prior to Design Freeze		401/402, 403, 801/802
DTX-0946	BSC-MT-007862	BSC-MT-007869	Boston Scientific - Final Protocol - Digestive Disease Week (DDW) and Society of Gastroenterology Nurses and Associates (SGNA) Demonstrations		401/402, 403, 801/802
DTX-0947	BSC-MT-008026	BSC-MT-008042	Presentation: Boston Scientific - Resolution™ 360		401/402, 403, 801/802
DTX-0948	BSC-MT-008043	BSC-MT-008058	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0949	BSC-MT-008059	BSC-MT-008074	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0950	BSC-MT-008075	BSC-MT-008091	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0951	BSC-MT-008092	BSC-MT-008108	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0952	BSC-MT-008109	BSC-MT-008125	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0953	BSC-MT-008126	BSC-MT-008142	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802
DTX-0954	BSC-MT-008143	BSC-MT-008159	Presentation: Boston Scientific - ResolutionTM 360		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0955	BSC-MT-010194	BSC-MT-010198	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Controllability Rationale		401/402, 403, 801/802
DTX-0956	BSC-MT-010199	BSC-MT-010203	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Controllability Rationale		401/402, 403, 801/802
DTX-0957	BSC-MT-010204	BSC-MT-010208	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Controllability Rationale		401/402, 403, 801/802
DTX-0958	BSC-MT-010209	BSC-MT-010223	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0959	BSC-MT-010224	BSC-MT-010234	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0960	BSC-MT-010235	BSC-MT-010248	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0961	BSC-MT-010598	BSC-MT-010602	Boston Scientific- Next Generation Resolution Clip Rotation Controlability Rationale		401/402, 403, 801/802
DTX-0962	BSC-MT-010603	BSC-MT-010607	Boston Scientific- Next Generation Resolution Clip Rotation Controlability Rationale		401/402, 403, 801/802
DTX-0963	BSC-MT-010608	BSC-MT-010612	Boston Scientific- Next Generation Resolution Clip Rotation Controlability Rationale		401/402, 403, 801/802
DTX-0964	BSC-MT-010750	BSC-MT-010750	Excel Spreadsheet, Braid Options		401/402, 403, 801/802
DTX-0965	BSC-MT-010920	BSC-MT-010933	Boston Scientific - Market Specification - Hemostatic Clipping Device (HCD)		401/402, 403, 801/802
DTX-0966	BSC-MT-011903	BSC-MT-011950	Presentation: Boston Scientific - E0432 Next Generation Clip Rotation		401/402, 403, 801/802
DTX-0967	BSC-MT-012333	BSC-MT-012337	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Controllability Rationale		401/402, 403, 801/802
DTX-0968	BSC-MT-012338	BSC-MT-012342	Boston Scientific- Next Generation Resolution Clip Rotation Controlability Rationale		401/402, 403, 801/802
DTX-0969	BSC-MT-012343	BSC-MT-012347	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Controllability Rationale		401/402, 403, 801/802
DTX-0970	BSC-MT-012348	BSC-MT-012357	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0971	BSC-MT-012358	BSC-MT-012367	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0972	BSC-MT-012368	BSC-MT-012377	Boston Scientific- Next Generation (Rotatable) Resolution Clip Rotation Fixture Setup Rationale		401/402, 403, 801/802
DTX-0973	BSC-MT-013909	BSC-MT-013927	Presentation: Boston Scientific - Vendors		401/402, 403, 801/802
DTX-0974	BSC-MT-014783	BSC-MT-015021	File History for U.S. Patent No. 8,709,027		401/402, 403
DTX-0975	BSC-MT-015865	BSC-MT-016223	File History for U.S. Patent No. 9,271,731		401/402, 403
DTX-0976	BSC-MT-016750	BSC-MT-017098	File History for U.S. Patent No. 7,879,052		401/402, 403
DTX-0977	BSC-MT-017136	BSC-MT-017272	File Wrapper for U.S. Patent Application 13/009,094		401/402, 403
DTX-0978	BSC-MT-017284	BSC-MT-017449	Presentation: Boston Scientific - Hemostasis Update AGW 2012		401/402, 403, 701/702, 801/802
DTX-0979	BSC-MT-017450	BSC-MT-017532	Presentation: Make an Impact - Endoscopy National Sales Meeting 2012		401/402, 403, 701/702, 801/802
DTX-0980	BSC-MT-019367	BSC-MT-019425	Presentation: Boston Scientific - Clipping Strategy Session		401/402, 403, 701/702, 801/802
DTX-0981	BSC-MT-019427	BSC-MT-019484	Presentation: Boston Scientific - Clipping Strategy Session		401/402, 403, 701/702, 801/802
DTX-0982	BSC-MT-019495	BSC-MT-019546	Presentation: Boston Scientific - Clipping Strategy Session		401/402, 403, 701/702, 801/802
DTX-0983	BSC-MT-019614	BSC-MT-019692	Presentation: Make an Impact - Endoscopy National Sales Meeting 2012		401/402, 403, 701/702, 801/802
DTX-0984	BSC-MT-019794	BSC-MT-019797	Cook Competitive Response Best Practice - Demonstrating Resolution™ Clip		401/402, 403, 701/702, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-0985	BSC-MT-019798	BSC-MT-019800	Cook Competitive Response Best Practice - Demonstrating Resolution™ Clip		401/402, 403, 701/702, 801/802
DTX-0986	BSC-MT-019801	BSC-MT-019803	Cook Competitive Response Best Practice - Demonstrating Resolution™ Clip		401/402, 403, 701/702, 801/802
DTX-0987	BSC-MT-019804	BSC-MT-019806	Boston Scientific - Competitive Clip Success Story		401/402, 403, 801/802
DTX-0988	BSC-MT-019807	BSC-MT-019807	Excel Spreadsheet, Rocky Mtn Clip at risk		401/402, 403, 801/802
DTX-0989	BSC-MT-020650	BSC-MT-020653	Email Re New Cook Clip Update		401/402, 403, 801/802
DTX-0990	BSC-MT-020889	BSC-MT-020891	Email Re Cook Clip		401/402, 403, 801/802
DTX-0991	BSC-MT-022323	BSC-MT-022323	Boston Scientific Letter Re Resolution Clip Clearance for MR Conditional Claim		401/402, 403, 801/802
DTX-0992	BSC-MT-022355	BSC-MT-022358	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-0993	BSC-MT-022409	BSC-MT-022448	Boston Scientific - Idea Disclosure		401/402, 403, 801/802
DTX-0994	BSC-MT-022449	BSC-MT-022450	Draft Boston Scientific Letter		401/402, 403, 801/802
DTX-0995	BSC-MT-022495	BSC-MT-022496	BSC Invention Disclosure 03-D1076		401/402, 403, 801/802
DTX-0996	BSC-MT-022518	BSC-MT-022522	Letter Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-0997	BSC-MT-022523	BSC-MT-022525	Confidentiality Agreement between Target Therapeutics and BSC		401/402, 403, 801/802
DTX-0998	BSC-MT-022526	BSC-MT-022528	Confidentiality Agreement between Boston Scientific Scimed and MedVenture		401/402, 403, 801/802
DTX-0999	BSC-MT-022529	BSC-MT-022531	Confidentiality Disclosure Agreement between Target Therapeutics and MedVenture		401/402, 403, 801/802
DTX-1000	BSC-MT-022532	BSC-MT-022535	Draft Boston Scientific Letter		401/402, 403, 801/802
DTX-1001	BSC-MT-022536	BSC-MT-022538	Amendment No. 1 to Development and Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1002	BSC-MT-022539	BSC-MT-022593	Development and Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1003	BSC-MT-022594	BSC-MT-022596	Boston Scientific Memorandum Re MedVenture HCD Contract		401/402, 403, 801/802
DTX-1004	BSC-MT-022597	BSC-MT-022597	Amendment No. 1 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1005	BSC-MT-022598	BSC-MT-022602	Letter Re Amendment to Development and Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1006	BSC-MT-022603	BSC-MT-022650	Development and Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1007	BSC-MT-022651	BSC-MT-022659	Amendment No. 2 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1008	BSC-MT-022660	BSC-MT-022660	Amendment No. 3 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1009	BSC-MT-022661	BSC-MT-022662	Amendment to Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1010	BSC-MT-022663	BSC-MT-022666	Amendment No. 4 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1011	BSC-MT-022667	BSC-MT-022694	Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1012	BSC-MT-022695	BSC-MT-022695	Amendment No. 3 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1013	BSC-MT-022696	BSC-MT-022697	Amendment No.7 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1014	BSC-MT-022698	BSC-MT-022702	Amendment No.8 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1015	BSC-MT-022703	BSC-MT-022710	Amendment No.6 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1016	BSC-MT-022711	BSC-MT-022714	Amendment No.11 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1017	BSC-MT-022715	BSC-MT-022716	Amendment No.12 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1018	BSC-MT-022717	BSC-MT-022722	Amendment No.5 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1019	BSC-MT-022723	BSC-MT-022724	Amendment No.14 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1020	BSC-MT-022725	BSC-MT-022736	Master Design/Development Service Agreement between BSC and MedVenture		401/402, 403, 801/802
DTX-1021	BSC-MT-022737	BSC-MT-022741	Amendment No.13 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1022	BSC-MT-022742	BSC-MT-022750	Amendment No.10 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1023	BSC-MT-022751	BSC-MT-022760	Amendment No.18 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1024	BSC-MT-022761	BSC-MT-022762	Amendment No.16 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1025	BSC-MT-022763	BSC-MT-022777	Master Services Agreement between BSC and MedVenture		401/402, 403, 801/802
DTX-1026	BSC-MT-022778	BSC-MT-022778	Letter of Understanding between BSC and MedVenture		401/402, 403, 801/802
DTX-1027	BSC-MT-022779	BSC-MT-022783	Amendment No.15 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1028	BSC-MT-022784	BSC-MT-022787	Attachment A1 - Endoscopic Rotatable Clip		401/402, 403, 801/802
DTX-1029	BSC-MT-022788	BSC-MT-022793	Amendment No.19 to Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1030	BSC-MT-022794	BSC-MT-022799	Attachment A3 - Endoscopic Rotatable Clip		401/402, 403, 801/802
DTX-1031	BSC-MT-022800	BSC-MT-022804	Attachment A3B - Endoscopic Rotatable Clip		401/402, 403, 801/802
DTX-1032	BSC-MT-022805	BSC-MT-022847	Letter Re Design Services Agreement between BSC and MedVenture		401/402, 403, 801/802
DTX-1033	BSC-MT-022848	BSC-MT-022851	Attachment A2 - Endoscopic Rotatable Clip		401/402, 403, 801/802
DTX-1034	BSC-MT-022852	BSC-MT-022854	Email Re MedVenture Contract		401/402, 403, 801/802
DTX-1035	BSC-MT-022855	BSC-MT-022878	Draft Development and Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1036	BSC-MT-022985	BSC-MT-023053	Presentation: Boston Scientific - MSC/MTC Meeting - Marketing Update		401/402, 403, 801/802
DTX-1037	BSC-MT-023246	BSC-MT-023260	Presentation: Boston Scientific - Resolution™ Clip		401/402, 403, 801/802
DTX-1038	BSC-MT-024723	BSC-MT-024742	Presentation: Boston Scientific - Resolution™ Clip Marketing Plan		401/402, 403, 801/802
DTX-1039	BSC-MT-024743	BSC-MT-024743	Diagram: Hemostasis Non Varicel Treatment Evolution		401/402, 403, 801/802
DTX-1040	BSC-MT-024744	BSC-MT-024744	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.10		401/402, 403, 801/802
DTX-1041	BSC-MT-024746	BSC-MT-024746	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.2		401/402, 403, 801/802
DTX-1042	BSC-MT-024747	BSC-MT-024747	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.3		401/402, 403, 801/802
DTX-1043	BSC-MT-024748	BSC-MT-024748	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.4		401/402, 403, 801/802
DTX-1044	BSC-MT-024749	BSC-MT-024749	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.5		401/402, 403, 801/802
DTX-1045	BSC-MT-024750	BSC-MT-024750	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.6		401/402, 403, 801/802
DTX-1046	BSC-MT-024751	BSC-MT-024751	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.7		401/402, 403, 801/802
DTX-1047	BSC-MT-024752	BSC-MT-024752	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.8		401/402, 403, 801/802
DTX-1048	BSC-MT-024753	BSC-MT-024753	Excel Spreadsheet, embedded.Clip Marketing Plan 2004.9		401/402, 403, 801/802
DTX-1049	BSC-MT-024754	BSC-MT-024775	Presentation: Boston Scientific - Resolution™ Clip Marketing Plan		401/402, 403, 801/802
DTX-1050	BSC-MT-024776	BSC-MT-024776	Diagram: Hemostasis Non Variceal Treatment Evolution		401/402, 403, 801/802
DTX-1051	BSC-MT-024777	BSC-MT-024777	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1052	BSC-MT-024778	BSC-MT-024778	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1053	BSC-MT-024779	BSC-MT-024779	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1054	BSC-MT-024780	BSC-MT-024780	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1055	BSC-MT-024781	BSC-MT-024781	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1056	BSC-MT-024782	BSC-MT-024782	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1057	BSC-MT-024783	BSC-MT-024783	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1058	BSC-MT-024784	BSC-MT-024784	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1059	BSC-MT-024785	BSC-MT-024785	Excel Spreadsheet, embedded.Clip Marketing Plan 2004		401/402, 403, 801/802
DTX-1060	BSC-MT-024786	BSC-MT-024787	"T'was the Night Before Clip Mas"		401/402, 403, 801/802
DTX-1061	BSC-MT-024788	BSC-MT-024788	Resolution™ Clip Advertisement		401/402, 403, 801/802
DTX-1062	BSC-MT-024789	BSC-MT-024789	Placeholder Text		401/402, 403, 801/802
DTX-1063	BSC-MT-024790	BSC-MT-024790	Video		401/402, 403, 801/802, ID
DTX-1064	BSC-MT-024791	BSC-MT-024791	Video		401/402, 403, 801/802, ID
DTX-1065	BSC-MT-024792	BSC-MT-024792	Resolution™ Clip Product Information		401/402, 403, 801/802
DTX-1066	BSC-MT-024793	BSC-MT-024793	Draft Press Release		401/402, 403, 801/802
DTX-1067	BSC-MT-024796	BSC-MT-024796	Photo of Clipping Device		401/402, 403, 801/802
DTX-1068	BSC-MT-024797	BSC-MT-024803	Corp. SOP - Quality Records		401/402, 403, 801/802
DTX-1069	BSC-MT-024804	BSC-MT-024814	Global SOP Records and Information Management		401/402, 403, 801/802
DTX-1070	BSC-MT-032827	BSC-MT-032874	Resolution™ Clip Device Product Information		401/402, 403, 801/802
DTX-1071	BSC-MT-033575	BSC-MT-033575	Excel Spreadsheet, Res I Insource Model 1-18-12		401/402, 403, 801/802
DTX-1072	BSC-MT-033580	BSC-MT-033582	Boston Scientific - Resolution I Summary		401/402, 403, 801/802
DTX-1073	BSC-MT-033605	BSC-MT-033954	Boston Scientific - IMS 2015 Q2		401/402, 403, 801/802
DTX-1074	BSC-MT-034813	BSC-MT-034832	Lab Notebook No. N0261 for M. Adams		401/402, 403, 701/702, 801/802
DTX-1075	BSC-MT-037020	BSC-MT-037020	Excel Spreadsheet, Clips Fcst WW Aug 2002		401/402, 403, 801/802
DTX-1076	BSC-MT-037126	BSC-MT-037126	Excel Spreadsheet, Multiclip Model		401/402, 403, 801/802
DTX-1077	BSC-MT-037256	BSC-MT-037286	Presentation: Boston Scientific - Hemostasis Clip Device - Pricing Update		401/402, 403, 801/802
DTX-1078	BSC-MT-037435	BSC-MT-037472	Charts Re Market Size		401/402, 403, 801/802
DTX-1079	BSC-MT-037941	BSC-MT-037945	Boston Scientific -Resolution II Core Meeting Minutes		401/402, 403, 801/802
DTX-1080	BSC-MT-037986	BSC-MT-037990	Resolution Clip MDM FSO Reasearch		401/402, 403, 801/802
DTX-1081	BSC-MT-038006	BSC-MT-038007	Cook - TriClip Endoscopic Clipping Device		401/402, 403, 801/802
DTX-1082	BSC-MT-038008	BSC-MT-038011	Article: Watanabe, "A New Type of Hemoclip Device"		401/402, 403, 801/802
DTX-1083	BSC-MT-038012	BSC-MT-038015	Olympus Product Information		401/402, 403, 801/802
DTX-1084	BSC-MT-038016	BSC-MT-038013	Commed Catalog		401/402, 403, 801/802
DTX-1085	BSC-MT-038221	BSC-MT-038244	Boston Scientific Integrated Business Plan - Resolution II		401/402, 403, 801/802
DTX-1086	BSC-MT-039366	BSC-MT-039366	Chart: Resolution™ Features/Intended Benefits		401/402, 403, 801/802
DTX-1087	BSC-MT-039564	BSC-MT-039584	Boston Scientific - Clips Survey - Europe (Draft)		401/402, 403, 801/802
DTX-1088	BSC-MT-040904	BSC-MT-040904	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II 2-28-05		401/402, 403, 801/802
DTX-1089	BSC-MT-040905	BSC-MT-040905	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II 4-5-05		401/402, 403, 801/802
DTX-1090	BSC-MT-040906	BSC-MT-040906	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II No Rotation with Duo 4-7-05DC		401/402, 403, 801/802
DTX-1091	BSC-MT-040907	BSC-MT-040907	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation 2-28-05		401/402, 403, 801/802
DTX-1092	BSC-MT-040908	BSC-MT-040908	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation 3-10-05		401/402, 403, 801/802
DTX-1093	BSC-MT-040909	BSC-MT-040909	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation 4-5-05		401/402, 403, 801/802
DTX-1094	BSC-MT-040910	BSC-MT-040910	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation 4-5-05DC		401/402, 403, 801/802
DTX-1095	BSC-MT-040911	BSC-MT-040911	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation 4-7-05		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1096	BSC-MT-040912	BSC-MT-040912	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II with Rotation		401/402, 403, 801/802
DTX-1097	BSC-MT-040913	BSC-MT-040913	Excel Spreadsheet, Final ROI SUMMARY Model Resolution II		401/402, 403, 801/802
DTX-1098	BSC-MT-040915	BSC-MT-040915	Excel Spreadsheet, Resolution II Project Financial Model 5-18-05		401/402, 403, 801/802
DTX-1099	BSC-MT-040916	BSC-MT-040916	Excel Spreadsheet, Resolution II Project Financial Model 5-24-05		401/402, 403, 801/802
DTX-1100	BSC-MT-040917	BSC-MT-040917	Excel Spreadsheet, Resolution II Project Financial Model 5-25-05		401/402, 403, 801/802
DTX-1101	BSC-MT-040918	BSC-MT-040918	Excel Spreadsheet, Resolution II Project Financial Model 6-1-05DC		401/402, 403, 801/802
DTX-1102	BSC-MT-041095	BSC-MT-041114	Olympus Optical Co., Ltd. Competitive Profile		401/402, 403, 801/802
DTX-1103	BSC-MT-041467	BSC-MT-041472	Resolution Clip MDM FSO Research		401/402, 403, 801/802
DTX-1104	BSC-MT-041473	BSC-MT-041483	Boston Scientific - Resolution Clip FSO Survey		401/402, 403, 801/802
DTX-1105	BSC-MT-044334	BSC-MT-044339	Boston Scientific Competitor Strategies		401/402, 403, 801/802
DTX-1106	BSC-MT-051833	BSC-MT-051848	MVE Hemostasis 2002 Marketing Plan		401/402, 403, 801/802
DTX-1107	BSC-MT-051854	BSC-MT-051871	2001 Goals and Objectives US Hemostasis Franchise		401/402, 403, 801/802
DTX-1108	BSC-MT-053043	BSC-MT-053044	Email Re Clip Market in Japan		401/402, 403, 801/802
DTX-1109	BSC-MT-053139	BSC-MT-053185	Boston Scientific - Clipping VOC - Quantitative Findings		401/402, 403, 801/802
DTX-1110	BSC-MT-064070	BSC-MT-064124	Boston Scientific - Resolution 360™ Commercialization Plan		401/402, 403, 801/802
DTX-1111	BSC-MT-064142	BSC-MT-064181	Boston Scientific - Resolution 360™ Clip		401/402, 403, 801/802
DTX-1112	BSC-MT-064654	BSC-MT-064697	Presentation: Boston Scientific - E0455 - Rotatable Resolution - Development Update		401/402, 403, 801/802
DTX-1113	BSC-MT-064806	BSC-MT-064807	Boston Scientific - Team Hemo		401/402, 403, 801/802
DTX-1114	BSC-MT-065624	BSC-MT-065624	Email Re Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1115	BSC-MT-065874	BSC-MT-065876	Email Re Commercial Availability of the Olympus Quic k Clip Pro		401/402, 403, 801/802
DTX-1116	BSC-MT-066547	BSC-MT-066596	Presentation: Boston Scientific - Advanced Hemostasis Portfolio		401/402, 403, 801/802
DTX-1117	BSC-MT-066647	BSC-MT-066668	Presentation: Boston Scientific - Advanced Hemostasis Portfolio		401/402, 403, 801/802
DTX-1118	BSC-MT-066669	BSC-MT-066670	Email Re Resolution/Hemoclip Financials		401/402, 403, 801/802
DTX-1119	BSC-MT-067146	BSC-MT-067147	Presentation: Boston Scientific - Resolution II Clip - Account Conversion Plan		401/402, 403, 801/802
DTX-1120	BSC-MT-067162	BSC-MT-067162	Excel Spreadsheet, RJ4 Supply Chain Forecast 3-17-06		401/402, 403, 801/802
DTX-1121	BSC-MT-067251	BSC-MT-067300	Presentation: Boston Scientific - Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1122	BSC-MT-067301	BSC-MT-067350	Presentation: Boston Scientific - Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1123	BSC-MT-067351	BSC-MT-067414	Presentation: Boston Scientific - Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1124	BSC-MT-067415	BSC-MT-067484	Presentation: Boston Scientific - Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1125	BSC-MT-067572	BSC-MT-067588	Presentation: Boston Scientific - Resolution II Launch Package		401/402, 403, 801/802
DTX-1126	BSC-MT-067595	BSC-MT-067598	(Draft) Commercialization Plan for Resolution II Clip - Account Conversion Strategy		401/402, 403, 801/802
DTX-1127	BSC-MT-067599	BSC-MT-067621	(Draft) Resolution II - Account Conversion Strategy		401/402, 403, 801/802
DTX-1128	BSC-MT-067622	BSC-MT-067623	Boston Scientific - Resolution II - Account Clip Conversion Plan		401/402, 403, 801/802
DTX-1129	BSC-MT-067624	BSC-MT-067631	Presentation: Boston Scientific - Resolution II Clip		401/402, 403, 801/802
DTX-1130	BSC-MT-067990	BSC-MT-068089	Presentation: Boston Scientific - Resolution II Clip - Global Commercialization Plan		401/402, 403, 801/802
DTX-1131	BSC-MT-069534	BSC-MT-069534	Excel Spreadsheet, Cole Lafferty Franchise 2013 Education Programs		401/402, 403, 801/802
DTX-1132	BSC-MT-071371	BSC-MT-071382	Presentation: Boston Scientific - E0455 - Rotatable Res - COGs Summary		401/402, 403, 801/802
DTX-1133	BSC-MT-071756	BSC-MT-071758	Endoscopy R&D - Project Review		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1134	BSC-MT-071765	BSC-MT-071765	Excel Spreadsheet, FourVoicesGuidingQs-v4 - Marketing		401/402, 403, 801/802
DTX-1135	BSC-MT-074233	BSC-MT-074236	Boston Scientific - Clinical Outcomes - Leave Nothing to Chance		401/402, 403, 801/802
DTX-1136	BSC-MT-074832	BSC-MT-074832	Excel Spreadsheet, Hemoclip ROI 10-24-03		401/402, 403, 801/802
DTX-1137	BSC-MT-075312	BSC-MT-075312	Excel Spreadsheet, Forecasting Tool Hemo F3 2014 8.11.14		401/402, 403, 801/802
DTX-1138	BSC-MT-075359	BSC-MT-075396	Presentation: Boston Scientific - Core GI/ Surgical Endoscopy- 2008 Marketing Plan		401/402, 403, 801/802
DTX-1139	BSC-MT-075675	BSC-MT-075682	Presentation: Resolution II Design Concept Review		401/402, 403, 801/802
DTX-1140	BSC-MT-075831	BSC-MT-075832	Email Re HCD Transfer Price Estimates		401/402, 403, 801/802
DTX-1141	BSC-MT-075983	BSC-MT-075983	Chart Re Product Comparisons		401/402, 403, 801/802
DTX-1142	BSC-MT-077650	BSC-MT-077650	Boston Scientific - Resolution™ Clip Packaging Information		401/402, 403, 801/802
DTX-1143	BSC-MT-077760	BSC-MT-077762	Email Re Resolution Clips Exceeds 1 Million Units Sold in 2013		401/402, 403, 801/802
DTX-1144	BSC-MT-077767	BSC-MT-077768	Email Re Resolution Clip Training/Education Programs		401/402, 403, 801/802
DTX-1145	BSC-MT-077822	BSC-MT-077823	Email Re Portfolio Review Action Items		401/402, 403, 801/802
DTX-1146	BSC-MT-077827	BSC-MT-077827	Excel Spreadsheet, Copy of Res IIIw.rotationMJApril26.2011		401/402, 403, 801/802
DTX-1147	BSC-MT-077846	BSC-MT-077846	Email Re Cook Clips		401/402, 403, 801/802
DTX-1148	BSC-MT-077850	BSC-MT-077850	Email Re Cook's New Clip		401/402, 403, 801/802
DTX-1149	BSC-MT-078061	BSC-MT-078062	Email Re Financial Model Preparation for Portfolio Review		401/402, 403, 801/802
DTX-1150	BSC-MT-078107	BSC-MT-078125	Chart Re MSpec, Performance Expectation, DIDR Plan etc.		401/402, 403, 801/802
DTX-1151	BSC-MT-078152	BSC-MT-078152	Excel Spreadsheet, Dec14 Sales v Plan - Hemo		401/402, 403, 801/802
DTX-1152	BSC-MT-078161	BSC-MT-078161	Email Spreadsheet, embedded.43710 2.3		401/402, 403, 801/802
DTX-1153	BSC-MT-078168	BSC-MT-078170	Email Re AMEA Endoscopy Report October 2015		401/402, 403, 801/802
DTX-1154	BSC-MT-078171	BSC-MT-078175	AMEA Endoscopy Report October 2015		401/402, 403, 801/802
DTX-1155	BSC-MT-078240	BSC-MT-078250	Presentation: Boston Scientific - Olympus Strategy Task Force - EBR Review		401/402, 403, 801/802
DTX-1156	BSC-MT-078278	BSC-MT-078278	Excel Spreadsheet, Dec14 Sales v Plan - Hemo		401/402, 403, 801/802
DTX-1157	BSC-MT-078279	BSC-MT-078280	Email Re Previous Vanguard Pricing on Instinct		401/402, 403, 801/802
DTX-1158	BSC-MT-078287	BSC-MT-078288	Email Re Previous Vanguard Pricing on Instinct		401/402, 403, 801/802
DTX-1159	BSC-MT-078332	BSC-MT-078334	Email Re Commercial Availability of the Olympus QuickClipPro		401/402, 403, 801/802
DTX-1160	BSC-MT-078341	BSC-MT-078343	Email Re AMEA Endoscopy Report February 2015		401/402, 403, 801/802
DTX-1161	BSC-MT-078344	BSC-MT-078347	AMEA Endoscopy Report February 2015		401/402, 403, 801/802
DTX-1162	BSC-MT-079329	BSC-MT-079331	Email Re Scope - New GIE Guidelines		401/402, 403, 801/802
DTX-1163	BSC-MT-079388	BSC-MT-079388	Email Spreadsheet		401/402, 403, 801/802, ID
DTX-1164	BSC-MT-079391	BSC-MT-079391	Email Spreadsheet		401/402, 403, 801/802, ID
DTX-1165	BSC-MT-079393	BSC-MT-079393	Email Spreadsheet		401/402, 403, 801/802, ID
DTX-1166	BSC-MT-079482	BSC-MT-079484	Boston Scientific - 2013 Global Competitive Market Intelligence Report		401/402, 403, 801/802
DTX-1167	BSC-MT-079497	BSC-MT-079497	Email Re Resolution/Instinct Retention Study		401/402, 403, 801/802
DTX-1168	BSC-MT-079941	BSC-MT-079962	Presentation: Boston Scientific - Hemostasis - Resolution Clip & Core Hemo		401/402, 403, 801/802
DTX-1169	BSC-MT-080118	BSC-MT-080119	Email Re Engaging Cook Clip Accounts on Jaw Comparisons and MRI		401/402, 403, 801/802
DTX-1170	BSC-MT-080124	BSC-MT-080125	Email Re Engaging Cook Clip Accounts on Jaw Comparisons and MRI		401/402, 403, 801/802
DTX-1171	BSC-MT-080878	BSC-MT-080880	Email Re Additional Feedback on Cook Instinct Clip		401/402, 403, 801/802
DTX-1172	BSC-MT-081277	BSC-MT-081277	Excel Spreadsheet, NG Clip NPV Model MRI Only - Best Case May '12		401/402, 403, 801/802
DTX-1173	BSC-MT-081278	BSC-MT-081278	Excel Spreadsheet, NG Clip revenue and SOM projections		401/402, 403, 801/802
DTX-1174	BSC-MT-081510	BSC-MT-081511	Email Re Cook Instinct Clip Update		401/402, 403, 801/802
DTX-1175	BSC-MT-081538	BSC-MT-081539	Email Re Cook Instinct Clip Update		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1176	BSC-MT-082417	BSC-MT-082417	Graph: 2013 Resolution Deman/Capacity		401/402, 403, 801/802
DTX-1177	BSC-MT-082438	BSC-MT-082483	Presentation: Boston Scientific - Hemostatic Clip Overview		401/402, 403, 801/802
DTX-1178	BSC-MT-082558	BSC-MT-082558	Email Re Draft FSO Communication on Clip Advertisement		401/402, 403, 801/802
DTX-1179	BSC-MT-082659	BSC-MT-082660	Email Re New Cook Clip Competitive Response Materials		401/402, 403, 801/802
DTX-1180	BSC-MT-082745	BSC-MT-082746	Email Re New Cook Clip Competitive Response Materials iPad Tool		401/402, 403, 801/802
DTX-1181	BSC-MT-082749	BSC-MT-082749	Email Re Cook Instinct Clip Update		401/402, 403, 801/802
DTX-1182	BSC-MT-082784	BSC-MT-082784	Email Re US Clip Market Share Analysis - Cook Impact		401/402, 403, 801/802
DTX-1183	BSC-MT-082787	BSC-MT-082788	Email Re Booth Walk Through Talking Points		401/402, 403, 801/802
DTX-1184	BSC-MT-082912	BSC-MT-082914	Email Re Competitive Clip Update		401/402, 403, 801/802
DTX-1185	BSC-MT-083174	BSC-MT-083176	Email Re National Training Conference - Clipping Key Points		401/402, 403, 801/802
DTX-1186	BSC-MT-083225	BSC-MT-083226	Email Re Resolution Clip and Cook Instinct Clip DDW/SGNS Update		401/402, 403, 801/802
DTX-1187	BSC-MT-083345	BSC-MT-083419	Boston Scientific Endoscopy - 2012 Global Hemoclip Strategy Review		401/402, 403, 801/802
DTX-1188	BSC-MT-083497	BSC-MT-083534	Boston Scientific - Clipping Strategy Session		401/402, 403, 801/802
DTX-1189	BSC-MT-083680	BSC-MT-083717	Boston Scientific - Clipping Strategy Session		401/402, 403, 801/802
DTX-1190	BSC-MT-083941	BSC-MT-083942	Email Re New Cook Instinct Clip Competitive Response iPad Tool		401/402, 403, 801/802
DTX-1191	BSC-MT-084384	BSC-MT-084384	Cook Instinct Clip Timeline		401/402, 403, 801/802
DTX-1192	BSC-MT-084716	BSC-MT-084717	Email Re Cook Instinct Clip Launch Update		401/402, 403, 801/802
DTX-1193	BSC-MT-084883	BSC-MT-084885	Email Re Cook Instinct Clip Launch Update		401/402, 403, 801/802
DTX-1194	BSC-MT-085205	BSC-MT-085278	Boston Scientific Endoscopy - 2012 Global Hemoclip Strategy Review		401/402, 403, 801/802
DTX-1195	BSC-MT-085311	BSC-MT-085312	Email Re Cook Instinct Clip Launch Update		401/402, 403, 801/802
DTX-1196	BSC-MT-085965	BSC-MT-085968	Email Re MDM Competitive Clip Pole Info		401/402, 403, 801/802
DTX-1197	BSC-MT-086278	BSC-MT-086280	Email Re Instinct Clip Product Performance - Competitive Update		401/402, 403, 801/802
DTX-1198	BSC-MT-086402	BSC-MT-086403	Email Re Instinct Clip Product Performance - Competitive Update		401/402, 403, 801/802
DTX-1199	BSC-MT-086795	BSC-MT-086797	Email Re Call		401/402, 403, 801/802
DTX-1200	BSC-MT-086896	BSC-MT-086897	Email Re Clip Field Ride - France		401/402, 403, 801/802
DTX-1201	BSC-MT-087369	BSC-MT-087370	Email Re Petrou Call		401/402, 403, 801/802
DTX-1202	BSC-MT-087399	BSC-MT-087401	Boston Scientific - Global Competitive Market Intelligence Report		401/402, 403, 801/802
DTX-1203	BSC-MT-087541	BSC-MT-087541	Excel Spreadsheet, December Master Clips At risk Accounts Monthly Tracker		401/402, 403, 801/802
DTX-1204	BSC-MT-087545	BSC-MT-087545	Excel Spreadsheet, December Master Clips At risk Accounts Monthly Tracker		401/402, 403, 801/802
DTX-1205	BSC-MT-087712	BSC-MT-087713	Email Re Instinct		401/402, 403, 801/802
DTX-1206	BSC-MT-088424	BSC-MT-088425	Email Re Call with Dr. Holm		401/402, 403, 801/802
DTX-1207	BSC-MT-088634	BSC-MT-088634	Excel Spreadsheet, embedded.57380 1.6		401/402, 403, 801/802
DTX-1208	BSC-MT-089663	BSC-MT-089665	Email Re Cook Instinct Talking Points		401/402, 403, 801/802
DTX-1209	BSC-MT-089669	BSC-MT-089670	Email Re Cook Instinct Talking Points		401/402, 403, 801/802
DTX-1210	BSC-MT-090875	BSC-MT-090875	Excel Spreadsheet, embedded.57836 1.1		401/402, 403, 801/802
DTX-1211	BSC-MT-091384	BSC-MT-091414	Biosurgicals for Hemostasis in GI Endoscopy		401/402, 403, 801/802
DTX-1212	BSC-MT-091540	BSC-MT-091541	Email Re Risk/Lost Accounts Instinct		401/402, 403, 801/802
DTX-1213	BSC-MT-091962	BSC-MT-091962	Excel Spreadsheet, Res PPMS Data		401/402, 403, 801/802
DTX-1214	BSC-MT-091965	BSC-MT-091965	Excel Spreadsheet, Endoscopy Master Price List 2005 11-05		401/402, 403, 801/802
DTX-1215	BSC-MT-091966	BSC-MT-091966	Excel Spreadsheet, Endoscopy Master Price List 2006 10-06		401/402, 403, 801/802
DTX-1216	BSC-MT-091967	BSC-MT-091967	Excel Spreadsheet, Endoscopy Master Price List 2007 12-07		401/402, 403, 801/802
DTX-1217	BSC-MT-091968	BSC-MT-091968	Excel Spreadsheet, Endoscopy Master Price List 2008 12-08		401/402, 403, 801/802
DTX-1218	BSC-MT-091969	BSC-MT-091969	Excel Spreadsheet, Endoscopy Master Price List 2009 10-09		401/402, 403, 801/802
DTX-1219	BSC-MT-091970	BSC-MT-091970	Excel Spreadsheet, Endoscopy Master Price List 2010 12-10		401/402, 403, 801/802
DTX-1220	BSC-MT-091971	BSC-MT-091971	Excel Spreadsheet, Endoscopy Master Price List 2011 12-11		401/402, 403, 801/802
DTX-1221	BSC-MT-091972	BSC-MT-091972	Excel Spreadsheet, Endoscopy Master Price List 2012 11-12		401/402, 403, 801/802
DTX-1222	BSC-MT-091973	BSC-MT-091973	Excel Spreadsheet, Endoscopy Master Price List 2013 10-13		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1223	BSC-MT-091974	BSC-MT-091974	Excel Spreadsheet, Endoscopy Master Price List 2014 10-14		401/402, 403, 801/802
DTX-1224	BSC-MT-091975	BSC-MT-091975	Excel Spreadsheet, Endoscopy Master Price List 2015 10-15		401/402, 403, 801/802
DTX-1225	BSC-MT-091976	BSC-MT-091976	Excel Spreadsheet, Endoscopy Master Price List 2016 10-16		401/402, 403, 801/802
DTX-1226	BSC-MT-091985	BSC-MT-091985	Excel Spreadsheet, Resolution Clip Legal Request 2004 - 2016		401/402, 403, 801/802
DTX-1227	BSC-MT-091999	BSC-MT-091999	Excel Spreadsheet, R&D project list		401/402, 403, 801/802
DTX-1228	BSC-MT-092000	BSC-MT-092000	Excel Spreadsheet, P&L guide - what to allocate vs direct expenses		401/402, 403, 801/802
DTX-1229	BSC-MT-092001	BSC-MT-092001	Excel Spreadsheet, US Global P&L 2012-2016		401/402, 403, 801/802
DTX-1230	BSC-MT-092384	BSC-MT-092390	2014 Forecast Summary & Assumptions - Resolution Clip		401/402, 403, 801/802
DTX-1231	BSC-MT-092758	BSC-MT-092785	8th Annual SIES 2015		401/402, 403, 801/802
DTX-1232	BSC-MT-092968	BSC-MT-092986	Boston Scientific - Hemostasis Franchise Technology Review		401/402, 403, 801/802
DTX-1233	BSC-MT-093324	BSC-MT-093348	Boston Scientific - Resolution 360™ Clip		401/402, 403, 801/802
DTX-1234	BSC-MT-093392	BSC-MT-093397	Boston Scientific - Resolution 360™ Value Story		401/402, 403, 801/802
DTX-1235	BSC-MT-093441	BSC-MT-093443	Boston Scientific - 2014 Clip Growth Analysis		401/402, 403, 801/802
DTX-1236	BSC-MT-101217	BSC-MT-101251	Presentation: Boston Scientific - Next Generation Clip - Rotation		401/402, 403, 801/802
DTX-1237	BSC-MT-101452	BSC-MT-101454	Email Re AMC Call		401/402, 403, 801/802
DTX-1238	BSC-MT-101507	BSC-MT-101508	Email Re AMC Call		401/402, 403, 801/802
DTX-1239	BSC-MT-101597	BSC-MT-101600	Email Re Clip Pricing Strategy		401/402, 403, 801/802
DTX-1240	BSC-MT-101603	BSC-MT-101606	Email Re Clip Pricing Strategy		401/402, 403, 801/802
DTX-1241	BSC-MT-101614	BSC-MT-101628	Email Re Hemostasis Road Trip		401/402, 403, 801/802
DTX-1242	BSC-MT-101669	BSC-MT-101674	Email Re Clip Pricing Strategy		401/402, 403, 801/802
DTX-1243	BSC-MT-101716	BSC-MT-101719	Email Re Feedback on Resolution 360 - San Diego Territory		401/402, 403, 801/802
DTX-1244	BSC-MT-101737	BSC-MT-101976	B bliography - Endoclip/Hemoclip		401/402, 403, 801/802
DTX-1245	BSC-MT-102272	BSC-MT-102272	Boston Scientific - Q3 Mid America Division Strategic Priorities		401/402, 403, 801/802
DTX-1246	BSC-MT-102773	BSC-MT-102774	Graph: Clip ADU/ASP Timeline		401/402, 403, 801/802
DTX-1247	BSC-MT-102984	BSC-MT-102990	Email Re ISP - Resolution 360 for Cook Instrinct		401/402, 403, 801/802
DTX-1248	BSC-MT-102997	BSC-MT-103019	Presentation: Boston Scientific - Pricing Clips in Germany 2017-2018		401/402, 403, 801/802
DTX-1249	BSC-MT-104096	BSC-MT-104099	Email Re Micro-Tech - New Hemoclip in Market		401/402, 403, 801/802
DTX-1250	BSC-MT-104406	BSC-MT-104410	Email Re 360		401/402, 403, 801/802
DTX-1251	BSC-MT-106002	BSC-MT-106004	Email Re Micro-Tech Call		401/402, 403, 801/802
DTX-1252	BSC-MT-106005	BSC-MT-106007	Email Re Micro-Tech Call		401/402, 403, 801/802
DTX-1253	BSC-MT-106008	BSC-MT-106010	Email Re Micro-Tech Call		401/402, 403, 801/802
DTX-1254	BSC-MT-106011	BSC-MT-106022	Email Re Literature Request		401/402, 403, 801/802
DTX-1255	BSC-MT-106023	BSC-MT-106026	Email Re Res 360 Sales		401/402, 403, 801/802
DTX-1256	BSC-MT-106027	BSC-MT-106030	Email Re Res 360 Sales		401/402, 403, 801/802
DTX-1257	BSC-MT-106031	BSC-MT-106035	Email Re Res 360		401/402, 403, 801/802
DTX-1258	BSC-MT-106036	BSC-MT-106041	Email Re Res 360 Results from UEGW/DDW		401/402, 403, 801/802
DTX-1259	BSC-MT-106042	BSC-MT-106047	Email Re Res 360 Results from UEGW/DDW		401/402, 403, 801/802
DTX-1260	BSC-MT-106048	BSC-MT-106053	Email Re Res 360 Results from UEGW/DDW		401/402, 403, 801/802
DTX-1261	BSC-MT-106054	BSC-MT-106059	Email Re Res 360 Results from UEGW/DDW		401/402, 403, 801/802
DTX-1262	BSC-MT-106060	BSC-MT-106062	Email Re Endoscopy Brothers on Twitter		401/402, 403, 801/802
DTX-1263	BSC-MT-106063	BSC-MT-106065	Email Re Endoscopy Brothers on Twitter		401/402, 403, 801/802
DTX-1264	BSC-MT-106066	BSC-MT-106070	Email Re 360 Training Points		401/402, 403, 801/802
DTX-1265	BSC-MT-106071	BSC-MT-106075	Email Re Res 360 Video		401/402, 403, 801/802
DTX-1266	BSC-MT-106076	BSC-MT-106080	Email Re Res 360 Video		401/402, 403, 801/802
DTX-1267	BSC-MT-106081	BSC-MT-106089	Email Re 360 Training Points		401/402, 403, 801/802
DTX-1268	BSC-MT-106108	BSC-MT-106114	Email Re ISP - Resolution 360 for Cook Instrinct		401/402, 403, 801/802
DTX-1269	BSC-MT-106197	BSC-MT-106202	Email Re 2016 Bench Study		401/402, 403, 801/802
DTX-1270	BSC-MT-106828	BSC-MT-106837	Presentation: Resolution 360 Limited Launch - Lab In-Service Ideas		401/402, 403, 801/802
DTX-1271	BSC-MT-106879	BSC-MT-106885	Email Re ISP - Resolution 360 for Cook Instrinct		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1272	BSC-MT-107192	BSC-MT-107192	Excel Spreadsheet, embedded.59663_1.2		401/402, 403, 801/802
DTX-1273	BSC-MT-107454	BSC-MT-107507	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1274	BSC-MT-109416	BSC-MT-109417	Email Re Jan 25th Res 360 Value Meeting		401/402, 403, 801/802
DTX-1275	BSC-MT-109673	BSC-MT-109674	Email Re VoV		401/402, 403, 801/802
DTX-1276	BSC-MT-109887	BSC-MT-109940	Boston Scientific - Commercialization Plan		401/402, 403, 801/802
DTX-1277	BSC-MT-109954	BSC-MT-110003	Boston Scientific - Commercialization Plan		401/402, 403, 801/802
DTX-1278	BSC-MT-110018	BSC-MT-110067	Boston Scientific - Commercialization Plan		401/402, 403, 801/802
DTX-1279	BSC-MT-110072	BSC-MT-110072	Excel Spreadsheet		401/402, 403, 801/802
DTX-1280	BSC-MT-110075	BSC-MT-110075	Excel Spreadsheet		401/402, 403, 801/802
DTX-1281	BSC-MT-110076	BSC-MT-110076	Excel Spreadsheet		401/402, 403, 801/802
DTX-1282	BSC-MT-110077	BSC-MT-110077	Excel Spreadsheet,		401/402, 403, 801/802
DTX-1283	BSC-MT-110078	BSC-MT-110078	Excel Spreadsheet		401/402, 403, 801/802
DTX-1284	BSC-MT-111487	BSC-MT-111725	Boston Scientific - Resolution 360™ Clip - 510(k) - K151082		401/402, 403, 801/802, PMIL
DTX-1285	BSC-MT-111888	BSC-MT-111889	Boston Scientific - Endoscopy R&D Project Review		401/402, 403, 801/802
DTX-1286	BSC-MT-111890	BSC-MT-111908	Presentation: Boston Scientific - E0455 - Rotatable Res Clip Progress Review		401/402, 403, 801/802
DTX-1287	BSC-MT-111955	BSC-MT-111985	Presentation: Boston Scientific - Hemostatic Clip Overview		401/402, 403, 801/802
DTX-1288	BSC-MT-112193	BSC-MT-112287	Presentation: Boston Scientific - GI & Pulmonary Therapies Portfolio Review Introduction		401/402, 403, 801/802
DTX-1289	BSC-MT-112316	BSC-MT-112389	Presentation: Boston Scientific - GI Therapies Portfolio Review Introduction		401/402, 403, 801/802
DTX-1290	BSC-MT-112390-	BSC-MT-112407	Presentation: Boston Scientific Endoscopy - Portfolio Guidance		401/402, 403, 801/802
DTX-1291	BSC-MT-112484	BSC-MT-112530	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1292	BSC-MT-112574	BSC-MT-112630	Presentation: Boston Scientific - Resolution 360™ - Commercialization Review		401/402, 403, 801/802
DTX-1293	BSC-MT-112651	BSC-MT-112704	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1294	BSC-MT-112705	BSC-MT-112758	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1295	BSC-MT-112759	BSC-MT-112808	Boston Scientific - Hemostats Strategic Plan 2015-2020		401/402, 403, 801/802
DTX-1296	BSC-MT-112876	BSC-MT-112918	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1297	BSC-MT-114246	BSC-MT-114247	Email Re Clip Competitive Update - New Olympus Clip Has FDA Clearance		401/402, 403, 801/802
DTX-1298	BSC-MT-114595	BSC-MT-114596	Olympus Production Information		401/402, 403, 801/802
DTX-1299	BSC-MT-116599	BSC-MT-116604	Contract Manufacturing Agreement between BSS and BSC		401/402, 403, 801/802
DTX-1300	BSC-MT-116627	BSC-MT-116628	Amendment to Agreement for Contract Research and Development between Scimed and BSC		401/402, 403, 801/802
DTX-1301	BSC-MT-116629	BSC-MT-116638	Agreement for Contract Research and Development between Scimed and BSC		401/402, 403, 801/802
DTX-1302	BSC-MT-116680	BSC-MT-116680	Excel Spreadsheet, US Global PL 2012-2016 updated		401/402, 403, 801/802
DTX-1303	BSC-MT-116681	BSC-MT-116681	Excel Spreadsheet, Resolution Clip Legal Request 2004 - 2017_updated		401/402, 403, 801/802
DTX-1304	BSC-MT-116682	BSC-MT-116693	1Q 2011 Hemo Clips		401/402, 403, 801/802
DTX-1305	BSC-MT-116694	BSC-MT-116694	ASP 2004 Q2 - 2006 Q2		401/402, 403, 801/802
DTX-1306	BSC-MT-116695	BSC-MT-116695	Dollar Market Share 2004 Q2 - 2006 Q2		401/402, 403, 801/802
DTX-1307	BSC-MT-116696	BSC-MT-116696	US Market Share 2004 Q2 - 2006 Q2		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1308	BSC-MT-116697	BSC-MT-116697	Hemostasis Market Share Size		401/402, 403, 801/802
DTX-1309	BSC-MT-116698	BSC-MT-116698	Hemostasis Market Share Size		401/402, 403, 801/802
DTX-1310	BSC-MT-116699	BSC-MT-116699	Hemostasis Market Share Size		401/402, 403, 801/802
DTX-1311	BSC-MT-116700	BSC-MT-116700	Hemostasis Market Share Size		401/402, 403, 801/802
DTX-1312	BSC-MT-116701	BSC-MT-116701	Excel Spreadsheet, US Markets for Gastrointestinal Endoscopy 2007		401/402, 403, 801/802
DTX-1313	BSC-MT-116702	BSC-MT-116713	4Q 2010 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1314	BSC-MT-116714	BSC-MT-116725	2Q 2010 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1315	BSC-MT-116726	BSC-MT-116737	2Q 2011 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1316	BSC-MT-116738	BSC-MT-116749	4Q 2007 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1317	BSC-MT-116750	BSC-MT-116761	3Q 2010 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1318	BSC-MT-116762	BSC-MT-116773	3Q 2011 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1319	BSC-MT-116774	BSC-MT-116785	1Q 2012 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1320	BSC-MT-116786	BSC-MT-116797	4Q 2011 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1321	BSC-MT-116798	BSC-MT-116809	3Q 2011 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1322	BSC-MT-116810	BSC-MT-116821	2Q 2012 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1323	BSC-MT-116834	BSC-MT-116845	4Q 2012 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1324	BSC-MT-116846	BSC-MT-116857	4Q 2013 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1325	BSC-MT-116858	BSC-MT-116869	1Q 2013 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1326	BSC-MT-116870	BSC-MT-116881	1Q 2014 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1327	BSC-MT-116942	BSC-MT-116953	4Q 2015 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1328	BSC-MT-116954	BSC-MT-116965	2Q 2008 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1329	BSC-MT-116966	BSC-MT-116977	2Q 2016 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1330	BSC-MT-116978	BSC-MT-116989	1Q 2009 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1331	BSC-MT-116990	BSC-MT-117001	3Q 2009 Hemo Clips Percent Market Share		401/402, 403, 801/802
DTX-1332	BSC-MT-117050	BSC-MT-117074	Boston Scientific - Hemostasis - Rolling 12 Month Market Share		401/402, 403, 801/802
DTX-1333	BSC-MT-117075	BSC-MT-117086	2Q 2015 Over the Scope Clips		401/402, 403, 801/802
DTX-1334	BSC-MT-117087	BSC-MT-117098	2Q 2016 Over the Scope Clips		401/402, 403, 801/802
DTX-1335	BSC-MT-117099	BSC-MT-117123	Boston Scientific - 3Q 2006 Hemostasis - Rolling 12 Month Market Share		401/402, 403, 801/802
DTX-1336	BSC-MT-117124	BSC-MT-117163	2Q 2007 Hemostasis Percent Market Share		401/402, 403, 801/802
DTX-1337	BSC-MT-117164	BSC-MT-117203	1Q 2007 Hemostasis Percent Market Share		401/402, 403, 801/802
DTX-1338	BSC-MT-117204	BSC-MT-117436	U.S. Markets for Gastrointestinal Devices 2010		401/402, 403, 801/802
DTX-1339	BSC-MT-117437	BSC-MT-117544	U.S. Markets for Gastrointestinal Endoscopy Devices 2007		401/402, 403, 801/802
DTX-1340	BSC-MT-117545	BSC-MT-117675	U.S. Markets for Gastrointestinal Endoscopy Devices 2005		401/402, 403, 801/802
DTX-1341	BSC-MT-117676	BSC-MT-117940	U.S. Markets for Gastrointestinal Endoscopy Devices 2008		401/402, 403, 801/802
DTX-1342	BSC-MT-117941	BSC-MT-117941	Excel Spreadsheet, Europe 2017		401/402, 403, 801/802
DTX-1343	BSC-MT-117942	BSC-MT-117942	Excel Spreadsheet, Europe Market Model 2014		401/402, 403, 801/802
DTX-1344	BSC-MT-117943	BSC-MT-117943	Excel Spreadsheet, Europe Market Model 2015		401/402, 403, 801/802
DTX-1345	BSC-MT-117944	BSC-MT-117944	Excel Spreadsheet, Europe2016		401/402, 403, 801/802
DTX-1346	BSC-MT-117945	BSC-MT-117945	Excel Spreadsheet, Europe_Market_Model 2013v2		401/402, 403, 801/802
DTX-1347	BSC-MT-117946	BSC-MT-117946	Excel Spreadsheet, Scrap Res Clips 2012-2017		401/402, 403, 801/802
DTX-1348	BSC-MT-117947	BSC-MT-117947	Boston Scientific- Resolution™ Clip Device Product Information		401/402, 403, 801/802
DTX-1349	BSC-MT-117948	BSC-MT-117957	Boston Scientific- Resolution™ Clip Device Product Information		401/402, 403, 801/802
DTX-1350	BSC-MT-117958	BSC-MT-117959	Boston Scientific - Key Insights from Pricing Research		401/402, 403, 801/802
DTX-1351	BSC-MT-118097	BSC-MT-118124	Presentation: Boston Scientific - Resolution II - Discrete Choice Model		401/402, 403, 801/802
DTX-1352	BSC-MT-118125	BSC-MT-118130	Presentation: Boston Scientific - Resolution II -Launch Update		401/402, 403, 801/802
DTX-1353	BSC-MT-118131	BSC-MT-118136	Presentation: Boston Scientific - Senior Management Request		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1354	BSC-MT-118137	BSC-MT-118153	Presentation: Boston Scientific - Resoltion™ Clip MR Conditional Claim - Launch Training		401/402, 403, 801/802
DTX-1355	BSC-MT-118154	BSC-MT-118194	Presentation: Boston Scientific - Clipping VOC - Quantitative Findings		401/402, 403, 801/802
DTX-1356	BSC-MT-118195	BSC-MT-118208	Presentation: Boston Scientific - Competitive Analysis Summary (Updated)		401/402, 403, 801/802
DTX-1357	BSC-MT-118209	BSC-MT-118272	Presentation: Boston Scientific - GI & Pulmonary Therapy		401/402, 403, 801/802
DTX-1358	BSC-MT-118312	BSC-MT-118320	Boston Scientific - Resolution 360™ Clip Product Information		401/402, 403, 801/802
DTX-1359	BSC-MT-118321	BSC-MT-118328	Boston Scientific - Competitive Hemostasis Clip Analysis		401/402, 403, 801/802
DTX-1360	BSC-MT-118337	BSC-MT-118359	Presentation: Boston Scientific- Pricing Clips in Germany 2017 & 2018		401/402, 403, 801/802
DTX-1361	BSC-MT-118362	BSC-MT-118374	Presentation: Boston Scientific - Future Frontier for Clips		401/402, 403, 801/802
DTX-1362	BSC-MT-118391	BSC-MT-118444	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1363	BSC-MT-118445	BSC-MT-118452	Cook Medical DHC-7-230 Description and Product Investigation		401/402, 403, 801/802
DTX-1364	BSC-MT-118453	BSC-MT-118477	Presentation: Boston Scientific - Rotatable Res Clip Project E0455		401/402, 403, 801/802
DTX-1365	BSC-MT-118478	BSC-MT-118487	Presentation: Boston Scientific - Competitive Clip Update		401/402, 403, 801/802
DTX-1366	BSC-MT-118488	BSC-MT-118515	Presentation: Boston Scientific - Resolution 360™ Wide		401/402, 403, 801/802
DTX-1367	BSC-MT-118516	BSC-MT-118546	Presentation: Boston Scientific - Clipping Competitive Environment		401/402, 403, 801/802
DTX-1368	BSC-MT-118547	BSC-MT-118591	Presentation: Boston Scientific - Resolution 360™ Clip - Commercialization Plan		401/402, 403, 801/802
DTX-1369	BSC-MT-118612	BSC-MT-118622	Presentation: Boston Scientific - Clipping Competitive Environment		401/402, 403, 801/802
DTX-1370	BSC-MT-118627	BSC-MT-118660	Presentation: Boston Scientific - Cook Hemoclip Competitive Response		401/402, 403, 801/802
DTX-1371	BSC-MT-118794	BSC-MT-118824	Presentation: Boston Scientific - Advanced Hemostasis Portfolio		401/402, 403, 801/802
DTX-1372	BSC-MT-119069	BSC-MT-119075	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Plaintiffs' Second Supplemental Objections and Responses to Defendants' Interrogatory Nos. 1-2 (Original No. 1)		401/402, 403, 801/802
DTX-1373	BSC-MT--119997	BSC-MT--120226	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Cook's Final Invalidity Contentions for U.S. Patent No. 8,974,371		401/402, 403, 801/802
DTX-1374	BSC-MT-120570	BSC-MT-120600	U.S. Patent Application Publication US 2002/0128667 A1		401/402, 403
DTX-1375	BSC-MT-120611	BSC-MT-120619	Japanese Patent Publication No. 62-288147		401/402, 403
DTX-1376	BSC-MT-120620	BSC-MT-120665	WO/99/15089		401/402, 403
DTX-1377	BSC-MT-120666	BSC-MT-120802	Olympus Instructions Disposable Clip Fixing Device		401/402, 403, 801/802
DTX-1378	BSC-MT-120803	BSC-MT-120816	U.S. Patent No. 5,174,276 by Crockard		401/402, 403
DTX-1379	BSC-MT-122354	BSC-MT-122415	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Michael Lynn		401/402, 403, 801/802, AA, Legal, MC
DTX-1380	BSC-MT-123300	BSC-MT-123418	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Demetrios Petrou		401/402, 403, 801/802, AA, Legal, MC
DTX-1381	BSC-MT-126365	BSC-MT-126554	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Rebuttal Expert Report of Vincent Thomas		401/402, 403, 801/802
DTX-1382	BSC-MT-126555	BSC-MT-126648	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Reply Expert Report of Vincent Thomas		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1383	BSC-MT-127267	BSC-MT-127302	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Expert Report of Dr. Oleh Haluszka		401/402, 403, 801/802
DTX-1384	BSC-MT-128523	BSC-MT-128551	Boston Scientific - Resolution II - Market Specification		401/402, 403, 801/802
DTX-1385	BSC-MT-128568	BSC-MT-128593	Presentation: Boston Scientific - A Value Based Approach to Global Product Pricing		401/402, 403, 801/802
DTX-1386	BSC-MT-128596	BSC-MT-128621	Global Product Pricing Roadmap		401/402, 403, 801/802
DTX-1387	BSC-MT-128624	BSC-MT-128649	Global Product Pricing Roadmap		401/402, 403, 801/802
DTX-1388	BSC-MT-128652	BSC-MT-128674	Presentation: Boston Scientific - Value Based Product Pricing - Revised Proposal		401/402, 403, 801/802
DTX-1389	BSC-MT-128677	BSC-MT-128698	Presentation: Boston Scientific - Value Based Product Pricing - Revised Proposal		401/402, 403, 801/802
DTX-1390	BSC-MT-128701	BSC-MT-128722	Presentation: Boston Scientific - Value Based Product Pricing - Revised Proposal		401/402, 403, 801/802
DTX-1391	BSC-MT-128726	BSC-MT-128747	Presentation: Boston Scientific - Value Based Product Pricing - Revised Proposal		401/402, 403, 801/802
DTX-1392	BSC-MT-128750	BSC-MT-128771	Presentation: Boston Scientific - Value Based Product Pricing - Revised Proposal		401/402, 403, 801/802
DTX-1393	BSC-MT-128774	BSC-MT--128797	Presentation: Boston Scientific - A Value Based Approach to Global Product Pricing		401/402, 403, 801/802
DTX-1394	BSC-MT-128942	BSC-MT-128942	Quant Survey		401/402, 403, 801/802
DTX-1395	BSC-MT-128977	BSC-MT-128977	Excel Spreadsheet, Microsoft Excel Worksheet		401/402, 403, 801/802
DTX-1396	BSC-MT-128978	BSC-MT-128978	Excel Spreadsheet, Microsoft Excel Worksheet1		401/402, 403, 801/802
DTX-1397	BSC-MT-128980	BSC-MT-128980	Excel Spreadsheet, Microsoft Excel Worksheet4		401/402, 403, 801/802
DTX-1398	BSC-MT-128981	BSC-MT-128981	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-1399	BSC-MT-128982	BSC-MT-128982	Excel Spreadsheet, Microsoft Excel Worksheet9		401/402, 403, 801/802
DTX-1400	BSC-MT-129559	BSC-MT-129601	Presentation: Boston Scientific - Clips Market Research		401/402, 403, 801/802
DTX-1401	BSC-MT-129677	BSC-MT-129677	Excel Spreadsheet, data cut v1		401/402, 403, 801/802
DTX-1402	BSC-MT-129798	BSC-MT-129798	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet1		401/402, 403, 801/802
DTX-1403	BSC-MT-129799	BSC-MT-129799	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet5		401/402, 403, 801/802
DTX-1404	BSC-MT-129800	BSC-MT-129800	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet6		401/402, 403, 801/802
DTX-1405	BSC-MT-129801	BSC-MT-129801	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet7		401/402, 403, 801/802
DTX-1406	BSC-MT-129802	BSC-MT-129802	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet8		401/402, 403, 801/802
DTX-1407	BSC-MT-129803	BSC-MT-129803	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet10		401/402, 403, 801/802
DTX-1408	BSC-MT-129804	BSC-MT-129804	Excel Spreadsheet, Microsoft Excel 97-2003 Worksheet11		401/402, 403, 801/802
DTX-1409	BSC-MT-129811	BSC-MT-129850	Ipsos Business Consulting -Market Assessment Study - Micro-Tech		401/402, 403, 801/802
DTX-1410	BSC-MT-130033	BSC-MT-130048	Ipsos Business Consulting -Market Assessment Study - Micro-Tech		401/402, 403, 801/802
DTX-1411	BSC-MT-130093	BSC-MT-130131	Presentation: Boston Scientific - Resolution Clip Commercial Strategy		401/402, 403, 801/802
DTX-1412	BSC-MT-130134	BSC-MT-130134	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-1413	BSC-MT-130139	BSC-MT-130139	Excel Spreadsheet, Microsoft Excel Worksheet9		401/402, 403, 801/802
DTX-1414	BSC-MT-130140	BSC-MT-130140	Excel Spreadsheet, Microsoft Excel Worksheet8		401/402, 403, 801/802
DTX-1415	BSC-MT-130141	BSC-MT-130141	Excel Spreadsheet, Microsoft Excel Worksheet7		401/402, 403, 801/802
DTX-1416	BSC-MT-130435	BSC-MT-130662	iData Research - Chinese Market for Gastrointestinal Endoscopic Devices		401/402, 403, 801/802
DTX-1417	BSC-MT-131026	BSC-MT-131043	Presentation: Boston Scientific - Resolution II E0354		401/402, 403, 801/802
DTX-1418	BSC-MT-131425	BSC-MT-131443	Presentation: Boston Scientific - Resolution™ Clip Marketing Plan		401/402, 403, 801/802
DTX-1419	BSC-MT-131455	BSC-MT-131480	Presentation: Boston Scientific - Welcome to the Resolution™ Clip Device Training		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1420	BSC-MT-131531	BSC-MT-131540	Marketing Research Agreement between BSC and Clearstate Medical Market Research		401/402, 403, 801/802
DTX-1421	BSC-MT-131605	BSC-MT-131644	Clearstate - China Customer Insights Proposal		401/402, 403, 801/802
DTX-1422	BSC-MT-131645	BSC-MT-131805	IMS Consulting Group - China Endo Market Opportunity Assessment - Final Project Report		401/402, 403, 801/802
DTX-1423	BSC-MT-131896	BSC-MT-131939	Presentation: Boston Scientific - China Growth Acceleration 2014-2018		401/402, 403, 801/802
DTX-1424	BSC-MT-131941	BSC-MT-132290	Marketstrat - Gastrointestinal Endoscopy Device Worldwide - A Market Strategy Report		401/402, 403, 801/802
DTX-1425	BSC-MT-132297	BSC-MT-132384	Presentation: Deliver Peak Performance		401/402, 403, 801/802
DTX-1426	BSC-MT-132705	BSC-MT-132757	Boston Scientific - Clipping VOC - Quantitative Findings		401/402, 403, 801/802
DTX-1427	BSC-MT-132913	BSC-MT-132956	Boston Scientific - Clipping VOC - Quantitative Findings		401/402, 403, 801/802
DTX-1428	BSC-MT-135782	BSC-MT-135782	E0455 Resolution 360 Progress Review		401/402, 403, 801/802
DTX-1429	BSC-MT-135783	BSC-MT-135783	E0455 Resolution 360 Progress Review		401/402, 403, 801/802
DTX-1430	BSC-MT-135784	BSC-MT-135784	E0455 Resolution 360 Progress Review		401/402, 403, 801/802
DTX-1431	BSC-MT-136217	BSC-MT-136317	Presentation: Boston Scientific - Resolution 360™ Clip Human Use - Commercial Release		401/402, 403, 801/802
DTX-1432	BSC-MT-136962	BSC-MT-136984	Presentation: Boston Scientific - Resolution 360™ Clip Commercialization Update and Team Recognition		401/402, 403, 801/802
DTX-1433	BSC-MT-137044	BSC-MT-137044	Excel Spreadsheet, E0455- Project Management Plan-April 2015		401/402, 403, 801/802
DTX-1434	BSC-MT-137063	BSC-MT-137063	E0455 Res 360 AOP 2016		401/402, 403, 801/802
DTX-1435	BSC-MT-137075	BSC-MT-137075	RD Financial Model		401/402, 403, 801/802
DTX-1436	BSC-MT-137077	BSC-MT-137077	RD Financial Model		401/402, 403, 801/802
DTX-1437	BSC-MT-137078	BSC-MT-137078	RD Financial Model		401/402, 403, 801/802
DTX-1438	BSC-MT-137079	BSC-MT-137079	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB Jim's baseline V2		401/402, 403, 801/802
DTX-1439	BSC-MT-137080	BSC-MT-137080	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB V4 - MG Plan		401/402, 403, 801/802
DTX-1440	BSC-MT-137081	BSC-MT-137081	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB V4 - MG Transfer - Sandbox		401/402, 403, 801/802
DTX-1441	BSC-MT-137082	BSC-MT-137082	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB V4 - MG Transfer		401/402, 403, 801/802
DTX-1442	BSC-MT-137083	BSC-MT-137083	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB V4 - MTC Plan		401/402, 403, 801/802
DTX-1443	BSC-MT-137084	BSC-MT-137084	Excel Spreadsheet, RD Financial Model - Rotatable Clip-April PIB V4		401/402, 403, 801/802
DTX-1444	BSC-MT-137085	BSC-MT-137085	Excel Spreadsheet, RD Financial Model - Rotatable Clip-November PIB (gensight edits)		401/402, 403, 801/802
DTX-1445	BSC-MT-137086	BSC-MT-137086	Excel Spreadsheet, Res 360 Fin Model with MG SandBox		401/402, 403, 801/802
DTX-1446	BSC-MT-137087	BSC-MT-137087	Excel Spreadsheet, Res 360 Fin Model with MG-MTC transfer - Sandbox		401/402, 403, 801/802
DTX-1447	BSC-MT-137088	BSC-MT-137088	Excel Spreadsheet, Res 360 Fin Model with MG-MTC transfer		401/402, 403, 801/802
DTX-1448	BSC-MT-137089	BSC-MT-137089	Excel Spreadsheet, Res 360 Fin Model with MG		401/402, 403, 801/802
DTX-1449	BSC-MT-137090	BSC-MT-137090	Excel Spreadsheet, Res 360 Fin Model with MTC Plan		401/402, 403, 801/802
DTX-1450	BSC-MT-137091	BSC-MT-137091	Excel Spreadsheet, Res 360 Fin Model with MTC Proposal		401/402, 403, 801/802
DTX-1451	BSC-MT-137092	BSC-MT-137092	Excel Spreadsheet, Rotatable Clip Aug-15 PIB		401/402, 403, 801/802
DTX-1452	BSC-MT-137093	BSC-MT-137093	Excel Spreadsheet, Rotatable Clip Jan-16 PIB Sandbox		401/402, 403, 801/802
DTX-1453	BSC-MT-137094	BSC-MT-137094	Excel Spreadsheet, Rotatable Clip Jan-16 PIB V2		401/402, 403, 801/802
DTX-1454	BSC-MT-137095	BSC-MT-137095	Excel Spreadsheet, Rotatable Clip June-15 PIB		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1455	BSC-MT-137096	BSC-MT-137096	Excel Spreadsheet, Rotatable Clip Feb-16 Update1 - New assumptions EU and US		401/402, 403, 801/802
DTX-1456	BSC-MT-137097	BSC-MT-137097	Excel Spreadsheet, Rotatable Clip Feb-16 Update1 - New assumptions EU only		401/402, 403, 801/802
DTX-1457	BSC-MT-137132	BSC-MT-137136	KDPD Award		401/402, 403, 801/802
DTX-1458	BSC-MT-137437	BSC-MT-137464	Presentation: Boston Scientific - Resolution 360™ Clip Commercialization Update		401/402, 403, 801/802
DTX-1459	BSC-MT-137493	BSC-MT-137527	Presentation: Boston Scientific - E0455 Rotatable Resolution Development Updat and Risk Mitigation Strategy		401/402, 403, 801/802
DTX-1460	BSC-MT-137626	BSC-MT-137626	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-1461	BSC-MT-137630	BSC-MT-137630	Excel Spreadsheet, Microsoft Excel Worksheet6		401/402, 403, 801/802
DTX-1462	BSC-MT-137631	BSC-MT-137631	Excel Spreadsheet, Microsoft Excel Worksheet7		401/402, 403, 801/802
DTX-1463	BSC-MT-137644	BSC-MT-137672	Presentation: Boston Scientific - Resolution 360™ Clip Management Update		401/402, 403, 801/802
DTX-1464	BSC-MT-137676	BSC-MT-137676	Excel Spreadsheet, Microsoft Excel Worksheet5		401/402, 403, 801/802
DTX-1465	BSC-MT-137677	BSC-MT-137677	Excel Spreadsheet, Microsoft Excel Worksheet6		401/402, 403, 801/802
DTX-1466	BSC-MT-137678	BSC-MT-137678	Excel Spreadsheet, Microsoft Excel Worksheet7		401/402, 403, 801/802
DTX-1467	BSC-MT-137680	BSC-MT-137701	Presentation: Boston Scientific - Resolution 360™ Clip Voice of Value		401/402, 403, 801/802
DTX-1468	BSC-MT-137704	BSC-MT-137752	Presentation: Boston Scientific - Rotatable Resolution Clip		401/402, 403, 801/802
DTX-1469	BSC-MT-137773	BSC-MT-137773	Presentation: Boston Scientific - Resolution 360™ Clip Voice of Value		401/402, 403, 801/802
DTX-1470	BSC-MT-138175	BSC-MT-138234	Presentation: Boston Scientific - Resolution™ II Clip		401/402, 403, 801/802
DTX-1471	BSC-MT-138353	BSC-MT-138391	Cook Clip Summary		401/402, 403, 801/802
DTX-1472	BSC-MT-138665	BSC-MT-138690	Endoscopy National Training Conference 2013		401/402, 403, 801/802
DTX-1473	BSC-MT-138693	BSC-MT-138723	Endoscopy National Training Conference 2013		401/402, 403, 801/802
DTX-1474	BSC-MT-139874	BSC-MT-139930	Boston Scientific - Micro-Tech Competitive Analysis - Final Report		401/402, 403, 801/802
DTX-1475	BSC-MT-139931	BSC-MT-139941	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1476	BSC-MT-139942	BSC-MT-139950	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1477	BSC-MT-139951	BSC-MT-139959	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1478	BSC-MT-139960	BSC-MT-139968	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1479	BSC-MT-139969	BSC-MT-139978	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1480	BSC-MT-139979	BSC-MT-139986	Boston Scientific - Complaint Summary Report		401/402, 403, 801/802
DTX-1481	BSC-MT-140058	BSC-MT-140058	Spreadsheet 2018-2020 sale data		401/402, 403, 801/802
DTX-1482	BSC-MT-140061	BSC-MT-140061	Rotatable Clip Update		401/402, 403, 801/802
DTX-1483	BSC-MT-140062	BSC-MT-140062	Sales Data		401/402, 403, 801/802
DTX-1484	BSC-MT-140074	BSC-MT-140085	Intangible Property License Agreement between Boston Scientific Ltd. And Boston Scientific de Costa Rica		401/402, 403, 801/802
DTX-1485	BSC-MT-140086	BSC-MT-140091	Manufacturing Agreement between Boston Scientific Ltd. And Boston Scientific de Costa Rica		401/402, 403, 801/802
DTX-1486	BSC-MT-140111	BSC-MT-140115	Assignment of Intellectual Property between Boston Scientific Ltd. And Boston Scientific de Costa Rica		401/402, 403, 801/802
DTX-1487	BSC-MT-140124	BSC-MT-140131	Intangible Property License Agreement between Boston Scientific Ltd. And Boston Scientific de Costa Rica		401/402, 403, 801/802
DTX-1488	BSC-MT-140132	BSC-MT-140134	Termination Agreement between Boston Scientific Ltd. And Boston Scientific de Costa Rica		401/402, 403, 801/802
DTX-1489	BSC-MT-140141	BSC-MT-140142	Consent Letter		401/402, 403, 801/802
DTX-1490	BSC-MT-140183	BSC-MT-140195	Elevate Program Agreement – January 2020		401/402, 403, 801/802
DTX-1491	BSC-MT-140213	BSC-MT-140435	Resolution II Clip Recall - Removal		401/402, 403, 801/802
DTX-1492	BSC-MT-140436	BSC-MT-140439	Email Re K193424S001 - Resolution 360 Ultra Clip		401/402, 403, 801/802
DTX-1493	BSC-MT-140440	BSC-MT-140451	Resolution 360™ Ultra Clip Product Information		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1494	BSC-MT-140452	BSC-MT-140453	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1495	BSC-MT-140454	BSC-MT-140455	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1496	BSC-MT-140456	BSC-MT-140467	Resolution 360™ Ultra Clip Directions For Use		401/402, 403, 801/802
DTX-1497	BSC-MT-140468	BSC-MT-140469	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1498	BSC-MT-140470	BSC-MT-140471	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1499	BSC-MT-140472	BSC-MT-140511	NAMSA Test Report		401/402, 403, 801/802
DTX-1500	BSC-MT-140524	BSC-MT-140525	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1501	BSC-MT-140526	BSC-MT-140527	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1502	BSC-MT-140528	BSC-MT-140539	Resolution 360™ Ultra Clip Directions For Use (Update)		401/402, 403, 801/802
DTX-1503	BSC-MT-140540	BSC-MT-140541	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1504	BSC-MT-140542	BSC-MT-140543	Resolution 360™ Ultra Clip Patient Information Card		401/402, 403, 801/802
DTX-1505	BSC-MT-140544	BSC-MT-140544	Email Re K193424S001 Review Complete		401/402, 403, 801/802
DTX-1506	BSC-MT-140545	BSC-MT-140546	FDA Letter		401/402, 403, 801/802
DTX-1507	BSC-MT-140547	BSC-MT-140547	DHHS Lndications of Use - K193424		401/402, 403, 801/802, PMIL
DTX-1508	BSC-MT-140548	BSC-MT-140550	510(k) Summary for K193424		401/402, 403, 801/802, PMIL
DTX-1509	BSC-MT-140551	BSC-MT-140551	Excel Spreadsheet, Res Clip and Res 360 Clip Complaint History - US only		401/402, 403, 801/802
DTX-1510	BSC-MT-140552	BSC-MT-140651	510(K) Number K12039		401/402, 403, 801/802, PMIL
DTX-1511	CMD 0001	CMD 0076	ConMed DuraClip Product Information		401/402, 403, 801/802
DTX-1512	CMD 0230	CMD 0230	Excel Spreadsheet, Forecast Agreement Hemostasis Clip (DuraClip)		401/402, 403, 801/802
DTX-1513	CMD 0325	CMD 0330	Document Re Micro-Tech USA Onsite Visit		401/402, 403, 801/802
DTX-1514			Exhibit Intentionally Omitted		
DTX-1515	CMD 1872	CMD 1875	ConMed DuraClip Product Information		401/402, 403, 801/802
DTX-1516	CMD 2044	CMD 2045	ConMed DuraClip Hemostasis Clip Presentation		401/402, 403, 801/802
DTX-1517	CMD 2077	CMD 2077	ConMed DuraClip Hemostasis Clip Presentation		401/402, 403, 801/802
DTX-1518	CMD 2130	CMD 2133	ConMed DuraClip Hemostasis Presentation		401/402, 403, 801/802
DTX-1519	CMD 2254	CMD 2258	OEM Product Release Checklist		401/402, 403, 801/802
DTX-1520	CMD 2259	CMD 2259	ConMed Financial Summary		401/402, 403, 801/802
DTX-1521	CMD 2260	CMD 2260	ConMed Financial Summary Assumptions		401/402, 403, 801/802
DTX-1522	CMD 2261	CMD 2261	ConMed Financial Summary Assumptions		401/402, 403, 801/802
DTX-1523	CMD 2283	CMD 2283	Excel Spreadsheet, Forecast Agreement - DuraClip		401/402, 403, 801/802
DTX-1524	CMD 2654	CMD 2654	ConMed DuraClip Advertisement		401/402, 403, 801/802
DTX-1525	CMD 2672	CMD 2673	ConMed DuraClip Advertisement		401/402, 403, 801/802
DTX-1526	CMD 2674	CMD 2675	ConMed DuraClip Advertisement		401/402, 403, 801/802
DTX-1527	CMD 2755	CMD 2755	Excel Spreadsheet, Financial Information re DuraClip HemoClip		401/402, 403, 801/802
DTX-1528	CMD 2768	CMD 2768	Excel Spreadsheet, EU Forecast for		401/402, 403, 801/802
DTX-1529	CMD 2769	CMD 2769	Excel Spreadsheet, Forecast Agreement Hemostasis Clip		401/402, 403, 801/802
DTX-1530	CMD 3482	CMD 3482	DuraClip 16mm Repositionable Hemostasis Clip Cost/Sale Information		401/402, 403, 801/802
DTX-1531	CMD 3483	CMD 3483	Excel Spreadsheet, DuraClip 16mm Repositionable Hemostasis Clip		401/402, 403, 801/802
DTX-1532	CMD 4017	CMD 4021	Hemostatic Clips for GI - Overview and Clinical Use		401/402, 403, 801/802
DTX-1533	CMD 4071	CMD 4074	ConMed Purchase Order		401/402, 403, 801/802
DTX-1534	CMD 4075	CMD 4076	ConMed DuraClip Advertisement		401/402, 403, 801/802
DTX-1535	CMD 4077	CMD 4081	ConMed Innovative New Products and Hands-On Sessions		401/402, 403, 801/802
DTX-1536	CMD 4082	CMD 4082	List of Website Pages for DuraClip		401/402, 403, 801/802
DTX-1537	CMD 4083	CMD 4086	ConMed DuraClip Product Information		401/402, 403, 801/802
DTX-1538	CMD 4087	CMD 4089	ConMed Product Information		401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1539	CMD 4090	CMD 4097	ConMed Innovative New Products and Dynamic Physician Presentations		401/402, 403, 801/802
DTX-1540	CMD 4098	CMD 4101	ConMed Product Advertisement		401/402, 403, 801/802
DTX-1541	CMD 4102	CMD 4113	ConMed Innovative New Products and Vendor Program		401/402, 403, 801/802
DTX-1542	CMD 4131	CMD 4131	Excel Spreadsheet, Forecast Agreement - Duraclip (10/CS)		401/402, 403, 801/802
DTX-1543	CMD 4233	CMD 4266	Presentation: ConMed Global Sales Meeting - February 2016		401/402, 403, 801/802
DTX-1544	CMD 4304	CMD 4306	Excel Spreadsheet, Forecast Agreement - Duraclip (10/CS)		401/402, 403, 801/802
DTX-1545	CMD 4336	CMD 4344	ConMed - Support DuraClip Hemostasis Clip Product Launch		401/402, 403, 801/802
DTX-1546	CMD 4516	CMD 4517	Graphs Re Market Share		401/402, 403, 801/802
DTX-1547	CMD 4614	CMD 4615	Email Re DuraClip Project Background and Available Documentation		401/402, 403, 801/802
DTX-1548	CMD 4616	CMD 4617	DuraClip Oracle Entry Hot Sheet		401/402, 403, 801/802
DTX-1549	CMD 4829	CMD 4830	Email Re DuraClip Sales Revenue thru June 2017		401/402, 403, 801/802
DTX-1550	CMD 4831	CMD 4831	Excel Spreadsheet, Forecast Agreement - DuraClip		401/402, 403, 801/802
DTX-1551	CMD 4838	CMD 4850	ConMed Value Analysis Presentation DuraClip Repositionable Hemostasis Clip		401/402, 403, 801/802
DTX-1552	CMD 4894	CMD 4895	Email Re Micro-Tech New EndoClip Meeting		401/402, 403, 801/802
DTX-1553	CMD 4896	CMD 4896	Excel Spreadsheet, Forecast Agreement - Hemostasis Clip (DuraClip)		401/402, 403, 801/802
DTX-1554	CMD 5094	CMD 5111	Charts Re Global Endoscopic Market		401/402, 403, 801/802
DTX-1555	CMD 5112	CMD 5112	Excel Spreadsheet, Forecast Agreement - Duraclip (10/CS)		401/402, 403, 801/802
DTX-1556	CMD 5115	CMD 5126	Presentation: Micro-Tech - Expanding the Scope of Endoscopy		401/402, 403, 801/802
DTX-1557	COOK3P_BSCvMT	COOK3P_BSCvMT	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Expert Report of John R. Bone		401/402, 403
DTX-1558	COOK3P_BSCvMT	COOK3P_BSCvMT	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Reply Expert Report of John R. Bone		401/402, 403
DTX-1559	COOK3P_BSCvMT	COOK3P_BSCvMT	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Expert Report of John R. Bone		401/402, 403
DTX-1560	COOK3P_BSCvMT	COOK3P_BSCvMT	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Reply Expert Report of John R. Bone		401/402, 403
DTX-1561			Plaintiffs Responses to Defendant's First Set of Requests for Production of Documents and Things (Nos. 1-45)		401/402, 403, 801/802, AA, Legal
DTX-1562			Defendants' Responses to Plaintiffs First Set of Common Requests for Production of Documents (Nos. 1-40)		401/402, 403, 801/802, AA, Legal
DTX-1563			Defendants' Responses to Plaintiffs' First Set of Common Interrogatories (Nos. 1-10)		401/402, 403, 801/802, AA, Legal
DTX-1564			Plaintiff's Responses to Defendants' Second Set of Requests for Production of Documents and Things		401/402, 403, 801/802, AA, Legal
DTX-1565			Defendants' Responses to Plaintiffs' Second Sdet of Common Interrogatories (No. 11)		401/402, 403, 801/802, AA, Legal
DTX-1566			Defendant Micro-Tech (Nanjing) Co. Ltd.'s Responses to Plaintiffs' First Set of Common Requests for Documents and Things (Nos. 1-40)		401/402, 403, 801/802, AA, Legal
DTX-1567			Defendant Micro-Tech (Nanjing) Co. Ltd.'s Responses to Plaintiffs' First Set of Common Interrogatories (Nos. 1-10)		401/402, 403, 801/802, AA, Legal
DTX-1568			Plaintiffs' Objections to Defendants' Third Set of Requests for Production of Documents		401/402, 403, 801/802, AA, Legal
DTX-1569			Plaintiffs' Objections to Defendants' Fourth Set of Requests for Production of Documents		401/402, 403, 801/802, AA, Legal

Schedule 8 - Defendants' Trial Exhibit List

DTX-1570		Verification of Defendant Micro-Tech (Nanjing) Co. Ltd.'s Supplemental Responses to Plaintiffs' First Set of Common Interrogatories (Nos. 1-10)		401/402, 403, 801/802, AA, Legal
DTX-1571		Defendants' Reponses to Plaintiffs' First Set of Requests for Admission (Nos. 1-5)		401/402, 403, 801/802, AA, Legal
DTX-1572		Defendants' Second Supplemental Responses to Plaintiffs' First Set of Common Interrogatories		401/402, 403, 801/802, AA, Legal
DTX-1573		Verification of Henry Schein's Responses to Plaintiffs' First Set of Common Interrogatories (Nos. 1-10)		401/402, 403, 801/802, AA, Legal
DTX-1574		Defendant Henry Schein's Supplemental Responses to Defendants' First and Second Sets of Common Interrogatories		401/402, 403, 801/802, AA, Legal
DTX-1575		Defendants' Supplemental Responses to Defendants' First and Second Sets of Common Interrogatories		401/402, 403, 801/802, AA, Legal
DTX-1576		U.S. Patent No. 8,685,048 by Adams et al.		401/402, 403
DTX-1577		U.S. Patent No. 9,138,234 by Li et al.		401/402, 403
DTX-1578		U.S. Patent No. 10,470,775 by Shi		401/402, 403
DTX-1579		510(k) Premarket Notification for Anrei Medical (Hangzhou) Co., FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201771.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201771.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1580		510(k) Premarket Notification for Finemedix Co., Ltd.,FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183021.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183021.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1581		510(k) Premarket Notification for Finemedix Co., Ltd, DA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200217.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200217.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1582		510(k) Premarket Notification for Hangzhou AGS MedTech CO., Ltd, FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172727.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172727.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1583		510(k) Premarket Notification for Zhejiang Chuangxiang Medical Technology Co, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172762.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172762.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1584		510(k) Premarket Notification, FDA, < <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1585		510(k) Premarket Notification AGS Hemoclip (K172727), FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172727.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172727.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1586		510(k) Premarket Notification Anrei Single Use Rotatable, FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183021.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183021.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1587		510(k) Premarket Notification Finemedix ClearEndoclip (K200217) < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200217.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200217.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1588		510(k) Premarket Notification Olympus (K123601), , < <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K123601">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K123601</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1589		510(k) Premarket Notification Single Use Hemoclip (K172762), FDA, March 20, 2018, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172762.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172762.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1590		510(k) Submission Process, FDA, , < <a href="https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process">https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process</a> >.		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1591		510K Summary (Instinct Endoscopic Hemoclip), FDA, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf13/K132809.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf13/K132809.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL

Schedule 8 - Defendants' Trial Exhibit List

DTX-1592		2016 Hangzhou AGS MedTech Co., Ltd. annual new product promotion, AGS Medtech, < <a href="http://www.bioags.com/home.php?s=/articles_334.html&amp;lan=en">http://www.bioags.com/home.php?s=/articles_334.html&amp;lan=en</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1593		About Us, Endo-Therapeutics, < <a href="https://endotherapeutics.com/about-us">https://endotherapeutics.com/about-us</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1594		About US, KeySurgical, < <a href="https://www.keysurgical.com/about">https://www.keysurgical.com/about</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1595		About Us, MT Nanjing, < <a href="http://www.micro-tech.com.cn/en/web/about/about_us_1.html">http://www.micro-tech.com.cn/en/web/about/about_us_1.html</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1596		Access GUDID National Institute of Health, < <a href="https://accessgudid.nlm.nih.gov/">https://accessgudid.nlm.nih.gov</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1597		Access GUDID, National Institute of Health, < <a href="https://accessgudid.nlm.nih.gov/devices/00849771039181">https://accessgudid.nlm.nih.gov/devices/00849771039181</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1598		Access GUDID, National Institute of Health, < <a href="https://accessgudid.nlm.nih.gov/devices/08809327353088">https://accessgudid.nlm.nih.gov/devices/08809327353088</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1599		AGS Medtech Hemoclip, < <a href="http://www.bioags.com/home.php?s=/lists_71.html">http://www.bioags.com/home.php?s=/lists_71.html</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1600		Ambulatory Surgery Center Growth Accelerates Is Medtech Ready, Bain & Company, September 23, 2019, < <a href="https://www.bain.com/insights/ambulatory-surgery-center-growth-accelerates-is-medtech-ready">https://www.bain.com/insights/ambulatory-surgery-center-growth-accelerates-is-medtech-ready</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1601		Ambulatory Surgery Centers Are High-Quality, Low-Cost Key for Outpatient, Inside Digital Health, < <a href="https://www.chiefhealthcareexecutive.com/view/ambulatory-surgery-centers-are-highquality-lowcost-key-for-outpatient-procedures">https://www.chiefhealthcareexecutive.com/view/ambulatory-surgery-centers-are-highquality-lowcost-key-for-outpatient-procedures</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1602		ASCs at a Tipping Point: The New Reality of Surgical Services for Health, Health Systems 100 – Leadership Conference, < <a href="https://www.healthsystem100.com/application/files/8615/0420/6320/ASCs_at_a_Tipping_Point_-Whitepaper.pdf">https://www.healthsystem100.com/application/files/8615/0420/6320/ASCs_at_a_Tipping_Point_-Whitepaper.pdf</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1603		Benchtop testing and comparisons among three types of through-the-scope, , Division of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center, January 5, 2013, < <a href="https://pubmed.ncbi.nlm.nih.gov/23292554/">https://pubmed.ncbi.nlm.nih.gov/23292554</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1604		Class 2 Device Recall Resolution II Clip FDA initiated July 19 2011, FDA, initiated July 19, 2011, < <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=102859">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=102859</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1605		ClearEndoclip, Finemedix, " Finemedix, < <a href="http://www.finemedix.com/en/pf/clearendoclip">http://www.finemedix.com/en/pf/clearendoclip</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1606		Clip Device, Zhiji Pengtian Medical Equipment Co., Ltd., < <a href="https://www.pengtianmed.com/product/jiazizhuangzhi/jiazizhuangzhi.html">https://www.pengtianmed.com/product/jiazizhuangzhi/jiazizhuangzhi.html</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1607		Clip Fixing Devices, Olympus, < <a href="https://medical.olympusamerica.com/products/quickclipro">https://medical.olympusamerica.com/products/quickclipro</a> >.		401/402, 403, 801/802, 901/902, 1003

Schedule 8 - Defendants' Trial Exhibit List

DTX-1608		Commercial Insurance Cost Savings in Ambulatory Surgery, SCA – HealthSmart, < <a href="https://www.ascassociation.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=829b1dd6-0b5d-9686-e57c-3e2ed4ab42ca">https://www.ascassociation.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=829b1dd6-0b5d-9686-e57c-3e2ed4ab42ca</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1609		Company Profile, Micro-Tech (Nanjing) Co., Ltd., < <a href="http://www.micro-tech.com.cn/en/web/about/about_us_1.html">http://www.micro-tech.com.cn/en/web/about/about_us_1.html</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1610		Device for endoscopic hemostasis of nonvariceal GI Bleeding American Society for Gastrointestinal, American Society for Gastrointestinal Endoscopy, Volume 4, No. 7, 2019, < <a href="https://www.videogie.org/article/S2468-4481(19)30042-6/pdf">https://www.videogie.org/article/S2468-4481(19)30042-6/pdf</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1611		DuraClip Brochure (U.S. Only) ConMed, , < <a href="https://www.conmed.com/-/media/conmed/documents/literature/mcm2016089-duraclip-brochureus-only3lr.ashx">https://www.conmed.com/-/media/conmed/documents/literature/mcm2016089-duraclip-brochureus-only3lr.ashx</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1612		DuraClip Brochure ConMed, , < <a href="https://www.conmed.com/-/media/conmed/documents/literature/mcm2015188-rev-a-duraclip-product-brochure-rev-lr.ashx">https://www.conmed.com/-/media/conmed/documents/literature/mcm2015188-rev-a-duraclip-product-brochure-rev-lr.ashx</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1613		DuraClip Repositionable Hemostasis Clip, ConMed < <a href="https://www.conmed.com/en/medical-specialties/gastroenterology-and-pulmonology/polypectomy/conmed-solutions/duraclip-repositionable-hemostasis-clips">https://www.conmed.com/en/medical-specialties/gastroenterology-and-pulmonology/polypectomy/conmed-solutions/duraclip-repositionable-hemostasis-clips</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1614		Endoscopic clip application devices, American Society for Gastrointestinal Endoscopy, 2006, < <a href="https://www.asge.org/docs/default-source/education/Technology_Reviews/doc-090e3f1186fe4bc194845c2dbaa48c7e.pdf">https://www.asge.org/docs/default-source/education/Technology_Reviews/doc-090e3f1186fe4bc194845c2dbaa48c7e.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1615		Endoscopic clips Past, present, and future, Canadian Journal of Gastroenterology, Canadian Journal of Gastroenterology, < <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694648/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694648/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1616		Endoscopic closure devices A review of technique and application for hemostasis, International Journal of Gastrointestinal Intervention (IJGII), July 31, 2019, < <a href="https://www.ijgii.org/journal/view.html?doi=10.18528/jgii190012#B8">https://www.ijgii.org/journal/view.html?doi=10.18528/jgii190012#B8</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1617		Frequently Asked Questions, Zhiji Pengtian Medical Equipment Co., Ltd., < <a href="https://www.pengtianmed.com/product/jiazizhuangzhi/jiazizhuangzhi.html">https://www.pengtianmed.com/product/jiazizhuangzhi/jiazizhuangzhi.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1618		Gastrenterology and Pulmonary Product Catalog, ConMed, p. 17, < <a href="https://www.conmed.com/-/media/conmed/documents/catalog/20191016_cet_-gastroenterology-and-pulmonary-product-catalog_lr.ashx">https://www.conmed.com/-/media/conmed/documents/catalog/20191016_cet_-gastroenterology-and-pulmonary-product-catalog_lr.ashx</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1619		Hawk Clip, Anrei Medical, < <a href="http://www.anrei.com.cn/en/prodt.aspx?N_id=927">http://www.anrei.com.cn/en/prodt.aspx?N_id=927</a> >		401/402, 403, 801/802, 901/902, 1003

Schedule 8 - Defendants' Trial Exhibit List

DTX-1620		HemoClip Life Partners Europe, May 9, 2016, < <a href="https://www.vingmed.se/wp-content/uploads/2013/10/Hemoclip.pdf">https://www.vingmed.se/wp-content/uploads/2013/10/Hemoclip.pdf</a> > (distributed by Life Partners, manufactured by Nova Lightsystems		401/402, 403, 801/802, 901/902, 1003
DTX-1621		Hemostasis Clip, KeySurgical, < <a href="https://www.keysurgical.com/products/endoscopy/clinical-products/hemoclips/en10400a-16">https://www.keysurgical.com/products/endoscopy/clinical-products/hemoclips/en10400a-16</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1622		Hemostasis Clip, KeySurgical, < <a href="https://www.keysurgical.com/products/endoscopy/clinical-products/hemoclips/en10400a">https://www.keysurgical.com/products/endoscopy/clinical-products/hemoclips/en10400a</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1623		Endo-Therapeutics Home Page, < <a href="https://endotherapeutics.com/">https://endotherapeutics.com/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1624		How ASCs and Endoscopy Centers Can Reduce Costs with Quality Products ConMed, June 2020, < <a href="https://www.conmed.com/-/media/conmed/documents/literature/20191881_cet_ascs_endoscopybrochure.ashx">https://www.conmed.com/-/media/conmed/documents/literature/20191881_cet_ascs_endoscopybrochure.ashx</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1625		Irreparable Injury, Cornell Law School, < <a href="https://www.law.cornell.edu/wex/irreparable_injury">https://www.law.cornell.edu/wex/irreparable_injury</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1626		K151802 (Resolution 360 Clip) FDA 510k Approval FDA, August 6, 2015, < <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf15/K151802.pdf">https://www.accessdata.fda.gov/cdrh_docs/pdf15/K151802.pdf</a> >		401/402, 403, 801/802, 901/902, 1003, PMIL
DTX-1627		Lockado Hemostasis Clip, Micro-Tech Endoscopy, < <a href="https://www.mtendoscopy.com/products/hemostasis-2/lockado-hemostasis-clip/">https://www.mtendoscopy.com/products/hemostasis-2/lockado-hemostasis-clip/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1628		Lockado Product Information Sheet, Micro-Tech Endoscopy, < <a href="https://www.mtendoscopy.com/wp-content/uploads/2020/08/Lockado_MPW30800A-Rev-2-FNL.pdf">https://www.mtendoscopy.com/wp-content/uploads/2020/08/Lockado_MPW30800A-Rev-2-FNL.pdf</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1629		Management of Surgical Hemostasis Independent Study Guide, Association of periOperative Registered Nurses (AORN), 2013, < <a href="https://www.aorn.org/-/media/aorn/guidelines/tool-kits/medication-safety/management-of-surgical-hemostasis-independent-study-guide.pdf">https://www.aorn.org/-/media/aorn/guidelines/tool-kits/medication-safety/management-of-surgical-hemostasis-independent-study-guide.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1630		Micro-Tech Endoscopy – About, Micro-Tech, < <a href="https://mtendoscopy.com/ambulatory-surgery-centers/about/">https://mtendoscopy.com/ambulatory-surgery-centers/about/</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1631		Micro-Tech Endoscopy Product Catalog Micro-Tech, < <a href="https://www.mtendoscopy.com/wp-content/uploads/2018/11/MTE_Catalog_MPW001-Rev-5.pdf">https://www.mtendoscopy.com/wp-content/uploads/2018/11/MTE_Catalog_MPW001-Rev-5.pdf</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1632		Microtech Endoscopy Unmatched Endoscopy Solutions at an Economical Price, Med Tech Outlook, Med Tech Outlook, < <a href="https://endoscopy.medicaltechoutlook.com/vendor/microtech-endoscopy-unmatched-endoscopy-solutions-at-an-economical-price-cid-77-mid-12.html">https://endoscopy.medicaltechoutlook.com/vendor/microtech-endoscopy-unmatched-endoscopy-solutions-at-an-economical-price-cid-77-mid-12.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1633		Micro-Tech Endoscopy USA, Micro-Tech, < <a href="https://mtendoscopy.com/ambulatory-surgery-centers/">https://mtendoscopy.com/ambulatory-surgery-centers/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1634		Olympus Launches New Hemostasis Clip with Advanced Control for GI Endoscopy, Olympus, < <a href="https://medical.olympusamerica.com/articles/olympus-launches-new-hemostasis-clip-advanced-control-gi-endoscopy">https://medical.olympusamerica.com/articles/olympus-launches-new-hemostasis-clip-advanced-control-gi-endoscopy</a> >		401/402, 403, 801/802, 901/902, 1003

Schedule 8 - Defendants' Trial Exhibit List

DTX-1635		Providers, Arizona Centers for Digestive Health, < <a href="https://azcdh.com/providers/">https://azcdh.com/providers/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1636		RePlay Hemostasis Clip Diversatek, < <a href="https://www.diversatekhealthcare.com/wp-content/uploads/2019/10/DiversatekHealthcare_RePlay_HemostasisClip_Brochure.pdf">https://www.diversatekhealthcare.com/wp-content/uploads/2019/10/DiversatekHealthcare_RePlay_HemostasisClip_Brochure.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1637		RePlay Hemostasis Clip Instructions for Use Diversatek, September 2018, < <a href="http://www.diversatekhealthcare.com/wp-content/uploads/2018/09/063-0055-rev.-B-Website-IFU-RePlay.pdf">http://www.diversatekhealthcare.com/wp-content/uploads/2018/09/063-0055-rev.-B-Website-IFU-RePlay.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1638		RePlay Hemostasis Clips, Diversatek, < <a href="https://www.diversatekhealthcare.com/replay-hemostasis-clip/">https://www.diversatekhealthcare.com/replay-hemostasis-clip/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1639		Resolution 360 Ultra Clip, BSC, < <a href="https://www.bostonscientific.com/en-EU/products/clips/resolution-360-ultra-clip.html">https://www.bostonscientific.com/en-EU/products/clips/resolution-360-ultra-clip.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1640		Resolution 360 Clip, < <a href="https://www.bostonscientific.com/content/gwc/en-US/products/clips/Resolution-360-Clip.html">https://www.bostonscientific.com/content/gwc/en-US/products/clips/Resolution-360-Clip.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1641		Resolution 360 Clip Product Information, < <a href="https://www.bostonscientific.com/content/dam/bostonscientific/endo/portfolio-group/resolution-clip/Resolution-360-Clip/Resolution_360_eBrochure.pdf">https://www.bostonscientific.com/content/dam/bostonscientific/endo/portfolio-group/resolution-clip/Resolution-360-Clip/Resolution_360_eBrochure.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1642		Resolution 360 Clip Product Information, < <a href="https://www.bostonscientific.com/content/gwc/en-US/products/clips/Resolution-360-Clip.html">https://www.bostonscientific.com/content/gwc/en-US/products/clips/Resolution-360-Clip.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1643		Resolution 360 Clip Brochure, < <a href="https://www.bostonscientific.com/content/dam/bostonscientific/endo/portfolio-group/resolution-clip/Resolution-360-Clip/Resolution_360_eBrochure.pdf">https://www.bostonscientific.com/content/dam/bostonscientific/endo/portfolio-group/resolution-clip/Resolution-360-Clip/Resolution_360_eBrochure.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1644		Resolution Clip Product Information, < <a href="https://www.bostonscientific.com/content/gwc/en-US/products/clips/resolution-clip.html">https://www.bostonscientific.com/content/gwc/en-US/products/clips/resolution-clip.html</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1645		SciMed Medical Equipment and Products, Medwrench, < <a href="https://www.medwrench.com/manufacturer/2280/scimed">https://www.medwrench.com/manufacturer/2280/scimed</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1646		Services Page - Endo-Therapeutics, Inc., < <a href="https://endotherapeutics.com/services/">https://endotherapeutics.com/services/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1647		Single Use Hemoclip (06970401811212) – K172762, National Institute of Health, < <a href="https://accessguides.nlm.nih.gov/devices/06970401811212">https://accessguides.nlm.nih.gov/devices/06970401811212</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1648		Single Use Hemoclip Product Information < <a href="http://www.med-nova.com/en/product-details.asp?Id=443">http://www.med-nova.com/en/product-details.asp?Id=443</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1649		Single Use Hemoclip Product Information < <a href="http://www.med-nova.com/en/product-details.asp?Id=443">http://www.med-nova.com/en/product-details.asp?Id=443</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1650		Single Use Hemoclip, Anrei Medical, < <a href="http://www.medincn.com/sell_offers/180415/Single-Use-Hemoclip.html">http://www.medincn.com/sell_offers/180415/Single-Use-Hemoclip.html</a> >.		401/402, 403, 801/802, 901/902, 1003
DTX-1651		Single Use Hemoclip, Mednova Zhejiang Chuangxiang Medical Technology Co., LTD, < <a href="http://www.med-nova.com/en/product-details.asp?Id=443">http://www.med-nova.com/en/product-details.asp?Id=443</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1652		Micro-Tech Product Information < <a href="https://mtendoscopy.com/products/hemostasis-2/sureclip/">https://mtendoscopy.com/products/hemostasis-2/sureclip/</a> >		401/402, 403, 801/802, 901/902, 1003

Schedule 8 - Defendants' Trial Exhibit List

DTX-1653			SureClip Product Information < <a href="https://mtendoscopy.com/wp-content/uploads/2019/10/SureClip_MPW30000R_Rev5.pdf">https://mtendoscopy.com/wp-content/uploads/2019/10/SureClip_MPW30000R_Rev5.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1654			SureClip Product Information < <a href="https://mtendoscopy.com/wp-content/uploads/2019/08/SureClip_MPW30000-Rev.8.pdf">https://mtendoscopy.com/wp-content/uploads/2019/08/SureClip_MPW30000-Rev.8.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1655			SureClip Hemostasis Clip Brochure< <a href="https://mtendoscopy.com/wp-content/uploads/2019/10/SureClip_MPW30000R_Rev5.pdf">https://mtendoscopy.com/wp-content/uploads/2019/10/SureClip_MPW30000R_Rev5.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1656			SureClip Hemostasis Clip Product Sheet< <a href="https://mtendoscopy.com/wp-content/uploads/2019/08/SureClip_MPW30000-Rev.8.pdf">https://mtendoscopy.com/wp-content/uploads/2019/08/SureClip_MPW30000-Rev.8.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1657			SureClip Hemostatic 11mm 165cm 2 Pk		401/402, 403, 801/802, 901/902, 1003
DTX-1658			SureClip Hemostatic 11mm 165cm 10 Bx		401/402, 403, 801/802, 901/902, 1003
DTX-1659			SureClip Hemostatic 11mm 235cm 2 Pk		401/402, 403, 801/802, 901/902, 1003
DTX-1660			SureClip Hemostatic 11mm 235cm 10 Bx		401/402, 403, 801/802, 901/902, 1003
DTX-1661			The History of Clips in Endoscopy, Cook Medical, < <a href="https://www.cookmedical.com/endoscopy/the-history-of-clips-in-endoscopy/">https://www.cookmedical.com/endoscopy/the-history-of-clips-in-endoscopy/</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1662			Transfer Pricing - Establishing Policy for an MNC, Deloitte, 2015, < <a href="https://www.bcasonline.org/files/res_material/resfiles/0602162401EstablishingTransferPricingpolicyforMNC's2014-7March2015-FINAL.pdf">https://www.bcasonline.org/files/res_material/resfiles/0602162401EstablishingTransferPricingpolicyforMNC's2014-7March2015-FINAL.pdf</a> >		401/402, 403, 801/802, 901/902, 1003
DTX-1663			Upper and lower digestive tract diagnosis and treatment series, <a href="http://www.bioags.com/home.php?se=lists_71.html">www.bioags.com/home.php?se=lists_71.html</a>		401/402, 403, 801/802, 901/902, 1003
DTX-1664			Zhejiang Chuangxiang Medical Technology_Show Chinese Entrepreneurship AND Pursue Excellence, <a href="http://www.med-nova.com/en/news-details.asp?id=366">www.med-nova.com/en/news-details.asp?id=366</a>		401/402, 403, 801/802, 901/902, 1003
DTX-1665	BSC-MT-122195	BSC-MT-122293	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of M. Sprague		401/402, 403, 801/802, AA, Legal, MC
DTX-1666	BSC-MT-122433	BSC-MT-122522	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Kevin Wilcox		401/402, 403, 801/802, AA, Legal, MC
DTX-1667	BSC-MT-123034	BSC-MT-123162	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Christopher Davis		401/402, 403, 801/802, AA, Legal, MC
DTX-1668	BSC-MT-123419	BSC-MT-123473	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Javier Jimenez		401/402, 403, 801/802, AA, Legal, MC
DTX-1669	BSC-MT-123529	BSC-MT-123568	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Peter Gafner		401/402, 403, 801/802, AA, Legal, MC
DTX-1670	BSC-MT-123651	BSC-MT-123735	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition Transcript of Marcia Nardone		401/402, 403, 801/802, AA, Legal, MC
DTX-1671	BSC-MT-123176	BSC-MT-123251	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Hearing Transcript		401/402, 403, 801/802, AA, Legal, MC
DTX-1672	BSC-MT-118046	BSC-MT-118095	Boston Scientific - Resolution Clip - Competitive Handling Tool		401/402, 403, 801/802
DTX-1673	HS00000002	HS00000003	Product Information		401/402, 403, 801/802
DTX-1674			Expert Report of Gary Reiss	Reiss Deposition Ex. 1	701/702, 801/802, 901/902, 1006
DTX-1675			Curriculum vitae of G. Reiss		

Schedule 8 - Defendants' Trial Exhibit List

DTX-1676		List of Materials Considered		
DTX-1677		510(K) Summary (2004)		401/402, 403, 801/802, PMIL
DTX-1678		DuraClip Brochure		401/402, 403, 801/802
DTX-1679		Haider, Gastroenterology and Hepatology (2010)		401/402, 403, 801/802
DTX-1680		Jensen, Gastrointestinal Endoscopy (2009)		401/402, 403, 801/802
DTX-1681		Lockado Hemostasis Clip Micro-Tech Endoscopy USA Inc		401/402, 403, 801/802
DTX-1682		Lockado Product Information Sheet		401/402, 403, 801/802
DTX-1683		Maiss et al., Gastrointestinal Endoscopy (2008)		401/402, 403, 801/802
DTX-1684		Maiss, Gastrointestinal Endoscopy (2006)		401/402, 403, 801/802
DTX-1685		Raju, Gastroenterology (2002)		401/402, 403, 801/802
DTX-1686		Resolution 360 eBrochure		401/402, 403, 801/802
DTX-1687		ResolutionClip - Boston Scientific - Boston Scientific		401/402, 403, 801/802
DTX-1688		Saxena et al., Saudi Journal Gastroenterology (2014)		401/402, 403, 801/802
DTX-1689		SureClip Micro-Tech Endoscopy USA Inc		401/402, 403, 801/802
DTX-1690		SureClip_MPW30000R_Rev5		401/402, 403, 801/802
DTX-1691		SureClip_MPW30000-Rev.8		401/402, 403, 801/802
DTX-1692		Tang, Surgical Endoscopy (2013)		401/402, 403, 801/802
DTX-1693		Use of Endoclip - Gastroenterology Education and CPD for trainees and specialists		401/402, 403, 801/802
DTX-1694		Wellington et al., Endoscopic Closure Devices (2019)		401/402, 403, 801/802
DTX-1695		Yeh et al., Techniques in Gastrointestinal Endoscopy (2006)		401/402, 403, 801/802
DTX-1696	BSC-MT-123474	BSC-MT-123528	Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Cook Group Inc. and Cook Medical LLC: Deposition of Jennifer Kimball	401/402, 403, 801/802, AA, Legal, MC
DTX-1697	BSC-MT-002207	BSC-MT-002209	USPTO Notice of Recordation of Assignment	401/402, 403, 801/802
DTX-1698	BSC-MT-002451	BSC-MT-002452	Patent Assignment Cover Sheet	401/402, 403, 801/802
DTX-1699	BSC-MT-002489	BSC-MT-002489	USPTO Notice of Recordation of Assignment	401/402, 403, 801/802
DTX-1700	BSC-MT-002719	BSC-MT-002729	USPTO Combined Declaration and Assignment	401/402, 403, 801/802
DTX-1701	BSC-MT-021252	BSC-MT-021256	Letter Re Consulting Agreement between CURE Foundation, Dennis Jensen and Boston Scientific Corp.	401/402, 403, 801/802
DTX-1702	BSC-MT-021292	BSC-MT-021296	Letter Re Consulting Agreement between CURE Foundation, Dennis Jensen and Boston Scientific Corp.	401/402, 403, 801/802
DTX-1703	BSC-MT-026949	BSC-MT-026950	Boston Scientific Microvasive Memorandum	401/402, 403, 801/802
DTX-1704	BSC-MT-028782	BSC-MT-028783	Boston Scientific Microvasive Memorandum	401/402, 403, 801/802
DTX-1705	BSC-MT-033584	BSC-MT-033586	Amendment No. 15 to Supply Agreement between MedVenture and Boston Scientific	401/402, 403, 801/802
DTX-1706	BSC-MT-040085	BSC-MT-040190	Endoscopic Clipping Systems Investigation	401/402, 403, 801/802
DTX-1707	BSC-MT-046254	BSC-MT-046347	Investigator Sponsored Study Agreement	401/402, 403, 801/802
DTX-1708	BSC-MT-075312	BSC-MT-075312	Excel Spreadsheet, Forecasting Tool Hemo F3 2014 8.11.14	401/402, 403, 801/802
DTX-1709	BSC-MT-075512	BSC-MT-075518	Resolution Design Validation Plan	401/402, 403, 801/802
DTX-1710	BSC-MT-075981	BSC-MT-075981	Excel Spreadsheet, Hemo Clip Feedback US Customers	401/402, 403, 801/802
DTX-1711	BSC-MT-091961	BSC-MT-091961	Excel Spreadsheet, Freudenburg - Medventure Invoice Details	401/402, 403, 801/802
DTX-1712	BSC-MT-136192	BSC-MT-136200	Resolution 360 Product Performance Qualification Protocol	401/402, 403, 801/802
DTX-1713	BSC-MT-137051	BSC-MT-137056	Boston Scientific Purchase Requisition	401/402, 403, 801/802
DTX-1714	BSC-MT-137098	BSC-MT-137109	Fraunhofer Project Proposal - Flexible Shaft Processing System	401/402, 403, 801/802
DTX-1715	BSC-MT-137110	BSC-MT-137116	Fraunhofer Project Proposal - Improvements, Shipping Preparation, Installation and Training for the Shaft Processing System	401/402, 403, 801/802
DTX-1716	BSC-MT-137117	BSC-MT-137131	Master Services Agreement between BSC and Fraunhofer USA	401/402, 403, 801/802
DTX-1717	BSC-MT-137138	BSC-MT-137140	Boston Scientific - Global Form Supplier Change Impact Assessment	401/402, 403, 801/802
DTX-1718	BSC-MT-137263	BSC-MT-137277	Master Services Agreement between BSC and MedVenture	401/402, 403, 801/802

Schedule 8 - Defendants' Trial Exhibit List

DTX-1719	BSC-MT-137278	BSC-MT-137305	Supply Agreement between MedVenture and BSC		401/402, 403, 801/802
DTX-1720	BSC-MT-137306	BSC-MT-137319	Quality System Plan - Rotatable Resolution Clip		401/402, 403, 801/802
DTX-1721	BSC-MT-137325	BSC-MT-137340	Quality System Plan - Rotatable Resolution Clip		401/402, 403, 801/802
DTX-1722	BSC-MT-137418	BSC-MT-137434	Quality System Plan - Resolution 360 Clip		401/402, 403, 801/802
DTX-1723	BSC-MT-140705	BSC-MT-140705	Excel Spreadsheet, Copy of Scrap Res Clips 2012-2020		401/402, 403, 801/802
DTX-1724	BSC-MT-140706	BSC-MT-140706	Excel Spreadsheet, Copy of MT Litigation BSC Financials		401/402, 403, 801/802
DTX-1725	BSC-MT-140707	BSC-MT-140707	Excel Spreadsheet, 2004 to 2021 Sales		401/402, 403, 801/802
DTX-1726	BSC-MT-140708	BSC-MT-140708	Excel Spreadsheet, US Global PL 2011 to 2020 (3.11.2020)		401/402, 403, 801/802
DTX-1727			Exhibit Intentionally Omitted		
DTX-1728			Notice of Deposition of Vance Brown	Brown Deposition Ex. 101	401/402, 403, 801/802, AA, Legal
DTX-1729	BSC-MT-116639	BSC-MT-116649	Agreement for Sharing Research and Development Costs between Scimed and Bostin Scientific Ltd.	Brown Deposition Ex. 102	401/402, 403, 801/802
DTX-1730	BSC-MT-116650	BSC-MT-116662	Amended and Restated Agreement for Sharing Research and Development Costs between Scimed and Bostin Scientific Ltd.	Brown Deposition Ex. 103	401/402, 403, 801/802
DTX-1731	BSC-MT-116663	BSC-MT-116679	Second Amended and Restated Agreement for Sharing Research and Development Costs between Scimed and Bostin Scientific Ltd.	Brown Deposition Ex. 104	401/402, 403, 801/802
DTX-1732	BSC-MT-140092	BSC-MT-140110	Third Amended and Restated Agreement for Sharing Research and Development Costs between Scimed and Bostin Scientific Ltd.	Brown Deposition Ex. 105	401/402, 403, 801/802
DTX-1733	BSC-MT-140135	BSC-MT-140140	Amended and Restated Agreement for Sharing Intangible Development Costs between Boston Scientific Ltd. And Boston Scientific de Costa Rica	Brown Deposition Ex.106	401/402, 403, 801/802
DTX-1734	BSC-MT-140116	BSC-MT-140123	Intellectual Property Transfer Agreement between Boston Scientific Ltd. And Boston Scientific Medical Device Ltd.	Brown Deposition Ex.107	401/402, 403, 801/802
DTX-1735	BSC-MT-116614	BSC-MT-116626	Distributorship Agreement between BSS and BSC	Brown Deposition Ex. 108	401/402, 403, 801/802
DTX-1736	BSC-MT-116605	BSC-MT-116613	Agreement for Contract Research and Development between Scimed and BSC	Brown Deposition Ex. 109	401/402, 403, 801/802
DTX-1737	BSC-MT-140065	BSC-MT-140073	International Distribution Agreement between BSL abd BSC	Brown Deposition Ex. 110	401/402, 403, 801/802
DTX-1738	BSC-MT-140696	BSC-MT-140704	FDA Letter		401/402, 403, 801/802, ID
DTX-1739	BSC-MT-140709	BSC-MT-140709	OPEX Detail		401/402, 403, 801/802
DTX-1740			Expert Report of John R. Bone, CPA, CFF	Bone Deposition Ex. 1	
DTX-1741			Curriculum Vitae of J. Bone	Bone Deposition Ex. 2	
DTX-1742			List of Documents Considered Re Expert Report	Bone Deposition Ex. 3	
DTX-1743			Exhibits1-26.1 to Expert Report of J. Bone	Bone Deposition Ex. 4	
DTX-1744			Reply Expert Report of John R. Bone, CPA, CFF dated December 16, 2020	Bone Deposition Ex.5	
DTX-1745			Errata to Expert Report of John R. Bone, CPA, CFF dated October 23, 2020	Bone Deposition Ex. 6	
DTX-1746			Opening Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725	Leinsing Deposition Ex. 131	
DTX-1747			Reply Expert Report of Karl R. Leinsing Regarding Infringement of U.S. Patent Nos. 7,094,245, 8,974,371, and 9,980,725	Leinsing Deposition Ex. 132	
DTX-1748			Exhibit K - Opening Expert Report of Karl R. Leinsing	Leinsing Deposition Ex. 133	
DTX-1749			Exhibit B – Materials Considered - Opening Expert Report of Karl R. Leinsing	Leinsing Deposition Ex. 134	
DTX-1750			Exhibit Intentionally Omitted		
DTX-1751			Image 1	Leinsing Deposition Ex. 136	401/402, 403, 801/802, MC
DTX-1752			Image 2	Leinsing Deposition Ex. 137	401/402, 403, 801/802, MC
DTX-1753			Image 3	Leinsing Deposition Ex. 138	401/402, 403, 801/802, MC
DTX-1754			Image 4	Leinsing Deposition Ex. 139	401/402, 403, 801/802, MC

Schedule 8 - Defendants' Trial Exhibit List

DTX-1755		Image 5	Leinsing Deposition Ex. 140	401/402, 403, 801/802, MC
DTX-1756		Image 6	Leinsing Deposition Ex. 141	401/402, 403, 801/802, MC
DTX-1757		Image 7	Leinsing Deposition Ex. 142	401/402, 403, 801/802, MC
DTX-1758		Image 8	Leinsing Deposition Ex. 143	401/402, 403, 801/802, MC
DTX-1759		Image 9	Leinsing Deposition Ex. 144	401/402, 403, 801/802, MC
DTX-1760		Image 10	Leinsing Deposition Ex. 145	401/402, 403, 801/802, MC
DTX-1761		Image 11	Leinsing Deposition Ex. 146	401/402, 403, 801/802, MC
DTX-1762		Image 12	Leinsing Deposition Ex. 147	401/402, 403, 801/802, MC
DTX-1763		Image 13	Leinsing Deposition Ex. 148	401/402, 403, 801/802, MC
DTX-1764		Image 14	Leinsing Deposition Ex. 149	401/402, 403, 801/802, MC
DTX-1765		Image 15	Leinsing Deposition Ex. 150	401/402, 403, 801/802, MC
DTX-1766		Image 16	Leinsing Deposition Ex. 151	401/402, 403, 801/802, MC
DTX-1767		Image 20	Leinsing Deposition Ex. 152	401/402, 403, 801/802, MC
DTX-1768		Image 21	Leinsing Deposition Ex. 153	401/402, 403, 801/802, MC
DTX-1769		Image 22	Leinsing Deposition Ex. 154	401/402, 403, 801/802, MC
DTX-1770		Image 23	Leinsing Deposition Ex. 155	401/402, 403, 801/802, MC
DTX-1771		Image 24	Leinsing Deposition Ex. 156	401/402, 403, 801/802, MC
DTX-1772		Image 25	Leinsing Deposition Ex. 157	401/402, 403, 801/802, MC
DTX-1773		Image 27	Leinsing Deposition Ex. 158	401/402, 403, 801/802, MC
DTX-1774		Rebuttal Expert Report of Karl R. Leinsing Regarding Validity of U.S. Patent Nos. 7,094,245; 8,974,371; and 9,980,725	Leinsing Deposition Ex. 159	
DTX-1775	OAI000001	OAI000075	Olympus EndoTherapy – Instructions – Rotatable Clip Fixing Device	Leinsing Deposition Ex. 160
DTX-1776			U.S. Patent App. Publication 2002/0045909 by Kimura et al.	Leinsing Deposition Ex. 161
DTX-1777			U.S. Patent App. Publication 2003/0069592 by Adams et al.	Leinsing Deposition Ex. 162
DTX-1778			U.S. Patent App. Publication 2002/0177861 by Sugiayama et al.	Leinsing Deposition Ex. 163
DTX-1779			Expert Report of Dr. Oleh Haluska dated October 23, 2020	Haluska Deposition Ex. 164
DTX-1780			Reply Expert Report of Dr. Oleh Haluska dated December 16, 2020	Haluska Deposition Ex. 165
DTX-1781			Excerpts from EPO Opposition Proceeding for EP No. 1328199	401/402, 403, 801/802, PMIL, 1002

Schedule 8 - Defendants' Trial Exhibit List

DTX-1782		Communication for File History EP No. 1328199		401/402, 403, 801/802, PMIL, 1002
DTX-1783		Exhibit L - Opening Expert Report of Karl R. Leinsing		
DTX-1784		Exhibit N - Opening Expert Report of Karl R. Leinsing		
DTX-1785		Exhibit O - Opening Expert Report of Karl R. Leinsing		
DTX-1786		Plaintiff's Final Infringement Contentions		401/402, 403, 801/802, AA, Legal
DTX-1787		Exhibit E - Opening Expert Report of Karl R. Leinsing		
DTX-1788		American Heritage College Dictionary (2000), p. 1378		401/402, 403, 801/802
DTX-1789		Webster's II New College Dictionary (2001), p. 1120		401/402, 403, 801/802
DTX-1790		Exhibit M - Opening Expert Report of Karl R. Leinsing		
DTX-1791		Exhibit P - Opening Expert Report of Karl R. Leinsing		
DTX-1792		Impact of Distal Pin (Video)		401/402, 403, 701/702, 801/802
DTX-1793		Kimura Inventor Oath and Declaration		401/402, 403, 801/802
DTX-1794		Kimura Transmittal of New Application		401/402, 403, 801/802
DTX-1795		Defendant's Amended Initial Invalidity Contentions		401/402, 403, 801/802, AA, Legal
DTX-1796		U.S. Patent Application Publication No. 2004/0106866 by Ookubo et al.		401/402, 403, 801/802
DTX-1797		U.S. Patent Application Publication No. 2012/0109162 by Durgin et al.		401/402, 403, 801/802
DTX-1798		U.S. Patent Application Publication No. 2005/0070758 by Wells et al.		401/402, 403, 801/802
DTX-1799		U.S. Patent No. 7,494,461 by Wells et al.		401/402, 403, 801/802
DTX-1800		U.S. Patent No. 7,452,327 by Durgin et al.		401/402, 403, 801/802
DTX-1801		U.S. Patent No. 6,966,891 by Ookubo et al.		401/402, 403, 801/802
DTX-1802		Supplemental Expert Report of Michael Plishka		701/702, 801/802, 901/902, PMIL
DTX-1803		Boston Scientific Corp. 10-K (FY 2016)		401/402, 403, 801/802
DTX-1804		Boston Scientific Corp. 10-K (FY 2018)		401/402, 403, 801/802
DTX-1805		Boston Scientific Corp. 10-K (FY 2019)		401/402, 403, 801/802
DTX-1806		Commed Corp. 10-K (FY 2019)		401/402, 403, 801/802
DTX-1807		Henry Schein Inc. 10-K (FY 2016)		401/402, 403, 801/802
DTX-1808		Henry Schein Inc. 10-K (FY 2019)		401/402, 403, 801/802
DTX-1809		Cook Grp. Inc. v. Bos. Sci. Scimed, Inc., 809 F. App'x 977 (Fed. Cir. 2020)		401/402, 403, Legal, PMIL
DPX-xx		Physical Exh bits – Micro-Tech SureClip and Lockado hemostasis clips		Boston Scientific reserves the right to object to each of Defendants' Physical Exhibits in accordance with the Pretrial Order
DPX-xx		Physical Exh bits – Boston Scientific Resolution and Resolution 360 hemostasis clips		Boston Scientific reserves the right to object to each of Defendants' Physical Exhibits in accordance with the Pretrial Order
DPX-xx		Physical Exh bits – Olympus QuickClip hemostasis clips		Boston Scientific reserves the right to object to each of Defendants' Physical Exhibits in accordance with the Pretrial Order
DPX-xx		Physical Exh bits – Other physical exhibits to be identified		Boston Scientific reserves the right to object to each of Defendants' Physical Exhibits in accordance with the Pretrial Order

Boston Scientific objects to each of Defendants' exhibits at least under Fed. R. Evid. 106 and 1002 to the extent that such exhibit improperly contains annotations or highlighting not present in the original document, or removes pages from the original document.

# **SCHEDULE 9**

SCHEDULE 9

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**PLAINTIFFS' WITNESS LIST (SCHEDULE 9)**

Pursuant to Local Rule 16.3(c), Plaintiffs expect to call the following witnesses to testify live or by deposition at trial. Plaintiffs reserve the right to revise or supplement this list consistent with the Pretrial Order or as otherwise permitted by the Court. If any witness Plaintiffs intend to call to testify live is unavailable, Plaintiffs reserve the right to offer deposition testimony from such witness. Plaintiffs also reserve the right to call live or by deposition anyone appearing on Defendants' witness list. Plaintiffs further reserve the right to call live or by deposition any witness to provide foundational testimony should any party contest the authenticity or admissibility of any material proffered at trial. Plaintiffs reserve the right to call any witness for impeachment purposes. Finally, Plaintiffs reserve the right to call live or by deposition any fact witness designated

by Defendants in their List of Witnesses that Defendants elect not to call at trial.

Plaintiffs are not required to present testimony from any witness on its list of witnesses.

**WILL CALL LIST**

<b><u>EXPERT WITNESS</u></b>	<b><u>LIVE OR BY DEPOSITION</u></b>
John Bone (CV included as Attachment A hereto)	Live
Oleh Haluszka (CV included as Attachment B hereto)	Live
Karl Leinsing (CV included as Attachment C hereto)	Live

**MAY CALL LIST**

<b><u>WITNESS</u></b>	<b><u>LIVE OR BY DEPOSITION</u></b>
Vasily P. Abramov	By deposition
Mark Adams	By deposition
Niklas Andersson	Live
Danielle Bogartz	Live
Vance Brown	Live
Gregory R. Furnish	By deposition
Kurt Geitz	Live
Elena Hennessey	Live
Scott Jackson	By deposition
William C. Mers Kelly	By deposition

SCHEDULE 9

Claudia Schulz Kendall	Live
Christopher Li	By deposition
Lauren Moscato	Live
Collin Murray	Live
Ronald Perry	By deposition
David Pierce	Live
Steven Raderstorf	Live
Vincent Turturro	By deposition
Brian Keith Wells	By deposition

# Attachment A

**John Bone**  
Managing Director  
**Damages Expert / Forensic Accountant**



Chicago, IL USA  
Office: +1 312.752.3378  
Mobile: +1 312.451.2844  
[jbone@stout.com](mailto:jbone@stout.com)

**Education**

M.B.A., Statistics and Finance  
University of Chicago  
B.B.A., Accounting and Finance  
University of Michigan

**Designations**

Certified Public Accountant (CPA)  
Certified in Financial Forensics (CFF)

**Practice Areas**

Complex Business Litigation  
Intellectual Property Disputes  
Trade Secrets & Restrictive Covenants  
Forensic Investigations  
Contract Compliance

**Industry Focus**

Diversified Industrials  
Healthcare & Life Sciences  
Technology, Media &  
Telecommunications

John Bone is a Managing Director in the Disputes, Compliance, & Investigations group. He has over 30 years of experience serving as either an expert witness or consultant in an array of matters, including commercial contract disputes, franchisor/franchisee disputes, intellectual property disputes including disputes over FRAND encumbered Standard Essential Patents (SEPs) and forensic investigations. He has testified in federal court, state court, U.S. bankruptcy court and at American Arbitration Association proceedings on a variety of issues, most of which included an analysis and evaluation of economic and financial data for the purpose of determining the extent of damages.

Mr. Bone also has experience with the analysis of accounting, production, and financial data for the purpose of assessing the economic basis for injunctive relief as well as liability and causation. In performing these analyses, Mr. Bone has applied numerous financial tools and methodologies, such as discounted cash flow analysis, regression models, and incremental cost analysis.

He has worked across a broad number of industries and subsectors, including agriculture, automotive, biotech, chemicals, consumer products, computer software, computer hardware, insurance, industrial equipment, medical products, medical equipment, pharmaceuticals, professional services, publishing, quick serve restaurants, real estate, telecommunications, textiles, transportation, and wireless communications.

Prior to joining Stout, Mr. Bone was a Vice President for Charles River Associates (CRA), where he led their Chicago office.

**Recognition**

Mr. Bone has been nationally recognized as a top economic expert witness six consecutive years (2014, 2015, 2016, 2017, 2018, 2019) by the IAM Patent 1000.

**Professional Memberships**

- American Institute of Certified Public Accountants
- Illinois CPA Society
- Intellectual Property Owners Association

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



### Testimony Experience: Testimony before Trier of Fact

Trial Testimony—On behalf of Defendants in bioMérieux, S.A., bioMérieux, Inc. v. Hologic, Inc., Grifols, S.A., and Grifols Diagnostic Solutions Inc., U.S. District Court for the District of Delaware

Arbitration Testimony—On behalf of Claimant in Abbott Diabetes Care Inc. v. GSIPC, LLC, as successor in interest to GSI Technologies, LLC, ADR Systems – Commercial Division

Trial Testimony—On behalf of Defendant (Briggs) in Exmark Manufacturing Company, Inc. v. Briggs & Stratton Corporation, U.S. District Court for the District of Nebraska

Trial Testimony—On behalf of Plaintiff in Raymond Cahnman v. Timber Court LLC, David Zazove and Barron Development LLC, Circuit Court of Cook County, Illinois, County Department - Chancery Division

Trial Testimony—On behalf of Plaintiff in Brown & Brown of Kentucky, Inc. v. David Walker and CBI Holdings LLC d/b/a CBI Insurance, Jefferson Circuit Court, Division Ten (10)

Trial Testimony—On behalf of Defendants in Samson Lift Technologies LLC v. Jerr-Dan Corporation and Oshkosh Corporation, Supreme Court of New York County

Trial Testimony—On behalf of Defendants in Sonos, Inc. v. D&M Holdings, Inc. d/b/a The D+M Group, D&M Holdings U.S. Inc. and Denon Electronics (USA), LLC, U.S. District Court for the District of Delaware

Trial Testimony—On behalf of Plaintiff in Parallel Networks Licensing LLC v. Microsoft Corporation, U.S. District Court for the District of Delaware

Trial Testimony—On behalf of Defendant in Life Plans, Inc. v. Security Life of Denver Insurance Company, U.S. District Court for the Northern District of Illinois, Eastern Division

Trial Testimony—On behalf of Defendants in Zylon Corp. and Alan Zamore v. Medtronic, Inc., Medtronic Vascular, Inc., and Medtronic Vascular Holdings Ltd. f/k/a AVE Galway Ltd., Supreme Court of the State of New York, County of New York

Pre-Trial Hearing and Trial Testimony—On behalf of Defendant in Michael Anthony G. Wilbern and Wilbern Enterprises, LLC v. Culver Franchising System, Inc., U.S. District Court for the Northern District of Illinois, Eastern Division

Trial Testimony—On behalf of Defendant (Briggs) in Exmark Manufacturing Co. Inc., v. Briggs & Stratton Power Products Group, LLC and Schiller Grounds Care, Inc., U.S. District Court for the District of Nebraska

Arbitration Testimony—On behalf of Plaintiff in The Allant Group, Inc., v. Helzberg's Diamond Shops, Inc. d/b/a Helzberg Diamonds, American Arbitration Association – Chicago, IL

Trial Testimony—On behalf of Defendants in Banning Lary, et al. v. Boston Scientific Corporation, et al., U.S. District Court for the Southern District of Florida

Trial Testimony—On behalf of Plaintiffs in Ericsson, Inc., et al. v. D-Link Corporation, et al., U.S. District Court for the Eastern District of Texas, Tyler Division

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Trial Testimony—On behalf of Defendant in First Merit Venture, First Merit Realty Services, Inc., and Gary Z. Baxter v. Scott I Canel, Scott I Canel & Associates, Richard Price, Ten South Management, et al., Circuit Court of Cook County, Illinois, County Department, Law Division

Arbitration Testimony—On behalf of Plaintiff in Halliburton Energy Services, Inc. v. BJ Services Company, American Arbitration Association – Houston, TX

Arbitration Testimony—On behalf of Respondent in Jeep Eagle 17. v. Chrysler Group LLC. American Arbitration Association – Wayne, NJ

Arbitration Testimony—On behalf of Respondent in Arlington Chrysler Jeep Dodge. v. Chrysler Group LLC. American Arbitration Association – Chicago, IL

Arbitration Testimony—On behalf of Respondent in Continental Chrysler Jeep, Inc. v. Chrysler Group LLC. American Arbitration Association – Chicago, IL

Arbitration Testimony—On behalf of Respondent in Montrose Dodge, Inc. v. Chrysler Group LLC. American Arbitration Association – Washington, D.C.

Trial Testimony—On behalf of Defendants in DNT LLC v. Sprint Spectrum, LP and Nextel Operations, Inc.; Cellco Partnership d/b/a Verizon Wireless; T-Mobile USA, Inc.; Alltel Communication, LLC; and United States Cellular Corporation. U.S. District Court, Eastern District of Virginia, Richmond Division

Arbitration Testimony—On behalf of Defendant in Molten Metal Equipment Innovations, Inc. v. Pyrotek Inc. American Arbitration Association – Cleveland, Ohio

Trial Testimony—On behalf of Defendant in Telecommunication Systems, Inc. v. Mobile 365, Inc. and WiderThan Americas, Inc. U.S. District Court, Eastern District of Virginia, Richmond Division

Trial Testimony—On behalf of Defendant in Ethos Technologies, Inc. v. RealNetworks, Inc. U.S. District Court—District of Massachusetts

Trial Testimony—On behalf of Defendant in InsureOne Independent Insurance Agency, LLC, et al. v. James P. Hallberg, et al. Circuit Court of Cook County, Illinois, County Department, Chancery Division

Arbitration Testimony—On behalf of Plaintiff in Biomet, Inc. and Biomet Orthopedics, Inc. v. Biomet-Ross and B. Keith Ross. American Arbitration Association—Columbus, Ohio

Testimony at Preliminary Injunction Hearing—On behalf of Defendant in Smith Wholesale Company, Inc. v. R.J. Reynolds Tobacco Company. U.S. District Court—Eastern District of Tennessee

Trial Testimony—On behalf of Plaintiff in John Donovan Enterprises v. Allied Plastics and Thermo King. U.S. District Court—Western District of Wisconsin

Trial Testimony—On behalf of Defendant in W.R. Grace & Co.—CONN v. Intercat, Inc. and Conoco, Inc. U.S. District Court—District of Delaware

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Trial Testimony—On behalf of Smart Data, Inc. U.S. Bankruptcy Court—Northern District of Illinois, Eastern Division

### Testimony Experience: Deposition Testimony

On behalf of Defendants/Counter-Plaintiffs in Days Corporation d/b/a/ Equalizer Systems v. Lippert Components, Inc. and Innovative Design Solutions, Inc., U.S. District Court for the Northern District of Indiana, South Bend Division

On behalf of Defendants in ICM Controls Corp. and International Controls and Measurements Corp. v. Honeywell International, Inc. and Resideo Technologies, Inc., U.S. District Court for the Northern District of New York

On behalf of Defendants in Vital Pharmaceuticals, Inc. d/b/a VPX Sports v. Monster Energy Company and Reign Beverage Company, LLC, U.S. District Court, Southern District of Florida

On behalf of Plaintiff in Specialty Earth Sciences, LLC v. Carus Corporation, U.S. District Court for the Northern District of Illinois - Eastern Division

On behalf of Defendants in bioMérieux, S.A., bioMérieux, Inc. v. Hologic, Inc., Grifols, S.A., and Grifols Diagnostic Solutions Inc., U.S. District Court for the District of Delaware

On behalf of Defendant in Osseo Imaging, LLC v. Planmeca USA Inc., U.S. District Court for the District of Delaware

On behalf of Defendant in Airhawk International, LLC v. Ontel Products Corporation, U.S. District Court, Southern District of California

On behalf of Plaintiff/Counter-Defendant in Guaranteed Rate, Inc. v. Netrix, Inc., Circuit Court of Cook County, Illinois, Chancery Division

On behalf of Plaintiff in Brown & Brown of Kentucky, Inc. v. David Walker and CBI Holdings LLC d/b/a CBI Insurance, Jefferson Circuit Court, Division Ten (10)

On behalf of Defendant in Exmark Manufacturing Co., Inc. v. Briggs & Stratton Power Corporation, U.S. District Court for the District of Nebraska

On behalf of Plaintiffs in Boston Scientific Corporation and Boston Scientific Neuromodulation Corporation v. Nevro Corp., U.S. District Court for the District of Delaware

On behalf of Defendants in Nevro Corp. v. Boston Scientific Corporation and Boston Scientific Neuromodulation Corporation, U.S. District Court for the Northern District of California

On behalf of Defendants in Egan Marine Corporation v. ExxonMobil Oil Corporation, Exxon Mobil Corporation, et al., Circuit Court of Cook County, Illinois, County Department, Law Division

On behalf of Plaintiffs in D&M Holdings, Inc. d/b/a The D+M Group and D&M Holdings U.S. Inc. v. Sonos, Inc., U.S. District Court for the District of Delaware

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



---

On behalf of Defendant in Fogg Filler Company v. Closure Systems International, Inc., U.S. District Court for the Western District of Michigan – Southern Division

On behalf of Defendants in Sonos, Inc. v. D&M Holdings, Inc. d/b/a The D+M Group, D&M Holdings U.S. Inc. and Denon Electronics (USA), LLC, U.S. District Court for the District of Delaware

On behalf of Plaintiffs in United States of America, *ex rel.* Michael McGee, and People of the State of Illinois *ex rel.* Michael McGee v. IBM Corporation, Johnson Controls Incorporated, Wireless Information Technologies Enterprise, LLC, Technology Alternatives, Inc., TechAlt, Inc., Public Safety Communications, Inc., MWOBIE Controls, Inc., Services by Designwise, Ltd., I.T. Suite, Inc., et al., U.S. District Court for the Northern District of Illinois, Eastern Division

On behalf of Plaintiff in C.D.S. Inc v. Bradley Zetler, CDS, LLC, Rapid Systems CC, et al., U.S. District Court for the Southern District of New York

On behalf of Defendant in Sauder Manufacturing Company v. J Squared, Inc. d/b/a University Loft Company, U.S. District Court for the Northern District of Ohio, Western Division

On behalf of Plaintiffs in C&C Power and uPower Supplies, LLC v. C&D Technologies, Inc., Diversified Assembly Technologies Corporation, EnXergy, LLC and Gary Gray, Circuit Court of Cook Country, Illinois, County Department, Law Division

On behalf of Defendant (Marquette Bank) in Daniel L. O’Malley, et al. v. William O’Malley, Thomas O’Malley, Joan O’Malley Gross, Frank K. Neidhart, Jr., McCarthy Duffy, LLP, Michael P. Rhodes, Kovitz Shifrin & Nesbit, P.P., Smart & Associates, Con Murphy, FGMK, LLC and Marquette Bank, Circuit Court of Cook County, Illinois, County Department, Law Division

On behalf of Defendants in Enzo Life Sciences, Inc. v. Hologic, Inc., and Enzo Life Sciences, Inc. v. Gen-Probe, Incorporated, U.S. District Court for the District of Delaware

On behalf of Plaintiff in Parallel Networks Licensing LLC v. Microsoft Corporation, U.S. District Court for the District of Delaware

On behalf of Defendants in Dr. Quingsheng Zhu and Dr. Julio Spinelli, acting jointly as the Stockholder Representative Committee for Action Medical, Inc. v. Boston Scientific Corporation and Cardiac Pacemakers, Inc., U.S. District Court for the District of Delaware

On behalf of Plaintiff in Parallel Networks Licensing LLC v. International Business Machines Corporation, U.S. District Court for the District of Delaware

On behalf of Plaintiffs in Kimberly-Clark Worldwide Inc. and Kimberly-Clark Global Sales, LLC v. First Quality Baby Products, LLC, First Quality Retail Services, LLC, and First Quality Consumer Products, LLC, U.S. District Court for the Eastern District of Wisconsin

On behalf of Plaintiff in The Viking Corporation v. Victaulic Company, U.S. District Court for the Western District of Michigan – Southern Division

**John Bone**

Managing Director

**Damages Expert / Forensic Accountant**



On behalf of Defendant (Phoenix Aromas & Essential Oils) in Victorino Huerta, et al. v. Aldrich Chemical Co., et al, Circuit Court of Cook County, Illinois, County Department, Law Division

On behalf of Plaintiffs in Kangaroo Media, Inc., and Immersion Entertainment LLC, v. Yinzcam, Inc., U.S. District Court for the Western District of Pennsylvania

On behalf of Defendant (Briggs) in Exmark Manufacturing Co. Inc., v. Briggs & Stratton Power Products Group, LLC and Schiller Grounds Care, Inc., U.S. District Court for the District of Nebraska

On behalf of Plaintiff in Verco Decking Inc. v. Consolidated Systems Inc., U.S. District Court for the District of Arizona, Phoenix Division

On behalf of Defendant in Lawrence S. Kirsch, as Shareholders' Representative of Lawrence S. Kirsch, Charles W. Kriete, Michael J. Chase and George Puszka v. Brightstar Corp., U.S. District Court for the Northern District of Illinois, Eastern Division

On behalf of Plaintiff in Nalco Company v. Turner Designs, Inc., U.S. District Court for the Northern District of California

On behalf of Defendants in Banning Lary, et al., v. Boston Scientific Corporation, et al., U.S. District Court for the Southern District of Florida

On behalf of Defendants in Samson Lift Technologies LLC v. Jerr-Dan Corporation and Oshkosh Corporation, Supreme Court of New York County

On behalf of Defendants in Mobile Medical International Corporation v. Advanced Mobile Hospital Systems, Inc., Tractus Medical, Inc. and Does 1-10, U.S. District Court for the District of Vermont

On behalf of Plaintiff in Roll-Rite, LLC v. Shur-Co, LLC, U.S. District Court for the Eastern District of Michigan

On behalf of Plaintiff in Medtronic, Inc. and Medtronic USA, Inc. v. Edwards Lifesciences Corp, et al., U.S. District Court for the District of Minnesota

On behalf of Plaintiff in Medtronic, Inc. v. Edwards Lifesciences Corporation, et al., U.S. District Court for the Central District of California

On behalf of Defendants in Banning Lary, et al., v. Boston Scientific Corporation, et al., U.S. District Court for the Southern District of Florida

On behalf of Defendants in Edwards Lifesciences LLC, et al. v. Medtronic Corevalve LLC, et al., U.S. District Court for the District of Delaware

On behalf of Plaintiffs in Ericsson, Inc., et al. v. D-Link Corporation, et al., U.S. District Court for the Eastern District of Texas, Tyler Division

On behalf of Defendant in Alexsam, Inc. v. Best Buy Stores, L.P., et al., U.S. District Court for the Eastern District of Texas, Marshall Division

**John Bone**

Managing Director

**Damages Expert / Forensic Accountant**



---

On behalf of Defendant in Life Plans, Inc. v. Security Life of Denver Insurance Company, U.S. District Court for the Northern District of Illinois, Eastern Division

On behalf of Defendant in Zylon Corp. and Alan Zamore v. Medtronic, Inc., Medtronic Vascular, Inc., and Medtronic Vascular Holdings Ltd. f/k/a AVE Galway Ltd., Supreme Court of the State of New York, County of New York

On behalf of Plaintiff in Halliburton Energy Services, Inc. v. BJ Services Company, American Arbitration Association – Houston, TX

On behalf of Defendant in First Merit Venture, First Merit Realty Services, Inc., and Gary Z. Baxter v. Scott I Canel, Scott I Canel & Associates, Richard Price, Ten South Management, et al., Circuit Court of Cook County, Illinois, County Department, Law Division

On behalf of Defendant in Samson Lift Technologies v. Jerr-Dan Corporation and Oshkosh Corporation, U.S. District Court, Middle District of Pennsylvania

On behalf of Defendant in Synventive Molding Solutions v. Husky Injection Molding Systems, Inc. U.S. District Court for the District of Vermont

On behalf of Defendants in DNT LLC v. Sprint Spectrum, LP and Nextel Operations, Inc.; Celco Partnership d/b/a Verizon Wireless; T-Mobile USA, Inc.; Alltel Communication, LLC; and United States Cellular Corporation. U.S. District Court, Eastern District of Virginia, Richmond Division

On behalf of Defendant in Molten Metal Equipment Innovations, Inc. v. Pyrotek Inc. American Arbitration Association

On behalf of Defendant in Telecommunication Systems, Inc. v. Mobile 365, Inc. and WiderThan Americas, Inc. U.S. District Court, Eastern District of Virginia, Richmond Division

On behalf of Plaintiff/Counterclaim Defendant in Static Control Components, Inc. v. Lexmark International, Inc. U.S. District Court, Eastern District of Kentucky at Lexington

On behalf of Plaintiff in 7-Eleven, Inc. v. Philip Morris USA, Inc. U.S. District Court, Northern District of Texas, Dallas Division

On behalf of Defendant in Ethos Technologies, Inc. v. RealNetworks, Inc. U.S. District Court—District of Massachusetts

On behalf of Defendant in InsureOne Independent Insurance Agency, LLC, et al. v. James P. Hallberg, et al. Circuit Court of Cook County, Illinois, County Department, Chancery Division

On behalf of Plaintiff in Static Control Components, Inc. v. Intersolution Ventures LTD, et al. U.S. District Court, Middle District of North Carolina, Durham Division

On behalf of Plaintiff in First Midwest Bank, N.A. v. LaSalle National Bank, et al. Circuit Court of Cook County, County Department, Law Division

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



On behalf of Defendant in Subhash C. Katial v. Massachusetts Mutual Life Insurance Company. U.S. District Court—Northern District of Illinois, Eastern Division

On behalf of Plaintiff in John Donovan Enterprises v. Allied Plastics and Thermo King. U.S. District Court—Western District of Wisconsin

On behalf of Defendant in W. R. Grace & Co.—CONN v. Intercat, Inc. and Conoco, Inc. U.S. District Court—District of Delaware

On behalf of Defendant in Holder v. USAir, Inc. et al. U.S. District Court—Northern District of Ohio (Cleveland)

### Testimony Experience: Written Testimony

Expert Report—On behalf of Plaintiff in Parkervision, Inc. v Qualcomm Incorporated, Qualcomm Atheros, Inc., HTC Corporation, and HTC America, Inc., U.S. District Court for the Middle District of Florida, Orlando Division

Expert Report—On behalf of Plaintiff in Scrum Alliance, Inc. v. Scrum Inc, Jeff Sutherland and J.J. Sutherland, U.S. District Court for the Eastern District of Texas, Sherman Division

Expert Report—On behalf of Plaintiffs in Cytiva Sweden AB and Global Life Sciences Solutions USA LLC v. Bio-Rad Laboratories, Inc. U.S. District Court for the District of Delaware

Expert Report—On behalf of Defendants in ICM Controls Corp. and International Controls and Measurements Corp. v. Honeywell International, Inc. and Resideo Technologies, Inc., U.S. District Court for the Northern District of New York

Expert Report—On behalf of Defendants/Counter-Plaintiffs in Days Corporation d/b/a/ Equalizer Systems v. Lippert Components, Inc. and Innovative Design Solutions, Inc., U.S. District Court for the Northern District of Indiana, South Bend Division

Expert Report—On behalf of Plaintiff in PSC Industries, Inc. v. David E. Johnson, U.S. District Court for the Middle District of Tennessee - Nashville Division

Rebuttal Expert Report—On behalf of Plaintiff/Counter-Defendant in A&A Coating, Inc. v. Wheelabrator Group, Inc., U.S. District Court for the Eastern District of Texas, Marshall Division

Expert Report—On behalf of Defendants in Vital Pharmaceuticals, Inc. d/b/a VPX Sports v. Monster Energy Company and Reign Beverage Company, LLC, U.S. District Court, Southern District of Florida

Rebuttal Expert Report—On behalf of Defendants in bioMérieux, S.A., bioMérieux, Inc. v. Hologic, Inc., Grifols, S.A., and Grifols Diagnostic Solutions Inc., U.S. District Court for the District of Delaware

Rebuttal Expert Report—On behalf of Defendant in Osseo Imaging, LLC v. Planmeca USA Inc., U.S. District Court for the District of Delaware

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Expert Disclosure—On behalf of Claimant in Abbott Diabetes Care Inc. v. GSIPC, LLC, as successor in interest to GSI Technologies, LLC, ADR Systems - Commercial Division

Rebuttal Expert Report—On behalf of Plaintiff/Counter-Defendant in Guaranteed Rate, Inc. v. Netrix, Inc., Circuit Court of Cook County, Illinois, Chancery Division

Expert Report—On behalf of Plaintiffs in HP Tuners, LLC v. Kevin Sykes-Bonnett, Syked Ecu Tuning Incorporated and John Martinson, U.S. District Court, Western District of Washington at Tacoma

Expert Report—On behalf of Plaintiffs in New Flyer Industries Canada ULC and New Flyer of America Inc. v. Rugby Aviation LLC d/b/a San Juan Airlines, U.S. District Court for the Western District of Washington at Seattle

Expert Report—On behalf of Defendant in Airhawk International, LLC v. Ontel Products Corporation, U.S. District Court, Southern District of California

Expert Report—Specialty Earth Sciences, LLC v. Carus Corporation, U.S. District Court for the Northern District of Illinois - Eastern Division

Expert Report—On behalf of Plaintiff in Top Shelf Barber Supplies, LLC d/b/a Top Shelf Brands v. Think Operations, LLC, U.S. District Court for the Western District of Michigan, Southern Division

Expert Report—On behalf of Plaintiff in Guaranteed Rate, Inc. v. Netrix, Inc., Circuit Court of Cook County, Illinois, Chancery Division

Expert Report—On behalf of Plaintiff in Raymond Cahnman v. Timber Court LLC, David Zazove and Barron Development LLC, Circuit Court of Cook County, Illinois, County Department - Chancery Division

Expert Report—On behalf of Plaintiff in Brown & Brown of Kentucky, Inc. v. David Walker and CBI Holdings LLC d/b/a CBI Insurance, Jefferson Circuit Court, Division Ten (10)

Expert Report—On behalf of Defendant in Exmark Manufacturing Co., Inc. v. Briggs & Stratton Corporation, U.S. District Court for the District of Nebraska

Declaration—On behalf of Patent Owner in Nevro Corp. (Petitioner) v. Boston Scientific Neuromodulation Corp. (Patent Owner) *Inter Partes Review*, U.S. Patent and Trademark Office before the Patent Trial and Appeal Board

Expert Report—On behalf of Plaintiffs in Boston Scientific Corp. and Boston Scientific Neuromodulation Corp. v. Nevro Corp., U.S. District Court for the District of Delaware

Expert Report—On behalf of Plaintiffs in Domtar Corporation and Associated Hygienic Products, LLC v. First Quality Retail Services, LLC, U.S. District Court, Eastern District of North Carolina, Western Division

Expert Report—On behalf of Defendants in Nevro Corp. v. Boston Scientific Corporation and Boston Scientific Neuromodulation Corporation, U.S. District Court for the Northern District of California

Expert Report and Surrebuttal Expert Report—On behalf of Defendants in Egan Marine Corporation v. ExxonMobil Oil Corporation, Exxon Mobil Corporation, et al., Circuit Court of Cook County, Illinois, County Department, Law Division

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Rebuttal Expert Report—On behalf of Defendant in CE Resource, Inc. d/b/a CME Resource and Net CE v. Elite Continuing Education, U.S. District Court for the Southern District of Florida

Expert Report—On behalf of Plaintiffs in D&M Holdings Inc. d/b/a The D+M Group, and D&M Holdings U.S. Inc. v. Sonos, Inc., U.S. District Court for the District of Delaware

Rebuttal Expert Report—On behalf of Defendant in Fogg Filler Company v. Closure Systems International, Inc., U.S. District Court for the Western District of Michigan - Southern Division

Expert Report and Rebuttal Expert Report—On behalf of Plaintiffs in United States of America, *ex rel.* Michael McGee, and People of the State of Illinois *ex rel.* Michael McGee v. IBM Corporation, Johnson Controls Incorporated, Wireless Information Technologies Enterprise, LLC, Technology Alternatives, Inc., TechAlt, Inc., Public Safety Communications, Inc., MWOBIE Controls, Inc., Services by Designwise, Ltd., I.T. Suite, Inc., et al., U.S. District Court for the Northern District of Illinois, Eastern Division

Expert Report—On behalf of Plaintiffs in Boston Scientific Corporation and Boston Scientific Scimed, Inc. v. Cook Group Incorporated and Cook Medical LLC, United States District Court for the District of Delaware

Supplemental Expert Report—On behalf of Defendants in Sonos, Inc. v. D&M Holdings Inc. d/b/a The D+M Group, D&M Holdings U.S. Inc., and Denon Electronics (USA), LLC, U.S. District Court for the District of Delaware

Expert Report—On behalf of Plaintiff in C.D.S. Inc v. Bradley Zetler, CDS, LLC, Rapid Systems CC, et al., U.S. District Court for the Southern District of New York

Expert Report—On behalf of Defendant in Sauder Manufacturing Company v. J Squared, Inc. d/b/a University Loft Company, U.S. District Court for the Northern District of Ohio, Western Division

Expert Report—On behalf of Defendant in BlackBerry Limited v. BLU Products, Inc., U.S. District Court for the Southern District of Florida, Miami Division

Rebuttal Expert Report—On behalf of Defendants in Sonos, Inc. v. D&M Holdings, Inc. d/b/a The D+M Group, D&M Holdings U.S. Inc. and Denon Electronics (USA), LLC, U.S. District Court for the District of Delaware

Expert Report—On behalf of Plaintiffs in C&C Power and uPower Supplies, LLC v. C&D Technologies, Inc., Diversified Assembly Technologies Corporation, Enxergy, LLC and Gary Gray, Circuit Court of Cook County, Illinois, County Department, Law Division

Expert Report—On behalf of Defendants in International Biomedical, Ltd. v. General Electric Company and Datex-Ohmeda, Inc. (d/b/a GE Healthcare), U.S. District Court for the Western District of Texas, Austin Division

Rebuttal Expert Report—On behalf of Defendant in Cornell University, Cornell Research Foundation, Inc., Life Technologies Corporation and Applied Biosystems, LLC. v. Illumina, Inc., U.S. District Court for the District of Delaware

**John Bone**  
Managing Director  
**Damages Expert / Forensic Accountant**



Rebuttal Expert Report—On behalf of Defendant (Marquette Bank) in Daniel L. O’Malley, et al. v. William O’Malley, Thomas O’Malley, Joan O’Malley Gross, Frank K. Neidhart, Jr., McCarthy Duffy, LLP, Michael P. Rhodes, Kovitz Shifrin & Nesbit, P.P., Smart & Associates, Con Murphy, FGMK, LLC and Marquette Bank, Circuit Court of Cook County, Illinois, County Department, Law Division

Rebuttal Expert Report—On behalf of Defendant in Michael Anthony G. Wilbern and Wilbern Enterprises, LLC v. Culver Franchising System, Inc., U.S. District Court for the Northern District of Illinois, Eastern Division

Expert Report, Rebuttal Report and Reply report—On behalf of Defendant in Enzo Life Sciences, Inc. v. Hologic, Inc., U.S. District Court for the District of Delaware

Expert Report, Rebuttal Report and Reply report—On behalf of Defendant in Enzo Life Sciences, Inc. v. Gen-Probe, Incorporated, U.S. District Court for the District of Delaware

Expert Report—On behalf of Defendant in Ficep Corporation v. Voortman USA Corp., U.S. District Court for the District of Maryland

Expert Report—On behalf of Plaintiffs in Kimberly-Clark Worldwide Inc. and Kimberly-Clark Global Sales, LLC v. First Quality Baby Products, LLC, First Quality Retail Services, LLC, and First Quality Consumer Products, LLC, U.S. District Court for the Eastern District of Wisconsin

Expert Report—On behalf of Plaintiff in Parallel Networks Licensing LLC v. Microsoft Corporation, U.S. District Court for the District of Delaware

Expert Report—On behalf of Defendants in Dr. Quingsheng Zhu and Dr. Julio Spinelli, acting jointly as the Stockholder Representative Committee for Action Medical, Inc. v. Boston Scientific Corporation and Cardiac Pacemakers, Inc., U.S. District Court for the District of Delaware

Expert Report—On behalf of Plaintiff in Parallel Networks Licensing LLC v. International Business Machines Corporation, U.S. District Court for the District of Delaware

Expert Report—On behalf of Defendant (Phoenix Aromas & Essential Oils) in Victorino Huerta, et al. v. Aldrich Chemical Co., et al, Circuit Court of Cook County, Illinois, County Department, Law Division

Reply Expert Report—On behalf of Plaintiffs in Kangaroo Media, Inc., and Immersion Entertainment LLC, v. Yinzcam, Inc., U.S. District Court for the Western District of Pennsylvania

Expert Report—On behalf of Plaintiff in The Viking Corporation v. Victaulic Company, U.S. District Court for the Western District of Michigan – Southern Division

Expert Report—On behalf of Defendant (Briggs) in Exmark Manufacturing Co., Inc. v. Briggs & Stratton Power Products Group, LLC and Schiller Grounds Care, Inc., U.S. District Court for the District of Nebraska (update following removal of stay pending reexamination)

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



---

Expert Report—On behalf of Plaintiffs in Kangaroo Media, Inc., and Immersion Entertainment LLC, v. Yinzcam, Inc., U.S. District Court for the Western District of Pennsylvania

Expert Report—On behalf of Plaintiff in The Allant Group, Inc., v. Helzberg's Diamond Shops, Inc. d/b/a Helzberg Diamonds, American Arbitration Association – Chicago, IL

Expert Report—On behalf of Defendant in Lawrence S. Kirsch, as Shareholders' Representative of Lawrence S. Kirsch, Charles W. Kriete, Michael J. Chase and George Puszka v. Brightstar Corp., U.S. District Court for the Northern District of Illinois, Eastern Division

Expert Report—On behalf of Plaintiff in Verco Decking Inc. v. Consolidated Systems Inc., U.S. District Court for the District of Arizona, Phoenix Division

Expert Report—On behalf of Plaintiff in Nalco Company v. Turner Designs, Inc., U.S. District Court for the Northern District of California

Expert Report—On behalf of Defendants in Banning Lary, et al., v. Boston Scientific Corporation, et al., U.S. District Court for the Southern District of Florida

Expert Report—On behalf of Defendants in Samson Lift Technologies LLC v. Jerr-Dan Corporation and Oshkosh Corporation, Supreme Court of New York County

Rebuttal Expert Report—On behalf of Plaintiff in Medtronic, Inc. and Medtronic USA, Inc. v. Edwards Lifesciences Corp, et al., U.S. District Court for the District of Minnesota

Expert Report—On behalf of Defendants in Mobile Medical International Corporation v. Advanced Mobile Hospital Systems, Inc., Tractus Medical, Inc. and Does 1-10, U.S. District Court for the District of Vermont

Expert Report—On behalf of Plaintiff in Medtronic, Inc. and Medtronic USA, Inc. v. Edwards Lifesciences Corp, et al., U.S. District Court for the District of Minnesota

Expert Report—On behalf of Plaintiff in Roll-Rite, LLC v. Shur-Co, LLC, U.S. District Court for the Eastern District of Michigan

Expert Report—On behalf of Plaintiff in Medtronic, Inc. v. Edwards Lifesciences Corporation, et al., U.S. District Court for the Central District of California

Expert Report and Response Report —On behalf of Defendants in Banning Lary, et al., v. Boston Scientific Corporation, et al., U.S. District Court for the Southern District of Florida

Expert Report—On behalf of Defendants in Edwards Lifesciences LLC, et al. v. Medtronic Corevalve LLC, et al., U.S. District Court for the District of Delaware

Expert Report—On behalf of Plaintiffs in Ericsson, Inc., et al. v. D-Link Corporation, et al., U.S. District Court for the Eastern District of Texas, Tyler Division

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Expert Report—On behalf of Defendant in Alexsam, Inc. v. Best Buy Stores, L.P., et al., U.S. District Court for the Eastern District of Texas, Marshall Division

Expert Report—On behalf of Defendant in Life Plans, Inc. v. Security Life of Denver Insurance Company, U.S. District Court for the Northern District of Illinois, Eastern Division

Disclosure—On behalf of Defendant in Zylon Corp. and Alan Zamore v. Medtronic, Inc., Medtronic Vascular, Inc., and Medtronic Vascular Holdings Ltd. f/k/a AVE Galway Ltd., Supreme Court of the State of New York, County of New York

Expert Report—On behalf of Defendant (Briggs) in Exmark Manufacturing Co., Inc. v. Briggs & Stratton Power Products Group, LLC and Schiller Grounds Care, Inc., U.S. District Court for the District of Nebraska

Expert Report—On behalf of Plaintiff in Halliburton Energy Services, Inc. v. BJ Services Company, American Arbitration Association – Houston, TX

Expert Report—On behalf of Defendant in Medversant Technologies, LLC. v. Morrissey Associates, Inc., U.S. District Court for the Southern District of California

Declaration—On behalf of Defendant in Rally Manufacturing, Inc. v. Federal Mogul Corporation, U.S. District Court for the Southern District of Florida

Expert Report—On behalf of Defendant in First Merit Venture, First Merit Realty Services, Inc., and Gary Z. Baxter v. Scott I Canel, Scott I Canel & Associates, Richard Price, Ten South Management, et al., Circuit Court of Cook County, Illinois, County Department, Law Division

Expert Report—On behalf of Defendant in Rally Manufacturing, Inc. v. Federal Mogul Corporation, U.S. District Court for the Southern District of Florida

Disclosure—On behalf of Carrols Corporation in Carrols Corporation v. Cain Restaurants Company, U.S. District Court, Eastern District of Michigan (Detroit)

Expert Report—On behalf of Plaintiff in Osmose, Inc. v. Arch Chemicals, Inc., Arch Wood Protection, Inc., Arch Treatment Technologies, Inc., Cox Industries, Inc., Rocky Top Building Products, Inc., and Madison Wood Preservers. U.S. District Court, Eastern District of Virginia, Norfolk Division

Expert Report—On behalf of Defendants in Samson Lift Technologies v. Jerr-Dan Corporation and Oshkosh Corporation, U.S. District Court, Middle District of Pennsylvania

Disclosure —On behalf of Respondent in Jeep Eagle 17. v. Chrysler Group LLC. American Arbitration Association – Wayne, NJ

Disclosure —On behalf of Respondent in Arlington Chrysler Jeep Dodge. v. Chrysler Group LLC. American Arbitration Association – Chicago, IL

Disclosure—On behalf of Respondent in Melchiorre, Inc. D/B/A Warner Chrysler Jeep. v. Chrysler Group LLC. American Arbitration Association – Philadelphia, PA

**John Bone**  
Managing Director  
**Damages Expert / Forensic Accountant**



Disclosure—On behalf of Respondent in Continental Chrysler Jeep, Inc. v. Chrysler Group LLC. American Arbitration Association – Chicago, IL

Disclosure—On behalf of Respondent in Montrose Dodge, Inc. v. Chrysler Group LLC. American Arbitration Association – Washington, D.C.

Disclosure—On behalf of Respondent in D Patrick, Inc. v. Chrysler Group LLC. American Arbitration Association – Indianapolis, IN.

Declaration—On behalf of Plaintiffs in Kimberly-Clark Worldwide Inc. and Kimberly-Clark Global Sales, LLC v. First Quality Baby Products, LLC and First Quality Retail Services, LLC. U.S. District Court, Eastern District of Wisconsin, Green Bay Division

Expert Report—On behalf of Defendant in Synventive Molding Solutions v. Husky Injecting Molding Systems, Inc. U.S. District Court for the District of Vermont

Expert Report—On behalf of Defendant in Molten Metal Equipment Innovations, Inc. v. Pyrotek Inc. American Arbitration Association

Expert Report—On behalf of Defendants in DNT LLC v. Sprint Spectrum, LP and Nextel Operations, Inc.; Cellco Partnership d/b/a Verizon Wireless; T-Mobile USA, Inc.; Alltel Communication, LLC; and United States Cellular Corporation. U.S. District Court, Eastern District of Virginia, Richmond Division

Expert Report—On behalf of Defendant in Etigra, LLC, et al. v. Bayer CropScience LP, et al. U.S. District Court, Eastern District of North Carolina, Western Division

Expert Report—On behalf of Plaintiff in Bayer CropScience AG, et al. v. NuFarm Americas, Inc. U.S. District Court, Eastern District of Virginia, Richmond Division

Expert Report—On behalf of Defendant in Telecommunication Systems, Inc. v. Mobile 365, Inc. and WiderThan Americas, Inc. U.S. District Court, Eastern District of Virginia, Richmond Division

Expert Report—On behalf of Plaintiff in Patriot Homes, Inc., et al. v. Forest River Housing, Inc., et al. U.S. District Court of Indiana, South Bend Division

Expert Report—On behalf of Plaintiff/Counterclaim Defendant in Static Control Components, Inc. v. Lexmark International, Inc. U.S. District Court, Eastern District of Kentucky at Lexington

Expert Report—On behalf of Plaintiff in 7-Eleven, Inc. v. Philip Morris USA, Inc. U.S. District Court, Northern District of Texas, Dallas Division

Expert Report—On behalf of Defendant in InsureOne Independent Insurance Agency, LLC, et al. v. James P. Hallberg, et al. Circuit Court of Cook County, Illinois, County Department, Chancery Division

Expert Report and Response Report—On behalf of Plaintiff in Static Control Components, Inc. v. Intersolution Ventures LTD, et al. U.S. District Court, Middle District of North Carolina, Durham Division

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



Expert Report—On behalf of Plaintiff in Mobility Electronics, Inc. v. Formosa Electronic Industries, Inc. U.S. District Court, Eastern District of Texas, Texarkana Division

Expert Reports—On behalf of Defendant in Ethos Technologies, Inc. v. RealNetworks, Inc. U.S. District Court—District of Massachusetts

Expert Report—On behalf of Defendant in Lampi Corporation v. American Power Products, Inc. U.S. District Court—Northern District of Illinois, Eastern Division

Expert Report—On behalf of Plaintiff in Biomet, Inc. and Biomet Orthopedics, Inc. v. Biomet-Ross and B. Keith Ross. American Arbitration Association—Columbus, Ohio

Declaration—On behalf of Defendant in Smith Wholesale Company, Inc. v. R.J. Reynolds Tobacco Company. U.S. District Court—Eastern District of Tennessee

Expert Report—On behalf of Plaintiff in First Midwest Bank, N.A. v. LaSalle National Bank, et al. Circuit Court of Cook County, County Department, Law Division

Expert Report—On behalf of Defendant in Subhash C. Katial v. Massachusetts Mutual Life Insurance Company. U.S. District Court—Northern District of Illinois, Eastern Division

Expert Report—On behalf of Plaintiff in John Donovan Enterprises v. Allied Plastics and Thermo King. U.S. District Court—Western District of Wisconsin

Report on Valuation of IP Assets—Submitted opinion regarding value of intellectual property on behalf of the Estate of Sheldon Silverstein (author of children's books)

## Publications

“Independent Economic Value’ Crucial In Trade Secret Cases,” Law360, June 2020

“To Apportion or Not to Apportion?” *The Stout Journal*, Fall/Winter 2017

“Akamai Technologies, Inc.: Federal Circuit Weighs in on a Lost Profits Opinion Involving Head-to-Head Competitors,” *The SRR Journal*, Spring 2016

“VirnetX: Clarity from the Federal Circuit Regarding Reasonable Royalty Determination,” *The SRR Journal*, Spring 2015

“An Interview of Judge Richard A. Posner on Patent Litigation,” *SRR Journal*, Fall 2013

“Interview with Former Chief Judge David Folsom of the U.S. District Court for the Eastern District of Texas,” *The SRR Journal*, Spring 2013

“View from the Federal Circuit: An Interview with Chief Judge Randall R. Rader,” *The SRR Journal*, Fall 2012

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



"Settling on Settlement Negotiation Production," The SRR Journal, Fall 2012

"Spectralytics, Inc. v. Cordis Corporation and Norman Noble, Inc.," The SRR Journal, Spring 2012

"Federal Circuit Reaffirms Need to Compare Market Segments in Evaluating Lost Profits: Siemens Medical Solutions USA, Inc. v. Saint-Gobain Ceramics & Plastics, Inc." The SRR Journal, Fall 2011

"Damage Approach Found Acceptable to the Court at the Time" The SRR Journal, Spring 2011

"Auditing Self-Reporting Agreements," The SRR Journal, Fall 2010

"Court Once Again Addresses Insufficient Support for Damages Award in a Patent Case," The SRR Journal, Fall 2010

"Court Weighs in on License Agreements Used in Support of Damages Award", The SRR Journal, Spring 2010

"Intersection between Litigation and Business Objectives." With Kathryn Lennox, Esq. Published in connection with IPO Recent Developments, Strategies, and Tactics in IP Damages Law Conference, March 27, 2007

"Recent Developments Concerning IP Damages" With Michael Berta, Esq. Published in connection with presentation at the IP Law & Business Spring Briefing on Innovations in IP Litigation, May 17, 2006

"What Expert Should Fear Most" published in Expert Alert, the newsletter of the Expert Witness Committee of the Section of Litigation, American Bar Association, Volume 1, No. 1, winter 2005

"Court of Appeals Affirms Unprecedented Decision Regarding Patent Infringement Damages, Broadens Definition of Acceptable Non-Infringing Substitute." With Raymond S. Sims and Peter Baldwin. Mealey's Litigation Report—Intellectual Property, November 19, 1999

## Speeches and Seminars

"Patent Damages 2017: A Year in Review," webinar hosted by the American Intellectual Property Law Association, February 15, 2018

Guest Lecturer - Trade Secret Law Class, LLM in Intellectual Property Law Program, John Marshall Law School, November 8, 2017

"Damages in SEP, FRAND and RAND Litigation," panel discussion at the Intellectual Property Owner's Association Patent Damages Summit, Palo Alto, CA, May 24, 2016

"Litigating Reasonable Royalty Damages," panel discussion at the Intellectual Property Owner's Association Damages and Injunctions Committee Conference, Washington DC, May 27, 2015

"Patent Infringement Royalty Damages: Lessons Learned From Recent Federal Circuit Decisions," with Michele Riley and Brian Kacedon. Presented by the Bar Association of the District of Columbia, March 27, 2014

## John Bone

Managing Director

**Damages Expert / Forensic Accountant**



“Leveraging Expert Testimony for Big Wins: Strategies for a Changing Legal Landscape,” panel discussion sponsored by The National Law Journal at the Union League Club of Chicago on October 16, 2013

“Understanding Patent Damages - Patent damages theories and recent opinions affecting the quantification of patent damages,” Presented at the 2011 Intellectual Property Spring Seminar presented by the Intellectual Property Law Section of the State Bar of Michigan and in cooperation with the Institute of Continuing Legal Education, March 28, 2012

“IP Enforcement: Protecting Your Brand and Content within New Media,” Moderated panel discussion at the Inside Counsel’s 11th Annual Super Conference, May 23, 2011

“Role and Use of the Expert in Developing Damages Evidence,” Presented at the Illinois State Bar Association Program entitled “Meet the Labor and Employment Experts” October 15, 2010

“Patent Damages: Managing the Risks and Contingent Costs,” With Rick Bero. Presented at the BVR/Morningstar Summit on Best Practices in Intellectual Property Valuation, September 15, 2010

“Intersection between Litigation and Business Objectives,” IPO Recent Developments, Strategies, and Tactics in Damages Law Conference, March 27, 2007

“Recent Developments Concerning IP Damages,” With Michael Berta, Esq. Presented at the IP Law & Business Spring Briefing on Innovations in IP Litigation, May 17, 2006

“The Expert’s Role in the Client’s Discovery Efforts,” presented at Law Seminars International’s two day conference on “Effective Development & Presentation of Expert Testimony” March 20, 2006

“Understanding the Latest Methods and Tools to Better Manage Risks and Opportunities of IP Litigation and Licensing,” With Jeffrey Snell. Presented at the IP Law and Business Winter Briefing on Corporate Strategies For Leveraging Your Intellectual Property, November 29, 2005

“Litigation Strategies that Strengthen the Business without Breaking the Bank,” Panel discussion with Sharon R. Barner, Esq., Andy Horstman, Esq. and J. Bruce Schelkopf, Esq. in connection with the IP Law & Business Spring Briefing on Enterprise Management: Integrating IP & Business, May 4, 2005

“Legal and Economic Issues in Cases Involving Non-Infringing Alternatives, Price Erosion and Convoyed Sales,” Panel discussion with James A. Klenk, Esq. and Kristofer K. Swanson. Presented at Law Seminars International’s advanced workshop on Calculating & Proving Patent damages, April 20, 2005

“The Use of Experts in Commercial Litigation,” With Raymond S. Sims. Presented at the Northwestern University School of Law, Dispute Resolution Class, January 25, 2003

“Damages in Patent Infringement Litigation,” With Charles W. Shifley, Esq. Presented at the Licensing Executives Society 2002 Annual Meeting, September 4, 2002

“The Role of Litigation in Intellectual Property Management,” With Raymond Sims. Presented to the New York chapter of the Licensing Executives Society, November 11, 1996

## Attachment B

**OLEH HALUSZKA, MD**

**CURRICULUM VITAE**

**PERSONAL**

**HOME ADDRESS:** 6640 North Alvernon Way  
Tucson, AZ 85718  
CP: 215-292-2055  
Email: thescopist@gmail.com

**HOME TELEPHONE:** (520) 395-0805

**BIRTHPLACE:** Perth Amboy, NJ

**CITIZENSHIP STATUS:** United States

**MILITARY SERVICE:**

- General Medical Officer  
Naval Station Branch Medical Clinics  
San Diego, CA  
July 1983 – January 1984
- General Medical Office  
Emergency Department  
US Naval Hospital  
Okinawa, Japan  
January 1984 – June 1985
- Staff Physician  
Department of Internal Medicine  
US Naval Hospital  
San Diego, CA  
July 1987 – July 1988
- Staff Gastroenterologist  
Division of Gastroenterology  
US Naval Hospital  
San Diego, CA  
July 1990 – June 1993
- Commander (05)/ Director of Endoscopy  
Division of Gastroenterology  
US Naval Hospital  
San Diego, CA  
January 1994 – April 1995
- Captain, USNR  
December 1998 – April 2005

**OLEH HALUSZKA, MD**

**EDUCATION AND TRAINING:**

<b>UNDERGRADUATE SCHOOL DEGREE/YR/SUBJECT</b>	<b>DATES MONTH/YEAR</b>	
Dartmouth College Hanover, NH	September 1973 – May 1977	BA , Biology

**GRADUATE/PROFESSIONAL SCHOOL**

Uniformed Services University of the Health Sciences Bethesda, MD	September 1978 – May 1982	MD
---	---------------------------	----

**GRADUATE MEDICAL EDUCATION**

Internship, Internal Medicine	US Naval Hospital San Diego, CA	July 1982 – June 1983
Residency, Internal Medicine	US Naval Hospital San Diego, CA	July 1985 – June 1987
Fellowship, Gastroenterology	US Naval Hospital	July 1988 – June 1990
Therapeutic Endoscopy Fellowship	Medical College Wisconsin	1992

**LICENSURE**

California	1983-1996	#GFE51014
Maryland	1995-2002	#D47439
Pennsylvania	2002-2018	#MD418831
Arizona	2018-present	#56095

## OLEH HALUSZKA, MD

## **BOARD CERTIFICATION**

American Board of Internal Medicine Subspecialty of Gastroenterology	1987 1991	#112066 #112066
Recertification in GI	2011	#112066

## **ACADEMIC HONORS AND AWARDS**

Alpha Omega Alpha      Uniformed Services  
University of the Health Sciences      1982

## APPOINTMENTS

ACADEMIC

Assistant Professor of Medicine,  
University of Maryland  
Baltimore, Maryland May 1995 – April 2002

Associate Professor  
Gastroenterology  
Fox Chase Cancer Center  
Philadelphia, PA  
July 2002-June 2011

Professor and Chief Gastroenterology  
Temple University  
Philadelphia, PA

Professor of Medicine  
Gastroenterology and Hepatology  
University of Arizona School of Medicine      2016-Present

**HOSPITAL** (include type of appointment, directorships, etc.)

Director, Gastrointestinal Endoscopy  
Fox Chase Cancer Center  
Philadelphia, PA June 2002 – June 2011

Chief of Gastroenterology  
Temple Health System  
Philadelphia, PA

**OLEH HALUSZKA, MD**

Staff Gastroenterologist  
Banner University Medical Group

January 2019 – present

**MISCELLANEOUS**

Consultant, White House Medical Unit  
Washington, DC

August 1996 – July 2000

**ADMINISTRATIVE**

Reviewer, Gastrointestinal Endoscopy	1996–2001
Member ASGE Ad Hoc EUS Committee	1998–1999
Member ASGE Scientific Program Committee	2003–2006
Member ASGE Scientific Program Committee	2009– 2013
Board Member DVS GE	2002–2008
Reviewer: Gastroenterology, Gastrointestinal Endoscopy	2005– present
Reviewer: Digestive Disease and Sciences	2007– present
Pancreatico-Biliary Editor, Current Reports in Gastroenterology	2015–present

**MISCELLANEOUS AWARDS:**

TOP DOC Gastroenterology Philadelphia 2004-2016  
TOP DOC GI Cancer multiple years

**PROFESSIONAL ACTIVITIES**

**PRESENTATIONS**

January 2011

Internal Medicine Grand Rounds: Endoscopic Ultrasound of the Pancreas  
Jeanes Hospital, Philadelphia, PA

September 2010

Gastroenterology Grand Rounds: Thinking Deep: What we have learned from device assisted enteroscopy  
Hospital of the University of Pennsylvania  
Philadelphia, PA

June 2010

Lectures: Endoluminal Stenting and Device Assisted Enteroscopy  
VIth World Conference of Interventional Oncology  
Loews Hotel, Philadelphia, PA

June 2010

Lecture: Complications of EMR and Hands on Instructor  
ASGE Program Endoscopic Mucosal Resection  
Chicago, IL

**OLEH HALUSZKA, MD**

March 2010

Speaker and Endoscopist for Live Program:  
VIth International Course in Gastroenterology and Digestive Endoscopy  
La Paz, Bolivia

September 2009

Speaker and Endoscopist for Live Program:  
Third International Congress of Evidence Based Digestive Endoscopy  
Bogota, Columbia

March 2009

Evolving Technologies in Gastroenterology:  
How they will Impact the Daily Practice of Medicine  
Sinai Hospital of Baltimore  
Baltimore, MD

August 2008

3<sup>rd</sup> International Conference on Double Balloon Endoscopy  
DBE versus Capsule in the Diagnosis of Tumors  
Chicago, IL

May 2008

State of the Art Lecture: Advances in Colonoscopy  
Digestive Disease Week,  
Chicago, Il

March 2007

NMC Grand Rounds  
National Naval Medical Center  
Endoscopic Therapies for Barrett's Esophagus  
Bethesda, MD

September 2007

Georgia Gastro Society  
2007 Regional Postgraduate Course and Annual Meeting  
Endoscopic Evaluation of Biliary Strictures  
Augusta, Georgia

September 2007

Pennsylvania Society for Gastroenterology  
Chronic Pancreatitis  
Philadelphia, PA

**OLEH HALUSZKA, MD**

September 2007

5<sup>th</sup> Annual Symposium Gastrointestinal Cancers 2007  
Double Balloon Enteroscopy  
St. Louis, MO

October 2007

ASGE Enteroscopy in the 21<sup>st</sup> Century  
Instructor Hands-on Course  
Chicago, IL

March 2006

American Russian Conference  
Endoscopic Management of Pancreatic Cancer  
Moscow, Russia

May 2005

Endoscopic Mucosal Resection for Barrett's Esophagus  
Department of Surgery Grand Rounds  
Temple University Hospital  
Philadelphia, PA

January 2005

Biliary Sphincterotomy, Enteral Stenting for Malignant Obstruction  
Rocky Mountain Interventional Endoscopy 2005  
Denver, CO

November 2004

Screening and Endoscopic Intervention for Colorectal Cancer  
Update on the Management of Colorectal Cancer  
Harrisburg, PA

September 2003

Therapeutic ERCP: The U.S. Experience  
Japan Digestive Disease Week  
Osaka, Japan

April 2003

Endoscopic Approaches to GI Malignancies  
Medical Staff Grand Rounds  
Our Lady of Lourdes Medical Center  
Camden, N.J.

October 2002

New Tools to Detect and Manage Early GI Neoplasms  
Fox Chase Cancer Center Symposium  
Philadelphia, PA

**OLEH HALUSZKA, MD**

December 2001

The Argon Plasma Coagulator- A new tool in Therapeutic Endoscopy  
Medical Grand Rounds, Dept of Medicine  
Marshall University School of Medicine, Huntington, WV

November 2001

Endoscopic Management of Bleeding due to Portal Hypertension  
Mercy Hospital Grand Rounds  
Baltimore, MD

April 2001

Endoscopic Management of Bleeding Due to Portal Hypertension  
Fifth Annual Seminar in Liver Disease  
Camden Yards, Baltimore, MD

April 2000

Endoscopic Approaches to the Biliary Tree  
Fourth Annual Seminar in Liver Diseases  
Camden Yards, Baltimore, MD

November 1999

The Latest Advances in Endoscopic Stenting  
Surgical Grand Rounds, Mercy Hospital  
Baltimore, MD

October 1999

Beyond Diagnostic ERCP  
Invited Lecture and Symposium Panelist  
Japan Digestive Disease Week  
Hiroshima, Japan

October 1999

CO-Director and Speaker  
Advances in Gastroenterology for the Primary Care Physician  
University of Maryland sponsored CME  
Annapolis, MD

September 1999

Advanced Therapeutic Endoscopy  
Medical Grand Rounds, National Naval Medical Center  
Bethesda, MD

January 1999

Advances in Endoscopic Therapies  
Internal Medicine Grand Rounds, University of Maryland

**OLEH HALUSZKA, MD**

October 1998

Developments in Therapeutic Endoscopy  
Astra Pharmaceuticals GI Symposium, Baltimore MD

January 1998

Endoscopic Therapy of Pancreatic Disease  
Medical Grand Rounds, Mercy Medical Center, Baltimore, MD

December 1997

Advances in Therapeutic Endoscopy  
Maryland Chapter meeting of American College of Physicians, Ellicott City, MD

November 1997

Endoscopic Therapy of Esophageal Cancer  
Radiation Oncology Grand Rounds/ UMMS

September 1997

Advances in Therapeutic Endoscopy Medical Ground Rounds, UMMS

September 1997

Endoscopic Ultrasound Staging of GI Malignancy  
Seminar-Admiral Fell Inn/Greenbaum Cancer Center

September 1997

Advances in Endoscopic Therapy  
Medical Grand Rounds, Harbor Hospital Center, Baltimore, MD

April 1997

Advanced Biliary Endoscopy and Endoscopic Ultrasound for Biliary Malignancies  
Seminars in Liver Diseases, UMMS, Camden Yards, Baltimore, MD

March 1996

Endoscopic Management of Esophageal and Gastric Varices. - Gastroenterology CME  
Tidewater Inn - Easton, MD

The role of ERCP/Surgery for bile duct stones

Updates in Gastrointestinal Diseases for the Primary Care Physician, Course Co-Director,  
Division of Gastroenterology CME Course, Towson, MD

February 1996

Acute pancreatitis - Didactic lecture  
Pulmonary/Critical Care Conference, University of Maryland Medical Center, Baltimore,  
Maryland

**OLEH HALUSZKA, MD**

September 1995

ERCP for biliary tract disease -Didactic lecture  
Medical Grand Rounds, University of Maryland Medical Center, Baltimore, Maryland

Invited Faculty Live Endoscopy Courses:

ASGE Star Upper and Lower EMR courses 2014  
ITT Center, Chicago

Advanced ERCP/ ASGE Hands – On Endoscopy Series  
Cincinnati, Ohio

Hands-On Endoscopic Training for the Practicing Gastroenterologist  
Philadelphia, PA

**PROFESSIONAL ORGANIZATIONS**

American College of Physicians	1985 - 2005
San Diego Gastroenterology Society	1990 -1994
American Society of Gastrointestinal Endoscopy	1991- present
Maryland Society of Gastrointestinal Endoscopy	1995- 2002
American College of Gastroenterology	1996 - present
Delaware Valley Society of Gastrointestinal Endoscopy	2002 – present

**PUBLICATIONS**

**PEER REVIEWED ARTICLES:**

1. Haluszka O, Rabetoy GM, Mosley CA, Duke MS. Bilateral artery stenosis presenting as a case of scleroderma renal crisis. Clinical Nephrology 1989;32:262-265.
2. Person JL, Haluszka O, Grimm IS. Biliary stent migration. Gastrointestinal Endoscopy 1991;37:210-211.
3. Grimm IS, Schindler WR, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. American Journal of Gastroenterology 1992;87:775-779.
4. Ove R, Haluszka O, Darwin P, Kennedy A. Postoperative Endoscopic Retrograde HDR Brachytherapy for Cholangiocarcinoma. Am J Clin Oncology 2000;23:559-561.
5. Varanasi R, Fleisher S, Darwin P, King C, Haluszka O. Colonoscopic sclerotherapy of ileal varices (Case Report). Gastrointestinal Endoscopy 2000;52:109-111.
6. Darwin P, Zangara J, Heller T, Haluszka O, Lauren J. Unsedated Esophagoscopy

**OLEH HALUSZKA, MD**

- for the Diagnosis of Esophageal Varices in Patients with Cirrhosis. *Endoscopy* 2000; 32:971-73.
7. Haluszka O, Campbell A, Horvath K. Endoscopic Management of Pancreatic Pseudocyst in Children. *Gastrointestinal Endoscopy* 2002;55:128-31.
  8. Osei-Boateng K, Ravendhran N, Haluszka O, Darwin PE. Endoscopic Treatment of a post-traumatic biliary stricture mimicking a Klatskin tumor. *Gastrointestinal Endoscopy* 2002;55:274-76.
  9. Greenwald B, Caldwell SH, Hespenheide EE, Patrie JT, Williams J, Binmoeller KF, Woodall L, Haluszka O. N-2-buty cyanoacrilate for bleeding gastric varices: A United States pilot study and cost analysis. *American Journal of Gastroenterology* 2003; 98:1982-1988.
  10. Goldberg E, Titus M, Haluszka O, Darwin P. Pancreatic duct stenting facilitates difficult common bile duct cannulation. *Gastrointestinal Endoscopy* 2005;62(4):592-6.
  11. Haluszka O. Palliative Gastroenterology. *Semin Oncol*. 2005; 32:174-178.
  12. Haluszka O, Greenwald BD, Tokar J. Endoscopic oncology, Current problems in cancer, 2005;29:40-112
  13. Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, Adler L. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. *Int J Radiat Oncol Biol Phys*. 2005;15:61(4):1123-8.
  14. Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. *Semin Oncol*. 2005;32(6 Suppl 9):S63-7.
  15. Tokar JL, Haluszka O, Weinberg DS. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. *Semin Radiat Oncol*. 2007;17(1):10-21
  16. Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. *Int J Radiat Oncol Biol Phys*. 2007;69(2):358-63
  17. Ross A, Mehdizadeh S, Tokar J, Leighton JA, Kamal A, Chen A, Schembre D, Chen G, Binmoeller K, Kozarek R, Waxman I, Dye C, Gerson L, Harrison ME,

**OLEH HALUSZKA, MD**

Haluszka O, Lo S, Semrad C. Double Balloon Enteroscopy detects small bowel mass lesions missed by capsule endoscopy. *Dig Dis Sci*, 2008.

18. Maranki, JL, Haluszka, O. Developments in the Treatment of Bleeding Gastric Varices. *US Gastroenterology Review*, Volume 4, Issue 1, 2008.
19. Haluszka, O. Small-Bowel Endoscopy. *Clinical Update ASGE*:15(4) 2008.
20. Hegde S, Haluszka O, Tokar JL. Endoscopic Ultrasound in Gastric Cancer in the Endoscopic Ultrasound. *Clinical Gastroenterology* pending publication 2009. Humana Press.
21. Ke E, Patel BB, Liu T, Li XM, Haluszka O, Hoffman J, Ehya H, Young NA, Watson JC, Weinberg D, Nguyen M, Cohen SJ, Meropol NJ, Litwin S, Tokar JL, and Yeung AT. "Proteomic Analyses of Pancreatic Cyst Fluids". *Pancreas* 2009; 38(2):233-42.
22. Haley M, Konski A, Li T, Cheng JD, Maurer A, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Influence of Diabetes on the Interpretation Of PET Scans in Patients with Esophageal Cancer, *Gastrointest Cancer Res* 2009;3:149-52.
23. Gerson LB, Tokar J, Chiorean M, Lo S, Decker GA, Cave D, Bouhaidar D, Mishkin D, Dye C, Haluszka O, Leighton JA, Zfass A, Semrad C, Complications associated with double balloon enteroscopy at nine US centers, *Clinical Gastro Hepatol*;2009:11:1177-82.
24. Hegde SE, Iffrig K, Li T, Downey S, Heller SJ, Tokar J, Haluszka O, Double balloon enteroscopy in the elderly: safety, findings, and diagnostic and therapeutic success, *Gastrointest Endosc* 2010; 71:983-89.
25. Morgan D, Upchurch B, Draganov P, Binmoeller KF, Haluszka O, Jonnalagadda S, Okolo P, Grimm I, Juday J, Tokar J, Chiorean M, Spiral Enteroscopy: Prospective Multicenter U.S. Study in Patients with Small Bowel Disorders, *Gastrointest Endosc* 2010;72:992-8.
26. Heller SJ, Tokar JL, Nguyen MT, Haluszka O, Weinberg DS, Management of bleeding GI Tumors, *Gastrointest Endosc* 2010;72:817-24.
27. Chun YS, Milestone BN, Watson JC Cohen SJ, Burtness B, Engstrom PF, Haluszka O, et al, Defining venous involvement in borderline resectable pancreatic cancer, *Ann Surg Oncol* 2010;17:2832-38.
28. Chen YK, Parsi MA, Binmoeller KF, Hawes RH, Pleskow DK, Slivka A, Haluszka O, et al, Single operator cholangiscopy in patients requiring evaluation of bile duct disease or therapy of bile duct stones, *Gastrointest Endosc* 2011;74:805-14.
29. Partridge B, Tokar JL, Haluszka O, Heller SJ, Small Bowel Cancers Diagnosed by

**OLEH HALUSZKA, MD**

Device-Assisted Enteroscopy at a U.S. Referral center: A Five Year Experience, *Dig Dis Sci* 2011;56:2701-5.

30. Sharma NK, Silverman JS, Li T, Cheng K, Yu JQ, Haluszka O, et al, Decreased post treatment SUV on PET scan is associated with improved local control in medically inoperable esophageal cancer, *Gastrointest Cancer Res* 2011;4:84-9.
31. Konski A, Li T, Christensen M, Cheng J, Yu JQ, Crawford K, Haluszka O, et al, Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer, *Radiother Oncol* 2012;104:72-7.
32. Keller D Jaffe J, Philip MM, Haluszka O, Khanna A, Should all endoscopically excised rectal polyps be tattooed? A plea for localization, *Surg Endosc* 2012; 26:3101-5.
33. Siddiqui AA, Chaaya A, Shelton C, Marmion J, Kowalski TE, Loren DE, Heller SJ, Haluszka O, Adler DG, Tokar JL, Use of the short double-balloon enteroscope to perform pancreatico-biliary interventions in patients with surgically altered anatomy in a US multicenter study, *Dig Dis Sci* 2013;58:858-64.
34. Makipour K, Modiri AN, Ehrlich A, Friedenberg FK, Maranki J, Enestvedt BK, Heller S, Tokar J, Haluszka O, Double balloon enteroscopy: Effective and minimally invasive method for removal of retained video capsules, *Dig Endosc* 2014;26:646-49.
35. Lewis A, Partridge B, Haluszka O, The role of endoscopy in the management of pancreatic necrosis, *Curr Gastroenterol Rep* 2014; 406.
36. Dimao CJ, Kolb JN, Benias PC, Shah H, Shah S, Haluszka O, et al., Initial experience with a novel EUS-guided biopsy needle (SharkCore): results of a large North American multicenter study, *Endosc Int Open* 2016;4:E974-9.
37. Kashab MA, El Zein MH, Sharzehi K, Marson FP, Haluszka O, et al., EUS guided biliary drainage or enteroscopy assisted ERCP in patients with surgical anatomy and biliary obstruction: an international comparative study, *Endosc Int Open*: 2016;E1322-E1327.
38. Sahar N, Ross A, Lakhtakia S, Cote G, Neuhaus H, Bruno M, Haluszka, O, et.al., Reducing the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis using 4Fr pancreatic plastic stents placed with common-type guidewires: Results from a prospective multinational registry, *Dig Endosxc*, doi:10.1111/den.13311; 2018

**OLEH HALUSZKA, MD**

**ABSTRACTS**

1. Haluszka O, Bohorfoush AG, Arndorfer R, Komorowski R. A new combination dilation/biopsy catheter provides histology and flow cytometry of bile duct strictures. Gastrointestinal Endoscopy 1994; 40:382.
2. Haluszka O, Bohorfoush AG, Earnest M, Adams M. Endoscopic management of biliary tract complications following orthotopic liver transplantation. Gastrointestinal Endoscopy 1994; 40:383.
3. Earnest M, Bohorfoush AG, Haluszka O, Carron DA. AIDS related cholangiopathy: Incidence after the Milwaukee cryptosporidium outbreak. Gastroenterology 1994; 106:675.
4. Meyer F, Blaas S, Malstrom CE, Fantry GT, Greenwald BD, Haluszka O, James SP. Gastric mucosal T cell anergy in H.pylori gastritis. Gastroenterology 1996, 110:A967.
6. Greenwald BD, Haluszka O, Levine JG, Krasna M, White C, Comparison of Endoscopic Ultrasound and Magnetic resonance Imaging to Thoracoscopy/Laparoscopy in Staging Esophageal Cancer, Gastrointestinal Endoscopy 1996; 43: 420.
7. Cho E, Flowers JL, Darwin PD, Haluszka O, Endoscopic Decompression for Traumatic Biliary Fistulae, American Journal of Gastroenterology 1997; 92:1632.
8. Bhandare N, Suntharalingam M, Haluszka O, Greenwald BD, Interaction of Radiation and Esophageal self expanding metal stents: effect on dose delivery, Gastrointestinal Endoscopy 1997; 45:A158.
9. Bohorfoush A, Franco J, Komorowski R, Gardner P, Varma R, Haluszka O, Flow Cytometric Analysis of bile duct epithelium in Primary Sclerosing Cholangitis potentially assists timing of Liver Transplantation, Gastrointestinal Endoscopy 1998;45: A394.
10. Darwin P, Rosenstein A, Haluszka O, A Prospective Randomized Trial to assess the Usefulness of Glucagon in Training During ERCP, Gastrointestinal Endoscopy 1999;49:A47.
11. Zangara J, Heller T, Laurin J Haluszka O, Darwin P, Peroroal unsedated esophagoscopy to screen for esophageal varices is well tolerate and significantly less expensive than conventional EGD, Gastrointestinal Endoscopy 1999; 49:A173.
12. Shamoun D, Darwin P, Greenwald B, Haluszka O, Treatment of Gastric Antral Vascular Ectasia with Argon Plasma Coagulation, Gastrointestinal Endoscopy 2000; 51:A7156.
13. Johnston MH, Horwhat JD, Haluszka O, Moses FM, Depth of Injury Following Endoscopic Spray Cryotherapy: EUS Assisted Evaluation of Mucosal Ablation and Subsequent Healing in A Swine Model, Gastrointestinal Endoscopy 2000;51:A102513

**OLEH HALUSZKA, MD**

14. Ross A, Mehdizadeh S, Tokar J, Leighton J, Kamal A, Chen A, Schembre D, Chen G, Binmoeller K, Gerson L, Kozarek R, Waxman I, Harrison E, Dye C, Haluszka O, Lo S, Semrad C: “Double Balloon Enteroscopy for the Detection of Small Bowel Mass Lesions Presenting as Obscure Gastrointestinal Bleeding. Do We Have a New Gold Standard?” April 2005 (Issue 4, Abstract).
15. Tokar JL, Nguyen M, Downey S, Weinberg DS, Haluszka O: “Initial Description of Technical Aspects of Double Balloon Enteroscopy in a US Population” Gastrointestinal Endoscopy, April 2005 (Issue 4, Abstract).
16. Tokar JL, Nguyen M, Downey S, Weinberg DS, Haluszka O: “Findings and Perceived Impact of Double Balloon Enteroscopy in a US Population.” Gastrointestinal Endoscopy. April 2005 (Issue 4, Abstract).
17. Tokar JL, Alnounou A, Nguyen M, Weinberg D, Haluszka O: “Correlation Between Double Balloon Endoscopy and Capsule Endoscopy in Presumed Small Bowel Bleeding.” Gastrointestinal Endoscopy, April 2007;65:AB173.
18. Tokar JL, Alnounou M, Nguyen M, Weinberg D, Haluszka O: “Double Balloon Endoscopy for Presumed Small Bowel Bleeding: A Single Center Experience.” Gastrointestinal Endoscopy, April 2007;65:AB173.
19. Alnounou M, Tokar JL, Haluszka O: “Combined Partial Endoscopic Biliary Sphincterotomy and Endoscopic Balloon Sphincteroplasty in the Management of Difficult Bile Duct Stones.” Gastrointestinal Endoscopy, April 2007;65:AB220.
20. Sanaka S, Alnounou M, Tokar JL, Haluszka O: “Correlation Between Molecular Analysis of Aspirates from Cystic Lesions of the Pancreas with Surgical Pathology and Cytology.” Gastrointestinal Endoscopy, April 2007;65:AB302.
21. Stevens PD, Chen YK, Pleskow DK, Haluszka O, Peterson B. “Biliary Stone Extraction (BSE) Guided By Direct Visualization Using the New SpyGlass™ Direct Visualization System.” Gastrointestinal Endoscopy, April 2007;65:AB96.
22. Pleskow D, Parsi MA, Chen YK, Neuhaus H, et al. “Biopsy of Indeterminate Biliary Strictures- Does Direct Visualization Help?”. Gastrointest Endosc 2008;67:AB 103
23. Loren D, Kowalski TE, Conn M, Singu B, et al. “Clinical Applications of the Spyglass Direct Visualization System: A Multicenter Experience”. Gastrointest Endosc 2008;67:AB 230.
24. Chen YK, Parsi MA, Binmoeller KF, Hawes RH, et al. “Peroral Cholangioscopy (PO) Using a Disposable Steerable Single Operator Catheter for Biliary Stone Therapy and Assessment of Indeterminate Strictures – A Multicenter Experience Using Spyglass”. Gastrointest Endosc 2008;67:AB 103.

**OLEH HALUSZKA, MD**

25. Abdel Aziz AM, Sherman S, Binmoeller KF, Deviere J, et al. "Spyglass Cholangioscopy- Impact on Patients with Bile Duct Filling Defect(s) of Uncertain Etiology". Gastrointest Endosc 2008;67:AB235.
26. Hegde SR, Iffrig K, Downey S, Heller SJ, et al. "Double Balloon Enteroscopy in the Elderly: Indications, Findings, and Agreement with Video Capsule Endoscopy". Gastrointest Endosc 2009;69:AB197.
27. Hegde SR, Iffrig K, Downey S, Heller SJ, et al. "Safety of Double Balloon Enteroscopy in Patients >Age 75 Years: A Single center One-Year Experience". Gastrointest Endosc 2009;69:AB200.
28. Bachegowda L, Heller SJ, Partridge BJ, Ehya H, Haluszka O, Tokar J, The diagnosis of metastatic cancer to the pancreas by endoscopic ultrasound guided fine needle aspiration, Gastrointestinal Endoscopy 2010; 71: AB293.
29. Partridge BJ, Kalra A, Tokar JL, Heller SJ, Cooper HS, Haluszka O, Endoscopic Management of Granular Cell Tumors of the Esophagus, Gastrointestinal Endoscopy 2010; 71: AB325.
30. Partridge BJ, Heller SJ, Tokar JL, Ramzan Z, Haluszka O, The diagnostic yield of Device-assisted enteroscopy for acute middle gastrointestinal bleeding, Gastrointestinal Endoscopy 2010; 71: AB 372.
31. Partridge BJ, Heller SJ, Tokar JL, Haluszka O, Small bowel cancer diagnosed at a referral center for device assisted enteroscopy: a five year experience, Gastrointestinal Endoscopy 2010; 71: AB 372.

**BOOKS, MONOGRAPHS, CHAPTERS**

Haluszka O, Dieulafoy Lesion. In Capsule Endoscopy by Case Study, Edited by Raines D, Published by ACG 2011.

# Attachment C





















# **SCHEDULE 9D**

SCHEDULE 9

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**PLAINTIFFS' WITNESS LIST (SCHEDULE 9)**

Pursuant to Local Rule 16.3(c), Plaintiffs expect to call the following witnesses to testify live or by deposition at trial. Plaintiffs reserve the right to revise or supplement this list consistent with the Pretrial Order or as otherwise permitted by the Court. If any witness Plaintiffs intend to call to testify live is unavailable, Plaintiffs reserve the right to offer deposition testimony from such witness. Plaintiffs also reserve the right to call live or by deposition anyone appearing on Defendants' witness list. Plaintiffs further reserve the right to call live or by deposition any witness to provide foundational testimony should any party contest the authenticity or admissibility of any material proffered at trial. Plaintiffs reserve the right to call any witness for impeachment purposes. Finally, Plaintiffs reserve the right to call live or by deposition any fact witness designated

by Defendants in their List of Witnesses that Defendants elect not to call at trial.

Plaintiffs are not required to present testimony from any witness on its list of witnesses.

**WILL CALL LIST**

<b><u>EXPERT WITNESS</u></b>	<b><u>LIVE OR BY DEPOSITION</u></b>
John Bone (CV included as Attachment A hereto)	Live
Oleh Haluszka (CV included as Attachment B hereto)	Live
Karl Leinsing (CV included as Attachment C hereto)	Live

**MAY CALL LIST**

<b><u>WITNESS</u></b>	<b><u>LIVE OR BY DEPOSITION</u></b>
Vasily P. Abramov	By deposition
Mark Adams	By deposition
Niklas Andersson	Live
Danielle Bogartz	Live
Vance Brown	Live
Gregory R. Furnish	By deposition
Kurt Geitz	Live
Elena Hennessey	Live
Scott Jackson	By deposition
William C. Mers Kelly	By deposition

SCHEDULE 9

Claudia Schulz Kendall	Live
Christopher Li	By deposition
Lauren Moscato	Live
Collin Murray	Live
Ronald Perry	By deposition
David Pierce	Live
Steven Raderstorf	Live
Vincent Turturro	By deposition
Brian Keith Wells	By deposition

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, INC., )  
                                       )  
Plaintiffs,                         )  
                                       ) C.A. No. 18-1869-CFC-CJB  
v.                                     )  
                                       )  
MICRO-TECH ENDOSCOPY USA INC., )  
MICRO-TECH (NANJING) CO., LTD., and )  
HENRY SCHEIN INC.,                 )  
                                       )  
Defendants.                         )

**DEFENDANTS' OBJECTIONS TO  
PLAINTIFFS' WITNESS LIST (SCHEDULE 9)**

Pursuant to Rule 26(a)(3)(B) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d), Defendants Micro-Tech Endoscopy USA, Inc., Micro-Tech (Nanjing) Co. Ltd., and Henry Schein, Inc. (collectively, “Defendants”) hereby object to the Witness List provided by Plaintiffs. Defendants reserve the right to supplement, revise, correct, clarify, withdraw, or otherwise amend these objections based on new information, new positions taken by the parties, future rulings of the Court, including, but not limited to, rulings on the parties’ pending motions for summary judgment, Daubert motions, motions *in limine*, and/or evidentiary objections raised by the parties prior to trial. Defendants make these objections without waiver of, and without prejudice to, any motions, arguments, or evidentiary objections Defendants have presented or may present separately to the Court. Defendants reserve the right to object to and/or to move to strike questions, testimony, and/or documents Plaintiffs may offer in connection with any proposed witness, whether presented live or by deposition. Defendants also incorporate herein their Objections to Plaintiffs’ Deposition Designations and Objections to Plaintiffs’ Exhibit List.

Defendants further object under Fed. R. of Civ. Pro. 32 and Fed. R. of Evid. 804 to Plaintiffs’ blanket attempts to (i) reserve the right to offer deposition testimony from witnesses who are unavailable to testify live, and (ii) reserve the right to call live or by deposition any fact witness on Defendants’ witness list. These purported reservations of rights also fail to give adequate notice of witnesses to be called or testimony to be presented at trial in violation of Fed. R. Civ. Pro. 26(a)(3) and Local Rule 16.3(c)(7).

Defendants also specifically object to Plaintiffs’ witnesses as follows:

#### **Objections to Plaintiffs’ Will Call List**

John Bone (Live): Defendants object to testimony from Mr. Bone for reasons set forth in Defendants’ pending Motion to Exclude Certain Opinions of Plaintiffs’ Damages Expert, John R.

Bone (D.I. 257). Defendants further object to Mr. Bone testifying with respect to any matter that is a subject of Defendants' pending (1) Motions for Summary Judgment (D.I. 235, 246, 251, 254); (2) Oppositions to Plaintiffs' Motions for Partial Summary Judgment (D.I. 294, 297); or (3) Opposition to Plaintiffs' Motion to Partially Exclude Testimony of Defendants' Expert Michael Plishka (D.I. 291); or (4) motions *in limine*. To the extent one or more of those motions are resolved by the Court prior to trial and/or remain pending at the time of trial, Defendants' object to Mr. Bone testifying in any matter inconsistent with the Court's rulings and/or potential rulings on the motions.

Oleh Haluszka (Live): Defendants object to Dr. Haluszka testifying with respect to any matter that is a subject of Defendants' pending (1) Motions for Summary Judgment (D.I. 235, 246, 251, 254); (2) Oppositions to Plaintiffs' Motions for Partial Summary Judgment (D.I. 294, 297); (3) Opposition to Plaintiffs' Motion to Partially Exclude Testimony of Defendants' Expert Michael Plishka (D.I. 291); (4) Motion to Exclude Certain Opinions of Plaintiffs' Damages Expert, John R. Bone (D.I. 257); and/or (5) motions *in limine*. To the extent one or more of those motions are resolved by the Court prior to trial and/or remain pending at the time of trial, Defendants object to Dr. Haluszka testifying in any matter inconsistent with the Court's rulings and/or potential rulings on the motions.

Karl Leinsing (Live): Defendants object to Mr. Leinsing testifying with respect to any matter that is a subject of Defendants' pending (1) Motion to Exclude Opinions of Plaintiffs' Expert, Karl Leinsing (D.I. 259); (2) Motions for Summary Judgment (D.I. 235, 246, 251, 254); (3) Oppositions to Plaintiffs' Motions for Partial Summary Judgment (D.I. 294, 297); (4) Defendants' Opposition to Plaintiffs' Motion to Partially Exclude Testimony of Defendants' Expert Michael Plishka (D.I. 291); and/or (5) motions *in limine*. To the extent one or more of

those motions are resolved by the Court prior to trial and/or remain pending at the time of trial, Defendants' object to Mr. Leinsing testifying in any matter inconsistent with the Court's rulings and/or potential rulings on the motions. Defendants further object to Mr. Leinsing testifying in a manner inconsistent with the Court's rulings during the February 23, 2021 teleconference and Oral Orders (D.I. 280, 281, 303) on Defendants' Motion to Strike (D.I. 226) or inconsistent with the Court's Claim Construction rulings (D.I. 140) or controlling Federal Circuit precedent.

### **Objections to Plaintiffs' May Call List**

Vasily P. Abramov (Deposition): Defendants object to Plaintiffs' presentation of any deposition testimony of Mr. Abramov because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to presentation of deposition testimony of Mr. Abramov because Plaintiffs have not complied with 26(a)(3)(A)(ii).

Mark Adams (Deposition): Defendants object to Plaintiffs' presentation of any deposition testimony of Mr. Adams because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to Plaintiffs' presentation of deposition testimony of Mr. Adams because Plaintiffs have not complied with 26(a)(3)(A)(ii).

Niklas Andersson (Live): No objection.

Danielle Bogartz (Live): No objection.

Vance Brown (Live): No objection.

Gregory R. Furnish (Deposition): Defendants object to Plaintiffs' presentation of any deposition testimony of Mr. Furnish because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to Plaintiffs' presentation of deposition testimony of Mr. Furnish because Plaintiffs have not complied with 26(a)(3)(A)(ii).

Kurt Geitz (Live): Defendants object to testimony by Mr. Geitz because Plaintiffs failed

to disclose him as required by Fed. R. Civ. Pro. 26(a)(1)(A)(i) or Rule 26(e). As such, any trial testimony from Mr. Geitz is precluded under Fed. R. Civ. Pro. 37(c)(1). In addition, Mr. Geitz was not identified in response to any interrogatory or other discovery request or in any deposition in this litigation as a person with information relevant to this action. Defendants thus have been denied any opportunity to obtain discovery from or about Mr. Geitz, as well as to pursue any follow-on discovery to obtain additional information, including potential impeachment or rebuttal evidence, relating to Mr. Geitz or any possible testimony Plaintiffs may now want him to offer. Accordingly, permitting testimony at trial from Mr. Geitz would be unfair and unduly prejudicial to Defendants. Having failed ever to say a single word about Mr. Geitz or to identify him even as “an individual likely to have discoverable information,” Rule 26(a)(1)(A)(i), Plaintiffs should not be permitted to identify him for the first time in the Joint Pretrial Order and to call him as a witness at trial.

Elena Hennessy (Live): No objection.

Scott Jackson (Deposition): Defendants incorporate by reference their objections and counter-designations to Plaintiffs’ designation of deposition testimony of Mr. Jackson.

William C. Mers Kelly (Deposition): Defendants object to Plaintiffs’ presentation of any deposition testimony of Mr. Mers Kelly because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to Plaintiffs’ presentation of deposition testimony of Mr. Mr. Mers Kelly’s because Plaintiffs have not complied with 26(a)(3)(A)(ii).

Claudia Schulz Kendall (Live): No objection.

Chris Li (Deposition): Defendants incorporate by reference their objections and counter-designations to Plaintiffs’ designation of testimony of Mr. Li.

Lauren Moscato (Live): No objection.

Collin Murray (Live): No objection.

Ron Perry (Deposition): Defendants incorporate by reference their objections and counter-designations to Plaintiffs' designation of testimony of Mr. Perry.

David Pierce (Live): Defendants object to testimony by Mr. Pierce because Plaintiffs failed to disclose him as required by Fed. R. Civ. Pro. 26(a)(1)(A)(i) or Rule 26(e). As such, any trial testimony from Mr. Pierce is precluded under Fed. R. Civ. Pro. 37(c)(1). In addition, Mr. Pierce was not identified in response to any interrogatory or other discovery request or in any deposition in this litigation as a person with information relevant to this action. Defendants thus have been denied any opportunity to obtain discovery from or about Mr. Pierce, as well as to pursue any follow-on discovery to obtain additional information, including potential impeachment or rebuttal evidence, relating to Mr. Pierce or any possible testimony Plaintiffs may now want him to offer. Accordingly, permitting testimony at trial from Mr. Pierce would be unfair and unduly prejudicial to Defendants. Having failed ever to say a single word about Mr. Pierce or to identify him even as "an individual likely to have discoverable information," Rule 26(a)(1)(A)(i), Plaintiffs should not be permitted to identify him for the first time in the Joint Pretrial Order and to call him as a witness at trial.

Steven Raderstorf (Live): No objection.

Vincent Turturro (Deposition): Defendants object to Plaintiffs' presentation of any deposition testimony of Mr. Turturro because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to Plaintiffs' presentation of deposition testimony of Mr. Turturro because Plaintiffs have not complied with 26(a)(3)(A)(ii).

Brian Keith Wells (Deposition): Defendants object to Plaintiffs' presentation of any deposition testimony of Mr. Wells because Plaintiffs cannot satisfy the requirements of Fed. R. Civ. Pro. 32 or Fed. R. Evid. 804. Defendants further object to Plaintiffs' presentation of any deposition testimony of Mr. Wells because Plaintiffs have not complied with 26(a)(3)(A)(ii).

# **SCHEDULE 10**

**SCHEDEULE 10**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-CFC-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**DEFENDANTS' WITNESS LIST (SCHEDULE 10)**

**SCHEDULE 10**

Pursuant to Rule 26(a)(3)(A) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(c)(7), Defendants Micro-Tech Endoscopy USA, Inc., Micro-Tech (Nanjing) Co. Ltd., and Henry Schein, Inc. (collectively, "Defendants") hereby identify the following witnesses whom Defendants may call at trial, live or by deposition:

**Will Call List**

1. Dr. Morten Jensen (Expert CV included as Attachment A)
2. Michael Milani (Expert CV included as Attachment B)
3. Michael Plishka (Expert CV included as Attachment C)
4. Dr. Gary Reiss (Expert CV included as Attachment D)
5. Chris Li
6. Scott Jackson
7. Ron Perry

**May Call List**

1. Mark Adams (by deposition)
2. Niklas Andersson (by deposition)
3. Danielle Bogartz (by deposition)
4. Vance Brown (by deposition)
5. Christopher Davis (by deposition)
6. Elena Hennessey (by deposition)
7. Javier Jiminez (by deposition)
8. Claudia Schulz Kendall (by deposition)
9. William Lafferty (by deposition)
10. Michael Lynn (by deposition)

**SCHEDULE 10**

11. Lauren Moscato (by deposition)
12. Collin Murray (by deposition)
13. Representatives of Olympus America Inc. (live)
14. Demetrios Petrou (by deposition)
15. Steven Raderstorf (by deposition)
16. Matthew Sprague (by deposition)
17. Zhi (Edgar) Tang (live)
18. Vincent Turturro (by deposition)
19. Kevin Wilcox (by deposition)

The above list is not a commitment that Defendants will call or present testimony of any particular witness at trial, or a representation that any of the witnesses listed are available or will appear for trial. If any witness listed as a person whom Defendants intend to call to testify live is unavailable pursuant to Fed. R. Civ. Pro. 32 and Fed. R. Evid. 804, Defendants reserve the right to offer deposition testimony from such witness in lieu of live examination. Defendants further reserve the right to introduce testimony through deposition or live examination for any witness that Plaintiffs identify on their list, for any expert witness that submitted an expert report on behalf of Plaintiffs, as counter-designations to any deposition testimony designated by Plaintiffs, or as necessary to provide foundational testimony or establish authenticity or admissibility of any trial exhibit if the authenticity or admissibility of the exhibit is challenged by Plaintiffs.

# Attachment A

**Morten Olgaard Jensen, PhD, DrMed**

Department of Biomedical Engineering

University of Arkansas, Fayetteville, AR, USA

Ph.: +1 404 431 1031 / E-mail: [mojensen@uark.edu](mailto:mojensen@uark.edu)

Civil Status: Married to Hanna Jensen, MD, PhD

---

**Education:**

- Doctor of Medical Science (DrMed), School of Medicine / Faculty of Health Sciences, The University of Aarhus, Aarhus, Denmark, March 2015
  - Doctor of Philosophy (PhD), School of Medicine / Faculty of Health Sciences, The University of Aarhus, Aarhus, Denmark, November 2008
  - Master of Science (M.Sc.), Biomedical Engineering (GPA: top 10%), Georgia Institute of Technology / Emory University School of Medicine, Atlanta, GA, USA, May 2000
  - Bachelor of Science (B.Sc.) in Engineering with honors, Electrical and Computer Engineering, The Engineering College of Aarhus, Aarhus, Denmark, July 1997
- 

**Professional Experience:**

- Associate Professor of Biomedical Engineering and Arkansas Research Alliance Scholar, Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA (*Aug. '15 – present*)
- Chief Technology Officer, Vivas LLC – Company creates flow model phantoms with synthetic medical gel in partnership with Humimic Medical LLC, sales worldwide (*Nov. '17 – present*)
- Associate Professor, Dept. of Cardiothoracic Surg., The Univ. Hosp. of Aarhus, DK (*Jul. '09 – Dec'13, Adjunct Jan '14 - present*)
- Associate Professor and Director of Research, The Scandinavian School of Cardiovascular Technology (*Oct. '09 – Aug. '15*)
- Research Faculty, Department of Biomedical Engineering, Georgia Tech / Emory, Atlanta, GA, USA (*Feb. '14 – Aug. '15*)
- Honorary Senior Lecturer, Department of Mechanical Engineering, University College London, London, UK (*Apr. '13 – Feb. '14*)
- Honorary Clinical Fellow and Senior Lecturer, Cardiology, The Heart Hospital, University College London, London, UK (*Apr. '13 – Feb. '14*)
- Assistant Professor, Department of Biomedical Engineering, Engineering College of Aarhus, Aarhus, DK (*Oct. '07 – Jul. '09*)
- Consulting Services Unit / Worldwide Business Development Group, National Instruments, Austin, TX, USA (*June '00-Aug. '05*)
- Danish Army Corps of Engineers, Communications Unit, Denmark (*Aug. '92 - Jun. '93*)

**Professional Experience Keywords:**

- Research Leadership; Biofluids & Medical Devices; Biomaterials & Tissue Engineering; Medical Instrumentation; Patient Specific Heart Valve Therapy; TAVR; TMVR; In Vitro, In Vivo; In Silico Modeling; Biomedical Technology and Research; Experimental Cardiac Surgery; Microelectronics-Photonics Program; Innovative Devices for Improved Interventions; Course Development and Teaching; Customer Education; Engineering Leadership Program; International Collaborations and Student Exchange Agreement; Blood Pressure and Flow Measurement; Cardiovascular Fluid Mechanics; Biomechanics; Heart Valve Surgery; Medical Devices; Ultrasound; Nitinol; Minimally Invasive Devices; Pacemakers; Implantable Electronics; Force Measurement in Tissue; Manage Image Acquisition and Motion Control Group; Course Development and Inaugural Execution; Image Acquisition & Processing; Consulting Services; Business Development; Integrated Systems Design; Subsystem Level Proof of Concept; R&D (Research & Development); Certified Professional Instructor: LabVIEW, Data Acquisition (DAQ), Signal Conditioning, IMAQ Machine Vision & Image Processing, Motion Control, Simulation, System Identification, Control Design, TestStand; Marketing Conventions; Show Captain; Medical Device & Manufacturing; Recruiting Manager; Hemodynamic Performance; Design and Improvement of Mechanical and Tissue Engineered Prosthetic Heart Valve Devices: Flow Visualization, Pressure Drop, and other FDA required device testing measurements on both mechanical and bioprosthetic mitral and aortic heart valves, Measurement, Analysis, and Presentation of Turbulent Blood Flow Distal to Artificial Aortic Valves; Medical Imaging Quality Assurance (MRI, CT, X-Ray, Doppler Ultrasound) and Intra-operative Heart Surgery Monitoring Systems; Entrepreneurship; Grant Proposals; Research Funding

### **Awards / Nominations**

- American Heart Association Heart Hero, November 2018
- Biomedical Engineering Society / Medtronic Coulter College Design Scholar Award Mentor, August 2018
- Outstanding Mentor, University of Arkansas Office of Nationally Competitive Awards - for Goldwater Scholar “*Nation’s most prestigious award for undergraduate students who plan doctoral studies and research careers in the fields of science, mathematics or engineering*” April 2018
- AcademicKeys Who's Who in Engineering Higher Education (WWEHE)
- Excellence in Research Dissemination Award, College of Engineering, University of Arkansas, May 2017
- Outstanding Teaching Award, Department of Biomedical Engineering, University of Arkansas, May 2017
- Southeastern Conference Travel Award 2016
- Arkansas Research Alliance Scholar Award, August 2015
- Honorary Clinical Fellow, Cardiology, The Heart Hospital Specialist Board, UCLH
- Young Investigator Award, Leducq MITRAL Transatlantic Network, May 2010
- The Danish Engineering Service Award, June 2009
- The Danish Engineering Service Award, January 2009
- The Danish Society of Engineers Honorary Award of Excellence (Elektroprisen), May 2008
- Faculty of Health Sciences 1st Prize Award for Excellent Scientific Contribution at the University of Aarhus Graduate School of Health Sciences, January 2008, Aarhus, Denmark
- Paper Competition Finalist, The Bioengineering Division of the American Society of Mechanical Engineers, June 2008, Marco Island, Florida, USA
- C. Walton Lillehei / St. Jude Medical Young Investigators Award Presentation Finalist, Fourth Biennial Meeting of the Society for Heart Valve Disease, June 2007, New York, NY, USA
- 1st Prize, Award Presentation Session, 25th Danish Annual Congress in Biomedical Engineering, September 2007, Brædstrup, Denmark
- 1st Prize for Excellent Scientific Contribution at the University of Aarhus Graduate School of Health Sciences, January 2006, Aarhus, Denmark
- Young Investigators Award 2nd Place: The Scandinavian Society for Research in CardioThoracic Surgery, 16th Annual Meeting, February 2006, Geilo, Norway

### **Patents / Patent Application Publications / IP**

- Jensen M, Girardot M: “Venus Valve Bio-prosthesis Prepared from Animal Tissue Optimized for Human Implantation” Provisional Patent Filed.
- Jensen M, Brickey K, Harris N: “Acute Ischemic Stroke Clot Dissolver and Capture Device”. Provisional Patent Filed.
- Jensen M, Hestekin J, Maier A, White M: “Inexpensive, Reproducible Vasculature Modeling Process”. Trade Secret filed with the University of Arkansas Technology Ventures Office.
- Maigaard, T, Jensen, M: “A device for indicating contamination of the abdominal cavity or the like” Ref. ID# PA2011 702452457DK00. Priority Date May 18th, 2011
- Jensen, Gadgaard, Hoest, Madsen, Rasmussen: “Expandable Diffuser”, International Patent Filed on June 25, 2009 under No.: PA 2009 00787, Published Internationally on December 29<sup>th</sup>, 2010 (WO/2010/149168A1)
- Balent, JS.; Jensen MO: “Signal Analysis Using Image Processing Techniques”, U.S. provisional application Serial No. 60/357,691, U.S. utility application Serial No. 10/365,568; U.S. Patent Publications # 2003-0165259 A1, Patents Official Gazette, September 04, 2003

### **Board of Directors Memberships, Appointments, Committees**

- National Institutes of Health (NIH) RO1 Bioengineering, Technology and Surgical Sciences Study Section panel member, Center for Scientific Review (CSR)
- Mentor at the 2018 American Heart Association Research Leaders Academy, Salt Lake City, Utah

- Department of Defense (DoD) National Defense Science and Engineering Graduate (NDSEG) Fellowships Review Committee
- National Institutes of Health (NIH) F10A Study Section panel member, Center for Scientific Review (CSR) Special Emphasis Panel (SEP) / Fellowship Grant Applications: Physiology and Pathobiology of Cardiovascular and Respiratory Systems (F30, F31, F32, F33)
- National Institutes of Health (NIH) AREA / R15 Study Section panel member, Center for Scientific Review (CSR): Cardiovascular Differentiation and Development (CDD), Electrical Signaling, Ion Transport, and Arrhythmias (ESTA)
- Appointed to the Danish Academy of Engineers
- Member of the Arkansas Research Alliance Academy of Scholars and Fellows
- The Center for Innovative Cardiovascular Technologies (CICT)
- Board of Directors at the Danish Society for Biomedical Engineering (DMTS) (Member 2009-2014, Consultant 2014-present)
- The Danish Accreditation Council
- Board of Advisors for the Danish Cardiovascular Research Academy
- Board of Directors for the Cardiovascular PhD Education, School of Medicine, University of Aarhus
- Academic Assessment Committee, University of Aalborg
- Academic Assessment Committee, University of Aarhus, Faculty of Health

#### **Editor / Editorial Board**

- K. Dremstrup, S. Rees, M. Ø. Jensen: Editors, Proceedings of the 15<sup>th</sup> Nordic-Baltic Conference on Biomedical Engineering and Medical Physics, Volume 34, the International Federation for Medical and Biological Engineering, ISBN 1680-0737, Springer DOI 10.1007/978-3-642-21683-1
- Editorial Board of the American Journal of Cardiovascular Disease (PubMed Indexed, [www.ajcd.us](http://www.ajcd.us))

#### **Reviewer / Journal Referee**

- Circulation Heart Failure (American Heart Association)
- Journal of Heart Valve Disease
- Annals of Thoracic Surgery
- Cardiovascular Engineering and Technology
- Journal of Biomechanics
- Annals of Biomedical Engineering
- Medical Engineering & Research
- Journal of Biological Engineering
- Public Library Of Science (PLOS) ONE
- Biomechanics and Modeling in Mechanobiology
- Experimental Mechanics
- International Journal for Numerical Methods in Biomedical Engineering
- Journal of Biomedical Materials Research
- Journal of Biomechanical Engineering (American Society of Mechanical Engineers)
- Journal of Cardiovascular Translational Research
- IEEE Transactions on Biomedical Engineering
- Journal of NeuroInterventional Surgery
- Heart
- Measurement
- Computer Methods in Biomechanics and Biomedical Engineering
- International Journal of Artificial Organs
- Journal of Surgical Research
- Clinical Physiology and Functional Imaging
- Journal of Computational Biology and Bioinformatics Research
- Medical & Biological Engineering & Computing

- Hult International Business School
- University of Bordeaux, IdEx Post-doctoral Fellowships program – evaluate candidates
- Associate Abstract Referee: Danish Annual Congress in Biomedical Engineering

#### **Conference Chairman / Moderator**

- Oral Session Chair, Cardiovascular Engineering, Device Technologies and Biomedical Robotics: Vascular Devices and Hemodynamics, Biomedical Engineering Society 2018 Annual Meeting, October 19th, Atlanta, Georgia, USA
- Oral Session Chair, Hemodynamics and Vascular Mechanics, Biomedical Engineering Society 2015 Annual Meeting, October 8th, Tampa, Florida, USA
- Oral Session Moderator, 33<sup>rd</sup> Annual meeting of the Scandinavian Society of ExtraCorporeal Technology, Aarhus, Denmark August 22<sup>nd</sup> - 24<sup>th</sup>, 2013
- Poster Session Moderator, 62<sup>nd</sup> Annual Meeting of Scandinavian Association for Thoracic Surgery, Aarhus, Denmark August 22<sup>nd</sup> - 24<sup>th</sup>, 2013
- Award Presentation Committee Chairman, 31<sup>st</sup> Danish Annual Congress in Biomedical Engineering, September 18<sup>th</sup>, 2013, Brædstrup, Denmark
- Award Presentation Committee Chairman, 30<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 19<sup>th</sup>, 2012, Brædstrup, Denmark
- Award Poster Presentation Committee Chairman, 30<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 20<sup>th</sup>, 2012, Brædstrup, Denmark
- Moderator: "Beyond the Limits of Mitral Valve Repair", Mitral Valve Replacement Symposium, September 29<sup>th</sup>, 2011, Aarhus University Hospital, Denmark
- Session Chairman, 60<sup>th</sup> Scandinavian Conference in Cardiothoracic Surgery, Tampere, Finland, 18 - 20 Aug 2011
- International Federation for Medical and Biological Engineering (IFMBE) Young Investigator Awards Committee, June 14-17<sup>th</sup>, 2011, Aalborg, Denmark
- Panel Discussion Member: "Biomedical Engineering Education", 15<sup>th</sup> Nordic – Baltic Conference on Biomedical Engineering and Medical Physics, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark
- Chairman: "Cardiovascular & Pulmonary Engineering", 15<sup>th</sup> Nordic – Baltic Conference on Biomedical Engineering and Medical Physics, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark
- 29<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark
- Session Chairman, 30<sup>th</sup> Scandinavian Conference in ExtraCorporeal Technology, Oslo, Norway, 26 - 28 Aug 2010
- Session Chairman, PhD-day, Faculty of Health Sciences, Aarhus University, Denmark, January 15<sup>th</sup>, 2010
- Award Presentation Session Committee, 27<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 22<sup>nd</sup>, 2010, Brædstrup, Denmark
- Award Poster Presentation Session Committee, 27<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 23<sup>rd</sup>, 2010, Brædstrup, Denmark
- Session Chairman, 19<sup>th</sup> World Congress of the World Society of Cardio-Thoracic Surgeons
- Buenos Aires, Argentina, November 4<sup>th</sup> – 6<sup>th</sup>, 2009
- Award Presentation Session Committee, 28<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 17<sup>th</sup>, 2009, Brædstrup, Denmark

#### **Conference Organizing / Scientific Committee**

- 31<sup>st</sup> National Meeting at the Danish Society for Biomedical Engineering, September 17<sup>th</sup> – 19<sup>th</sup>, 2013, Braedstrup, Denmark
- 30<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 19<sup>th</sup> – 20<sup>th</sup>, 2012, Braedstrup, Denmark
- 15<sup>th</sup> Nordic – Baltic Conference on Biomedical Engineering and Medical Physics, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark
- 29<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark

- 28<sup>h</sup> National Meeting at the Danish Society for Biomedical Engineering, September 21<sup>st</sup> - 23<sup>rd</sup>, 2010, Braedstrup, Denmark
- 27<sup>h</sup> National Meeting at the Danish Society for Biomedical Engineering, September 22<sup>nd</sup> - 24<sup>rd</sup>, 2009, Braedstrup, Denmark

### **Publications Summary**

- 66 peer reviewed publications (hereof 53 journal papers and 13 refereed conference proceedings)
- 19 magazine articles
- 11 books / book chapters
- 6 conference keynote addresses
- 81 conference oral presentations
- 55 conference poster presentations
- 28 seminars / invited guest speaker
- 6 patents / patent application publications / trade secrets

### **Peer Reviewed Paper Publications**

- 1) Laughlin M, Stephens S, Jensen H, Jensen M, Millett P: "Fluid-Structure Interaction Modeling and Validation of Idealized Left Ventricular Blood Flow" *Proceedings of the American Society of Mechanical Engineers 2020 Fluids Engineering Division Meeting Pages: 1-8*
- 2) Ilkjaer C, Ropcke DM, Skov SN, Tjornild MJ, Vibaek A, Jensen MO, Nielsen SL: "Functional and biomechanical effects of ring annuloplasty on tissue engineered tricuspid tube-graft" *Interactive CardioVascular and Thoracic Surgery, June 2019 in press*
- 3) Collins RT; Laughlin M; Lang S; Bolin E; Daily J; Jensen H; Jensen M: "Real-Time Transthoracic Vector Flow Imaging of the Heart in Pediatric Patients" *Progress in Pediatric Cardiology 2019, Volume 53, June 2019, Pages 28-36. DOI: <https://doi.org/10.1016/j.ppedcard.2019.02.003>*
- 4) Easson G, Laughlin M, Jensen H, Haney K, Girardot M, Jensen M: "Performance Changes of Venous Valves following Tissue Treatment with Novel In Vitro System"; *Phlebology. 2019 Jun;34(5):347-354. doi: 10.1177/0268355518804360.*
- 5) Patrick C Bonasso; Kevin W Sexton; Steven C Mehl; Michael S Golinko; Morten O Jensen; Jingxian Wu; Samuel D Smith; Jeffrey M Burford; Melvin S Dassinger: "Lessons learned measuring peripheral venous pressure waveforms in an anesthetized pediatric population." *Biomedical Physics & Engineering Express, 28 March 2019, Volume 5, Number 3.* <https://doi.org/10.1088/2057-1976/ab0ea8>
- 6) Bonasso PC, Sexton KW, Hayat MA, Wu J, Jensen HK, Jensen MO, Burford JM, Smith SD, Dassinger SM: "Venous physiology predicts dehydration in pediatric patients." *J Surg Res. 2019 Feb 15;238:232-239.*
- 7) Preut A, Laughlin M, Jensen H, Hestekin J, Jensen M: Novel Method for Emboli Analog Formation Towards Improved Stroke Retrieval Devices" *J Biomech. October 26, 2018 Volume 80, Pages 121–128*
- 8) Jensen MO, Jensen H, Skov SN, Levine RA, Nygaard H, Hasenkam JM, Nielsen SL: "New Mitral Valve Annuloplasty Concept: Optimizing Annular Dynamics and Force Distribution" *J Heart Valve Dis. 2018 Jan;27(1):38-46.*

- 9) Bonasso, PC; Dassinger, MS; Jensen, MO; Smith, SD; Burford, JM; Sexton, KW: "Optimizing peripheral venous pressure waveforms in an awake pediatric patient by decreasing signal interference", *Journal of Clinical Monitoring and Computing*, 2018 Dec;32(6):1149-1153
- 10) Stephens SE, Liachenko S, Ingels NB, Wenk JF, Jensen MO (2017) High resolution imaging of the mitral valve in the natural state with 7 Tesla MRI. PLoS ONE 12(8): e0184042. <https://doi.org/10.1371/journal.pone.0184042>
- 11) Skov SN, Ropcke DM, Tjornild MJ, Ilkjær C, Rasmussen J, Nygaard H, Hasenkam JM, Jensen MO, Nielsen SL: "Remodeling Mitral Annuloplasty Ring Concept with Preserved Dynamics of the Annular Height" *J Heart Valve Dis.* 2017 May;26(3):295-303
- 12) Skov SN, Røpcke DM, Tjørnild MJ, Ilkjær C, Rasmussen J, Nygaard H, Jensen MO, Nielsen SL: "The effect of different mitral annuloplasty rings on valve geometry and annular stress distribution" *Interact CardioVasc Thorac Surg* 2017;24:683–90.
- 13) Skov SN, Ropcke DM, Tjornild MJ, Ilkjær C, Rasmussen J, Nygaard H, Jensen MO, Nielsen SL: "Semi-rigid Mitral Annuloplasty Rings Improves Myocardial Stress Adaptation Compared to a Rigid Ring", *European Journal of Cardiothoracic Surgery (EJCTS)*, 2017 May 1;51(5):836-843
- 14) Sasa Grbic, Thomas F. Easley, Tommaso Mansi, Charles H. Bloodworth, Eric L. Pierce, Ingmar Voigt, Dominik Neumann, Julian Krebs, David D. Yuh, Morten O. Jensen, Dorin Comaniciu, Ajit P. Yoganathan: "Personalized Mitral Valve Closure Computation and Uncertainty Analysis from 3D Echocardiography" *Medical Image Analysis Volume 35, January 2017, Pages 238–249*
- 15) Pantoja JL, Morgan AE, Grossi EA, Jensen MO, Weinsaft JW, Levine RA, Ge L, Ratcliffe MB: "Undersized Mitral Annuloplasty Increases Strain in the Proximal Lateral Left Ventricular Wall". *Cover Article in Ann Thorac Surg. 2016 Oct 5 (8 pages).*
- 16) Charles H. Bloodworth IV, B.S.; Eric L. Pierce, B.S.; Thomas F. Easley, M.S.; Andrew Drach, Ph.D.; Amir H. Khalighi, M.S.; Milan Toma, Ph.D.; Morten Ø. Jensen, Ph.D., Dr.Med.; Michael S. Sacks, Ph.D., Ajit P. Yoganathan, Ph.D.: "Ex Vivo Methods for Informing Computational Models of the Mitral Valve", *Ann Biomed Eng. 2017 Feb;45(2):496-507. doi: 10.1007/s10439-016-1734-z. Epub 2016 Oct 3.*
- 17) Eric L. Pierce, Jean Pierre M. Rabbah, Karl Thiele, Qifeng Wei, Brani Vidakovic, Morten O. Jensen, Judy Hung, Ajit P. Yoganathan: "Three-Dimensional Field Optimization Method: Gold-Standard Validation of a Novel Color Doppler Method for Quantifying Mitral Regurgitation" *Journal of the American Society of Echocardiography (JASE) 2016 Oct;29(10):917-925*
- 18) Søren Nielsen Skov, Diana Mathilde Røpcke, Christine Ilkjær, Jonas Rasmussen, Marcell Juan Tjørnild, Jorge H. Jimenez, Ajit P. Yoganathan, Hans Nygaard, Sten Lyager Nielsen, Morten Olgaard Jensen: "New mitral annular force transducer optimized to distinguish annular segments and multi-plane forces", *Journal of Biomechanics, Volume 49, Issue 5, 21 March 2016, Pages 742–748.*
- 19) Eric L. Pierce, Andrew W. Siefert, Deborah M. Paul, Sarah K. Wells, Charles H. Bloodworth, IV, Satoshi Takebayashi, Chikashi Aoki, Morten O. Jensen, Matthew J. Gillespie, Robert C. Gorman, Joseph H. Gorman, III, Ajit P. Yoganathan: "How Local Annular Force and Collagen Density Govern Mitral Annuloplasty Ring Dehiscence Risk" *Annals of Thoracic Surgery (ATS), August 2016, Volume 102, Issue 2, Pages 518–526.*

- 20) DM Ropcke, C Ilkjær, T Hejslet, AV Sørensen, H Jensen, MOJ Jensen, VE Hjortdal, SL Nielsen: "Functional and Biomechanical Performance of Stentless Extracellular Matrix Tricuspid Tube Graft: An Acute Experimental Porcine Evaluation" *The Annals of Thoracic Surgery*, 2016 Jan;101(1):125-32.
- 21) Toma M, Jensen MØ, Einstein DR, Yoganathan AP, Cochran RP, Kunzelman KS.: "Fluid-Structure Interaction Analysis of Papillary Muscle Forces Using a Comprehensive Mitral Valve Model with 3D Chordal Structure." *Annals of Biomedical Engineering* 2016, Apr;44(4):942-53
- 22) Robert Levine, Albert Hagege, Daniel Judge, Muralidhar Padala, Jacob Dal-Bianco, Elena Aikawa, Jonathan Beaudoin, Joyce Bischoff, Nabila Bouatia-Naji, Patrick Bruneval, Jonathan Butcher, Alain Carpentier, Miguel Chaput, Adrian Chester, Catherine Clusel, Francesca Nesta Delling, Harry Dietz, Christian Dina, Ronen Durst, Leticia Fernandez, Mark Handschumacher, Morten Jensen, Xavier Jeunemaitre, Hervé Le Marec, Thierry Le Tourneau, R Markwald, Jean Merot, Emmanuel Messas, David Milan, Tui Neri, Russell Norris, David Peal, Maelle Perrocheau, Vincent Probst, Michael Puceat, Nadia Rosenthal, Jorge Solis-Martin, Jean-Jacques Schott, Ehud Schwammenthal, Susan Slaugenhouette, Jae-Kwan Song, and Magdi Yacoub: "Unifying Concepts of Mitral Valve Disease: From Morphology to Mechanisms and Beyond" *Nature Reviews Cardiology* 2015 Dec; 12(12),689–710
- 23) Eric L. Pierce, Charles H. Bloodworth IV, Ajay Naran, Thomas F. Easley, Morten O. Jensen, Ajit P. Yoganathan: "Novel Method to Track Soft Tissue Deformations by Micro-Computed Tomography: Application to the Mitral Valve" *Annals of Biomedical Engineering* 2015 Nov 9. 2016 Jul;44(7):2273-81.
- 24) Søren N. Skov, Diana M. Røpcke, Kristine Telling, Christine Ilkjær, Marcell J. Tjørnild, Hans Nygaard, Sten L. Nielsen, Morten O. Jensen: "Simultaneous in- and out-of-plane Mitral Valve Annular Force Measurements" *Cardiovascular Engineering and Technology 2015 special issue on Mitral Valve Function, Pathology, and Therapeutic Options*, Page 185-192.
- 25) Drach A., Khalighi A.H., ter Huurne F.M., Lee C.H., Bloodworth C., Pierce E.L., Jensen M.O., Yoganathan A.P., Sacks M.S.: "Population-Averaged Geometric Model of Mitral Valve from Patient-Specific Imaging Data" *Journal of Medical Devices*, September 2015, Vol.9, 030952:1-3
- 26) Henrik Jensen, Morten O. Jensen, Sten L. Nielsen: "Surgical Treatment of Functional Ischemic Mitral Regurgitation" *Review paper, J. Heart Valve Dis.* 2015 Jan;24(1):30-42.
- 27) Tommy Bechsgaard, Jesper Langhoff Honge, Hans Nygaard, Morten Olgaard Jensen: "In Vivo Wireless Monitoring System of Cardiovascular Force Data" *Cardiovascular Engineering and Technology Volume 6, Issue 1 (2015)*, p. 2-7.
- 28) Diana M Ropcke, Morten OJ Jensen, Henrik Jensen, Tine Hejslet, Sten L Nielsen: "Papillary Muscle Force Distribution following Total Tricuspid Reconstruction using Porcine Extracellular Matrix" *The Journal of Heart Valve Disease* 2014;23:788-794.
- 29) Andrew Siefert, Eric Pierce, Madonna Lee, Morten Jensen, Chikashi Aoki, Satoshi Takebayashi, Robert Gorman, Joseph Gorman, Ajit Yoganathan: "Suture Forces in Undersized Mitral Annuloplasty: Novel Device and Measurements" *Ann Thorac Surg* 2014;98:305–9.
- 30) Morten O. Jensen, Jesper L. Honge, Jon A. Benediktsson, Andrew W. Siefert, Henrik Jensen, Ajit P. Yoganathan, Teresa K. Snow, J. Michael Hasenkam, Hans Nygaard, DMSc, Sten L. Nielsen: "Mitral valve annular downsizing forces: Implications for annuloplasty device development", *J Thorac Cardiovasc Surg*. 2014 Jul;148(1):83-9.

- 31) Henrik Jensen; Morten O Jensen; Farhad Waziri; Jesper L Honge; Erik Sloth; Morten Fenger-Grøn; Sten L Nielsen: "Transapical Neochord Implantation: Is Tension of Artificial Chordae Tendineae Dependent on Insertion Site?" *J Thorac Cardiovasc Surg.* 2014 Jul;148(1):138-43.
- 32) Morten O. Jensen, Albert A. Hagège, Yutaka Otsuji, Robert A. Levine: "The Unsaddled Annulus: Biomechanical Culprit in Mitral Valve Prolapse?" *Circulation Editorial*, 2013 Feb 19;127(7):766-8
- 33) ES Kragsnaes, JL Honge, JB Askov, SL Nielsen, H Nygaard, MO Jensen: "In-plane Tricuspid Valve Force Measurements: Development of Strain Gauge Instrumented Annuloplasty Ring" *Cardiovascular Engineering and Technology*, June 2013, Volume 4, Issue 2, pp 131-138.
- 34) Rahmani A, Rasmussen AQ, Honge JL, Ostli B, Levine RA, Hagège AA, Nygaard H, Nielsen SL, Jensen MO: "In Vitro Simulation Model Shows Adverse Mitral Valve Mechanics Following Leaflet Patch Augmentation" *The Journal of Heart Valve Disease*, 2013;22:28-35.
- 35) H Jensen, MO Jensen, S Vind-Kezunovic, R Vestergaard, S Ringgaard, MH Smerup, JL Honge, JM Hasenkam, SL Nielsen: "Surgical Relocation of the Papillary Muscles in Functional Ischemic Mitral Regurgitation - What are the Forces of the Relocation Stitch Acting on the Myocardium?" *The Journal of Heart Valve Disease* 2013 Jul;22(4):524-31.
- 36) Röpcke DM, Hjortdal VE, Toft GE, Jensen MO, Kristensen SD: "Remote ischemic preconditioning reduces thrombus formation in the rat", *Journal of Thrombosis and Haemostasis*, Volume 10, Issue 11, 2013, 2405-2406.
- 37) JB Askov, JL Honge, MO Jensen, H Nygaard, JM Hasenkam, SL Nielsen: "Significance of Force Transfer in Mitral Valve - Left Ventricular Interaction: In Vivo Assessment" *The Journal of Thoracic and Cardiovascular Surgery*, 2013 Jun;145(6):1635-41.
- 38) Morten O. Jensen, Henrik Jensen, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: "External Approach to In Vivo Force Measurement On Mitral Valve Traction Suture", *Journal of Biomechanics*, 45, (2012): 908–912.
- 39) Ostli B, Vester-Petersen J, Askov JB, Honge JL, Levine RA, Hagege AA, Nielsen SL, Hasenkam JM, Nygaard H, Jensen MO: "In Vitro System for Measuring Chordal Force Changes Following Mitral Valve Patch Repair", *Cardiovascular Engineering and Technology*: Volume 3, Issue 3 (2012), Page 263-268.
- 40) Jensen MO, Jensen H, Levine RA, Yoganathan AP, Andersen NT, Nygaard H, Hasenkam JM, Nielsen SL "Saddle-shaped mitral valve annuloplasty rings improve leaflet coaptation geometry", *The Journal of Thoracic and Cardiovascular Surgery* 2011 September;142(3):697-703.
- 41) Mathieu Granier\*, Morten O. Jensen\*, Jesper L. Honge, Alain Bel, Philippe Menasché, Sten L. Nielsen, Alain Carpentier, Robert A. Levine, Albert A. Hagège: "Consequences of mitral valve prolapse on chordal tension: Ex vivo and in vivo studies in large animal models" *The Journal of Thoracic and Cardiovascular Surgery*, 2011 Dec;142(6):1585-7.
- 42) JB Askov, JL Honge, H Nygaard, JM Hasenkam, SL Nielsen, MO Jensen: "Papillary Muscle Force Transducer for Measurement In Vivo", *Cardiovascular Engineering and Technology*, September 2011, Volume 2; Issue 3; p196-202.
- 43) A Stigo, P Johansen, M Jensen, K Sivesgaard, H Nygaard, E Sloth: An automated in-vitro model for the evaluation of Ultrasound modalities measuring myocardial deformation. *Cardiovasc Ultrasound* 2010 Sep 7;8:40.

- 44) Henrik Jensen, Morten Ølgaard Jensen, Morten H. Smerup, Steffen Ringgaard, Niels Trolle Andersen, Per Wierup, J. Michael Hasenkam, Sten Lyager Nielsen: Does down-sized ring annuloplasty induce papillary muscle relocation in ischemic mitral regurgitation? *J Heart Valve Dis.* 2010 Nov;19(6):692-700.
- 45) Henrik Jensen, Morten Ølgaard Jensen, Morten H. Smerup, Steffen Ringgaard, Thomas S. Sørensen, Per Wierup, J. Michael Hasenkam, Sten Lyager Nielsen: Three-dimensional Assessment of Papillary Muscle Displacement in Ischemic Mitral Regurgitation in Pigs. *The Journal of Thoracic and Cardiovascular Surgery* 2010 Dec;140(6):1312-8.
- 46) Henrik Jensen, Morten Ølgaard Jensen, Sten Lyager Nielsen; Morten Smerup; Stefan Vind-Kezunovic; Rikke Vestergaard; Niels Trolle Andersen; Michael Hasenkam; Steffen Ringgaard; Per Nils Johan Fredrik Wierup; "Impact of Papillary Muscle Relocation as Adjunct Procedure to Mitral Ring Annuloplasty in Functional Ischemic Mitral Regurgitation" *Circulation* 2009;120:S92-S98.
- 47) Jeppe H. Christensen, Mads B. T. Soerensen, Zhong Linghui, Sun Chen, Morten O. Jensen: Pre-diagnostic digital imaging prediction model to discriminate between malignant melanoma and benign pigmented skin lesion, *Skin Research and Technology* 2009, Volume 16, Issue 1, Pages 98 – 108
- 48) Morten O. Jensen, Henrik Jensen, Morten Smerup, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: Saddle-shaped Mitral Valve Annuloplasty Rings Provide Superior Annular Force Distribution Compared with Flat Rings. *Circulation* 2008;118(suppl 1):250-255.
- 49) Jensen, M. O., Jensen, H., Nielsen, S.L., Smerup, M., Johansen, P., Yoganathan, A. P., Nygaard, H., Hasenkam, J. M.: What Forces Act on a Flat Rigid Mitral Annuloplasty Ring. *J Heart Valve Dis* 2008;17:267-275.
- 50) Nielsen PF, Funder JA, Jensen MO, Nygaard H: Influence of Venous Reservoir Level on Microbubbles in Cardiopulmonary Bypass, *Perfusion* 2008, Vol. 23, No. 6, 347-353.
- 51) Henrik Jensen, Morten Ø. Jensen, Steffen Ringgaard, Morten H. Smerup, Thomas S. Sorensen, Won Y. Kim, Erik Sloth, P. Wierup, J. Michael Hasenkam, Sten L. Nielsen "Geometric Determinants of Chronic Functional Ischemic Mitral Regurgitation: Insights from Three-Dimensional Cardiac Magnetic Resonance Imaging" *The Journal of Heart Valve Disease* 2008 Jan;17(1):16-22; discussion 23.
- 52) Jensen MO, Lemmon JD, Gessaghi VC, Conrad CP, Levine RA, Yoganathan AP. Harvested porcine mitral xenograft fixation: impact on fluid dynamic performance. *J Heart Valve Dis* 2001 Jan;10(1):111-24.
- 53) Jensen MO, Fontaine AA, Yoganathan AP. Improved *in vitro* quantification of the force exerted by the papillary muscle on the left ventricular wall: three dimensional force vector measurement system. *Ann Biomed Eng.* 2001 May;29(5):406-13.
- 54) He S, Weston MW, Lemmon J, Jensen M, Levine RA, Yoganathan AP. Geometric distribution of chordae tendineae: an important anatomic feature in mitral valve function. *J Heart Valve Dis.* 2000 Jul;9(4):495-501; discussion 502-3.
- 55) He S, Lemmon JD Jr, Weston MW, Jensen MO, Levine RA, Yoganathan AP. Mitral valve compensation for annular dilatation: *in vitro* study into the mechanisms of functional mitral regurgitation with an adjustable annulus model. *J Heart Valve Dis.* 1999 May;8(3):294-302.

## **Refereed Conference Publications**

- 56) Bean MJ, Jiang D, Manoharan F, Nowell AE, Uretsky B, Jensen HK, Timmins LH, Jensen MO: "Modeling Percutaneous Intervention of Coronary Artery Bifurcations", *SB3C2020 Summer Biomechanics, Bioengineering and Biotransport Conference, June 17 – 20, 2020: Virtual Conference*
- 57) Crimmins LD, Henry KR, Hayat MA, Bonasso PC, Wu J, Jensen HK, Sexton KW, Jensen MO: "Dehydration and Anesthesia Influence on The Relationship Between Arterial and Venous Pressure Waveforms", *SB3C2020 Summer Biomechanics, Bioengineering and Biotransport Conference, June 17 – 20, 2020: Virtual Conference*
- 58) Jiang D, Zimmerman BK, Bean MJ, Maas SA, Jensen MO, Ateshian GA, Timmins LH: "Towards the Establishment of Lesion-Specific Stenting Strategies: Validation of a Coupled Balloon-Stent Finite Element Framework for Vascular Stent Deployment", *SB3C2020 Summer Biomechanics, Bioengineering and Biotransport Conference, June 17 – 20, 2020: Virtual Conference*
- 59) Kaylee R. Henry, Ali Z. Al-Alawi, Md Abul Hayat, Hanna K. Jensen, Jingxian Wu, Patrick C. Bonasso, Kevin W. Sexton, and Morten O. Jensen: "Isoflurane Effect on Peripheral Venous Pressure" *SB3C2019 Summer Biomechanics, Bioengineering and Biotransport Conference* June 25 -28, Seven Springs, PA, USA
- 60) Bean MJ, Jiang D, Stephens SE, Laughlin ME, Jensen HK, Uretsky B, Timmins LH, Jensen MO: "Experimental Modeling of Coronary Intervention: Towards Computational Simulation", *Proceedings of the SB3C2019 Summer Biomechanics, Bioengineering and Biotransport Conference, June 25-28, 2019, Seven Springs, PA, USA*
- 61) Henson JC, Batta-Mpouma J, Chivers C, Sinha A, Jensen H, Kim J, Jensen M, Kim JW: "Nanopatterned Polycaprolactone/Cellulose Nanocrystal Composite Scaffold for Cardiovascular Tissue Engineering"; *IEEE NANOMED 2018*, December 2-5, Waikiki Beach, Hawaii
- 62) Easson G, Laughlin M, Jensen H; Haney, K; Girardot M; Jensen MO: "Development of an in Vitro System for Physiological Testing of Native and Prosthetic Venous Valves", *Journal of Phlebology, Volume 32, Issue 2, Dec 2017 p. 33-36*
- 63) Stephens SE, Liachenko S, Wenk JF, Jensen MO: "In vitro left heart system with 7T MRI provides high resolution mitral valve 3D imaging datasets for computational modeling", *Proceedings of the SB<sub>3</sub>C2017 Summer Biomechanics, Bioengineering and Biotransport Conference, June 21-24, 2017, Tucson, Arizona, USA*
- 64) Wenk JF, Jensen MO: "Finite Element Modeling of Mitral Valve Patch Augmentation and Effects on Chordal Force Distribution", *Proceedings of the SB<sub>3</sub>C2017 Summer Biomechanics, Bioengineering and Biotransport Conference, June 21-24, 2017, Tucson, Arizona, USA*
- 65) Qusay Alfaori, Ashok Saxena, Hanna Jensen and Morten Jensen: "Rupture in Abdominal Aortic Aneurysm", *Proceedings of First Structural Integrity Conference and Exhibition (SICE-2016), Bangalore, India, July 4-6, 2016*
- 66) Eric L. Pierce, Charles H. Bloodworth IV, Ajay Naran, Thomas F. Easley, Morten O. Jensen, Ajit P. Yoganathan: "Novel Medical Imaging Technique for Soft Tissue Deformation Tracking – Application to The Mitral Valve" *Proceedings of the SB<sub>3</sub>C2015 Summer Biomechanics, Bioengineering and Biotransport Conference, June 17-20, 2015, Snowbird Resort, Utah, USA.*

- 67) Milan Toma, Morten O. Jensen, Daniel R. Einstein, Ajit P. Yoganathan, Richard P. Cochran, Karyn S. Kunzelman: "Fluid-Structure Interaction Analysis of Mitral Valve Forces Using a Comprehensive Model With 3D Chordal Structure: Synergy of Modeling and Experiments" *Proceedings of the SB<sub>3</sub>C2015 Summer Biomechanics, Bioengineering and Biotransport Conference (Podium Presentation)*, June 17-20, 2015, Snowbird Resort, Utah, USA.
- 68) C. H. Bloodworth IV, E. L. Pierce, T. F. Easley, M. Toma, A. Khalighi, C-H. Lee, M. Sacks, A. W. Siefert, M. Ø. Jensen, A. P. Yoganathan: "Design of an In Vitro Simulation Pipeline for the Development of Computational Mitral Valve Modeling", *Proceedings of the SB<sub>3</sub>C2015 Summer Biomechanics, Bioengineering and Biotransport Conference*, June 17-20, 2015 (Podium), Snowbird Resort, Utah, USA.
- 69) Khalighi A.H., Drach A., ter Huurne F.M., Lee C.H., Bloodworth C., Pierce E.L., Jensen M.O., Yoganathan A.P., Sacks M.S.: "A Complete Framework for the Charactrization of Complete Mitral Valve Geometry for the Development of A Population-averaged Model", *8th International Conference on Functional Imaging and Modeling of the Heart*, June 25-27, 2015, Maastricht, Netherlands. ISBN: 978-3-319-20308-9 (Print) 978-3-319-20309-6 (Online): page 164-171, 2015.
- 70) Andrew Drach, Amir H. Khalighi, Fleur M. ter Huurne, Chung-Hao Lee, Charles Bloodworth, Morten O. Jensen, Ajit P. Yoganathan, Michael S. Sacks: "Population-Averaged Geometric Model of Mitral Valve from Patient-Specific Imaging Data" *Proceedings of the Design of Medical Devices Conference April 13-16, 2015, Minneapolis, MN, Technical Brief in the June 2015 issue of ASME Journal of Medical Devices*.
- 71) Sasa Grbic, Thomas F. Easley, Tommaso Mansi, Charles H. Bloodworth, Eric L. Pierce, Ingmar Voigt, Dominik Neumann, Julian Krebs, David D. Yuh, Morten O. Jensen, Dorin Comaniciu, and Ajit P. Yoganathan: "Multi-modal Validation Framework of Mitral Valve Geometry and Functional Computational Models" *Proceedings of the Medical Image Computing and Computer Assisted Intervention Society 2014 Annual Meeting*.
- 72) JB Askov, MO Jensen, JL Honge, H Nygaard, JM Hasenkam, SL Nielsen: "Miniature Transducer for Chordal Force Measurements In Vivo" *Proceedings of the ASME Summer Bioengineering Conference June 16, 2010, Proc. ASME. 44038, ASME ID SBC2010-19181*, p 617-618.
- 73) Morten O. Jensen, Peter Johansen, Hans Nygaard: Development of an Implantable Heart Valve Force Transducer. *Proceedings of the ASME Summer Bioengineering Conference June 25, 2008, Proc. ASME. 43215, ASME ID SBC2008-192309*, p 247-248.

### **Magazine Articles**

- 74) Megan Laughlin, Jamie Hestekin, Morten Jensen: "Inno-vein-tion: How U of A researchers are creating new technology that simulates human blood vessels" *Arkansas Engineer, October 2018*
- 75) Jensen, Morten; Chitney, Anton: "Measuring forces in a beating heart" *VPG Micro-Measurements Case Study, December 2017*
- 76) Kim Dremstrup, Morten Jensen: "Forty, Fresh and Ready". *Editorial for the 40-year anniversary of the Danish Biomedical Engineering Society, Medical Technology and Informatics*, No. 5, November 2013, p. 4.
- 77) Morten Jensen: "Students in Focus". *Editorial, Medical Technology and Informatics*, No. 1, March 2012, p. 4.

- 78) Naia Bang (Featured Article): "Trækker i trådene, når klappen går ned". *Medical Technology and Informatics*, No. 4, August 2011, p. 16.
- 79) Besenbacher Bente, Johansen Peter, Jensen Morten: "Health Technology in Aarhus". *Medical Technology and Informatics*, No. 2, April 2011, p. 4-6.
- 80) Engineers for a Better World: "Help to Heart Patients" *Genius Issue #3, Nov '10* ([www.aha.dk/genius](http://www.aha.dk/genius) and <http://magazine.heyday.dk/ha/genius3/>).
- 81) Jesper Askov and Morten Jensen: "Materials Science in Analyzing Forces in the Heart." *Medical Technology and Informatics*, No. 3, June 2009, p. 10-12.
- 82) Morten Jensen: Force balance in the mitral valve annulus: How to interpret the function of annuloplasty devices. *Medical Technology and Informatics supplement for the 25th Danish annual congress in biomedical engineering, 2009*.
- 83) Mette Stougaard (Featured Article) "Intelligent Hjertering med Lang Levetid" *Hjertenyt, (Danish Heart Association Magazine)*, Nov. '08 pg. 12-13.
- 84) Morten Jensen: Kraftbalancen i mitralklappen og venstre ventrikel. *Ugeskrift for Læger* 2008;170(47):3877.
- 85) Jensen, Morten: Collaboration between Engineers and Doctors can save lives. *Medical Technology and Informatics*, No. 7, October 2006, p. 38-41.
- 86) Ben Black, Morten Jensen, Wayne Book: Georgia Tech Intelligent Machine Dynamics Laboratory Utilizing National Instruments Platform for Developing Haptic Devices. *National Instruments Academia*, Jan 2005.
- 87) Morten Jensen: Using National Instruments System Identification, Control Design and Simulation Products for Designing and Testing a Controller for an Unidentified System. *NI Developer Zone*, Jan 2005.
- 88) Jensen, Morten: SISO Plant Simulator for Evaluating the NI LabVIEW Control Design and Simulation Bundle for Designing and Testing a Controller to an Unidentified System. *NI Developer Zone*, May 2005.
- 89) Morten Jensen, Ash Prabala, Doug Benson, William Bridson, Joseph Corsi: Automating Fluorescent Imaging Techniques. *National Instruments Online Developer Zone*, July 2004.
- 90) Guettler RD, Saxena R, Jensen MO. Bacterial Colony and Plaque Picking: An Automated Solution for DNA sample preparation (Cover Article). *Scientific Computing and Instrumentation Sep. 2002* pg. 12-22.
- 91) Min J. Yang, Ph.D., Ron Bonner, Ph.D., Morten Jensen: Vision in Mass Spectrometry. *Scientific Computing and Instrumentation Sep. 2002* pg. 18-24.
- 92) Jensen, Morten: Calculating Camera Sensor Resolution and Lens Focal Length. *National Instruments Developer Zone*, October 2001.

### **Books and Book Chapters**

- 93) Jensen M, Siefert A, Okafor I, Yoganathan AP: "Measurement technologies for heart valve function", Chapter in "Advances in Heart Valve Biomechanics: Valvular Physiology, Mechanobiology, and Bioengineering", 1st Edition released on February 14, 2019. P 1-Xs ISBN-10: 3030019918
- 94) Henson J, Jensen H, Balachandran K, Rao R, Kim J-W, Jensen M: "Cues from the Nano-environment: The role of Nanomaterials in Stem Cell Differentiation and Stem Cell Tissue Engineering" *Soft Materials in Nano/Bio Medicine*, 2019
- 95) Raghav V, Jensen M, Arjunon S, Teoh SH, Yoganathan AP: "Heart Valve Prostheses and Repair Devices", *Materials Science and Materials Engineering - Comprehensive Structural Integrity*, 2018(2017), by Editors-in-Chief: I. Milne, R. O. Ritchie, and B. Karihaloo. ISBN: 978-0-08-043749
- 96) Alfaori Q, Saxena A, Jensen HA, Jensen MO: "Collagen Degradation Effect on Rupture in Abdominal Aortic Aneurysm", *Advances in Structural Integrity* 2017, ISBN 978-981-10-7197-3
- 97) Jensen H, Martin E, Jensen M, Rome F, Di Carlo A, Kim JW, Mehta JL. "Nanotechnology-Based Stem Cell Applications and Imaging". In: "Imaging in Stem Cell Transplant and Cell-based Therapy (In: Stem Cell Biology and Regenerative Medicine)". *Springer Book Series*. June 2017, ISBN 978-3-319-51831-2, DOI 10.1007/978-3-319-51833-6
- 98) Sasa Grbic, Thomas F. Easley, Tommaso Mansi, Charles H. Bloodworth, Eric L. Pierce, Ingmar Voigt, Dominik Neumann, Julian Krebs, David D. Yuh, Morten O. Jensen, Dorin Comaniciu, Ajit P. Yoganathan: "Multi-modal Validation Framework of Mitral Valve Geometry and Functional Computational Models" *Statistical Atlases and Computational Models of the Heart - Imaging and Modeling Challenges 2015*, pp 239-248.
- 99) Dremstrup, Kim; Rees, Steve; Jensen, Morten Ølgaard (Eds.): "15th Nordic-Baltic Conference on Biomedical Engineering and Medical Physics", 1<sup>st</sup> Edition., 2011, XVI, 280 p. 245 illus. (Springer eBook link: <http://dx.doi.org/10.1007/978-3-642-21683-1>).
- 100) Jensen, Morten: "Ensemble Averaging of Physiologic Signals: A LabVIEW based Software Package Assisting the Analysis of Cyclic Data", *Book Chapter in "Virtual Bio-Instrumentation" by Jon B. Olansen and Eric Rosow, Prentice Hall 2002*.
- 101) Jensen Morten: "Stentless Mitral Valve Fixation: Impact on Hemodynamic Performance", *Master's Thesis 2000*.
- 102) Jensen Morten: "Mitral Valve Force Balance: The Left Ventricular Tug of War", *PhD Thesis 2008*.
- 103) Jensen Morten: "Biomechanical Aspects of Mitral Valve Function and Repair", *DMSc (Dr.Med.) Thesis 2015*.

### **Conference Keynote Addresses / Invited Lectures**

- 1) Jensen, M: "Biomechanical Aspects of FMR". *2019 Annual Meeting of the Heart Valve Society (HVS), Apr 11 - 13, 2019, Sitges, Catalonia, Spain. Mitral Valve Session Discussant Panel with Discussants: Jerry Braun, MD, PhD, Morten O. Jensen, DrMed, PhD, Resham Barauh, MD, Michael Borger, MD, Vinod Thourani, MD, Mark Ratcliffe, MD*

- 2) Jensen, M (f. Yoganathan, A): "Cardiovascular Devices: From the Bench and Computer to Bedside/Bassinet" 2014, *BMES Annual Meeting October 22-25, 2014, San Antonio, Texas.*
- 3) Morten Jensen, PhD; Jesper Honge, MD: "Cardiac Dynamics", *15th Nordic – Baltic Conference on Biomedical Engineering and Medical Physics, June 14<sup>th</sup> - 17<sup>th</sup>, 2011, Aalborg, Denmark.*
- 4) Morten Jensen: "Inspiration and Recognition of Science and Technology", *(FIRST) LEGO League, Herning, Denmark, October 1<sup>st</sup> 2010.*
- 5) Morten Jensen: "Computer based Measurements in Experimental Heart Surgery", *National Instruments Annual Conference, Hørsholm, Denmark, May 6<sup>th</sup> 2010.*
- 6) Morten O. Jensen: What Forces Act on Rigid Mitral Annuloplasty Rings? Implications for Annuloplasty Ring Designs. *Keynote Address at the Robert Levine Symposium on New Frontiers in Mitral Valve Repair.*
- 7) *Targeting the Natural History of Mitral Valve Regurgitation, Tuesday January 20<sup>th</sup>, 2009, Aarhus, Denmark.*

#### **Conference Abstracts: Oral Presentations**

- 8) Gal DB, Stephens S, MacMillen K, Jensen HK, Bolin E, Daily J, Millett P, Jensen M, Collins RT: "A Patient-based Computational Model that Predicts Pressure Drop in Supravalvar Aortic Stenosis in Patients with Williams Syndrome", *American Association of Pediatrics, San Diego, CA, Oct. 2-6, 2020*
- 9) Gal DB, MacMillen K, Jensen M, Jensen H, Bolin E, Daily J, Collins RT: "Percent Change in Diameter from Aortic Annulus to Sinotubular Junction Predicts Supravalvar Aortic Stenosis Gradient in Williams Syndrome" *American Society of Echocardiography, Denver, Colorado, June 19-22, 2020*
- 10) Megan Laughlin, Sam Stephens, Hanna Jensen, Morten Jensen, Paul Millett: "Fluid-Structure Interaction Modeling and Validation of Idealized Left Ventricular Blood Flow". *American Society of Mechanical Engineers FEDS Meeting, Orlando, FL July 12-16*
- 11) Joseph Batta-Mpouma, Cody Chivers, Garrett Huffstutler, Hanna K. Jensen, Morten O. Jensen, Jangho Kim, and Jin-Woo Kim: "Hybrid Composites of Cellulose Nanocrystal and Polycaprolactone as Scaffold Materials for Cardiomyocyte Regeneration" *13th IEEE International Conference on Nano/Molecular Medicine & Engineering (IEEE-NANOMED 2019), 21-24 November 2019, Gwangju, Korea.*
- 12) Jensen M, Wenk J: "Optimizing Imaging and Force Validation for Computational Modeling of Cardiac Valve Function and Intervention" *15th U.S. Congress on Computational Mechanics, Minisymposium: Computational Modeling of Cardiac Valve Function and Intervention, Austin, Texas, USA, July 28-August 1, 2019*
- 13) Bonasso, PC; Sexton, KW; Hayat MA; Al-Alawi A; Jingxian W; Jensen, HK; Jensen, MO; Smith SD; Burford, JM; Dassinger, MS: "Ventricular physiology predicts anesthetic induced hypotension in infants" *American College of Surgeons Clinical Congress, Boston MA, October 2018*
- 14) Stephens SE, Liachenko S, Wenk JF, Jensen MO: "In vitro left heart system with 7T MRI provides high resolution mitral valve 3D imaging datasets for computational modeling", *SB<sub>3</sub>C2017 Summer*

*Biomechanics, Bioengineering and Biotransport Conference, June 21, 2017, Tucson, Arizona, USA*

- 15) Qusay Alfaori, Ashok Saxena, Hanna Jensen, Morten Jensen: "Rupture Prediction in Abdominal Aortic Aneurysms". *43rd Annual Symposium on Vascular and Endovascular Issues, November 15 - 19, 2015, New York, NY, USA.*
- 16) Skov SN, Ropcke DM, Tjornild MJ, Ilkjær C, Rasmussen J, Nygaard H, Jensen MO, Nielsen SL: "Semi-rigid Mitral Annuloplasty Rings Improves Myocardial Stress Adaptation Compared to a Rigid Ring" *30th Annual Meeting of The European Association for Cardio-Thoracic Surgery, October 1-5, 2016, Barcelona, Spain*
- 17) Qusay Alfaori, Ashok Saxena, Hanna Jensen and Morten Jensen: "Rupture in Abdominal Aortic Aneurysm", *Proceedings of First Structural Integrity Conference and Exhibition (SICE-2016), Bangalore, India, July 4-6, 2016*
- 18) Pantoja JL, Morgan AE, Ge L, Grossi EA, Weinsaft JW, Jensen MO, Levine RA, Ratcliffe MB: "Undersized Ring Annuloplasty Increases Strain in the Left Ventricle: Finite Element Analysis", *2nd Annual Meeting of the Heart Valve Society, March 17-19, 2016, New York City, NY.*
- 19) Skov SN, Ropcke DM, Ilkjær C, Rasmussen J, Tjoernild MJ, Nygaard H, Jensen MO, Nielsen SL: "What are the Remodelling Forces of a Rigid Mitral Annuloplasty Ring – A Potential Risk Factor for Ring Dehiscence in Mitral Valve Repair?", *2nd Annual Meeting of the Heart Valve Society, March 17-19, 2016, New York City, NY.*
- 20) DM Røpcke, C Ilkjær, T Hejslet, AV Sørensen, H Jensen, MO Jensen, VE Hjortdal, SL Nielsen: "Functional and biomechanical performance of stentless extracellular matrix tricuspid tubegraft in pigs" *26th annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 11th –13th, 2016.*
- 21) SN Skov, DM Røpcke, C Ilkjær, J Rasmussen, MJ Tjørnild, H Nygaard, MO Jensen, SL Nielsen: "What are the remodelling forces of a rigid mitral annuloplasty ring – a potential risk factor in mitral valve repair?" *26th annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 11th –13th, 2016.*
- 22) C Ilkjær, DM Røpcke, SN Skov, MJ Tjørnild, AV Sørensen, MO Jensen, SL Nielsen: "Functional and biomechanical effects of conventional ring annuloplasty on a novel tissue engineered tricuspid tube graft prosthesis–preliminary results" *26th annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 11th –13th, 2016.*
- 23) Qusay Alfaori, Ashok Saxena, Hanna Jensen, Morten Jensen: "Rupture in Abdominal Aortic Aneurysms". *42nd Annual Symposium on Vascular and Endovascular Issues, November 17 - 21, 2015, New York, NY, USA.*
- 24) C.H. Lee, C.H. Bloodworth, M.O. Jensen, A.P. Yoganathan, M.S. Sacks: "Effects of leaflet microstructure and constitutive model on the closing behavior of the mitral valve" *Summer Biomechanics, Biongineering and Biotransport Conference (SB3C2015), Snowbird, UT, Jun 17-20, 2015.*
- 25) Skov, Søren Nielsen; Røpcke, Diana Mathilde; Ilkjær, Christine; Rasmussen, Jonas; Tjørnild, Marcell Juan; Nygaard, Hans; Jensen, Morten Ølgaard Jegstrup; Nielsen, Sten Lyager: "Biomechanical Features of a Rigid Remodeling Versus a Fully Flexible Mitral Annuloplasty Ring" *33rd National Meeting at the Danish Society for Biomedical Engineering, September 17th, 2015, Braedstrup, Denmark.*

- 26) Amir H. Khalighi, Andrew Drach, Chung-Hao Lee, Charles Bloodwoth, Eric L. Pierce, Morten O. Jensen, Robert C. Gorman, Joseph H. Gorman, Ajit P. Yoganathan, and Michael S. Sacks: "Development of a Population-Averaged Model of the Complete Mitral Valve Geometry", *Biomedical Engineering Society 2015 Annual Meeting, October 7-9, Tampa, Florida, USA.*
- 27) Skov, Søren Nielsen; Røpcke, Diana Mathilde; Ilkjær, Christine; Rasmussen, Jonas; Tjørnild, Marcell Juan; Nygaard, Hans; Jensen, Morten Ølgaard Jegstrup; Nielsen, Sten Lyager: "Rigid Remodelling Versus Fully Flexible Mitral Annuloplasty Rings - A Novel Assessment Tool for Biomechanical Characterization" *29th Annual Meeting of the European Association For Cardio-Thoracic Surgery (EACTS), Amsterdam, The Netherlands, 3 - 7 October 2015.*
- 28) Milan Toma, Morten O. Jensen, Daniel R. Einstein, Ajit P. Yoganathan, Richard P. Cochran, Karyn S. Kunzelman: "Fluid-Structure Interaction Analysis of Mitral Valve Forces Using a Comprehensive Model With 3D Chordal Structure: Synergy of Modeling and Experiments", *SB3C2015 Summer Biomechanics, Bioengineering and Biotransport Conference June 17-20, 2015, Snowbird Resort, Utah, USA.*
- 29) Charles H. Bloodworth, Eric L. Pierce, Thomas F. Easley, Milan Toma, Morten O. Jensen, Ajit P. Yoganathan: "Capturing Detailed 3D Mitral Valve Geometry for Computational Valve Modeling" *SB3C2015 Summer Biomechanics, Bioengineering and Biotransport Conference June 17-20, 2015, Snowbird Resort, Utah, USA.*
- 30) Toma M; Jensen MO; Einstein DR; Yoganathan AP; Cochran RP; Kunzelman KS: "Validating Fluid Structure Interaction in Medical Device Design with Force Measurements", *2015 BMES Frontiers in Medical Devices Conference: Innovations in Modeling and Simulation, May 18-20, 2015, Washington DC.*
- 31) Chung-Hao Lee, Charles H. Bloodworth, Morten O. Jensen, Ajit P. Yoganathan, Michael S. Sacks: "Predictive Computational Simulations of the Functioning Mitral Valve" *2015 BMES Frontiers in Medical Devices Conference: Innovations in Modeling and Simulation, May 18-20, 2015, Washington DC.*
- 32) Skov, Søren Nielsen; Røpcke, Diana Mathilde; Ilkjær, Christine; Tjørnild, Marcell Juan; Nygaard, Hans; Jensen, Morten Ølgaard Jegstrup; Nielsen, Sten Lyager: "How to measure the Forces in Mitral Annuloplasty Rings" *3rd Iranian Cardiovascular Joint Congress, 3rd-6th of March 2015, Teheran, Iran.*
- 33) Skov, Søren Nielsen; Røpcke, Diana Mathilde; Siefert, Andrew W; Ilkjær, Christine; Tjørnild, Marcell Juan; Nygaard, Hans; Nielsen, Sten Lyager; Jensen, Morten Ølgaard Jegstrup: "New concept for quantifying two-dimensional forces acting on an implanted mitral annuloplasty ring" *3rd Iranian Cardiovascular Joint Congress, 3rd-6th of March 2015, Teheran, Iran.*
- 34) SN Skov, DM Røpcke, AW Siefert, C Ilkjær, MJ Tjørnild, A Yoganathan, H Nygaard, SL Nielsen, M Jensen: "New concept for quantifying two-dimensional forces acting on an implanted mitral annuloplasty ring" *25th annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 12<sup>th</sup> –14<sup>th</sup>, 2015.*
- 35) DM Røpcke, C Ilkjær, T Hejslet, AV Sørensen, H Jensen, MOJ Jensen, VE Hjortdal, SL Nielsen: "Functional and biomechanical performance of stentless extracellular matrix tricuspid tubegraft in pigs", *25th annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 12<sup>th</sup> –14<sup>th</sup>, 2015.*

- 36) J Grønlund, N Telinius, SN Skov, MO Jensen, VE Hjortdal: "A validation study of near infrared fluorescence imaging of lymphatic vessels in humans", *25<sup>th</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 12<sup>th</sup> –14<sup>th</sup>, 2015.*
- 37) Sasa Grbic, Thomas Easley, Tommaso Mansi, Dominik Neumann, Eric Pierce, Morten Jensen, Charlie Bloodworth, Andrew W. Siefert, Julian Krebs, David D. Yuho, Ajit P. Yoganathan, Dorin Comaniciu: "Multi-Modal Validation Framework of Mitral Valve Geometry and Biomechanical Models", *2014 BMES Annual Meeting October 22-25, 2014, San Antonio, Texas.*
- 38) C. H. Bloodworth IV, E. L. Pierce, T. F. Easley, M. Toma, A. Khalighi, C-H. Lee, M. Sacks, A. W. Siefert, M. Ø. Jensen, A. P. Yoganathan: "Design of an In Vitro Simulation Pipeline for the Development of Computational Mitral Valve Modeling", *2014 BMES Annual Meeting October 22-25, 2014, San Antonio, Texas.*
- 39) DM Ropcke, T Hejslet, AV Sørensen, C Ilkjær, H Jensen, MOJ Jensen, SL Nielsen: "Characterization of Extracellular Matrix Tricuspid Tubegrafts with Comparison to Native Tricuspid Valves in a Porcine Model", *28<sup>th</sup> EACTS Annual Meeting, Milan, Italy 2014 11-15 October 2014.*
- 40) Søren N. Skov, Diana M. Røpcke, Andrew W. Siefert, Christine Ilkjær, Marcell J. Tjørnild, Ajit Yoganathan, Hans Nygaard, Sten L. Nielsen, Morten Jensen: "New Concept For Measuring The Forces In Mitral Valve Annuloplasty Rings" *32<sup>nd</sup> National Meeting at the Danish Society for Biomedical Engineering, September 17th, 2014, Braedstrup, Denmark.*
- 41) Madonna Lee, Andrew Siefert, Eric Pierce, Chikashi Aoki, Satoshi Takebayashi, Morten Jensen, Robert Gorman, Ajit Yoganathan, Joseph Gorman: "Mitral Annuloplasty Cyclic Suture Forces: True-sized Versus Undersized Rings", *AATS Cardiovascular Valve Symposium, Istanbul, Turkey, September 4-6 2014.*
- 42) Jensen MO; Siefert AW; Toma M; Gorman RC; Gorman III JH; Yoganathan AP: "Utilizing Computational and Experimental Tools in Tandem for Development and Evaluation of Mitral Valve Devices" *FDA Medical Device and Innovation Consortium Annual Meeting, Washington, DC, June 2014.*
- 43) SN Skov, K Telling, D Røpcke, C Ilkjær, MJ Tjørnild, H Nygaard, SL Nielsen, MØ Jensen: "Simultaneous in- and out-of-plane Mitral Valve Annular Force Measurements" *24<sup>th</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 13<sup>th</sup> –15<sup>th</sup>, 2014.*
- 44) C Ilkjær, MO Jensen, JL Honge, ES Kragnæs, SL Nielsen: "Effect of annuloplasty ring implantation on the tricuspid valvular complex dynamics and geometry" *24<sup>th</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surgery, Geilo, Norway, February 13<sup>th</sup> –15<sup>th</sup>, 2014.*
- 45) H Jensen, MO Jensen, F Waziri, JL Hønge, E Sloth, M Fenger-Gron, SL Nielsen: "Transapical neochord implantation: Is tension of artificial chordae tendineae dependent on insertion site?", *62<sup>nd</sup> Annual Meeting of Scandinavian Association for Thoracic Surgery, Aarhus, Denmark August 22<sup>nd</sup> - 24<sup>th</sup>, 2013.*
- 46) Diana M. Ropcke, Sten L. Nielsen, Henrik Jensen, Morten Ø. J. Jensen, Jesper L. Hønge, Vibeke E. Hjortdal.: "Total Tricuspid Valve Reconstruction Using Porcine Extracellular Matrix: Functional and Biomechanical Aspects" *7<sup>th</sup> Biennial Congress of the Society for Heart Valve Disease and the Heart Valve Society of America, June 25<sup>th</sup>, 2013, Venice, Italy.*

- 47) CH Ilkjær, JL Hønge, MO Jensen, SL Nielsen: "Effect of ring annuloplasty on tricuspid valvular complex dynamics and geometry" *23<sup>rd</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surg.*, Saturday, Feb 9<sup>th</sup>, 2013, Geilo, Norway.
- 48) H Jensen, MO Jensen, F Waziri, JL Hønge, E Sloth, M Fenger-Gron, SL Nielsen: "Transapical neochord implantation: Is tension of artificial chordae tendineae dependent on insertion site?" *23<sup>rd</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surg.*, Friday, Feb 8<sup>th</sup>, 2013, Geilo, Norway.
- 49) DM Røpcke, VE Hjortdal, GE Toft, MO Jensen, SD Kristensen: "Remote ischemic preconditioning reduces thrombus formation in the rat" *23<sup>rd</sup> annual meeting of the Scandinavian Society for Research in Cardiothoracic Surg.*, Friday, Feb 8<sup>th</sup>, 2013, Geilo, Norway.
- 50) Røpcke DM, Hjortdal VE, Toft GE, Jensen MO, Kristensen SD "Remote Ischemic Preconditioning Reduces Thrombus Formation In The Rat", *49<sup>th</sup> annual Meeting of The Society of Thoracic Surgeons, January 26-30 2013, Los Angeles, California, USA*.
- 51) TH Jorgensen, IJ Nielsen, JL Honge, H Nygaard, SL Nielsen, MO Jensen: "Mitral Valve Leaflet Patch Augmentation Reduces Regurgitant Orifice Area" *30<sup>th</sup> National Meeting at the Danish Society for Biomechanics, October 26<sup>th</sup>, 2012, Aarhus, Denmark*.
- 52) TH Jorgensen, IJ Nielsen, JL Honge, H Nygaard, SL Nielsen, MO Jensen: "Mitral Valve Leaflet Patch Augmentation Reduces Regurgitant Orifice Area" *30<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 19<sup>th</sup>, 2012, Braedstrup, Denmark*.
- 53) MO Jensen, JA Benediktsson, JL Honge, H Nygaard, SL Nielsen: "Downsizing the Mitral Valve Annulus: Impact on Tissue Biomechanics" *30<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 19<sup>th</sup>, 2012, Braedstrup, Denmark*.
- 54) Røpcke DM, Hjortdal VE, Toft GE, Jensen MO, Kristensen SD "Remote arterial preconditioning reduces thrombus formation in the rat", *4<sup>th</sup> Joint Scandinavian Conference in Cardiothoracic Surgery, Vilnius, Lithuania, August 16<sup>th</sup>-18<sup>th</sup> 2012*.
- 55) Henrik Jensen, Morten O. Jensen, Stefan Vind-Kezunovic, Rikke Vestergaard, Steffen Ringgaard, Morten H. Smerup, Jesper L. Hønge, J. Michael Hasenkam, Sten L. Nielsen: "Papillary Muscles Relocation Stitches – What are the Cyclic Tension Alterations Imposed on the Myocardium?" *Fourth Annual Joint Scientific Meeting of the Heart Valve Society of America and Society for Heart Valve Disease, April 12<sup>th</sup>, 2012, New York, NY, USA*.
- 56) Honge JL, Askov JB, Jensen MOJ, Hasenkam JM, Nielsen SL: "Effect of Mitral Ring Flexibility on Chordal Force balance and Mitral Annular Geometry", *Fourth Annual Joint Scientific Session of the Heart Valve Society of America and Society for Heart Valve Disease, Valves in the Heart of the Big Apple VII, April 12-14, 2012, New York, NY, USA*.
- 57) A Rahmani, AQ Rasmussen, B Ostli, J Vester-Petersen, JB Askov, JL Honge, RA Levine , A Hagège, SL Nielsen, H Nygaard, MO Jensen: "Mitral valve mechanics following posterior leaflet patch augmentation", *21<sup>st</sup> meeting of the Scandinavian Society for Research in Cardiothoracic Surg.*, Thursday, Feb 3<sup>rd</sup>, 2011, Geilo, Norway.
- 58) H Jensen, MO Jensen, MH Smerup, S Ringgaard, NT Andersen, P Wierup, JM Hasenkam, SL Nielsen: "Does down-sized ring annuloplasty induce papillary muscle relocation in ischemic mitral regurgitation?" *21<sup>st</sup> meeting of the Scandinavian Society for Research in Cardiothoracic Surg.*, Thursday, Feb 3<sup>rd</sup>, 2011, Geilo, Norway.

- 59) JB Askov, JL Honge, MO Jensen, H Nygaard, JM Hasenkam, SL Nielsen: "Novel Papillary Muscle Force Transducer: Tests and Results" *28<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 23<sup>rd</sup>, 2010, Braedstrup, Denmark.*
- 60) JB Askov, JL Honge, MO Jensen, H Nygaard, JM Hasenkam, SL Nielsen: Novel Papillary Muscle Force Transducer: Initial Tests and Results. *6<sup>th</sup> World Congress on Biomechanics, Aug. 1-6, 2010, Singapore.*
- 61) JB Askov, JL Honge, MO Jensen, H Nygaard, JM Hasenkam, SL Nielsen: Novel Papillary Muscle Force Transducer: Initial Tests and Results. *Biomedical Engineering Society 2010 Annual Meeting, October 6-9, Austin, Texas, USA.*
- 62) Jensen, MO; Nielsen, JVD; Amstrup, M; Jensen, SH; Rasmussen, M: Optimization of Flow Conditions for Aortic Cannulas. *30<sup>th</sup> Scandinavian Conference in ExtraCorporal Technology, Oslo, Norway, 27<sup>th</sup> Aug, 2010.*
- 63) JB Askov, MO Jensen, J Honge, H Nygaard, JM Hasenkam, SL Nielsen: "New Miniature Chordal Force Transducer for Measurements In Vivo", *4<sup>th</sup> Biennial Heart Valve Biology and Tissue Engineering Meeting, Monday, March 8<sup>th</sup>, 2010, Hilton Head Island, SC, USA.*
- 64) Albert Hagege and Morten Jensen: "Surgical Models of Mitral Valve Prolapse", Leducq MITRAL Transatlantic Network of Excellence, Nantes, France, May 2010.
- 65) MOJ Jensen, H Jensen, RA Levine, AP Yoganathan, H Nygaard, SL Nielsen, JM Hasenkam: "What Forces are Transmitted from the Mitral Valve Apparatus to the Papillary Muscles In Vivo". *19<sup>th</sup> World Congress of the World Society of Cardio-Thoracic Surgeons, Buenos Aires, Argentina, November 4<sup>th</sup>, 2009.*
- 66) JB Askov, MO Jensen, H Nygaard, JM Hasenkam, SL Nielsen: "New Miniature Chordal Force Transducer for In Vivo Measurements" *27<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 23<sup>rd</sup>, 2009, Braedstrup, Denmark.*
- 67) Nielsen, PF; Funder, JA; Jensen, MO; Nygaard, H: Influence of Venous Reservoir Level on Microbubbles in Cardiopulmonary Bypass, *13<sup>th</sup> European Congress on Extracorporeal Circulation Technology, June 17<sup>th</sup>-20<sup>th</sup>, 2009, Aarhus, Denmark.*
- 68) Morten Ø. Jensen, Henrik Jensen, Jesper B. Askov, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, Sten L. Nielsen, J. Michael Hasenkam: Flexible Mitral Valve Annuloplasty Rings Provide Superior Annular Dynamics and Force Distribution. *19<sup>th</sup> Annual Meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 5<sup>th</sup> – 7<sup>th</sup>, 2009, Geilo, Norway.*
- 69) Jesper B. Askov, Morten Ø. Jensen, Lyager, Hasenkam, Nygaard: Impact of Mitral Annuloplasty Ring Flexibility on 3D Geometry and Stress distribution of the Mitral Valve Annulus and Leaflets. *The Robert Levine Symposium on New Frontiers in Mitral Valve Repair Targeting the Natural History of Mitral Valve Regurgitation, Tuesday January 20<sup>th</sup>, 2009, Aarhus, Denmark.*
- 70) Morten Ø. Jensen, Henrik Jensen, Morten Smerup, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: Saddle-shaped Mitral Valve Annuloplasty Rings Provide Superior Annular Force Distribution. *18<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2nd, 2008, Geilo, Norway.*

- 71) Morten Ø. Jensen, Henrik Jensen, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, Sten L. Nielsen, J. M. Hasenkam: Left Ventricular Force Balance. *26<sup>th</sup> Danish Annual Congress in Biomedical Engineering, September 17, 2008, Brædstrup, Denmark.*
- 72) Jensen, Henrik; Jensen, Morten Ølgaard Jegstrup; Ringgaard, Steffen; Smerup, Morten Holdgaard; Sørensen, Thomas Sangild; Wierup, Per; Hasenkam, John Michael; Nielsen, Sten Lyager: "Geometric Culprits of Papillary Muscle Displacement in Functional Ischemic Mitral Regurgitation assessed by 3D Magnetic Resonance Imaging" *18<sup>th</sup> World Conference of the World Society of Cardio-Thoracic Surgeons (WSCTS 2008), May 3rd, 2008, Kos Island, Greece*, Abstract published in Heart Surgery Forum, Vol. 11, Nr. Suppl. 1, 2008, s. 358.
- 73) Jensen, Morten; Jensen, Henrik; Levine, Robert; Yoganathan, Ajit; Nygaard, Hans; Nielsen, Sten Lyager; Hasenkam, J. Michael: In Vivo Force Measurement on Mitral Valve Traction Suture: Insights to Left Ventricular Force Balance. *18<sup>th</sup> World Conference of the World Society of Cardio-Thoracic Surgeons (WSCTS 2008), May 3rd, 2008, Kos Island, Greece.*
- 74) Jensen, Henrik; Jensen, Morten Ølgaard Jegstrup; Ringgaard, Steffen; Smerup, Morten Holdgaard; Sørensen, Thomas Sangild; Wierup, Per; Hasenkam, John Michael; Nielsen, Sten Lyager: "Geometric culprits of papillary muscle displacement in functional ischemic mitral regurgitation assessed by 3D magnetic resonance imaging" *57<sup>th</sup> Annual Meeting of the Scandinavian Society of Thoracic Surgery and the 28<sup>th</sup> Annual Meeting of Scandinavian Society of Extra Corporeal Technology, Aug 21-23, 2008, Copenhagen, Denmark.*
- 75) Henrik Jensen, Morten Ø. Jensen, Steffen Ringgaard, Morten H. Smerup, Thomas S. Sørensen, Per Wierup, J. Michael Hasenkam, Sten Lyager Nielsen: Geometric Culprits of Papillary Muscle Displacement in Functional Ischemic Mitral Regurgitation Assessed by 3D Magnetic Resonance Imaging. *18<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, Feb. 2008, Geilo, Norway.*
- 76) Morten O. Jensen, Henrik Jensen, Morten Smerup, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: Saddle-shaped Mitral Valve Annuloplasty Rings Provide Superior Annular Force Distribution. *American Heart Association Scientific Sessions, Nov. 5, 2007, Orlando, FL, USA.*
- 77) Morten O. Jensen, Henrik Jensen, Morten Smerup, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: Saddle-shaped Mitral Valve Annuloplasty Rings Improve Leaflet Coaptation Geometry. *American Heart Association Scientific Sessions, Nov. 7, 2007, Orlando, FL, USA.*
- 78) Morten Jensen: Force balance in the mitral valve annulus: How to interpret the function of annuloplasty devices. *25<sup>th</sup> Danish Annual Congress in Biomedical Engineering, Sept. 19<sup>th</sup>-20<sup>th</sup>, 2007, Brædstrup, Denmark.*
- 79) Morten Ø. Jensen, Henrik Jensen, Sten L. Nielsen, Morten Smerup, Peter Johansen, Ajit P. Yoganathan, Hans Nygaard, J. M. Hasenkam: Force Balance In The Mitral Valve Annulus: How To Interpret The Function Of Annuloplasty Devices. *Fourth Biennial Meeting of the Society for Heart Valve Disease, June 17<sup>th</sup> 2007, New York, NY, USA.*
- 80) Henrik Jensen, Morten Ø. Jensen, Morten Smerup, Won Yong Kim, Steffen Ringgaard, J. Michael Hasenkam, Sten Lyager Nielsen: 3d Cardiac MRI Assessment Of Posterior Papillary Muscle Displacement In Chronic Functional Ischemic Mitral Regurgitation. *Fourth Biennial Meeting of the Society for Heart Valve Disease, June 18<sup>th</sup> 2007, New York, NY, USA.*

- 81) M. Ø. Jensen, S. L. Nielsen, M. Smerup, P. Johansen, H. Jensen, A. P. Yoganathan, J. M. Hasenkam, H. Nygaard: New Insight into the Mitral Valve Force Balance. *Biomedical Engineering Society Annual Meeting, October 2006, Chicago, Illinois, USA.*
- 82) Morten Jensen, Jeff Buterbaugh, PhD: Recent Advancements in Fluorescence Imaging. *PittCon, March 2nd, 2005, Orlando, Florida, USA.*
- 83) Jensen, Morten: Using NI Vision and Motion for Automated Inspection of Medical Devices and Pharmaceutical Processes. *PittCon, March 7th 2004, Chicago, IL, USA.*
- 84) Morten Oelgaard Jensen: Advances in Analytical Techniques for High Throughput Screening Applications. *AOAC INTERNATIONAL Annual Meeting & Exposition, Sept. 19th–23rd, 2004, St. Louis, Missouri, USA.*
- 85) Yoganathan, A.P. and Jensen, M., Harvested Porcine Mitral Xenograft Fixation: Impact on Fluid Dynamic Performance. *4th International Symposium on Stentless Bioprostheses, May 2001, San Diego, CA, USA.*
- 86) M. Jensen, J. Lemmon, S. He, M. Weston, V. Gessaghi, R. Levine, A. Yoganathan: Bioprosthetic Valve Fixation: Adverse Hemodynamic Impact. *World Congress on Medical Physics and Biomedical Engineering, July 2000, Chicago, Illinois, USA.*
- 87) Morten O. Jensen, Ajit P. Yoganathan: Bioprosthetic Heart Valve Fixation: Adverse Hemodynamic Impact. *VIII International Symposium Cardiac Bioprostheses, Friday, November 3rd, 2000, Cancun, Mexico.*
- 88) He S., Lemmon J.D., Weston M.W., Jensen M.O., Levine R.A., and Yoganathan A.P. Functional Characteristics of the Natural Mitral Valve: An In Vitro Assessment. *Third International Symposium on Stentless Bioprostheses, May 1999, Grand Cayman Island.*
- 89) He S., Lemmon J.D., Weston M.W., Jensen M.O., Fontaine A.A., Levine R.A., and Yoganathan A.P. Mechanism of Persistent Functional Mitral Regurgitation Despite Annuloplasty: In Vitro Studies. *American Society of Echocardiography 10th Annual Scientific Sessions, June, 1999, Washington, DC, USA.*
- 90) He S., Lemmon J.D., Weston M.W., Jensen M.O., Yoganathan A.P., Levine R.A.: Mechanism of Mitral Regurgitation In Patients With Annuloplasty: In Vitro Study. *American Society of Echocardiography 10th Annual Scientific Sessions, June, 1999, Washington, DC, USA.*
- 91) He S., Lemmon J.D., Weston M.W., Jensen M.O., Fontaine A.A., Levine R.A. and Yoganathan A.P. In Vitro Engineering Study of Mitral Regurgitation. *International Forum on Ischemic Mitral Valve Regurgitation, March 1999, Nice, France.*

#### **Conference Abstracts: Poster Presentations**

- 92) Maxwell J. Bean, David Jiang, Sam E. Stephens, Megan E. Laughlin, Hanna K. Jensen, Barry Uretsky, Lucas H. Timmins, Morten O. Jensen. "Experimental Modeling of Coronary Intervention: Towards Computational Simulation". *SB3C2019 Summer Biomechanics, Bioengineering and Biotransport Conference June 25 -28, Seven Springs, PA, USA*
- 93) Kaylee R. Henry, Ali Z. Al-Alawi, Md Abul Hayat, Hanna K. Jensen, Jingxian Wu, Patrick C. Bonasso, Kevin W. Sexton, and Morten O. Jensen: "Isoflurane Effect on Peripheral Venous Pressure" *SB3C2019 Summer Biomechanics, Bioengineering and Biotransport Conference June 25 -28, Seven Springs, PA, USA*

- 94) Megan Laughlin, Mohamed Almadi, John Moore II, Jamie Hestekin, Wei-Chiang Lin, Morten Jensen: "Characterization of a New Commercially Available Medical Gel for Phantoms" *Biomedical Engineering Society 2019 Meeting, October 16-19, Philadelphia, PA*
- 95) Megan Laughlin, Mason Belue, Hanna Jensen, R. Thomas Collins, Elijah Bolin, Joshua Daily, Morten Jensen: "Analysis of Blood Flow in the Pediatric Left Ventricle Using Vector Flow Imaging" *Biomedical Engineering Society 2019 Meeting, October 16-19, Philadelphia, PA*
- 96) Sam E. Stephens, Marinna R. Tadros, Neil B. Ingels, Jonathan F. Wenk, Morten O. Jensen: "Bonding Mitral Valve Leaflets in The Closed Configuration for High Resolution Micro-CT Imaging" *2019 Annual Meeting of the Heart Valve Society (HVS), Apr 11 - 13, 2019, Sitges, Barcelona, Catalonia, Spain*
- 97) Ali AlAlawi, Kaylee Henry, Md Abul Hayat, Hanna K. Jensen, Melvin S. Dassinger, Jeffrey M. Burford, Patrick C. Bonasso, Kevin W. Sexton, Jingxian Wu, Morten O. Jensen: "Propofol affects peripheral venous tone in anesthetized patients" *16th Annual Midsouth Computational Biology & Bioinformatics Society (MCBIOS) Conference 2019 at Mississippi State University, Starkville, MS.*
- 98) Collins II RT, Laughlin M, Jensen H, Lang S, Bolin E, Daily J, Jensen M: "Vector Flow Imaging for Cardiovascular Applications in Pediatric Patients and Models", *Biomedical Engineering Society 50th Annual Meeting, Thursday, October 18th, 2018, Atlanta, Georgia*
- 99) Preut A, Laughlin M, Jensen H, Hestekin J, Jensen M: "Novel Method for Emboli Analog Formation Towards Improved Stroke Retrieval Devices". *Biomedical Engineering Society 50th Annual Meeting, Thursday, October 18th, 2018, Atlanta, Georgia*
- 100) Al-Alawi A, Hayat A, Bonasso P, Burford JM, Dassinger MS, Jensen HK, Wu J, Sexton KW, and Jensen MO: "Hydration Level Assessment with Peripheral Venous Pressure Waveform Analysis", *Biomedical Engineering Society 50th Annual Meeting, Thursday, October 18th, 2018, Atlanta, Georgia*
- 101) Brazhkina O, Laughlin M, Jensen H, Haney K, Girardot M, Jensen M: "Development of a Model for Accelerated Fatigue Testing of Venous Valves". *Biomedical Engineering Society 50th Annual Meeting, Saturday, October 20th, 2018, Atlanta, Georgia*
- 102) Henson J, Kim J-W, Jensen H, Jensen M: "Size, Concentration, And Time Dependent Effects of PEGylated Gold Nanoparticles on Cardiovascular Cell Viability", *Biomedical Engineering Society 50th Annual Meeting, Thursday, October 18th, 2018, Atlanta, Georgia*
- 103) Bonasso PC, Sexton KW, Hayat MDA, Al-Alawi A, Wu J, Jensen HK, Jensen MO, Smith SD, Burford JM, Dassinger MS: "Venous physiology predicts anesthetic induced hypotension in infants" *American College of Surgeons, Boston, Massachusetts, October 21-25, 2018. doi: 10.1007/s10877-018-0124-5*
- 104) Hayat MD, Wu J, Jensen HK, Jensen MO, Dassinger MS, Burford JM, Bonasso PC, Sexton KW: "Predicting Dehydration in Pediatric Patients with Peripheral Venous Waveforms" *15th Annual Midsouth Computational Biology & Bioinformatics Society (MCBIOS) Conference 2018 at Mississippi State University, Starkville, MS.*
- 105) Wenk JF, Jensen MO: "Finite Element Modeling of Mitral Valve Patch Augmentation and Effects on Chordal Force Distribution", *SB<sub>3</sub>C2017 Summer Biomechanics, Bioengineering and Biotransport Conference, June 22, 2017, Tucson, Arizona, USA*

- 106) Easson G, White M; Jensen H, Girardot M, Jensen M: "Development of an In Vitro Model for Physiological Testing Native and Prosthetic Venous Valves" *International Vein Congress, April 20-22, 2017. Miami Beach, FL*
- 107) Easson G; Laughlin M; Jensen H; Haney K; Girardot M; Jensen M: "New System for Evaluation of Biomechanical Properties and Performance of Glutaraldehyde Fixed Versus Fresh Venous Valves: Towards a Biomechanically Optimal Replacement Device" *2017 Annual Congress of the American College of Phlebology, Austin, TX, Nov. 2<sup>nd</sup>-5<sup>th</sup>, 2017*
- 108) Morten O Jensen, Henrik Jensen, Soren S Nielsen, Robert A Levine, Hans Nygaard, J M Hasenkam, Sten L Nielsen: "New Mitral Valve Annuloplasty Concept: Optimizing Annular Dynamics and Force Distribution" *American Heart Association Scientific Sessions 2016, New Orleans, LA, USA, 12 - 16 NOV., 2016* [http://circ.ahajournals.org/content/134/Suppl\\_1/A15744](http://circ.ahajournals.org/content/134/Suppl_1/A15744)
- 109) Skov SN, Ropcke DM, Tjornild MJ, Ilkjær C, Rasmussen J, Nygaard H, Hasenkam JM, Jensen MO, Nielsen SL: "Novel Intelligent Mitral Annuloplasty Ring that Preserves the Dynamic Saddle Shaped Annulus while Fixating the Septal-lateral Dimension" *American Heart Association Scientific Sessions 2016, New Orleans, LA, USA, 12 - 16 NOV., 2016* [http://circ.ahajournals.org/content/134/Suppl\\_1/A19419](http://circ.ahajournals.org/content/134/Suppl_1/A19419)
- 110) Skov, Søren Nielsen; Røpcke, Diana Mathilde; Ilkjær, Christine; Rasmussen, Jonas; Tjørnild, Marcell Juan; Nygaard, Hans; Jensen, Morten Ølgaard Jegstrup; Nielsen, Sten Lyager: "Remodelling Forces of a Rigid Mitral Annuloplasty Ring - A Potential Risk Factor for Ring Dehiscence in Mitral Valve Repair? 2nd Annual Meeting, Heart Valve Society, March 17-19, New York, NY, United States.
- 111) Eric L. Pierce, Charles H. Bloodworth IV, Ajay Naran, Thomas F. Easley, Morten O. Jensen, Ajit P. Yoganathan: "Novel Micro-Computed Tomography Technique for Soft Tissue Deformation Tracking – Application to the Mitral Valve" *SB3C2015 Summer Biomechanics, Bioengineering and Biotransport Conference June 17-20, 2015, Snowbird Resort, Utah, USA.*
- 112) E. L. Pierce, D. D. Spragan, C. H. Bloodworth, T. Kawamura, T. Takayama, M. O. Jensen, A. W. Siefert, R. C. Gorman, J. H. Gorman, A. P. Yoganathan: "Can Optimized Annuloplasty Ring Size and Shape Mitigate Risk of Dehiscence?" *American Association of Thoracic Surgery Mitral Conclave, NY, NY, USA April 23-24 2015.*
- 113) Amir H. Khalighi, Andrew Drach, Fleur M. ter Huurne, Chung-Hao Lee, Charles Bloodworth, Eric L. Pierce, Morten O. Jensen, Ajit P. Yoganathan, Michael S. Sacks: "On the Characterization of Mitral Valve Geometry and Development of a Population-Averaged Model", *SB3C2015 Summer Biomechanics, Bioengineering and Biotransport Conference June 17-20, 2015, Snowbird Resort, Utah, USA.*
- 114) Amir H. Khalighi, Andrew Drach, Fleur M. ter Huurne, Chung-Hao Lee, Charles Bloodworth, Eric Pierce, Morten O. Jensen, Ajit P. Yoganathan, and Michael S. Sacks: "Multi-Scale Geometric Framework for Population-Averaging of the Mitral Valve Apparatus", *2015 BMES Frontiers in Medical Devices Conference: Innovations in Modeling and Simulation, May 18-20, 2015, Washington DC.*

- 115) Eric L. Pierce, Deborah M. Paul, Sarah K. Wells, Charles H. Bloodworth, Morten O. Jensen, Andrew W. Siefert, Robert C. Gorman, Joseph H. Gorman, Ajit P. Yoganathan: "Why is Annuloplasty Ring Dehiscence More Common on the Posterior Mitral Valve Annulus?" Inaugural Meeting of New International Heart Valve Society, 6-9 May, 2015, Grimaldi Forum, Monte Carlo, Monaco.
- 116) A. Drach, A.H. Khalighi, C.H. Lee, M.O. Jensen, C.H. Bloodworth, A.P. Yoganathan, M.S. Sacks. "Population-averaged geometric model of mitral valve from patient-specific imaging data" *14th Annual Design of Medical Devices Conference, Minneapolis, MN, Apr 13-16, 2015*.
- 117) Røpcke, Diana Mathilde; Jørgensen, Tine Hejslet; Jensen, Morten Ølgaard Jegstrup; Nielsen, Sten Lyager: "Total tricuspid valve reconstruction using porcine extracellular matrix. An in vitro characterization" *2014 Annual meeting of the Danish Society of Thoracic Surgery, Nyborg, Denmark*.
- 118) S. Nielsen Skov, D. Mathilde Røpcke, A. W. Siefert, C. Ilkjær, M. Juan Tjørnild, A. Yoganathan, H. Nygaard, S. Lyager Nielsen, and M. Jensen: "New Concept for Measuring the Forces in Mitral Valve Annuloplasty Rings" *2014 BMES Annual Meeting October 22-25, 2014, San Antonio, Texas*.
- 119) Jean-Pierre M. Rabbah, Eric Pierce, Qifeng Wei, Karl Thiele, Morten Jensen, Ajit P. Yoganathan: "Validated, Accurate Quantification of Mitral Regurgitation Through 3D Echocardiography Using an Automated Field Optimization Method", *American Society of Echocardiography 25th Annual Scientific Sessions, June 20-24, 2014, Portland, Oregon, USA*.
- 120) Claudio Capelli, Claus Rath, Francesco Ruffini, Dario Biscarini, Francesco Migliavacca, Spyros Tzamtzis, Morten Jensen, Gaetano Burriesci, Martin Andreas, Silvia Schievano, Alfred Kocher: "Evaluation of a Novel Aortic Valve Prosthesis: Integration of Clinical Data With Experimental And Computational Tools" *7th World Congress of Biomechanics, July 6-11, 2014, Boston, Massachusetts, USA*.
- 121) TH Jorgensen, IJ Nielsen, JL Honge, H Nygaard, SL Nielsen, MO Jensen: "Mitral Valve Posterior Leaflet Patch Augmentation Reduces Regurgitant Orifice Area", *62nd Annual Meeting of Scandinavian Association for Thoracic Surgery, Aarhus, Denmark August 22<sup>nd</sup> - 24<sup>th</sup>, 2013*.
- 122) Skov, Søren Nielsen; Jensen, Morten Ølgaard Jegstrup; Jensen, Henrik; Askov, Jesper Brink; Nygaard, Hans; Levine, Robert; Yoganathan, Ajit; Hasenkam, J. Michael" New Mitral Valve Annuloplasty Concept Minimize Out-of-plane Force Distribution" *31<sup>st</sup> National Meeting at the Danish Society for Biomedical Engineering, September 17<sup>th</sup> - 19<sup>th</sup>, 2013, Braedstrup, Denmark*.
- 123) C Ilkjaer, JL Honge, MO Jensen, SL Nielsen: "Effect of Annuloplasty Ring Implantation on Tricuspid Valvular Complex Dynamics and Geometry – a Clinical Experiment in Pigs", *62nd Annual Meeting of Scandinavian Association for Thoracic Surgery, Aarhus, Denmark August 22<sup>nd</sup> - 24<sup>th</sup>, 2013*.
- 124) ES Kragsnaes, JL Honge, JB Askov, SL Nielsen, H Nygaard, MO Jensen: "In-plane Tricuspid Valve Force Measurements: Development of Strain Gauge Instrumented Annuloplasty Ring" *Biomedical Engineering Society 2012 Annual Meeting, October 27<sup>th</sup> 2012, Georgia World Congress Center, Atlanta, Georgia, USA*.
- 125) T Bechsgaard, JL Honge, H Nygaard, MO Jensen: "In Vivo Wireless Transmission of ECG and Force Data" *30<sup>th</sup> National Meeting at the Danish Society for Biomedical Engineering, September 19<sup>th</sup>, 2012, Braedstrup, Denmark*.

- 126) A Rahmani, AQ Rasmussen, B Ostli, J Vester-Petersen, JB Askov, JL Honge, RA Levine, A Hagège, SL Nielsen, H Nygaard, MO Jensen: "Mitral valve mechanics following posterior leaflet patch augmentation", *5<sup>th</sup> Biennial Meeting on Heart Valve Biology and Tissue Engineering, May 18<sup>th</sup> – 20<sup>th</sup>, 2012, Myconos Island, Greece.*
- 127) Jesper B. Askov, Jesper L. Honge, Morten O. Jensen, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: "Mitral Valve Replacement with Total Chordal Preservation Increases Force Transmission to the Papillary Muscle-Left Ventricular Wall Complex", *Society For Heart Valve Disease & Heart Valve Society of America, 6<sup>th</sup> Biennial Meeting, 25-28 June, 2011, Barcelona, Spain.*
- 128) JB Askov, JL Honge, H Nygaard, JM Hasenkam, SL Nielsen, MO Jensen, "Novel Papillary Muscle Force Transducer: Tests and Results", *21<sup>st</sup> Scientific Meeting of the Scandinavian Society for Research in Cardiothoracic Surgery Geilo, Norway, February 3–5, 2011.*
- 129) Henrik Jensen, Morten O. Jensen, Farhad Waziri, Jesper L. Honge, Erik Sloth, Niels T. Andersen, Per Wierup, J. Michael Hasenkam, Sten L. Nielsen, "Is Tension Alterations of Transapical Artificial Chordae Tendineae Potentially Detrimental for Mitral Repair Durability?" *American College of Cardiology Scientific Sessions, April 3-5, 2011, New Orleans, Louisiana, USA.*
- 130) Morten Jensen, Jesper Langhoff Honge, Sten Lyager Nielsen, J. Michael Hasenkam, Robert R. Levine, Mathieu Granier, Albert Hagege: "In Vitro Simulation of Mitral Valve Prolapse and Chordal force balance", *Leducq MITRAL Transatlantic Network Meeting, Nantes, France, May 2010*
- 131) J.B. Askov, J.L. Honge, M.O. Jensen, H. Nygaard, J.M. Hasenkam, S.L. Nielsen, "Novel Papillary Muscle Force Transducer: Initial Tests And Results", *University of Aarhus Graduate School of Medicine Annual PhD Day, January 16<sup>th</sup> 2009, Aarhus, Denmark.*
- 132) JB Askov, MO Jensen, JL Honge, SL Nielsen, H Nygaard, JM Hasenkam: "Effect of Mitral Valve Ring Annuloplasty on in vivo Chordal Tension" *19<sup>th</sup> World Congress of the World Society of Cardio-Thoracic Surgeons November 4<sup>th</sup>, 2009, Buenos Aires, Argentina.*
- 133) A Stigo, K Sivesgaard, P Johansen, M Jensen, H Nygaard, E Sloth: "Reliability of Speckle Tracking Ultrasound for assessment of myocardial strain", *Third International Conference on Mechanics of Biomaterials and Tissues, 13 – 17 December 2009, Clearwater Beach, Florida, USA.*
- 134) Morten Ølgaard Jensen, Henrik Jensen, Jesper Brink Askov, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, Sten Lyager Nielsen, J. Michael Hasenkam: "Flexible Mitral Valve Annuloplasty Rings Provide Superior Annular Dynamics And Force Distribution" *Society for Heart Valve Disease, Fifth Biennial Meeting of The Society for Heart Valve Disease, June 27-30, 2009, Berlin, Germany.*
- 135) S. Vind-Kezunovic, H. Jensen, A. Rutz, R. Vestergaard, S. Ringgaard, M.Ø. Jensen, M. Smerup, S.L. Nielsen, J.M. Hasenkam: Does papillary muscle relocation surgery affect regional wall motion? *19<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2009, Geilo, Norway.*
- 136) Askov, J.B., Jensen, M.O., Nielsen, S.L., Nygaard, H., Hasenkam, J.M.: New Miniature Transducers for in vivo Chordae Tendineae Force Measurements. *University of Aarhus Graduate School of Medicine Annual PhD Day, January 16<sup>th</sup> 2009, Aarhus, Denmark.*

- 137) A. Stigo, K. Sivesgaard, M. Ø. Jensen, H. Nygaard, E. Sloth: Reliability of Speckle Tracking and Doppler Tissue Velocity Imaging for Assessment of Myocardial Strain. *19<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2009, Geilo, Norway.*
- 138) J.B. Askov, M.O. Jensen, S.L. Nielsen, H. Nygaard, J.M. Hasenkam: New Miniature Transducers for In Vivo Chordae Tendineae Force Measurements. *19<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2009, Geilo, Norway.*
- 139) E Hansen, JB Askov, H Jensen, MØ Jensen, JA Funder, JM Hasenkam, SL Nielsen: The impact of complete and partial mitral ring annuloplasty on mitral and aortic annular dynamics and interactions. *19<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, Feb. 2009, Geilo, Norway.*
- 140) Henrik Jensen, Morten Ø Jensen, Morten H Smerup, Stefan Vind-Kezunovic, Steffen Ringgaard, Rikke Vestergaard, Per Wierup, J Michael Hasenkam, Sten L Nielsen: Impact of Papillary Muscle Relocation as Adjunct Procedure to Mitral Ring Annuloplasty in Functional Ischemic Mitral Regurgitation. *American Heart Association Scientific Sessions, November 10, 2008, New Orleans, Louisiana, USA.*
- 141) Morten O. Jensen, Peter Johansen, Hans Nygaard: Development of an Implantable Heart Valve Force Transducer. *ASME 2008 Summer Bioengineering Conference (SBC2008), June 25-29, Marriott Resort, Marco Island, Florida, USA.*
- 142) M. Ø. Jensen, H. Jensen, S. Lyager Nielsen, M. Smerup, P. Johansen, A. P. Yoganathan, H. Nygaard, J. M. Hasenkam: Force Balance in the Mitral Valve Annulus: New Results from Novel Modalities and Measurement Techniques. *17<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2007, Geilo, Norway.*
- 143) H. Jensen, M. Smerup, M. Jensen, M. Bjerre, J. D. Andersen, E. Sloth, W.Yong Kim, S. Ringgaard, J. M. Hasenkam, S. Lyager Nielsen: Papillary muscle relocation in addition to down-sized ring annuloplasty improves mitral valve coaptation geometry in chronic functional ischemic mitral valve regurgitation. *17<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2007, Geilo, Norway.*
- 144) Morten O. Jensen, Henrik Jensen, Morten Smerup, Robert A. Levine, Ajit P. Yoganathan, Hans Nygaard, J. Michael Hasenkam, Sten L. Nielsen: Saddle-shaped Mitral Valve Annuloplasty Rings Improve Leaflet Coaptation Geometry. *American Heart Association Scientific Sessions, Nov. 7<sup>th</sup>, 2007, Orlando, Florida, USA.*
- 145) MO Jensen, H Jensen, SL Nielsen, M Smerup, P Johansen, AP Yoganathan, H Nygaard, JM Hasenkam: Force Balance in the Mitral Valve Annulus: New Results from Novel Modalities and Measurement Techniques. *17<sup>th</sup> annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2007, Geilo, Norway.*
- 146) M. Ø. Jensen, S. L. Nielsen, M. Smerup, P. Johansen, H. Jensen, A. P. Yoganathan, J. M. Hasenkam, H. Nygaard: Stress Distribution and 3D Geometry in Mitral Valve Annuloplasty Rings: Ring Selection Implications. *Advances in Innovative Technologies and Tissue Engineering For the Treatment of Heart Valve Disease, 10th Annual Meeting February, 2006, Hilton Head, South Carolina, USA.*

- 147) M. Ø. Jensen, S. L. Nielsen, M. Smerup, P. Johansen, H. Jensen, A. P. Yoganathan, J. M. Hasenkam, H. Nygaard: New Insight into the Mitral Valve Force Balance. *55th Annual Meeting of the Scandinavian Association for Thoracic Surgery and the 26th Annual Meeting of the Scandinavian Society for Extracorporeal Technology, August 2006, Reykjavík, Iceland.*
- 148) M. Ø. Jensen, S. L. Nielsen, M. Smerup, P. Johansen, H. Jensen, A. P. Yoganathan, J. M. Hasenkam, H. Nygaard: 3D Geometry and Stress Distribution in Mitral Valve Annuloplasty Rings. *16th annual meeting of The Scandinavian Society for Research in Cardio Thoracic Surgery, February 2006, Geilo, Norway.*
- 149) MØ Jensen, SL Nielsen, M Smerup, P Johansen, AP Yoganathan, JM Hasenkam, H Nygaard: The Effect of Mitral Annuloplasty Rings on Mitral Valve 3D Geometry and Stress Distribution. *University of Aarhus Graduate School of Medicine Annual PhD Day, January 16th 2006, Aarhus, Denmark.*

**Seminars / Invited Guest Lecturer & Speaker**

- 150) Invited Speaker / Discussant in the Mitral Valve session titled *Functional Mitral Regurgitation: The Ongoing Controversy*. Title of talk “*Biomechanical Aspects of Functional Mitral Regurgitation*”, the Heart Valve Society Annual Scientific Meeting, Sitges, Spain, April 12<sup>th</sup>, 2019
- 151) Collins RT, Laughlin M, Lang S, Bolin E, Daily J, Jensen H, Jensen M: “Vector Flow Imaging for Surgical Decision-Making in Pediatric Cardiology” *Arkansas Exercise and Nutrition Research Symposium: The Science of Diet and Exercise 2nd Annual Center for Human Nutrition Research Symposium*. Feb 22, 2019.
- 152) Invited speaker at the Fayetteville, Arkansas Rotary Club: “Cardiovascular Disease and Research in Arkansas”, Fayetteville, Arkansas, February 18<sup>th</sup>, 2016.
- 153) Invited keynote speaker at the Sixth Nanotechnology for Health Care Conference “Nanoscale Materials and Sensors in Cardiovascular Medicine”, Winthrop Rockefeller Institute, Morrilton, Arkansas, December 2<sup>nd</sup>, 2015.
- 154) Invited guest lecturer at the National Center for Toxicological Research “A Team of Hearts, Jensen Cardiovascular Research; the Past, the Present and the Future”, November 19<sup>th</sup>, 2015.
- 155) Invited guest lecturer at the Georgia Institute of Technology Biomedical Engineering BMED 6784 Cardiovascular Biomechanics, April 2<sup>nd</sup>, 2015.
- 156) Invited seminar speaker at the University of Texas, Austin ICES Center for Cardiovascular Simulation: “Utilizing Computational and Experimental Tools in Tandem for Development and Evaluation of Cardiovascular Devices” October 27<sup>th</sup>, 2014.
- 157) Invited Panelist at the NIH “Broadening Experiences in Scientific Training” (BEST) Program. Emory University and the Georgia Institute of Technology. July 23<sup>rd</sup>, 2014.
- 158) Invited Speaker at the Department of Engineering, Cambridge University: “The Left Heart Tug of War: Engineering and Medicine Joining Forces, January 21<sup>st</sup>, 2013, Cambridge, UK.
- 159) Invited Speaker at the Department of Bioengineering, Imperial College London: “The Left Heart Tug of War: Engineering and Medicine Joining Forces, December 10<sup>th</sup>, 2012, London, UK.

- 160) Invited Speaker at Imaging Sciences & Biomedical Engineering, Kings College London / St. Thomas Hospital: "The Left Heart Tug of War: Engineering and Medicine Joining Forces, July 31<sup>st</sup>, 2012, London, UK.
- 161) Invited Speaker at the Institute of Biomedical Engineering, University of Oxford: "The Left Heart Tug of War: Engineering and Medicine Joining Forces, February 29<sup>th</sup>, 2012, Oxford, UK.
- 162) Invited Speaker at the Danish Biomechanical Society: "Biomechanical Approaches in Mapping the Left Heart Force Balance", DBS Annual Meeting, October 14<sup>th</sup>, 2011, Odense, Denmark.
- 163) BioPeople Innovation Tour 2011: "Requirements for Design, Function, Materials, and Communication", Invited Speaker for Cluster of Health and Life Sciences companies (Novo Nordisk, Delta, Coloplast etc.) Nov. 29<sup>th</sup>, 2011.
- 164) Invited Speaker at the Danish Engineering Foundation: "Coupling between Research and Industry: Why, How?" Health Technology Potential Workshop, Viborg, Denmark, September 27<sup>th</sup>, 2011.
- 165) 2011 Biomedical Engineering Invited Guest Presentation: "The Left Heart Tug of War: Engineering and Medicine Joining Forces", Auspices at the Center for Innovative Cardiovascular Technologies, Atlanta, Georgia, July 28<sup>th</sup>, 2011.
- 166) Morten Jensen: "Experimental Heart Surgery in Denmark", Division of Adult Cardiothoracic Surgery and Cardiac Biomechanics, University of California, San Francisco, CA, USA, August 2<sup>nd</sup>, 2011.
- 167) Morten Jensen: "Experimental Heart Surgery in Denmark", Department of Biomedical Engineering, University of Oulu, Oulu, Finland, August 10<sup>th</sup>, 2011.
- 168) Morten Ø. Jensen: "Engineering in Experimental Heart Surgery", Danish Institute for Study Abroad (DIS, Copenhagen), September 2009.
- 169) Morten Ø. Jensen: "Repairing the Heart", The Danish Society of Engineers, (Aarhus, Denmark), October 20<sup>th</sup>, 2009.
- 170) Morten Ø. Jensen: "Repairing the Heart", 19<sup>th</sup> Danish Biomedical Engineering Society Annual Conference, Denmark September 22<sup>nd</sup> – 24<sup>th</sup>, 2009.
- 171) Morten Ø. Jensen: "Repairing the Heart", iNANO: The interdisciplinary nanoscience center at Aarhus University, March 10<sup>th</sup>, 2009.
- 172) Guest Lecturer: "Engineering in Experimental Heart Surgery", Technical University of Denmark (DTU, Copenhagen), September 2008.
- 173) Guest Lecturer: "Engineering in Experimental Heart Surgery", The Danish Society of Engineers (Copenhagen), September 2008.
- 174) Jensen, M. O: "Mitral Valve Biomechanics and Fluid Dynamics", Department of Cardiology, April 2008, Aarhus University Hospital, Skejby, Aarhus, Denmark.
- 175) Jensen, M. O. J., Bering, J., "Vision Analysis: Techniques and Applications", Virtual Instrumentation Seminar, Engineering College of Aarhus, Denmark, Dec. 6<sup>th</sup>, 2006.

- 176) Jensen, M. O. J.: "Image Acquisition and Analysis", Virtual Instrumentation Seminar, Engineering College of Aarhus, Denmark, April 1<sup>st</sup>, 2006.
- 177) Virtual Bioinstrumentation and Industry Discussion Panelist Partnership for Educational Bioengineering Laboratories (PEBEL), Lansdowne, VA, June 4-6, 2004.
- 178) "LabVIEW Control Design and Simulation", NI Symposium, Cape Town, South Africa, Nov. 24<sup>th</sup> 2004.
- 179) Jensen, Morten: "Microscope Control with LabVIEW and IMAQ Vision" National Instruments Scientific Imaging Symposium, Boston, MA, November 13, 2003.

**Public Media Appearances:**

- Alliance-recruited researchers doing COVID-19 work in Arkansas, talkbusiness.net, April 30<sup>th</sup>, 2020
- UA researchers customize 'aerosol boxes' to protect workers at Washington Regional, [www.nwahomepage.com](http://www.nwahomepage.com) (KNWA/Fox24), newsbreak.com, Aerosol boxes created to protect clinicians from COVID-19, April 17<sup>th</sup>, 2020
- Researchers Customize 'Aerosol Boxes' for Washington Regional, news.uark.edu, researchfrontiers.uark.edu, April 17<sup>th</sup>, 2020
- NIH Supports Engineering Researchers to Improve Heart Procedures and Surgeries, news.uark.edu, Jan. 24, 2020
- "Vector Flow Imaging Helps Visualize Blood Flow in Pediatric Hearts", [Week in BioE \(May 31, 2019\)](#), Penn Bioengineering Blog
- "Researchers Test New Imaging Method for First Time on Human Patients" - Article news story on [radiologybusiness.com](http://radiologybusiness.com), [www.HealthDataManagement.com](http://www.HealthDataManagement.com), [news.uark.edu](http://news.uark.edu), [www.dotmed.com](http://www.dotmed.com), [www.auntminnie.com](http://www.auntminnie.com) etc.
- "American Heart Association Heart Hero" – AHA websites, University of Arkansas Websites, November 1<sup>st</sup>, 2018,
- "U of A Student Named as 2018 Barry M. Goldwater Scholar", [news.uark.edu](http://news.uark.edu) April 17<sup>th</sup>, 2018
- "UA professors aid medical field", Democrat Gazette front page of Business Section and [www.arkansasonline.com](http://www.arkansasonline.com)
- "New Biomedical Company Helps Train Clinicians and Test Medical Equipment", [news.uark.edu](http://news.uark.edu) April 16<sup>th</sup>, 2018.
- "UA researchers form new medical testing venture, receive help from Fort Smith company" [talkbusiness.net](http://talkbusiness.net), April 16<sup>th</sup>, 2018. As of April 19<sup>th</sup>, 2018: 325 views and 56 shares.
- "Two Biomedical Engineering Faculty Receive Grants from the American Heart Association" [news.uark.edu](http://news.uark.edu) April 5<sup>th</sup>, 2018
- "Increasing Numbers of Engineering Students Take Advantage of Semester Study Abroad Opportunities" [news.uark.edu](http://news.uark.edu) June 7<sup>th</sup>, 2017
- "Brazilian Students and Biomedical Engineering Professors Collaborate on Summer Research". [news.uark.edu](http://news.uark.edu) August 3<sup>rd</sup>, 2016
- "Happy, Healthy Heart Advice", KNWA-TV and Fox 24 News, February 10<sup>th</sup>, 2016
- "American Heart Awareness Month Heart Health Advice", [www.nwahomepage.com](http://www.nwahomepage.com), February 10<sup>th</sup>, 2016
- "Healthy Heart Tips for Valentine's Day", [www.publicnow.com](http://www.publicnow.com), February 10<sup>th</sup>, 2016
- "Healthy Heart Tips for Valentine's Day", [news.uark.edu](http://news.uark.edu), February 9<sup>th</sup>, 2016
- "Alliance recruits 2 more scholars" Front page article of the Business Section of Northwest Arkansas Democrat Gazette and [www.arkansasonline.com](http://www.arkansasonline.com), Arkansas, August 14<sup>th</sup>, 2015
- "Research Alliance Brings Two Bright Minds To Arkansas" [UALR Public Radio](#), News & Culture for Arkansas, August 13<sup>th</sup>, 2015
- "ARA Scholars Program Introduces Newest Researchers" Arkansas Business Online, August 13<sup>th</sup>, 2015

- "Research Alliance Brings Two Bright Minds To State" *Talk Business & Politics*, August 13<sup>th</sup>, 2015
- "Arkansas Research Alliance Scholars Join University of Arkansas Faculty" [news.uark.edu](http://news.uark.edu), August 13<sup>th</sup>, 2015
- "ARA Scholars announced" Article, [thecabin.net](http://thecabin.net), August 13<sup>th</sup>, 2015
- "ARA Scholars Program Strengthened by New Research Leaders: Scholars drive innovation through research and discovery" Article, [aralliance.org](http://aralliance.org), August 13<sup>th</sup>, 2015
- "2 professors joining UA through alliance grant" Article, [thv11.com](http://thv11.com), August 13<sup>th</sup>, 2015
- "Computer heart can save pigs" *Machine Magazine (online)*, Denmark, April 10<sup>th</sup>, 2013
- "Computer model can speed up heart research" *Natural and Technical Science (online)*, Aarhus University, April 10<sup>th</sup>, 2013
- "Danske ingeniørstuderende og forskere bag succesfuld teknik til hjerteoperationer", Interview, [ing.dk](http://ing.dk), July 5<sup>th</sup>, 2012
- "Danske ingeniører bag banebrydende hjerteteknologi" Interview, [teknikogviden.dk](http://teknikogviden.dk), June 8, 2012
- "Danske ingeniører bag banebrydende hjerteteknologi" *Altinget / Forskning og Innovation*, June 6<sup>th</sup>, 2012
- "Danske ingeniører bag banebrydende hjerteteknologi" Interview, [iha.dk](http://iha.dk), June 6<sup>th</sup>, 2012
- "New Danish Invention Limits Turbulence in the Aorta" Article, [ing.dk](http://ing.dk), December 16<sup>th</sup>, 2011
- "Engineering College files for patent on heart canula" Interview, [iha.dk](http://iha.dk), December 15<sup>th</sup>, 2011
- "Aarhus-delegation til international konference om sundhedsteknologi" Interview, [iha.dk](http://iha.dk), June 14<sup>th</sup>, 2011
- "Helping Heart Patients" *GENIUS Issue #3, November 2010*
- "International Collaboration and Student Exchange Agreement Established" [iha.dk](http://iha.dk), 10<sup>th</sup> September 2010
- "Researchers use Pigs" *TV2 Østjylland News*, 22<sup>nd</sup> February 2010
- "Århus-ingeniører hjælper hjertepatienter" ("Aarhus-Engineers help heart patients") [holme-net.dk](http://holme-net.dk), [nyheder.tdconline.dk](http://nyheder.tdconline.dk), [nyhederne.org](http://nyhederne.org), [news.dk](http://news.dk), [jp.dk](http://jp.dk), [iha.dk](http://iha.dk) 31<sup>st</sup> August 2009
- "Engineers Strengthen Weak Hearts" *Århus Stiftstidende*, 6<sup>th</sup> July 2009
- "Århus-studerende vinder pris for hjerteteknologi" *Jyllandsposten*, 6<sup>th</sup> July 2009
- "Big price to Århus-students for landmark heart technology" [presswire.dk](http://presswire.dk), 6<sup>th</sup> July 2009
- "Ingeniørstuderende fra Århus hjælper hjerter" *Lokalavisen/Århus*, 6<sup>th</sup> July 2009
- "Stor pris til Århus-studerende for skelsættende hjerteteknologi" [iha.dk](http://iha.dk), 6<sup>th</sup> July 2009
- "Heart Valve Research" *NEXT no. 6 Conference, Innovation Lab, Aarhus, Denmark*, April 2-3 2009
- "Ny hjertekanyle reducerer blodpropper" *Ingeniøren*, Feb 27<sup>th</sup>, 2009
- "Ny hjertekanyle giver færre blodpropper" [www.hjerteforeningen.dk](http://www.hjerteforeningen.dk), Feb 2<sup>nd</sup>, 2009
- "To unge får pris for kanyle" *Århus Stiftstidende*, Feb. 1<sup>st</sup>, 2009, Pg. 16
- "Danish discovery could help cardiac patients" *Biotech Scandinavia*, [www.idg.se](http://www.idg.se), Dec. 1<sup>st</sup>, 2009
- "Studerende får pris for hjertekanyle" [www.tv2oj.dk](http://www.tv2oj.dk), January 27<sup>th</sup>, 2009
- "Maskiningeniørstuderende udvikler hjertekanyle" [www.jernindustri.dk](http://www.jernindustri.dk), January 27<sup>th</sup>, 2009
- "Studerende får pris for kanyle" [www.stiften.dk](http://www.stiften.dk), January 27<sup>th</sup>, 2009
- "Studerende bag banebrydende hjerteteknologi" [www.jp.dk](http://www.jp.dk), January 27<sup>th</sup>, 2009
- "Ny dansk hjertekanyle skal nedsætte risiko for blodpropper" [www.dagensmedicin.dk](http://www.dagensmedicin.dk), January 27<sup>th</sup> 2009
- "Studerende vandt pris for banebrydende hjertekanyle" [www.iha.dk](http://www.iha.dk), January 27<sup>th</sup> 2009
- "Studerende opfinder banebrydende hjertekanyle" [www.iha.dk](http://www.iha.dk), January 22<sup>nd</sup> 2009
- "Verdenskendt hjertemediciner besøger Ingeniørhøjskolen" [www.iha.dk](http://www.iha.dk), January 16<sup>th</sup> 2009
- "Ingeniører og læger udvikler hjertering" *Annual Report, Engineering College of Aarhus*, 2008, p 16
- "Studerende bag banebrydende hjerteteknologi" *Jyllandsposten* s. 7, *Urban* s. 8, January 28<sup>th</sup>, 2008
- "The Danish Society of Engineers annual Honorary Award of Excellence, May 2008" *Featured in Århus Stiftstidende* (May 7<sup>th</sup> 2008 p. 22), *TV2 Østjylland*, *Aarhus Universitet* ([www.au.dk](http://www.au.dk)), *Dagens Medicin*, [www.ida.dk](http://www.ida.dk), *Aarhus University Hospital* ([www.sundhed.dk](http://www.sundhed.dk)), *Engineering*

College of Aarhus ([www.ihadk.dk](http://www.ihadk.dk)), Nordjyske Stiftstidende (May 7<sup>th</sup> 2008 p. 12), Fyns Amts Avis, Fredericia Dagblad, Vejle Amts Folkeblad, Horsens Folkeblad, Stiftet.dk, The Danish Heart Foundation ([www.hjerteforeningen.dk](http://www.hjerteforeningen.dk))

- "Help to Heart Patients" *Frederiksbor Amts Newspaper*, October 17<sup>th</sup> 2008, 1<sup>st</sup> section, pg. 5
- "New Research Helps Heart Patients" *Ritzaus Bureau* October 16<sup>th</sup>, 2008'
- "Breakthrough in Heart Valve Defect Surgery Research" October 16<sup>th</sup>, 2008, *TV2 News*
- "Heart valve patients can look forward to better treatment" October 2008, *Denmarks Radio News*
- "New research can improve the treatment for patients with leaking mitral heart valves" October 2008, [www.sundhed.dk](http://www.sundhed.dk)
- "New Research Helps Heart Patients" October 18th 2008, *Aarhus Stiftstidende*, section 1, page 5
- "Ny forskning til hjælp for hjertepatienter" October 20th 2008, *Nordjyske Stiftstidende*, page 26
- "Intelligent hjertering med lang levetid" *Hjertenyt*, (Danish Heart Association Magazine), Nov. '08 pg. 12-13
- "Ny Intelligent Hjertering" *P4 Danmarks Radio, Radioavisen*, 3:00PM, December 15<sup>th</sup>, 2008
- "Aarhus Engineer and Skejby Professor Invents New Heart Ring" [www.jp.dk](http://www.jp.dk), December 15th, 2008
- "Engineers & Medical Doctors Invents Intelligent Heart Ring" [www.ihadk](http://www.ihadk.dk), December 15th, 2008
- "Engineers & Medical Doctors Invents Intelligent Heart Ring" [www.dr.dk](http://www.dr.dk), December 15th, 2008
- "Ingenører og læger udvikler intelligent hjertering" Radio Interview (in Danish): <http://jp.dk/radio/>, Length: 5min 45sec., December 15<sup>th</sup>, 2008
- "Flexible Rings Improves Lives for Heart Patients" *Aarhus Stiftstidende*, Friday November 28th, 2008, p. 21
- "Mitral Valve Force Balance: The Left Ventricular Tug of War" Publication of PhD defense, *Jyllandsposten*, Friday November 28th, 2008, p. 20
- "Den intelligente hjertering på størrelse med en køkkenelastik" *24 Timer*, December 16<sup>th</sup>, 2008, pg. 22
- "Perspectives in Collaboration between Doctors and Engineers, July 2006" Featured in *TV2 News*, *Jyllandsposten*, *Politiken*, *Hjertenyt*, (Danish Heart Association), *Urban Newspaper*, *IHA News*, etc.
- "Eyes for Machines" *Interview in J&M/Industry-Technique*, Week 32, 2003, page 30

#### **Academic Courses Taught and Developed**

- Cardiovascular Biomechanics (graduate level)
- Blood Pressure and Flow Measurement (PhD Level, including course development)
- Hemodynamics (BS, MS, and PhD Level, including course development)
- Biofluids (BS, MS, and PhD Level, including course development)
- Cardiovascular Modelling (MS, and PhD Level, including course development)
- Biomechanics (BS and MS Level, including course development)
- Physics (BS Level)
- Medical Instrumentation (BS Level)
- Medical Research and Presentation Techniques (BS and MS Level, including course development)

#### **Industry Customer Education Courses Taught and Developed**

- Advanced Graphical Programming in LabVIEW
- Virtual Instrumentation, Data Acquisition (DAQ)
- Signal Conditioning
- Machine Vision & Image Processing (including course development)
- Motion Control
- System Identification and Simulation (including course development)
- Control Design (including course development)
- LabVIEW TestStand

**Professional Society Memberships**

- Biomedical Engineering Society (BMES)
- The Danish Heart Foundation
- The Danish Society of Engineers (IDA)
- American Heart Association (AHA)
- Institute of Electrical and Electronics Engineers (IEEE)
- Engineering in Medicine and Biology Society (EMBS)
- U S Association for Computational Mechanics (USACM)
- Danish Society for Biomedical Engineering (DMTS)
- Cardiothoracic Surgery Network (CTSNet)
- Danish Cardiovascular Research Academy (DaCRA)
- The Society for Heart Valve Disease (SHVD)
- The Scandinavian Society for Research in Cardiothoracic Surgery (SSRCTS)
- International Federation for Medical and Biological Engineering (IFMBE) - *affiliated*
- European Alliance for Medical and Biological Engineering & Science (EAMBES) - *affiliated*

## Attachment B



**OCEAN TOMO®**  
INTELLECTUAL CAPITAL EQUITY®

## MICHAEL K. MILANI CURRICULUM VITAE

**Michael K. Milani** is a Managing Director in the Expert Testimony practice of Ocean Tomo. Ocean Tomo assists clients with the monetization of intellectual property (IP) through service offerings such as expert testimony, valuation, strategy, investments and transactions. He combines close to 25 years of litigation experience with 6 years of corporate strategy expertise, and has been identified by IAM as one of the world's leading IP strategists.

Mr. Milani's litigation experience covers all types of IP matters, as well as other types of complex commercial litigation. He has testified in matters pending in Federal Court, State Court, the Patent Trial and Appeals Board (PTAB) and Alternative Dispute Resolution (ADR) proceedings, offering opinions relating economic damages, commercial success and irreparable harm. Mr. Milani has also testified at the International Trade Commission (ITC), where he has offered opinions relating to domestic industry, remedy, bond, public interest and commercial success.

All combined, Mr. Milani has worked on over 200 assignments, consulting clients in all phases of the litigation process. In addition to his litigation related work, Mr. Milani provides IP related transaction, valuation, and management advice. He also has experience performing intellectual property, business, and product line valuations, inside and outside of litigation.

Mr. Milani's professional experience covers a wide range of industries including consumer products and electronics, medical equipment and devices, pharmaceuticals, semiconductors, computer networking equipment, cellular technologies, avionics, retail security, industrial/building products, lighting products, automotive products and carpeting/flooring products, among others.

Prior to joining Ocean Tomo, Mr. Milani was a Senior Manager with a multi-national consulting firm. In connection with that experience, Mr. Milani spent more than 6 years developing comprehensive business strategies for a wide variety of companies.

In addition to his professional experience, Mr. Milani has served as an Adjunct Professor, spending several years teaching both graduate level business and law school classes related to intellectual property management and monetization. Mr. Milani has also spoken on similar topics at a number of additional law school and business programs, including Northwestern University, University of Notre Dame, New York University, the University of Michigan and the University of Illinois, further reflecting his affinity for teaching. In addition to his teaching and speaking experience, Mr. Milani has also authored several publications which discuss financial, accounting, business, and/or legal issues relating to the work he performs.

Mr. Milani holds a Bachelor of Science degree in Finance from the University of Illinois and a Masters in Business Administration from Northwestern University with concentrations in Finance, Marketing and Strategy. He is also a Certified Licensing Professional and has served as a member of the recertification committee.

**EDUCATION/ CERTIFICATIONS** Northwestern University Kellogg Graduate School of Management. M.B.A with concentrations in Finance, Marketing and Strategy.

University of Illinois College of Business. B.S. with concentration in Finance. Graduation with honors.

Certified Licensing Professional (CLP), Licensing Executives Society, Certificate No. 2045

---

**EXPERIENCE** Managing Director, Ocean Tomo  
2007 to present

Director, Ocean Tomo  
2004 to 2006

Sr. Manager, BearingPoint (formerly KPMG Consulting)  
2002 to 2004

Sr. Manager, Arthur Andersen Business Consulting  
2001 to 2002

Manager, Arthur Andersen Business Consulting  
1998 to 2001

Associate, IPC Group  
1994 to 1998

Staff Consultant, IPC Group  
1990-1994

---

**MEMBERSHIPS/ AFFILIATIONS** Member of the Intellectual Property Owners Association  
Member of the Licensing Executives Society  
Member Certified Licensing Professional Re-Certification Committee  
Associate Member of the American Bar Association: IP Law Section  
Member of the Board of Editors for Patent Strategy & Management (past)  
University of Illinois Business Consulting Mentorship Program (past)  
Chicago-Kent College of Law, Adjunct Professor, IP Financial Markets and Legal Principals (past)  
Illinois Institute of Technology, Adjunct Professor, Maximizing IP Value (past)

---

**SPEAKING ENGAGEMENTS / PUBLICATIONS** “Section 337 Exclusion Orders for New Technology and Mock Hearing on Public Interest for Infringing Biologic Product,” Practitioners’ Think-Tank on ITC Litigation & Enforcement, June 28, 2019.

“Choosing the Right Expert and Demonstration of Expert Testimony,” Practicing Law Institute, November 14, 2018.

**SPEAKING  
ENGAGEMENTS /  
PUBLICATIONS  
Continued...**

“Discussion of the Value Associated with Pharmaceutical Incentives,” Global Intellectual Property Committee Meeting, Pharmaceutical Manufacturers and Researchers of America, October 30, 2017.

“Patent Value in Litigation: U.S. - China IP Cooperation Dialogue,” Global Intellectual Property Center, U.S. Chamber of Commerce, September 18, 2017.

“The Expert Relationship,” Notre Dame Law School Trail Advocacy Program, August 2017.

“Legal and Economic Considerations Associated with Litigating at the ITC,” Licensing Executives Society 2017 Spring Meeting, May 2017.

“Valuation of Trade Secrets,” AIPLA Trade Secret Law Summit, March 3, 2017.

“Valuing Trade Secrets Under The Defend Trade Secrets Act,” 2017 AIPLA Trade Secret Law Summit, March 2-3, 2017.

“IP Valuation and Patent Damages,” New York University Law School, April 18, 2016.

“Money Talks: Making Early and Well-Informed Dispute Resolution Decisions Using Damages Valuation Models,” GSU Corporate IP Institute, October 28, 2015.

“Additional Guidance from the CAFC on Apportionment,” LES Insights, Feature Article for the Week of October 19, 2015.

“Additional Guidance from the CAFC on Reasonable Royalty Damages,” LES Insights, Feature Article for the Week of August 17, 2015.

“Additional Guidance from the CAFC on Territorial Restrictions and the Overall Reasonableness of Damage Claims.” LES Insights, Feature Article for the Week of July 27, 2015.

“Determining Litigation Royalty Rates for Standard Essential Patents,” Licensing Executives Society 2015 Spring Meeting, May 2015.

“Lump Sum Damages Award Relates to Products Not Tried by The Jury,” LES Insights, September 2011.

“Hot Topics in Patent Damages,” Boston Bar Association, November 15, 2010.

“IP Value and Monetization,” Northwestern University Law School, January 15, 2010.

“Lucent v. Gateway: An Overview of the CAFC’s Views on Patent Damages,” Patent Strategy and Management, December 2009.

**SPEAKING  
ENGAGEMENTS /  
PUBLICATIONS  
Continued...**

“Damage Calculations Post eBay: The Economic Considerations,” Patent Strategy and Management, July 2009.

“Bait and Switch: From the Showroom to the Courtroom,” Patent Strategy and Management, October 2008.

“Introduction to IP Financial Markets and Legal Principals,” Chicago-Kent College of Law, August 2008.

“The Securities Act of 1933, Assessing and Managing IP Liability,” Patent Strategy and Management, February 2008.

“Derivative Applications for Patent License Agreements,” Patent Strategy and Management, September 2007.

“Benefits of Proactive Damages Planning,” Drinker Biddle Gardner Carton, IP Law Practice, June 27, 2007.

“IP Valuation,” Corporate Mergers and Acquisitions Graduate Studies Program, The University of Illinois at Urbana Champaign, April 2007.

“Determinants of Patent Value in U.S. Litigation- Part One,” Patent Strategy and Management, April 2007.

“Determinants of Patent Value in U.S. Litigation- Part Two,” Patent Strategy and Management, March 2007.

“Intellex v. Cranbrooke – Damages Testimony, Presentation and Discussion,” Notre Dame Law School Trail Advocacy Program, November 2006.

“What Patent Lawyers Can Learn From Trademark Law: The New Use of Surveys in Patent Litigation,” IPL Newsletter, Spring 2006.

“Surveys in Patent Infringement Litigation: The Next Frontier,” Patent Strategy and Management, May 2006.

“Intellex v. Cranbrooke – Damages Testimony, Presentation and Discussion,” Notre Dame Law School Trail Advocacy Program, March 2006.

“Web Based Patent Marking – A Better Mousetrap,” Patent Strategy and Management, February 2006.

“Intellectual Capital Merchant Banking,” The University of Michigan-College of Business, September 2005.

“The Emergence of IP Finance,” Patent Strategy and Management, July 2005.

“Enabling IP Securitization by Improving Cash Flow Predictability,” Patent Strategy and Management, April 2005.

**SPEAKING  
ENGAGEMENTS /  
PUBLICATIONS  
Continued...**

"Federal Circuit Damages Decision Emphasizes the Importance of Sound Economic Models," IP Review, June 2004.

"The IP Merchant Banking Model," The OSBI Consulting Group, the University of Illinois at Urbana Champaign, May 2004.

"Dealing with Intellectual Property in Business Combinations," IP Strategies Report, January 2004.

---

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
(Retained on behalf  
of underlined party)**

Mohawk Industries, Inc. and Shaw Industries, Inc. v. Interface, Inc.  
Civil Action Number: 4:07-CV-212  
United States District Court, Northern District of Georgia, Rome Division  
Expert Report and Deposition Testimony  
Claim(s): Patent False Marking  
Filed: November 6, 2007

Lewis J. Borsellino, and I.M. Acquisitions, L.L.C. v. Gerald D. Putman,  
Marrgwen Townsend, and Chicago Trading & Arbitrage, L.L.C.,  
Civil Action Number: 00 CH 13958  
Circuit Court of Cook County  
Expert Report and Deposition Testimony  
Claim(s): Fraud, Breach of Contract  
Filed: December 2, 2011

Se-Kure Controls, Inc. v. Pop Displays, USA, LLC, POP Displays, LLC,  
POP Displays, Inc., Diam USA, Inc., and Diam International, Inc.  
Civil Action Number: 1:06-cv-4857  
United States District Court, Northern District of Illinois, Eastern Division  
Expert Report  
Claim(s): Patent Infringement  
Filed: September 7, 2006

In the Matter of Certain Short Wavelength Light Emitting Diodes, Laser Diodes and Projects Containing Same, on behalf of Respondents Motorola Solutions, Inc. and Panasonic Corporation  
Investigation No. 337-TA-640  
United States International Trade Commission  
Filed: February 19, 2008

Semiconductor Insights Inc. v. Thunderbird Technologies, Inc.  
AAA Case Number: 50-117-T-00050-09  
American Arbitration Association  
Claim(s): Breach of Contract

Sandra K. Zimnicki v. Cinmar, L.P. d/b/a Frontgate, Menard, Inc., Neo-Neon International LTD., and Seasonal Concepts, Inc.  
Civil Action Number: 1:06-cv-4879  
United States District Court, Northern District of Illinois, Eastern Division  
Expert Report  
Claim(s): Copyright Infringement  
Filed: September 8, 2006

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

Affinity Labs of Texas, LLC v. JVC Americas Corp. and Kenwood USA Corporation

Civil Action Number: 9:08-CV-00171

United States District Court, Eastern District of Texas, Lufkin Division

Expert Report and Deposition Testimony

Claim(s): Patent Infringement

Filed: August 29, 2008

Inter-Ego Systems, Inc. d/b/a Pinnacle Speakers v. DBL Distributing LLC.

AAA Case Number: 50 133T00316 06

American Arbitration Association

Expert Report and Hearing Testimony

Claim(s): Breach of Contract, Copyright Infringement

Precision Dynamics Corp. v. The Standard Register Co.

Civil Action Number: 2:09-cv-03555

United States District Court for the Central District of California

Claim(s): Patent Infringement

Filed: May 19, 2009

Lighting Ballast Control LLC. v. Universal Lighting Technologies, Inc.

Civil Action Number: 7:09-cv-00029

United States District Court, Northern District of Texas, Wichita Falls

Expert Report and Trial Testimony

Claim(s): Patent Infringement

Filed: February 4, 2009

Lantiq Deutschland GMBH v. Ralink Technology Corporation

Civil Action Number: 5:11-cv-00234

United States District Court for the Northern District of California

Claim(s): Patent Infringement

Filed: January 14, 2011

Ralink Technology Corp. v. Lantiq Deutschland GmbH

Civil Action Number: 11-cv-01549

United States District Court for the Northern District of California

Claim(s): Patent Infringement

Filed: March 30, 2011

XY, LLC v. Matthias J.G. Ottenberg, Propel Labs Inc., SIDIS Corp., Daniel N. Fox, George C. Malachowski and Tidhar Sadeh

Civil Action Number: 11-cv-02920

United States District Court of Colorado

Expert Report and Deposition Testimony

Claim(s): Trade Secret Misappropriation, Patent Infringement

Filed: November 9, 2011

Cree, Inc. v. SemiLEDs, Inc. and Helios Crew Corp.

Civil Action Number: 1:10-cv-00866

United States District Court for the District of Delaware

Claim(s): Patent Infringement

Filed: October 10, 2010

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

AT Engine Controls Ltd. v. Goodrich Corporation and Goodrich Pump & Engine Systems, Inc.  
Civil Action Number: 3:10-cv-01539  
United States District Court of Connecticut  
Expert Report and Deposition Testimony  
Claim(s): Trade Secret Misappropriation, Breach of Contract  
Filed: September 28, 2010

L'Oréal S.A. and L'Oréal USA, Inc. v. Merck and Co., Inc.  
Civil Action Number: 12-99-GMS  
United States District Court of Delaware  
Expert Report, Deposition Testimony, Hearing Testimony  
Claim(s): Patent Infringement  
Filed: January 27, 2012

L'Oréal S.A. and L'Oréal USA, Inc. v. Johnson & Johnson, Inc. and Neutrogena Corporation  
Civil Action Number: 12-98-GMS  
United States District Court of Delaware  
Expert Report  
Claim(s): Patent Infringement  
Filed: January 27, 2012

O.S. Security LLC v. BRK Brands, Inc.  
Civil Action Number: SACV 14-00310 AG (DFMx)  
United States District Court for the Central District of California  
Claim(s): Patent Infringement  
Filed: March 3, 2014

Gratz College v. Synergis Education, Inc.  
Civil Action Number: 2:14-cv-06966  
United States District Court for the Eastern District of Pennsylvania  
Expert Report and Deposition Testimony  
Claim(s): Breach of Contract  
Filed: December 8, 2014

Signal IP, Inc. v. Kia Motors America, Inc.  
Civil Action Number: LA CV14-02457 JAK  
United States District Court for the Central District of California  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: April 1, 2014

Intellectual Ventures I LLC and Intellectual Ventures II LLC v. Ricoh Company, Ltd., Ricoh Americas Corporation and Ricoh Electronics, Inc.  
Civil Action Number: 1:13-CV-00474-SLR-SRF  
United States District Court for the District of Delaware  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement, Objective Indicia of Non-Obviousness  
Filed: March 25, 2013

**EXPERT**

**ASSIGNMENTS**

**AND**

**TESTIMONY**

Continued...

(Retained on behalf  
of underlined party)

Supermax, Inc., and Glovepaq Manufacturing, LLC., v. Jordan Fund, LLC  
and Earl Jordan

Civil Action Number: 14 CH 15979

Circuit Court of Cook County

Claim(s): Breach of Contract

Filed: October 3, 2014

In the Matter of Certain Personal Transporters, Components Thereof and  
Manuals Therefore, on behalf of Complainants Segway Inc., DEKA  
Products Limited Partnership and Ninebot (Tinjin) Technology Co., Ltd.

Investigation No. 337-TA-1007 / 1021 (Consolidated)

United States International Trade Commission

Expert Reports (2), Deposition Testimony, Declaration Testimony,  
Hearing Testimony

Claim(s): Patent Infringement, Trademark Infringement

Filed: May 17, 2016

Arroweye Solutions, Inc. v. Harry & David Operations, Inc.

Civil Action No. 1:15-cv-11524

United States District Court for the Northern District of Illinois

Claim(s): Patent Infringement

Filed: December 22, 2015

Got I LLC and Kids II, Inc. v. XRT, Inc. and David Eugene Silvergate

Civil Action No. 1:16-cv-00038-WSD

United States District Court for the Northern District of Georgia

Claim(s): Breach of Contract

Filed: January 6, 2016

Swimways Corporation and Kelsyus LLC v. Bestway (USA), Inc.

Civil Action No. 1:16-cv-608 (LMB/IDD)

United States District Court for the Eastern District of Virginia

Expert Report and Deposition Testimony

Claim(s): Patent Infringement

Filed: June 6, 2016

Valencell, Inc. v. Apple, Inc.

Civil Action No. 5:16-cv-00001-D

United States District Court for the Eastern District of North Carolina

Claim(s): Patent Infringement and Unfair Competition

Filed: January 4, 2016

Remote Year, Inc. v. We Roam, LLC

Civil Action No. 1:17-cv-00142-RGA

United States District Court for the District of Delaware

Claim(s): Trade Secret Misappropriation, Fraud, Tortious Interference

Filed: February 9, 2017

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

Ignite USA, LLC v. Pacific Market International, LLC  
Civil Action No. 0:16-cv-01429  
United States District Court for the Northern District of Illinois  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: February 7, 2014

OptoLum, Inc. v. Cree, Inc.  
Civil Action No. 2:16-cv-03828-DLR  
United States District Court for the District of Arizona  
Transfer to Middle District of North Carolina  
Claim(s): Patent Infringement  
Filed: November 3, 2016

Cree, Inc. v. OptoLum, Inc.  
Cases IPR2017-01260, IPR2017-01261 and IPR2017-01511  
Declarations (3)  
Patent Trial and Appeal Board  
Filed: April 11, 2017 and May 31, 2017

Riddell, Inc., v. Kranos Corporation, d/b/a Schutt Sports  
Civil Action No. 1:16-cv-4496  
United States District Court for the Northern District of Illinois  
Expert Report, Trial Testimony  
Claim(s): Patent Infringement  
Filed: April 21, 2016

In the Matter of Certain X-Ray Breast Imaging Devices and Components  
Thereof, on behalf of Respondents FUJIFILM Corporation, FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM Techno Products Co., Ltd  
Investigation No. 337-TA-1063  
United States International Trade Commission  
Expert Reports (2), Deposition Testimony, Hearing Testimony  
Claim(s): Patent Infringement  
Filed: June 28, 2017

Acceleron, LLC v. Dell, Inc.  
Civil Action No. 1:12-CV-04123  
United States District Court for the Northern District of Georgia  
Expert Reports (2), Deposition  
Claim(s): Patent Infringement  
Filed: November 28, 2012

Team Worldwide Corporation v. Wal-Mart Stores, Inc., Wal-Mart Stores Texas, LLC, Wal-Mart.com USA LLC, Sam's West, Inc. D/B/A Sam's Club and Intervenor Defendant Bestway (USA), Inc.  
Civil Action No. 2:17-cv-235  
United States District Court for the Eastern District of Texas  
Claim(s): Patent Infringement  
Filed: March 29, 2017

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

Serta Simmons Bedding, LLC , and Dreamwell, LTD. v. Casper Sleep Inc.  
Civil Action No. 17-cv-7468  
United States District Court for the Southern District of New York  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: September 29, 2017

TeleCommunications Systems, Inc. and Comtech Telecommunications Corp. v. Information Systems Audit and Control Association, Inc.  
AAA Case Number: 01-17-0003-0244  
American Arbitration Association  
Claim(s): Breach of Contract, Trademark Infringement, Unfair Competition, Fraud, Deceptive Trade Practices, Conversion  
Filed: May 23, 2017

Webasto Thermo & Comfort North America, Inc. and Webasto-Edscha Cabrio USA Inc. v. Bestop, Inc.  
Civil Action No. 16-13456  
United States District Court for the Eastern District of Michigan  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: September 23, 2016

Kranos IP Corporation, Kranos IP II Corporation, Kranos Corporation dba Schutt Sports v. Riddell, Inc.  
Civil Action No. 1:17-cv-06802  
United States District Court for the Eastern District of Texas  
Transfer to Northern District of Illinois  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: May 18, 2017

The Valspar Corporation and Valspar Sourcing, Inc. v. PPG Industries  
Civil Action No. 0:16-cv-01429  
United States District Court for the District of Minnesota  
Claim(s): Patent Infringement  
Filed: May 23, 2016

The Sherwin-Williams Company v. PPG Industries, Inc.  
Civil Action No. 2:17-cv-01023  
United States District Court for the Western District of Pennsylvania  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: August 4, 2017

Fujifilm Corporation and Fujifilm Medical Systems U.S.A., Inc., v. Hologic, Inc.  
Civil Action No. 18-343-GMS  
United States District Court for the District of Delaware  
Claim(s): Patent Infringement, Antitrust, Unfair Competition, Tortious Interference  
Filed: March 2, 2018

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

Evoqua Water Technologies, LLC v. M.W. Watermark, LLC; Michael Gethin, Daniel Janisse, Paul Malik, Andrew Hagen, David Higgins and James Driesenga  
Civil Action No. 17-4997-CB  
State of Michigan in the Circuit Court for the County of Ottawa  
Expert Report, Deposition Testimony, Hearing Testimony  
Claim(s): Trade Secret Misappropriation, Breach of Contract, Conversion, Unfair Competition and Unjust Enrichment  
Filed: June 26, 2017

MLC Intellectual Property, LLC v. Micron Technology, Inc.  
Civil Action No. 3:14-cv-03657  
United States District Court for the Northern District of California  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: August 12, 2014

Edgewell Personal Care Brands, LLC and International Refills Company Ltd. v. Munchkin, Inc.  
Civil Action No. 2:18-cv-03005  
United States District Court for the Central District of California  
Expert Report and Deposition Testimony  
Claim(s): Patent Infringement  
Filed: April 10, 2018

FMC Corporation and FMC ARGO Singapore PTE. LTD. v. Syngenta Crop Protection AG  
CPR Institute for Dispute Resolution Non-Administered Arbitration  
Expert Report and Hearing Testimony  
Claim(s): Breach of Contract  
Filed: December 20, 2018

In the Matter of Certain Pocket Lighters, on behalf of Complainant BIC Corporation  
Investigation No. 337-TA-1142  
United States International Trade Commission  
Expert Report and Deposition Testimony  
Claim(s): Trademark Infringement  
Filed: December 6, 2018

Infinity Computer Products, Inc. v. Konica Minolta Business Solutions, U.S.A., Inc.  
Civil Action No. 2:12-cv-06802  
United States District Court for the Eastern District of Pennsylvania  
Claim(s): Patent Infringement  
Filed: December 5, 2012

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

Unicorn Global, Inc., Hangzhou Chic Intelligent Technology Co., Ltd., and Shenzen Uni-Sun Electronic Co., Ltd. v. Golabs, Inc., d/b/a Gotrax, Walmart Inc., Wal-Mart Stores Texas, LLC, and Wal-Mart.com USA LLC

Civil Action No. 3:19-CV-00754-N

United States District Court in the Northern District of Texas

Claim(s): Patent Infringement

Filed: March 26, 2019

Golabs, Inc., d/b/a Gotrax, Walmart Inc., Wal-Mart Stores Texas, LLC, and Wal-Mart.com USA LLC v. Unicorn Global, Inc., Hangzhou Chic Intelligent Technology Co., Ltd., and Shenzen Uni-Sun Electronic Co., Ltd.

Civil Action No. 3:19-CV-00754-N

United States District Court in the Northern District of Texas

Declarations (2) and Deposition Testimony (2)

Claim(s): Unfair Competition, Tortious Interference

Filed: June 27, 2019

Wi-Lan Inc.; Wi-Lan USA, Inc.; and Wi-Lan Labs, Inc. v. LG Electronics, Inc.; LG Electronics U.S.A., Inc.; LG Electronics Mobilecomm U.S.A., Inc.

Civil Action No. 3:18-CV-01577

United States District Court in the Southern District of California

Expert Report

Claim(s): Patent Infringement

Filed: July 11, 2018

Orthopaedic Hospital d/b/a Orthopaedic Institute for Children v. DJO Global, Inc. and DJO Finance LLC

Civil Action No. 3:19-CV-00970

United States District Court in the Southern District of California

Expert Report

Claim(s): Patent Infringement

Filed: May 23, 2019

Fraunhofer – Gesellschaft Zur Forderung Der Angewandten Forschung E.V. v. Sirius XM Radio Inc.

Civil Action No. 1:17-CV-00184

United States District Court in the District of Delaware

Claim(s): Patent Infringement

Filed: February 22, 2017

In the Matter of Certain Audio Players and Controllers, Components Thereof, and Products Containing Same, on behalf of Complainant Sonos Inc.

Investigation No. 337-TA-1191

United States International Trade Commission

Expert Report and Deposition Testimony

Claim(s): Patent Infringement

Filed: January 7, 2020

**EXPERT  
ASSIGNMENTS  
AND  
TESTIMONY  
Continued...  
(Retained on behalf  
of underlined party)**

In the Matter of Certain Wearable Monitoring Devices, Systems and Components Thereof, on behalf of Respondents Fitbit Inc. and Garmin Ltd.

Investigation No. 337-TA-1190

United States International Trade Commission

Expert Report, Deposition Testimony and Hearing Testimony

Claim(s): Patent Infringement

Filed: December 10, 2019

Boston Scientific Corporation and Boston Scientific Scimed, Inc.

v. Micro-Tech Endoscopy USA Inc., Micro-Tech (Nanjing ) Co., Ltd. and Henry Schein Inc.

Civil Action No. 1:18-cv-01869-CFC

United States District Court in the District of Delaware

Claim(s): Patent Infringement

Filed: November 26, 2018

Ultravision Technologies, LLC v. Yaham Optoelectronics., Ltd., and Yaham U.S.A., Inc.

Civil Action No. 2:18-cv-00118

United States District Court for the Eastern District of Texas, Marshall Division

Expert Report

Claim(s): Patent Infringement

Filed: March 27, 2018

Ultravision Technologies, LLC v. Yaham Optoelectronics., Ltd.

Civil Action No. 2:19-cv-00398

United States District Court for the Eastern District of Texas, Marshall Division

Expert Report

Claim(s): Patent Infringement

Filed: December 6, 2019

Chervon (HK) Limited, Chervon North America Inc. v. One World Technologies, Inc., Techtronic Industries Co. LTD.

Civil Action No. 1:19-cv-01293

United States District Court for the District of Delaware

Claim(s): Patent Infringement

Filed: July 11, 2019

**OTHER  
REPRESENTATIVE  
ENGAGEMENT  
EXPERIENCE,  
INCLUDING AT  
LEAST LAST 5  
YEARS  
(Retained on behalf of  
underlined party)**

**Patent Infringement Matters:**

- Virginia Innovation Sciences, Inc. v. Samsung Electronics Co., Ltd.; Samsung Electronics America, Inc.; Samsung Telecommunications America LLC
- Radware, Ltd. v. F5 Networks, et al.
- Boston Scientific Corporation and Target Therapeutics, Inc. v. Cordis Corporation

**OTHER  
REPRESENTATIVE  
ENGAGEMENT  
EXPERIENCE,  
INCLUDING AT  
LEAST LAST 5  
YEARS  
Continued...  
(Retained on behalf of  
underlined party)**

- St. Clair Intellectual Property Consultants v. Fuji Photo Film Co., Ltd., Fuji Photo Film U.S.A., Inc., Fujifilm America, Inc., et al.
- St. Clair Intellectual Property Consultants v. Panasonic Corporation
- St. Clair Intellectual Property Consultants v. Victor Company of Japan aka JVC
- St. Clair Intellectual Property Consultants v. High Tech Computer Corp., aka HTC Corp.
- Fujifilm Corporation v. Motorola Mobility LLC
- Forgent Networks v. Digeo, Inc.
- Forgent Networks v. Scientific Atlanta, Inc.
- Forgent Networks v. Motorola, Inc.
- Grand Haven Stamped Products Company v. Dura Automotive Systems, Inc.
- Andrx Pharmaceuticals, LLC. v. Glaxosmithkline, PLC and Smithkline Beecham Corporation D/B/A Glaxosmithkline
- Interface, Inc., et al., v. Mohawk Industries, Inc., et al.
- Power Integrations, Inc. v. Fairchild Semiconductor International, Inc., et al
- Compression Labs, Inc. v. Fuji Photo Film U.S.A.
- Prism Technologies, LLC v. AT&T Mobility, LLC
- Fairchild Semiconductor Corporation and System General Corporation v. Power Integrations, Inc.
- Analog Devices, Inc. v. Knowles Electronics, LLC
- Knowles Electronics, LLC v. Analog Devices, Inc.
- Keurig, Incorporated v. Kraft Foods Global, Inc., Tassimo Corporation, and Kraft Foods, Inc.
- Network-1 Security Solutions, Inc. v. Hewlett Packard Company et al.
- Consumer Satellite Radio, LLC v. Sirius XM Radio, Inc., et al.
- Medgraph, Inc. v. Medtronic, Inc.
- Datalogic Scanning, Inc., v. Metrologic Instruments, Inc.
- Nomadix, Inc. v. Hewlett-Packard Company et al.
- Innovention Toys, LLC v. MGA Entertainment, Inc., Wal-Mart Stores, Inc. and Toys 'R Us, Inc.
- Digital-Vending Services International, Inc. v. The University of Phoenix, Inc. et al.
- Lincoln Electric Company, et al. v. National Standard, LLC
- Callpod, Inc. v. GN Netcom, Inc., A/S, GN Store Nord, A/S (a/k/a GN Great Nordic, Ltd.), and Hello Direct, Inc.
- Fotomedia Technologies, LLC v. AOL, LLC, Photobucket.com, Inc., Shutterfly, Inc., CNET Networks, Inc., and Yahoo!, Inc.

**OTHER  
REPRESENTATIVE  
ENGAGEMENT  
EXPERIENCE,  
INCLUDING AT  
LEAST LAST 5  
YEARS**

Continued...

(Retained on behalf of  
underlined party)

- Bendix Commercial Systems LLC, et al. v. WABCO Automotive Control Systems, Inc. et al.
- Allen J. Rushing, Ph.D. v. NexPress Solutions
- Nissim Corp. v. Clearplay, Inc.
- MEI, Inc. v. JCM American Corp & Japan Cash Machine Co. Ltd.

**International Trade Commission Matters:**

- In the Matter of Certain Wiper Blades (Inv. No. 337-TA-816), on behalf of Respondents Corea Autoparts Producing Corp. d/b/a CAP America, CAP America, Inc., PIAA Corp. U.S.A., ADM21 Co., Cequent Consumer Products, Inc., RainEater LLC, and Daewoo International Corp.
- In the Matter of Certain Silicon Microphone Packages and Products Containing Same (Inv. No. 337-TA-888), on behalf of Complainant Knowles Electronics, LLC.
- In the Matter of Certain Electronic Devices Including Handheld Wireless Communication Devices (Inv. No. 337-TA-673), on behalf of Respondent Panasonic Corporation
- In the Matter of Certain Short Wavelength Light Emitting Diodes, Laser Diodes and Projects Containing Same (Inv. No. 337 -TA-640), on behalf of Respondents Panasonic Corporation and Motorola

**Trade Secret Misappropriation Matters:**

- Tekmira Pharmaceuticals Corporation and Protiva Pharmaceuticals, Inc. v. Alnylam Pharmaceuticals, Inc. and AlCana Technologies, Inc.
- Gaya Limited v. Applied Medical Resources Corporation
- Netlist, Inc. v. Smart Storage Systems, Inc. and Diablo Technologies, Inc.
- W.C Heraeus GMBH & Co.K.G and Heraeus Incorporated v. Marjorie Joy Lynn, Lynn plasma Inc. and Nxedge, Inc.

**Trademark/Copyright Matters:**

- Oracle America Inc. v. Google Inc.
- Rosetta Stone Ltd. v. Google Inc.
- Express, LLC. v. Fetish Group, Inc.

**False Advertising Matters:**

- Dyson, Inc. v. Bissell Homecare, Inc.
- Bracco Diagnostics, Inc. v. Amersham Health Inc., Amersham Health AS, Amersham plc and Amersham Health Inc. v. Bracco Diagnostics, Inc.
- Ashley Furniture Industries v. Laura Ashley Holdings Plc and Laura Ashley, Inc.

**OTHER  
REPRESENTATIVE  
ENGAGEMENT  
EXPERIENCE,  
INCLUDING AT  
LEAST LAST 5  
YEARS  
Continued...  
(Retained on behalf of  
underlined party)**

**Other Commercial Litigation Matters:**

- W.C Heraeus GMBH & Co.K.G and Heraeus Incorporated v. Marjorie Joy Lynn, Lynn plasma Inc. and Nxedge, Inc.
- Nomir Medical Technologies, Inc. v. McDermott Will & Emery LLP, Simona Levi-Minzi, Mark Lappin and G. Matthew McCloskey
- Leclerc & Masselon, et al. v. MGA Entertainment, Inc.
- Discovision Associates v. Fuji Photo Film Co., Ltd.
- Boyce Thompson Institute for Plant Research v. Medimmune, Inc.
- City of Hope v. Juno Therapeutics, Inc.

# Attachment C

**Michael Plishka | President  
ZenStorming™, LLC**  
michael@zenstorming.com, Cell: (847)791-3655

---

### **Professional Experience Summary**

Founder and President of ZenStorming™, a Design and Innovation Consultancy.  
Twenty-Five+ years designing, developing and launching medical products

#### ***FOCUS ON THE CUSTOMER***

*Clinical Relationship Builder*

*Extensive experience in Sterile Environments*

*Trained clinicians and sales staff on device use in cadaver and mock labs*

*Established hospital based training programs for engineers*

*Market Research studies*

*Product Research = Product Requirements = New Product Directions*

*Product Complaint Support*

*Assembled Clinical Advisory Boards to guide product portfolio strategy*

*Instructional Videos and Label Copy*

#### ***APPLIED CREATIVITY***

*Idea Generation*

*Innovator for Next Generation Products*

*Product Platform Development*

*Strategic Technology Planning*

*Technology Assessment*

*Intellectual Property Portfolio Development*

*Expedited Project Feasibility*

*3D Printing and Prototyping*

*Product Problem Solving*

#### ***REGULATORY SPECIALISMS***

*Presenter at 2017 Midwest Sensors Conference,*

*“Sensor-Driven Healthcare: Innovative Applications Today & Tomorrow”*

*Presenter at 2008 International Silicone Conference,*

*“Working with Medical Device Companies – The Essentials”*

*QSR Procedures (Design Controls, GMP, GLP, etc.)*

*Validation and testing protocols for*

*packaging, new products and processes*

*Risk Assessment Process development*

*Authorship of 510 (k) submissions*

*Engineering Regulatory Compliance*

## PROFESSIONAL EXPERIENCE

### *Expert Witness*

- Purewick – Court Case (Purewick v Sage) – (2020)
- BD– IPR (Baxter v BD) – 2020
- Bard – IPR (Bard v Medline ) – 2019
- Nevro – IPR plus Court Case (Nevro v. Boston Scientific) – 2017; Current/Stayed
- Endoevolution – Arbitration (Endoevolution v Ethicon) – 2017
- Carefusion– Court Case (Willie Harris v Carefusion) – 2014 (Settled)
- Hologic – Court Case (Ethicon EndoSurgery v. Hologic Inc and Suros Surgical Systems, Case No. 1:07-CV-00834) - 2010

### *ZenStorming Solutions, LLC*

*4/08 to Present*

- Carefusion (BD/Bard Partnership) (2010-Present) – New Product Conception/Strategy/Design/Development, Research/Development of Disruptive Innovation Portfolio, Technology Assessment, IP Development, Sales/Clinical Training, Mobile App Story-Boarding
- Albee Systems, LLC 0 (2020) –Systems to contain aerosolized pathogens during surgical/dental procedures
- Zavation (2019-Present) – Bone Cement Delivery System Development
- Matnovation (2015-Present)- Design and development of a bronchoscope (endoscope) with disposable components
- Surgimatix(2011-Present) – Endoscopic Suture Device Development, Quality System Development, Validation Support
- Hines VA (2009-Present) – Electrode Deployment Device Development, Grant Funding and Engineering Support
- TransMax(2016) – Product Development, Engineering Advisor for CPR Training Device
- Xavier Moreno (2017-Present)– Epidural Catheter Measurement Device, Engineering Design and Development
- AOK Inc. – (2011-Present) New Product Development: Thoracic Access, Toy Robot Development
- 510(k) Authorship and Patent Research for Entrepreneurs (Ongoing)
- King Systems (Ambu) (2011-Present) – Respiratory Products and Emergency Airway Access, New Product Design/Development
- Inventor Anesthesiologist (2015) – Technical Guidance on Development and Licensing of Drug Dispenser Adapter
- Hollister (2010-Present)– New Product Idea Generation - Brainstorming Moderation
- Ferring Pharmaceuticals – (2009-2012)Developed Marketing Awareness Campaign
- Testicular Cancer Society (2009-10)- Developed Marketing Awareness Campaign
- Baxter Healthcare (2008)– IP Portfolio Development

### *Baxter Healthcare*

*6/06 to 4/08*

#### *Position: Engineering Specialist; Access Systems Business Unit*

- Lead Innovator for generating IP for Next Generation Vascular Access Products such as luer activated devices. resulting in multiple cross platform patent applications in heavily populated patent landscape
- Spearheaded development of resources that enabled manufacture of prototypes in half the time at a cost savings of 50%.
- Determined feasibility of new IV Access product and benchmarked against key competitive products in six months
- Engineering Lead for Market Research Studies
- Developed relationships with clinicians resulting in six new hospital sites for engineers to study clinician behaviors.
- Led Clinical Advisory Board Meetings in conjunction with Marketing.
- Drafted business unit plan for World Wide Technology/Product Planning Committees
- Mentor for younger engineers
- Company Representative in off-site college recruitment program.
- Direct Supervisory Responsibility for Junior Engineer

### *Cardinal Health (Allegiance Healthcare Corporation)*

*4/99 to 6/06*

#### *Position: Engineering Specialist; Special Procedures Business Unit*

- Engineering Project Lead driving the development of products from conception through launch while meeting aggressive timelines. Products included drainage catheters, biopsy devices and interventional vertebral repair.
- Physician Advisory Board Team Leader for new product development projects
- Technical Expert assessed and recommended new technologies and/or products for business development
- Developed patented, product platforms/line-extensions that provided 35% of all revenues in the Special Procedures

business unit.

- Developed training materials and trained Sales Staff /Clinicians on new products in cadaver labs and lecture settings
- Developed and updated Quality System/Design Controls, minimizing documentation volume and time without sacrificing safety (Design Controls, Risk Analysis, GMP, GLP, etc.)
- Authored and performed validation and testing protocols for new products and processes
- Supported 510 (k) regulatory submissions
- Developed company-wide Technical Development Career track for non-degreed Designers/Technicians
- Direct supervisory responsibility for Designer and EDP (Engineering Development Program) Engineer
- Mentor for younger engineers
- Indirect managerial responsibility for cross-cultural Project Team
- Company Representative in off-site college recruitment program.

**Manan Medical Products**

**3/95 to 4/99**

**Position: New Product Development Engineer**

- Worked with clinicians to develop novel and patented drainage catheters/accessories and biopsy products
- Managed manufacturing scale-up through product launch.
- Developed advertising, labeling (instructions), packaging and manufacturing procedures for new products.
- Filed and successfully received 510(k) approval on new and modified products.
- Wrote and performed validation and testing protocols for products, packaging and processes.
- Head of Engineering Regulatory Compliance Team achieving ISO registration and passing FDA audit with no corrective action taken
- Developed Design Control and Hazard Analysis procedures as per QSR and ISO

**Hines VA Hospital/Loyola Medical Center**

**3/91 to 5/94**

**Position: Biomedical Engineer**

- Developed bi-polar surface electrode for use on perineum.
- Co-developed implantable "mesh" electrode for use on bladder wall.
- Co-designed supra-pubic indwelling catheter for use in bladder studies.
- Generated computer simulation of bladder in cooperation with University of Illinois.
- Co-authored papers which applied research to practical, diagnostic use.

**INVENTIONS (Partial List)**

US5730724 Drainage Catheter Apparatus

US5989241 Drainage Catheter Apparatus

US 7018343 Biopsy Needle and Device Containing the Same

D478987S Biopsy device

CA2413665 Multi-Use Surgical Cement Dispenser Apparatus And Kit For Same

CA2429357 Improved Paracentesis Device Having Multiple Detachable Components

WO03086201 Improved Biopsy Needle And Biopsy Device Containing The Same

WO03000121 Multi-Use Surgical Cement Dispenser Apparatus And Kit For Same

WO03022337 Improved Paracentesis Device Having Multiple Detachable Components

Curable Material Injection Device-Pending

Curable Material Mixing and Delivery Device -Pending

Paracentesis Device - Pending

Luer Activated Device –Three Patents Pending

Biopsy Devices – Two Pending

## EDUCATION

*Bachelor of Science Mechanical Engineering*

*University of Illinois at Chicago*

*Honors: Phi Eta Sigma for Honor Roll in multiple consecutive semesters*

*Master of Arts*

*Loyola University of Chicago*

## PROFESSIONAL SOCIETIES

*IDSA – Industrial Design Society of America*

*IEEE - Institute of Electrical and Electronics Engineers*

*EMBS – Engineering in Medicine and Biology Society*

*RSNA – Radiological Society of North America*

## PUBLICATIONS

“Mind Opening Exercise” Illustration in "Lifespan Human Development" (Sigelman, Rider, De George-Walker, 2013)

Walter, J. S., Wheeler, J. S., Zaszczurynski, P., & Plishka, M. "Urodynamic measure of urethral cross-sectional area: Application for obstructive uropathy." *Neurourology and urodynamics* 13.5 (1994): 571-582.

Damaser, M. S., Walter, J. S., & Plishka, M. "Letter." *International Urogynecology Journal* 5.3 (1994): 191-191.

Walter, J. S., Wheeler, J. S., Morgan, C., Zaszczurynski, P., & Plishka, M. "Measurement of urethral compliance in females with stress incontinence." *Engineering in Medicine and Biology Society, 1992 14th Annual International Conference of the IEEE*. Vol. 4. IEEE, 1992.

Walter, J. S., Wheeler, J. S., Morgan, C., Zaszczurynski, P., & Plishka, M. "Measurement of total urethral compliance in females with stress incontinence." *Neurourology and urodynamics* 12.3 (1993): 273-276.

Walter, J. S., Wheeler, J. S., Cogan, S. F., Plishka, M., Riedy, L. W., & Wurster, R. D. "Evaluation of direct bladder stimulation with stainless steel woven eye electrodes." *The Journal of urology* 150.6 (1993): 1990-1996.

## HONORS/SKILLS

### *Presentations:*

- Presenter at 2017 Midwest Sensors Conference, “Sensor-Driven Healthcare: Innovative Applications Today & Tomorrow”
- Presenter at 2008 International Silicone Conference, “Working with Medical Device Companies – The Essentials”

### *Awards:*

- Received Foster G. McGaw Contribution for Ava-Tex™ Bone Cement Delivery System (2005).
- Received Karl D. Bays New Product Award for development of Temno Evolution Biopsy Device (2004).
- Received Karl D. Bays New Product Award for development of Safe-T-Centesis Drainage System (2003).
- Received Allegiance Innovation Award for development and launch of Ava-Tex™ Bone Cement Delivery System in nine months (2001).
- Received Technical Excellence Award from Technical Council in 2001 and 2003.

## ITEMIZED PROJECT EXPERIENCE ADDENDUM

**Innovation:** Worked with clinicians to design the following:

- Biliary Catheters
- General Drainage Catheters
- Nephrostomy Catheters
- Guide Wire Introducers and Introducer sheaths
- MRI Compatible Biopsy Needles
- Vertebroplasty Systems
  - Delivery System
  - Mixing System
  - Access System
- Repositionable Para/thoracentesis Catheters
- Drainage Systems (Bottle and Bag based)
- Fully Automatic Breast Biopsy Device
- Catheter Fixation Disk
- Interventional Drainage Bag
- Laryngoscope
- Anesthesia Filters
- Tissue/Fiduciary Markers
- Surgical Heating Systems
- Thoracic Entry Systems
- Laparoscopic Suturing Device

*Electrodes*

- Perineal
- Implantable Woven Mesh

*Vascular Access*

- Luer Activated Devices

**Clinical Procedural Attendance:**

- Biopsy
- Vertebroplasty
- PICC Placement
- Kyphoplasty
- Angioplasty/Stent Placement
- Interventional Drainage Catheter Placement
- Interventional Diagnostics
- Vascular Access

**Materials Knowledge:** Partial list of materials used in product developed:

- Implant grade steels
- MRI Compatible Materials
- Polycarbonate
- Polyurethane
- PMMA
- ABS
- Polypropylene
- Silicones
- PEEK
- Nylon

**Innovation Process:**

- Improved Brainstorming Processes
- Technical Expert involved in cross-business innovation
- Independent Reviewer of Cross-business products
- IP Generation and Portfolio Management
- Key Opinion/Clinical User Boards

**Process Engineering:** Manufacturing of the following devices:

- Interventional Drainage Catheters
- Needles
- Hand Held Injectors
- Cement Delivery Tubes
- Hot and Cold Pads
- Drainage Bags
- Guide Wire Catheters
- Luer Activated Devices
- Tissue Markers

**Anatomy/Physiology:** Working knowledge in the following areas:

- Human physiology
- Spine Mechanics
- Interventional Visualization Systems
- Vascular Biology
- Modelling of Heat Transfer under Anesthesia

**Coating/Impregnated Materials:** Experience with the following coatings:

- Hydrophilic Coating
- Antimicrobial Silver Coatings
- Parylene & PTFE Coating
- Lubricious materials (Impregnated)
- Antimicrobials (Impregnated)

# Attachment D

**Gary (Taavi) Reiss**

639 Esplanade Avenue  
New Orleans, LA 70116

e-mail: taavi@stanfordalumni.org

(415) 260-0370 • (504)349-6444 (fax)

---

***Education***

---

2005-2008	<b>Tulane University Medical Center</b> , Gastroenterology fellowship
2002-2005	<b>Stanford University Hospital and Clinics</b> , Internal Medicine residency
1998-2002	<b>Louisiana State University Health Science Center, MD</b> May 2002 (with honors)
1998-2002	<b>Louisiana State University School of Graduate Studies, MPH</b> May 2002
1999-2001	<b>University of New Orleans, MBA</b> August 2001
1993-1997	<b>Stanford University</b> , BA in History and Human Biology (dual major)

***Employment & Professional Activity***

---

2008-Present	<b>Metropolitan Gastroenterology Associates</b> , Partner. Director / Founder GI oncology specialty clinic Director / Founder therapeutic endoscopy program
2007-2008	<b>Chabert Medical Center</b> , Hospitalist.
2004-2008	<b>San Mateo County Medical Center</b> , Hospitalist.
2004-2006	<b>Health Science Center for Continuing Medical Education</b> . Independent content reviewer for CME symposiums pertaining to gastrointestinal disease.
2004-2005	<b>FA Davis Company</b> . Content reviewer, medical text books.
2002-2005	<b>Kaplan Medical, Inc.</b> Content designer for USMLE II&III review material.
Winter, 2004	<b>Sujansky &amp; Associates</b> , Medical informatics consultant.

***Academic, Organizational, Administrative Activity***

---

2013-Present	<b>West Jefferson Medical Center</b> , Director of Endoscopy
2010-Present	<b>Louisiana State University Health Science Center</b> , Clinical associate professor of medicine, gastroenterology, therapeutic endoscopy. Train senior fellows in advanced endoscopic technique.
2015-2016	<b>Tulane University Medical Center</b> , Clinical instructor, gastroenterology, therapeutic endoscopy. Train senior fellows in advanced endoscopic techniques.
2008-2012	<b>Louisiana State University Therapeutic Endoscopy Conference</b> Founded first national conference on ERCP / advanced endoscopy in region. Course director first five years of conference.
2008-Present	<b>Louisiana Gastroenterology Association</b> , Member

**Gary (Taavi) Reiss**

639 Esplanade Avenue  
New Orleans, LA 70116

e-mail: taavi@stanfordalumni.org

(415) 260-0370 • (504)349-6444 (fax)

---

2006-Present     **American College of Gastroenterology**, Member  
Fellowship status awarded 2015

2006-Present     **American Society Gastrointestinal Endoscopy**, Member

2006-Present     **American Gastroenterology Association**, Member

---

***Research & Publications***

Smith MS,... US Collaborative WATS Study Group (**Reiss G**, et al.) Wide-Area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's esophagus: analysis from a prospective multicenter community-based study. *Dis Esophagus* 2019 Mar 1;32(3):1-8.

Spera M., **Reiss G**. Endoscopic Treatment of Reflux-A Review. *The Journal of East Jefferson General Hospital* October 2017

April 30<sup>th</sup>, 2015 Interviewed in: Signs You Could Have "Silent Reflux." US News & World Report:  
<http://health.usnews.com/health-news/patient-advice/articles/2015/04/30/signs-you-could-have-silent-reflux>

Stover J, Meltzer S, Haydeck J, Cattau E, **Reiss G**. Comparison of Traditional Histology and Histology with Molecular Diagnostic Testing for Risk Stratification of Barrett's Esophagus: A Multi-Center Study. *Gastroenterology* 2014;146:5-Sa1082.

Gendusa P, Martinez I, **Reiss G**, Landreneau SW. Management of choledocholithiasis in pregnancy. *J La State Med Soc*. 2013;165:110.

Martinez I, Gendusa P, Jenkins P, **Reiss G**, Landreneau SW. Pregnancy rocks: management of choledocholithiasis in pregnancy. Poster presented at American College of Gastroenterology Regional Meeting. March 2012, New Orleans, LA.

**Reiss G**, Sickel J, See-Tho K, Ramrakhiani S. Intrapancreatic splenic cyst mimicking pancreatic cystic neoplasm diagnosed by endoscopic ultrasound guided fine needle aspiration. *Gastrointest Endosc*. 2009;70:557-8.

**Reiss G**, Gopi R, Ramrakhiani S. Unusual cause of colonic obstruction: Gallstone impaction requiring mechanical lithotripsy. *Clin Gastroenterol Hepatol*: 2009;7:A20.

**Reiss G**, Ramrakhiani S. Abnormal pancreatic imaging: ambiguity necessitates endoscopic ultrasound. *Gastrointest Endosc*. 2008;68:243-5.

**Reiss G**, Keeffe EB. Vaccination against hepatitis B in patients with chronic liver disease. Year in Hepatitis Vaccines Volume 2. 2008.

**Reiss G**, Keeffe EB. Response letter to Dr. Morrow et al. *J Am Geriatr Soc*. 2007;55(1):142.

**Gary (Taavi) Reiss**

639 Esplanade Avenue  
New Orleans, LA 70116

e-mail: taavi@stanfordalumni.org

(415) 260-0370 • (504)349-6444 (fax)

---

**Reiss G**, Keeffe EB. Vaccination against hepatitis B in patients with chronic liver disease. Current Hepatitis Reports. 2006; 5:58-62

**Reiss G**, Kunz P, Koin D, Keeffe EB: Escherichia coli O157:H7 Infection in Nursing Homes: Report of Recent Outbreak and Review of Literature. J Am Geriatr Soc. 2006 54(4):680-4. Originally presented in poster format, 2005 American College of Physicians, San Francisco, CA.

Mitiku T, **Reiss G**, Vagelos R: Capecitabine induced coronary vasospasm: A report of 2 cases. Poster, 2005 American College of Physicians, San Francisco, CA.

**Reiss G**, Keeffe EB: Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord. 2005;5(4):195-205.

**Reiss G**, Keeffe EB: Hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004 Apr;19:715-27.

**Reiss G**, Kopicko J, O'Brien M, Clark RA: Lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir. J Acquir Immune Def Synd 2001;26:513-6. Poster, 2000 Infectious Disease Society of America, New Orleans, LA.

Summer, 1998   **Research Assistant**, New Orleans Regional AIDS Planning Council. Special Populations: HIV/AIDS Needs Assessment for the New Orleans EMA. Found, interviewed, and quantified needs of underserved HIV+ populations.

Spring, 1998   **Research Assistant**, New Orleans Office of Health Policy. "Cost per Unit of Service Assessment of HIV/AID Patients in the New Orleans Area."

### ***Clinical Research***

---

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety And Efficacy Of XXX In Male Obese Subjects With Hypogonadotropic Hypogonadism

A 6 Month, Double-Blind Safety Extension Study of XXX Evaluating the Effects of Long Term Treatment with XXX on Bone Mineral Density

A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and NSAID-Controlled Study to Evaluate the Efficacy and Safety of XXX in Patients with Pain Due to Osteoarthritis of the Knee or Hip

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of XXX in Relieving Symptoms of Gastroparesis

**Gary (Taavi) Reiss**

639 Esplanade Avenue  
New Orleans, LA 70116

e-mail: taavi@stanfordalumni.org

(415) 260-0370 • (504)349-6444 (fax)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of XXX in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A *Clostridium difficile* Vaccine In Adults 50 Years Of Age And Older

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of XXX in Patients with Lactose Intolerance

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral XXX Administered to Patients with Gastroesophageal Reflux Disease while receiving

Proton Pump Inhibitors

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral XXX as Induction Therapy for Moderately to Severely Active Crohn's Disease

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of XXX in Participants with Moderately to Severely Active Ulcerative Colitis

A Multicentre, Randomised, Double-Blind (Sponsor-Unblinded), Placebo-Controlled Study With Open Label Extension To Investigate The Safety And Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of XXX In Subjects With Active Ulcerative Colitis.

Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study

Prospective Collection of Colon Fluids for Gastrointestinal Disease Detection. Protocol CRTX1-101

***Honors and Activities***

---

2015 – present    **Fellow, American College of Gastroenterology**

2011 - present    **Best Doctors in America, New Orleans Region;** among 5% elected by peers

Summer, 2005    **Franklin G. Ebaugh, Jr. Award**  
Recognition of outstanding research by a Stanford Internal Medicine resident.

Summer, 2002    **Norma C. Ragland Memorial Award**  
Recognition of outstanding academic success throughout medical school.

Summer, 2002    **Hull-Akenhead Cardiology Award;** top medical student in cardiology.

**Gary (Taavi) Reiss**

639 Esplanade Avenue  
New Orleans, LA 70116

e-mail: [taavi@stanfordalumni.org](mailto:taavi@stanfordalumni.org)

(415) 260-0370 • (504)349-6444 (fax)

---

Winter, 2001      **AOA Honors Society**, junior member signifying class ranking of top 7%.

Fall, 2000      **Assistant Editor, Southern Medicine**; 1 of 2 founding editors, 47 schools

Fall, 1999      **Honors Curriculum & Research Track**: based on grades/research proposal

# **SCHEDULE 10P**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-SB-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**PLAINTIFFS' OBJECTIONS TO DEFENDANTS' WITNESS LIST (SCHEDULE 10)**

Pursuant to Rule 26(a)(3) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d),

Boston Scientific hereby objects to the Witness List provided by Defendants. Boston Scientific makes these objections without waiving and without prejudice to any motions, arguments, or further objections Boston Scientific may present separately to the Court.

Boston Scientific objects to testimony by “Representatives of Olympus America Inc.” as vague and undefined. As a result, Defendants should not be permitted to call such a witness at trial.

Boston Scientific further objects to the unreasonable volume of witnesses Defendants may call by deposition as creating an unduly and unnecessary burden on Boston Scientific to prepare its case, and Boston Scientific reserves its right to provide further specific objections when Defendants have fairly narrowed their designations to a reasonable volume for a one-week jury trial.

# **SCHEDULE 11**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-SB-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**PLAINTIFFS' DEPOSITION DESIGNATIONS, DEFENDANTS' OBJECTIONS TO  
PLAINTIFFS' DEPOSITION DESIGNATIONS, AND DEFENDANTS'  
COUNTER-DESIGNATIONS (SCHEDULE 11)**

**Boston Scientific's Statement**

Pursuant to Rule 26(a)(3) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d),

Boston Scientific provides this list of deposition designations. Boston Scientific reserves the right to supplement, revise, clarify, withdraw, or otherwise amend these objections, including, but not limited to, based on new information, new positions taken by the parties, future rulings of the Court, including, but not limited to, rulings on the parties' pending motions for summary judgment, Daubert motions, motions *in limine*, and/or evidentiary objections raised by the parties prior to trial. Boston Scientific also incorporates herein its Objections to Defendants' Exhibit List and Objections to Defendants' Witness List.

**Defendants' Statement**

Pursuant to Rule 26(a)(3)(B) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d), Defendants Micro-Tech Endoscopy USA, Inc., Micro-Tech (Nanjing) Co. Ltd., and Henry Schein, Inc. (collectively, "Defendants") hereby object to Plaintiffs' Deposition

**SCHEDULE 11**

Designations. Defendants reserve the right to supplement, revise, correct, clarify, withdraw, or otherwise amend these objections based on new information, new positions taken by the parties, future rulings of the Court, including, but not limited to, rulings on the parties' pending motions for summary judgment, Daubert motions, motions *in limine*, and/or evidentiary objections raised by the parties prior to trial. Defendants make these objections without waiver of, and without prejudice to, any motions, arguments, or evidentiary objections Defendants have presented or may present separately to the Court. Defendants further reserve the right to object to and/or move to strike individual questions asked, testimony given or proffered, and/or documents used in the examination with respect to any witnesses whether presented live or by deposition. Defendants also incorporate herein Defendants' Objections to Plaintiffs' Exhibit List and Objections to Plaintiffs' Witness List.

**SCHEDULE 11**

**DEFENDANTS' OBJECTION KEY FOR OBJECTIONS  
TO PLAINTIFFS' DEPOSITION DESIGNATIONS**

<b>CODE</b>	<b>OBJECTION</b>
106	Incomplete. Fed. R. Evid. 106
402	Not relevant. Fed. R. Evid. 401, 402
403	Unduly prejudicial, confusing, wasteful, or cumulative. FRE 403
701	Improper lay opinion. Fed. R. Evid. 701
802	Hearsay if offered for the truth of the matter asserted. FRE 802
1002	Violates best evidence rule. Fed. R. Evid. 1002
AA	Asked and answered
Arg	Argumentative
C	Compound
F	Lacks foundation/lacks personal knowledge/speculation
IH	Incomplete Hypothetical
LC	Calls for a legal conclusion
Lead	Leading
Mis	Misstates prior testimony
NT	Not testimony
OS	Outside Scope of Rule 30(b)(6) Topic
V	Vague and ambiguous
X	Calls for expert testimony
SJ	Subject to exclusion pending Motion for Summary Judgment
Daub	Subject to exclusion pending Daubert Motion
MIL	Subject to exclusion pending Motion <i>in limine</i>

Li, Christopher July 27, 2020				
Plaintiffs' Initial Designations	Defendants' Objections	Defendants' Counter Designations	Plaintiffs' Objections	Plaintiffs' Counter-Counter Designations
		From / To		From / To
7:21-8:1		17:2-17:19		
8:13-8:15		19:1-19:10		
9:1-9:3		19:22-20:2		
10:12-10:16		21:15-22:12		22:13-21
11:13-11:24		25:3-25:7		
16:7-17:1		27:2-27:12		
17:20-17:22		50:11-50:20		
18:9-18:15		51:18-52:9		
19:18-19:21		53:5-54:10		
20:20-21:10	106, V	61:22-62:15		
24:10-25:2		68:18-21		68:5-10
25:8-25:19		70:4-70:10		
27:13-29:6		86:4-86:12		
30:11-31:2		87:9-87:16		
39:6-39:9				
43:6-43:9				
43:19-44:1	106, F, V			
47:13-47:20	402, 403			
50:4-50:10				
50:21-51:14				
58:12-58:24				
60:23-61:3	106, V			
61:10-61:13	106, V			
63:1-63:10				
63:18-63:23				
66:4-66:8				

21212  
**SCHEDULE 11**

<b>Li, Christopher</b> <b>July 27, 2020</b>				
<b>Plaintiffs' Initial Designations</b>	<b>Defendants' Objections</b>	<b>Defendants' Counter Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter-Counter Designations</b>
		<b>From / To</b>		<b>From / To</b>
67:12-67:15				
67:20-67:24				
69:2-69:14				
70:21-71:2				
71:5-72:6	106, V			
81:17-81:20				
81:22-82:8				
84:18-85:22				
86:1-86:2				
86:13-87:7				
87:17-87:23				
101:13-102:1				
102:13-103:19				
107:12-107:18				
108:16-110:6				
114:1-114:22	106, V			
122:11-122:14				

## SCHEDULE 11

Jackson, Scott July 15, 2020				
Plaintiffs' Initial Designations	Defendants' Objections	Defendants' Counter Designations	Plaintiffs' Objections	Plaintiffs' Counter-Counter Designations
		From / To		From/To
9:2-12:10				
12:22-13:17	402, 403, 106	14:3-5		
14:20-15:5	F, 106	15:7-11		
17:15-18:22				
20:15-21:7	F, 106	21:8-22:8		
23:17-23:18				
24:1-24:7	F			
24:11				
24:13-24:15	F, 402			
24:17-24:18				
24:20-24:24	F			
25:4-25:15	403, AA, 106	25:16-26:15		
26:16-27:13	F, AA, 403			
27:17-27:24	F, AA, 403			
29:15-29:17				
29:21-29:22				
29:24-30:24	106	31:1-31:13; 31:16-32:16; 34:12-35:21		
36:4-36:24				
37:2-37:24	F			
38:4-38:6	106	38:7-8		
38:9-38:15				
38:17-38:23	Mis, 403			
40:18-40:21				
41:7-41:15				
41:22-41:24				
42:2-42:14	106	42:15-43:7		32:17-33:4, 33:16-34:10

Jackson, Scott July 15, 2020				
Plaintiffs' Initial Designations	Defendants' Objections	Defendants' Counter Designations	Plaintiffs' Objections	Plaintiffs' Counter-Counter Designations
		From / To		From/To
49:8-50:22	F			
52:3-53:3	F, 402, 403			
53:7-53:13				
53:15-53:19	F, AA, 403			
56:9-56:14	F, NT, 106	56:15-16		
60:5-60:19	106	60:20-61:6		
61:7-61:22	106	62:12-63:5		
63:22-64:24	106	63:12-63:21; 65:1-4; 65:8-15		83:13-84:16
66:6-67:6				
68:2-68:20	LC			
84:17-84:24				
85:2-86:6				
92:23-93:1	F			
93:7-94:20	106, F, Mis, AA, 403			
94:22-94:23				
95:1	106, F, Mis, AA, 403			
95:4-95:6	106, F, Mis, AA, 403			
95:9-97:16				
123:12-123:23				
124:5-137:12				
139:21-140:5				
140:9-142:17				

**SCHEDULE 11**

Perry, Ron July 22, 2020				
Plaintiffs' Initial Designations	Defendants' Objections	Defendants' Counter Designations	Plaintiffs' Objections	Plaintiffs' Counter-CounterDesignations
		From / To		From / To
9:7-9:23	106	9:24-10:5		
11:7-11:10	106	11:11		
11:17-12:3				
19:6-21:1	F, 402, 403	21:2-5		
21:6-22:13				
23:2-23:17				
34:21-35:19	F, 402, C			
36:7-36:18	402	36:19-37:3		
37:4-37:9		37:10-21		
39:18-39:21	106	39.21-39.17, 39.22- 40.2		
40:3-40:19				
46:8-48:12	F, 402, 403, 106	44.0-44.7, 48.15- 50.15		
57:1-58:24	F, AA, 106	52:3-56:23, 59:1-60:5		
69:20-70:2	106	67:4-69:19		
84:18-85:1				
87:15-89:14	F, 402, 403, 106	90:3-91:21		50:16-51:1
98:10-99:21	F, 402, 403, 106	95:13-96:2		60:6-14
99:24-100:13	F, 402, 403, AA, 106	100:14-102:14		97:24-98:9
102:15-102:24				
103:7-103:22				
106:5-106:20	402, 403, 803, AA			
106:24-107:1				
107:4-107:9	402, 403, 803, AA, 106	107:10-108:8		
115:18-115:24				
117:9-123:8	106, 402, 403	116:4-117:4		
123:20-124:14				
124:17-129:24				

<b>Perry, Ron</b> <b>July 22, 2020</b>				
<b>Plaintiffs' Initial Designations</b>	<b>Defendants' Objections</b>	<b>Defendants' Counter Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter-CounterDesignations</b>
<b>From / To</b>		<b>From / To</b>		<b>From / To</b>
147:3-148:1	C, F			
148:4				
148:8-152:2	C, F, OS			
152:18-154:3	F, 402, 403, OS, Mis			
154:18-154:20				
154:22-154:23	106			
158:17-158:24				
159:18-164:3	C, F			
164:7-165:13	C, F			
166:1-167:7	F, OS			
167:10-167:21	F, OS, AA			
169:11-169:13	F, V			
169:22-173:16	F, V			
173:24-178:1	F, V			

# **SCHEDULE 12**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION	)
and BOSTON SCIENTIFIC SCIMED, INC.,	)
	)
Plaintiffs,	)
	) C.A. No. 18-1869-CFC-CJB
v.	)
	)
MICRO-TECH ENDOSCOPY USA INC.,	)
MICRO-TECH (NANJING) CO., LTD., and	)
HENRY SCHEIN INC.,	)
	)
Defendants.	)

**DEFENDANTS' DEPOSITION DESIGNATIONS, PLAINTIFFS' OBJECTIONS TO  
DEFENDANTS' DEPOSITION DESIGNATIONS, AND PLAINTIFFS'  
COUNTER-DESIGNATIONS (SCHEDULE 12)**

**Defendants' Statement**

Pursuant to Rule 26(a)(3) of the Federal Rules of Civil Procedure and D. Del. LR 16.3(d), Defendants Micro-Tech Endoscopy USA Inc., Micro-Tech (Nanjing) Co., Ltd. and Henry Schein Inc. (collectively, “Defendants”) provide this list of deposition designations. Defendants reserve the right to supplement, revise, clarify, withdraw, or otherwise amend these objections, including, but not limited to, based on new information, new positions taken by the parties, future rulings of the Court, including, but not limited to, rulings on the parties’ pending motions for summary judgment, Daubert motions, motions *in limine*, and/or evidentiary objections raised by the parties prior to trial. Defendants also incorporate herein its Objections to Plaintiffs’ Exhibit List and Objections to Plaintiffs’ Witness List.

**Boston Scientific’s Statement**

Pursuant to Rule 26(a)(3)(B) of the Federal Rules of Civil Procedure and D. Del. L.R. 16.3(d), Boston Scientific hereby objects to Defendants’ Deposition Designations and provides

**SCHEDULE 12**

its counter-designations. Boston Scientific objects to the unreasonable volume of deposition designations as creating an unduly and unnecessary burden to specifically object to each of Defendants' voluminous depositions and Boston Scientific reserves its right to provide further specific objections when Defendants have fairly narrowed their designations to a reasonable volume for a one-week jury trial.

As such, Boston Scientific objects to Defendants' designations at least under Federal Rules of Evidence 106, 401, 402, 403, 501, 502, 602, 701, 702, 801, 802, 901, 902, 1002, 1003, and 1006, to all testimony that falls within the scope of any motion *in limine* granted by the Court, and to all testimony of a Rule 30(b)(6) witness that was objected to as being outside the scope of the respective 30(b)(6) notice of deposition.

<b>Objection Key</b>	
Code	Objection
106	partial document/lacks context (FRE 106)
401/402	lacks relevance (FRE 401/402)
403	unduly prejudicial/confusing/waste of time (FRE 403)
501/502	Privilege/Work Product (FRE 501/502)
602/LOF	lacks foundation/speculative (FRE 602)
701/702	improper opinion (FRE 701/702)
801-802	hearsay (FRE 802)
901/902	lacks authenticity (FRE 901/902)
1002	original document required (FRE 1002)
1003	incomplete/illegible (FRE 1003)
1006	improper summary (FRE 1006)
ID	insufficient/incorrect description
L	late/not produced
AA	attorney argument improperly offered as evidence; contains counsel colloquy or objections
C	compound
Legal	calls for a legal conclusion
Leading	leading question of a non-hostile witness
MC	Mischaracterizes/misstates witness's testimony
NR	nonresponsive
PMIL	Subject of pending motion in limine
P	privilege
OS	beyond the scope
V	Vague and/or ambiguous

**SCHEDULE 12**

**MARK ADAMS (Deposition taken on Mar. 21, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
6:12-14		
21:16-22:13	401/402, 403	
24:18-23	401/402, 403, MC	22:14-24:17
26:12-27:15	401/402, 403, MC	26:6-11
28:7-30:12	401/402, 403	28:5-6
36:6-20	401/402, 403, 701/702, Legal	
37:5-7	401/402, 403, 701/702, Legal	49:14-50:6
37:9-11	401/402, 403, 701/702, Legal	50:8-18
37:13-38:15	401/402, 403, 701/702, Legal	53:12-21
39:7-10	401/402, 403, 701/702, Legal	
39:12-40:8	401/402, 403, 701/702, Legal	
45:14-23	401/402, 403	
46:14-47:8	401/402, 403	
47:23-49:13	401/402, 403	
51:25-52:23	401/402, 403, 701/702, Legal	
53:7-11	401/402, 403	
54:1-10	401/402, 403	

**SCHEDULE 12**

NIKLAS ANDERSSON (Deposition taken on Sept. 18, 2020)		
Defendants' Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations
6:14-18		6:19-7:3
11:3-12:9	401/402, 403	
13:1-14:7	401/402, 403	
20:18-21:10	401/402, 403, 602/LOF	
22:11-23:4	401/402, 403, 602/LOF	
23:22-26:6	401/402, 403	28:22-30:12
31:3-32:10	401/402, 403, V	
33:15-37:19	401/402, 403, 701/702, V	39:21-42:22
43:4-45:3	401/402, 403	
46:21-50:12	401/402, 403	
51:11-53:25	401/402, 403	
63:18-65:22	401/402, 403, AA	
66:6-67:4	401/402, 403	
79:7-80:2	401/402, 403	80:3-13
84:18-86:21	401/402, 403	
94:8-97:7	401/402, 403	97:8-98:7
98:8-19	401/402, 403	
102:2-103:10	401/402, 403	103:11-104:25
105:1-108:2	401/402, 403	
117:11-119:8	401/402, 403	119:9-120:14

**SCHEDULE 12**

**DANIELLE BOGARTZ (Deposition taken Sept. 11, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
7:4-8		
9:21-14:17		
16:6-19:8	401/402, 403	
20:11-21:8	401/402, 403	
21:19-23:14	401/402, 403	
24:6-27:4	401/402, 403	
27:16-32:4	401/402, 403	
34:11-35:12	401/402, 403	
36:4-39:1	401/402, 403	
39:2-40:11	401/402, 403	
41:7-42:10	401/402, 403	42:11-18
42:19-45:15	401/402, 403	
62:2-10	401/402, 403, 602/LOF, MC	
63:15-65:20	401/402, 403	
66:5	401/402, 403	
67:5-69:2	401/402, 403, MC	69:3-17
69:18-70:12	401/402, 403	
73:3-76:10	401/402, 403	76:11-77:4
77:16-19	401/402, 403	
78:1-79:13	401/402, 403	
82:10-84:20	401/402, 403	
85:13-86:1	401/402, 403	
86:4-88:14	401/402, 403	
90:8-19	401/402, 403	
91:17-95:20	401/402, 403	
96:5-97:1	401/402, 403	98:5-99:16
99:17-101:5	401/402, 403	
102:10-106:7	401/402, 403	

**SCHEDULE 12**

**DANIELLE BOGARTZ (Deposition taken Sept. 11, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
106:13-107:9	401/402, 403	
109:11-112:8	401/402, 403	
113:5-114:7	401/402, 403	
122:6-126:18	401/402, 403	
138:3-9	401/402, 403	
146:13-147:7	401/402, 403	

**SCHEDULE 12**

**VANCE BROWN (Deposition taken Sept. 9, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
7:13-15		
8:10-13		
8:19-9:17	401/402, 403	9:18-11:3
12:1-13:3	401/402, 403	
13:4-13:15	401/402, 403	
13:17-14:2	401/402, 403	
14:3-16:4	401/402, 403	16:5-12
16:13-17	401/402, 403	
19:12-20:2	401/402, 403	18:21-19:11
23:11-20	401/402, 403	22:5-23:3
23:22-25:16	401/402, 403	
25:17-26:14	401/402, 403	
26:16-27:3	401/402, 403	
27:5-27:7	401/402, 403	27:9-13
27:14-28:4	401/402, 403	28:5-8, 28:10-14, 28:16-29:19
29:20-31:9	401/402, 403	
31:10-33:2	401/402, 403	
33:10-19	401/402, 403	
33:20-21	401/402, 403	
34:1-16	401/402, 403	
35:4-36:21	401/402, 403	
37:2-17	401/402, 403	37:18-41:10
43:6-44:17	401/402, 403	48:10-21, 50:7-51:5, 52:8-53:9
65:12-66:16	401/402, 403	67:15-70:20
70:21-71:6	401/402, 403, 801/802, OS	
71:9-13	401/402, 403, 801/802, OS	
71:19-72:2	401/402, 403, 801/802, OS	

**SCHEDULE 12**

**VANCE BROWN (Deposition taken Sept. 9, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
74:3-11	401/402, 403, 801/802, OS	
74:16-75:15	401/402, 403, 801/802, OS	
80:11-81:10	401/402, 403, 801/802, OS, V	
88:6-11		

**SCHEDULE 12**

**CHRISTOPHER DAVIS (Deposition taken Apr. 25, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
16:18-19:16	401/402, 403	
19:18-22:18	401/402, 403	
53:1-13	401/402, 403	
53:15-61:18	401/402, 403	
61:20-62:24	401/402, 403	
74:3-75:15	401/402, 403	75:16-76:4
76:5-77:21	401/402, 403	
85:17-86:8	401/402, 403, MC	
86:11-21	401/402, 403, MC	121:1-20, 127:22-128:13, 136:3-13
157:2-25	401/402, 403	
175:3-13	401/402, 403	
175:15-176:1	401/402, 403	
176:3-5	401/402, 403	
176:7	401/402, 403	
178:12-179:19	401/402, 403	
179:21-23	401/402, 403	
180:1-5	401/402, 403	
180:7-181:18	401/402, 403	
183:7-184:5	401/402, 403	198:6-199:17
219:8-12	401/402, 403, 801/802	
219:15-22	401/402, 403, 801/802	
219:24-220:20	401/402, 403, 801/802	
220:23-221:6	401/402, 403, 801/802	
221:11-15	401/402, 403, 801/802	

**SCHEDULE 12**

**CHRISTOPHER DAVIS (Deposition taken Apr. 25, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
221:19-21	401/402, 403, 801/802	
225:2-11	401/402, 403	224:19-21, 224:23-225:1
225:13-22	401/402, 403	
225:24-226:2	401/402, 403	
227:18-229:17	401/402, 403	
247:5-8	401/402, 403, MC, V	
259:2-5	401/402, 403	
259:8-14	401/402, 403	
269:5-25	401/402, 403	

**SCHEDULE 12**

**ELENA HENNESSEY (Deposition taken Aug. 25, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
7:1-15		6:22-25, 7:16-18
11:8-14		
13:18-21		
13:22-14:22		15:2-23
16:14-22		
18:24-19:5		
29:21-33:19	401/402, 403, PMIL	
36:3-9	401/402, 403, PMIL	
36:13-37:15	401/402, 403, PMIL	
37:17-38:2	401/402, 403	
38:8-39:4	401/402, 403	
80:15-19	401/402, 403	
81:3-85:18	401/402, 403	
85:23-87:11	401/402, 403	
87:14-88:1	401/402, 403	89:8-90:24
126:5-136:22	401/402, 403, PMIL	
142:24-143:6		

**SCHEDULE 12**

**JAVIER JIMINEZ (Deposition taken Apr. 21, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
13:15-15:2		
24:3-14	401/402, 403	24:15-17
40:14-24	401/402, 403	
41:8-16	401/402, 403	
43:3-10	401/402, 403	
61:4-15	401/402, 403	

**SCHEDULE 12**

**WILLIAM LAFFERTY (Deposition taken Apr. 27, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
11:11-12		
12:22-16:11	401/402, 403	
17:6-24	401/402, 403	
21:7-22:4	401/402, 403	22:22-25:13
35:7-19	401/402, 403	
35:21-36:16	401/402, 403	

**SCHEDULE 12**

**MICHAEL LYNN (Deposition taken June 13, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
20:4-10	401/402, 403, V	53:3-16
57:16-58:18	401/402, 403, MC, V, Legal	53:18-25
58:20-59:4	401/402, 403, MC, V, Legal	56:2-24
99:19-100:16	401/402, 403, MC, V, Legal	
107:6-14;	401/402, 403, MC, V, Legal	
107:16	401/402, 403, MC, V, Legal	108:1-19
109:5-16	401/402, 403, MC, V, Legal	
109:18-110:9	401/402, 403, MC, V, Legal, OS	17:12-20:3
110:17-22	401/402, 403, MC, V, Legal, OS	
110:24-111:7	401/402, 403, MC, V, Legal, OS	
111:9-13	401/402, 403, MC, V, Legal, OS	

**SCHEDULE 12**

**LAUREN MOSCATO (Deposition taken Aug. 12, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
14:7-21		
15:16-16:3		16:8-13
18:20-19:20		
20:20-24:23		
25:5-10		25:11-24
25:25-26:7	401/402, 403	
26:8-12;	401/402, 403	
26:13-27:1	401/402, 403	
27:14-24		27:2-13
27:25-28:14	401/402, 403	
29:11-25	401/402, 403	30:1-33:3
33:4-35:15		35:16-36:1
39:1-40:3		38:2-25
40:19-48:9		
50:19-51:3		51:4-56:25
57:1-58:22	401/402, 403, 701/702	
59:21-60:22	401/402, 403	
61:1-4	401/402, 403	
61:6-7	401/402, 403	61:14-63:8
63:9-66:2	401/402, 403	
67:1-68:5		
68:12-14		
68:17-70:5		
70:8-23		71:3-73:18
73:19-76:1	401/402, 403, 701/702	
76:4-81:12	401/402, 403, 701/702	
81:17-83:21	401/402, 403, 701/702	83:22-88:9

**SCHEDULE 12**

**LAUREN MOSCATO (Deposition taken Aug. 12, 2020)**

Defendants' Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations
88:10-89:20	OS, MC	
89:22-91:1	OS, MC	91:5-19
98:6-100:7	401/402, 403	100:8-101:14
101:15-102:6	401/402, 403	102:7-106:4
106:24-111:11	401/402, 403	
111:21-112:23	401/402, 403	112:24-114:8
114:9-114:19	401/402, 403	
115:3-24	401/402, 403	115:25-117:6
119:14-123:25	401/402, 403	124:1-126:15
127:7-133:6	401/402, 403, 701/702	133:7-137:4
137:5-139:6	401/402, 403	
139:9-143:17	401/402, 403	143:18-150:4
150:5-16		153:6-154:10, 154:11-180:4
180:5-186:14	401/402, 403, 701/702	
192:19-193:24		
216:2-217:19	401/402, 403, 701/702	214:21-216:1
243:1-20	401/402, 403, 701/702, OS	246:4-247:3
247:16-19	401/402, 403, 701/702, OS	
247:22-248:11	401/402, 403, 701/702, OS	
248:17-249:8	401/402, 403, 701/702, OS	
249:11-14	401/402, 403, 701/702, OS	251:13-253:25
287:3-23		
251:9-12		
254:1-257:8	401/402, 403, 701/702	268:1-271:10
282:19-285:17	401/402, 403	278:13-281:4, 287:24-290:3
290:4-292:16	401/402, 403	292:17-298:1
298:2-7	401/402, 403, MC	
298:10-299:2	401/402, 403	299:3-303:4

**SCHEDULE 12**

**LAUREN MOSCATO (Deposition taken Aug. 12, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
303:5-6		
303:12-21		303:22-306:4
306:5-307:4	401/402, 403, 701/702	307:5-9
307:10-308:23	401/402, 403, 701/702	308:24-311:8
311:3-8	401/402, 403, MC	
311:11-313:24	401/402, 403	311:25-313:18
327:10-330:22	401/402, 403, 701/702	
331:1-333:13	401/402, 403, AA, NR	331:14-333:25

**SCHEDULE 12**

**COLLIN MURRAY (Deposition taken Aug. 6, 2020)**

Defendants' Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations
11:4-6; 12:1-8		12:9-13
15:5-16		
23:15-24:14	401/402, 403	
26:16-23	401/402, 403, 701/702	25:22-26:15
29:6-13		28:2-6
33:24-34:19	401/402, 403	30:17-31:7
35:7-36:17	401/402, 403	34:20-35:6
36:18-37:5	401/402, 403	
37:19-38:22	401/402, 403	
39:9-40:23	401/402, 403, 701/702	40:24-41:22
50:21-52:6	401/402, 403, 701/702	
57:6-9	401/402, 403, 701/702	
58:4-9	401/402, 403, 701/702	
59:8-60:4	401/402, 403, 701/702	
88:19-92:19		
95:9-19		97:5-13
151:12-153:2	401/402, 403, 701/702, PMIL	
153:4-6	401/402, 403, 701/702, PMIL	
153:8-18	401/402, 403, 701/702, PMIL	153:20-154:19
171:9-20	401/402, 403, PMIL	
171:22-172:19	401/402, 403, PMIL	
176:24-177:6	401/402, 403, 701/702, PMIL	177:7-178:8
213:3-6	401/402, 403, 701/702, PMIL	212:8-213:1
213:14-21	401/402, 403, 701/702, PMIL	213:7-13, 213:22-214:10
222:6-16	401/402, 403, 701/702, PMIL	
223:20-224:9	401/402, 403	

**SCHEDULE 12**

**COLLIN MURRAY (Deposition taken Aug. 6, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
232:20-233:14	401/402, 403, 701/702, PMIL	233:15-234:4
281:6-282:4	401/402, 403, 701/702, PMIL	
282:6-19	401/402, 403, 701/702, PMIL	
285:15-19	401/402, 403, 701/702, PMIL	
311:9-12		
311:16-21		
312:21-24		
314:17-315:5		315:6-7
316:1-10		
317:5-9		
317:15-318:2		
318:11-319:12		319:13-320:8
320:9-12		320:13-321:7, 322:6-323:3
324:20-325:21	401/402, 403	323:18-324:19

**SCHEDULE 12**

<b>DEMETRIOS (JIM) PETROU (Deposition taken Apr. 19, 2017)</b>		
<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
16:18-23		
27:4-28:18	401/402, 403, MC	26:21, 26:25-27:3
35:4-22	401/402, 403	38:7-39:1, 41:13-44:15
58:1-59:18	401/402, 403	47:24-51:11
91:6-21	401/402, 403, MC	91:22-92:3
92:13-98:5	401/402, 403	253:8-18
98:19-21	401/402, 403	253:21-255:2
98:24-99:7	401/402, 403	
99:17-20	401/402, 403	
106:4-107:9	401/402, 403	107:15-108:11
167:2-170:22	401/402, 403	
170:24-172:3	401/402, 403	259:1-11, 259:22-260:1
172:6-173:9	401/402, 403	260:3-16, 260:19-261:9
173:12-174:10	401/402, 403	262:18-23, 263:3-17
174:12-180:4	401/402, 403	267:13-18, 267:21-268:7
181:1-15	401/402, 403, 801/802, V	
185:13-186:1	401/402, 403	
231:1-19	401/402, 403	

**SCHEDULE 12**

**STEVEN RADERSTORF (Deposition taken Aug. 27, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
3:6-25		
4:9-6:10		
11:13-18:17	401/402, 403	19:18-22:25
24:24-25:10	401/402, 403	25:24-27:9
84:21-85:8	401/402, 403	81:1-84:20

**SCHEDULE 12**

**CLAUDIA SCHULZ KENDALL (Deposition taken Aug. 14, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
4:9-13		
4:22-9:12		
4:18-21		
10:4-11:17		
11:18-12:2	602/LOF, OS	12:3-10
12:11-18	401/402, NR, OS	12:19-25
13:8-14:2		14:3-8
14:9-16:2		
16:3-16		
17:12-18:4		18:5-11
18:12-19:7		19:8-22:5
22:6-23:8	602/LOF	
24:10-26:22		26:23-27:3
27:15-27:25		
28:8-10		
28:15-29:7		29:8-30:9
38:14-20	401/402, 403, NR, OS	37:13-38:13
39:22-43:22	401/402, 403	
54:15-23		
55:11-57:16		
57:17-59:19		
62:21-63:14	401/402, 403	
63:15-65:24	401/402, 403	
66:20-67:6	401/402, 403, OS	65:25-66:19
67:7-68:2	401/402, 403, OS, 602/LOF	69:14-70:7
72:4-75:4	401/402, 403, OS, 602/LOF	70:13-72:3; 75:5-17

**SCHEDULE 12**

**CLAUDIA SCHULZ KENDALL (Deposition taken Aug. 14, 2020)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
77:8-22		77:23-78:10
85:25		
94:17-95:13	401/402, 403, 602/LOF	95:14-19
103:3-21		
103:22-25		
104:21-106:10		104:2-20
108:25-109:6		
111:13-23	602/LOF	109:22-111:12; 113:3-17
116:10-118:11	401/402, 403, V, 602/LOF	
119:10-122:12	401/402, 403	122:13-20
127:20-129:9	401/402, 403	
129:10-15	401/402, 403	
131:25-132:13	401/402, 403	132:14-19
134:24-138:24	401/402, 403, 602/LOF	133:23-134:23, 138:25-139:3
139:4-15		
140:3-142:6	401/402, 403	
142:13-20	401/402, 403	142:21-143:2
143:3-7	401/402, 403	
143:8-145:25	401/402, 403, 701/702	
154:4-155:22	401/402, 403, OS, 602/LOF	
157:19-158:2	401/402, 403, 701/702	156:13-24, 157:14-18
159:7-160:5	401/402, 403	58:8-12, 158:24-159:4

**SCHEDULE 12**

**MATTHEW SPRAGUE (Deposition taken May 9, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
13:16-14:6		
127:4-131:11	401/402, 403	

**SCHEDULE 12**

<b>VINCENT TURTURRO (Deposition taken Apr. 11, 2017)</b>		
<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
27:15-17		
27:22-28:25		
30:21-31:9		
44:8-45:11	401/402, 403	
58:21-23	401/402, 403	
59:1-5	401/402, 403	
59:8	401/402, 403	
38:22-39:5	401/402, 403, 602/LOF, 701/702	34:3-35:19, 35:22-36:17
151:21-25	401/402, 403, 602/LOF, V	
152:3-17	401/402, 403, 602/LOF, V	
61:4-5;	401/402, 403, 701/702	
61:9;	401/402, 403, 701/702	
61:11-62:22	401/402, 403, 701/702	
62:25-63:6	401/402, 403, 701/702	
63:9-20	401/402, 403, 701/702	
63:22-64:5	401/402, 403, 701/702	
64:8-65:21	401/402, 403, 701/702	
65:24-66:4	401/402, 403, 701/702	
90:4-12	401/402, 403, 701/702	
90:14-21	401/402, 403, 701/702	
90:23-91:3	401/402, 403, 701/702	91:4-5, 91:7-20
92:16-17	401/402, 403, 701/702	
92:20-93:2	401/402, 403, 701/702	
93:8-11	401/402, 403, 701/702	
93:13-14	401/402, 403, 701/702	
93:16-23	401/402, 403, 701/702	

**SCHEDULE 12**

**VINCENT TURTURRO (Deposition taken Apr. 11, 2017)**

Defendants' Designations	Plaintiffs' Objections	Plaintiffs' Counter Designations
93:25-94:8	401/402, 403, 701/702	
95:10-12	401/402, 403, 701/702	
95:15	401/402, 403, 701/702	
105:21-106:5	401/402, 403	
106:7-12	401/402, 403, V	
108:15-16	401/402, 403, V	
108:18-109:2	401/402, 403, V	
109:4-6	401/402, 403, V	
109:15-17	401/402, 403, V	
109:19-24	401/402, 403, V	
110:1-3	401/402, 403, 602/LOF, V	
110:6-14	401/402, 403, 602/LOF, V	
110:16	401/402, 403, V	
117:15-22	401/402, 403, V	
118:5-10	401/402, 403, V	
118:12	401/402, 403, V	
120:6-10	401/402, 403, V	
120:12-17	401/402, 403, V	
122:9-11	401/402, 403, V, MC	
122:14-18	401/402, 403, V, MC	
122:20	401/402, 403, V, MC	
123:9-10	401/402, 403, V	
123:12-21	401/402, 403, V	123:22-124:6, 124:8-10
124:12-125:2	401/402, 403, V	
125:4-11	401/402, 403, V	
125:13-126:10	401/402, 403, V	
126:12-127:5	401/402, 403, V	
127:7-21	401/402, 403, V	137:1-2, 137:4-20

**SCHEDULE 12**

**VINCENT TURTURRO (Deposition taken Apr. 11, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
221:9-13	401/402, 403, V, MC	
222:17-19	401/402, 403	
222:21-24	401/402, 403	
233:22-23	401/402, 403, 701/702, MC	233:2-4, 233:12-18
233:25-234:3	401/402, 403, 701/702, MC	234:5-13, 236:4-7, 236:1, 236:12-237:8
243:24-25	401/402, 403, 701/702, MC	241:4-7, 241:10-19, 241:21-24, 242:2-6
244:2-3	401/402, 403, 701/702, MC	242:8-10, 242:12-24, 243:14-18, 243:21-22

**SCHEDULE 12**

**KEVIN WILCOX (Deposition taken Apr. 18, 2017)**

<b>Defendants' Designations</b>	<b>Plaintiffs' Objections</b>	<b>Plaintiffs' Counter Designations</b>
14:5-13		
130:3-4;	401/402, 403	
130:6-14	401/402, 403	
158:19-161:4	401/402, 403, MC, V	156:3-157:9
161:7-18	401/402, 403, MC, V	161:19-162:5, 162:8-20, 163:3-6
186:4-188:10	401/402, 403, V	
188:13-19	401/402, 403, V	

# **SCHEDULE 13**

SCHEDULE 13

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**STATEMENT OF WHAT PLAINTIFFS INTEND TO PROVE**

SCHEDULE 13

Pursuant to Local Rule 16.3(c)(8), Plaintiffs Boston Scientific Corporation and Boston Scientific Scimed, Inc. (collectively “Boston Scientific” or “Plaintiffs”) submit the following brief statement of the principal matters Plaintiffs intend to prove at trial. This statement is not exhaustive, and Plaintiffs reserve the right to prove any matter identified in its pleadings, discovery responses, expert reports, and the accompanying statement of issues of facts and issues of law that remain to be litigated at trial. Plaintiffs may also provide additional proof to rebut any proof offered by Defendants before and during trial, in response to rulings by the Court, or for other good cause. Plaintiffs reserve the right to modify or amend this Statement to the extent necessary to reflect any future rulings by the Court, to supplement or amend this Statement to fairly respond to any new issues that Defendants may raise, or to address any new discovery produced by Defendants. Plaintiffs incorporate by reference their expert reports in support of any proof to be presented by expert testimony.

**I. INFRINGEMENT**

**A. Literal Infringement**

1. Boston Scientific intends to prove that Defendants are liable for direct infringement of claims 1, 3, 7, and 13 of the ’245 Patent.

2. Boston Scientific intends to prove that Defendants are liable for indirect infringement of claim 15 of the '245 Patent.
3. Boston Scientific intends to prove that Defendants are liable for direct infringement of claims 8 and 9 of the '371 Patent.
4. Boston Scientific intends to prove that Defendants are liable for direct infringement of claims 1-3, 6, and 8-12 of the '725 Patent.

**B. Doctrine of Equivalents**

5. Boston Scientific intends to prove that, to the extent Defendants do not literally infringe claims 1 and 3 of the '245 patent, claim 1 of the '371 patent, and claims 1 and 12 of the '725 patent either directly or indirectly, they are liable for infringement of those claims under the doctrine of equivalents.

**II. WILLFULNESS**

6. Boston Scientific intends to prove that Defendants' infringement of the Asserted Claims of the Patents-in-Suit has been willful.

**III. REMEDIES**

7. Boston Scientific intends to prove the amount of past damages to which it is entitled in the form of lost profits due to lost sales relating to Defendants' infringement of the Patents-in-Suit, beginning as of November 26, 2018.

8. Boston Scientific intends to prove the amount of past damages to which it is entitled in the form of a reasonable royalty relating to the portion of Defendants' infringing U.S. sales, beginning as of November 26, 2018, for which lost profits due to lost sales are not awarded.

9. Boston Scientific intends to prove that it is entitled to enhanced damages pursuant to 35 U.S.C. § 284, including, but not limited to, as a result of Defendants' willful infringement of one or more of the Asserted Claims of the Patents-in-Suit.

10. Boston Scientific intends to prove that it is entitled to a permanent injunction pursuant to 35 US.C. § 283, enjoining each Defendant, its officers, agents, servants, employees, and those persons acting in active concert or participation with all or any of them from making, using, offering to sell, or selling the Accused Devices within the United States, or importing the Accused Devices into the United States, or contributing to or inducing such activities by another, prior to the expiration of the Asserted Claims of the Patents-in-Suit.

#### **IV. EXCEPTIONAL CASE**

11. Boston Scientific intends to prove that this is an exceptional case under 35 U.S.C. § 285, and that Boston Scientific should be awarded attorneys' fees and costs.

**V. VALIDITY**

12. Boston Scientific will show that Defendants have failed to prove by clear and convincing evidence that any Asserted Claim of the '245 Patent, '371 Patent, or '725 Patent is invalid as anticipated.

13. Boston Scientific will show that Defendants have failed to prove by clear and convincing evidence that any Asserted Claim of the '245 Patent, '371 Patent, or '725 Patent is invalid as obvious.

14. Boston Scientific will show that Defendants have failed to prove that collateral estoppel renders any Asserted Claim of the '371 Patent or '725 Patent invalid.

15. Boston Scientific will show that Defendants have failed to prove by clear and convincing evidence that Claim 3 of the '245 Patent or any Asserted Claim of the '371 Patent or '725 Patent is invalid as indefinite.

16. Boston Scientific will show that Defendants have failed to prove by clear and convincing evidence that any Asserted Claim of the '245 Patent, '371 Patent, or '725 Patent is invalid as lacking written description.

17. Boston Scientific will show that Defendants have failed to prove by clear and convincing evidence that any Asserted Claim of the '245 Patent, '371 Patent, or '725 Patent is invalid as not enabled.

## VI. PATENT MISUSE

18. Boston Scientific will show that Defendants have failed to prove that Boston Scientific has pursued this litigation in the interest of impermissibly restraining trade or by pursuing infringement for patent claims that it knows or reasonably should know are not infringed and/or are invalid or unenforceable, or by seeking damages or other relief beyond what is supported by law.

19. Boston Scientific objects to Defendants' assertion of this defense and the allegations in support of this defense set forth in Defendants' portions of this Order. To the extent Defendants are permitted to introduce such evidence, Boston Scientific intends to rebut the substance of those allegations.

# **SCHEDULE 14**

SCHEDULE 14

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

Defendants.

CA. No. 18-1869-SB/CJB

**STATEMENT OF WHAT DEFENDANTS INTEND TO PROVE**

## TABLE OF CONTENTS

A.	No Infringement of Any Asserted Patent Claim.....	3
B.	Invalidity of All Asserted Patent Claims .....	4
C.	Unenforceability.....	5
D.	Patent Misuse .....	6
E.	Alleged Damages / Relief / Willful Infringement.....	8

Defendants respectfully submit this summary of the principal points we intend to prove at trial. This summary provides a high-level overview of Defendants' case, as opposed to an exhaustive or detailed statement of points Defendants intend to prove at trial. Defendants further refer to and incorporate herein their Statements of the Issues of Fact and Law that remain to be litigated, which further identify matters Defendants may prove at trial. Defendants reserve the right to supplement or amend this Statement, including in response to Court rulings on pending motions and Plaintiffs' further pretrial disclosures, and to offer additional proof in response to evidence or argument presented at trial.

Nothing in this statement is intended to admit or suggest the existence of any genuine issue of material fact that might preclude summary judgment or any other ruling by the Court as a matter of law. Defendants further address herein certain issues reserved for resolution by the Court, if necessary, in post-trial proceedings, including issues under 35 U.S.C. § 285 and relating to injunctive relief.

## **SUMMARY OF WHAT DEFENDANTS INTEND TO PROVE**

1. Plaintiffs have characterized themselves in this action as the "innovation leader" in the field of hemostasis clips ("hemoclips") in an effort to promote patent infringement and damages claims that are without merit and to impugn the good faith and reasonableness of Defendants' business practices. Defendants will prove at trial that Plaintiffs' self-characterization is false.

SCHEDULE 14

2. Defendants will prove that Plaintiffs have in fact been slow in bringing new hemoclip devices and technologies to the market, and even their belated development efforts have been marked by repeated failures, device recalls, and products that have failed to adequately meet physician and patient needs. Plaintiffs routinely have responded to competitors' improvements in hemoclip device performance with aggressive business tactics and unfounded legal threats.

3. Defendants further will prove that Plaintiffs built a dominant market position in the U.S. largely by use of intricate group contracts and pricing programs, which have had the effect of compelling institutions to purchase Plaintiffs' hemoclip products at excessive prices.

4. Using Plaintiffs' own internal documents and employee testimony, Defendants will prove that Plaintiffs have sought to exclude Defendants from the U.S. market because Defendants offer hemoclip products with new features that benefit physicians and patients at reasonable prices, thereby posing a perceived threat to Plaintiffs' dominant market position and high profit margins.

5. Relevant to the above points, and also for purposes of responding to any lost profits damages claim that remains in the case, Defendants will offer evidence regarding certain non-party medical device manufacturers and marketers of hemoclip devices, including but not limited to Olympus Corporation ("Olympus") and Cook Medical ("Cook"). Such evidence is important to

explaining the parties' conduct and market positions and to evaluating the truth of Plaintiffs' claims about their role in inventing and developing hemoclip devices. Defendants will also offer evidence regarding other non-parties that manufacture and/or market hemoclip devices to explain that Plaintiffs' claims for damages and other relief are baseless.

**A. No Infringement of Any Asserted Patent Claim**

6. Defendants will present evidence that Micro-Tech has sold three different device types relevant to this action: (1) SureClip® devices with the “Original” or “J-Hook” configuration, which were sold in the United States from 2015 through 2019; (2) SureClip® devices with the “Buckle” configuration, which have been sold in the United States beginning in 2019, and (3) Lockado® devices, which have been sold in the United States beginning in 2020. Micro-Tech also manufactures hemoclip devices for ConMed Corporation, a medical technology company based in New York State, that has sold those products in the United States since 2016 under the DuraClip™ name. ConMed is not a party to this action.

7. There are multiple differences between the SureClip Original, SureClip Buckle, Lockado, and DuraClip devices, many of which are relevant to the jury's consideration of disputed issues in the case, including infringement issues. In particular, Lockado Devices differ substantially from the SureClip Devices in a number of respects material to this action, including because Lockado Devices use

an attachment configuration that is completely different from any other Accused Devices, which significantly affects the nature of Plaintiffs' infringement claims and the evidence that will be presented at trial on those claims.

8. Defendants will present evidence sufficient to rebut any allegation by Plaintiffs that any of Defendants' products directly infringe, literally or under the doctrine of equivalents, any of claims 1, 3, 7, and 13 of the '245 Patent.

9. Defendants will present evidence sufficient to rebut any allegation by Plaintiffs that any of Defendants' products directly infringe, literally or under the doctrine of equivalents, any of claims 8 and 9 of the '371 Patent.

10. Defendants will present evidence sufficient to rebut any allegation by Plaintiffs that any of Defendants products directly infringe, literally or under the doctrine of equivalents, any of claims 1-3, 6, and 8-12 of the '725 Patent.

11. Defendants will present evidence sufficient to rebut any allegation by Plaintiffs that Defendants have induced infringement of claim 15 of the '245 Patent

**B. Invalidity of All Asserted Patent Claims**

12. Defendants will prove that each asserted claim of the '245 Patent, '371 Patent, and '725 Patent is invalid as anticipated.

13. Defendants will prove that each asserted claim of the '245 Patent, '371 Patent, and '725 Patent is invalid as obvious.

14. Defendants will prove that the final decision of the Federal Circuit in the '371 Patent IPR proceedings has collateral estoppel effect and that, as a consequence, Plaintiffs are estopped from taking positions with respect to the invalidity of the '371 Patent and '725 Patent contrary to the Federal Circuit's decision, and as a further consequence, that the asserted claims of the '371 Patent are invalid.

15. Defendants will prove that claim 3 of the '245 Patent, and all asserted claims of the '371 Patent and '725 Patent are invalid as indefinite.

16. Defendants will prove that the asserted claims of the '371 Patent and '725 Patent are invalid as lacking written description.

17. Defendants will prove that the asserted claims of the '371 Patent and '725 Patent are invalid as not enabled.

### C. Unenforceability

18. Defendants will prove that the '245 Patent, the '371 Patent, and the '725 Patent are unenforceable due to inequitable conduct.

19. As part of their proof of inequitable conduct, Defendants will prove that Olympus was among the first medical device manufacturers to seek FDA clearance to market a hemoclip device in the United States, which it did by filing the following 510(k) submissions with the FDA between 1996 and 2001: K013066 (filed 9/12/2001), K990687 (filed 3/1/1999), and K963160 (filed 8/14/1996). In

SCHEDULE 14

connection with its initial FDA 510(k) submission for the BSC Resolution I Device, Boston Scientific referred to and described the devices of the above Olympus 510(k) filings as the “Olympus Clip Fixing Devices,” thereby reflecting Boston Scientific’s knowledge of those Olympus devices. The “Olympus Clip Fixing Devices” described in those Olympus 510(k) filings were known or used in the United States prior to October 5, 2001.

**D. Patent Misuse**

20. Defendants will prove that Plaintiffs have sought to exclude Defendants from the U.S. hemoclip market and to impermissibly restrain trade and competition in that market by asserting against Defendants and other competitors patent claims that Plaintiffs knew were not infringed and/or were invalid or unenforceable and by seeking damages and other relief beyond what is supported by law.

21. To support their Patent Misuse defense, as well as to provide context for their invalidity case (discussed above) and rebut Plaintiffs’s claims for lost profits damages (discussed further below), Defendants will introduce evidence of BSC’s efforts to dominate the U.S. hemoclip market and to exclude competitors from that market, including by asserting patents that Plaintiffs knew or should have known were not infringed and/or invalid, and by attempting to disparage and unreasonably inhibit adoption of improved hemoclip products that better served physicians and patients than the products BSC marketed in the U.S.

SCHEDULE 14

22. Defendants' proof will include evidence regarding BSC's three generations of Resolution Clips, beginning in 2005 with the first version, known as the "Resolution I" or "Resolution Legacy" Clips. BSC continues to sell and derive substantial profit margins from these clips today, despite their outdated technology and lack of features. BSC next began marketing Resolution II Clips in early 2011, but that product was removed from the U.S. market in July 2011 pursuant to an FDA-required recall due to safety issues and risk to patient health. The third BSC Resolution Clip devices marketed in the US are referred to in this action as the "Resolution 360 Clips," which BSC first marketed in the U.S. in 2016. More recently, in late 2020, BSC introduced a new version of the Resolution 360 Clip that sought to add features to the clip that had been available for years in hemoclip products marketed in the U.S. by Defendants and other competitors.

23. Defendants will introduce evidence that the recall of the Resolution II Clip, coupled with Cook's introduction of more advanced products with features not available in the Resolution I products, caused BSC to lose substantial market share from 2012 to 2015 (from over 90% to less than 70%), *before* Defendants' entered the U.S. hemoclip market.

24. Defendants will show that the above decline in Plaintiffs' U.S. market share, which resulted from Plaintiffs' own failure to develop products that met the needs of physicians and patients, motivated Plaintiffs to file lawsuits against Cook

and later Defendants asserting claims Plaintiffs knew to be without merit and making claims for excessive and enhanced damages beyond what could be supported by a reasonable or good faith application of governing law in an effort to maintain a dominant market position and exclude Defendants from the U.S. market.

**E. Alleged Damages / Relief / Willful Infringement**

25. Defendants will present sufficient evidence to rebut any showing by Plaintiffs that Plaintiff Boston Scientific Corporation is an exclusive licensee or has standing to sue.

26. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will present evidence sufficient to rebut any showing by Plaintiffs that they are entitled to lost profits damages under 35 U.S.C. § 284 for some or all of the period of time after the date Plaintiffs filed this action (November 26, 2018), which is the earliest date from which Plaintiffs have sought such damages.

27. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will prove that the only appropriate form of damages in this action is a reasonable royalty, and they further will provide the jury with an appropriate method for determining such damages.

28. Defendants further will show that the amount of any damages requested by Plaintiffs is excessive and fails to take account of a number of factors, including

the ready availability to Defendants of non-infringing alternatives and the existence of many alternative suppliers of hemoclip products for hemoclip distributors and purchasers. In addition to Defendants, Olympus and Cook, other non-party companies that manufacture and market hemoclip products include Diversatek, Med Nova (Zhejiang Chuangxiang Medical Technology Co. Ltd.), Anrei Medical, Finemedix, AGS Medtech, Key Surgical, Inc., Nova LightSystems, Zhuji Pengtian Medical Equipment Co., Ltd., Endo-Therapeutics, and Ovesco.

29. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will present evidence sufficient to rebut any showing by Plaintiffs that any of Defendants' infringement has been willful after the date Plaintiffs filed this action (November 26, 2018) which is the earliest date from which Plaintiffs may argue any infringement was willful.

30. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will present evidence sufficient to rebut any showing by Plaintiffs that Plaintiffs are entitled to enhanced damages, exceptional case treatment, or attorneys' fees.

31. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will present evidence sufficient to rebut any showing by Plaintiffs that Plaintiffs are entitled to costs or pre- or post-judgment interest.

SCHEDULE 14

32. To the extent Plaintiffs prove Defendants are liable for any infringement of the '245, '371, or '725 Patents, Defendants will present evidence sufficient to rebut any showing by Plaintiffs that Plaintiffs are entitled to an injunction.

33. Defendants will prove that this is an exceptional case for which the Court may award Defendants attorneys' fees and the amount of attorneys' fees and other relief that should be awarded to Defendants.

34. Defendants will prove the amount of costs that should be awarded to Defendants.

# **SCHEDULE 15**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S MIL #1 TO EXCLUDE EVIDENCE OR  
ARGUMENT RELATED TO COMPARISONS OF BOSTON  
SCIENTIFIC'S DEVICES TO DEFENDANTS' DEVICES  
OR PRIOR ART DEVICES FOR PURPOSES OF  
NON-INFRINGEMENT OR INVALIDITY**

Infringement requires comparing the Accused Devices to the asserted patent claims. Invalidity requires comparing the asserted patent claims to the prior art. Neither involve comparing the patent holders' device to the accused device or the prior art, much less an FDA submission. Accordingly, under F.R.E. 401 and 403, Defendants should be barred from making any such improper comparisons in attempting to prove non-infringement or invalidity.

**Infringement:** For purposes of infringement, it is error to compare "the accused product or process with the patentee's commercial embodiment or other version of the product or process; the only proper comparison is with the claims of the patent." *Zenith Labs., Inc. v. Bristol-Myers Squibb Co.*, 19 F.3d 1418, 1423

(Fed. Cir. 1994) (citing *Martin v. Barber*, 755 F.2d 1564, 1567 (Fed. Cir. 1985) (“Infringement … is determined by comparing the accused device with the claims in suit, not with a preferred or commercial embodiment of the patentee’s claimed invention.”). But that is exactly what Defendants intend to do at trial.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Such comparisons are irrelevant, prejudicial, and regularly excluded in patent cases. See *Clintec Nutrition Co. v. Baxa Corp.*, 1998 WL 560284, at \*8 (N.D. Ill. Aug. 26, 1998) (“[The disputed] evidence is not relevant to infringement since [plaintiff]’s actual [device] may not be compared with [defendant’s device]. It is [plaintiff]’s claims that count. The possible prejudicial effect is obvious.”); *Smartflash LLC v. Apple Inc.*, 2015 WL 11089593, at \*1 (E.D. Tex. Jan. 29, 2015) (precluding defendant from “presenting arguments or opinions that compare or contrast the accused products to smart cards or commercial embodiments”); *EcoServices, LLC v.*

*Certified Aviation Servs., LLC*, 2018 WL 3090013, at \*3 (C.D. Cal. June 19, 2018); *GenSci OrthoBiologics v. Osteotech, Inc.*, 2001 WL 36239743, at \*7 (C.D. Cal. Oct. 18, 2001).

**Invalidity:** Establishing invalidity requires comparison of the asserted claims to the prior art, not the patentee's commercial embodiment of the patent. It is hornbook law that the proper comparison for invalidity purposes is of the "properly construed claim to the prior art." *See Medichem, S.A. v. Rolabo, S.L.*, 353 F.3d 928, 933 (Fed. Cir. 2003).



[REDACTED]

[REDACTED]

[REDACTED]

The argument is a legal non-sequitur and would create substantial risk of jury confusion. The regulatory definition of “substantial equivalence” and patent law framework for obviousness are wholly different. Whether there is “substantial equivalence” in safety between two medical devices says nothing about whether they are the same for purposes of validity. As a result, the Federal Circuit has emphasized that “FDA equivalence is irrelevant to patent law because it involves fundamentally different inquiries.” *The Johns Hopkins Univ. v. Datascope Corp.*, 543 F.3d 1342, 1348 n.3 (Fed. Cir. 2008).

Defendants intend to argue that Boston Scientific’s claim in the Res-Clip 510(k) of “substantial equivalence” to the prior art Olympus device is evidence of obviousness. It is not. The potential for jury confusion on this issue is real, and Defendants should be precluded from introducing evidence or argument in support of such theories at trial under F.R.E. 401 and 403.

Dated: May 28, 2021

Of Counsel:

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

Respectfully submitted,

FARNAN LLP

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 750 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: May 28, 2021

# EXHIBIT A

**REDACTED**

# EXHIBIT B

**REDACTED**

# EXHIBIT C

**REDACTED**

# EXHIBIT D

**REDACTED**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC )  
CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
)  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and )  
HENRY SCHEIN INC., )  
Defendants. )

**DEFENDANTS' OPPOSITION TO PLAINTIFFS' MOTION IN LIMINE #1**  
**TO EXCLUDE EVIDENCE OR ARGUMENT RELATED TO**  
**COMPARISONS OF BOSTON SCIENTIFIC'S DEVICES TO**  
**DEFENDANTS' DEVICES OR PRIOR ART DEVICES FOR PURPOSES**  
**OF NON-INFRINGEMENT OR INVALIDITY**

Plaintiffs' MIL #1 should be denied because it seeks a categorical or blanket exclusion of evidence that *plainly is admissible* based on an unfounded hypothesis that Defendants' might try to use it at trial for some improper purpose. Any such objection is at best premature and not proper grounds for a motion *in limine*.

## **ARGUMENT**

1. As to infringement, Plaintiffs fail to point to any specific instance of *Defendants* comparing accused products to Boston Scientific's Resolution clips to prove non-infringement. Plaintiffs instead cite to the following:



Finally, contrary to Plaintiffs' Motion, Federal Circuit case law "does not contain a blanket prohibition against comparing the accused product to a commercial embodiment." *Adams Respir. Ther., Inc. v. Perrigo Co.*, 616 F.3d 1283, 1288-89 (Fed. Cir. 2010); *accord, e.g., Almirall LLC v. Taro Pharm. Indus. Ltd.*, No. 17-cv-663, 2019 WL 316742, at \*4 (D. Del. Jan. 24, 2019) (denying motion *in limine* to exclude evidence that compares the accused ANDA product to the patentee's NDA).

2. As to invalidity, it is unclear what Plaintiffs' motion seeks to exclude, which itself is grounds to deny the motion. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] Plaintiffs' sole legal support, *Johns Hopkins Univ. v. Datascope Corp.*, 543 F.3d 1342, 1348 n.3 (Fed. Cir. 2008), merely holds that a 510(k) "substantial equivalence" determination does not establish infringement; it does not support a blanket *in limine* exclusion of 510(k) submissions.

The image consists of nine horizontal black bars arranged vertically. The bars decrease in length from top to bottom. The top bar is the longest, followed by a shorter one, then a very long one, then another short one, then a medium-length one, then two more short ones, and finally the shortest bar at the bottom.

Additionally, comparisons between the Olympus clips and Resolution clips are highly probative of the nexus requirement in secondary considerations. Boston Scientific alleges secondary considerations such as commercial success and industry praise based on its Resolution device. A comparison of prior art Olympus clips and Resolution clips shows that to the extent the Resolution clips have been commercially successful and praised, it is attributed to features that had already been in prior art Olympus clips. *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1312 (Fed. Cir. 2006) (“if the feature that creates the commercial success was known in the prior art, the success is not pertinent”).

For the foregoing reasons, the Court should deny Plaintiffs' MIL #1.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 7, 2021

# Exhibit A

**REDACTED**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S REPLY IN SUPPORT OF MIL #1 TO EXCLUDE  
EVIDENCE OR ARGUMENT RELATED TO COMPARISONS OF  
BOSTON SCIENTIFIC'S DEVICES TO DEFENDANTS' DEVICES  
OR PRIOR ART DEVICES FOR PURPOSES OF  
NON-INFRINGEMENT OR INVALIDITY**

Defendants try to justify improper comparison evidence under Rule 801(d)(2), but that Rule makes corporate testimony not hearsay; it doesn't make it relevant or admissible consistent with Rule 403, issues which Defendants ignore. Testimony about irrelevant/prejudicial topics does not become admissible simply because Defendants elicit it at corporate depositions.

Defendants' cases—*Adams* and *Almirall*—were narrow holdings in ANDA cases permitting comparisons only when commercial products are limited to and coextensive with “all of the claim limitations.” *Adams Respiratory Therapeutics, Inc. v. Perrigo Co.*, 616 F.3d 1283, 1288-89 (Fed. Cir. 2010); *Almirall LLC v. Taro Pharm. Indus. Ltd.*, 2019 WL 316742, at \*4 (D. Del. Jan. 24, 2019). That narrow

exception is inapplicable here, where the “commercial embodiment includes several features not found in the asserted claims, including features from dependent, unasserted claims.” *Gillette Co. LLC v. Dollar Shave Club, Inc.*, 2019 WL 1254773, at \*1-2 (D. Del. Mar. 19, 2019).

Further, Defendants are wrong that the inventors’ knowledge of Olympus clips is relevant to obviousness, because “[p]atentability shall not be negated by the manner in which the invention was made.”<sup>1</sup> 35 U.S.C. § 103.

Finally, the relevant prior art inquiry concerning secondary indicia/considerations of non-obviousness is whether a particular “claimed feature” was known—which involves comparing prior art to patent claims, not commercial embodiments. *Ormo Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1312 (Fed. Cir. 2006).

Dated: June 11, 2021

Respectfully submitted,

Of Counsel:

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
kevin.flannery@dechert.com

FARNAN LLP

/s/ Brian E. Farnan  
\_\_\_\_\_  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301

---

<sup>1</sup> To the extent the inventors’ knowledge of Olympus is relevant to unenforceability, that issue will not be tried to the jury.

daniel.roberts@dechert.com

bfarnan@farnanlaw.com

mfarnan@farnanlaw.com

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
robert.rhoad@dechert.com

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 249 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S MIL #2 TO EXCLUDE EVIDENCE RELATED  
TO PTAB PROCEEDINGS REGARDING THE '371 PATENT**

Boston Scientific moves to preclude evidence or argument at trial concerning *inter partes* review (IPR) proceedings before the PTAB regarding patent claims not asserted in this case.<sup>1</sup> Rulings in those proceedings are not proper evidence for a jury to consider and would cause juror confusion, unfairly prejudice Boston Scientific, and waste time. Accordingly, such evidence should be excluded under F.R.E. 403.

Federal courts in this District and elsewhere routinely exclude evidence of factual findings, decisions, and legal conclusions from IPR and other PTAB proceedings as having minimal probative value that is substantially outweighed by the unfair prejudice and confusion that would be sowed if such evidence were

---

<sup>1</sup> See *Cook Grp. Inc. v. Bos. Sci. Scimed, Inc.*, 809 F. App'x 977 (Fed. Cir. 2020).

admitted. *See, e.g., Interdigital Commc 'ns Inc. v. Nokia Corp.*, 2014 WL 8104167, at \*1 (D. Del. Sept 18, 2014); *Personalized User Model, L.L.P. v. Google Inc.*, 2014 WL 807736, at \*3 (D. Del. Feb. 27, 2014); *Magna Elecs., Inc. v. TRW Auto. Holdings Corp.*, 2016 WL 4238769, at \*2-3 (W.D. Mich. Jan. 28, 2016); *Vaporstream, Inc. v. Snap Inc.*, 2020 WL 978731, at \*8 (C.D. Cal. Feb. 28, 2020); *Milwaukee Elec. Tool Corp. v. Snap-On Inc.*, 2017 WL 4570787, at \*6 (E.D. Wis. Oct. 12, 2017). Indeed, in *Reckitt Benckiser Pharm. Inc. v. Watson Labs., Inc.*, 2015 U.S. Dist. LEXIS 167982, at \*2 (D. Del. Dec. 16, 2015), this Court excluded such evidence in a bench trial, where potential jury confusion was not an issue.

The evidence has little probative value, given that Boston Scientific only asserts '371 patent claims 8 and 9, which the PTAB did not address. Each patent claim stands on its own, is entitled to the statutory presumption of validity, and can be proven invalid only by clear and convincing evidence. *Creative Compounds, LLC v. Starmark Labs.*, 651 F.3d 1303, 1309-10 (Fed. Cir. 2011).

Moreover, problems arise because the PTAB applies “different standards, procedures and presumptions” than the jury must apply. *Ultratec, Inc. v. Sorenson Commc 'ns, Inc.*, 2014 WL 5023098, at \*2 (W.D. Wis. Oct. 8, 2014). Here, the PTAB applied a lesser burden of proof (preponderance of the evidence) and different claim construction standard (broadest reasonable interpretation), and it

construed the claims differently than this Court has.<sup>2</sup> Ex. A (PTAB Decision) at 4, 10-14. Accordingly, “evidence concerning the [PTAB’s] proceedings is irrelevant and highly prejudicial to the jury’s determination of the validity of the patents.” *Ultratec*, 2014 WL 5023098, at \*2; *IA Labs CA, LLC v. Nintendo Co.*, 857 F. Supp. 2d 550, 552 (D. Md. 2012) (“[T]he Court agrees with the vast majority of courts that [] evidence [of IPR proceedings] has little relevance to the jury’s independent deliberations on the factual issues underlying the question of obviousness”).

“[T]he complexity involved in giving the full context” of the PTAB’s decision would confuse jurors and prejudice Boston Scientific. *Interdigital*, 2014 WL 8104167, at \*1; *Vaporstream*, 2020 WL 978731, at \*8. Jurors are unlikely to understand the differences between their role and the standards they apply, and those of the PTAB. *Magna*, 2016 WL 4238769, at \*2-3 (explaining the difference between district court litigation and related IPR proceedings would create “needless jury confusion”). Moreover, “taking the time to explain to the jury the difference between the proceedings and how the standards differ with respect to

---

<sup>2</sup> For example, the PTAB construed “coupled to the sheath” as “linked together, connected, or joined to the sheath” (Ex. A at 11), whereas the Court construed it as “linked together, connected, or joined but not slidable within to the sheath” (D.I. 140). In addition, the PTAB construed some terms the Court has not construed, and vice-versa.

invalidity, and so forth, would [] waste time.” *Interdigital*, 2014 WL 8104167, at \*1; *Magna*, 2016 WL 4238769, at \*2-3; *see also Milwaukee Elec.*, 2017 WL 4570787, at \*6 (properly orienting jurors “will consume enormous amounts of time”).

These concerns are particularly acute here because the asserted patent claims were not addressed by the PTAB, adding an additional layer of complexity and confusion for the jury, and because the PTAB construed the claims differently than the Court has here (*see fn 2 supra*). *See Prisua Eng’g Corp. v. Samsung Elecs. Co., Ltd.*, No. 16-21761, ECF No. 268 at 5 (S.D. Fla. Feb. 13, 2018) (excluding PTAB evidence because it “employed a different standard of review, considered different evidence, and made conclusions regarding an unasserted claim”).

## **CONCLUSION**

The Court should exclude all evidence and argument concerning the rulings and outcome of the IPR proceedings.

Dated: May 28, 2021

Respectfully submitted,

Of Counsel:

FARNAN LLP

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
kevin.flannery@dechert.com

/s/ Brian E. Farnan  
\_\_\_\_\_  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301

daniel.roberts@dechert.com

bfarnan@farnanlaw.com

mfarnan@farnanlaw.com

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
robert.rhoad@dechert.com

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 750 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: May 28, 2021

# EXHIBIT A

[Trials@uspto.gov](mailto:Trials@uspto.gov)  
Tel: 571-272-7822

Paper: 82  
Entered: November 15, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COOK GROUP INCORPORATED  
and  
COOK MEDICAL LLC,  
Petitioner,

v.

BOSTON SCIENTIFIC SCIMED, INC.,  
Patent Owner.

---

Case IPR2017-00135  
Patent 8,974,371 B2

---

Before JAMES T. MOORE, JAMES A. TARTAL,  
and ROBERT L. KINDER, *Administrative Patent Judges*.

KINDER, *Administrative Patent Judge*.

FINAL WRITTEN DECISION  
*Inter Partes Review*  
*35 U.S.C. § 318(a) and 37 C.F.R. § 42.73*

IPR2017-00135  
Patent 8,974,371 B2

filed an additional Motion to Exclude Evidence. Paper 71. Supplemental oral argument was held before the Board on September 17, 2018. Paper 80 (“Sep. Tr.”).

We have jurisdiction under 35 U.S.C. § 6. This Final Written Decision is issued pursuant to 35 U.S.C. § 318(a). For the reasons that follow, we determine that Petitioner has shown by a preponderance of the evidence that claims 1, 3–5, and 10 are unpatentable. Petitioner has not shown by a preponderance of the evidence that claims 7, 11–15 and 17 are unpatentable. Additionally, we address the Parties’ Motions to Exclude as set forth below.

## I. BACKGROUND

### A. The ’371 Patent (Ex. 1027)

The ’371 patent is titled “Through the Scope Tension Member Release Clip,” and claims “[a]n apparatus for applying clips to tissue[.]” Ex. 1027, [54], 16:59. The claimed invention relates to devices for causing hemostasis of a blood vessel through an endoscope. *Id.* at 1:17–28. As explained by the ’371 patent, “[h]emostatic clipping tools have been inserted through endoscopes to deploy hemostatic clips which stop internal bleeding by clamping together the edges of a wound.” *Id.* at 1:21–23.

The Specification describes an assembly designed to provide multiple stages of “feedback” to the physician during such a procedure. *Id.* at 1:44–62, 9:43–64. This feedback allows the user, *inter alia*, to be “certain of the status of” the clip assembly during the deployment operation, reducing the likelihood of deployment of a clip at an incorrect location. *Id.* at 1:33–35, 9:37–39. For example, a control element is described as “frangible” such

IPR2017-00135  
Patent 8,974,371 B2

## II. CLAIM CONSTRUCTION

Petitioner identifies several terms for construction. Pet. 8–10. Claim construction is a legal determination based on a hierarchy of evidence—  
intrinsic evidence, including the claim language, the specification, and the  
prosecution history will direct our analysis. *See Phillips v. AWH Corp.*, 415  
F.3d 1303, 1317 (Fed. Cir. 2005) (en banc). Claims in an *inter partes*  
review are presently given the “broadest reasonable construction in light of  
the specification of the patent in which [they] appear[].” 37 C.F.R. §  
42.100(b) (2016); *Cuozzo Speed Techs., LLC v. Lee*, 136 S. Ct. 2131, 2136  
(2016). Below we construe terms that are necessary to resolve the  
controversy before us.

### A. Bushing “Coupled to the Sheath”

Relying only on Patent Owner’s litigation position from the related  
district court proceeding, Petitioner contends that “coupled to the sheath”  
means “slideable inside the sheath” and “the sheath confines the bushing.”  
Pet. 9. Petitioner provides no additional support. The district court  
tentatively rejected this broad interpretation. *See* Ex. 2003, 27–28 (“[T]he  
Court recommends that ‘coupled to the sheath’ be construed as ‘linked  
together, connected, or joined, but not slideable inside the sheath.’”).

Patent Owner contends that Petitioner’s proposed construction of  
“coupled to the sheath” is “unreasonably broad,” but provides little citation  
to the intrinsic record before us. Prelim. Resp. 13–14. Instead, Patent  
Owner notes that the plain and ordinary meaning of coupled is “linked  
together, connected, or joined,” citing to an unrelated Federal Circuit  
decision as well as the related district court determination. *Id.* at 14;  
Ex. 2003, 28.

IPR2017-00135  
Patent 8,974,371 B2

In our proceeding, Petitioner has not provided persuasive evidence or argument to support its claim interpretation by merely pointing to what Patent Owner purportedly argued in district court. Based on the final record before us, “coupled to the sheath” means “linked together, connected, or joined” to the sheath. Our construction is consistent with the district court’s analysis and reflects the common understanding of the term “coupled” in the mechanical arts to require more than simply abutting or contacting. *See generally Ex Parte Paul Robert Homrich*, Appeal 2014-005786, 2016 WL 3541285, at \*3 (PTAB, June 27, 2016) (“When used in mechanical systems, the plain and ordinary meaning of ‘coupled’ means to link together or connect,” and coupled requires more than contact or abut.).

*B. “Releasably Coupled” and “Removably Connected”*

Patent Owner contends that “the BRI of ‘releasably coupled’ and ‘removably connected’ is ‘coupled and capable of being released/removed within the body.’” PO Resp. 7 (citing Ex. 2029 ¶¶ 40–46). According to Patent Owner, “each of claims 1 and 11, by their express terms, require the capability to release or remove the ‘bushing’ and ‘control member’ (claim 1), or a ‘control element’ and a ‘sheath’ (claim 11), *within the body.*” *Id.*

Patent Owner notes that “[c]laim 1 is directed to ‘[a]n apparatus for applying clips to tissue’ and includes a ‘flexible sheath’ that, ‘in an *operative configuration*,’ must ‘extend[ ] *into a living body* to a target portion of tissue to be clipped’ (emphasis added).” *Id.* Patent Owner points to two reasons why “the claims describe that, in the operative configuration, the bushing is within a living body.” *Id.* First, the claim “further includes a ‘bushing extending between a proximal end coupled to the sheath and a distal end releasably coupled to the capsule.” *Id.* Secondly, “[b]ecause the distal end

IPR2017-00135  
Patent 8,974,371 B2

of the flexible sheath extends into a living body, and the proximal end of the bushing is coupled to the sheath,” then the claims require the bushing to also be within a living body. *Id.*

Likewise, Patent Owner contends that “the ‘control member’ must be ‘releasably coupled’ to the clip assembly while the ‘control member’ and the ‘clip assembly’ are within a living body in an operative configuration.” *Id.* at 8.

After examining the relevant language of claim 11, Patent Owner similarly argues that “claim 11 requires: (1) a releasable connection between the distal end of the sheath and the capsule; and (2) a removable connection between the control element and the clip assembly, housed within the capsule, when both are within a living body for applying clips to tissue.” *Id.* Patent Owner argues that the express language of claims 1 and 11 “requires the capability to release the capsule from the sheath and remove the connector element from the clip assembly *within the body.*” *Id.*

Patent Owner points out that its interpretation is supported by “the specification, which uses the word ‘release’ consistently to refer to decoupling after the clip has been deployed while inside the body.” *Id.* at 8–10 (citing Ex. 1027, 1:35–40, 3:46–50, 3:56–59, 5:3–7, 6:55–59, 9:28–31). Patent Owner also points out that the Specification warns of the importance of ensuring that the capsule and clip are released within the patient’s body. *Id.* at 10 (citing Ex. 1027, 10:5–8 (“If this condition is not satisfied, a situation may occur where the clip assembly 106 is locked in place on the patient’s tissue, but cannot be released from the clipping device 100. It will be apparent that this situation should be avoided.”)). Thus, Patent Owner concludes that “the broadest reasonable interpretation of ‘releasably

IPR2017-00135  
Patent 8,974,371 B2

coupled’ and ‘removably connected’ is ‘coupled and capable of being released/removed within the body.’” *Id.* at 10.

Petitioner responds that “claim 1 does not require the ‘control member’ (or ‘bushing’) to be releasably coupled *while the sheath is in the operative configuration.*” Pet. Reply 3–4. Instead, Petitioner argues that “[c]laim 1 is silent as to when, and under what conditions, these components decouple.” *Id.* at 4. According to Petitioner, “claim 11 does not require that the ‘control element’ decouple from the ‘connector element’ (or the ‘sheath’ from the ‘capsule’) within the body.” *Id.*

Reading both independent claims as a whole, we agree with Patent Owner that each of claims 1 and 11, by their express terms, require the capability to release or remove the ‘bushing’ and ‘control member’ (claim 1), or a ‘control element’ and a ‘sheath’ (claim 11), within the body.

Claim 1 is directed to an “apparatus for applying clips to tissue” that further requires “in an operative configuration,” must “extend[ ] into a living body to a target portion of tissue to be clipped.”

The claim further includes a “bushing extending between a proximal end coupled to the sheath and a distal end releasably coupled to the capsule.” We determine that because the distal end of the flexible sheath extends into a living body, and the proximal end of the bushing is coupled to the sheath, the most logical interpretation is that the claims require, in the operative configuration, the bushing to be within a living body. Further, the specification consistently uses the word “release” to refer to decoupling after the clip has been deployed while inside the body, as set forth by Patent Owner above.

Although we find Patent Owner’s position more persuasive on the

IPR2017-00135  
Patent 8,974,371 B2

final record, as explained below, our ultimate decision related to Sackier would not be materially impacted if we were to adopt Petitioner's interpretations.

*C. "Frangible Link"*

Petitioner contends "that the term 'frangible link' means 'a link between at least two components that become unlinked when a tensile load is applied.'" Pet. 10. Petitioner's only supporting evidence is citation to Patent Owner's litigation position in district court. Patent Owner agrees with Petitioner's proposed construction. *See* PO Resp. 12.

Based on the final trial record, we agree that "frangible link" means "a link between at least two components that become unlinked when a tensile load is applied."

### III. ANALYSIS

A petition must show how the construed claims are unpatentable under the statutory ground it identifies. 37 C.F.R. § 42.104(b)(4). Petitioner bears the burden of demonstrating a reasonable likelihood that Petitioner would prevail with respect to at least one challenged claim for a petition to be granted. 35 U.S.C. § 314(a).

*A. Principles of Law*

*1. Anticipation*

To establish anticipation, each and every element in a claim, arranged as recited in the claim, must be found in a single prior art reference. *Net MoneyIN, Inc. v. VeriSign, Inc.*, 545 F.3d 1359, 1369 (Fed. Cir. 2008). "To anticipate a claim, a prior art reference must disclose every limitation of the claimed invention, either explicitly or inherently." *In re Schreiber*, 128 F.3d

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC.,  
  
Defendants.

**DEFENDANTS' OPPOSITION TO PLAINTIFFS' MOTION IN LIMINE #2  
TO EXCLUDE EVIDENCE RELATED TO PTAB PROCEEDINGS  
REGARDING THE '371 PATENT**

## I. INTRODUCTION

The Federal Circuit has entered final judgment on an appeal from an IPR of the '371 patent invalidating all but two of the claims asserted against Defendants in this action, neither of which were ruled on in the IPR. That judgment and its underlying rulings are binding and dispositive on most if not all validity issues regarding the two remaining '371 patent claims. They also directly rebut Plaintiffs' allegations of willful infringement. The Court and jury must consider those rulings.

## II. BACKGROUND

The PTAB issued a Final Written Decision ("FWD") on November 15, 2018 that claims 1, 3-5, and 10 of the '371 patent were unpatentable. Plaintiffs filed this action *after* the FWD issued, and yet Plaintiffs still accused Defendants of infringing '371 patent claims that the PTAB had ruled unpatentable. Ex. A.

The Federal Circuit affirmed the unpatentability of claims 1, 3-5, and 10, and it further reversed the PTAB and held claims 11, 15, and 17 also unpatentable. *Cook Grp. Inc. v. Bos. Sci. Scimed, Inc.*, 809 F. App'x 977 (Fed. Cir. 2020). As a result, *all '371 patent claims* asserted against Defendants in this action (claims 1, 3, 11, and 15) that were addressed in the IPR were ruled unpatentable.

Only claims 8 and 9 remain here. Those claims depend from claim 1, and thus include all the limitations of that unpatentable claim. Defendants have moved for summary judgment on claims 8 and 9 based on collateral estoppel. D.I. 235, 236.

### III. ARGUMENT

1. The '371 IPR proceedings are highly probative—and in some respects dispositive—evidence of invalidity. Defendants' pending summary judgment motion shows that '371 patent claims 8 and 9 are not materially different from invalid claim 1. But even if, as Plaintiffs argue, disputed factual issues were to preclude summary judgment (D.I. 288 at 6-9), and claims 8 and 9 were to remain in this case, then the jury must receive evidence of the IPR proceedings and Federal Circuit judgment—e.g., that all limitations of claim 1 have been ruled obvious over prior art—to discharge its duties consistent with prior binding rulings. So too for the jury's consideration of the asserted '725 patent, which is related to the '371 patent and has asserted claims that significantly overlap with the invalid '371 patent claims.

The cases Plaintiffs cite are inapposite, as none concerned a PTAB proceeding resulting in a final judgment of invalidity through appeals. Indeed, some expressly relied on the non-final status of PTAB proceedings as a basis for excluding evidence. *E.g., Personalized User Model, LLP v. Google Inc.*, 2014 WL 807736, at \*3 (D. Del. Feb. 27, 2014). All the cases are otherwise factually distinct, for example, because the IPRs involved prior art and arguments not at issue at trial. *E.g., Vaporstream, Inc. v. Snap Inc.*, 2020 WL 978731, at \*7 (C.D. Cal. Feb. 28, 2020). Beside citing inapposite cases, Plaintiffs merely rehash arguments made in opposing summary judgment, which Defendants already have addressed. D.I. 236, 324.

2. Plaintiffs' claim of willful infringement is an independent reason to deny Plaintiffs' motion. *See D.I. 141, ¶¶ 20, 50.* Willful infringement turns on Defendants' state of mind during the period of challenged conduct; here, *after* Plaintiffs filed this lawsuit. *See Halo Elecs., Inc. v. Pulse Elecs., Inc.*, 136 S. Ct. 1923, 1932-35 (2016). During that entire period, Defendants knew that the Patent Office already had invalidated claim 1—which is almost identical to remaining claims 8 and 9, and which Defendants believe is not materially different for invalidity purposes. It would be manifestly unjust to allow Plaintiffs to argue that Defendants' conduct was so “wanton, malicious, [and] bad-faith” that it constituted willful infringement (*see Halo*, 136 S. Ct. at 1932), while not allowing Defendants to rebut that argument with evidence showing that, at minimum, Defendants had good reason to believe that claims 8 and 9 also are invalid, in addition to the claims of the related '725 patent.

Plaintiffs' own cited case law supports admitting the '371 IPR evidence. In *Ultratec Inc. v. Sorenson Commc'ns, Inc.*, the court ruled that “should the question of subjective willfulness be presented to the jury, defendants may introduce the [PTAB's] decision as evidence showing their good faith belief in invalidity.” 2014 WL 5023098, at \*2 (W.D. Wis. Oct. 8, 2014); *see also Hillman Grp., Inc. v. KeyMe, LLC*, 2021 WL 1248180, at \*3 (E.D. Tex. Mar. 30, 2021) (materials from IPR proceeding may be introduced in “defense against willfulness”).

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 7, 2021

# Exhibit A

**REDACTED**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S REPLY IN SUPPORT OF MIL #2 TO EXCLUDE  
EVIDENCE RELATED TO PTAB PROCEEDINGS REGARDING THE  
'371 PATENT**

While criticizing Boston Scientific for “merely rehash[ing]” summary judgment arguments, Defendants do just that. They repeat their incorrect argument that Claims 8 and 9 of the ’371 patent are not materially different from Claim 1, which they say makes the ’371 IPR proceedings “highly probative.” Opp. 2. They are wrong: Defendants have never rebutted Boston Scientific’s showing that Claims 8 and 9 are materially different from Claim 1 (D.I. 288 at 6-9), so the ’371 IPR proceedings are irrelevant.

Next, Defendants insist the jury “must” hear about the ’371 IPR proceedings, but they cite no supporting case law. Opp. 2. Though Defendants try to distinguish the many contrary decisions by pointing to the Federal Circuit’s affirmance of the PTAB decision, they make no showing that this affirmation

makes the IPR proceedings relevant to any disputed issue, nor do they show that the probative value of this affirmance outweighs the overwhelming concerns over juror confusion, waste of time, and prejudice that courts routinely invoke to exclude evidence of IPR proceedings, including PTAB final decisions.

Finally, the proffered evidence is irrelevant to Defendants' willful infringement of Claims 8 and 9 for a simple reason: the IPR did not address those claims. Accordingly, Defendants' purported knowledge that the PTAB invalidated certain claims of the '371 patent is irrelevant to their belief as to whether they were infringing Claims 8 and 9—two materially different, presumptively valid claims that the PTAB did not address, let alone invalidate.

Dated: June 11, 2021

Respectfully submitted,

Of Counsel:

FARNAN LLP

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200

robert.rhoad@dechert.com

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 243 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S MIL #3 TO EXCLUDE EVIDENCE OR  
ARGUMENT RELATED TO BOSTON SCIENTIFIC'S SIZE, WEALTH,  
OR TOTAL REVENUES**

The Court should exclude any evidence or argument related to Boston Scientific's size, wealth, or total revenues, particularly as it relates to any disparities between Boston Scientific and Defendants. This information is irrelevant to any issue in this case and would prejudice the jury.

**ARGUMENT**

**A. Boston Scientific's Size, Wealth, and Overall Revenues Are Irrelevant**

The size of Boston Scientific has nothing to do with any party's claim or defense in this case. Defendants have not offered any legal or factual conclusion that depends on this information, and this information is therefore irrelevant and inadmissible under F.R.E. 401. *See Biomerieux, S.A. v. Hologic, Inc.*, 2020 WL 583917, at \*2 (D. Del. Feb. 6, 2020) (excluding evidence of movant's "overall

financial state or revenues not tied to the accused products and not tied to [] expert opinion regarding a reasonable royalty calculation”); *Inventio AG v. Thyssenkrupp Elevator Corp.*, No. 08-874, 2014 WL 554853, at \*3 (D. Del. Feb. 6, 2014) (excluding evidence of company size and overall revenues because the non-movant “fails to point the Court to any conclusion that actually uses this information. Therefore the Court finds that the overall revenues are irrelevant to the expert’s conclusion and is therefore inadmissible for the purposes of this trial.”).

Further, it is not relevant to damages. See *Am. Tech. Ceramics Corp., v. Presidio Components, Inc.*, No. 14-6544, 2019 WL 2330885, at \*6 (E.D.N.Y. May 31, 2019) (“[N]either party will be permitted to refer to the parties’ wealth, size, or finances to the extent it is irrelevant . . . [f]or instance, a comparison of the relative ownership structure and wealth of the parties would not be relevant to a determination of a reasonable royalty”); Order at 11, *HTC Corp. v. Tech. Props. Ltd.*, No. 08-00882 (N.D. Cal. Sept. 9, 2013), ECF No. 564 (“Federal Circuit case law does not permit the use of a company’s overall size or revenue as a check to confirm the reasonableness of a jury award”) (citing *Uniloc v. USA, Inc. v. Microsoft Corp.*, 632 F.3d 1292, 1312 (Fed. Cir. 2011)).

Accordingly, the Court should exclude any such evidence or argument.

**B. References To Boston Scientific’s Size, Wealth, and Overall Revenues Should Be Excluded Under Rule 403**

Additionally, the Court should exclude evidence or argument about Boston’s Scientific’s size or overall revenues under F.R.E. 403. As a mountain of case law shows, permitting this information would unfairly prejudice the jury. *See Inventio AG*, 2014 WL 554853, at \*3 (D. Del. Feb. 6, 2014) (“[C]onsistent with Federal Circuit decisions in various cases, the evidence [of size and overall revenues] would be excluded under Rule 403 as the prejudice to [movant] substantially outweighs its probative value”); *Oil-Dri Corp. of Am. v. Nestle Purina PetCare Co.*, No. 15-1067, 2019 WL 1098925, at \*3 (N.D. Ill. Mar. 8, 2019) (excluding evidence or argument that movant was “large company” or “large multinational corporation” because it “runs the risk of unfairly prejudicing the jury”); *Wielgus v. Ryobi Techs., Inc.*, No. 08-1597, 2012 WL 1853090, at \*6 (N.D. Ill. May 21, 2012) (“[W]hat little probative value the evidence of the defendant’s bottom-line financial status has is substantially outweighed by the danger of unfair prejudice it might cause in coloring the jury’s perception of the relevant issues.”); *Advanced Tech. Incubator, Inc. v. Sharp Corp.*, No. 09-135, 2010 WL 11451797, at \*7 (E.D. Tex. Mar. 31, 2010) (excluding evidence that movant was “large” such that “no pejorative remarks will be made based on [] corporate size”). The Court should follow this case law and exclude any such evidence or argument.

In particular, the Court should exclude any reference to financial disparities between Boston Scientific and Micro-Tech. It is well-established that “it is improperly prejudicial for counsel to appeal to financial disparity between parties before the jury.” *Greenleaf v. Garlock, Inc.*, 174 F.3d 353, 364 n.9 (3d Cir. 1999). As a result, courts routinely exclude arguments that draw attention to differences in the size, wealth, and power of the parties. *Am. Tech. Ceramics*, 2019 WL 2330885, at \*6; *Bausch & Lomb Inc. v. Vitamin Health, Inc.*, No. 13-6498, 2016 WL 3742156, at \*2 (W.D.N.Y. July 7, 2016); *Advanced Tech. Incubator*, 2010 WL 11451797, at \*7. To prevent unfair prejudice to Boston Scientific, the Court should do the same here.

### **CONCLUSION**

For the foregoing reasons, the Court should exclude any evidence or argument related to Boston Scientific’s size, wealth, or overall revenues.

Dated: May 28, 2021

Respectfully submitted,

Of Counsel:

FARNAN LLP

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 732 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: May 28, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC )  
CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
)  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and )  
HENRY SCHEIN INC., )  
Defendants. )

**DEFENDANTS' OPPOSITION TO PLAINTIFFS' MOTION IN LIMINE #3  
TO EXCLUDE EVIDENCE OR ARGUMENT RELATED TO BOSTON  
SCIENTIFIC'S SIZE, WEALTH, OR TOTAL REVENUES**

Plaintiffs' MIL #3 would improperly exclude evidence and argument that are highly probative of issues the jury would need to resolve if this case were to go to trial. A blanket exclusion of references to a party's size, wealth, or total revenues is impermissibly vague and would encompass information required to understand and determine damages, Plaintiffs' standing, and Defendant's patent misuse defense. The motion is also premature, as Plaintiffs have not identified or limited the motion to a context where such evidence or argument could be unduly prejudicial.

## **ARGUMENT**

Boston Scientific's size, wealth, and revenues are plainly relevant to its lost profits claims. The *Panduit* factors for establishing lost profits broadly include plaintiff's "but-for" profits absent the alleged infringement as well as manufacturing and marketing capabilities; evidence on these subjects inevitably would involve the parties' size, wealth, and revenue. *Panduit Corp. v. Stahlin Bros. Fibre Works, Inc.*, 575 F.2d 1152, 1156 (6th Cir. 1978).

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] See *ABS Global, Inc. v. Inguran, LLC*, No. 14-cv-503-wmc, 2016 WL 3996167, at \*2 (W.D. Wis. July 22, 2016) (allowing evidence of the relative size of the parties in the relevant market because it is relevant to certain claims).

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

The case law cited by Plaintiffs is inapposite. In the *Biomerieux* and *Inventio* cases, evidence was excluded because it was not tied to any specific issues or expert opinions to be presented at trial. *Biomerieux, S.A. v. Hologic, Inc.*, No. 18-21-LPS, 2020 WL 583917, at \*2 (D. Del. Feb. 6, 2020) (ruling that evidence was “not tied to Plaintiffs’ expert opinion regarding a reasonable royalty calculation”); *Inventio AG v. Thyssenkrupp Elev. Corp.*, No. 08-874, 2014 WL 554853, at \*3 (D. Del. Feb. 6, 2014) (excluding evidence where party “fails to point the court to any conclusion that actually uses this information”). Here, Defendants have tied the evidence and argument in question to specific damages, standing, and patent misuse issues for

trial. Any further consideration of probative value or potential prejudice should await trial, when evidence or argument is offered in the context of a specific issue.

Plaintiffs also err in their blanket assertion that a company's size, wealth, and revenue "is not relevant to damages." In *Am. Tech. Ceramics Corp. v. Presidio Components, Inc.*, No. 14-6544, 2019 WL 2330855, at \*6 (E.D.N.Y. May 31, 2019), the court actually permitted evidence such as "financial and production capacity" and "relative market positions" because they are relevant to damages determination.

Finally, Plaintiffs are wrong to suggest that any reference to their size, wealth, and revenue would violate Rule 403 by "unfairly prejudice[ing] the jury." Mot. at 4. Plaintiffs' case law involves improper appeals to juror sympathies by characterizing the dispute as one of "David versus Goliath." E.g., *Am. Tech. Ceramics*, 2019 WL 2330855, at \*5. This is not the case here. Plaintiffs have not provided any evidentiary context to justify an overbroad exclusion based on prejudice and jury confusion. Plaintiffs can object at trial if they perceive any remarks to be improper. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] Accordingly, the issue in Plaintiffs' MIL #3 is better suited for ruling during trial on a case-by-case basis, rather than *in limine*, and the Court should deny Plaintiffs' MIL #3.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 7, 2021

# Exhibit A

**REDACTED**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S REPLY IN SUPPORT OF MIL #3 TO EXCLUDE  
EVIDENCE OR ARGUMENT RELATED TO BOSTON SCIENTIFIC'S  
SIZE, WEALTH, OR TOTAL REVENUES**

**Damages:** Defendants insist that the lost profits analysis “inevitably” involves evidence of size, wealth, and revenues, but fail to cite any decision where courts have permitted such evidence for that purpose. *ABS Global* is inapplicable as it relates to niche issues arising from the Sherman Act and contract negotiations, both irrelevant here. *ABS Global, Inc. v. Inguran, LLC*, 2016 WL 3996167, at \*2 (W.D. Wis. July 22, 2016). Though the *Panduit* factors require a showing that Plaintiff had the marketing capacity to meet lost sales demand, Defendants have not explained how *Micro-Tech's relative size* is relevant to this inquiry, nor have they identified any related evidence in their expert reports. Opp. 1-2; *Am. Tech. Ceramics Corp. v. Presidio Components, Inc.*, 2019 WL 2330855, at \*6 (E.D.N.Y.

May 31, 2019) (permitting “financial and production capacity evidence,” not comparative size, and only if “properly disclosed in an expert report”).

**Standing & Patent Misuse:** First, Defendants have not shown how the “financial relationship” between the Boston Scientific entities is relevant to standing. Second, the patent misuse doctrine has a “narrow scope” and Defendants have not explained how “evidence of BSC’s size” is relevant to “one of the specific ways . . . outside the otherwise broad scope of the patent grant.” *Princo Corp. v. Int’l Trade Comm’n*, 616 F.3d 1318, 1329 (Fed. Cir. 2010).

Dated: June 11, 2021

Respectfully submitted,

Of Counsel:

FARNAN LLP

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 221 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 11, 2021

# **SCHEDULE 16**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., ) C.A. No. 18-1869-CFC-CJB  
Plaintiffs, )  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC., )

Defendants.

**DEFENDANTS' MOTION IN LIMINE NO. 1 RE EVIDENCE  
OR ARGUMENT REGARDING EUROPEAN LITIGATION  
BETWEEN MICRO-TECH AND BOSTON SCIENTIFIC**

## I. INTRODUCTION

Defendants respectfully move *in limine* to exclude any evidence or argument regarding related parties' litigation in Europe over certain European patents.

## II. BACKGROUND

Boston Scientific and Micro-Tech entities are engaged in patent litigation in Europe. Boston Scientific Limited ("BSL"), which is related to the Plaintiffs in this action, filed litigation in Germany against Micro-Tech (Nanjing) Co., Ltd. ("MTN"), a Defendant in this action, and Micro-Tech Europe GmbH ("MTE"). MTN and MTE in turn filed opposition proceedings in Europe against BSL's patents. Those European proceedings are ongoing.

## III. ARGUMENTS

The Court should exclude any evidence or argument regarding the existence of, or any rulings in, the European litigation. The evidence should be excluded under FRE 401-403, as it would not be relevant to the claims or defenses of any party, would cause jury confusion, and could unfairly prejudice Defendants.

Judges in this district and other district courts routinely exclude evidence of other litigations under FRE 401-403. In *Johns Hopkins Univ. v. Alcon Labs Inc.*, C.A. No. 15-525-MSG-SRF, 2018 WL 4178159 at \*21 (D. Del. Aug. 30, 2018), for example, the court precluded the plaintiff from referencing prior litigation involving the defendant, unless the evidence was otherwise specially allowed under FRE 613 or 801(d)(1) (concerning prior statements). The court reasoned that "[p]rior lawsuits

against a defendant are ‘generally inadmissible,’” and rejected the plaintiff’s proposal that the prior litigation could be broadly used as impeachment evidence regarding topics such as the defendant’s corporate policies and practices. *Id; accord, e.g., Siemens Mobility Inc. v. Westinghouse Air Brake Techs. Corp.*, C.A. No. 16-284-LPS, 2019 WL 77046 at \*1 (D. Del. 2019) (excluding evidence or argument about “other litigations between the parties”); *Wonderland Nursery Goods Co. v. Thorley Indus., LLC*, Case No. 12-cv-00196, 2014 WL 289446 at \*1-3 (W.D. Pa. Jan. 12, 2014) (ruling that “the probative value of the existence of other litigation and disputes is substantially outweighed by the danger of unfair prejudice, confusion of the issues, misleading the jury, and undue delay”).

When the other litigation is in a foreign country, the risk of prejudice and jury confusion is even higher. *Wasica Finance GmbH v. Schrader Int’l, Inc.*, C.A. No. 13-1353-LPS, 2020 WL 509182 at \*1 (D. Del. Jan. 31, 2020) (“reference to foreign patent litigation … is appropriately excluded pursuant to [FRE 403] as the risks of confusion, waste of time, and unfair prejudice far outweigh whatever minimal probative value such evidence may have”); *In re Biogen ’755 Patent Litig.*, Case No. 10-cv-02734-CCC-JBC, 2018 WL 3613162 at \*3 (D.N.J. Jul. 26, 2018) (“informing the jury of the outcomes of foreign legal proceedings involving, and determinations reached by foreign tribunals regarding, [party’s] other patents and patent applications would risk unduly prejudicing [party]”).

While the existence of foreign litigation and rulings should be excluded, the exclusion should not extend to admissions, evidence, or statements from such litigation, if they are relevant and otherwise admissible. *Siemens Mobility*, 2019 WL 77046 at \*1 (“evidence that has been developed in an IPR or other litigation … may be used at trial, provided that it is done without referring the IPR or other litigation … and subject to the Federal Rules of Evidence and the Court’s procedures”). For example, a party admission made in a foreign proceeding can be admissible under FRE 801(d)(2). *Ferring B.V. v. Serenity Pharms., LLC*, Case No. 17-cv-09922-CM, 2020 WL 1164700 at \*5 (S.D.N.Y. Mar. 11, 2020) (allowing a party to introduce arguments made in a European Patent Office proceeding).

#### **IV. CONCLUSION**

For the foregoing reasons, the Court should exclude any evidence or argument regarding or reference to litigation proceedings in Europe.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng(Ethan) Ma

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S RESPONSE TO DEFENDANTS' MOTION  
IN LIMINE NO. 1 RE EVIDENCE OR ARGUMENT REGARDING  
EUROPEAN LITIGATION BETWEEN MICRO-TECH  
AND BOSTON SCIENTIFIC**

Defendants are trying to have it both ways. While they ask the Court to exclude “any evidence or argument” related to Boston Scientific’s successful European litigation against Defendants, they will attempt to prove non-infringement by introducing a statement that Boston Scientific made during those proceedings. The Court should not grant Defendants’ motion unless this additional evidence is excluded as well.

**ARGUMENT**

As an initial matter, Defendants do not identify any specific document, ruling, or argument from the foreign proceedings they seek to exclude. But they likely seek to exclude any reference to findings by the German court that

Defendants' devices infringe Boston Scientific's European patents (Ex. A at 6-10, 16) and the court-appointed expert's finding that the devices include links (hooks) that break (Ex. B at 8). Any ruling excluding evidence concerning the EPO proceedings from the jury should apply to both sides—such that Defendants are likewise precluded from introducing evidence they seek to use.

In particular, Defendants intend to introduce statements Boston Scientific made to the European Patent Office ("EPO") regarding the meaning of terms in one of its European patents. *See* Ex. C (EPO Proceeding) at -9145; Ex. D (Plishka Rebuttal) at ¶ 40. Defendants cited this statement during claim construction, and the Court relied on it in construing the "breakable link" limitation in claim 1 of the '245 patent. Ex. E (Markman Transcript) at 33-34. During the meet-and-confer process, Defendants acknowledged they intend to introduce this evidence, notwithstanding the present motion.

The Court should exclude this evidence, as allowing Defendants to introduce the statement would confuse the jury, unduly prejudice Boston Scientific, and require the parties to waste time explaining the differences between this litigation and the EPO proceedings. *W.L. Gore & Assocs., Inc. v. C.R. Bard, Inc.*, 2015 WL 7709855, at \*1 (D. Del. Nov. 24, 2015) (excluding evidence and argument related to EPO proceedings due to "serious risk of unfair prejudice and confusion of the

jury”); *Wasica Fin. GmbH v. Schrader Int’l, Inc.*, 2020 WL 509182, at \*1 (D. Del. Jan. 31, 2020).

Moreover, this evidence is irrelevant to any disputed issue at trial. Generally, “[t]here is little if any probative value to [] EPO evidence, as it concerns a different patent evaluated according to different standards by a non U.S. agency.” See *W.L. Gore*, 2015 WL 7709855, at \*1; *Edwards Lifesciences LLC v. Medtronic CoreValve LLC*, 2014 WL 12927825, at \*1 (D. Del. Jan. 2, 2014). Here, the relevance of Boston Scientific’s statement to the EPO relates to the proper construction of the “breakable link” limitation, a legal issue for the Court, not the jury, to decide. Indeed, the Court has already construed that limitation (D.I. 140), and the jury’s task will be to apply that construction in deciding infringement.<sup>1</sup> Defendants seek to use the evidence to invade the province of the Court and re-argue claim construction to the jury. That should not be permitted. See *CytoLogix Corp. v. Ventana Med. Sys., Inc.*, 424 F.3d 1168, 1172 (Fed. Cir. 2005); *EMC Corp. v. Pure Storage, Inc.*, 2016 WL 775742, at \*3 (D. Del. Feb. 25, 2016) (excluding evidence that amounted to “impermissible claim construction”).

---

<sup>1</sup> Specifically, the jury will have to decide, *inter alia*, whether the accused products “mechanically fail by fracturing” in accordance with the Court’s construction of “breakable link.”

*Ferring B.V. v. Serenity Pharm., LLC*, 2020 WL 1164700 (S.D.N.Y. Mar. 11, 2020), does not hold otherwise. There, the court denied a motion to exclude evidence of statements the defendant/counterclaimant made to the EPO that the patent-in-suit was not enabled, which were directly relevant to a disputed fact issue in the case—i.e., whether that patent was invalid for lack of enablement. *Id.* at \*5.<sup>2</sup> Thus, the statement addressed the very patent at issue and was directly relevant as an admission against interest regarding a disputed fact issue in that case. By contrast, Boston Scientific’s statement to the EPO addressed a European patent not at issue here and is irrelevant to any issue that the jury will decide.

## **CONCLUSION**

Defendants cannot have it both ways—excluding evidence from the EPO proceedings that hurts its case, while seeking to use evidence it likes. If the Court were to grant the motion, it should exclude all evidence and argument concerning the EPO proceedings, including the statement cited by Defendants’ infringement expert.

---

<sup>2</sup> The patent-in-suit was cited as prior art to a European patent, and the defendant/counterclaimant argued to the EPO that it was not enabled and therefore could not qualify as proper prior art. *Id.*

Dated: June 7, 2021

Of Counsel:

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

Respectfully submitted,

FARNAN LLP

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 749 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 7, 2021

# EXHIBIT A

**I-15 U 4/20**

4c O 94/18

RC Düsseldorf



Delivered on 29.04.2021

Paulowitz, Judicial

Employee as Clerk of the  
Court office

## DÜSSELDORF HIGHER REGIONAL COURT

### ON BEHALF OF THE PEOPLE

### DECISION

In the matter

1. **Micro-Tech Europe GmbH**, represented by the Managing Director Daniel Kuhn, Mündelheimer Weg 48, 40472 Düsseldorf,
2. **Shanghai International Holding Corporation GmbH (Europe)**, represented by Managing Director Liang Jin, Eiffestraße 80, 20537 Hamburg, Germany,

Defendants and Appellants,

Attorneys to 1, 2:



Attorneys at law HOYNG ROKH MONEGIER  
Partnerschaftsgesellschaft, Steinstraße 20,  
40212 Düsseldorf,


versus

**Boston Scientific Limited**, represented by Douglas John Cronin and Daniel J. Brennan, Directors, Clarendon House, 2 Church Street, Hamilton HM11, Bermuda, United States,

Plaintiff and Appellee,

Attorneys at law Kather Augenstein,  
Bahnstraße 16, 40212 Düsseldorf,





Accordingly, a guide rails is formed in the proximal base of each clip arm and oval protrusions are provided. The distal pin is located in the guide rails and is fixed to the distal end of the capsule, which has two corresponding holes for this purpose. The oval holes accommodate the shorter proximal pin. This connects the two clip legs and is connected via two J-hooks to the control wire, which is sheathed in a helically wound, axially expandable wire (coil shaft).

Pulling the control wire causes the proximal pin to be pulled proximally, causing the base of each clip arm to be pulled into the capsule. The guide rails in the base of the clip legs are guided along the fixed distal pin and the baffle shape causes the legs to close in the clipping area. The sleeve ("capsule") is provided with slots in the area where the base of the arms is accommodated. By moving the control wire proximally or distally, the clip legs can be opened and closed several times.

If the control wire is moved in the proximal direction with a certain force, the J-hooks detach from the proximal pin. The control wire together with the coil shaft can be removed from the body. The clip and the capsule remain in the patient's body.

The Plaintiff considers the offer and distribution of the attacked embodiments in the Federal Republic of Germany to be a literal use of the claim 9 asserted in a limited version and therefore claims injunctive relief, information and rendering account, recall and destruction as well as a declaration of liability for damages on the merits against the Defendants.

In the first instance, the Defendants denied use and took the view that the attacked embodiments had neither a clip nor a lock sleeve nor a retainer release arrangement and also no axially rigid sheath. Moreover, information and rendering account in electronic form could not be demanded if their cost would increase. In any case, the legal dispute had to be suspended, since the patent in suit would not prove to be legally valid in the opposition proceedings due to lack of novelty and inadmissible extension.

In its decision of January 16, 2020 (pp. 214 et seq. Court file), as amended by the corrective order of February 6, 2020 (pp. 285 et seq. Court file), the Regional Court sentenced the Defendants in accordance with the most recent motions and refrained from staying the litigation. In its reasoning, it essentially stated:

Apart from the requirement that the clip must have at least two clip legs, the skilled person could not find any further information on the detailed design of the clip, neither in the claim itself nor in the patent specification. In particular, the necessity of the design as a structural unit was not apparent. The two clip legs do not always have to be able to be opened and closed in dependence on each other and/or the two clip legs do not have to be (spring) pretensioned. The skilled person could only take an indication from the term clamp or clip that the device had to be suitable for clipping, but not how or in what way the clipping function had to be ensured, whether by pretensioning in one of the directions of movement or in some other way. Accordingly, it could not be determined from the excerpts from dictionaries submitted by the parties that the skilled person assigns a certain function and/or design to a clip, in particular that he translates the English term clip with spring clip. The system of claims and the technical-functional approach did not lead to any other understanding. The invention is aimed at a clip which - unlike the prior art clips - is at least partially reversible. In this respect, the skilled person also recognizes that the two clip legs must not only be closed, but also - at least to a certain extent - be able to be opened again and should only be secured at the end of the setting process, when no further correction is required, and the endoscope is removed again. The patent in suit leaves open how the arms are to be secured at

the end of the setting process when no further correction is required, and the endoscope is removed again. Nor does anything else follow from the description and the preferred embodiments shown. On the contrary, from the mention of a pretension with regard to some embodiments in figures 14A-14C, 18A-18E it is clear that a pretension is only an option. Based on this, the attacked embodiments had two clip legs, whereby these even appeared as a structural unit due to the connection via the "distal pin" and the "proximal pin".

The patent in suit defines an axially stiff sheath for the control wire as a sheath which is suitable for counteracting the (tensile and compressive) forces occurring when the control wire is actuated. The sheath must therefore be so rigid that it can withstand these forces. At the same time, the skilled person recognizes that the sheath must not be too stiff or rigid since the entire device is inserted into the patient's body and therefore a certain flexibility is required for adaptation to the place of use. It was already clear from para. [0023] et seq. that it was not necessary that the sheath should neither be able to be compressed nor to be pulled apart. Deformation did not have to be excluded.

The attacked embodiments have a lock sleeve according to the claim. As the wording already makes clear, the lock sleeve should secure (lock) the clip or clip legs after their final closure in such a way that the rest of the device can be removed from the patient's body without the clip opening unintentionally. In addition, the sleeve must be designed in such a way that the clip can be - at least partially - pulled through it. The skilled person could not infer any further requirements or specifications for the spatial and physical design of the sleeve either from the wording of the claim or from the other components of the patent application. The process of pulling through must be in connection with the closing of the clip legs, whereby this is not only to be understood as a temporal connection. Rather, the patent in suit requires an actual correlation. On the other hand, the claim does not require that the pulling through the sleeve may be the only cause or the only mechanism for the closing of the arms. In the attacked embodiments, the component referred to as the "capsule" constitutes a lock sleeve and not, as the Defendants contended, only the lower distal portion of the sleeve with the annular web. This is because the extensions (with slot) facing the clip are integrally connected to the sleeve and, in interaction with the components of the clip, contribute to the clip ultimately remaining locked.

The sleeve also makes a decisive causal contribution to the closing of the clip.

A retainer release arrangement in the sense of the patent in suit is a component or a device which is designed to ensure, in interaction with the retainer that the clip remaining in the body together with the lock sleeve is uncoupled from the rest of the device so that it can be pulled out of the patient's body. The spatial and physical design of the retainer release arrangement is at the discretion of the person skilled in the art. In the attacked embodiments, the component referred to as the "hypotube" is a retainer release arrangement.

Because of the further factual findings and the reasoning, reference is made to the judgment of the Regional Court of January 16, 2020 (sheet 214 et seq. Court file), in the version of the rectification order of February 6, 2020 (sheet 285 et seq. Court file), § 540 ZPO [German Code of Civil Procedure].

The Defendants appealed against this judgment, which was served on January 16, 2020, in a written statement dated January 28, 2020, received by the Higher Regional Court on January 29, 2020. The Defendants continue to seek dismissal of the action. Repeating and supplementing their submissions at first instance, they essentially justify the appeal as follows:

The Regional Court erred in law in deriving the task from para. [0016]. In this paragraph, only particular advantages were mentioned. Based on the generic prior art, US 3 958 576 A (Exhibit KAP II 2, hereinafter: US '576), the remaining task was to further develop the aforementioned medical device and to further simplify this handling.

The skilled person translates the term "clip" used in the language of the process in the claim as clip and understands this to mean a construction consisting of at least two clip legs which are preformed but deformable. Clip is a clamp which is capable of exerting a force with the aid of a pretension. This also follows from the prior art, which differentiates between "clip" and "clamp" or between "clip" and other means with a clamping effect and discloses only clips with pretension. The clip legs would be pressed together in each case by a pressure from the outside. On the priority date, there were no endoscope-guided, detachable hemostasis clips that did not require pretensioning of the clip legs. Such clips had only been developed well after the priority date of the patent in suit, as evidenced by the grant of EP '174. Also all technical embodiments described in the patent in suit exclusively showed solutions with pretensioned clamping legs,

For further details of the facts of the case and of the dispute, reference is made to the pleadings of the parties on file together with the exhibits thereto.

**B.**

The admissible appeal of the Defendant is unfounded. The attacked embodiments make use of the technical teaching of the asserted restricted claim 9 of the patent in suit. The Plaintiff is therefore entitled to the claims awarded by the Regional Court for injunctive relief, provision of information and rendering of accounts, recall, destruction and a declaration of liability for damages on the merits under Article 64 EPC in conjunction with Sections 139 (1) and (2), 140a (3), 140b (1) and (3) PatG [German Patent Act], Sections 242, 259 BGB [German Civil Code].

**I.**

The patent in suit relates to a hemostatic clamping device. Such devices are used in particular in endoscopic procedures to actively and/or prophylactically stop bleeding inside the body. The usual field of application are diseases of the gastrointestinal tract.

Gastrointestinal bleeding poses a significant risk to patients, and treatment of such bleeding is extremely time critical. Diagnosis and treatment of the bleeding can be done either surgically or by endoscopy.

According to the patent in suit, surgical interventions lead to safe stopping of bleeding, but they cause higher costs and higher morbidity and mortality rates than endoscopy (para. [0003]). Therefore, from the perspective of the patent in suit, endoscopic treatments are to be preferred.

In the prior art, two common endoscopic treatment options are known, thermotherapy and injection therapy, as well as some less frequently used therapies. The patent in suit considers these to be disadvantageous for various reasons: although thermotherapy is quite successful in stopping bleeding, it often requires more than one attempt and more frequent

# EXHIBIT B

04.05.2021-13:45

0211875651260

RC Duesseldorf

s. 1/10

### Transcript

**Public hearing  
of the 4 c. Civil Chamber of the  
Regional Court**

Düsseldorf, 27.04.2021

Docket no.:  
4c O 89/18

**Present:**

Presiding Judge at the Regional Court Klepsch  
as Presiding Judge  
Judge at the Regional Court Dr. Schmitz  
Judge at the Regional Court Wimmers  
as associate judges

- Without secretary § 159 ZPO / minutes were recorded provisionally on sound carrier –

In the civil case

Boston Scientific Limited v. Micro-Tech Europe GmbH, et al.

appeared at the calling of the case

for Plaintiff by videoconference Attorney Kiefer, Attorney Dr. Kather, Attorney Dr. Pesch,  
Patent Attorneys Asmussen and Salzer all together in Düsseldorf, Ms. Lane in the USA and  
the interpreters Ms. Meier and Ms. Sasse in Munich

for Defendants Attorney Dr. Weinert and Patent Attorney Albrecht

as well as by video conference Attorney Dr. Metelski in Düsseldorf, Attorney Gspandl in  
Düsseldorf, the managing director of the Defendant 1 Mr. Kuhn in Düsseldorf, Mr. Weinhold,  
Patent Attorney trainee with Patent Attorney Albrecht in Neuss.

Furthermore, the court appointed expert Prof. Dr. Hammer in Regensburg is connected via  
video conference.

Parties' representatives refer to the motions in the oral hearing of December 12, 2019 (sheet  
192 of the A.).

04.05.2021-13:45

0211875651260

RC Duesseldorf

s. 8/10

Thereupon, Expert replied:

I can't see a breaking. However, the quality of the illustrations is not very good either. With the right bracket, you could imagine something like that. However, the resolution is not very good that you cannot see it exactly.

In response to further questioning by the Defendant's representative with regard to the hook with the number 22:

Professor Hammer, can you see a break here?

To this the expert replied:

The left of the two hooks is completely breakd and broken off. Concerning the right hook, I can see a crack. This should be similar to the picture number 1.

The parties stated that they had no further questions for the expert.

Thereupon, Expert still stated in addition:

The materials have not been specified. However, for medical use, it is high-alloy steel. This has both very good plastic deformability to brittle properties. The force that has to be applied when using the devices; does not so much lead to plastic deformation, but rather to brittle break. This is also due to the surface quality of the materials, which is not good. It can also be seen in the high hardness indicated in the expert opinion. However, predetermined breaking points are certainly introduced. The hardness values indicate highresistance.

In response to a question from Plaintiff's representative about this addition: did we understand you correctly that the material properties cause the hooks to break, the expert replied:

Yes.

In response to a question from Defendants' representative:

I did not address these test reports in the expert opinion but have now included them.

In response to further questioning by Defendant's representative as to whether Expert had analyzed the surface quality, Expert replied:

We could not make any analyses because we did not have any material. I could only refer to the photographs in the test reports. These showed a material quality that was not very good or left much to be desired.

In response to further questioning by Defendants' representative as to whether Expert meant by test reports also Exhibit KAP 29, Expert replied:

# EXHIBIT C

EPO - Munich  
100  
30. Sep. 2019

EP 02 77 5909.1 / 1328199

Patentee: Boston Scientific Limited

Opposition by: MTW Endoskopie W. Haag KG; Cook Medical  
Technologies LLC; Micro-Tech Europe GmbH

Our Ref.: X1901 OPP(EP) S5

## Observations

– COVER PAGE –

Please note that this petition contains coloured images.

not satisfactory – reopen and reposition the clip until the desired tissue pinching is accomplished. The device's ability to repeatedly open and close the clip by the reversible operation of the control wire leads to quicker procedures, requiring less clips to be deployed (see paragraph [0015]). In addition, by providing a link that is broken in order to uncouple the control wire from the clip, the device of the contested patent allows for a better adjustment of the desired release point and force.

## II. Interpretation of Claim 1

1. Features 10 and 11 of claim 1 specify that “the frangible link is adapted to be **broken** by a first predetermined tensile force” and that “when the frangible link is **broken**, the control wire uncouples from the clip”. Claim 1 thus requires the link to be broken, wherein “to break” is clearly given the meaning and scope which the term normally has in the art, *i.e.* that a fracture of the link into two or more pieces takes place (cf. GL, F-4.2).
  
2. This is also (i) what the patent itself understands the term “breakable link” to mean and (ii) how the claim was understood by the Examining Division and, subsequently, by the Board of Appeal in T 639/13.
  - 2.1 More specifically, it will be appreciated by the Opposition Division that the patent (as well as the application as originally filed) uses the term “frangible link” for referring to a link that may **either** deform **or** break upon application of a first predetermined tensile force. In contrast, the term “breakable link” refers to a particular type of “frangible link” which indeed breaks.
    - 2.1.1 This understanding of the term is clear, for example, from claim 40 of the application as originally filed, which specifies (emphasis added):
 

“40. The medical device of claim 1, wherein a distal termination of the control wire comprises: a **frangible link**, wherein the frangible link is at least one of a wire reversibly deformed into a j-hook and a **breakable link**, wherein the j-hook is able to be straightened by a first predetermined tensile force; and wherein the breakable link is able to be broken by the first predetermined tensile force.”

The term “frangible link” clearly encompasses both, the reversibly deformable j-hook that is straightened by the first predetermined tensile force **and** the breakable link that is

# EXHIBIT D

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

**BOSTON SCIENTIFIC  
CORPORATION AND BOSTON  
SCIENTIFIC SCIMED, INC.,**

**PLAINTIFFS,**

**V.**

**C.A. NO. 18-1869-CFC/CJB**

**MICRO-TECH ENDOSCOPY USA  
INC., MICRO-TECH (NANJING)  
CO., LTD., AND HENRY SCHEIN  
INC.,**

**DEFENDANTS.**

---

**REBUTTAL EXPERT REPORT OF MICHAEL PLISHKA REGARDING  
NONINFRINGEMENT**

41. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

# EXHIBIT E

1 IN THE UNITED STATES DISTRICT COURT

2 IN AND FOR THE DISTRICT OF DELAWARE

3 - - -

4 BOSTON SCIENTIFIC : CIVIL ACTION

5 CORPORATION and BOSTON :

6 SCIENTIFIC SCIMED, INC., :

7 Plaintiffs, :

8 vs. :

9 MICRO-TECH ENDOSCOPY USA :

10 INC., MICRO-TECH (NANJING) :

CO., LTD., and HENRY SCHEIN :

11 INC., :

12 Defendants. : NO. 18-1869-CFC-CJB

13 - - -

14 Wilmington, Delaware

15 Wednesday, June 24, 2020

9:00 o'clock, a.m.

16 \*\*\*Telephone conference

17 - - -

18 BEFORE: HONORABLE COLM F. CONNOLLY, U.S.D.C.J.

19 APPEARANCES:

20

21 YOUNG CONAWAY STARGATT & TAYLOR, LLP

22 BY: PILAR G. KRAMAN, ESQ. and

KAREN L. PASCALE, ESQ.

23 -and-

24

25 Valerie J. Gunning

Official Court Reporter

1 that caveat, that as well as extrinsic, it is important to  
 2 be clear.

3 THE COURT: Okay. All right. So let me hear  
 4 from the plaintiff on this, this question of whether, you  
 5 know, what is the status of the statements made during the  
 6 prosecution of the foreign counterpart.

7 Boston Scientific, you agree. It's appropriate  
 8 for me to consider that. Right? I mean, the Federal  
 9 Circuit has done that in a number of cases, including Apple  
 10 against Motorola.

11 MR. FLANNERY: I think it would be inappropriate  
 12 in these circumstances, respectfully, Your Honor, because  
 13 I think the intrinsic record teaches us more, or teaches  
 14 one of ordinary skill in the art about what a breakable  
 15 link is.

16 And if I could refer to slide 17, the Examiner,  
 17 when examining the claims over the Gourlay reference, found  
 18 that this opening and closing of these arms 20 was  
 19 inherently a breakable link. That's what the U.S. Examiner,  
 20 that's what the U.S. Examiner said here, so that's something  
 21 more than just a fracturing.

22 And Boston Scientific -- and this is even in  
 23 plaintiffs' slides and in their brief -- Boston Scientific  
 24 took the position, okay. Even if those moveable arms are  
 25 inherently breakable, we've got another way to distinguish

1 the device designed to mechanically fail by fracturing at a  
 2 predetermined tensile load."

3 Boston Scientific argues that breaking the link  
 4 does not necessarily require fracturing the link. The link  
 5 could instead break through deformation. As evidence that  
 6 the breakable link can break by deforming, Boston Scientific  
 7 cites embodiments in the written description that include a  
 8 link called the J-hook that can release from the clip by  
 9 deforming to a straightened position at a predetermined  
 10 tensile load. And Boston Scientific asserts that the  
 11 breakable link claimed in dependent claim 3 is the  
 12 deformable J-hook.

13 I find, however, that the specification does not  
 14 establish that the breakable link can break through  
 15 deformation. The claims reveal that the patent  
 16 differentiates between the deformable J-hook and the  
 17 breakable link claimed in claim 1.

18 Claim 12 of the '245 patent differentiates  
 19 between the breakable link and the J-hook when it recites  
 20 "a frangible link wherein the frangible link is at least  
 21 one of wire reversibly deformed into a J-hook and the  
 22 breakable link, wherein the J-hook is able to be  
 23 straightened by the first predetermined tensile force, and  
 24 wherein the breakable link is able to be broken by the first  
 25 predetermined tensile force."

31

33

1 the Gourlay reference. That's acquiescence. That language,  
 2 Your Honor, even if, that's a statement of acquiescence.  
 3 That's not a statement of accepting a disclaimer. The  
 4 Patent Office said that those arms 20 are inherently  
 5 breakable and Boston Scientific said, okay. Well, even if  
 6 that's the case, we're going to distinguish the Gourlay  
 7 reference based upon the link being broken by a first  
 8 predetermined tensile force.

9 So there we have a statement from the -- this is  
 10 what the public can rely on, a statement from the Examiner  
 11 that that type of link is inherently breakable, and Boston  
 12 Scientific, using language even if, acquiesced in that.

13 So right there we have intrinsic evidence that  
 14 is teaching us or teaching one of ordinary skill in the art  
 15 in the context here that a breakable link can be something  
 16 more than fracturing. That's the U.S. evidence and the  
 17 foreign prosecution cannot trump that, Your Honor. It's a  
 18 single statement from the foreign prosecution.

19 I have the binder in front of me and the  
 20 appendix is many pages long, double-sided. We don't need to  
 21 consider that when U.S. intrinsic evidence tells the scope  
 22 of what a breakable link is and it does not limit it to  
 23 something that fractures.

24 THE COURT: Okay. I'm going to construe the  
 25 term breakable link adapted to be broken as "a component of

1 Moreover, the specification never describes the  
 2 J-hook as breaking, only as deforming or straightening.  
 3 Boston Scientific also argues that the breakable link term  
 4 should receive the same construction that this Court gave  
 5 the term frangible link as used in the '371 patent in the  
 6 Cook litigation.

7 So Boston Scientific does not persuasively  
 8 explain why I should construe breakable link as having the  
 9 same construction as a different term in a different patent.  
 10 Also, the patent frequently calls the J-hook a frangible  
 11 link, and as disclaimed above, the patent treats the J-hook  
 12 and the breakable link as discernibly different components.  
 13 I refer you specifically to column 7, lines 24 through 25 of  
 14 the '245 patent.

15 Although the term frangible link may include the  
 16 breakable link, a frangible link is not equivalent to the  
 17 breakable link because the frangible link clearly includes  
 18 the J-hook.

19 Now, I will limit the term breakable to breaking  
 20 via fracture because Boston Scientific disclaimed the scope  
 21 of the term during prosecution of the '245 patent's foreign  
 22 counterpart, which is at EP199. And as far as whether it is  
 23 appropriate to consider that, I do so based on the Federal  
 24 Circuit's decision in Apple against Motorola, 737 F3d.,  
 25 1286. And I think there's other case law incidentally in

1 which the Federal Circuit has considered and found it to be  
2 important, disclaimers and statements made during the course  
3 of the prosecution of a foreign counterpart to the U.S.  
4 patent that has been asserted in the litigation.

5 During the prosecution of the EP199, Boston  
6 Scientific distinguished the invention from prior art on the  
7 grounds that the prior art did not discuss or even suggest a  
8 breakable link adapted to be broken, but instead disclosed a  
9 deformable link in the form of a hook 51, but not a  
10 breakable one.

11 The European Patent Office accepted the  
12 argument, stating that claim 1 is characterized over the  
13 prior art by the presence of the breakable link, which  
14 breaks under a predetermined tensile force of a frangible  
15 (weakened, brittle) portion instead of a bendable in (or  
16 rather straightenable) engaging portion.

17 Moreover, in an opposition proceeding against  
18 the '199 European patent, Boston Scientific asserted that  
19 the claim thus requires the link to be broken wherein to  
20 break is clearly given the meaning and scope, which the term  
21 normally has in the art, i.e., that fracture of a link into  
22 two or more pieces takes place.

23 Finally, I will construe the term adapted to be  
24 broken as designed to be broken rather than capable of being  
25 broken. Claim language establishes that the breaking

1 parties have agreed that for the '245 patent, I'm going to  
2 give sheath its plain and ordinary meaning.

3 All right. I think the next disputed term is  
4 coupled to the sheath in claim 1 of the '371 patent. Is  
5 that correct?

6 MR. RHOAD: Yes, Your Honor.

7 THE COURT: Okay. Let me hear from Boston  
8 Scientific first.

9 MR. RHOAD: Certainly, Your Honor. Again, this  
10 is Bob Rhoad.

11 So this is a term -- for the term sheath, we  
12 argued that, proposed that the Court adopt the same  
13 construction that it did in the Cook case, and here we are  
14 arguing for a different construction than what the Court had  
15 adopted in that case, and it's really -- we respectfully  
16 submit that the Court found the disavowal that was not clear  
17 and unequivocal and that the patentees, in fact, never did  
18 disavow the ordinary meaning of the term coupled to the  
19 sheath.

20 We look at the claim term in context, and if  
21 Your Honor has our slides available, on slide 24, we show  
22 the term in context. It's referring to a bushing being  
23 coupled to the sheath, and I don't think there's any dispute  
24 that our construction, proposed construction, reflects the  
25 ordinary meaning of the term coupled to being linked

35

1 results from a design choice because it explains that the  
2 breaking occurs at a predetermined tensile load. I refer  
3 the parties to the In re: Man Machine Interface case at 822  
4 F3d., 1282, in which the Federal Circuit construed adapted  
5 to as "made or designed to."

6 All right. The next term is sheath. And you  
7 all can't agree to just let the jury have this and just  
8 leave it as plain and ordinary meaning. Is that right,  
9 plaintiffs?

10 MR. RHOAD: I think we would be -- we would be  
11 fine with plain and ordinary meaning. We think that's -- we  
12 simply proposed the -- oh, I'm sorry.

13 Let me just state for the record, this is Bob  
14 Rhoad. Good morning, Your Honor. And, you know, we simply  
15 proposed the construction that the Court gave this term in  
16 the Cook case, and we think the Court gave the ordinary  
17 meaning construction, and we are certainly, I think, happy  
18 to just leave it as the plain and ordinary meaning of the  
19 term sheath.

20 THE COURT: How about the defendants?

21 MR. HIGGINS: Your Honor, for the '245 patent  
22 alone, we are fine with plain and ordinary meaning on sheath  
23 and will address it separately for the other patent.

24 THE COURT: Okay. Well, that was an agreement,  
25 so there's no need for me to explain a ruling. And so the

37

1 together, connected, or joined to the sheath. And, in fact,  
2 defendants' construction includes that same language.  
3 So the dispute really here is whether or not  
4 there's anything to limit that ordinary meaning, and their  
5 argument is based on a disavowal.

6 So the question is: Is the prosecution, was  
7 there any disavowal of claim scope that would result in a  
8 disavowal of not slidably within the sheath. And on slide  
9 25, I think we have the key issues here. And so on the top  
10 of 25, we see the figure showing the Kimura device and the  
11 alleged disavowal occurred in connection with the patentee  
12 distinguishing that Kimura device.

13 And so if we look at that figure, we've  
14 highlighted the relevant components. What the Examiner said  
15 was, the "bushing" was the No. 12, the hooked section of No.  
16 12 highlighted in blue there. And we see the sheath is  
17 sheath 8 that's highlighted and sort of reddish, pinkish,  
18 and in yellow we have the control wire.

19 So, again, the claim language is the bushing  
20 coupled to the sheath. And so the Examiner said that the --  
21 what he was calling the bushing, the blue, hook Section 12,  
22 is coupled to the sheath 8, the red section. And we see in  
23 the figure what it is, what it is clearly connected to,  
24 joined to, is the control wire 7 in yellow. We have an  
25 arrow pointing that out for Your Honor.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORA- )  
TION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
)  
v. )  
)  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC.,  
  
Defendants.

**DEFENDANTS' REPLY TO PLAINTIFFS' RESPONSE TO  
DEFENDANTS' MOTION IN LIMINE NO. 1 RE EVIDENCE OR  
ARGUMENT REGARDING EUROPEAN LITIGATION BETWEEN  
MICRO-TECH AND BOSTON SCIENTIFIC**

Plaintiffs are wrong, Defendants are not “trying to have it both ways.” We ask the Court to apply the same standard to both sides. The existence of and rulings in the European litigation should be excluded because they are irrelevant to this action. But admissions, evidence, and statements from that litigation should be allowed *from either side*, if relevant and admissible for the purposes offered at trial. Plaintiffs admit that standard is proper in their discussion of the *Ferring* case and agree that the German court’s rulings should not be admitted.

Plaintiffs argue that the Court should exclude Boston Scientific’s statements about how one of ordinary skill in the art would understand “break” and “fracture,” even though they directly contradict the position taken by Plaintiffs and endorsed by their expert in this case. Introducing evidence of those statements would not “re-argue claim construction to the jury” – Plaintiffs already lost that issue at claim construction, which is one reason why the Court should grant summary judgment on the ’245 patent, or at least exclude the contradictory testimony of Plaintiff’s expert. *See* D.I. 252, 260. But if the ’245 patent remains in the case, Boston Scientific’s statements from the European litigation are *non-hearsay* party admissions under Fed. R. Evid. 801(d)(2), and Defendants should be permitted to introduce them to rebut and impeach Plaintiffs’ evidence and argument.<sup>1</sup>

---

<sup>1</sup> Plaintiffs also raise statements of a court-appointed expert. His statements support Micro-Tech’s position in many respects. Regardless, they are hearsay and should be excluded, unless offered at trial under a specific exclusion to Rule 801.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., ) C.A. No. 18-1869-CFC-CJB  
Plaintiffs, )  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC., )

Defendants.

**DEFENDANTS' MOTION IN LIMINE NO. 2 RE EVIDENCE OR  
ARGUMENTS AS TO THE DECISION AGAINST INSTITUTION IN  
IPR2020-00185**

## I. INTRODUCTION

Defendants respectfully move *in limine* to exclude any evidence or argument regarding the Patent Trial and Appeal Board’s (“PTAB’s) Decision Denying Institution of *Inter Partes* Review (“IPR”) in IPR2020-00185. A PTAB non-institution decision lacks probative value to the issues in suit and would pose a substantial risk of prejudice and jury confusion.

## II. BACKGROUND

On May 4, 2020, the PTAB denied institution of IPR2020-00185, filed by Micro-Tech Endoscopy USA Inc. and Micro-Tech (Nanjing) Co., Ltd., to challenge claims 1-15 of U.S. Patent No. 7,094,245 (the “’245 Patent”), one of the patents in suit in this action. IPR2020-00185, Paper No. 11 (“the PTAB ’245 Decision”).

## III. ARGUMENT

Judges in this district have consistently held that PTAB decisions denying IPR institutions should be excluded under Federal Rules of Evidence 401-403 because they are not decisions on the merits, lack probative value, and pose significant risk of prejudicing a party and confusing the jury. For example, in *Evolved Wireless, LLC v. Apple Inc.*, C.A. No. 15-542-JFB-SRF, 2019 WL 1100471 at \*3 (D. Del. Mar. 7, 2019), the court granted the defendant’s motion *in limine* because “[t]he denial to institute proceedings has no estoppel effect and the minimal probative value it may have to the validity issue is substantially outweighed by the potential for prejudice

and confusion to the jury.” *Accord, e.g., Alarm.com Inc. v. SecureNet Techs. LLC*, C.A. No. 15-807, D.I. 253 (D. Del. Jan. 23, 2019) (excluding IPR non-institution decision because “PTAB’s decisions denying institution are not decisions on the merits and were decided under a different standard of proof”); *Bio-Rad Labs, Inc. v. 10x Genomics, Inc.*, C.A. No. 15-152-RGA, 2018 WL 6629705 at \*1 (D. Del. Oct. 12, 2018) (same); *Nox Medical Ehf v. Natus Neurology Inc.*, Case No. 15-cv-00709-RGA, 2018 WL 6629704 at \*1 (D. Del. Apr. 12, 2018) (same).<sup>1</sup>

This motion is limited to referencing the ’245 Patent IPR or the PTAB ’245 Decision. Statements made in the ’245 Patent IPR proceeding would not be excluded if relevant to positions of the party or witness in this action and otherwise admissible. See *Bio-Rad*, 2018 WL 6628705 at \*1 (allowing use of expert testimony from IPR proceedings for impeachment purposes); *Siemens Mobility Inc. v. Westinghouse Air Brake Techs. Corp.*, C.A. No. 16-284-LPS, 2019 WL 77046 at \*1 (D. Del. Jan. 2, 2019) (allowing evidence developed in IPR proceeding “provided that it is done without referencing the IPR”).

This motion also does not seek to limit use of evidence relating to the IPR proceedings involving U.S. Patent No. 8,974,371 (the “’371 Patent”). That IPR

---

<sup>1</sup> Other courts have adopted the same approach. *Plexxikon Inc. v. Novartis Pharm. Corp.*, Case No. 17-cv-04405-HSG, 2021 WL 1164749 at \*1 (N.D. Cal. Mar. 26, 2021); *Acantha, LLC v. DePuy Orthopaedics, Inc.*, Case No. 15-cv-01257, 2018 WL 2431852 at \*2-3 (E.D. Wis. May 30, 2018).

resulted in a final decision of the Federal Circuit that certain claims were invalid as obvious, including independent claim 1, on which asserted claims 8 and 9 depend. The Federal Circuit's final decision has collateral estoppel effect that is not only relevant to but also binding in this action, as explained in Defendants' pending Motion for Summary Judgment of Invalidity and Motion to Exclude Opinions of Plaintiffs' Expert Witness Karl Leinsing. *See* D.I. 235, 236, 259, 260, 324, 326. If dependent claims 8 and 9 were to remain in this case, then the jury may need to be informed of certain aspects of the '371 Patent IPR proceedings—e.g., that all limitations of independent claim 1 have already been ruled obvious over prior art—to discharge its duties consistent with prior binding PTAB and court rulings.

#### **IV. CONCLUSION**

The Court should grant Defendants' Motion *in limine* to exclude any evidence or argument regarding the PTAB '245 Decision.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng(Ethan) Ma

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S RESPONSE TO DEFENDANTS'  
MOTION IN LIMINE NO. 2 RE EVIDENCE OR ARGUMENTS AS TO  
THE DECISION AGAINST INSTITUTION IN IPR2020-00185**

Boston Scientific agrees that evidence of IPR proceedings lacks probative value and poses a substantial risk of prejudice and jury confusion. To that end, Boston Scientific proposed that the parties exclude evidence related to *all* IPR proceedings involving the asserted patents (i.e., '371 and '245 Patent IPR proceedings). Defendants refused. They now argue that the Court should exclude evidence related to the '245 Patent IPR proceedings (in which the PTAB found that Defendants failed to demonstrate invalidity, even under the lesser burden of proof that applies in such proceedings), but allow evidence related to the '371 Patent IPR proceedings. This position is contrary to the law; Defendants cannot have it both ways. The jury should either hear about both IPR proceedings or neither. It would be highly prejudicial and grossly unfair if Defendants were able to present the jury

with evidence concerning IPR proceedings that favors them, but Boston Scientific were precluded from doing the same. The Court should either allow or exclude evidence and argument concerning the factual findings, decisions, and legal conclusions from IPR proceedings equally across the board.

## ARGUMENT

Boston Scientific agrees, based on the great weight of the case law, that the Court should exclude from the jury all evidence and argument concerning *all* IPR proceedings, *including* the PTAB’s non-institution decision finding no “reasonable likelihood” that Micro-Tech would prevail in demonstrating invalidity of the ’245 Patent claims. Ex. A at 2, 7-8. As Boston Scientific argued in its MIL #2, such evidence is not proper for a jury to consider and would waste time at trial.<sup>1</sup> Defendants, however, wish to cherry-pick which IPR proceedings should be excluded, so they can present evidence from the proceedings with results they like, but preclude evidence from those they don’t like. MT MIL #2 at 2-3. Allowing Defendants to do so would be highly prejudicial. Although Boston Scientific believes the Court should exclude evidence related to *both* the ’245 and ’371

---

<sup>1</sup> Boston Scientific agrees that an expert’s prior statements made in an IPR proceeding are admissible for impeaching that expert “so long as this is done without referencing either the [IPR] or the [outcome].” *Personalized User Model, L.L.P. v. Google Inc.*, 2014 WL 807736, at \*3 (D. Del. Feb. 27, 2014).

Patent IPR proceedings, if the Court opts to deny Boston Scientific’s MIL #2, it should also deny Defendants’ related MIL.

In support of their MIL, Defendants rehash their erroneous summary judgment argument that the ’371 Patent IPR proceedings are relevant because the outcome of those proceedings has “collateral estoppel effect” on patent claims not addressed therein. *Id.* at 3. However, neither the Federal Circuit nor PTAB discussed, let alone adjudicated, whether the ’371 Patent claims asserted here—claims 8 and 9—are patentable. Claims 8 and 9 recite additional limitations not present in claim 1, and thus require a different validity analysis than claim 1.

Ex. B (’371 patent) at 17:28-33; D.I. 288 at 6-9. Moreover, the PTAB employed a lesser burden of proof and different claim construction standard, and it construed the claims differently than this Court has, rendering those proceedings irrelevant and highly prejudicial. BSC MIL #2 at 2-3. Indeed, PTAB decisions on different claims that use different legal standards do not have collateral estoppel effect. *See* D.I. 288 at 3-5; *Papst Licensing GmbH & Co., KG v. Samsung Elecs.*, 403 F.Supp. 3d 571, 602 (E.D. Tex. 2019).

Equally important, collateral estoppel is an issue of law for the Court, not the jury, to decide. Defendants argue that “the jury may need to be informed of certain aspects of the ’371 Patent IPR Proceedings,” but cite no case law, provide no justifiable reason why that is so, and fail to address the multi-faceted concerns

associated with doing so. Nor can they, because courts overwhelmingly exclude such evidence—including evidence from both non-institution and PTAB final decisions—due to its tendency to create “needless jury confusion” and waste trial time. *See, e.g., Magna Elecs. v. TRW Automotive Holdings Corp.*, 2016 WL 4238769, at \*2-3 (W.D. Mich. Jan. 28, 2016) (excluding evidence of PTAB final obviousness decision); *Milwaukee Elec. Tool Corp. v. Snap-On Inc.*, 2017 WL 4570787, at \*6 (E.D. Wisc. Oct. 12, 2007). Accordingly, the Court should exclude all evidence related to the ’371 Patent IPR proceedings.

## **CONCLUSION**

This MIL and Boston Scientific’s MIL #2 seek similar relief relating to IPR proceedings related to the patents-in-suit. The Court should either grant them both or deny them both; it should not grant Defendants’ MIL if it denies Boston Scientific’s.

Dated: June 7, 2021

Respectfully submitted,

Of Counsel:

FARNAN LLP

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 750 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 7, 2021

# EXHIBIT A

Trials@uspto.gov  
571-272-7822

Paper No. 11  
Entered: May 4, 2020

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MICRO-TECH (NANJING) CO., LTD. AND MICRO-TECH  
ENDOSCOPY USA, INC.,  
Petitioner,

v.

BOSTON SCIENTIFIC SCIMED, INC.,  
Patent Owner.

---

IPR2020-00185  
Patent 7,094,245 B2

---

Before JAMES A. TARTAL, MICHAEL L. WOODS, and  
AMANDA F. WIEKER, *Administrative Patent Judges*.

WIEKER, *Administrative Patent Judge*.

DECISION  
Denying Institution of *Inter Partes* Review  
*35 U.S.C. § 314*

IPR2020-00185  
Patent 7,094,245 B2

## I. INTRODUCTION

### A. Background

Micro-Tech (Nanjing) Co., Ltd and Micro-Tech Endoscopy USA, Inc. (“Petitioner”) filed a Petition requesting an *inter partes* review of claims 1–15 (“challenged claims”) of U.S. Patent No. 7,094,245 B2 (Ex. 1001, “the ’245 patent”). Paper 1 (“Pet.”). Boston Scientific Scimed, Inc. (“Patent Owner”) filed a Preliminary Response. Paper 10 (“Prelim. Resp.”).

We have authority to determine whether to institute an *inter partes* review, under 35 U.S.C. § 314 and 37 C.F.R. § 42.4. An *inter partes* review may not be instituted unless it is determined that “the information presented in the petition filed under section 311 and any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314; *see also* 37 C.F.R. § 42.4(a) (“The Board institutes the trial on behalf of the Director.”).

For the reasons provided below and based on the record before us, we determine that Petitioner has not demonstrated a reasonable likelihood that Petitioner would prevail in showing the unpatentability of at least one of the challenged claims. Accordingly, we do not institute an *inter partes* review.

### B. Related Proceedings

The parties state that the ’245 patent is at issue in a district court proceeding in the U.S. District Court for the District of Delaware, Case No. 1:18-cv-01869-CFC. Pet. 1; Paper 5, 2.

Patent Owner also states:

A number of patents and pending applications claim priority to the ’245 Patent. Several related patents were involved in proceedings before the Board (see, e.g., IPR2017-00131, 132,

IPR2020-00185  
Patent 7,094,245 B2

*E. Applied References*

Petitioner relies upon the following references:

Kortenbach et al., U.S. Patent No. 6,808,491 B2, filed May 20, 2002, issued October 26, 2004 (Ex. 1004, “Kortenbach I”);

Kortenbach et al., U.S. Patent No. 6,569,085 B2, filed August 16, 2001, issued Mat 27, 2003 (Ex. 1006, “Kortenbach II”);

Matsuno et al. U.S. Patent No. 5,766,184, filed Nov. 2, 1995, issued June 16, 1998 (Ex. 1007, “Matsuno”);

Rapacki et al., U.S. Patent No. 5,569,274, filed June 24, 1994, issued October 29, 1996 (Ex. 1008, “Rapacki”);

Kirsch et al., U.S. Patent No. 4,733,664, filed October 15, 1985, issued March 29, 1988 (Ex. 1009, “Kirsch”).

Pet. 3. Petitioner also submits the Declaration of Dr. Morton O. Jensen (Ex. 1002). Patent Owner does not offer declarant testimony at this stage of the proceeding.

*F. Asserted Grounds of Unpatentability*

Petitioner challenges claims 1–15 of the ’245 patent based on the following asserted grounds of unpatentability. Pet. 4–5.

<b>Claim(s) Challenged</b>	<b>35 U.S.C. §<sup>1</sup></b>	<b>Reference(s)/Basis</b>
1, 4, 5, 7, 8, 10, 12, 13, 15	102(e)	Kortenbach I
1, 3–5, 7, 9, 10, 12, 13, 15	103	Kortenbach I
1, 7, 9, 12, 13, 15	102(e)	Kortenbach II
1, 7, 9, 12, 13, 15	103	Kortenbach II

---

<sup>1</sup> The Leahy-Smith America Invents Act (“AIA”), Pub. L. No. 112-29, 125 Stat. 284, 287–88 (2011), amended 35 U.S.C. §§ 102, 103. Because the application from which the ’245 patent issued was filed before March 16, 2013, the effective date of the relevant amendment, the pre-AIA versions of §§ 102, 103 apply.

IPR2020-00185  
Patent 7,094,245 B2

<b>Claim(s) Challenged</b>	<b>35 U.S.C. §<sup>1</sup></b>	<b>Reference(s)/Basis</b>
1, 3–7, 9–15	102(b)	Matsuno
1, 3–7, 9–15	103	Matsuno, Kirsch <sup>2</sup>
1, 3–13, 15	103	Matsuno, Rapacki <sup>3</sup>
2	103	Kortenbach I, Kirsch

## II. DISCUSSION

### A. *Claim Construction*

For petitions filed on or after November 13, 2018, a claim shall be construed using the same claim construction standard that would be used to construe the claim in a civil action under 35 U.S.C. § 282(b), including construing the claim in accordance with the ordinary and customary meaning of such claim as understood by one of ordinary skill in the art and the prosecution history pertaining to the patent. 37 C.F.R. § 42.100(b) (2019). The Petition was filed November 26, 2019. Thus, we apply the claim construction standard as set forth in *Phillips v. AWH Corp.*, 415 F.3d 1303 (Fed. Cir. 2005) (en banc).

Accordingly, claim terms are generally given their ordinary and customary meaning as would have been understood by one with ordinary skill in the art in the context of the specification, the prosecution history, other claims, and even extrinsic evidence including expert and inventor testimony, dictionaries, and learned treatises, although extrinsic evidence is less significant than the intrinsic record. *Phillips*, 415 F.3d at 1312–1317.

---

<sup>2</sup> Petitioner identifies this ground as based on “Matsuno in view of the knowledge of a POSITA and/or Kirsch.” Pet. 4.

<sup>3</sup> Petitioner identifies this ground as based on “Matsuno in view of the knowledge of a POSITA and/or Rapacki.” *Id.*

# EXHIBIT B



US008974371B2

(12) **United States Patent**  
Durgin et al.

(10) **Patent No.:** US 8,974,371 B2  
(45) **Date of Patent:** \*Mar. 10, 2015

(54) **THROUGH THE SCOPE TENSION MEMBER RELEASE CLIP**

(75) Inventors: **Russell F. Durgin**, Attleboro, MA (US); **William C. Mers Kelly**, Crestwood, KY (US); **Lance Alan Wolf**, Floyds Knobs, IN (US); **Brian Keith Wells**, LaGrange, KY (US); **Vasily P. Abramov**, Louisville, KY (US); **Gregory R. Furnish**, Louisville, KY (US)

(73) Assignee: **Boston Scientific Scimed, Inc.**, Maple Grove, MN (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 549 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 13/328,171

(22) Filed: Dec. 16, 2011

(65) **Prior Publication Data**

US 2012/0109162 A1 May 3, 2012

**Related U.S. Application Data**

(60) Continuation of application No. 12/252,630, filed on Oct. 16, 2008, now Pat. No. 8,083,668, which is a division of application No. 10/955,624, filed on Sep. 30, 2004, now Pat. No. 7,452,327, which is a continuation-in-part of application No. 10/674,512, filed on Sep. 30, 2003, now Pat. No. 7,494,461.

(60) Provisional application No. 60/568,418, filed on May 5, 2004.

(51) **Int. Cl.**

**A61B 1/00** (2006.01)

**A61B 17/122** (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61B 17/122** (2013.01); **A61B 17/1285**

(2013.01); **A61B 17/1227** (2013.01); **A61B**

2017/003 (2013.01); **A61B 2017/00845** (2013.01); **A61B 2017/00849** (2013.01); **A61B 2017/12004** (2013.01); **A61B 2017/292** (2013.01); **A61B 2019/2242** (2013.01); **A61B 2019/2246** (2013.01); **A61B 2019/2292** (2013.01); **A61B 2019/304** (2013.01); **A61B 2019/307** (2013.01); **A61B 2019/308** (2013.01)  
USPC ..... **600/104**; 600/106; 600/129; 606/45; 606/139; 606/142; 606/161; 606/167; 606/158

(58) **Field of Classification Search**

USPC ..... 600/104; 606/139, 142, 151, 157–158  
See application file for complete search history.

(56)

**References Cited**

**U.S. PATENT DOCUMENTS**

3,882,854 A \* 5/1975 Hulka et al. ..... 600/104  
4,627,444 A 12/1986 Brooker  
(Continued)


*Primary Examiner* — Matthew J Kasztejna

(74) *Attorney, Agent, or Firm* — Fay Kaplun & Marcin, LLP

(57) **ABSTRACT**

Apparatus includes Flexible Sheath extending from a proximal end which extends into living body; Capsule extending from a proximal to a distal end and having an opening formed in a proximal end thereof; Clip Assembly provided in Capsule and configured to be operably movable between a closed configuration in which first and second arms of Clip Assembly are drawn toward one another and an expanded configuration in which the first and second arms are separated from one another to receive target tissue therebetween; Bushing extending between a proximal end coupled to Sheath and a distal end releasably coupled to Capsule via a tab on the distal end of Bushing engaging the opening of Capsule; and Control Member a distal end of which is releasably coupled to Clip Assembly to transmit to Clip Assembly forces applied thereto to move Clip Assembly between the insertion and expanded configurations.

**17 Claims, 28 Drawing Sheets**



US 8,974,371 B2

17

drawn toward one another and an expanded configuration in which the first and second arms are separated from one another to receive target tissue therebetween; a bushing extending between a proximal end coupled to the sheath and a distal end releasably coupled to the capsule via a tab on the distal end of the bushing engaging the opening of the capsule; and a control member a distal end of which is releasably coupled to the clip assembly to transmit to the clip assembly forces applied thereto to move the clip assembly between the insertion and expanded configurations.

5 10  
2. The apparatus of claim 1, wherein the opening is substantially A-shaped.

3. The apparatus of claim 1, wherein a proximal end of the control member is coupled to a control handle which, when the apparatus is in an operative position, remains outside the body accessible to a user.

4. The apparatus of claim 3, wherein the clip assembly further comprises a yoke slidably received in the capsule and releasably coupled to the control member.

5. The apparatus of claim 3, wherein the control member is coupled to the yoke via a frangible link.

6. The apparatus of claim 5, wherein the frangible link is formed as a reduced strength portion of the control member.

7. The apparatus of claim 5, wherein the distal end of the control member comprises a ball received in a socket in the yoke.

8. The apparatus of claim 1, wherein the proximal end of the capsule comprises a keyed portion aligning the capsule in a desired rotational orientation with respect to the bushing.

9. The apparatus of claim 8, wherein the distal end of the bushing comprises a feature configured to mate with the keyed portion of the capsule.

10. The apparatus of claim 1, further comprising a tension member slidably received in the capsule and configured to bias the first and second arms to the expanded configuration.

18

11. An apparatus for applying clips to tissue within a living body, comprising:  
a capsule;

a clip assembly housed within the capsule for movement between an insertion configuration in which first and second arms of the clip assembly are drawn toward one another and an expanded configuration in which the first and second arms are separated from one another to receive tissue therebetween;

a control element including a connector element, extending between a proximal end which, during use, remains outside the body accessible to a user and a distal end removably connected to the clip assembly via the connector element, wherein the control element detaches from the connector element via a frangible link; and a sheath extending from a proximal to a distal end and covering a portion of the control element, wherein the distal end of the sheath is releasably coupled to the capsule.

20 12. The apparatus of claim 11, wherein the frangible link is formed as a reduced diameter portion of the control element.

13. The apparatus of claim 11, wherein the clip assembly includes a yoke slidably received in the capsule and removably coupled to the control element.

14. The apparatus of claim 13, wherein the yoke is connected to the control element via a ball and socket joint.

15. The apparatus of claim 11, wherein the sheath is coupled to the capsule via a bushing including a tab on a distal end thereof received in an opening at a proximal end of the capsule.

30 16. The apparatus of claim 15, wherein the opening is substantially A-shaped.

17. The apparatus of claim 11, further comprising a tension member slidably received in the capsule and configured to bias the first and second arms to the expanded configuration.

\* \* \* \* \*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC.,  
  
Defendants.

**DEFENDANTS' REPLY TO PLAINTIFFS' RESPONSE TO  
DEFENDANTS' MOTION IN LIMINE NO. 2 RE EVIDENCE OR  
ARGUMENTS AS TO THE DECISION AGAINST INSTITUTION IN  
IPR2020-00185**

Plaintiffs agree with Defendants that the PTAB's non-institution decision in the '245 Patent IPR should be excluded. As Plaintiffs have presented no evidence or argument opposing Defendants' MIL #2 on this point, it should be granted.

Plaintiffs entire response is an attempt to tie this MIL to Plaintiffs' own MIL #2, seeking to exclude the final invalidity ruling in the '371 Patent IPR, but the law and proper analysis governing the '371 Patent IPR differ in two crucial respects, as further explained in our opposition to Plaintiffs' MIL #2 and Defendants' pending summary judgment motion on '371 Patent invalidity. *First*, the '371 Patent IPR resulted in a final Federal Circuit judgement of invalidity on the merits, which has collateral estoppel effect, whereas the '245 Patent IPR non-institution decision has no such effect. *Second*, the '371 Patent IPR and Federal Circuit affirmation provide highly probative evidence rebutting Plaintiffs' willful infringement allegation—a point Plaintiffs have not even acknowledged, much less rebutted.

The cases cited by Plaintiffs are distinguishable. *Milwaukee Elec. Tool. Corp. v. Snap-On Inc.*, 2017 WL 4570787 at \*6 (E.D. Wisc. Oct. 12, 2007) addressed the opposite situation in which a patentee sought to use the survival of patent claims in IPRs to show the claims' strength; moreover, the court already had ruled that prior art used in the IPR could not be used at trial. And *Magna Elecs., Inc. v. TRW Automotive Holdings Corp.*, 2016 WL 4238769 at \*2 (W.D. Mich. Jan. 28, 2016) did not address willful infringement or collateral estoppel.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 11, 2021

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC )  
CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
)  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC.,  
  
Defendants.

**DEFENDANTS' MOTION IN LIMINE NO. 3 RE EVIDENCE OR  
ARGUMENTS AS TO STATEMENTS CONCERNING PREDICATE  
DEVICES IN MICRO-TECH'S FDA 510(K) SUBMISSIONS**

## I. INTRODUCTION

Defendants respectfully move *in limine* to preclude Plaintiffs from offering evidence or argument that Micro-Tech's 510(k) submissions, which provide any evidence or inference that the accused Micro-Tech products infringe the asserted patents or copy BSC's products. The FDA requirement that a 510(k) submission demonstrate "substantial equivalence" to a previously cleared predicate device involves fundamentally different issues and inquiries than those involved in determining patent infringement or copying and therefore is of no probative value to such a determination.

## II. BACKGROUND

FDA "510(k) notifications are submittals of engineering and clinical information which are provided to the FDA to permit that agency to assess the safety and effectiveness of a new product with regard to a predicate product which is already on the market." *Sunrise Med. HHG Inc., v. AirSep Corp.*, 95 F. Supp. 2d 348, 405 (W.D. Pa. 2000). In 510(k) submissions, the FDA requires applicants to demonstrate "substantial equivalence" to a predicate device. 21 C.F.R. § 807.92. Certain of Micro-Tech's 510(k) submissions

. This is standard industry practice: for example, past BSC 510(k) submissions for certain of its Resolution devices listed the prior art Olympus clip

“fixing devices” as a predicate devices, and more recent BSC 510(k) submissions for Resolution devices list a Micro-Tech device as a predicate device.

### **III. ARGUMENT**

The identification of a predicate device in a 510(k) submission should be excluded under Fed. R. Evid. 401-403 if offered to prove infringement or copying. The Federal Circuit has held that, in an infringement inquiry, FDA equivalence to a predicate device “is irrelevant to patent law because it involves fundamentally different inquiries.” *The Johns Hopkins Univ. v. Datascope Corp.*, 543 F.3d 1342, 1349 n. 3 (Fed. Cir. 2008). Therefore, a statement of “substantial equivalence” to a predicate device in 510(k) submissions is not admissible to prove patent law claims such as infringement. *See e.g. Abbott Point of Care, Inc. v. Epocal, Inc.*, Case No. 08-cv-00543-NE, 2012 WL 13162732 at \*3-5 (N.D. Ala. Apr. 18, 2012) (excluding under FRE 403 all evidence of the accused infringer’s 510(k) submission because “the standard for ‘substantial equivalence’ in the FDA-approval context is so different from the standards for evaluating the similarity of inventions in the patent infringement context that the jury could easily be confused about the significance of statements made to the FDA.”); *Ethicon Endo-Surgery, Inc. v. Hologic, Inc.* 689 F. Supp. 2d, 929, 935-36 (S.D. Ohio 2010) (same). Similarly, courts have excluded evidence of “substantial equivalency” in 510(k) submissions as irrelevant to copying. *Optivus Tech., Inc. v. Ion Beam Applications*

S.A., Case No. 03-cv-02052-SJO, 2005 WL 6070811 at \*17 (C.D. Cal. Mar. 14, 2005) (noting that “the precise similarities between the accused device and the patents at issue are not discussed in the 510(k) report”).

#### IV. CONCLUSION

For the foregoing reasons, the Court should grant Defendants’ Motion *in limine* to exclude any evidence or argument offered to show that a party’s identification of a device as a “predicate device” in any way supports infringement or copying by the party.<sup>1</sup>

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
1601 Nanjing Road West  
Shanghai, 200040  
People’s Republic of China  
86-21-6109-7108

/s/ *John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: May 28, 2021

---

<sup>1</sup> The *in limine* ruling requested in this motion would not preclude the use of a 510(k) submission as evidence offered for other purposes, such as to show a person’s or party’s knowledge of a predicate device at the time of the submission.

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION  
and BOSTON SCIENTIFIC SCIMED,  
INC.,

Plaintiffs,

v.

MICRO-TECH ENDOSCOPY USA INC.,  
MICRO-TECH (NANJING) CO., LTD.,  
and HENRY SCHEIN INC.,

CA. No. 18-1869-SB-CJB

**BOSTON SCIENTIFIC'S RESPONSE TO DEFENDANTS'  
MOTION IN LIMINE NO. 3 RE EVIDENCE OR ARGUMENTS  
AS TO STATEMENTS CONCERNING PREDICATE DEVICES IN  
MICRO-TECH'S FDA 510(K) SUBMISSIONS**

The regulatory framework for clearing medical devices through the FDA 510(k) process is straightforward as it applies here: the inquiry is whether a proposed device is “substantially equivalent” for safety purposes to a “predicate” device on the market. As prescribed in its regulations, the FDA considers certain comparisons between the proposed device and the predicate device that has already been shown to be safe. Boston Scientific agrees that, as federal courts have repeatedly held, this “substantial equivalence” framework based on “predicate” device comparisons is irrelevant to patent law. To that end, Boston Scientific suggested that the parties could agree to exclude any argument or evidence related to it. Defendants refused, and now seek to exclude any references to “substantial

equivalence” for the purpose of proving infringement, even as they plan to invoke such evidence to argue non-infringement and invalidity. Defendants cannot have it both ways. The Court should exclude *any* argument related to 510(k) “substantial equivalence,” including those related to invalidity and the product comparisons that are the subject of Plaintiffs’ MIL #1.

## ARGUMENT

Boston Scientific agrees with Defendants that “FDA equivalence is irrelevant to patent law because it involves fundamentally different inquiries.” *The Johns Hopkins Univ. v. Datascope Corp.*, 543 F.3d 1342, 1348 n.3 (Fed. Cir. 2008). But, Defendants state the well-settled law only to suit their purpose while ignoring the full implications of it. The predicate device comparisons have no place for any of the inquiries in a patent jury trial, not just infringement or copying.

Defendants’ plans to improperly use Boston Scientific’s 510(k)s are described in Plaintiffs’ MIL #1, but one example bears repeating here for context. Defendants seek to argue that statements in Boston Scientific’s 510(k) for its Resolution™ clip regarding “substantial equivalence” to a prior art Olympus clip as the “predicate device” show that the asserted patent claims, which cover the Resolution™ clip, were obvious in light of the Olympus clip. *See* BSC MIL 1 at 3-4. But, the Federal Circuit has emphasized that any such argument is “irrelevant to patent law,” because “substantial equivalence” is equally irrelevant to both the

infringement and obviousness inquiries. *Johns Hopkins*, 543 F.3d at 1348 n.3; *Covidien Sales LLC v. Ethicon Endo-Surgery, Inc.*, 2020 WL 7040643, at \*6 (S.D. Ohio Dec. 1, 2020) (FDA “substantial equivalence” evidence was irrelevant to proving a “copying” secondary consideration of non-obviousness). The Court should therefore grant Defendants MIL only to the extent it applies equally to all parties, and to issues of infringement/non-infringement and validity/invalidity.

It must be further noted, however, that Boston Scientific agrees with Defendants’ comment in footnote 1 that the Court should not exclude ***all statements*** made in 510(k) submissions, as they may include other statements that are relevant and admissible for other purposes. Indeed, Defendants’ motion seeks only to exclude those statements in 510(k) submissions that relate to “substantial equivalence.” In ruling on the motion, the Court should be careful not to exclude other statements in 510(k) submissions unrelated to such equivalence, to the extent they are relevant to disputed issues in the case, including any Defendants might seek to add in reply. *See, e.g., Abbott Labs. v. Baxter Pharm. Prods., Inc.*, 2004 WL 2496459, at \*3-\*4 (N.D. Ill. November 3, 2004) (distinguishing cases where 510(k) statements were excluded, and admitting statements to the FDA that “relate directly to the infringement inquiry”); *Covidien*, 2020 WL 7040643, at \*7 (denying

motion to exclude all evidence relating to 510(k) submission because “there may be statements in the 510(k) materials that are relevant to the trial issues”).<sup>1</sup>

Here, for example, Micro-Tech’s 510(k) submissions include factual statements regarding the design and operation of its product that are directly relevant to issues before the jury. These include, among other things, statements about how the accused devices are intended to be used, features and functionality the accused devices have, and statements about the . See, e.g., Ex. A at -924. This evidence is directly relevant to the infringement analysis and should not be swept into any MIL the Court may grant.

## **CONCLUSION**

The Court should exclude all evidence or argument regarding the FDA’s “substantial equivalence” framework and any statements in 510(k) submissions about a proposed product being “substantially equivalent” to a predicate device, including the use of any such evidence or arguments to support alleged invalidity.

---

<sup>1</sup> See also *Cirba Inc. v. VMware, Inc.*, 2020 WL 1316464, at \*2 n.2 (D. Del. Jan. 6, 2020) (declining to address request to exclude evidence “raised only in [a] reply brief”).

Dated: June 7, 2021

Of Counsel:

Kevin M. Flannery  
Daniel Roberts  
DECHERT LLP  
Cira Centre, 2929 Arch St.  
Philadelphia, PA 19104  
(215) 994-2000  
[kevin.flannery@dechert.com](mailto:kevin.flannery@dechert.com)  
[daniel.roberts@dechert.com](mailto:daniel.roberts@dechert.com)

Robert D. Rhoad  
DECHERT LLP  
502 Carnegie Center Drive, Suite #104  
Princeton, New Jersey 08549  
(609) 955-3200  
[robert.rhoad@dechert.com](mailto:robert.rhoad@dechert.com)

Respectfully submitted,

FARNAN LLP

/s/ Brian E. Farnan  
Brian E. Farnan (#4089)  
Michael J. Farnan (#5165)  
919 North Market Street, 12th Floor  
Wilmington, DE 19801  
Tel. (302) 777-0300  
Fax (302) 777-0301  
[bfarnan@farnanlaw.com](mailto:bfarnan@farnanlaw.com)  
[mfarnan@farnanlaw.com](mailto:mfarnan@farnanlaw.com)

*Attorneys for Plaintiffs*

**CERTIFICATION OF COMPLIANCE**

The foregoing document complies with the type-volume limitation of this Court's March 2, 2020 form Scheduling Order. The text of this motion, including footnotes, was prepared in Times New Roman, 14 point. According to the word processing system used to prepare it, the brief contains 750 words, excluding the case caption, signature block, table of contents and table of authorities.

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)

Dated: June 7, 2021

# EXHIBIT A

CONFIDENTIAL

MT00000923

EXHIBIT

41



**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION )  
and BOSTON SCIENTIFIC SCIMED, )  
INC., )  
Plaintiffs, ) C.A. No. 18-1869-CFC-CJB  
v. )  
MICRO-TECH ENDOSCOPY USA )  
INC., )  
MICRO-TECH (NANJING) CO., )  
LTD., and  
HENRY SCHEIN INC.,  
  
Defendants.

**DEFENDANTS' REPLY TO PLAINTIFFS' RESPONSE TO  
DEFENDANTS' MOTION IN LIMINE NO. 3 RE EVIDENCE OR  
ARGUMENTS AS TO STATEMENTS CONCERNING PREDICATE  
DEVICES IN MICRO-TECH'S FDA 510(K) SUBMISSIONS**

Plaintiffs concede and agree with Defendants' position that statements in Micro-Tech's 510(k) submissions on "substantial equivalence" to a predicate device should be excluded from evidence and argument on infringement and copying. Accordingly, Defendants' MIL #3 should be granted.

Plaintiffs' Response goes on to argue any statements about "substantial equivalency" to a predicate device should be subject to a *blanket* exclusion. That is both incorrect and beyond the scope of the Motion. As Defendants explained in responding to Plaintiffs' MIL #1, Defendants are entitled to rely on Boston Scientific's 510(k) submissions that use a prior art Olympus clip as a predicate device to show an inventor's knowledge of the prior art, which is relevant to obviousness and inequitable conduct defenses. Defs.' Opp. to Pls.' MIL #1 at 3.

Plaintiffs also argue that "factual statements" in Micro-Tech's 510(k) submissions "regarding the design and operation of its product" should be admissible as they are not related to substantial equivalency. Response at 4. In their own MIL #1, however, Plaintiffs seek to exclude statements in Boston Scientific's 510(k) submission even though they are unrelated to substantial equivalency, such as statements about Boston Scientific's understanding of "fracturing" and testimony of Plaintiffs' Rule 30(b)(6) deponent about the 510(k) filings. Pls.' MIL #1 at 2. Applying Plaintiffs' own reasoning, this evidence should be allowed as well.

ASHBY & GEDDES

*Of Counsel:*

Steven J. Routh  
T. Vann Pearce, Jr.  
Christopher Higgins  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
Columbia Center  
1152 15<sup>th</sup> Street, N.W.  
Washington, DC 20005-1706  
(202) 339-8400

Yufeng (Ethan) Ma  
ORRICK, HERRINGTON & SUTCLIFFE LLP  
47/F Park Place  
1601 Nanjing Road West  
Shanghai, 200040  
People's Republic of China  
86-21-6109-7108

*/s/ John G. Day*

---

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
500 Delaware Avenue, 8<sup>th</sup> Floor  
P.O. Box 1150  
Wilmington, DE 19899  
(302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

*Attorneys for Defendants*

Dated: June 11, 2021